Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
A3GALT2,"A3GALT2P, IGB3S, IGBS3S",ENSG00000184389,"Alpha 1,3-galactosyltransferase 2",1,33306766-33321098,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Not detected,,,testis: 0.6,Not detected,,
A4GALT,"A14GALT, Gb3S, P(k), P1",ENSG00000128274,"Alpha 1,4-galactosyltransferase",22,42692121-42721298,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA001141, HPA076542",,,Supported,Mitochondria,Cervical cancer:2.48e-4 (favourable),Expressed in all,Mixed,,,seminal vesicle: 30.5,Mixed,,
AACS,"ACSF1, FLJ12389, SUR-5",ENSG00000081760,Acetoacetyl-CoA synthetase,12,125065379-125143333,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA058815,Approved,,Approved,Vesicles,,Expressed in all,Expressed in all,,,breast: 55.0,Expressed in all,,
AADAC,"CES5A1, DAC",ENSG00000114771,Arylacetamide deacetylase,3,151814037-151828488,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA002911,Approved,,,,"Ovarian cancer:5.58e-6 (favourable), Stomach cancer:2.19e-4 (unfavourable), Pancreatic cancer:5.02e-4 (unfavourable)",Tissue enriched,Group enriched,5,adrenal gland: 150.1;duodenum: 182.4;liver: 386.8;small intestine: 215.8,stomach: 43.5,Cell line enhanced,,A549: 7.3;EFO-21: 3.9;HBEC3-KT: 2.7
AADAT,"KAT2, KATII, KYAT2",ENSG00000109576,Aminoadipate aminotransferase,4,170060222-170091699,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037502,Enhanced,,Approved,Vesicles<br>Plasma membrane,Colorectal cancer:5.59e-4 (favourable),Expressed in all,Tissue enhanced,,liver: 34.7,prostate: 23.4,Mixed,,
AAK1,"DKFZp686K16132, KIAA1048",ENSG00000115977,AP2 associated kinase 1,2,69457997-69674349,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA017931, HPA020289",Enhanced,,Supported,Plasma membrane<br>Cytosol,Ovarian cancer:3.19e-4 (unfavourable),Expressed in all,Tissue enriched,7,parathyroid gland: 389.6,thyroid gland: 59.4,Expressed in all,,
AANAT,SNAT,ENSG00000129673,Aralkylamine N-acetyltransferase,17,76453351-76470117,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA054321,,,Supported,Cytosol,,Not detected,Tissue enhanced,,testis: 4.5,appendix: 2.2,Cell line enhanced,,A549: 2.2;SCLC-21H: 3.5;U-698: 2.5
AARS,"AlaRS, CMT2N",ENSG00000090861,Alanyl-tRNA synthetase,16,70252295-70289543,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB034261, HPA040870, HPA044223",Supported,,Enhanced,Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 178.0,Expressed in all,,
AARS2,"AARSL, bA444E17.1, KIAA1270",ENSG00000124608,"Alanyl-tRNA synthetase 2, mitochondrial",6,44299654-44313326,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035636, HPA061396",Approved,,Enhanced,Mitochondria,,Expressed in all,Mixed,,,parathyroid gland: 11.4,Expressed in all,,
AASS,"LKRSDH, LORSDH",ENSG00000008311,Aminoadipate-semialdehyde synthase,7,122075647-122144280,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020637, HPA020728, HPA020734",Enhanced,,Enhanced,Vesicles<br>Mitochondria,Liver cancer:9.81e-4 (favourable),Expressed in all,Mixed,,,ovary: 30.7,Cell line enhanced,,AN3-CA: 49.4;NTERA-2: 51.8
AATK,"AATYK, AATYK1, KIAA0641, LMR1, LMTK1, PPP1R77",ENSG00000181409,Apoptosis associated tyrosine kinase,17,81117295-81166077,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA009073,Enhanced,,Uncertain,Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 36.4;duodenum: 23.4,small intestine: 18.3,Group enriched,5,CACO-2: 35.4;SH-SY5Y: 15.1
ABAT,GABAT,ENSG00000183044,4-aminobutyrate aminotransferase,16,8674565-8784575,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041528, HPA041690",Enhanced,Supported,Supported,Mitochondria,"Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 164.5;kidney: 135.3;liver: 175.2,thyroid gland: 47.5,Cell line enhanced,,Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1
ABCB1,"ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1",ENSG00000085563,ATP binding cassette subfamily B member 1,7,87503633-87713323,"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB001716, HPA002199",Enhanced,,Approved,Nucleoplasm<br>Focal adhesion sites<br>Cytosol,"Renal cancer:2.95e-4 (favourable), Pancreatic cancer:3.33e-4 (favourable)",Tissue enhanced,Tissue enhanced,,adrenal gland: 137.8;small intestine: 82.4,kidney: 37.3,Cell line enhanced,,CACO-2: 56.6;HEL: 34.4;SH-SY5Y: 85.9
ABCB4,"GBD1, MDR2, MDR3, PFIC-3, PGY3",ENSG00000005471,ATP binding cassette subfamily B member 4,7,87401697-87480435,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA049395, HPA053288",Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites,,Tissue enriched,Tissue enriched,6,liver: 69.3,adrenal gland: 10.7,Group enriched,6,SH-SY5Y: 14.2;WM-115: 25.6
ABHD10,FLJ11342,ENSG00000144827,Abhydrolase domain containing 10,3,111979010-111993363,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA036991, HPA036992, HPA066081",Supported,,Approved,Mitochondria,"Renal cancer:4.72e-9 (favourable), Cervical cancer:7.57e-4 (favourable)",Expressed in all,Expressed in all,,,epididymis: 62.1,Expressed in all,,
ABHD12,"ABHD12A, BEM46L2, C20orf22, dJ965G21.2, DKFZP434P106",ENSG00000100997,Abhydrolase domain containing 12,20,25294743-25390983,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA026866,Uncertain,,,,"Cervical cancer:1.30e-5 (favourable), Breast cancer:3.81e-5 (unfavourable), Liver cancer:7.18e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 137.3,Expressed in all,,
ABHD2,LABH2,ENSG00000140526,Abhydrolase domain containing 2,15,89087459-89202360,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA005999,Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:2.18e-7 (favourable),Expressed in all,Expressed in all,,,testis: 93.8,Expressed in all,,
ABHD3,LABH3,ENSG00000158201,Abhydrolase domain containing 3,18,21650897-21704805,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010729,Approved,,Approved,Nucleus<br>Vesicles<br>Plasma membrane,Melanoma:8.52e-4 (unfavourable),Expressed in all,Expressed in all,,,rectum: 71.5,Cell line enhanced,,REH: 188.5;RPMI-8226: 159.6
ABHD4,FLJ12816,ENSG00000100439,Abhydrolase domain containing 4,14,22598237-22613215,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000600,Uncertain,,Approved,Nucleus,,Expressed in all,Expressed in all,,,testis: 62.8,Mixed,,
ABHD5,"CGI-58, NCIE2",ENSG00000011198,Abhydrolase domain containing 5,3,43690113-43734371,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB020685, HPA035851, HPA035852",Approved,,Approved,Vesicles,"Renal cancer:9.17e-5 (favourable), Colorectal cancer:8.89e-4 (favourable)",Expressed in all,Expressed in all,,,adipose tissue: 50.6,Expressed in all,,
ABHD6,,ENSG00000163686,Abhydrolase domain containing 6,3,58237506-58295693,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA017283, HPA073225",Uncertain,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.11e-11 (favourable), Colorectal cancer:1.13e-4 (favourable)",Expressed in all,Mixed,,,small intestine: 50.9,Mixed,,
ABL1,"ABL, c-ABL, JTK7, p150",ENSG00000097007,"ABL proto-oncogene 1, non-receptor tyrosine kinase",9,130713946-130887675,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB002686, HPA027251, HPA027280, HPA028409",Supported,,Enhanced,Nucleoplasm<br>Nuclear bodies,,Expressed in all,Expressed in all,,,parathyroid gland: 83.9,Expressed in all,,
ABL2,"ABLL, ARG",ENSG00000143322,"ABL proto-oncogene 2, non-receptor tyrosine kinase",1,179099327-179229684,"Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA001866, CAB017106, HPA072754",Uncertain,,Supported,Nucleoplasm,"Renal cancer:1.78e-7 (unfavourable), Cervical cancer:3.50e-4 (unfavourable), Urothelial cancer:8.40e-4 (unfavourable)",Expressed in all,Mixed,,,gallbladder: 20.3,Expressed in all,,
ACAA1,,ENSG00000060971,Acetyl-CoA acyltransferase 1,3,38103129-38137242,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006764, HPA007244",Enhanced,,Enhanced,Peroxisomes,"Renal cancer:6.99e-9 (favourable), Head and neck cancer:1.23e-4 (favourable), Breast cancer:3.00e-4 (favourable), Endometrial cancer:7.53e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 328.4,Expressed in all,,
ACAA2,DSAEC,ENSG00000167315,Acetyl-CoA acyltransferase 2,18,49782167-49813960,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA042303,Enhanced,,Supported,Mitochondria,"Renal cancer:1.36e-10 (favourable), Endometrial cancer:8.53e-4 (unfavourable)",Expressed in all,Expressed in all,,,liver: 509.5,Mixed,,
ACACA,"ACAC, ACC, ACC1",ENSG00000278540,Acetyl-CoA carboxylase alpha,17,37084988-37406818,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB013715, HPA036650, HPA063018",Approved,,Supported,Nucleoli fibrillar center<br>Actin filaments<br>Cytosol,Liver cancer:1.24e-5 (unfavourable),Expressed in all,Mixed,,,breast: 28.8,Expressed in all,,
ACACB,"ACC2, ACCB, HACC275",ENSG00000076555,Acetyl-CoA carboxylase beta,12,109116595-109268226,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA006554,Enhanced,,,,"Renal cancer:1.15e-5 (favourable), Pancreatic cancer:1.93e-4 (favourable)",Expressed in all,Tissue enriched,6,adipose tissue: 194.8,parathyroid gland: 30.6,Cell line enriched,13,ASC diff: 152.8
ACADL,"ACAD4, LCAD",ENSG00000115361,"Acyl-CoA dehydrogenase, long chain",2,210187939-210225491,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA011990,Enhanced,Supported,,,Renal cancer:1.58e-11 (favourable),Group enriched,Tissue enhanced,,thyroid gland: 32.0,prostate: 27.0,Cell line enhanced,,HAP1: 1.6;HeLa: 2.5;RPTEC TERT1: 2.5;U-2 OS: 1.9
ACADM,"ACAD1, MCAD, MCADH",ENSG00000117054,"Acyl-CoA dehydrogenase, C-4 to C-12 straight chain",1,75724347-75787575,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006198, HPA026542",Enhanced,,Enhanced,Mitochondria,"Renal cancer:3.83e-8 (favourable), Colorectal cancer:7.30e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 328.0,Expressed in all,,
ACADS,"ACAD3, SCAD",ENSG00000122971,"Acyl-CoA dehydrogenase, C-2 to C-3 short chain",12,120725735-120740008,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004799, CAB019284, HPA022271",Enhanced,,Enhanced,Mitochondria,"Renal cancer:3.33e-6 (favourable), Urothelial cancer:6.34e-5 (favourable), Liver cancer:2.43e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Glioma:9.94e-4 (unfavourable)",Expressed in all,Expressed in all,,,duodenum: 81.2,Cell line enhanced,,HMC-1: 30.0
ACADSB,"ACAD7, SBCAD",ENSG00000196177,"Acyl-CoA dehydrogenase, short/branched chain",10,123008979-123058311,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA041458,Enhanced,,Supported,Mitochondria,"Renal cancer:6.37e-12 (favourable), Pancreatic cancer:3.40e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 186.7,Expressed in all,,
ACADVL,"ACAD6, LCACD, VLCAD",ENSG00000072778,"Acyl-CoA dehydrogenase, very long chain",17,7217125-7225273,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA019006, HPA020595",Enhanced,,Supported,Nucleus<br>Nucleoli<br>Mitochondria,Pancreatic cancer:6.87e-4 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 453.7,Expressed in all,,
ACAT1,"ACAT, THIL",ENSG00000075239,Acetyl-CoA acetyltransferase 1,11,108121516-108147776,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004428, HPA007569",Enhanced,,Enhanced,Mitochondria,"Renal cancer:0.00e+0 (favourable), Liver cancer:1.43e-5 (favourable)",Expressed in all,Expressed in all,,,kidney: 534.2,Expressed in all,,
ACAT2,,ENSG00000120437,Acetyl-CoA acetyltransferase 2,6,159760328-159779055,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB021106, HPA025736, HPA025765, HPA025811",Enhanced,,Supported,Nucleus<br>Cytosol,"Colorectal cancer:1.12e-4 (favourable), Endometrial cancer:7.25e-4 (unfavourable), Renal cancer:7.38e-4 (unfavourable)",Expressed in all,Mixed,,,liver: 45.8,Expressed in all,,
ACE,"ACE1, CD143, DCP1",ENSG00000159640,Angiotensin I converting enzyme,17,63477061-63498380,"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002426, CAB002921, HPA029298, HPA069790",Enhanced,,Approved,Vesicles,,Expressed in all,Tissue enhanced,,duodenum: 178.9;small intestine: 291.6,testis: 83.7,Cell line enhanced,,ASC TERT1: 44.4;HUVEC TERT2: 28.2
ACE2,,ENSG00000130234,Angiotensin I converting enzyme 2,X,15561033-15602148,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"HPA000288, CAB026174",Enhanced,,,,"Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable)",Tissue enhanced,Group enriched,5,duodenum: 181.1;gallbladder: 100.2;kidney: 94.0;small intestine: 261.1;testis: 93.0,heart muscle: 27.9,Cell line enhanced,,HaCaT: 1.1
ACER1,ASAH3,ENSG00000167769,Alkaline ceramidase 1,19,6306142-6333629,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Group enriched,Tissue enriched,6,skin: 67.8,esophagus: 11.4,Cell line enhanced,,T-47d: 2.7
ACER2,"ALKCDase2, ASAH3L, FLJ41587",ENSG00000177076,Alkaline ceramidase 2,9,19409059-19452020,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,5,placenta: 14.8;stomach: 62.9;urinary bladder: 44.1,skin: 7.6,Group enriched,5,BEWO: 30.0;RT4: 62.6
ACHE,YT,ENSG00000087085,Acetylcholinesterase (Cartwright blood group),7,100889994-100896974,"Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA019704, HPA027098",,,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable)",Mixed,Tissue enhanced,,skeletal muscle: 58.5,cerebral cortex: 14.1,Cell line enhanced,,BEWO: 11.7;CACO-2: 17.5;K-562: 20.7;Karpas-707: 25.8
ACLY,"ACL, ATPCL, CLATP",ENSG00000131473,ATP citrate lyase,17,41866908-41930542,"Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB007783, HPA022434, HPA022953, HPA022959, HPA028758",Enhanced,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Cervical cancer:1.79e-4 (unfavourable), Liver cancer:3.66e-4 (unfavourable)",Expressed in all,Expressed in all,,,prostate: 100.5,Expressed in all,,
ACMSD,,ENSG00000153086,Aminocarboxymuconate semialdehyde decarboxylase,2,134838547-134902034,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA010533, HPA011179",Enhanced,,,,Renal cancer:2.39e-4 (favourable),Group enriched,Group enriched,10,kidney: 137.3;liver: 80.2,gallbladder: 10.8,Cell line enriched,16,RPTEC TERT1: 19.7
ACO1,"IREB1, IREBP, IRP1",ENSG00000122729,Aconitase 1,9,32384603-32454769,"Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019371, HPA024157",Enhanced,,Supported,Mitochondria<br>Cytosol,Renal cancer:5.73e-5 (favourable),Expressed in all,Expressed in all,,,adipose tissue: 105.1,Expressed in all,,
ACO2,ACONM,ENSG00000100412,Aconitase 2,22,41469125-41528989,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA001097,Enhanced,Supported,Supported,Mitochondria,Renal cancer:0.00e+0 (favourable),Expressed in all,Expressed in all,,,heart muscle: 308.9,Expressed in all,,
ACOD1,"CAD, IRG1",ENSG00000102794,Aconitate decarboxylase 1,13,76948497-76958642,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040143,Uncertain,,,,,Not detected,Tissue enriched,5,appendix: 1.9,lung: 0.3,Not detected,,
ACOT1,"ACH2, CTE-1, LACH2",ENSG00000184227,Acyl-CoA thioesterase 1,14,73537114-73543794,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043705,Approved,,Approved,Mitochondria,Renal cancer:5.09e-8 (favourable),Expressed in all,Mixed,,,smooth muscle: 29.4,Cell line enhanced,,T-47d: 35.8
ACOT12,"Cach, STARD15, THEAL",ENSG00000172497,Acyl-CoA thioesterase 12,5,81330005-81394179,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA037723, HPA037724",,,Approved,Nucleoplasm<br>Cytosol,Liver cancer:5.30e-4 (favourable),Tissue enriched,Tissue enriched,19,liver: 51.3,kidney: 2.7,Not detected,,
ACOT2,"Mte1, ZAP128",ENSG00000119673,Acyl-CoA thioesterase 2,14,73567620-73575658,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043705, HPA060170",Enhanced,,Approved,Mitochondria,Renal cancer:2.28e-6 (favourable),Expressed in all,Expressed in all,,,adipose tissue: 96.5,Mixed,,
ACOT4,"FLJ31235, PTE-Ib, PTE2B",ENSG00000177465,Acyl-CoA thioesterase 4,14,73591706-73596496,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000779,Enhanced,,,,"Renal cancer:8.43e-5 (favourable), Pancreatic cancer:1.77e-4 (unfavourable)",Expressed in all,Tissue enhanced,,kidney: 8.9,liver: 4.9,Cell line enhanced,,CAPAN-2: 9.1;SK-BR-3: 12.3;T-47d: 38.6
ACOT7,"ACH1, ACT, BACH, CTE-II, hBACH, LACH1, MGC1126",ENSG00000097021,Acyl-CoA thioesterase 7,1,6264269-6394391,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA025735, HPA025762",Enhanced,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:2.55e-6 (unfavourable), Liver cancer:2.31e-5 (unfavourable), Lung cancer:1.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 129.2,small intestine: 62.3,Expressed in all,,
ACOT8,"hACTE-III, hTE, NAP1, PTE-2, PTE1",ENSG00000101473,Acyl-CoA thioesterase 8,20,45841721-45857406,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB010261,Approved,,Supported,Vesicles<br>Mitochondria,Renal cancer:3.18e-4 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 30.1,Expressed in all,,
ACOX1,PALMCOX,ENSG00000161533,Acyl-CoA oxidase 1,17,75941507-75979363,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB021094, HPA021192, HPA021195, HPA028759",Approved,,Enhanced,Nucleus<br>Vesicles,Renal cancer:5.25e-7 (favourable),Expressed in all,Expressed in all,,,liver: 98.4,Expressed in all,,
ACOX2,"BRCACOX, BRCOX, THCCox",ENSG00000168306,Acyl-CoA oxidase 2,3,58505136-58537319,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038280, HPA064845",Enhanced,,Supported,Vesicles<br>Cytosol,,Tissue enhanced,Tissue enhanced,,liver: 87.9,kidney: 42.5,Cell line enhanced,,ASC diff: 10.4;ASC TERT1: 17.4;fHDF/TERT166: 6.6;Hep G2: 7.0;HSkMC: 11.8
ACOX3,,ENSG00000087008,"Acyl-CoA oxidase 3, pristanoyl",4,8366282-8440723,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035840, HPA035841",Uncertain,,Approved,Peroxisomes,Endometrial cancer:2.16e-4 (favourable),Expressed in all,Expressed in all,,,esophagus: 22.2,Expressed in all,,
ACP1,"HAAP, LMW-PTP, LMWPTP",ENSG00000143727,"Acid phosphatase 1, soluble",2,264140-278283,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA016754,Approved,,Approved,Nucleus<br>Cytosol,"Liver cancer:6.67e-6 (unfavourable), Melanoma:3.04e-4 (unfavourable)",Expressed in all,Expressed in all,,,adrenal gland: 128.8,Expressed in all,,
ACP2,LAP,ENSG00000134575,"Acid phosphatase 2, lysosomal",11,47239302-47248906,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Endometrial cancer:1.04e-4 (favourable),Expressed in all,Expressed in all,,,duodenum: 41.2,Expressed in all,,
ACP5,"HPAP, TRAP",ENSG00000102575,"Acid phosphatase 5, tartrate resistant",19,11574660-11579008,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB002584, HPA057655, HPA059463",Enhanced,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,lung: 254.0,lymph node: 86.3,Cell line enhanced,,BEWO: 36.2;SK-MEL-30: 85.3;U-138 MG: 97.5
ACP6,"ACPL1, LPAP",ENSG00000162836,"Acid phosphatase 6, lysophosphatidic",1,147629652-147670496,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA028560,Uncertain,,,,Urothelial cancer:6.44e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 27.1,Cell line enhanced,,RPTEC TERT1: 90.7
ACP7,"FLJ16165, PAPL, PAPL1",ENSG00000183760,"Acid phosphatase 7, tartrate resistant (putative)",19,39083913-39111493,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA042005, HPA042613",Uncertain,,,,,Group enriched,Group enriched,6,cerebral cortex: 1.8;skin: 6.9;tonsil: 2.3,"epididymis,prostate: 0.5",Cell line enhanced,,hTEC/SVTERT24-B: 9.3;U-87 MG: 43.5
ACPP,"ACP-3, ACP3, PAP",ENSG00000014257,"Acid phosphatase, prostate",3,132317367-132368298,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000071, HPA004335, HPA063916",Enhanced,,,,,Tissue enriched,Tissue enriched,145,prostate: 6030.6,esophagus: 41.4,Cell line enhanced,,BJ hTERT+: 14.1;RPMI-8226: 39.1;U-87 MG: 14.6
ACPT,,ENSG00000142513,"Acid phosphatase, testicular",19,50790415-50795224,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 1.4;testis: 2.2,parathyroid gland: 0.5,Cell line enhanced,,HEK 293: 1.3;U-266/84: 1.3
ACR,,ENSG00000100312,Acrosin,22,50738196-50745334,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA048687,Enhanced,,,,,Not detected,Tissue enriched,57,testis: 58.0,spleen: 1.0,Not detected,,
ACSBG1,"BG1, BGM, FLJ30320, hBG1, hsBG, KIAA0631, MGC14352",ENSG00000103740,Acyl-CoA synthetase bubblegum family member 1,15,78167468-78245688,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041642, CAB045955, HPA058869",Approved,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 25.6;skin: 13.3,adrenal gland: 8.1,Cell line enhanced,,NTERA-2: 3.3
ACSBG2,"BGR, DKFZp434K1635, PRTD-NY3",ENSG00000130377,Acyl-CoA synthetase bubblegum family member 2,19,6135247-6193094,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043421, HPA051013",Enhanced,,Uncertain,Cytosol,,Not detected,Tissue enriched,716,testis: 294.0,cerebral cortex: 0.4,Not detected,,
ACSL1,"ACS1, FACL1, FACL2, LACS, LACS1, LACS2",ENSG00000151726,Acyl-CoA synthetase long-chain family member 1,4,184755595-184826818,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA011316, HPA011964",Enhanced,,Supported,Nucleus<br>Mitochondria,Renal cancer:1.25e-5 (favourable),Expressed in all,Expressed in all,,,adipose tissue: 824.0,Expressed in all,,
ACSL3,"ACS3, FACL3, PRO2194",ENSG00000123983,Acyl-CoA synthetase long-chain family member 3,2,222860934-222944639,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA011315, HPA071021",Uncertain,,Approved,Nucleoli<br>Lipid droplets,"Liver cancer:2.75e-4 (unfavourable), Lung cancer:8.78e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 682.1,Expressed in all,,
ACSL4,"ACS4, FACL4, LACS4, MRX63, MRX68",ENSG00000068366,Acyl-CoA synthetase long-chain family member 4,X,109624244-109733403,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000286, HPA005552",Enhanced,,Approved,Golgi apparatus<br>Mitochondria,Urothelial cancer:5.73e-4 (favourable),Expressed in all,Expressed in all,,,"cervix, uterine: 70.7",Cell line enhanced,,HMC-1: 324.7
ACSL5,"ACS2, ACS5, FACL5",ENSG00000197142,Acyl-CoA synthetase long-chain family member 5,10,112374018-112428380,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA007162, CAB035986, CAB062546",Enhanced,,Supported,Nucleus<br>Mitochondria,Endometrial cancer:1.13e-4 (favourable),Expressed in all,Expressed in all,,,small intestine: 460.3,Cell line enhanced,,CAPAN-2: 121.7;RT4: 114.0
ACSL6,"ACS2, FACL6, KIAA0837, LACS2, LACS5",ENSG00000164398,Acyl-CoA synthetase long-chain family member 6,5,131949973-132012243,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040470,Enhanced,,,,,Group enriched,Group enriched,6,bone marrow: 18.0;cerebral cortex: 61.9;parathyroid gland: 22.5;seminal vesicle: 29.0;testis: 51.4,adrenal gland: 6.4,Group enriched,6,SCLC-21H: 13.0;U-937: 5.2
ACSM1,"BUCS1, MACS1",ENSG00000166743,Acyl-CoA synthetase medium-chain family member 1,16,20623237-20698890,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046291,Uncertain,,,,,Group enriched,Tissue enriched,49,breast: 298.7,prostate: 6.0,Group enriched,11,K-562: 3.2;NTERA-2: 15.6
ACSM2A,"A-923A4.1, ACSM2, MGC150530",ENSG00000183747,Acyl-CoA synthetase medium-chain family member 2A,16,20451461-20487667,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057699,Supported,,,,Liver cancer:1.41e-5 (favourable),Group enriched,Group enriched,580,kidney: 285.2;liver: 185.7,cerebral cortex: 0.4,Cell line enhanced,,Hep G2: 1.3
ACSM2B,"ACSM2, HXMA, HYST1046",ENSG00000066813,Acyl-CoA synthetase medium-chain family member 2B,16,20536226-20576427,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057699,Supported,,,,Liver cancer:3.31e-4 (favourable),Group enriched,Group enriched,136,kidney: 426.7;liver: 262.0,thyroid gland: 2.5,Cell line enhanced,,AF22: 2.8;Hep G2: 3.7
ACSM3,"SA, SAH",ENSG00000005187,Acyl-CoA synthetase medium-chain family member 3,16,20610243-20797581,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041013,Uncertain,,,,"Renal cancer:9.88e-6 (favourable), Ovarian cancer:1.97e-4 (favourable)",Mixed,Tissue enhanced,,liver: 93.2,kidney: 90.8,Group enriched,12,HEL: 85.7;HMC-1: 339.4;K-562: 258.6
ACSM4,,ENSG00000215009,Acyl-CoA synthetase medium-chain family member 4,12,7304284-7328724,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA049895,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 1.7,spleen: 0.7,Cell line enhanced,,HDLM-2: 1.6;NB-4: 1.1;SH-SY5Y: 2.2;U-87 MG: 2.8
ACSM5,FLJ20581,ENSG00000183549,Acyl-CoA synthetase medium-chain family member 5,16,20409534-20441336,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041435,Uncertain,,,,,Group enriched,Tissue enriched,5,liver: 142.6,adipose tissue: 26.9,Group enriched,5,ASC diff: 3.6;ASC TERT1: 8.0;HSkMC: 10.0;U-87 MG: 8.4
ACSM6,"bA310E22.3, C10orf129",ENSG00000173124,Acyl-CoA synthetase medium-chain family member 6,10,95194200-95228928,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA044593,Uncertain,,,,Urothelial cancer:7.71e-4 (favourable),Tissue enriched,Tissue enhanced,,stomach: 1.7,urinary bladder: 0.6,Cell line enriched,27,RT4: 3.0
ACSS1,"ACAS2L, AceCS2L, dJ568C11.3, MGC33843",ENSG00000154930,Acyl-CoA synthetase short-chain family member 1,20,25006230-25058980,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041014, HPA043228",Enhanced,,,,"Lung cancer:8.33e-5 (favourable), Cervical cancer:9.37e-4 (favourable)",Expressed in all,Expressed in all,,,placenta: 166.2,Cell line enhanced,,RPMI-8226: 51.0
ACSS2,"ACAS2, AceCS, ACS, ACSA, dJ1161H23.1",ENSG00000131069,Acyl-CoA synthetase short-chain family member 2,20,34872146-34927962,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA004141,Approved,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:2.04e-4 (favourable),Expressed in all,Mixed,,,adipose tissue: 55.9,Mixed,,
ACSS3,FLJ21963,ENSG00000111058,Acyl-CoA synthetase short-chain family member 3,12,80936414-81261205,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA039353, HPA047956, HPA061517",Approved,,Approved,Mitochondria,Renal cancer:0.00e+0 (favourable),Mixed,Mixed,,,parathyroid gland: 33.7,Cell line enhanced,,Hep G2: 28.4;RH-30: 18.1;SK-BR-3: 13.2
ACVR1,"ACVR1A, ACVRLK2, ALK2, SKR1",ENSG00000115170,Activin A receptor type 1,2,157736444-157875862,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007505, HPA046514",Approved,,Approved,Nucleoli<br>Cytosol,Urothelial cancer:5.17e-4 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 74.2,Mixed,,
ACVR1B,"ActRIB, ACVRLK4, ALK4, SKR2",ENSG00000135503,Activin A receptor type 1B,12,51951667-51997078,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB026126, HPA063761",Approved,,Enhanced,Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 54.6,Expressed in all,,
ACVR1C,"ACVRLK7, ALK7",ENSG00000123612,Activin A receptor type 1C,2,157526767-157629005,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007982, HPA011933",Approved,,,,,Mixed,Tissue enriched,8,adipose tissue: 34.1,ovary: 4.3,Cell line enhanced,,ASC diff: 7.5;HDLM-2: 4.8
ACVR2A,"ACTRII, ACVR2",ENSG00000121989,Activin A receptor type 2A,2,147844517-147930826,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,HPA046997,Approved,,Approved,Cytosol,Renal cancer:1.62e-4 (favourable),Expressed in all,Mixed,,,skin: 22.5,Mixed,,
ACVR2B,ActR-IIB,ENSG00000114739,Activin A receptor type 2B,3,38453851-38493142,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA007398, CAB025115, HPA040384",Approved,,Approved,Nucleus<br>Nuclear bodies<br>Cytosol,,Expressed in all,Mixed,,,parathyroid gland: 6.4,Cell line enhanced,,AF22: 20.5;NTERA-2: 25.8
ACVRL1,"ACVRLK1, ALK1, HHT, HHT2, ORW2",ENSG00000139567,Activin A receptor like type 1,12,51906908-51923361,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA007041,Approved,,,,,Expressed in all,Tissue enhanced,,placenta: 126.4,lung: 76.4,Cell line enhanced,,ASC diff: 42.2;EFO-21: 52.0;HUVEC TERT2: 171.4;TIME: 130.8
ACY1,,ENSG00000243989,Aminoacylase 1,3,51983278-51989202,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003695, HPA036174, HPA036175",Enhanced,,,,"Renal cancer:2.93e-4 (favourable), Urothelial cancer:6.77e-4 (favourable)",Expressed in all,Group enriched,5,duodenum: 130.8;kidney: 356.0;liver: 114.9;small intestine: 103.3,parathyroid gland: 35.0,Mixed,,
ACY3,"ACY-3, HCBP1, MGC9740",ENSG00000132744,Aminoacylase 3,11,67642555-67650659,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039219, HPA048187",Enhanced,,,,Endometrial cancer:4.80e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 80.6;kidney: 53.3;small intestine: 78.6,"cervix, uterine: 16.1",Cell line enhanced,,CACO-2: 8.4;CAPAN-2: 13.6;Daudi: 41.2
ACYP1,,ENSG00000119640,Acylphosphatase 1,14,75053221-75069483,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA034944,Approved,,Approved,Nucleus<br>Cytosol,"Liver cancer:6.14e-7 (unfavourable), Breast cancer:1.17e-4 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 46.4,Expressed in all,,
ACYP2,,ENSG00000170634,Acylphosphatase 2,2,53970838-54305300,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA035301,Uncertain,,Approved,Nucleoplasm,,Expressed in all,Expressed in all,,,skeletal muscle: 73.7,Expressed in all,,
ADA,,ENSG00000196839,Adenosine deaminase,20,44619522-44652233,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001399, CAB004307, HPA023884",Enhanced,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:2.94e-14 (unfavourable), Endometrial cancer:1.23e-7 (unfavourable), Liver cancer:6.77e-5 (unfavourable), Lung cancer:2.20e-4 (unfavourable)",Expressed in all,Tissue enriched,13,duodenum: 487.7,lymph node: 36.5,Cell line enriched,9,MOLT-4: 1479.5
ADAM10,"CD156c, HsT18717, kuz, MADM",ENSG00000137845,ADAM metallopeptidase domain 10,15,58588807-58749978,"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB001709, HPA050670",Approved,,Supported,Vesicles<br>Plasma membrane,"Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 47.9,Expressed in all,,
ADAM17,"CD156B, cSVP, TACE",ENSG00000151694,ADAM metallopeptidase domain 17,2,9488486-9555792,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA010738, CAB025906, HPA051575",Approved,,Supported,Cytosol,Urothelial cancer:4.23e-5 (unfavourable),Expressed in all,Expressed in all,,,placenta: 33.8,Expressed in all,,
ADAMTS13,"C9orf8, DKFZp434C2322, FLJ42993, MGC118899, MGC118900, TTP, vWF-CP, VWFCP",ENSG00000160323,ADAM metallopeptidase with thrombospondin type 1 motif 13,9,133414358-133459402,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA042014, HPA042844",Uncertain,,,,,Mixed,Mixed,,,liver: 6.2,Mixed,,
ADAMTS2,"ADAM-TS2, ADAMTS-3, hPCPNI, NPI, PCINP",ENSG00000087116,ADAM metallopeptidase with thrombospondin type 1 motif 2,5,179110851-179345430,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA028444,Uncertain,,Approved,Vesicles<br>Plasma membrane,Renal cancer:1.71e-8 (unfavourable),Expressed in all,Mixed,,,placenta: 14.7,Cell line enhanced,,HHSteC: 100.5;HSkMC: 69.6
ADAMTS4,"ADAMTS-2, ADMP-1, KIAA0688",ENSG00000158859,ADAM metallopeptidase with thrombospondin type 1 motif 4,1,161184308-161199056,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB025876, HPA051296, HPA068374",Uncertain,,Approved,Nuclear speckles,"Renal cancer:7.27e-7 (unfavourable), Lung cancer:5.00e-4 (unfavourable)",Expressed in all,Tissue enhanced,,adipose tissue: 62.8,appendix: 22.9,Cell line enhanced,,hTEC/SVTERT24-B: 11.8;HUVEC TERT2: 12.0;SH-SY5Y: 8.4;TIME: 9.9;U-251 MG: 9.0
ADAR,"ADAR1, G1P1, IFI4",ENSG00000160710,"Adenosine deaminase, RNA specific",1,154582062-154627999,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA003890, HPA051519, CAB056157",Enhanced,,Enhanced,Nucleus<br>Nucleoli,Renal cancer:7.30e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 121.4,Expressed in all,,
ADARB1,"ADAR2, ADAR2a, ADAR2a-L1, ADAR2a-L2, ADAR2a-L3, ADAR2b, ADAR2c, ADAR2d, ADAR2g, DRABA2, DRADA2, hRED1, RED1",ENSG00000197381,"Adenosine deaminase, RNA specific B1",21,45073853-45226560,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA029645,,,Supported,Nucleoplasm<br>Cytosol,"Colorectal cancer:8.16e-5 (unfavourable), Renal cancer:3.56e-4 (unfavourable)",Expressed in all,Expressed in all,,,lung: 30.2,Cell line enhanced,,HHSteC: 55.4
ADAT1,,ENSG00000065457,"Adenosine deaminase, tRNA specific 1",16,75596981-75623300,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040713, HPA040903",Approved,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,parathyroid gland: 91.2,Expressed in all,,
ADCK1,FLJ39600,ENSG00000063761,AarF domain containing kinase 1,14,77800083-77935012,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA051012, HPA055014",Uncertain,,Approved,Nucleoplasm,"Renal cancer:5.82e-6 (favourable), Lung cancer:4.11e-5 (favourable), Liver cancer:1.70e-4 (unfavourable)",Expressed in all,Mixed,,,cerebral cortex: 9.0,Mixed,,
ADCK2,MGC20727,ENSG00000133597,AarF domain containing kinase 2,7,140673153-140696261,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA036036,Approved,,Uncertain,Centrosome<br>Cytosol,Renal cancer:9.75e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 27.2,Mixed,,
ADCK5,FLJ35454,ENSG00000173137,AarF domain containing kinase 5,8,144373101-144393242,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA025692, HPA028679",Approved,,Approved,Plasma membrane<br>Cytosol,,Expressed in all,Mixed,,,duodenum: 9.6,Mixed,,
ADCY1,"AC1, DFNB44",ENSG00000164742,Adenylate cyclase 1,7,45574140-45723116,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB018364, HPA068274",Uncertain,,Approved,Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 35.0,"cervix, uterine: 8.2",Cell line enhanced,,hTERT-HME1: 17.5;SCLC-21H: 16.1;SH-SY5Y: 27.5;SK-MEL-30: 23.8;WM-115: 17.1
ADCY10,"HCA2, RP1-313L4.2, SAC, SACI, Sacy",ENSG00000143199,"Adenylate cyclase 10, soluble",1,167809388-167914215,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015243, HPA017749",Approved,,,,,Tissue enhanced,Tissue enriched,11,testis: 33.1,liver: 3.1,Cell line enhanced,,T-47d: 1.3
ADCY2,"AC2, HBAC2, KIAA1060",ENSG00000078295,Adenylate cyclase 2,5,7396208-7830081,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB031482, HPA038015, HPA038483",Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 57.2;skeletal muscle: 23.6,prostate: 8.4,Group enriched,7,AF22: 5.6;NTERA-2: 4.3;SK-MEL-30: 3.8
ADCY3,AC3,ENSG00000138031,Adenylate cyclase 3,2,24819169-24919839,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB010223,Approved,,,,Renal cancer:1.32e-9 (unfavourable),Expressed in all,Expressed in all,,,placenta: 122.5,Expressed in all,,
ADCY4,AC4,ENSG00000129467,Adenylate cyclase 4,14,24318349-24335093,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB005070, HPA048344",Approved,,,,"Renal cancer:7.01e-4 (unfavourable), Endometrial cancer:8.20e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 21.1,lung: 11.6,Group enriched,6,HUVEC TERT2: 7.8;TIME: 3.1
ADCY5,AC5,ENSG00000173175,Adenylate cyclase 5,3,123282296-123449758,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA017730, HPA077682",Uncertain,,Enhanced,Intermediate filaments,Renal cancer:7.46e-6 (favourable),Mixed,Tissue enhanced,,heart muscle: 69.1,"prostate,seminal vesicle: 30.0",Cell line enhanced,,MCF7: 11.9;RPTEC TERT1: 4.0
ADCY6,AC6,ENSG00000174233,Adenylate cyclase 6,12,48766194-48789037,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB018365,Approved,,Approved,Golgi apparatus,Liver cancer:8.23e-4 (unfavourable),Expressed in all,Mixed,,,adipose tissue: 44.6,Mixed,,
ADCY7,"AC7, KIAA0037",ENSG00000121281,Adenylate cyclase 7,16,50246137-50318135,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041218, HPA048241",Uncertain,,Approved,Cytosol,Cervical cancer:5.31e-4 (unfavourable),Mixed,Mixed,,,spleen: 44.0,Cell line enhanced,,HMC-1: 186.7;RPMI-8226: 76.6
ADCY8,"AC8, ADCY3, HBAC1",ENSG00000155897,Adenylate cyclase 8,8,130780301-131042426,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB018652, HPA024291",Supported,,,,,Group enriched,Group enriched,8,cerebral cortex: 12.9;epididymis: 27.8;fallopian tube: 6.2,seminal vesicle: 2.0,Group enriched,7,U-138 MG: 17.5;U-87 MG: 33.7
ADCY9,AC9,ENSG00000162104,Adenylate cyclase 9,16,3953387-4116185,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041328, HPA044225",Approved,,Approved,Cytosol,"Renal cancer:5.24e-8 (favourable), Endometrial cancer:2.55e-5 (unfavourable)",Expressed in all,Mixed,,,thyroid gland: 31.9,Mixed,,
ADGB,"C6orf103, CAPN16, dJ408K24.1, FLJ23121",ENSG00000118492,Androglobin,6,146598965-146815462,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036340, HPA036341",Enhanced,,Uncertain,Nucleoplasm<br>Mitochondria,,Not detected,Group enriched,25,fallopian tube: 14.9;testis: 58.5,lung: 1.4,Cell line enriched,25,HDLM-2: 13.3
ADH1A,ADH1,ENSG00000187758,"Alcohol dehydrogenase 1A (class I), alpha polypeptide",4,99276367-99291028,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009562, HPA047814, HPA060902",Enhanced,,Approved,Plasma membrane<br>Cytosol,Liver cancer:2.38e-4 (favourable),Tissue enriched,Tissue enriched,135,liver: 1367.7,gallbladder: 10.1,Cell line enhanced,,ASC diff: 3.7
ADH1B,ADH2,ENSG00000196616,"Alcohol dehydrogenase 1B (class I), beta polypeptide",4,99304964-99352760,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA047814, HPA060902",Supported,,Approved,Plasma membrane<br>Cytosol,Renal cancer:7.87e-4 (unfavourable),Tissue enriched,Group enriched,6,adipose tissue: 1624.6;liver: 3000.2,lung: 388.5,Cell line enriched,7,ASC diff: 4511.9
ADH1C,ADH3,ENSG00000248144,"Alcohol dehydrogenase 1C (class I), gamma polypeptide",4,99336492-99353027,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA047814, HPA060902",Supported,,Supported,Plasma membrane<br>Cytosol,"Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable)",Tissue enriched,Tissue enhanced,,duodenum: 508.1;liver: 888.0;stomach: 477.4,colon: 276.3,Cell line enhanced,,ASC TERT1: 2.5;HSkMC: 7.7
ADH4,ADH-2,ENSG00000198099,"Alcohol dehydrogenase 4 (class II), pi polypeptide",4,99123657-99157792,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA020525,Enhanced,,Uncertain,Nucleus<br>Cytosol,Liver cancer:7.08e-6 (favourable),Tissue enriched,Tissue enriched,16,liver: 2628.5,duodenum: 166.3,Cell line enriched,7,Hep G2: 15.2
ADH5,"ADH-3, ADHX, FDH, GSNOR",ENSG00000197894,"Alcohol dehydrogenase 5 (class III), chi polypeptide",4,99070978-99088801,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA044578, HPA061919",Approved,,,,"Renal cancer:4.58e-10 (favourable), Endometrial cancer:9.90e-5 (favourable), Melanoma:3.54e-4 (unfavourable)",Expressed in all,Expressed in all,,,endometrium: 198.2,Expressed in all,,
ADH6,ADH-5,ENSG00000172955,Alcohol dehydrogenase 6 (class V),4,99202638-99219537,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA067946, HPA069081",Enhanced,,,,,Tissue enriched,Tissue enriched,7,liver: 359.6,kidney: 53.5,Group enriched,8,Hep G2: 30.3;RPTEC TERT1: 6.8
ADH7,ADH-4,ENSG00000196344,"Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide",4,99412261-99435737,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039695,Enhanced,,Supported,Plasma membrane<br>Cytosol,,Group enriched,Tissue enriched,6,esophagus: 215.5,tonsil: 34.5,Cell line enhanced,,HaCaT: 1.0
ADHFE1,"ADHFe1, FLJ32430",ENSG00000147576,"Alcohol dehydrogenase, iron containing 1",8,66430185-66471601,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023062,Enhanced,,Approved,Vesicles,"Renal cancer:4.55e-5 (favourable), Breast cancer:5.76e-5 (favourable), Liver cancer:9.90e-5 (favourable)",Mixed,Mixed,,,liver: 14.3,Cell line enhanced,,ASC diff: 1.1;RPTEC TERT1: 1.2
ADI1,"APL1, ARD, FLJ10913, HMFT1638, MTCBP-1, mtnD, SIPL",ENSG00000182551,Acireductone dioxygenase 1,2,3497361-3519736,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA035403, HPA035404",Approved,,Supported,Nucleoplasm<br>Golgi apparatus,,Expressed in all,Expressed in all,,,liver: 228.3,Expressed in all,,
ADK,AK,ENSG00000156110,Adenosine kinase,10,74151185-74709303,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB032876, HPA038391, HPA038409",Approved,,Supported,Nucleoplasm<br>Cytosol,"Head and neck cancer:1.93e-4 (unfavourable), Liver cancer:9.91e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 77.6,Expressed in all,,
ADO,"C10orf22, FLJ14547",ENSG00000181915,2-aminoethanethiol dioxygenase,10,62804857-62808483,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039194, HPA040437",Approved,,,,Liver cancer:8.01e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 70.7,Expressed in all,,
ADPGK,"ADP-GK, DKFZp434B195",ENSG00000159322,ADP dependent glucokinase,15,72751369-72785846,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA045194, HPA058525",Approved,,Approved,Centrosome,"Renal cancer:4.52e-7 (unfavourable), Prostate cancer:2.22e-4 (unfavourable)",Expressed in all,Mixed,,,lung: 25.1,Expressed in all,,
ADPRH,ARH1,ENSG00000144843,ADP-ribosylarginine hydrolase,3,119579268-119589945,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB001701, HPA036961",Approved,,Approved,Nucleus<br>Nuclear membrane,Breast cancer:2.42e-4 (favourable),Expressed in all,Mixed,,,lung: 20.1,Cell line enhanced,,HDLM-2: 22.2;HMC-1: 16.3;Karpas-707: 18.2;U-266/70: 18.7
ADPRHL2,"ARH3, FLJ20446",ENSG00000116863,ADP-ribosylhydrolase like 2,1,36088875-36093932,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA027104, HPA027141",Approved,,Enhanced,Nucleoplasm,"Liver cancer:2.10e-7 (unfavourable), Renal cancer:3.71e-4 (unfavourable)",Expressed in all,Expressed in all,,,fallopian tube: 41.1,Expressed in all,,
ADPRM,"C17orf48, MDS006",ENSG00000170222,"ADP-ribose/CDP-alcohol diphosphatase, manganese dependent",17,10697594-10711233,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA023265, HPA023820",Approved,,,,"Endometrial cancer:2.38e-5 (favourable), Cervical cancer:1.69e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 16.0,Expressed in all,,
ADSL,,ENSG00000239900,Adenylosuccinate lyase,22,40346500-40390463,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000525, CAB019285",Enhanced,,Enhanced,Cytosol,"Liver cancer:5.81e-8 (unfavourable), Colorectal cancer:2.38e-4 (favourable)",Expressed in all,Expressed in all,,,skeletal muscle: 127.3,Expressed in all,,
ADSS,,ENSG00000035687,Adenylosuccinate synthase,1,244408494-244452134,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA024400,Enhanced,,Supported,Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 117.0,Expressed in all,,
ADSSL1,FLJ38602,ENSG00000185100,Adenylosuccinate synthase like 1,14,104724186-104747325,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,Renal cancer:4.99e-4 (unfavourable),Mixed,Tissue enriched,7,skeletal muscle: 428.0,heart muscle: 63.0,Cell line enhanced,,EFO-21: 13.7;MCF7: 10.4;SiHa: 23.7
AEBP1,ACLP,ENSG00000106624,AE binding protein 1,7,44104361-44114562,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB009966, HPA047724, HPA063595, HPA064970",Enhanced,,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,"Renal cancer:9.31e-9 (unfavourable), Glioma:1.10e-4 (unfavourable)",Expressed in all,Expressed in all,,,seminal vesicle: 300.4,Cell line enhanced,,BJ: 163.5;fHDF/TERT166: 162.3;WM-115: 116.5
AFG3L2,"SCA28, SPAX5",ENSG00000141385,AFG3 like matrix AAA peptidase subunit 2,18,12328944-12377314,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA004479, HPA004480",Enhanced,,Enhanced,Mitochondria,"Renal cancer:6.05e-14 (favourable), Endometrial cancer:8.68e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 123.6,Expressed in all,,
AFMID,"DKFZp686F03259, KF",ENSG00000183077,Arylformamidase,17,78187317-78207701,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA023861, HPA026536",Uncertain,,Approved,Mitochondria,,Expressed in all,Expressed in all,,,kidney: 87.5,Expressed in all,,
AGA,ASRG,ENSG00000038002,Aspartylglucosaminidase,4,177430770-177442503,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA031415, HPA031417",Enhanced,,,,"Liver cancer:1.99e-4 (unfavourable), Head and neck cancer:8.61e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 35.3,Expressed in all,,
AGBL1,"CCP4, FLJ32310",ENSG00000273540,ATP/GTP binding protein like 1,15,86079973-87029052,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,lung: 1.3;skeletal muscle: 4.4,esophagus: 1.0,Not detected,,
AGBL2,"CCP2, FLJ23598",ENSG00000165923,ATP/GTP binding protein like 2,11,47659591-47715389,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007718,Uncertain,,,,,Mixed,Group enriched,7,fallopian tube: 15.3;testis: 22.6,epididymis: 2.8,Cell line enhanced,,CAPAN-2: 4.0
AGBL3,"CCP3, MGC32955",ENSG00000146856,ATP/GTP binding protein like 3,7,134986508-135147963,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA020397, HPA024150",Uncertain,,Uncertain,Nuclear speckles<br>Mitochondria<br>Cytosol,Renal cancer:4.02e-4 (unfavourable),Mixed,Mixed,,,epididymis: 9.6,Cell line enhanced,,HEK 293: 5.1
AGBL4,"CCP6, FLJ14442",ENSG00000186094,ATP/GTP binding protein like 4,1,48532855-50023913,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA037994,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 7.9,fallopian tube: 4.6,Cell line enhanced,,NTERA-2: 1.1;SCLC-21H: 1.9
AGBL5,"CCP5, FLJ21839",ENSG00000084693,ATP/GTP binding protein like 5,2,27042364-27070622,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA030981,Uncertain,,Supported,Microtubules<br>Cytokinetic bridge<br>Cytosol,Liver cancer:6.87e-5 (unfavourable),Expressed in all,Tissue enriched,7,testis: 357.5,parathyroid gland: 50.4,Expressed in all,,
AGK,"FLJ10842, MULK",ENSG00000006530,Acylglycerol kinase,7,141551189-141655244,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA020959, HPA053471",Supported,,Supported,Vesicles<br>Mitochondria,,Expressed in all,Expressed in all,,,parathyroid gland: 26.9,Expressed in all,,
AGL,,ENSG00000162688,"Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase",1,99850084-99924023,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA028498, HPA054340",Approved,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:1.73e-10 (favourable),Expressed in all,Tissue enhanced,,skeletal muscle: 90.3,parathyroid gland: 35.1,Mixed,,
AGMAT,FLJ23384,ENSG00000116771,Agmatinase,1,15572353-15585110,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026443, HPA028321",Enhanced,,,,Renal cancer:5.13e-4 (favourable),Group enriched,Tissue enhanced,,kidney: 158.9,liver: 36.6,Cell line enhanced,,CACO-2: 35.2;Hep G2: 70.8
AGMO,"FLJ16237, TMEM195",ENSG00000187546,Alkylglycerol monooxygenase,7,15200318-15562015,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057900,,,Uncertain,Vesicles,,Tissue enriched,Tissue enhanced,,liver: 63.7,epididymis: 17.6,Cell line enhanced,,Karpas-707: 5.6;SCLC-21H: 3.8;WM-115: 15.2
AGO2,"CASC7, EIF2C2, hAGO2, LINC00980, Q10",ENSG00000123908,"Argonaute 2, RISC catalytic component",8,140520156-140635619,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB019309, HPA058075",Approved,,Supported,Nucleoplasm<br>Cell Junctions,"Renal cancer:1.82e-5 (unfavourable), Endometrial cancer:1.21e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 12.0,Expressed in all,,
AGPAT1,LPAAT-alpha,ENSG00000204310,1-acylglycerol-3-phosphate O-acyltransferase 1,6,32168212-32178096,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA048478, HPA073355",Approved,,Supported,Endoplasmic reticulum<br>Rods & Rings,"Breast cancer:1.93e-4 (unfavourable), Endometrial cancer:5.21e-4 (unfavourable)",Expressed in all,Mixed,,,epididymis: 52.2,Mixed,,
AGPAT2,"BSCL, LPAAT-beta",ENSG00000169692,1-acylglycerol-3-phosphate O-acyltransferase 2,9,136673143-136687423,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA019544,Uncertain,,Approved,Centrosome,,Expressed in all,Expressed in all,,,adipose tissue: 300.1,Mixed,,
AGPAT3,LPAAT-gamma,ENSG00000160216,1-acylglycerol-3-phosphate O-acyltransferase 3,21,43865186-43986536,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,"Renal cancer:2.29e-4 (favourable), Cervical cancer:8.31e-4 (unfavourable)",Expressed in all,Expressed in all,,,small intestine: 57.5,Mixed,,
AGPAT4,"dJ473J16.2, LPAAT-delta",ENSG00000026652,1-acylglycerol-3-phosphate O-acyltransferase 4,6,161129979-161274061,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA053287, HPA060525",Approved,,Approved,Nucleoli<br>Golgi apparatus<br>Vesicles,"Cervical cancer:1.45e-4 (unfavourable), Renal cancer:4.08e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 24.7,placenta: 12.3,Cell line enhanced,,AF22: 25.4
AGPAT5,"FLJ11210, LPAAT-e, LPAAT-epsilon",ENSG00000155189,1-acylglycerol-3-phosphate O-acyltransferase 5,8,6708357-6759666,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA010644, HPA010950",Approved,,,,"Liver cancer:4.57e-4 (unfavourable), Colorectal cancer:8.82e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 46.9,Expressed in all,,
AGPS,"ADAP-S, ADAS, ADHAPS, ADPS, ALDHPSY",ENSG00000018510,Alkylglycerone phosphate synthase,2,177392644-177559299,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA030209, HPA030210, HPA030211",Supported,,Enhanced,Peroxisomes,"Liver cancer:8.62e-6 (unfavourable), Pancreatic cancer:8.35e-4 (unfavourable), Renal cancer:9.45e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 50.4,Mixed,,
AGTPBP1,"CCP1, KIAA1035, Nna1",ENSG00000135049,ATP/GTP binding protein 1,9,85546539-85742029,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA057208,Approved,,Approved,Nucleoli<br>Vesicles,,Expressed in all,Expressed in all,,,bone marrow: 39.2,Expressed in all,,
AGXT,"AGT, AGT1, AGXT1, PH1, SPAT, SPT",ENSG00000172482,Alanine-glyoxylate aminotransferase,2,240868479-240880502,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035370, HPA035371",Enhanced,,Supported,Vesicles,Liver cancer:5.92e-5 (favourable),Tissue enriched,Tissue enriched,58,liver: 611.6,kidney: 10.4,Cell line enhanced,,Hep G2: 5.6;SK-BR-3: 1.1
AGXT2,AGT2,ENSG00000113492,Alanine--glyoxylate aminotransferase 2,5,34998101-35048135,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037382,Enhanced,,,,Renal cancer:7.47e-4 (favourable),Group enriched,Group enriched,33,kidney: 197.9;liver: 59.3,small intestine: 3.9,Not detected,,
AHCY,SAHH,ENSG00000101444,Adenosylhomocysteinase,20,34280268-34311802,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA041225, HPA044675",Approved,,Supported,Cytosol,,Expressed in all,Expressed in all,,,kidney: 159.4,Expressed in all,,
AHCYL2,KIAA0828,ENSG00000158467,Adenosylhomocysteinase like 2,7,129225023-129430211,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA053128,Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:1.08e-7 (favourable), Head and neck cancer:4.17e-4 (favourable)",Expressed in all,Expressed in all,,,rectum: 194.5,Cell line enriched,9,HDLM-2: 218.4
AICDA,"AID, ARP2, CDA2, HIGM2",ENSG00000111732,Activation induced cytidine deaminase,12,8602166-8612871,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,11,appendix: 4.9;lymph node: 18.7;tonsil: 11.0,spleen: 1.0,Group enriched,5,Daudi: 101.6;U-698: 81.2
AK1,,ENSG00000106992,Adenylate kinase 1,9,127866480-127877743,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006456, CAB009893",Enhanced,,Supported,Cytosol,Stomach cancer:7.31e-4 (favourable),Expressed in all,Expressed in all,,,fallopian tube: 774.9,Mixed,,
AK2,,ENSG00000004455,Adenylate kinase 2,1,33007940-33080996,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA018479,Approved,,,,"Breast cancer:4.37e-4 (favourable), Pancreatic cancer:6.40e-4 (unfavourable), Endometrial cancer:8.65e-4 (unfavourable), Liver cancer:9.32e-4 (unfavourable)",Expressed in all,Expressed in all,,,kidney: 183.3,Expressed in all,,
AK3,"AK3L1, AK6, AKL3L1",ENSG00000147853,Adenylate kinase 3,9,4709559-4742043,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA063324,Enhanced,,Supported,Mitochondria,Renal cancer:6.07e-9 (favourable),Expressed in all,Expressed in all,,,kidney: 106.2,Expressed in all,,
AK4,"AK3, AK3L1",ENSG00000162433,Adenylate kinase 4,1,65147549-65232145,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA042753, HPA049461",Enhanced,,Supported,Mitochondria,"Pancreatic cancer:4.34e-5 (unfavourable), Cervical cancer:4.17e-4 (unfavourable), Renal cancer:4.36e-4 (unfavourable), Stomach cancer:4.87e-4 (unfavourable), Head and neck cancer:8.83e-4 (unfavourable)",Expressed in all,Tissue enhanced,,kidney: 190.7,liver: 53.7,Cell line enhanced,,Hep G2: 141.9
AK5,,ENSG00000154027,Adenylate kinase 5,1,77282051-77559969,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019128, HPA057255",Enhanced,,Supported,Microtubule organizing center<br>Cytosol,Prostate cancer:3.88e-4 (favourable),Group enriched,Tissue enriched,9,cerebral cortex: 220.7,breast: 23.6,Cell line enhanced,,ASC TERT1: 65.9;BJ: 57.0;fHDF/TERT166: 60.0;LHCN-M2: 159.8;U-2 OS: 61.3
AK6,CINAP,ENSG00000085231,Adenylate kinase 6,5,69350984-69370013,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB005361, HPA034935",Supported,,Supported,Nucleoplasm,Liver cancer:9.54e-4 (unfavourable),Expressed in all,Expressed in all,,,epididymis: 26.8,Expressed in all,,
AK7,FLJ32864,ENSG00000140057,Adenylate kinase 7,14,96392111-96489427,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003543,Enhanced,,,,"Renal cancer:1.14e-4 (favourable), Endometrial cancer:3.18e-4 (favourable)",Mixed,Tissue enhanced,,fallopian tube: 38.8,parathyroid gland: 14.9,Cell line enhanced,,BEWO: 16.6;CAPAN-2: 13.2;MCF7: 37.9;REH: 32.2
AK8,"C9orf98, FLJ32704",ENSG00000165695,Adenylate kinase 8,9,132725578-132878777,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021443, HPA021445, HPA023894",Enhanced,,,,Renal cancer:1.61e-4 (favourable),Mixed,Tissue enhanced,,epididymis: 16.0;fallopian tube: 30.0;testis: 21.7,thyroid gland: 5.8,Cell line enhanced,,MCF7: 1.8;RPTEC TERT1: 2.0;T-47d: 1.6
AK9,"AKD1, AKD2, C6orf199, C6orf224, dJ70A9.1, FLJ25791, FLJ42177, MGC26954",ENSG00000155085,Adenylate kinase 9,6,109492856-109691217,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030804, HPA030805, HPA031779, HPA031781, HPA036324, HPA036711",Enhanced,,Approved,Nucleoplasm<br>Nuclear membrane,,Mixed,Tissue enhanced,,testis: 31.2,parathyroid gland: 17.1,Expressed in all,,
AKR1A1,"ALR, DD3",ENSG00000117448,Aldo-keto reductase family 1 member A1,1,45550543-45570049,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB006246, HPA017919, HPA019649, HPA027734",Approved,,Supported,Nucleoplasm<br>Cytosol,"Cervical cancer:2.66e-6 (favourable), Endometrial cancer:2.92e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 380.4,Expressed in all,,
AKR1B1,"ALDR1, AR",ENSG00000085662,Aldo-keto reductase family 1 member B,7,134442350-134459284,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA026425, CAB027391, CAB047353, HPA052751",Enhanced,,Supported,Nucleus<br>Cytosol,"Stomach cancer:2.44e-5 (unfavourable), Urothelial cancer:7.00e-4 (unfavourable)",Expressed in all,Tissue enriched,6,adrenal gland: 2486.1,seminal vesicle: 449.2,Cell line enhanced,,A549: 1469.5;BJ hTERT+: 2394.4
AKR1B15,,ENSG00000227471,Aldo-keto reductase family 1 member B15,7,134549136-134579875,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA020280, HPA073633",Uncertain,,Supported,Plasma membrane<br>Cytosol,"Liver cancer:1.80e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Head and neck cancer:8.36e-4 (favourable)",Mixed,Tissue enriched,13,breast: 179.9,duodenum: 13.7,Group enriched,8,A549: 14.3;HDLM-2: 11.8;Hep G2: 7.6;NTERA-2: 3.2;SK-BR-3: 3.8;U-87 MG: 6.4
AKR1C1,"DD1, DDH, DDH1, HAKRC, MBAB",ENSG00000187134,Aldo-keto reductase family 1 member C1,10,4963253-4983283,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB047303, HPA068265",Uncertain,,Enhanced,Endoplasmic reticulum<br>Cytosol,"Renal cancer:8.03e-9 (favourable), Liver cancer:1.56e-4 (unfavourable), Cervical cancer:3.05e-4 (favourable)",Tissue enhanced,Expressed in all,,,liver: 322.2,Group enriched,7,ASC diff: 2051.8;Hep G2: 3675.4
AKR1C2,"BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD",ENSG00000151632,Aldo-keto reductase family 1 member C2,10,4987400-5018031,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB047304, HPA068265",Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol,,Group enriched,Group enriched,5,adipose tissue: 330.4;breast: 105.2;esophagus: 94.9;gallbladder: 151.9;liver: 161.4;stomach: 126.5;urinary bladder: 143.0,duodenum: 29.8,Cell line enhanced,,A549: 1864.0;ASC diff: 1674.9;Hep G2: 2661.0;RT4: 940.6
AKR1C3,"DDX, HAKRB, HSD17B5, KIAA0119, PGFS",ENSG00000196139,Aldo-keto reductase family 1 member C3,10,5035354-5107686,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB010874, HPA068265",Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol,"Renal cancer:1.22e-4 (unfavourable), Liver cancer:1.96e-4 (unfavourable)",Expressed in all,Expressed in all,,,duodenum: 398.6,Cell line enhanced,,A549: 1217.9;AN3-CA: 359.6;ASC diff: 507.5;Hep G2: 391.2;RT4: 424.5
AKR1C4,"3-alpha-HSD, C11, CDR, CHDR, DD4, HAKRA, MGC22581",ENSG00000198610,Aldo-keto reductase family 1 member C4,10,5195462-5218949,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA044720, HPA068265",Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol,,Tissue enriched,Tissue enriched,6,liver: 360.3,gallbladder: 64.2,Cell line enriched,8,HDLM-2: 6.1
AKR1D1,SRD5B1,ENSG00000122787,Aldo-keto reductase family 1 member D1,7,138002324-138117986,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA057002,Enhanced,,Approved,Nucleoplasm<br>Cytosol,Liver cancer:9.91e-5 (favourable),Tissue enriched,Tissue enriched,31,liver: 229.4,breast: 7.2,Cell line enriched,16,Hep G2: 8.6
AKR1E2,"AKR1CL2, AKRDC1, MGC10612",ENSG00000165568,Aldo-keto reductase family 1 member E2,10,4786629-4848062,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037821, HPA037822",Enhanced,,Enhanced,Nucleoplasm<br>Golgi apparatus,,Mixed,Tissue enriched,5,testis: 29.8,thyroid gland: 5.6,Cell line enhanced,,U-2197: 19.2
AKR7A2,AFAR,ENSG00000053371,Aldo-keto reductase family 7 member A2,1,19303965-19312146,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB032587, CAB032841, HPA064638",Enhanced,,Supported,Cytosol,"Renal cancer:2.67e-4 (favourable), Urothelial cancer:8.59e-4 (unfavourable)",Expressed in all,Expressed in all,,,duodenum: 81.9,Expressed in all,,
AKT1,"AKT, PKB, PRKBA, RAC",ENSG00000142208,AKT serine/threonine kinase 1,14,104769349-104795751,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA002891, CAB003765",Enhanced,,Supported,Nucleus<br>Microtubules,"Renal cancer:2.12e-4 (favourable), Ovarian cancer:4.83e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 106.4,Expressed in all,,
AKT2,,ENSG00000105221,AKT serine/threonine kinase 2,19,40230317-40285536,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004204, HPA064521",Uncertain,,Supported,Nucleus<br>Vesicles<br>Cytosol,"Endometrial cancer:1.05e-6 (unfavourable), Prostate cancer:4.74e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 170.1,Expressed in all,,
AKT3,"PKBG, PRKBG, RAC-gamma",ENSG00000117020,AKT serine/threonine kinase 3,1,243488233-243851079,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB013090, HPA026441",Approved,,Supported,Cytosol,Urothelial cancer:9.27e-4 (unfavourable),Expressed in all,Mixed,,,cerebral cortex: 51.6,Mixed,,
ALAD,"ALADH, PBGS",ENSG00000148218,Aminolevulinate dehydratase,9,113386317-113401333,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021023, HPA022124",Enhanced,,,,"Colorectal cancer:7.33e-5 (unfavourable), Liver cancer:8.80e-5 (favourable), Renal cancer:1.65e-4 (favourable), Endometrial cancer:5.64e-4 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 147.1,Expressed in all,,
ALAS1,"ALAS, ALAS3",ENSG00000023330,5'-aminolevulinate synthase 1,3,52198086-52214327,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017498, HPA035860",Enhanced,,Enhanced,Nucleoplasm<br>Mitochondria,"Renal cancer:6.06e-7 (favourable), Liver cancer:1.82e-5 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 761.4,Expressed in all,,
ALAS2,ASB,ENSG00000158578,5'-aminolevulinate synthase 2,X,55009055-55031064,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA001638,Approved,,,,,Mixed,Tissue enriched,7,bone marrow: 335.6,placenta: 51.0,Group enriched,173,HEL: 42.0;K-562: 61.5
ALDH18A1,"GSAS, P5CS, PYCS, SPG9",ENSG00000059573,Aldehyde dehydrogenase 18 family member A1,10,95605929-95656706,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA008333, HPA012604",Approved,,Enhanced,Mitochondria,"Renal cancer:3.60e-9 (unfavourable), Endometrial cancer:4.20e-4 (favourable)",Expressed in all,Expressed in all,,,duodenum: 89.5,Expressed in all,,
ALDH1A1,"ALDH1, PUMB1, RALDH1",ENSG00000165092,Aldehyde dehydrogenase 1 family member A1,9,72900662-73080442,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA002123, CAB020690",Approved,Approved,Enhanced,Cytosol,Cervical cancer:7.77e-5 (favourable),Expressed in all,Expressed in all,,,liver: 760.0,Cell line enhanced,,A549: 3635.1;Hep G2: 855.5;RPTEC TERT1: 528.6
ALDH1A2,RALDH2,ENSG00000128918,Aldehyde dehydrogenase 1 family member A2,15,57953424-58497866,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA010022,Approved,,,,,Mixed,Tissue enhanced,,endometrium: 118.1;fallopian tube: 108.9,testis: 96.9,Group enriched,6,AN3-CA: 352.0;HEK 293: 116.8;K-562: 305.3;MOLT-4: 330.5
ALDH1A3,"ALDH6, RALDH3",ENSG00000184254,Aldehyde dehydrogenase 1 family member A3,15,100877714-100916626,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA046271, HPA064749",Enhanced,,Enhanced,Nucleus<br>Cytosol,,Group enriched,Tissue enhanced,,prostate: 217.5,adipose tissue: 74.8,Cell line enhanced,,HaCaT: 383.6;HBEC3-KT: 772.3;U-2197: 565.6;U-87 MG: 467.6;WM-115: 498.3
ALDH1B1,"ALDH5, ALDHX",ENSG00000137124,Aldehyde dehydrogenase 1 family member B1,9,38392664-38398661,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021037,Approved,,Supported,Nucleoplasm<br>Vesicles<br>Mitochondria,"Thyroid cancer:1.17e-5 (unfavourable), Renal cancer:2.05e-4 (favourable)",Expressed in all,Expressed in all,,,smooth muscle: 178.4,Mixed,,
ALDH1L1,"10-fTHF, FTHFD",ENSG00000144908,Aldehyde dehydrogenase 1 family member L1,3,126103562-126197994,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036900, HPA050139",Enhanced,Supported,Supported,Cytosol,Renal cancer:2.42e-8 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 121.2;liver: 190.4,adipose tissue: 80.9,Cell line enhanced,,Hep G2: 54.9;Karpas-707: 57.9;RT4: 174.8
ALDH1L2,"FLJ38508, mtFDH",ENSG00000136010,Aldehyde dehydrogenase 1 family member L2,12,105019784-105084577,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039481, HPA059282",Uncertain,,Enhanced,Mitochondria,,Mixed,Mixed,,,"cervix, uterine: 8.4",Cell line enhanced,,ASC TERT1: 58.5;fHDF/TERT166: 77.9
ALDH2,,ENSG00000111275,Aldehyde dehydrogenase 2 family (mitochondrial),12,111766887-111817529,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051065,Approved,,,,"Liver cancer:3.95e-7 (favourable), Renal cancer:5.24e-6 (favourable), Endometrial cancer:2.63e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable)",Expressed in all,Expressed in all,,,liver: 441.5,Cell line enhanced,,HHSteC: 81.5;SK-BR-3: 150.4
ALDH3A1,ALDH3,ENSG00000108602,Aldehyde dehydrogenase 3 family member A1,17,19737984-19748943,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB045957, HPA051150, HPA063783",Enhanced,,Enhanced,Vesicles<br>Plasma membrane<br>Cytosol,Head and neck cancer:7.55e-5 (favourable),Mixed,Group enriched,7,esophagus: 406.1;skin: 84.3;stomach: 207.2,tonsil: 31.0,Cell line enriched,21,A549: 4306.9
ALDH3A2,"ALDH10, FALDH, SLS",ENSG00000072210,Aldehyde dehydrogenase 3 family member A2,17,19648136-19677598,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA014769, CAB020692",Approved,,,,Renal cancer:3.85e-8 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 179.0,Cell line enhanced,,A549: 115.6
ALDH3B1,ALDH7,ENSG00000006534,Aldehyde dehydrogenase 3 family member B1,11,68008578-68029282,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA038525,Uncertain,,,,"Colorectal cancer:1.18e-4 (unfavourable), Pancreatic cancer:6.07e-4 (unfavourable)",Expressed in all,Tissue enhanced,,fallopian tube: 64.4;lung: 67.7,bone marrow: 30.7,Cell line enhanced,,A549: 137.9;CAPAN-2: 136.9
ALDH3B2,ALDH8,ENSG00000132746,Aldehyde dehydrogenase 3 family member B2,11,67662162-67681200,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045132,Enhanced,,,,,Mixed,Group enriched,6,breast: 89.9;esophagus: 103.4;skin: 122.2,tonsil: 19.0,Cell line enhanced,,MCF7: 49.6;SK-BR-3: 48.3;T-47d: 12.2
ALDH4A1,"ALDH4, P5CDh",ENSG00000159423,Aldehyde dehydrogenase 4 family member A1,1,18871430-18902781,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004645, HPA006401",Enhanced,,,,Cervical cancer:5.06e-4 (favourable),Expressed in all,Tissue enhanced,,kidney: 185.7;liver: 108.1,adipose tissue: 63.8,Expressed in all,,
ALDH5A1,"SSADH, SSDH",ENSG00000112294,Aldehyde dehydrogenase 5 family member A1,6,24494852-24537207,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA029715, HPA029716",Enhanced,,Enhanced,Mitochondria,"Liver cancer:7.61e-6 (favourable), Renal cancer:3.68e-4 (favourable), Ovarian cancer:6.20e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 46.8,Cell line enhanced,,Daudi: 88.4;U-698: 105.9
ALDH6A1,MMSDH,ENSG00000119711,Aldehyde dehydrogenase 6 family member A1,14,74056850-74084493,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA029072, HPA029073, HPA029074, HPA029075",Enhanced,,Enhanced,Mitochondria,"Renal cancer:2.00e-15 (favourable), Lung cancer:4.22e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 389.6,Expressed in all,,
ALDH7A1,"ATQ1, EPD, PDE",ENSG00000164904,Aldehyde dehydrogenase 7 family member A1,5,126531200-126595418,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA023296,Enhanced,,Supported,Mitochondria<br>Cytosol,Renal cancer:3.08e-4 (favourable),Expressed in all,Expressed in all,,,kidney: 120.6,Mixed,,
ALDH9A1,"ALDH4, ALDH7, ALDH9, E3",ENSG00000143149,Aldehyde dehydrogenase 9 family member A1,1,165662216-165698863,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA006077, HPA010873",Approved,,Approved,Cytosol,Pancreatic cancer:4.56e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 206.0,Mixed,,
ALDOA,,ENSG00000149925,"Aldolase, fructose-bisphosphate A",16,30053090-30070457,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA004177, CAB006252",Enhanced,,Supported,Cytosol,"Liver cancer:5.79e-5 (unfavourable), Lung cancer:7.32e-5 (unfavourable)",Expressed in all,Tissue enriched,7,skeletal muscle: 9377.0,esophagus: 1428.8,Expressed in all,,
ALDOB,,ENSG00000136872,"Aldolase, fructose-bisphosphate B",9,101420578-101435823,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002198, CAB020827",Enhanced,,,,,Tissue enriched,Group enriched,23,duodenum: 3705.7;kidney: 6574.8;liver: 5092.2;small intestine: 5611.2,gallbladder: 231.1,Cell line enhanced,,BEWO: 16.8;NB-4: 10.8;RPMI-8226: 13.6;SH-SY5Y: 17.3
ALDOC,,ENSG00000109107,"Aldolase, fructose-bisphosphate C",17,28573115-28577264,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003282, CAB020828, HPA067442",Enhanced,Supported,Approved,Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol,"Renal cancer:1.29e-7 (unfavourable), Head and neck cancer:9.80e-4 (unfavourable)",Tissue enriched,Tissue enriched,7,cerebral cortex: 766.6,heart muscle: 111.2,Cell line enhanced,,RPMI-8226: 165.2;U-266/70: 119.9
ALG1,"CDG1K, HMAT1, HMT-1, Mat-1",ENSG00000033011,"ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase",16,5033960-5087379,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA060392,Approved,,Approved,Nucleoli fibrillar center<br>Endoplasmic reticulum,"Colorectal cancer:5.79e-4 (favourable), Testis cancer:6.93e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 33.4,Expressed in all,,
ALG10,"ALG10A, DIE2, FLJ14751",ENSG00000139133,"ALG10, alpha-1,2-glucosyltransferase",12,34022281-34029694,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA043329, HPA063387",Approved,,Approved,Endoplasmic reticulum,,Mixed,Mixed,,,parathyroid gland: 4.6,Expressed in all,,
ALG10B,KCR1,ENSG00000175548,"ALG10B, alpha-1,2-glucosyltransferase",12,38316578-38329728,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA043329, HPA063387",Approved,,Approved,Endoplasmic reticulum,,Mixed,Mixed,,,parathyroid gland: 7.6,Expressed in all,,
ALG11,"CDG1P, KIAA0266",ENSG00000253710,"ALG11, alpha-1,2-mannosyltransferase",13,52012398-52029664,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA047214,Approved,,,,,Mixed,Expressed in all,,,thyroid gland: 23.6,Expressed in all,,
ALG12,"CDG1G, ECM39",ENSG00000182858,"ALG12, alpha-1,6-mannosyltransferase",22,49900229-49918458,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA003076, HPA051665",Approved,,Approved,Endoplasmic reticulum,"Renal cancer:3.60e-5 (favourable), Endometrial cancer:6.09e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 17.2,Expressed in all,,
ALG13,"CDG1S, CXorf45, FLJ23018, GLT28D1, MDS031, TDRD13, YGL047W",ENSG00000101901,"ALG13, UDP-N-acetylglucosaminyltransferase subunit",X,111665811-111760649,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002853,Approved,,,,Renal cancer:1.10e-6 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 30.4,Expressed in all,,
ALG2,"CDG1I, CDGIi, FLJ14511, hALPG2, NET38",ENSG00000119523,"ALG2, alpha-1,3/1,6-mannosyltransferase",9,99216426-99221956,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041512, HPA041601",Approved,,Enhanced,Actin filaments<br>Cytosol,"Renal cancer:2.28e-7 (favourable), Endometrial cancer:8.44e-5 (favourable), Head and neck cancer:1.56e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 77.1,Expressed in all,,
ALG3,"CDGS4, D16Ertd36e, Not56, NOT56L",ENSG00000214160,"ALG3, alpha-1,3- mannosyltransferase",3,184242301-184249548,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA045103,Approved,,,,"Liver cancer:1.58e-5 (unfavourable), Lung cancer:8.67e-5 (unfavourable), Renal cancer:1.25e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 33.4,Expressed in all,,
ALG5,bA421P11.2,ENSG00000120697,"ALG5, dolichyl-phosphate beta-glucosyltransferase",13,36949775-37000261,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA007989,Approved,,Approved,Cytosol,"Renal cancer:1.40e-5 (favourable), Head and neck cancer:2.11e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 96.6,Expressed in all,,
ALG6,,ENSG00000088035,"ALG6, alpha-1,3-glucosyltransferase",1,63367590-63438562,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA062536,,,Supported,Endoplasmic reticulum,"Renal cancer:2.63e-6 (unfavourable), Colorectal cancer:4.86e-4 (favourable), Liver cancer:9.46e-4 (unfavourable)",Expressed in all,Mixed,,,placenta: 11.9,Expressed in all,,
ALG8,MGC2840,ENSG00000159063,"ALG8, alpha-1,3-glucosyltransferase",11,78100936-78139660,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA051898,Approved,,Approved,Nucleoplasm,,Expressed in all,Expressed in all,,,testis: 86.2,Expressed in all,,
ALG9,DIBD1,ENSG00000086848,"ALG9, alpha-1,2-mannosyltransferase",11,111782195-111871581,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA038575,Approved,,Approved,Endoplasmic reticulum,Renal cancer:7.29e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 25.8,Expressed in all,,
ALK,CD246,ENSG00000171094,Anaplastic lymphoma receptor tyrosine kinase,2,29192774-29921566,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010694,Approved,,Supported,Plasma membrane,,Group enriched,Tissue enhanced,,cerebral cortex: 2.7;testis: 2.0,adrenal gland: 0.5,Cell line enriched,6,SH-SY5Y: 28.3
ALKBH1,"ABH, alkB, ALKBH, hABH",ENSG00000100601,"AlkB homolog 1, histone H2A dioxygenase",14,77672404-77708020,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA044087,Approved,,,,Renal cancer:1.80e-4 (favourable),Expressed in all,Mixed,,,placenta: 5.7,Expressed in all,,
ALKBH2,"ABH2, MGC90512",ENSG00000189046,"AlkB homolog 2, alpha-ketoglutarate dependent dioxygenase",12,109088188-109093631,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB011198, HPA045392, HPA051976",Approved,,Enhanced,Nucleus,"Renal cancer:1.41e-5 (unfavourable), Breast cancer:6.67e-5 (favourable), Urothelial cancer:8.67e-4 (favourable)",Expressed in all,Expressed in all,,,skin: 27.0,Expressed in all,,
ALKBH3,DEPC-1,ENSG00000166199,"AlkB homolog 3, alpha-ketoglutaratedependent dioxygenase",11,43880811-43920266,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA009674, HPA046489",Approved,,Enhanced,Nucleoplasm<br>Mitochondria,,Expressed in all,Expressed in all,,,epididymis: 32.4,Mixed,,
ALKBH8,"MGC10235, TRM9, TRMT9",ENSG00000137760,"AlkB homolog 8, tRNA methyltransferase",11,107502726-107565746,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038724, HPA038725, HPA061514",Approved,,Supported,Nucleoplasm<br>Nuclear bodies,,Expressed in all,Mixed,,,parathyroid gland: 9.6,Expressed in all,,
ALOX12,12S-LOX,ENSG00000108839,"Arachidonate 12-lipoxygenase, 12S type",17,6996065-7010736,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA010691, CAB019287",Approved,,Supported,Nuclear speckles<br>Cytosol,,Mixed,Group enriched,8,esophagus: 50.3;skin: 25.9,gallbladder: 5.0,Group enriched,5,A-431: 22.4;HEL: 36.7
ALOX15,15-LOX-1,ENSG00000161905,Arachidonate 15-lipoxygenase,17,4630902-4642294,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004962, CAB004963, HPA013859",Approved,,,,,Mixed,Tissue enhanced,,fallopian tube: 19.6;lung: 9.8,breast: 4.7,Group enriched,7,HMC-1: 13.6;MCF7: 10.8;T-47d: 3.9
ALOX15B,15-LOX-2,ENSG00000179593,"Arachidonate 15-lipoxygenase, type B",17,8039017-8049134,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA010562,Enhanced,,Supported,Plasma membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,breast: 145.0;prostate: 115.3,lung: 26.1,Group enriched,15,HHSteC: 6.5;HSkMC: 11.9;hTCEpi: 25.0
ALOX5,5-LOX,ENSG00000012779,Arachidonate 5-lipoxygenase,10,45374176-45446119,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA071285,Enhanced,,Supported,Nucleoplasm,"Renal cancer:1.80e-5 (unfavourable), Urothelial cancer:7.18e-4 (favourable)",Expressed in all,Tissue enhanced,,lung: 41.3,bone marrow: 28.8,Cell line enhanced,,BEWO: 10.4;Daudi: 22.8;HMC-1: 20.7;RT4: 14.0;U-266/70: 11.3
ALOXE3,"E-LOX, eLOX3",ENSG00000179148,Arachidonate lipoxygenase 3,17,8095900-8119047,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA023120, HPA078597",Enhanced,,Approved,Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enriched,16,skin: 36.5,breast: 2.2,Cell line enhanced,,A-431: 5.5;HBEC3-KT: 7.2;hTCEpi: 5.2;hTERT-HME1: 10.5;T-47d: 4.1
ALPI,,ENSG00000163295,"Alkaline phosphatase, intestinal",2,232456123-232460032,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA038764, HPA038765, HPA051699",Supported,,Approved,Plasma membrane,,Tissue enhanced,Group enriched,31,duodenum: 203.2;small intestine: 212.1,colon: 6.6,Cell line enriched,10,CACO-2: 5.9
ALPK1,"FLJ22670, KIAA1527, Lak",ENSG00000073331,Alpha kinase 1,4,112285509-112442620,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA027435, HPA027443",Approved,,Approved,Centrosome,"Renal cancer:5.82e-7 (unfavourable), Urothelial cancer:1.17e-4 (favourable)",Expressed in all,Mixed,,,parathyroid gland: 9.2,Mixed,,
ALPK2,HAK,ENSG00000198796,Alpha kinase 2,18,58481247-58628957,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027377, HPA027976, HPA028084, HPA029801",Uncertain,,Approved,Cytosol,Renal cancer:8.20e-5 (unfavourable),Tissue enriched,Tissue enhanced,,heart muscle: 28.6;skeletal muscle: 14.1,lymph node: 6.9,Cell line enhanced,,BJ: 44.5;BJ hTERT+: 25.8;fHDF/TERT166: 37.1;U-138 MG: 25.6
ALPK3,"KIAA1330, MAK, Midori",ENSG00000136383,Alpha kinase 3,15,84816680-84873482,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026558,Uncertain,,Approved,Nucleus,Renal cancer:3.95e-7 (favourable),Mixed,Tissue enhanced,,heart muscle: 32.8;parathyroid gland: 36.2;skeletal muscle: 47.6,adipose tissue: 12.3,Cell line enhanced,,BEWO: 12.8;HUVEC TERT2: 12.1;LHCN-M2: 16.5;NTERA-2: 12.1;RH-30: 34.1
ALPL,"HOPS, TNSALP",ENSG00000162551,"Alkaline phosphatase, liver/bone/kidney",1,21509372-21578412,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007105, HPA008765, CAB020829",Enhanced,,Approved,Cytosol,Melanoma:7.08e-4 (unfavourable),Expressed in all,Tissue enhanced,,lung: 78.8,kidney: 47.2,Group enriched,8,HAP1: 31.9;HSkMC: 126.3;hTEC/SVTERT24-B: 139.0;LHCN-M2: 85.3;NTERA-2: 40.7;SCLC-21H: 103.8
ALPP,,ENSG00000163283,"Alkaline phosphatase, placental",2,232378534-232382889,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB026327, HPA038764, HPA038765, HPA051699",Enhanced,,Approved,Plasma membrane,Pancreatic cancer:4.33e-4 (unfavourable),Tissue enhanced,Group enriched,14,"cervix, uterine: 25.5;placenta: 45.5",fallopian tube: 2.5,Group enriched,6,HaCaT: 311.4;SiHa: 103.4
ALPPL2,,ENSG00000163286,"Alkaline phosphatase, placental like 2",2,232406843-232410714,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB020698, HPA038764, HPA038765, HPA051699",Supported,,Approved,Plasma membrane,,Tissue enhanced,Tissue enhanced,,fallopian tube: 1.5,lung: 0.7,Group enriched,29,BEWO: 6.5;CAPAN-2: 29.9;HaCaT: 22.2
AMACR,"P504S, RACE",ENSG00000242110,Alpha-methylacyl-CoA racemase,5,33986178-34008108,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB001809, HPA019527, HPA020912",Enhanced,,Supported,Vesicles<br>Plasma membrane,Colorectal cancer:7.11e-4 (favourable),Expressed in all,Expressed in all,,,kidney: 135.3,Expressed in all,,
AMD1,SAMDC,ENSG00000123505,Adenosylmethionine decarboxylase 1,6,110874770-110895713,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA029281, HPA029282",Approved,,Approved,Nucleoplasm,"Liver cancer:1.91e-6 (unfavourable), Breast cancer:3.87e-4 (unfavourable), Renal cancer:4.28e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 323.8,Expressed in all,,
AMDHD1,MGC35366,ENSG00000139344,Amidohydrolase domain containing 1,12,95943293-95968716,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039720,Uncertain,,Approved,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,,Tissue enriched,Tissue enhanced,,testis: 25.8,liver: 22.0,Cell line enhanced,,HMC-1: 57.9;Karpas-707: 44.7;SiHa: 44.1;U-266/84: 42.8
AMDHD2,CGI-14,ENSG00000162066,Amidohydrolase domain containing 2,16,2520357-2531422,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041184, HPA041321",Enhanced,,Approved,Nucleoli<br>Cytosol,Cervical cancer:5.19e-4 (favourable),Expressed in all,Mixed,,,testis: 15.9,Mixed,,
AMFR,"gp78, RNF45",ENSG00000159461,Autocrine motility factor receptor,16,56361452-56425538,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB026381, HPA029018, HPA077835",Approved,,Supported,Endoplasmic reticulum<br>Golgi apparatus,,Expressed in all,Expressed in all,,,testis: 154.7,Expressed in all,,
AMHR2,"MISR2, MISRII",ENSG00000135409,Anti-Mullerian hormone receptor type 2,12,53423855-53431534,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,adrenal gland: 32.1;ovary: 40.9,testis: 10.1,Group enriched,19,HEL: 36.1;K-562: 19.9
AMPD1,"MAD, MADA",ENSG00000116748,Adenosine monophosphate deaminase 1,1,114673090-114695618,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA026478, HPA028080",Enhanced,,,,,Mixed,Tissue enriched,12,skeletal muscle: 193.6,duodenum: 16.5,Cell line enriched,32,U-266/70: 6.6
AMPD2,SPG63,ENSG00000116337,Adenosine monophosphate deaminase 2,1,109616104-109632051,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA027137, HPA045760, HPA050590",Approved,Approved,Enhanced,Cytosol,Renal cancer:3.78e-10 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 82.4,Expressed in all,,
AMPD3,,ENSG00000133805,Adenosine monophosphate deaminase 3,11,10308313-10507579,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038662, HPA047408",Uncertain,,Enhanced,Nuclear membrane,Endometrial cancer:2.37e-4 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 54.4,bone marrow: 41.4,Cell line enhanced,,BJ hTERT+: 35.8
AMT,"GCST, NKH",ENSG00000145020,Aminomethyltransferase,3,49416775-49422753,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA005566,Supported,,Supported,Nucleoplasm<br>Mitochondria,Renal cancer:3.90e-8 (favourable),Expressed in all,Mixed,,,parathyroid gland: 23.2,Group enriched,12,BEWO: 14.2;Hep G2: 30.0;NTERA-2: 7.6;SH-SY5Y: 11.8
AMY1A,AMY1,ENSG00000237763,"Amylase, alpha 1A (salivary)",1,103655290-103664554,"Enzymes, Predicted secreted proteins",Evidence at protein level,"CAB004310, HPA045394, HPA045399, HPA046980",Supported,,,,,Not detected,Tissue enriched,79,salivary gland: 8875.9,"cervix, uterine: 111.7",Not detected,,
AMY1B,AMY1,ENSG00000174876,"Amylase, alpha 1B (salivary)",1,103687415-103696680,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA045394, HPA045399, HPA046980",Supported,,,,,Tissue enhanced,Tissue enriched,15,salivary gland: 1841.0,"cervix, uterine: 126.4",Not detected,,
AMY1C,AMY1,ENSG00000187733,"Amylase, alpha 1C (salivary)",1,103750406-103758690,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA045394, HPA045399, HPA046980",Supported,,,,,Not detected,Tissue enhanced,,"cervix, uterine: 33.0;salivary gland: 101.8",pancreas: 26.4,Not detected,,
AMY2A,AMY2,ENSG00000243480,"Amylase, alpha 2A (pancreatic)",1,103616811-103625780,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,"HPA045394, HPA045399, CAB045960, HPA046980",Enhanced,,,,,Tissue enriched,Tissue enriched,313,pancreas: 31329.4,ovary: 99.9,Not detected,,
AMY2B,AMY2,ENSG00000240038,"Amylase, alpha 2B (pancreatic)",1,103553815-103579534,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA045394, HPA045399, HPA046980",Supported,,,,,Tissue enriched,Tissue enriched,66,pancreas: 6585.9,salivary gland: 99.6,Cell line enhanced,,EFO-21: 9.6
AMZ1,KIAA1950,ENSG00000174945,Archaelysin family metallopeptidase 1,7,2679522-2775500,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA020233,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 4.0,endometrium: 1.5,Cell line enhanced,,BEWO: 6.7;MCF7: 5.8;T-47d: 26.0
AMZ2,,ENSG00000196704,Archaelysin family metallopeptidase 2,17,68247574-68257164,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA023299, HPA052406",Approved,,Supported,Nucleoplasm<br>Nuclear bodies<br>Cytosol,"Liver cancer:1.32e-5 (unfavourable), Renal cancer:3.14e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 357.6,Expressed in all,,
ANKK1,X-kinase,ENSG00000170209,Ankyrin repeat and kinase domain containing 1,11,113387791-113400418,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA012813,Uncertain,,,,,Mixed,Tissue enhanced,,skin: 4.2,fallopian tube: 1.3,Cell line enhanced,,hTCEpi: 1.5
ANPEP,"CD13, gp150, LAP1, p150, PEPN",ENSG00000166825,"Alanyl aminopeptidase, membrane",15,89784889-89815401,"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB002417, HPA004625",Enhanced,,Supported,Plasma membrane,,Expressed in all,Group enriched,9,duodenum: 2386.4;small intestine: 2133.7,kidney: 263.2,Cell line enhanced,,BJ hTERT+: 958.3;HUVEC TERT2: 770.8;TIME: 760.6;U-2197: 926.0
AOAH,,ENSG00000136250,Acyloxyacyl hydrolase,7,36512949-36724549,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA021666, HPA026716",Uncertain,,,,,Expressed in all,Tissue enhanced,,spleen: 88.9,appendix: 45.9,Group enriched,6,HDLM-2: 3.4;NB-4: 16.7;THP-1: 13.5;U-937: 6.8
AOC1,"ABP1, DAO",ENSG00000002726,"Amine oxidase, copper containing 1",7,150824627-150861504,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA031032, HPA031033",Approved,,,,Prostate cancer:1.71e-4 (favourable),Group enriched,Tissue enhanced,,placenta: 716.9;small intestine: 247.6,duodenum: 183.2,Cell line enhanced,,CAPAN-2: 17.4;HaCaT: 5.4;THP-1: 17.8
AOC2,"DAO2, RAO",ENSG00000131480,"Amine oxidase, copper containing 2",17,42844600-42850707,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA057779,Uncertain,,,,Urothelial cancer:2.47e-4 (favourable),Tissue enhanced,Group enriched,5,adipose tissue: 6.2;testis: 5.8,spleen: 1.2,Cell line enhanced,,ASC diff: 7.7
AOC3,"HPAO, VAP-1, VAP1",ENSG00000131471,"Amine oxidase, copper containing 3",17,42851184-42858130,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA000980, CAB025797",Enhanced,,Approved,Golgi apparatus<br>Cytosol,"Renal cancer:1.79e-5 (unfavourable), Colorectal cancer:3.68e-4 (unfavourable), Urothelial cancer:6.98e-4 (unfavourable)",Expressed in all,Tissue enhanced,,adipose tissue: 450.1,smooth muscle: 205.7,Cell line enriched,17,ASC diff: 210.1
AOX1,"AO, AOH1",ENSG00000138356,Aldehyde oxidase 1,2,200585868-200677064,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040199, HPA040215",Enhanced,,,,Renal cancer:6.05e-5 (favourable),Tissue enriched,Group enriched,5,adrenal gland: 368.8;kidney: 97.5;liver: 432.3,ovary: 56.8,Cell line enhanced,,ASC diff: 241.4;ASC TERT1: 125.7;hTERT-HME1: 56.6
APEH,"D3F15S2, D3S48E, DNF15S2",ENSG00000164062,Acylaminoacyl-peptide hydrolase,3,49674002-49683963,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA029700, HPA029701, HPA029702, HPA029703",Enhanced,,Enhanced,Cytosol,Renal cancer:3.32e-10 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 101.6,Expressed in all,,
APEX1,"APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1",ENSG00000100823,Apurinic/apyrimidinic endodeoxyribonuclease 1,14,20455191-20457772,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000956, HPA002564, CAB004294, CAB047307",Enhanced,,Enhanced,Nucleus,Liver cancer:7.82e-5 (unfavourable),Expressed in all,Expressed in all,,,ovary: 176.5,Expressed in all,,
APEX2,"APE2, APEXL2, XTH2, ZGRF2",ENSG00000169188,Apurinic/apyrimidinic endodeoxyribonuclease 2,X,55000357-55009057,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA048577,,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Vesicles,"Liver cancer:6.13e-7 (unfavourable), Ovarian cancer:5.21e-4 (favourable), Cervical cancer:6.17e-4 (favourable), Urothelial cancer:6.63e-4 (favourable)",Expressed in all,Expressed in all,,,skin: 14.3,Expressed in all,,
APIP,"APIP2, CGI-29, Mmrp19",ENSG00000149089,APAF1 interacting protein,11,34853094-34916499,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021188, HPA024131",Approved,,Approved,Nucleoplasm<br>Cytosol,Liver cancer:1.99e-4 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 33.2,Expressed in all,,
APLF,"C2orf13, MGC47799, Xip1, ZCCHH1",ENSG00000169621,Aprataxin and PNKP like factor,2,68467561-68655862,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA029396, HPA034642, HPA034643",Uncertain,,Supported,Nucleoplasm,,Mixed,Mixed,,,skin: 3.3,Mixed,,
APOBEC1,"APOBEC-1, BEDP, CDAR1, HEPR",ENSG00000111701,Apolipoprotein B mRNA editing enzyme catalytic subunit 1,12,7649400-7665903,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Group enriched,Group enriched,21,duodenum: 31.9;small intestine: 31.0,stomach: 1.5,Cell line enriched,17,CAPAN-2: 2.4
APOBEC2,"ARCD1, ARP1",ENSG00000124701,Apolipoprotein B mRNA editing enzyme catalytic subunit 2,6,41053304-41064511,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA014252, HPA017957",Enhanced,,,,,Tissue enhanced,Group enriched,13,heart muscle: 120.7;skeletal muscle: 403.8,esophagus: 19.5,Cell line enhanced,,CACO-2: 3.3
APRT,,ENSG00000198931,Adenine phosphoribosyltransferase,16,88809339-88811944,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA026681,Approved,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,skin: 112.4,Expressed in all,,
ARAF,ARAF1,ENSG00000078061,"A-Raf proto-oncogene, serine/threonine kinase",X,47561100-47571920,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA046188, HPA066326",Approved,,Approved,Nucleus<br>Nucleoli fibrillar center,Renal cancer:1.45e-6 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 86.3,Expressed in all,,
AREL1,"FIEL1, KIAA0317",ENSG00000119682,Apoptosis resistant E3 ubiquitin protein ligase 1,14,74653437-74713115,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA051306,Uncertain,,,,Renal cancer:4.67e-6 (favourable),Expressed in all,Expressed in all,,,testis: 33.8,Expressed in all,,
ARG1,,ENSG00000118520,Arginase 1,6,131573144-131584332,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA003595, CAB009434, HPA024006, CAB056159",Enhanced,,,,,Tissue enriched,Tissue enhanced,,bone marrow: 171.2;liver: 566.2,skin: 78.2,Not detected,,
ARG2,,ENSG00000081181,Arginase 2,14,67619798-67651720,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000663, CAB009435",Enhanced,,Supported,Mitochondria,,Expressed in all,Tissue enhanced,,parathyroid gland: 94.0;prostate: 161.0;thyroid gland: 157.2,kidney: 63.4,Cell line enhanced,,HAP1: 54.8
ARSA,,ENSG00000100299,Arylsulfatase A,22,50622754-50628173,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA005554, CAB025183",Enhanced,,Uncertain,Golgi apparatus<br>Cytosol,Endometrial cancer:2.96e-5 (favourable),Expressed in all,Expressed in all,,,testis: 37.4,Cell line enhanced,,Karpas-707: 58.2
ARSB,,ENSG00000113273,Arylsulfatase B,5,78777209-78986087,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA037770, HPA037771",Enhanced,,Approved,Golgi apparatus,Urothelial cancer:3.42e-4 (unfavourable),Expressed in all,Mixed,,,smooth muscle: 18.2,Expressed in all,,
ART1,"ART2, CD296",ENSG00000129744,ADP-ribosyltransferase 1,11,3645128-3664416,"CD markers, Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA051148,Uncertain,,,,,Not detected,Tissue enriched,21,skeletal muscle: 16.4,esophagus: 0.7,Not detected,,
ART3,,ENSG00000156219,ADP-ribosyltransferase 3,4,76011184-76112802,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA011268,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,skeletal muscle: 77.0;testis: 174.4,heart muscle: 29.1,Group enriched,7,NB-4: 3.4;NTERA-2: 14.0;SK-MEL-30: 4.9
ART4,"CD297, DO, DOK1",ENSG00000111339,ADP-ribosyltransferase 4 (Dombrock blood group),12,14825569-14843495,"Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA075664,,,Approved,Rods & Rings,,Tissue enhanced,Tissue enhanced,,liver: 27.2;spleen: 26.9,gallbladder: 15.1,Cell line enhanced,,AN3-CA: 5.6;HEL: 10.9;Hep G2: 4.9;HUVEC TERT2: 22.5
ART5,,ENSG00000167311,ADP-ribosyltransferase 5,11,3638503-3642316,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,"HPA041637, HPA044099",Uncertain,,,,Renal cancer:1.85e-4 (favourable),Tissue enhanced,Tissue enhanced,,ovary: 10.2;testis: 22.6,endometrium: 5.1,Cell line enhanced,,BEWO: 2.9;HEK 293: 1.9;U-2 OS: 2.1
AS3MT,CYT19,ENSG00000214435,Arsenite methyltransferase,10,102869516-102901899,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA017856,Enhanced,,Approved,Nucleus<br>Mitochondria,,Tissue enhanced,Group enriched,6,adrenal gland: 251.5;parathyroid gland: 119.3,liver: 30.4,Cell line enhanced,,REH: 50.0;SH-SY5Y: 29.9;T-47d: 41.6
ASAH1,"AC, ACDase, ASAH, FLJ21558, PHP32",ENSG00000104763,N-acylsphingosine amidohydrolase 1,8,18055992-18084998,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA005468,Supported,,,,Renal cancer:3.08e-8 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 547.6,Expressed in all,,
ASAH2,,ENSG00000188611,N-acylsphingosine amidohydrolase 2,10,50182778-50248610,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA061171,Supported,,Approved,Focal adhesion sites,,Mixed,Group enriched,17,duodenum: 83.5;small intestine: 71.3,stomach: 4.6,Mixed,,
ASCC3,"ASC1p200, dJ121G13.4, dJ467N11.1, HELIC1, RNAH",ENSG00000112249,Activating signal cointegrator 1 complex subunit 3,6,100508194-100881372,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA031608, HPA031609, HPA031610",Enhanced,,Supported,Golgi apparatus<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 26.5,Expressed in all,,
ASH1L,"ASH1, ASH1L1, huASH1, KMT2H",ENSG00000116539,ASH1 like histone lysine methyltransferase,1,155335268-155562807,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004806,Approved,,Supported,Nucleoplasm<br>Golgi apparatus,Renal cancer:3.80e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 37.9,Expressed in all,,
ASL,,ENSG00000126522,Argininosuccinate lyase,7,66075798-66093558,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003696, HPA016646",Supported,,Approved,Cytosol,Cervical cancer:4.05e-6 (unfavourable),Expressed in all,Expressed in all,,,liver: 97.5,Expressed in all,,
ASMT,"ASMTY, HIOMT, HIOMTY",ENSG00000196433,Acetylserotonin O-methyltransferase,X,1615001-1643081,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,epididymis: 2.2,adrenal gland: 0.8,Not detected,,
ASNS,,ENSG00000070669,Asparagine synthetase (glutamine-hydrolyzing),7,97852118-97872542,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004924, HPA029318, HPA064737",Approved,,Enhanced,Cytosol,"Renal cancer:6.21e-7 (unfavourable), Liver cancer:9.42e-6 (unfavourable), Head and neck cancer:8.79e-5 (unfavourable), Endometrial cancer:4.24e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 74.0,Expressed in all,,
ASPA,"ACY2, ASP",ENSG00000108381,Aspartoacylase,17,3472374-3503419,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA022142, HPA022145",Enhanced,,Uncertain,Cytosol,,Tissue enhanced,Tissue enhanced,,kidney: 39.8,cerebral cortex: 24.7,Cell line enhanced,,ASC diff: 3.7;HSkMC: 5.5
ASPDH,,ENSG00000204653,Aspartate dehydrogenase domain containing,19,50511600-50514690,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042631, HPA042654",Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 17.9;kidney: 27.9;liver: 34.6,duodenum: 6.9,Cell line enhanced,,HEK 293: 12.4;MOLT-4: 13.3;SH-SY5Y: 9.8
ASPG,C14orf76,ENSG00000166183,Asparaginase,14,104085679-104115581,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA069761,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,liver: 29.5,esophagus: 13.9,Not detected,,
ASPH,"BAH, CASQ2BP1, HAAH, JCTN",ENSG00000198363,Aspartate beta-hydroxylase,8,61500556-61714640,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA055161, HPA059303",Uncertain,,Supported,Endoplasmic reticulum,"Renal cancer:1.57e-5 (unfavourable), Cervical cancer:8.07e-5 (unfavourable), Pancreatic cancer:1.75e-4 (unfavourable), Lung cancer:3.61e-4 (unfavourable), Thyroid cancer:4.24e-4 (unfavourable)",Expressed in all,Expressed in all,,,adipose tissue: 403.5,Mixed,,
ASRGL1,"ALP, ALP1, FLJ22316",ENSG00000162174,Asparaginase like 1,11,62337448-62393412,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA029725, HPA055572, CAB070192",Enhanced,,Approved,Nucleoplasm<br>Microtubules,"Renal cancer:4.32e-7 (favourable), Endometrial cancer:1.56e-5 (favourable), Colorectal cancer:6.14e-4 (favourable), Liver cancer:9.46e-4 (unfavourable)",Expressed in all,Expressed in all,,,"cervix, uterine: 181.6",Cell line enhanced,,HAP1: 86.4;SCLC-21H: 132.5
ASS1,"ASS, CTLN1",ENSG00000130707,Argininosuccinate synthase 1,9,130444929-130501274,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020896, HPA020934",Enhanced,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:8.14e-9 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 1259.9;liver: 1027.3,fallopian tube: 261.5,Cell line enhanced,,BJ hTERT+: 709.0;HaCaT: 734.6;RPMI-8226: 956.8;THP-1: 690.3
ASTL,"ovastacin, SAS1B",ENSG00000188886,Astacin like metalloendopeptidase,2,96123850-96138436,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA015620,Uncertain,,,,,Mixed,Tissue enhanced,,bone marrow: 2.4,seminal vesicle: 1.4,Not detected,,
ATAD1,FLJ14600,ENSG00000138138,"ATPase family, AAA domain containing 1",10,87751512-87841343,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA037569,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Mitochondria,Renal cancer:3.98e-6 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 29.0,Expressed in all,,
ATAD2,"CT137, DKFZp667N1320, MGC29843, MGC5254, PRO2000",ENSG00000156802,"ATPase family, AAA domain containing 2",8,123319850-123416350,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA029424, CAB056158",Enhanced,,Enhanced,Nucleoplasm,"Renal cancer:8.33e-15 (unfavourable), Endometrial cancer:2.04e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 34.4,Expressed in all,,
ATAT1,"C6orf134, Em:AB023049.7, FLJ13158, MEC17",ENSG00000137343,Alpha tubulin acetyltransferase 1,6,30626842-30646823,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA046816, HPA050999",Approved,,Approved,Golgi apparatus<br>Cytosol,"Liver cancer:1.03e-5 (unfavourable), Renal cancer:7.78e-5 (unfavourable), Urothelial cancer:1.35e-4 (favourable)",Expressed in all,Mixed,,,epididymis: 4.4,Cell line enhanced,,AF22: 7.3
ATE1,,ENSG00000107669,Arginyltransferase 1,10,121740421-121928801,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038444, HPA057549",Approved,,Supported,Nucleus,Renal cancer:2.67e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 31.5,Expressed in all,,
ATF2,"CRE-BP1, CREB2, HB16, TREB7",ENSG00000115966,Activating transcription factor 2,2,175072250-175168382,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB003769, HPA022134",Supported,,Enhanced,Nucleoplasm,Liver cancer:7.08e-5 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 54.0,Expressed in all,,
ATG4A,"APG4A, AUTL2",ENSG00000101844,Autophagy related 4A cysteine peptidase,X,108091668-108154671,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036374, HPA064759",Uncertain,,Approved,Actin filaments<br>Microtubules,Breast cancer:1.36e-5 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 17.8,Expressed in all,,
ATG4B,"APG4B, AUTL1, DKFZp586D1822, KIAA0943",ENSG00000168397,Autophagy related 4B cysteine peptidase,2,241637213-241673857,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB037195, HPA069803",Approved,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:2.79e-4 (unfavourable), Colorectal cancer:6.85e-4 (unfavourable), Urothelial cancer:9.64e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 44.0,Expressed in all,,
ATG4C,"APG4C, AUTL1, AUTL3, FLJ14867",ENSG00000125703,Autophagy related 4C cysteine peptidase,1,62784135-62865513,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007049,Approved,,Approved,Nucleoplasm<br>Cytosol,Colorectal cancer:9.83e-4 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 23.5,Expressed in all,,
ATG4D,"APG4-D, APG4D, AUTL4",ENSG00000130734,Autophagy related 4D cysteine peptidase,19,10543895-10553418,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA067683,Approved,,,,"Renal cancer:2.39e-7 (favourable), Cervical cancer:3.18e-5 (favourable), Stomach cancer:5.03e-4 (favourable), Pancreatic cancer:9.95e-4 (favourable)",Expressed in all,Expressed in all,,,small intestine: 25.2,Mixed,,
ATIC,"AICARFT, IMPCHASE, PURH",ENSG00000138363,5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase,2,215311817-215349773,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB013462, HPA021012",Supported,,Enhanced,Plasma membrane<br>Cytosol,"Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 44.8,Expressed in all,,
ATM,"ATA, ATC, ATD, ATDC, TEL1, TELO1",ENSG00000149311,ATM serine/threonine kinase,11,108222484-108369102,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000102, HPA067142",Supported,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,lymph node: 40.8,Expressed in all,,
ATP10A,"ATP10C, ATPVA, ATPVC, KIAA0566",ENSG00000206190,ATPase phospholipid transporting 10A (putative),15,25677273-25865172,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA041496, HPA042509",Uncertain,,,,Renal cancer:6.60e-5 (unfavourable),Expressed in all,Mixed,,,lung: 10.6,Cell line enhanced,,BJ: 16.3;fHDF/TERT166: 22.1;HMC-1: 16.2;SK-MEL-30: 20.1
ATP10B,"ATPVB, FLJ21477, KIAA0715",ENSG00000118322,ATPase phospholipid transporting 10B (putative),5,160563120-160852214,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA034574,Uncertain,,,,,Group enriched,Tissue enhanced,,colon: 36.0;rectum: 40.3,gallbladder: 21.4,Cell line enriched,23,WM-115: 13.6
ATP10D,"ATPVD, KIAA1487",ENSG00000145246,ATPase phospholipid transporting 10D (putative),4,47485288-47593486,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA050808,Approved,,Supported,Nucleoplasm<br>Plasma membrane,Renal cancer:5.00e-8 (favourable),Expressed in all,Mixed,,,parathyroid gland: 22.5,Cell line enhanced,,HAP1: 43.0
ATP11A,"ATPIH, ATPIS, KIAA1021",ENSG00000068650,ATPase phospholipid transporting 11A,13,112690329-112887168,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA035583, HPA035584",Approved,,Enhanced,Vesicles,Renal cancer:7.44e-4 (favourable),Expressed in all,Expressed in all,,,lung: 59.1,Mixed,,
ATP11B,"ATPIF, ATPIR, KIAA0956",ENSG00000058063,ATPase phospholipid transporting 11B (putative),3,182793500-182921635,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036237, HPA036238",Uncertain,,Approved,Microtubule organizing center<br>Cytosol,"Pancreatic cancer:1.09e-4 (unfavourable), Endometrial cancer:3.44e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 58.0,Expressed in all,,
ATP11C,"ATPIG, ATPIQ",ENSG00000101974,ATPase phospholipid transporting 11C,X,139726346-139945276,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA030830,Approved,,,,,Expressed in all,Mixed,,,liver: 25.6,Mixed,,
ATP12A,"#945, 2, ATP1AL1, HK",ENSG00000075673,ATPase H+/K+ transporting non-gastric alpha2 subunit,13,24680411-24712493,"Enzymes, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA039526,Approved,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 12.7;placenta: 8.2;tonsil: 14.1,skin: 7.1,Not detected,,
ATP1A1,,ENSG00000163399,ATPase Na+/K+ transporting subunit alpha 1,1,116372668-116410261,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB018702, CAB069993",Enhanced,,,,"Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 2487.1,Expressed in all,,
ATP1A2,"FHM2, MHP2",ENSG00000018625,ATPase Na+/K+ transporting subunit alpha 2,1,160115759-160143591,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,CAB022230,Approved,,,,,Tissue enriched,Group enriched,6,cerebral cortex: 434.2;skeletal muscle: 307.0,heart muscle: 57.5,Cell line enhanced,,AF22: 50.7;HHSteC: 12.3;RH-30: 16.2;U-87 MG: 10.1
ATP1A3,DYT12,ENSG00000105409,ATPase Na+/K+ transporting subunit alpha 3,19,41966582-41997497,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB033630, HPA045367, HPA056446",Enhanced,,,,"Renal cancer:3.02e-6 (unfavourable), Pancreatic cancer:6.15e-5 (favourable), Ovarian cancer:3.44e-4 (unfavourable)",Group enriched,Tissue enhanced,,cerebral cortex: 378.4;heart muscle: 86.0,testis: 54.5,Cell line enhanced,,Daudi: 39.5;SCLC-21H: 148.3;SH-SY5Y: 57.8
ATP1A4,ATP1AL2,ENSG00000132681,ATPase Na+/K+ transporting subunit alpha 4,1,160151570-160186977,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Urothelial cancer:2.20e-4 (favourable),Group enriched,Tissue enhanced,,placenta: 10.2;testis: 18.2;urinary bladder: 8.6,lymph node: 4.1,Group enriched,11,BEWO: 19.2;HDLM-2: 48.0;RT4: 49.0
ATP23,"KUB3, XRCC6BP1",ENSG00000166896,ATP23 metallopeptidase and ATP synthase assembly factor homolog,12,57941541-57957269,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035804, HPA043204",Uncertain,,Enhanced,Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol,Renal cancer:1.44e-5 (unfavourable),Expressed in all,Tissue enhanced,,testis: 26.8,rectum: 5.5,Expressed in all,,
ATP2A1,"ATP2A, SERCA1",ENSG00000196296,ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1,16,28878405-28904509,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002310, CAB032706",Enhanced,,Approved,Endoplasmic reticulum,,Tissue enhanced,Tissue enriched,96,skeletal muscle: 2781.9,esophagus: 29.1,Mixed,,
ATP2A2,"ATP2B, DAR, SERCA2",ENSG00000174437,ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2,12,110280756-110351093,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA062605, HPA067892",Enhanced,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,skeletal muscle: 1006.4,Expressed in all,,
ATP2A3,SERCA3,ENSG00000074370,ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3,17,3923870-3964464,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA007180, CAB010882",Approved,,,,"Cervical cancer:4.69e-5 (favourable), Head and neck cancer:2.51e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 118.4,Cell line enhanced,,Daudi: 133.8;HMC-1: 234.0;MOLT-4: 202.8;SK-BR-3: 146.3
ATP2B1,PMCA1,ENSG00000070961,ATPase plasma membrane Ca2+ transporting 1,12,89588049-89709300,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB005605, HPA011166, HPA012945",Enhanced,,Supported,Plasma membrane,Liver cancer:7.74e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 143.6,Expressed in all,,
ATP2B2,PMCA2,ENSG00000157087,ATPase plasma membrane Ca2+ transporting 2,3,10324023-10708031,"Enzymes, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,CAB005606,Enhanced,,,,,Tissue enhanced,Tissue enriched,7,cerebral cortex: 64.7,salivary gland: 9.7,Group enriched,7,EFO-21: 3.0;RPMI-8226: 5.4;SCLC-21H: 4.2;SH-SY5Y: 1.2
ATP2B3,"CFAP39, CLA2, PMCA3, SCAX1",ENSG00000067842,ATPase plasma membrane Ca2+ transporting 3,X,153517676-153582939,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA001583,Enhanced,,Uncertain,Golgi apparatus<br>Plasma membrane,,Not detected,Group enriched,8,adrenal gland: 12.1;cerebral cortex: 19.0,fallopian tube: 2.0,Cell line enhanced,,SCLC-21H: 11.7;SH-SY5Y: 3.1;THP-1: 1.7;U-937: 1.9
ATP2B4,"ATP2B2, MXRA1, PMCA4",ENSG00000058668,ATPase plasma membrane Ca2+ transporting 4,1,203626561-203744081,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB016118, HPA040431",Enhanced,,Supported,Plasma membrane,Renal cancer:1.21e-4 (unfavourable),Expressed in all,Expressed in all,,,smooth muscle: 254.6,Expressed in all,,
ATP2C1,"ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1",ENSG00000017260,ATPase secretory pathway Ca2+ transporting 1,3,130850595-131016712,"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB010207, HPA035116, HPA069684",Supported,,Enhanced,Golgi apparatus,"Liver cancer:5.06e-6 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Renal cancer:1.55e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 138.3,Expressed in all,,
ATP2C2,"KIAA0703, SPCA2",ENSG00000064270,ATPase secretory pathway Ca2+ transporting 2,16,84368527-84464187,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA052262, HPA075812",Approved,,Approved,Plasma membrane<br>Focal adhesion sites,Endometrial cancer:6.20e-6 (favourable),Mixed,Tissue enhanced,,rectum: 38.4,skin: 30.0,Cell line enhanced,,MCF7: 18.7;RT4: 15.1;SK-BR-3: 24.6;T-47d: 10.4
ATP4A,ATP6A,ENSG00000105675,ATPase H+/K+ transporting alpha subunit,19,35550043-35563658,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA039154,Enhanced,,,,,Tissue enriched,Tissue enriched,260,stomach: 557.9,pancreas: 2.1,Not detected,,
ATP5B,ATPSB,ENSG00000110955,"ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide",12,56638175-56646068,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001520, HPA001528, CAB017527",Enhanced,,Enhanced,Mitochondria,"Renal cancer:1.43e-9 (favourable), Breast cancer:7.17e-6 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 1254.0,Expressed in all,,
ATP6V1A,"ATP6A1, ATP6V1A1, VA68, Vma1, VPP2",ENSG00000114573,ATPase H+ transporting V1 subunit A,3,113747019-113812056,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB006910, HPA035083, HPA035084",Approved,,Supported,Nucleus<br>Vesicles<br>Cytosol,Renal cancer:3.82e-12 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 151.4,Expressed in all,,
ATP7A,MNK,ENSG00000165240,ATPase copper transporting alpha,X,77910656-78050395,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA012887, HPA048107",Approved,,Supported,Golgi apparatus<br>Vesicles,Renal cancer:8.38e-4 (favourable),Expressed in all,Mixed,,,parathyroid gland: 15.3,Mixed,,
ATP7B,WND,ENSG00000123191,ATPase copper transporting beta,13,51930436-52012125,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA009137, HPA013187",Supported,,Supported,Golgi apparatus,Endometrial cancer:5.01e-4 (unfavourable),Mixed,Mixed,,,testis: 13.9,Cell line enhanced,,BEWO: 31.8;HEL: 46.9;RPTEC TERT1: 22.2
ATP8A1,ATPIA,ENSG00000124406,ATPase phospholipid transporting 8A1,4,42408373-42657105,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA052935,Enhanced,,Supported,Vesicles,Renal cancer:5.54e-10 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 68.8;thyroid gland: 66.6,cerebral cortex: 58.2,Cell line enhanced,,AN3-CA: 25.5;Daudi: 33.1
ATP8A2,"ATPIB, ML-1",ENSG00000132932,ATPase phospholipid transporting 8A2,13,25372071-26025851,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA039926, HPA040033",Approved,,Supported,Nucleoplasm<br>Plasma membrane,,Mixed,Group enriched,6,cerebral cortex: 26.4;testis: 10.7,adrenal gland: 2.9,Cell line enhanced,,HMC-1: 19.3;SCLC-21H: 3.9
ATP8B1,"ATPIC, BRIC, FIC1, PFIC, PFIC1",ENSG00000081923,ATPase phospholipid transporting 8B1,18,57646426-57803101,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA018673, HPA018674",Enhanced,,,,"Colorectal cancer:2.60e-4 (favourable), Renal cancer:6.35e-4 (favourable)",Expressed in all,Expressed in all,,,colon: 94.6,Cell line enhanced,,RT4: 171.8
ATP8B2,"ATPID, KIAA1137",ENSG00000143515,ATPase phospholipid transporting 8B2,1,154325553-154351307,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA046680,Approved,,,,"Urothelial cancer:5.29e-5 (unfavourable), Pancreatic cancer:1.60e-4 (favourable)",Expressed in all,Mixed,,,smooth muscle: 61.1,Mixed,,
ATP8B3,ATPIK,ENSG00000130270,ATPase phospholipid transporting 8B3,19,1782075-1812276,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,Renal cancer:4.80e-9 (unfavourable),Mixed,Tissue enriched,7,testis: 28.7,bone marrow: 4.0,Cell line enhanced,,Karpas-707: 16.1;U-266/70: 14.2
ATP8B4,"ATPIM, KIAA1939",ENSG00000104043,ATPase phospholipid transporting 8B4 (putative),15,49858238-50182817,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040254,Approved,,Approved,Nucleoplasm<br>Vesicles,,Mixed,Tissue enhanced,,bone marrow: 23.0,endometrium: 9.3,Cell line enhanced,,HMC-1: 32.2;THP-1: 16.5;U-937: 60.0
ATP9A,"ATPIIA, KIAA0611",ENSG00000054793,ATPase phospholipid transporting 9A (putative),20,51596514-51768634,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB020699, HPA035630",Approved,,,,Renal cancer:5.67e-5 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 155.8,Mixed,,
ATP9B,ATPIIB,ENSG00000166377,ATPase phospholipid transporting 9B (putative),18,79069285-79378283,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029364,Approved,,,,,Expressed in all,Expressed in all,,,testis: 39.0,Expressed in all,,
ATR,"FRP1, MEC1, SCKL, SCKL1",ENSG00000175054,ATR serine/threonine kinase,3,142449235-142578826,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA054320,,,Supported,Nucleoplasm<br>Golgi apparatus,"Pancreatic cancer:1.23e-5 (unfavourable), Liver cancer:8.39e-5 (unfavourable)",Expressed in all,Mixed,,,parathyroid gland: 15.4,Expressed in all,,
ATRX,"JMS, MRX52, RAD54, XH2, XNP",ENSG00000085224,"ATRX, chromatin remodeler",X,77504878-77786269,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001906, CAB009372, HPA064684, CAB068176",Supported,,Supported,Nuclear bodies,,Expressed in all,Expressed in all,,,parathyroid gland: 54.4,Expressed in all,,
ATXN3,"ATX3, JOS, MJD, SCA3",ENSG00000066427,Ataxin 3,14,92038652-92106621,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB021976, HPA024123, HPA069338",Uncertain,,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,,Mixed,Mixed,,,testis: 18.6,Expressed in all,,
ATXN3L,MJDL,ENSG00000123594,Ataxin 3 like,X,13318236-13320399,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA024123, HPA027539",Uncertain,,,,,Not detected,Tissue enriched,37,testis: 4.9,placenta: 0.1,Not detected,,
AUH,,ENSG00000148090,AU RNA binding methylglutaconyl-CoA hydratase,9,91213815-91361913,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA004171,Enhanced,,,,Renal cancer:0.00e+0 (favourable),Expressed in all,Expressed in all,,,kidney: 65.4,Expressed in all,,
AURKA,"AIK, ARK1, AurA, BTAK, PPP1R47, STK15, STK6, STK7",ENSG00000087586,Aurora kinase A,20,56369389-56392337,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB001454, HPA002636",Approved,,Approved,Nucleus<br>Centrosome<br>Cytosol,"Renal cancer:1.47e-8 (unfavourable), Endometrial cancer:9.40e-5 (unfavourable), Liver cancer:1.49e-4 (unfavourable), Pancreatic cancer:6.13e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 53.5,lymph node: 24.0,Expressed in all,,
AURKB,"Aik2, AIM-1, ARK2, AurB, IPL1, PPP1R48, STK12, STK5",ENSG00000178999,Aurora kinase B,17,8204733-8210600,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005862, HPA037708",Enhanced,,Enhanced,Nucleoplasm<br>Midbody,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.24e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lymph node: 44.4,tonsil: 33.8,Mixed,,
AURKC,"ARK3, AurC, STK13",ENSG00000105146,Aurora kinase C,19,57230802-57235548,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA034859,Uncertain,,,,,Mixed,Tissue enriched,11,testis: 73.7,spleen: 6.9,Cell line enriched,7,NTERA-2: 39.0
AWAT1,DGAT2L3,ENSG00000204195,Acyl-CoA wax alcohol acyltransferase 1,X,70234655-70240627,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA063412,Supported,,,,,Not detected,Not detected,,,breast: 0.8,Not detected,,
AWAT2,"DGAT2L4, MFAT",ENSG00000147160,Acyl-CoA wax alcohol acyltransferase 2,X,70040542-70049938,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA062748,Approved,,,,,Tissue enriched,Tissue enhanced,,breast: 2.0;skin: 1.2,testis: 0.5,Not detected,,
AXL,"ARK, JTK11, Tyro7, UFO",ENSG00000167601,AXL receptor tyrosine kinase,19,41219203-41261766,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"CAB032501, HPA037422, HPA037423",Uncertain,,,,Renal cancer:2.53e-7 (unfavourable),Expressed in all,Expressed in all,,,smooth muscle: 54.6,Mixed,,
AZU1,"AZAMP, AZU, CAP37, HBP, HUMAZUR, NAZC",ENSG00000172232,Azurocidin 1,19,825097-832018,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA055851,Enhanced,,,,,Mixed,Tissue enriched,525,bone marrow: 1311.2,skin: 2.4,Cell line enriched,6,THP-1: 722.4
B3GALNT1,"B3GALT3, beta3Gal-T3, galT3, GLOB, P1",ENSG00000169255,"Beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)",3,161083883-161105384,"Blood group antigen proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA041204,,,Approved,Vesicles,,Expressed in all,Mixed,,,thyroid gland: 47.9,Cell line enhanced,,RT4: 111.0
B3GALT1,beta3Gal-T1,ENSG00000172318,"Beta-1,3-galactosyltransferase 1",2,167868948-167874041,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.2;colon: 3.7;rectum: 4.0,skeletal muscle: 1.8,Cell line enriched,7,AN3-CA: 33.1
B3GALT2,beta3Gal-T2,ENSG00000162630,"Beta-1,3-galactosyltransferase 2",1,193179045-193186654,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 29.0;gallbladder: 26.0,heart muscle: 14.9,Group enriched,5,AF22: 19.6;ASC TERT1: 6.1;LHCN-M2: 11.4;WM-115: 23.5
B3GALT4,"beta3Gal-T4, GalT4",ENSG00000235863,"Beta-1,3-galactosyltransferase 4",6,33277132-33284832,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA043001,Approved,,,,,Expressed in all,Mixed,,,testis: 3.8,Cell line enhanced,,CAPAN-2: 1.8;SCLC-21H: 1.4;SK-BR-3: 1.5
B3GALT6,beta3GalT6,ENSG00000176022,"Beta-1,3-galactosyltransferase 6",1,1232265-1235041,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Expressed in all,,,cerebral cortex: 12.0,Expressed in all,,
B3GAT1,"CD57, GlcAT-P, HNK-1, LEU7, NK-1",ENSG00000109956,"Beta-1,3-glucuronyltransferase 1",11,134378504-134411918,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002500, CAB010893, HPA069468",Enhanced,,Supported,Vesicles,,Group enriched,Tissue enriched,11,cerebral cortex: 115.4,thyroid gland: 10.3,Cell line enhanced,,AF22: 22.9;HMC-1: 22.4;NTERA-2: 22.3;SH-SY5Y: 9.0
B3GAT2,GlcAT-S,ENSG00000112309,"Beta-1,3-glucuronyltransferase 2",6,70856679-70957038,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA012059,Uncertain,,,,,Group enriched,Tissue enriched,10,cerebral cortex: 19.5,testis: 1.8,Cell line enriched,25,SCLC-21H: 25.9
B3GAT3,GlcAT-I,ENSG00000149541,"Beta-1,3-glucuronyltransferase 3",11,62615296-62622175,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA051328,Approved,,,,"Liver cancer:5.11e-6 (unfavourable), Glioma:5.96e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 36.9,Expressed in all,,
B3GNT2,"B3GN-T1, B3GN-T2, B3GNT-2, B3GNT1, BETA3GNT",ENSG00000170340,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2",2,62196113-62224731,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA005997,Approved,,Approved,Vesicles,Pancreatic cancer:1.62e-4 (unfavourable),Expressed in all,Expressed in all,,,lung: 51.0,Expressed in all,,
B3GNT3,"B3GN-T3, B3GNT-3, beta3Gn-T3, HP10328, TMEM3",ENSG00000179913,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3",19,17794828-17813082,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA024298,Enhanced,,,,"Lung cancer:4.25e-5 (unfavourable), Pancreatic cancer:2.16e-4 (unfavourable)",Mixed,Tissue enhanced,,rectum: 50.8,colon: 48.8,Cell line enhanced,,A-431: 43.3;BEWO: 45.1;CAPAN-2: 113.3;RT4: 37.2;SK-BR-3: 32.5
B3GNT4,"B3GN-T4, beta3Gn-T4",ENSG00000176383,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4",12,122203543-122208952,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA055261,Uncertain,,Approved,Nucleoli<br>Mitochondria,Renal cancer:3.52e-6 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 4.3;skin: 2.9,kidney: 1.9,Cell line enhanced,,HDLM-2: 4.5;hTCEpi: 4.9;T-47d: 5.0
B3GNT5,"B3GN-T5, beta3Gn-T5",ENSG00000176597,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5",3,183253244-183298504,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA017292,Uncertain,,Approved,Nucleoli,"Renal cancer:1.30e-7 (unfavourable), Pancreatic cancer:7.23e-6 (unfavourable), Liver cancer:5.09e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 49.1,Mixed,,
B3GNT6,B3Gn-T6,ENSG00000198488,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6",11,77034398-77041973,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA012158, HPA039805",Enhanced,Approved,,,Colorectal cancer:2.31e-4 (favourable),Group enriched,Tissue enhanced,,colon: 21.7;rectum: 18.2;stomach: 23.5,small intestine: 7.9,Not detected,,
B4GALNT1,"beta1-4GalNAc-T, GALGT, SPG26",ENSG00000135454,"Beta-1,4-N-acetyl-galactosaminyltransferase 1",12,57623410-57633355,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA008968, HPA015128",Enhanced,,,,Renal cancer:3.18e-14 (unfavourable),Tissue enriched,Tissue enriched,6,cerebral cortex: 26.2,seminal vesicle: 4.0,Cell line enhanced,,EFO-21: 33.8;HDLM-2: 29.7
B4GALNT3,"B4GalNac-T3, FLJ16224, FLJ40362",ENSG00000139044,"Beta-1,4-N-acetyl-galactosaminyltransferase 3",12,460364-563509,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA011404,Enhanced,,,,Endometrial cancer:1.69e-10 (favourable),Mixed,Tissue enhanced,,stomach: 69.3,colon: 21.5,Cell line enhanced,,BEWO: 37.3;NTERA-2: 17.2
B4GALNT4,"FLJ25045, NGalNAc-T1",ENSG00000182272,"Beta-1,4-N-acetyl-galactosaminyltransferase 4",11,369796-382116,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA053126,Uncertain,,Approved,Nucleoplasm<br>Microtubules<br>Cytokinetic bridge<br>Mitotic spindle,,Mixed,Tissue enhanced,,cerebral cortex: 30.9;ovary: 11.7,"endometrium,fallopian tube: 6.9",Cell line enhanced,,AF22: 38.5;NTERA-2: 34.8;SCLC-21H: 50.7;SH-SY5Y: 55.6
B4GALT1,"beta4Gal-T1, GGTB2",ENSG00000086062,"Beta-1,4-galactosyltransferase 1",9,33104082-33167356,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA010806, HPA010807",Enhanced,,Enhanced,Golgi apparatus,"Endometrial cancer:6.85e-7 (favourable), Lung cancer:1.25e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 140.5,Expressed in all,,
B4GALT2,beta4Gal-T2,ENSG00000117411,"Beta-1,4-galactosyltransferase 2",1,43978943-43991170,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007620, HPA047739",Enhanced,,Supported,Golgi apparatus<br>Vesicles,"Liver cancer:2.96e-5 (unfavourable), Renal cancer:3.62e-5 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 49.4,Mixed,,
B4GALT3,beta4Gal-T3,ENSG00000158850,"Beta-1,4-galactosyltransferase 3",1,161171310-161177968,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA010793,Approved,,Supported,Golgi apparatus,"Renal cancer:7.12e-7 (unfavourable), Liver cancer:5.87e-5 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 31.1,Expressed in all,,
B4GALT4,beta4Gal-T4,ENSG00000121578,"Beta-1,4-galactosyltransferase 4",3,119211732-119241103,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA046819, HPA063546",Approved,,Supported,Golgi apparatus,Liver cancer:4.04e-4 (unfavourable),Expressed in all,Expressed in all,,,epididymis: 75.8,Expressed in all,,
B4GALT6,beta4GalT-VI,ENSG00000118276,"Beta-1,4-galactosyltransferase 6",18,31622247-31685836,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB020701, HPA058284",Approved,,,,"Renal cancer:6.40e-5 (favourable), Pancreatic cancer:5.65e-4 (favourable)",Expressed in all,Mixed,,,cerebral cortex: 21.6,Cell line enhanced,,WM-115: 124.6
B4GALT7,"beta4Gal-T7, XGALT-1",ENSG00000027847,"Beta-1,4-galactosyltransferase 7",5,177600100-177610347,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA042330,Supported,,,,Glioma:1.90e-4 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 27.3,Expressed in all,,
BAAT,BAT,ENSG00000136881,Bile acid-CoA:amino acid N-acyltransferase,9,101360417-101383519,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021251, HPA021330",Supported,,Uncertain,Vesicles,"Renal cancer:4.24e-7 (unfavourable), Liver cancer:4.97e-4 (favourable)",Tissue enriched,Tissue enriched,16,liver: 340.4,gallbladder: 21.1,Cell line enhanced,,A549: 1.8
BACE1,BACE,ENSG00000186318,Beta-secretase 1,11,117285207-117316259,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,CAB016358,Approved,,Supported,Plasma membrane,Urothelial cancer:6.76e-4 (unfavourable),Expressed in all,Expressed in all,,,pancreas: 100.7,Mixed,,
BACE2,"AEPLC, ALP56, CEAP1, DRAP",ENSG00000182240,Beta-site APP-cleaving enzyme 2,21,41167801-41282518,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035416,Approved,,,,"Cervical cancer:1.11e-4 (unfavourable), Glioma:8.13e-4 (unfavourable)",Expressed in all,Mixed,,,stomach: 30.5,Cell line enhanced,,SK-BR-3: 43.8;WM-115: 41.2
BAP1,"hucep-6, KIAA0272, UCHL2",ENSG00000163930,BRCA1 associated protein 1,3,52401013-52410350,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004322, HPA028814, HPA028815, HPA055560",Approved,,Enhanced,Nucleoplasm<br>Cytosol,Renal cancer:3.29e-7 (favourable),Expressed in all,Expressed in all,,,testis: 118.2,Expressed in all,,
BARD1,,ENSG00000138376,BRCA1 associated RING domain 1,2,214725646-214809711,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB034106, HPA035354, HPA044864",Enhanced,,Supported,Nuclear speckles,,Expressed in all,Mixed,,,testis: 11.1,Mixed,,
BAZ1B,"WBSCR10, WBSCR9, WSTF",ENSG00000009954,Bromodomain adjacent to zinc finger domain 1B,7,73440398-73522278,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB037081, CAB037158, HPA067010",Supported,,Supported,Nuclear bodies,,Expressed in all,Expressed in all,,,parathyroid gland: 54.8,Expressed in all,,
BBOX1,"BBH, BBOX, G-BBH, gamma-BBH",ENSG00000129151,Gamma-butyrobetaine hydroxylase 1,11,27040725-27127809,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007600, HPA027823",Enhanced,Approved,,,"Renal cancer:1.45e-5 (favourable), Endometrial cancer:6.65e-4 (unfavourable)",Group enriched,Tissue enriched,7,kidney: 473.0,liver: 66.1,Cell line enhanced,,hTCEpi: 9.6;RPTEC TERT1: 6.3
BCAT1,BCT1,ENSG00000060982,Branched chain amino acid transaminase 1,12,24810022-24949459,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA048592,Uncertain,,,,"Renal cancer:1.38e-4 (unfavourable), Head and neck cancer:3.55e-4 (unfavourable), Stomach cancer:4.95e-4 (unfavourable), Urothelial cancer:8.54e-4 (unfavourable)",Expressed in all,Mixed,,,placenta: 21.4,Cell line enhanced,,NTERA-2: 283.1;RH-30: 298.1
BCAT2,"BCAM, BCT2",ENSG00000105552,Branched chain amino acid transaminase 2,19,48795062-48811029,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA054091,Enhanced,,,,Renal cancer:3.68e-5 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 54.1,Expressed in all,,
BCHE,"CHE1, CHE2, E1",ENSG00000114200,Butyrylcholinesterase,3,165772904-165837472,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA001560,Approved,,,,Head and neck cancer:1.06e-4 (unfavourable),Group enriched,Tissue enhanced,,liver: 265.5,endometrium: 67.7,Cell line enriched,7,Karpas-707: 542.1
BCKDHA,"MSU, OVD1A",ENSG00000248098,"Branched chain keto acid dehydrogenase E1, alpha polypeptide",19,41397460-41425005,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA036640,Supported,,,,"Renal cancer:5.33e-10 (favourable), Thyroid cancer:3.27e-5 (unfavourable), Head and neck cancer:9.37e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 56.0,Expressed in all,,
BCKDHB,,ENSG00000083123,Branched chain keto acid dehydrogenase E1 subunit beta,6,80106647-80346270,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA031580,Approved,,,,Renal cancer:5.54e-9 (favourable),Expressed in all,Expressed in all,,,liver: 39.9,Expressed in all,,
BCKDK,,ENSG00000103507,Branched chain ketoacid dehydrogenase kinase,16,31106107-31112791,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA017995, HPA056067",Supported,,Supported,Mitochondria,,Expressed in all,Expressed in all,,,parathyroid gland: 34.3,Expressed in all,,
BCO1,"BCDO, BCDO1, BCMO, BCMO1, FLJ10730",ENSG00000135697,Beta-carotene oxygenase 1,16,81238448-81291142,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA043811,,,Uncertain,Actin filaments<br>Microtubule organizing center,,Mixed,Tissue enhanced,,duodenum: 8.7;small intestine: 14.8,kidney: 3.3,Cell line enhanced,,A549: 9.9;EFO-21: 7.6;HAP1: 3.2;NTERA-2: 4.4;RPTEC TERT1: 6.2
BCO2,"B-DIOX-II, BCDO2, FLJ34464",ENSG00000197580,Beta-carotene oxygenase 2,11,112175467-112224699,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039825, HPA040695",Uncertain,,,,,Mixed,Tissue enhanced,,heart muscle: 21.7;liver: 25.7,adrenal gland: 16.9,Cell line enhanced,,CAPAN-2: 5.2;HHSteC: 10.3
BCR,"ALL, BCR1, CML, D22S11, D22S662, PHL",ENSG00000186716,"BCR, RhoGEF and GTPase activating protein",22,23179704-23318037,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB010421, CAB018545, HPA038337",Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:9.15e-10 (favourable),Expressed in all,Mixed,,,cerebral cortex: 47.0,Expressed in all,,
BDH1,"BDH, SDR9C1",ENSG00000161267,3-hydroxybutyrate dehydrogenase 1,3,197509783-197573323,"Candidate cardiovascular disease genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030947, HPA058709",Enhanced,,Enhanced,Mitochondria,"Renal cancer:7.12e-8 (favourable), Liver cancer:9.86e-7 (favourable), Cervical cancer:1.09e-4 (favourable)",Expressed in all,Tissue enriched,6,liver: 170.2,colon: 27.0,Cell line enhanced,,U-937: 60.1
BDH2,"DHRS6, FLJ13261, PRO20933, SDR15C1, UCPA-OR, UNQ6308",ENSG00000164039,3-hydroxybutyrate dehydrogenase 2,4,103079435-103099883,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036028, HPA036029",Enhanced,,Supported,Cytosol,"Renal cancer:4.45e-13 (favourable), Lung cancer:1.20e-4 (favourable), Endometrial cancer:5.21e-4 (favourable), Thyroid cancer:7.75e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 456.2,Expressed in all,,
BHMT,BHMT1,ENSG00000145692,Betaine--homocysteine S-methyltransferase,5,79111779-79132290,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038285, HPA058310",Enhanced,,Supported,Cytosol,Liver cancer:7.32e-4 (favourable),Tissue enhanced,Group enriched,225,kidney: 788.8;liver: 563.6,urinary bladder: 3.0,Cell line enhanced,,Hep G2: 2.4;NTERA-2: 1.4;SCLC-21H: 1.1
BHMT2,,ENSG00000132840,Betaine--homocysteine S-methyltransferase 2,5,79069717-79089466,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044573,Enhanced,,,,,Group enriched,Group enriched,6,kidney: 362.7;liver: 238.5,epididymis: 46.2,Cell line enhanced,,Hep G2: 53.5;hTEC/SVTERT24-B: 46.4;U-87 MG: 18.9
BIRC2,"API1, c-IAP1, cIAP1, hiap-2, MIHB, RNF48",ENSG00000110330,Baculoviral IAP repeat containing 2,11,102347211-102378670,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA005513, CAB020661",Supported,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 45.8,Mixed,,
BIRC3,"API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49",ENSG00000023445,Baculoviral IAP repeat containing 3,11,102317450-102339403,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002317,Enhanced,Approved,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:6.66e-6 (unfavourable), Pancreatic cancer:3.03e-4 (unfavourable), Breast cancer:3.60e-4 (favourable), Colorectal cancer:9.35e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 138.1,appendix: 117.5,Cell line enhanced,,CAPAN-2: 106.1;Daudi: 77.5;HDLM-2: 96.2;hTERT-HME1: 79.1
BIRC6,BRUCE,ENSG00000115760,Baculoviral IAP repeat containing 6,2,32357028-32618899,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA074409, HPA074738",,,Supported,Golgi apparatus<br>Vesicles<br>Mitotic spindle,,Expressed in all,Mixed,,,parathyroid gland: 31.4,Expressed in all,,
BIRC7,"KIAP, ML-IAP, mliap, RNF50",ENSG00000101197,Baculoviral IAP repeat containing 7,20,63235883-63240507,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047850,,,Supported,Nucleus<br>Microtubule organizing center<br>Cytosol,,Tissue enriched,Tissue enhanced,,placenta: 9.2,skin: 2.7,Cell line enhanced,,REH: 32.5;SK-MEL-30: 145.1;U-937: 33.0
BLK,MGC10442,ENSG00000136573,"BLK proto-oncogene, Src family tyrosine kinase",8,11494001-11564604,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005093, HPA069571",Approved,,Approved,Nucleoplasm,,Mixed,Group enriched,10,appendix: 22.0;lymph node: 61.2;spleen: 40.6;tonsil: 51.4,urinary bladder: 4.3,Group enriched,6,Daudi: 99.9;REH: 39.4;RPMI-8226: 47.4;U-698: 55.4;U-87 MG: 29.9
BLM,"BS, RECQ2, RECQL3",ENSG00000197299,Bloom syndrome RecQ like helicase,15,90717327-90816165,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA005689,Approved,,Supported,Nucleus<br>Cytosol,,Mixed,Mixed,,,lymph node: 3.8,Mixed,,
BLMH,BH,ENSG00000108578,Bleomycin hydrolase,17,30248195-30292056,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039548, HPA064307",Enhanced,,Supported,Nucleoplasm<br>Nuclear bodies<br>Cytosol,,Expressed in all,Expressed in all,,,skin: 139.9,Mixed,,
BLVRA,BLVR,ENSG00000106605,Biliverdin reductase A,7,43758680-43807342,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA019709, HPA042865, HPA054322",Approved,,Supported,Cytosol,Lung cancer:8.65e-4 (favourable),Expressed in all,Expressed in all,,,epididymis: 158.1,Mixed,,
BLVRB,"FLR, SDR43U1",ENSG00000090013,Biliverdin reductase B,19,40447789-40465840,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041698, HPA041937",Enhanced,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Pancreatic cancer:3.90e-4 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 338.3,Cell line enhanced,,A549: 442.0;K-562: 413.4
BMP1,PCOLC,ENSG00000168487,Bone morphogenetic protein 1,8,22164736-22212326,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA014572,Enhanced,,,,Renal cancer:3.37e-9 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 21.1,smooth muscle: 10.5,Mixed,,
BMP2K,"BIKe, DKFZp434K0614",ENSG00000138756,BMP2 inducible kinase,4,78776342-78916372,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026436, HPA026451, HPA026501",Approved,,Supported,Nuclear speckles,Colorectal cancer:1.74e-4 (favourable),Mixed,Mixed,,,testis: 32.8,Expressed in all,,
BMPR1A,"ACVRLK3, ALK3, CD292",ENSG00000107779,Bone morphogenetic protein receptor type 1A,10,86756601-86932838,"Cancer-related genes, CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB019398,Approved,,Approved,Cytosol,"Liver cancer:8.93e-4 (unfavourable), Glioma:9.38e-4 (favourable)",Expressed in all,Mixed,,,thyroid gland: 19.6,Mixed,,
BMPR1B,"ALK6, CDw293",ENSG00000138696,Bone morphogenetic protein receptor type 1B,4,94757968-95158448,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Endometrial cancer:2.84e-4 (favourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 37.2;prostate: 37.0",seminal vesicle: 21.0,Cell line enhanced,,A549: 21.1;SH-SY5Y: 20.1
BMPR2,"BMPR-II, BMPR3, BRK-3, PPH1, T-ALK",ENSG00000204217,Bone morphogenetic protein receptor type 2,2,202376936-202567751,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA017385, HPA049014",Approved,,Approved,Nucleoplasm<br>Plasma membrane,,Expressed in all,Expressed in all,,,placenta: 44.9,Mixed,,
BMX,"ETK, PSCTK3",ENSG00000102010,BMX non-receptor tyrosine kinase,X,15464246-15556529,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA001048, CAB032495",Enhanced,,Supported,Nucleoplasm<br>Plasma membrane,,Mixed,Tissue enriched,18,epididymis: 125.0,placenta: 6.9,Cell line enriched,125,HUVEC TERT2: 295.8
BPGM,,ENSG00000172331,Bisphosphoglycerate mutase,7,134646808-134679813,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA016493, HPA028735",Enhanced,,Approved,Nucleoli,"Renal cancer:1.54e-8 (favourable), Cervical cancer:7.95e-4 (favourable)",Expressed in all,Expressed in all,,,placenta: 65.1,Expressed in all,,
BPNT1,,ENSG00000162813,"3'(2'), 5'-bisphosphate nucleotidase 1",1,220057482-220090462,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA048461,Approved,,Approved,Nuclear speckles,Renal cancer:6.38e-4 (favourable),Expressed in all,Expressed in all,,,small intestine: 48.6,Expressed in all,,
BRAF,BRAF1,ENSG00000157764,"B-Raf proto-oncogene, serine/threonine kinase",7,140719327-140924764,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001328, CAB004552, HPA071048",Approved,,Approved,Vesicles<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 41.8,Expressed in all,,
BRAP,"BRAP2, IMP, RNF52",ENSG00000089234,BRCA1 associated protein,12,111642146-111685986,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA040357, HPA058820",Approved,,Supported,Nuclear membrane<br>Cytosol,Liver cancer:7.65e-6 (unfavourable),Expressed in all,Tissue enriched,6,testis: 120.9,bone marrow: 21.3,Expressed in all,,
BRCA1,"BRCC1, FANCS, PPP1R53, RNF53",ENSG00000012048,"BRCA1, DNA repair associated",17,43044295-43170245,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB001946, HPA034966, HPA057371",Enhanced,,,,,Expressed in all,Mixed,,,testis: 23.9,Expressed in all,,
BRCC3,"BRCC36, C6.1A, CXorf53",ENSG00000185515,BRCA1/BRCA2-containing complex subunit 3,X,155071420-155123074,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA048737,,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,parathyroid gland: 21.2,Expressed in all,,
BRIP1,"BACH1, FANCJ, OF",ENSG00000136492,BRCA1 interacting protein C-terminal helicase 1,17,61681266-61863521,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA005474,Approved,,Supported,Nucleus<br>Nuclear membrane,"Colorectal cancer:3.45e-5 (favourable), Head and neck cancer:3.62e-4 (favourable)",Mixed,Tissue enhanced,,testis: 14.4,bone marrow: 5.0,Cell line enhanced,,MCF7: 77.7
BRSK1,KIAA1811,ENSG00000160469,BR serine/threonine kinase 1,19,55282072-55312533,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA021212, HPA061719",Supported,,Supported,Nucleoplasm,"Renal cancer:7.98e-6 (unfavourable), Pancreatic cancer:1.02e-4 (favourable)",Expressed in all,Tissue enriched,6,cerebral cortex: 137.8,parathyroid gland: 24.6,Cell line enhanced,,SCLC-21H: 65.8;SH-SY5Y: 53.1
BRSK2,"C11orf7, PEN11B, STK29",ENSG00000174672,BR serine/threonine kinase 2,11,1389899-1462689,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA073690,,,Approved,Golgi apparatus,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 61.7;pancreas: 19.2,testis: 9.5,Cell line enhanced,,NTERA-2: 27.4;SCLC-21H: 74.9
BST1,CD157,ENSG00000109743,Bone marrow stromal cell antigen 1,4,15702950-15738313,"CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA050121,Uncertain,,,,,Expressed in all,Tissue enhanced,,bone marrow: 105.5,duodenum: 54.8,Cell line enhanced,,THP-1: 60.3;TIME: 39.6;U-937: 45.8;WM-115: 51.6
BTD,,ENSG00000169814,Biotinidase,3,15601341-15645822,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA052275,Uncertain,,,,Renal cancer:2.60e-9 (favourable),Expressed in all,Expressed in all,,,epididymis: 53.0,Mixed,,
BTK,"AGMX1, ATK, IMD1, PSCTK1, XLA",ENSG00000010671,Bruton tyrosine kinase,X,101349447-101390796,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001198, HPA002028, CAB016689",Enhanced,,Supported,Vesicles,,Expressed in all,Tissue enhanced,,lymph node: 65.2;tonsil: 70.8,spleen: 52.7,Cell line enhanced,,Daudi: 147.2;HEL: 256.7;HMC-1: 868.2
BUB1,"BUB1A, BUB1L, hBUB1",ENSG00000169679,BUB1 mitotic checkpoint serine/threonine kinase,2,110637698-110678114,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006123,,,Supported,Nucleoplasm<br>Cytosol,"Liver cancer:1.03e-5 (unfavourable), Pancreatic cancer:2.37e-5 (unfavourable), Endometrial cancer:3.65e-4 (unfavourable), Lung cancer:3.94e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 69.5,lymph node: 24.1,Mixed,,
BUB1B,"Bub1A, BUBR1, MAD3L, SSK1",ENSG00000156970,BUB1 mitotic checkpoint serine/threonine kinase B,15,40161023-40221136,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA008419,,,Supported,Cytosol,"Liver cancer:7.43e-6 (unfavourable), Pancreatic cancer:1.79e-4 (unfavourable), Lung cancer:3.56e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 40.3,lymph node: 14.9,Mixed,,
C1GALT1,"C1GALT, T-synthase",ENSG00000106392,"Core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1",7,7156934-7248651,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA011294, HPA012819",Enhanced,,Approved,Nuclear bodies<br>Cytosol,"Liver cancer:1.42e-5 (unfavourable), Cervical cancer:1.04e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 95.0,Expressed in all,,
C1R,,ENSG00000159403,Complement C1r,12,7080209-7092607,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001251, HPA001551",Uncertain,,Uncertain,Nucleoplasm<br>Cytosol,Renal cancer:1.94e-14 (unfavourable),Expressed in all,Expressed in all,,,liver: 1226.4,Cell line enhanced,,ASC diff: 1273.8;ASC TERT1: 658.4;BJ hTERT+: 685.9;BJ hTERT+ SV40 Large T+ RasG12V: 496.0;HSkMC: 797.4
C1RL,"C1r-LP, C1RL1",ENSG00000139178,Complement C1r subcomponent like,12,7089587-7109273,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA011338, CAB026172",Supported,,Approved,Microtubules<br>Cytosol,"Renal cancer:1.52e-7 (unfavourable), Breast cancer:7.92e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 83.7,Cell line enhanced,,HSkMC: 60.9
C1S,,ENSG00000182326,Complement C1s,12,6988259-7071032,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016722, HPA018852",Supported,,Approved,Nucleus<br>Cytosol,"Renal cancer:7.44e-15 (unfavourable), Liver cancer:7.73e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 1326.7,Cell line enhanced,,ASC diff: 521.6;ASC TERT1: 703.0;BJ hTERT+: 271.2;HSkMC: 390.5
C2,,ENSG00000166278,Complement C2,6,31897785-31945672,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB016775,Supported,,,,Renal cancer:2.64e-7 (unfavourable),Tissue enriched,Tissue enhanced,,liver: 86.3;lung: 42.6,placenta: 21.9,Group enriched,5,Hep G2: 30.0;Karpas-707: 94.7
C9orf3,"AOPEP, AP-O, APO, C90RF3, FLJ14675",ENSG00000148120,Chromosome 9 open reading frame 3,9,94726701-95087218,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA004633, HPA072729",Approved,,Approved,Cell Junctions,Renal cancer:6.33e-5 (favourable),Expressed in all,Expressed in all,,,skin: 50.0,Mixed,,
CA1,Car1,ENSG00000133742,Carbonic anhydrase 1,8,85327608-85379014,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006558, CAB025790",Enhanced,,,,,Group enriched,Group enriched,30,bone marrow: 1216.6;colon: 1022.8;rectum: 2316.0,smooth muscle: 49.9,Cell line enriched,1560,HEL: 1145.7
CA12,HsT18816,ENSG00000074410,Carbonic anhydrase 12,15,63321378-63382161,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA008773, CAB025181, CAB062549, CAB068179, HPA073203",Enhanced,,Approved,Nucleus<br>Vesicles,Pancreatic cancer:3.80e-6 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 308.4;skin: 168.3,rectum: 102.9,Cell line enhanced,,A549: 191.8;RT4: 180.0;T-47d: 269.1;U-138 MG: 295.7;U-87 MG: 352.6
CA13,"CAXIII, FLJ37995, MGC59868",ENSG00000185015,Carbonic anhydrase 13,8,85220587-85284073,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA024689, CAB025567",Enhanced,,Uncertain,Nucleus<br>Nucleoli<br>Vesicles,Renal cancer:9.40e-4 (favourable),Expressed in all,Mixed,,,small intestine: 16.5,Cell line enhanced,,HEL: 14.2
CA14,,ENSG00000118298,Carbonic anhydrase 14,1,150257159-150265078,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008482,Approved,,Approved,Plasma membrane,,Group enriched,Tissue enhanced,,cerebral cortex: 10.6;seminal vesicle: 21.2,skeletal muscle: 9.4,Group enriched,23,AF22: 83.4;AN3-CA: 46.6;NTERA-2: 65.8;SK-MEL-30: 134.5
CA2,"CA-II, CAII, Car2",ENSG00000104267,Carbonic anhydrase 2,8,85463852-85481493,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001550, CAB010102",Enhanced,,,,Renal cancer:5.57e-6 (favourable),Expressed in all,Tissue enhanced,,colon: 604.8;rectum: 627.5;stomach: 918.8,kidney: 308.3,Group enriched,11,HaCaT: 204.1;HEK 293: 884.1;THP-1: 278.7
CA3,"CAIII, Car3",ENSG00000164879,Carbonic anhydrase 3,8,85373436-85449040,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004967, HPA021775, HPA026700",Enhanced,,,,Breast cancer:4.24e-6 (favourable),Group enriched,Tissue enriched,13,skeletal muscle: 1838.7,prostate: 138.3,Group enriched,34,HEL: 44.2;RH-30: 77.2
CA4,"CAIV, Car4, RP17",ENSG00000167434,Carbonic anhydrase 4,17,60149936-60170899,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA011089, HPA017258",Enhanced,,Supported,Vesicles,,Mixed,Tissue enhanced,,colon: 253.5;rectum: 180.9,adipose tissue: 88.7,Not detected,,
CA5A,"CA5, CAV, CAVA",ENSG00000174990,Carbonic anhydrase 5A,16,87881546-87936529,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,liver: 1.3,bone marrow: 0.8,Cell line enhanced,,Hep G2: 1.4
CA5B,,ENSG00000169239,Carbonic anhydrase 5B,X,15688830-15788409,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA012618,Uncertain,,Supported,Mitochondria,Renal cancer:6.66e-6 (favourable),Expressed in all,Mixed,,,"cervix, uterine: 34.1",Cell line enhanced,,hTERT-HME1: 26.3
CA6,,ENSG00000131686,Carbonic anhydrase 6,1,8945867-8975092,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA028550, HPA028692",Enhanced,,,,,Mixed,Tissue enriched,154,salivary gland: 3805.4,breast: 24.7,Mixed,,
CA7,,ENSG00000168748,Carbonic anhydrase 7,16,66844379-66854153,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA047237,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,colon: 54.6;rectum: 49.8,small intestine: 10.7,Cell line enhanced,,REH: 1.0;SCLC-21H: 1.0;THP-1: 1.2
CA9,"CAIX, MN",ENSG00000107159,Carbonic anhydrase 9,9,35673856-35681159,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB005100, CAB017107, HPA055207",Enhanced,,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable)",Mixed,Tissue enhanced,,gallbladder: 36.0;stomach: 93.6,small intestine: 14.5,Group enriched,11,A-431: 152.1;HDLM-2: 84.3;U-87 MG: 337.9
CAD,,ENSG00000084774,"Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase",2,27217390-27243943,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB007781, HPA057266, HPA069341",Supported,,Supported,Nucleoplasm,"Liver cancer:1.72e-11 (unfavourable), Renal cancer:1.82e-4 (unfavourable)",Expressed in all,Expressed in all,,,skin: 22.0,Expressed in all,,
CAMK1,CaMKI,ENSG00000134072,Calcium/calmodulin dependent protein kinase I,3,9757342-9769992,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB031904, HPA051409",Approved,,Approved,Cytosol,Liver cancer:7.52e-4 (unfavourable),Expressed in all,Expressed in all,,,adrenal gland: 107.7,Cell line enhanced,,HMC-1: 344.4
CAMK1D,CKLiK,ENSG00000183049,Calcium/calmodulin dependent protein kinase ID,10,12349482-12835545,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA007266,Enhanced,,Approved,Nucleus<br>Cytosol,Lung cancer:1.67e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 52.0,"skin,thyroid gland: 21.9",Cell line enhanced,,HDLM-2: 105.6;U-266/70: 38.2
CAMK1G,"CLICKIII, dJ272L16.1, VWS1",ENSG00000008118,Calcium/calmodulin dependent protein kinase IG,1,209583717-209613938,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 32.3;ovary: 27.7,seminal vesicle: 7.4,Cell line enhanced,,hTEC/SVTERT24-B: 7.0;SK-MEL-30: 1.6
CAMK2A,"CAMKA, CaMKIINalpha, KIAA0968",ENSG00000070808,Calcium/calmodulin dependent protein kinase II alpha,5,150219491-150290291,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB004330, HPA051783, HPA051785, HPA053973",Enhanced,,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,,Tissue enriched,Tissue enriched,9,cerebral cortex: 283.6,skeletal muscle: 33.3,Cell line enhanced,,SCLC-21H: 6.2;U-87 MG: 4.3
CAMK2B,"CAM2, CAMK2, CAMKB",ENSG00000058404,Calcium/calmodulin dependent protein kinase II beta,7,44217150-44334577,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB006849, HPA026307, HPA051783, HPA051785, HPA053973",Enhanced,Supported,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 214.1,skeletal muscle: 46.1,Cell line enriched,12,SCLC-21H: 88.9
CAMK2D,CAMKD,ENSG00000145349,Calcium/calmodulin dependent protein kinase II delta,4,113451032-113761927,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA026281, HPA051783, HPA051785, HPA053973",Approved,,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,,Expressed in all,Expressed in all,,,heart muscle: 110.3,Mixed,,
CAMK2G,CAMKG,ENSG00000148660,Calcium/calmodulin dependent protein kinase II gamma,10,73812501-73874591,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA040656, HPA051783, HPA051785, HPA053973",Approved,,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,,Expressed in all,Expressed in all,,,cerebral cortex: 119.0,Expressed in all,,
CAMK4,CaMK-GR,ENSG00000152495,Calcium/calmodulin dependent protein kinase IV,5,111223653-111494886,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB004347, HPA011753, HPA017206",Approved,,Supported,Nucleoplasm<br>Nucleoli fibrillar center,,Mixed,Tissue enhanced,,cerebral cortex: 16.5;testis: 17.0,lymph node: 9.7,Cell line enhanced,,HDLM-2: 83.9;SH-SY5Y: 35.7
CAMKK1,"CAMKKA, DKFZp761M0423, MGC34095",ENSG00000004660,Calcium/calmodulin dependent protein kinase kinase 1,17,3860315-3894891,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009111, HPA028062",Approved,,Supported,Cytosol,Pancreatic cancer:2.65e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 51.5,seminal vesicle: 14.7,Cell line enhanced,,U-87 MG: 27.3
CAMKK2,"CAMKK, CAMKKB, KIAA0787, MGC15254",ENSG00000110931,Calcium/calmodulin dependent protein kinase kinase 2,12,121237691-121298308,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017389,Approved,,Supported,Cytosol,,Expressed in all,Expressed in all,,,cerebral cortex: 102.8,Expressed in all,,
CAMKMT,"C2orf34, CLNMT",ENSG00000143919,Calmodulin-lysine N-methyltransferase,2,44361950-44772592,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA067912,,,Supported,Nucleus,Glioma:5.39e-4 (favourable),Expressed in all,Expressed in all,,,testis: 24.3,Expressed in all,,
CAMKV,"MGC8407, VACAMKL",ENSG00000164076,CaM kinase like vesicle associated,3,49857988-49870222,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007656, CAB034931",Enhanced,,Approved,Nucleoplasm<br>Cytokinetic bridge,,Group enriched,Tissue enriched,55,cerebral cortex: 86.2,testis: 1.5,Cell line enhanced,,AF22: 6.4;HAP1: 8.9;NTERA-2: 30.7;SCLC-21H: 12.2;SH-SY5Y: 7.1
CANT1,"SCAN-1, SHAPY",ENSG00000171302,Calcium activated nucleotidase 1,17,78991717-79009867,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA019627, HPA019639, HPA022818",Enhanced,,,,"Liver cancer:1.41e-4 (unfavourable), Lung cancer:2.90e-4 (unfavourable), Renal cancer:6.21e-4 (unfavourable)",Expressed in all,Expressed in all,,,prostate: 115.7,Expressed in all,,
CAPN1,"CANP, CANPL1, muCANP, muCL",ENSG00000014216,Calpain 1,11,65180566-65212006,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA005992,Enhanced,,Supported,Cytosol,"Renal cancer:7.06e-8 (favourable), Pancreatic cancer:4.30e-4 (unfavourable)",Expressed in all,Expressed in all,,,esophagus: 243.9,Expressed in all,,
CAPN10,,ENSG00000142330,Calpain 10,2,240586716-240617705,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004170, HPA056098",Approved,,Approved,Nucleoplasm<br>Cytosol,"Liver cancer:4.78e-6 (unfavourable), Pancreatic cancer:7.94e-5 (favourable), Head and neck cancer:8.47e-5 (favourable)",Expressed in all,Mixed,,,"skin,spleen: 14.5",Expressed in all,,
CAPN11,,ENSG00000137225,Calpain 11,6,44158811-44184402,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB018070, HPA030955",Enhanced,,,,,Not detected,Tissue enriched,33,testis: 54.8,"adipose tissue,breast: 1.6",Group enriched,5,NTERA-2: 2.2;TIME: 4.7
CAPN12,,ENSG00000182472,Calpain 12,19,38730187-38769904,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA053322,,,Approved,Nucleoplasm<br>Focal adhesion sites,Renal cancer:5.90e-6 (unfavourable),Mixed,Group enriched,6,"cervix, uterine: 7.3;gallbladder: 35.5",lung: 3.8,Cell line enriched,16,HMC-1: 34.3
CAPN13,FLJ23523,ENSG00000162949,Calpain 13,2,30722771-30820542,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA029496, HPA029497, HPA030034",Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,rectum: 26.8;small intestine: 32.4;stomach: 26.5,duodenum: 20.8,Cell line enhanced,,RT4: 7.4;SK-BR-3: 16.4;T-47d: 2.8
CAPN14,,ENSG00000214711,Calpain 14,2,31173056-31233858,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enriched,26,esophagus: 88.2,tonsil: 3.3,Cell line enhanced,,U-266/70: 2.1
CAPN15,SOLH,ENSG00000103326,Calpain 15,16,527717-554636,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA011960,Uncertain,,Approved,Nucleus,,Expressed in all,Mixed,,,small intestine: 17.8,Expressed in all,,
CAPN2,"CANPL2, CANPml, mCANP",ENSG00000162909,Calpain 2,1,223701593-223776018,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA024470,Approved,Approved,Supported,Cytosol,"Renal cancer:2.19e-4 (favourable), Pancreatic cancer:2.50e-4 (unfavourable), Urothelial cancer:6.21e-4 (unfavourable)",Expressed in all,Expressed in all,,,lung: 267.0,Mixed,,
CAPN3,"CANP3, LGMD2, LGMD2A, nCL-1, p94",ENSG00000092529,Calpain 3,15,42359500-42412318,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA040052,Enhanced,,,,,Tissue enriched,Tissue enhanced,,epididymis: 217.3;skeletal muscle: 336.8,skin: 92.9,Cell line enriched,27,SK-MEL-30: 202.7
CAPN5,"ADNIV, HTRA3, nCL-3, VRNI",ENSG00000149260,Calpain 5,11,77066932-77126155,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,CAB033237,Uncertain,,,,Endometrial cancer:2.16e-6 (unfavourable),Expressed in all,Mixed,,,colon: 61.0,Mixed,,
CAPN6,"CalpM, CANPX, CAPNX",ENSG00000077274,Calpain 6,X,111245103-111270523,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040383,,,Uncertain,Cytosol,,Tissue enhanced,Tissue enhanced,,epididymis: 255.9;placenta: 117.0;seminal vesicle: 100.4,endometrium: 37.2,Group enriched,9,HAP1: 3.4;HDLM-2: 9.9;NTERA-2: 16.1
CAPN7,PalBH,ENSG00000131375,Calpain 7,3,15206152-15252918,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046617,Uncertain,,,,Colorectal cancer:4.85e-5 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 39.4,Expressed in all,,
CAPN8,nCL-2,ENSG00000203697,Calpain 8,1,223538007-223665734,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA073939,,,Approved,Nucleoplasm<br>Nuclear membrane<br>Vesicles,,Tissue enhanced,Tissue enriched,8,stomach: 286.5,rectum: 37.3,Cell line enriched,9,RT4: 62.5
CAPN9,"GC36, nCL-4",ENSG00000135773,Calpain 9,1,230747384-230802003,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA020398, CAB033483",Enhanced,,,,,Mixed,Tissue enhanced,,rectum: 25.2;stomach: 58.9,colon: 14.4,Cell line enriched,9,SCLC-21H: 17.8
CARM1,PRMT4,ENSG00000142453,Coactivator associated arginine methyltransferase 1,19,10871513-10923070,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB032961, HPA043561, HPA048073",Supported,,Enhanced,Nucleoplasm,"Renal cancer:7.88e-6 (unfavourable), Urothelial cancer:8.37e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 37.1,Expressed in all,,
CARNMT1,"C9orf41, FLJ25795",ENSG00000156017,Carnosine N-methyltransferase 1,9,74981020-75028423,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026756,Uncertain,,,,,Expressed in all,Expressed in all,,,testis: 30.0,Expressed in all,,
CARNS1,"ATPGD1, KIAA1394",ENSG00000172508,Carnosine synthase 1,11,67414968-67425607,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA038569,Enhanced,,,,,Group enriched,Group enriched,11,cerebral cortex: 37.1;skeletal muscle: 25.9,heart muscle: 2.9,Cell line enriched,10,RPMI-8226: 5.3
CARS,CARS1,ENSG00000110619,Cysteinyl-tRNA synthetase,11,3000922-3057613,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737",Enhanced,,Enhanced,Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.16e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 28.2,Mixed,,
CARS2,FLJ12118,ENSG00000134905,"Cysteinyl-tRNA synthetase 2, mitochondrial (putative)",13,110641412-110713603,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA041776,Uncertain,,Approved,Nucleoplasm<br>Mitochondria,"Renal cancer:2.49e-5 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Endometrial cancer:1.84e-4 (favourable)",Expressed in all,Expressed in all,,,"cervix, uterine: 28.4",Expressed in all,,
CASK,"CAGH39, FGS4, LIN2, TNRC8",ENSG00000147044,Calcium/calmodulin dependent serine protein kinase,X,41514934-41923463,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB001949, HPA023857",Enhanced,,Approved,Nucleoplasm<br>Cytosol,Pancreatic cancer:6.11e-5 (unfavourable),Expressed in all,Expressed in all,,,small intestine: 34.5,Mixed,,
CASP1,"ICE, IL1BC",ENSG00000137752,Caspase 1,11,105025443-105035250,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002685, HPA003056",Approved,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:3.11e-4 (unfavourable),Expressed in all,Mixed,,,small intestine: 139.8,Cell line enhanced,,BJ hTERT+: 91.3;U-937: 106.2
CASP10,MCH4,ENSG00000003400,Caspase 10,2,201182881-201229406,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003780, HPA017059",Approved,,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:6.05e-7 (unfavourable), Liver cancer:8.54e-4 (unfavourable)",Expressed in all,Mixed,,,spleen: 24.1,Cell line enhanced,,HUVEC TERT2: 21.4
CASP14,"MGC119078, MGC119079, MICE",ENSG00000105141,Caspase 14,19,15049384-15058293,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB010059, HPA027062",Enhanced,,Approved,Nucleus<br>Mitochondria<br>Cytosol,"Pancreatic cancer:5.96e-4 (unfavourable), Lung cancer:7.59e-4 (unfavourable)",Tissue enhanced,Tissue enriched,55,skin: 558.6,breast: 10.1,Cell line enriched,6,hTCEpi: 34.2
CASP2,"ICH1, MGC2181, NEDD2, PPP1R57",ENSG00000106144,Caspase 2,7,143288215-143307696,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012175, HPA050678",Approved,,Approved,Nucleoplasm,"Renal cancer:5.01e-6 (unfavourable), Liver cancer:2.34e-4 (unfavourable), Ovarian cancer:2.89e-4 (favourable), Cervical cancer:7.38e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 24.9,Expressed in all,,
CASP3,"apopain, CPP32, CPP32B, Yama",ENSG00000164305,Caspase 3,4,184627696-184649509,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000091, HPA002643, CAB008381",Enhanced,,Supported,Nucleoplasm<br>Mitochondria,"Renal cancer:2.30e-5 (unfavourable), Endometrial cancer:2.24e-4 (favourable)",Expressed in all,Expressed in all,,,duodenum: 54.4,Expressed in all,,
CASP4,"ICE(rel)II, ICH-2, TX",ENSG00000196954,Caspase 4,11,104942866-104969436,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027588, CAB037167",Approved,,Approved,Plasma membrane<br>Cytosol,Renal cancer:3.27e-11 (unfavourable),Expressed in all,Expressed in all,,,placenta: 71.8,Mixed,,
CASP5,ICE(rel)III,ENSG00000137757,Caspase 5,11,104994235-105023168,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA040937,Uncertain,,,,,Group enriched,Group enriched,6,appendix: 20.2;colon: 15.9;duodenum: 10.1;rectum: 14.5;small intestine: 18.9,smooth muscle: 2.7,Cell line enriched,8,HHSteC: 3.1
CASP6,MCH2,ENSG00000138794,Caspase 6,4,109688622-109703583,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB003775, HPA011337, HPA024303",Enhanced,,Supported,Nucleus<br>Cytosol,"Colorectal cancer:2.64e-5 (favourable), Urothelial cancer:9.93e-4 (favourable)",Expressed in all,Expressed in all,,,small intestine: 46.1,Expressed in all,,
CASP7,"CMH-1, ICE-LAP3, MCH3",ENSG00000165806,Caspase 7,10,113679162-113730907,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,CAB025563,Approved,,,,"Breast cancer:2.11e-4 (favourable), Renal cancer:5.90e-4 (unfavourable)",Expressed in all,Expressed in all,,,small intestine: 74.4,Mixed,,
CASP8,"Casp-8, FLICE, MACH, MCH5",ENSG00000064012,Caspase 8,2,201233443-201287711,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001302, CAB002047, HPA005688, HPA006191",Approved,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:1.27e-6 (unfavourable), Ovarian cancer:1.25e-4 (favourable), Liver cancer:3.02e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 44.8,Expressed in all,,
CASP9,"APAF-3, ICE-LAP6, MCH6, PPP1R56",ENSG00000132906,Caspase 9,1,15490832-15526534,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA001473, CAB004348, HPA046488",Approved,,Approved,Mitochondria,"Urothelial cancer:1.67e-5 (favourable), Breast cancer:5.91e-4 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 37.1,Expressed in all,,
CAT,,ENSG00000121691,Catalase,11,34438925-34472062,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB001515, HPA051282, HPA055838",Enhanced,,Supported,Vesicles<br>Cytosol,"Renal cancer:1.96e-8 (favourable), Liver cancer:9.67e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 625.4,Cell line enhanced,,HL-60: 310.1
CBL,"c-Cbl, CBL2, RNF55",ENSG00000110395,Cbl proto-oncogene,11,119206276-119313926,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004350, HPA027956",Enhanced,,Supported,Cytosol,,Expressed in all,Mixed,,,testis: 33.9,Expressed in all,,
CBLB,"Cbl-b, RNF56",ENSG00000114423,Cbl proto-oncogene B,3,105655461-105869552,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA018327, HPA019880",Approved,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,lymph node: 28.0,Cell line enhanced,,U-138 MG: 63.4
CBLC,"CBL-3, CBL-SL, RNF57",ENSG00000142273,Cbl proto-oncogene C,19,44777869-44800634,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB008087, HPA035266",Approved,,Approved,Nucleoplasm,Renal cancer:3.11e-6 (favourable),Mixed,Tissue enhanced,,duodenum: 52.5;skin: 41.9;small intestine: 44.0,colon: 21.4,Cell line enhanced,,A-431: 38.2;BEWO: 28.0;CACO-2: 23.9;CAPAN-2: 51.1;HaCaT: 37.6;HBEC3-KT: 25.9;RT4: 29.6;SK-BR-3: 24.0
CBLL1,"FLJ23109, HAKAI, RNF188",ENSG00000105879,Cbl proto-oncogene like 1,7,107743697-107761667,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021773, HPA026699",Enhanced,,Supported,Nuclear speckles,,Expressed in all,Expressed in all,,,testis: 36.2,Expressed in all,,
CBR1,"CBR, SDR21C1",ENSG00000159228,Carbonyl reductase 1,21,36069941-36073166,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA018433,Approved,,Approved,Nucleus<br>Cytosol,"Breast cancer:2.18e-4 (favourable), Renal cancer:4.75e-4 (favourable)",Expressed in all,Expressed in all,,,duodenum: 544.9,Mixed,,
CBR3,SDR21C2,ENSG00000159231,Carbonyl reductase 3,21,36134912-36146566,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA018434,Uncertain,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:5.95e-6 (unfavourable),Expressed in all,Mixed,,,skin: 20.7,Mixed,,
CBS,HIP4,ENSG00000160200,Cystathionine-beta-synthase,21,43053191-43076943,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA001223,Supported,,Approved,Nucleoli<br>Vesicles,,Mixed,Tissue enhanced,,liver: 56.6;ovary: 31.1,cerebral cortex: 19.8,Cell line enhanced,,HAP1: 171.2;HHSteC: 181.6
CBSL,,ENSG00000274276,Cystathionine-beta-synthase like,21,6444869-6468040,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001223,Supported,,Approved,Nucleoli<br>Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 45.9;liver: 27.3,thyroid gland: 22.2,Cell line enhanced,,AN3-CA: 123.4;NTERA-2: 245.4;SH-SY5Y: 82.5
CCNB1IP1,"C14orf18, HEI10",ENSG00000100814,Cyclin B1 interacting protein 1,14,20311368-20333312,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:5.18e-6 (favourable),Expressed in all,Expressed in all,,,ovary: 120.9,Expressed in all,,
CD38,,ENSG00000004468,CD38 molecule,4,15778275-15853230,"Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002493, HPA022132, CAB025255, HPA052381",Enhanced,,Supported,Plasma membrane,Endometrial cancer:9.68e-4 (favourable),Expressed in all,Mixed,,,seminal vesicle: 27.6,Cell line enhanced,,Daudi: 91.6;Karpas-707: 24.9;MOLT-4: 26.4;REH: 23.7;U-266/70: 20.4
CDA,CDD,ENSG00000158825,Cytidine deaminase,1,20588948-20618908,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA064202,Enhanced,,Approved,Nucleoplasm,"Pancreatic cancer:8.56e-5 (unfavourable), Cervical cancer:5.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,,bone marrow: 104.6;esophagus: 56.7,liver: 33.3,Cell line enhanced,,A-431: 142.3;CAPAN-2: 92.8;HeLa: 100.6;SiHa: 200.2
CDC14A,"cdc14, Cdc14A1, Cdc14A2, DFNB105",ENSG00000079335,Cell division cycle 14A,1,100345025-100520277,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA023783,Approved,,Supported,Nucleoplasm<br>Nuclear bodies<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 56.3,fallopian tube: 19.8,Cell line enhanced,,K-562: 25.8
CDC14B,"Cdc14B1, Cdc14B2, CDC14B3, hCDC14B",ENSG00000081377,Cell division cycle 14B,9,96490241-96619830,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA013312, HPA064747",Approved,,Supported,Nucleoplasm,"Renal cancer:2.97e-10 (favourable), Thyroid cancer:2.82e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 18.6,Cell line enhanced,,ASC TERT1: 21.4
CDC25A,,ENSG00000164045,Cell division cycle 25A,3,48157146-48188402,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA005855,,,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,,Tissue enhanced,Tissue enhanced,,testis: 24.4,bone marrow: 9.3,Expressed in all,,
CDC25B,,ENSG00000101224,Cell division cycle 25B,20,3786772-3806121,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038892, HPA038893, HPA075215",Enhanced,,Supported,Vesicles<br>Mitotic spindle,"Renal cancer:2.94e-13 (unfavourable), Liver cancer:1.19e-4 (unfavourable), Endometrial cancer:4.76e-4 (unfavourable)",Expressed in all,Mixed,,,lymph node: 56.6,Expressed in all,,
CDC25C,"CDC25, PPP1R60",ENSG00000158402,Cell division cycle 25C,5,138285265-138338355,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB003800, HPA066991",Approved,,Supported,Nuclear speckles,"Liver cancer:3.03e-6 (unfavourable), Colorectal cancer:2.49e-4 (favourable), Lung cancer:4.38e-4 (unfavourable)",Mixed,Tissue enriched,7,testis: 31.8,rectum: 4.4,Mixed,,
CDC34,"E2-CDC34, UBC3, UBE2R1",ENSG00000099804,Cell division cycle 34,19,531712-542092,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA002382, CAB005109, CAB047311",Approved,,Supported,Nuclear speckles<br>Cytosol,Liver cancer:7.57e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 63.5,Expressed in all,,
CDC42BPA,"FLJ23347, KIAA0451, MRCK, MRCKA, PK428",ENSG00000143776,CDC42 binding protein kinase alpha,1,226989865-227318474,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB070414, HPA071252",Approved,,Approved,Intermediate filaments,,Expressed in all,Expressed in all,,,testis: 45.2,Mixed,,
CDC42BPB,"KIAA1124, MRCKB",ENSG00000198752,CDC42 binding protein kinase beta,14,102932379-103057462,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA022821,Approved,,,,"Renal cancer:8.67e-10 (favourable), Lung cancer:2.38e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 75.1,Mixed,,
CDC42BPG,"DMPK2, HSMDPKIN, kappa-200, MRCKgamma",ENSG00000171219,CDC42 binding protein kinase gamma,11,64823387-64844569,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027382, HPA061836",Enhanced,,Supported,Cytosol,Renal cancer:5.99e-13 (favourable),Mixed,Tissue enhanced,,skin: 35.6,parathyroid gland: 14.5,Cell line enhanced,,BEWO: 30.1;HaCaT: 21.0;MCF7: 25.1;SCLC-21H: 19.6
CDC7,"CDC7L1, HsCdc7, Hsk1, huCdc7",ENSG00000097046,Cell division cycle 7,1,91500893-91525764,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002669, HPA035831",Enhanced,,Supported,Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle,"Renal cancer:1.89e-15 (unfavourable), Liver cancer:3.15e-6 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 32.0,spleen: 17.2,Expressed in all,,
CDIPT,"PIS, PIS1",ENSG00000103502,CDP-diacylglycerol--inositol 3-phosphatidyltransferase,16,29858357-29863736,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA056597,Approved,,Approved,Nucleoplasm<br>Nuclear membrane<br>Plasma membrane,Cervical cancer:9.40e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 112.7,Expressed in all,,
CDK1,"CDC2, CDC28A",ENSG00000170312,Cyclin dependent kinase 1,10,60778331-60794852,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA003387, CAB003799",Enhanced,,Enhanced,Nucleus<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.10e-6 (unfavourable), Pancreatic cancer:4.15e-6 (unfavourable), Lung cancer:7.88e-4 (unfavourable), Cervical cancer:8.81e-4 (favourable)",Expressed in all,Mixed,,,lymph node: 47.5,Expressed in all,,
CDK10,PISSLRE,ENSG00000185324,Cyclin dependent kinase 10,16,89680737-89696364,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007451, HPA059634, HPA067060",Uncertain,,Supported,Nucleoplasm<br>Midbody<br>Midbody ring,"Pancreatic cancer:2.69e-4 (favourable), Urothelial cancer:3.63e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 31.4,Expressed in all,,
CDK11A,"CDC2L2, CDC2L3, CDK11-p110, CDK11-p46, CDK11-p58, p58GTA, PITSLRE",ENSG00000008128,Cyclin dependent kinase 11A,1,1702730-1724324,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB010467, HPA025061, HPA073626",Enhanced,,Supported,Nuclear speckles<br>Cytosol,"Renal cancer:1.15e-6 (unfavourable), Melanoma:5.06e-4 (unfavourable)",Expressed in all,Expressed in all,,,small intestine: 35.1,Expressed in all,,
CDK12,"CRK7, CRKR, CRKRS, KIAA0904",ENSG00000167258,Cyclin dependent kinase 12,17,39461511-39564907,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA008038,Supported,,Supported,Nucleus,,Expressed in all,Expressed in all,,,testis: 33.8,Expressed in all,,
CDK13,"CDC2L, CDC2L5, CHED, KIAA1791",ENSG00000065883,Cyclin dependent kinase 13,7,39950037-40097134,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA059241,Uncertain,,Supported,Nuclear speckles,,Expressed in all,Expressed in all,,,parathyroid gland: 33.5,Expressed in all,,
CDK14,"PFTAIRE1, PFTK1",ENSG00000058091,Cyclin dependent kinase 14,7,90466424-91210590,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA015267,Approved,,Supported,Nucleus<br>Cytosol,"Breast cancer:5.86e-4 (favourable), Stomach cancer:7.79e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 56.7,Mixed,,
CDK15,"ALS2CR7, PFTAIRE2, PFTK2",ENSG00000138395,Cyclin dependent kinase 15,2,201790461-201895550,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA015786,Uncertain,,Approved,Nucleus<br>Golgi apparatus,,Not detected,Tissue enhanced,,epididymis: 21.2;ovary: 8.4,testis: 4.0,Cell line enhanced,,BJ hTERT+: 23.4;BJ hTERT+ SV40 Large T+ RasG12V: 22.4;HBF TERT88: 33.8;HMC-1: 58.6;LHCN-M2: 16.8
CDK16,"FLJ16665, PCTAIRE, PCTAIRE1, PCTGAIRE, PCTK1",ENSG00000102225,Cyclin dependent kinase 16,X,47217860-47229997,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000974, HPA001366, CAB016535",Approved,,Uncertain,Plasma membrane<br>Microtubules<br>Cytosol,Liver cancer:2.02e-6 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 96.9,Expressed in all,,
CDK17,"PCTAIRE2, PCTK2",ENSG00000059758,Cyclin dependent kinase 17,12,96278261-96400560,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA015325,Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:1.09e-6 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 71.8,Expressed in all,,
CDK18,"PCTAIRE3, PCTK3",ENSG00000117266,Cyclin dependent kinase 18,1,205504595-205532793,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045429,Approved,,Approved,Actin filaments,"Renal cancer:5.07e-6 (unfavourable), Urothelial cancer:2.81e-5 (favourable)",Expressed in all,Mixed,,,heart muscle: 62.0,Cell line enhanced,,HBEC3-KT: 25.4
CDK19,"bA346C16.3, CDC2L6, CDK11, KIAA1028",ENSG00000155111,Cyclin dependent kinase 19,6,110609978-110815958,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007053,Approved,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:4.72e-5 (unfavourable), Liver cancer:3.56e-4 (unfavourable)",Expressed in all,Mixed,,,prostate: 42.4,Expressed in all,,
CDK2,,ENSG00000123374,Cyclin dependent kinase 2,12,55966769-55972784,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB013115, HPA066915",Enhanced,,Enhanced,Nucleoplasm<br>Centrosome<br>Cytosol,"Renal cancer:1.46e-10 (unfavourable), Liver cancer:8.61e-5 (unfavourable), Head and neck cancer:9.94e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 65.5,Expressed in all,,
CDK20,"CCRK, p42",ENSG00000156345,Cyclin dependent kinase 20,9,87966441-87974753,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007666, HPA027379, HPA027401",Enhanced,,Supported,Nucleoplasm,"Renal cancer:2.12e-5 (favourable), Endometrial cancer:2.59e-4 (favourable)",Expressed in all,Mixed,,,fallopian tube: 20.7,Cell line enhanced,,SCLC-21H: 21.7;THP-1: 19.4
CDK3,,ENSG00000250506,Cyclin dependent kinase 3,17,76000906-76005999,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007420,Uncertain,,Approved,Cytosol,,Mixed,Mixed,,,skin: 29.2,Expressed in all,,
CDK4,PSK-J3,ENSG00000135446,Cyclin dependent kinase 4,12,57747727-57756013,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006024, CAB013116, CAB069405",Enhanced,,Supported,Nucleus<br>Nuclear membrane<br>Nucleoli<br>Cytosol,"Liver cancer:2.09e-7 (unfavourable), Renal cancer:3.15e-5 (unfavourable)",Expressed in all,Expressed in all,,,endometrium: 121.7,Group enriched,9,HBEC3-KT: 1874.1;LHCN-M2: 2370.6;RH-30: 8554.0
CDK5,PSSALRE,ENSG00000164885,Cyclin dependent kinase 5,7,151053812-151058530,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB008909, HPA064535",Enhanced,,Supported,Nucleus<br>Plasma membrane<br>Cell Junctions,,Expressed in all,Expressed in all,,,cerebral cortex: 49.9,Expressed in all,,
CDK6,PLSTIRE,ENSG00000105810,Cyclin dependent kinase 6,7,92604921-92836594,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA002637, CAB004363",Enhanced,,Supported,Nucleoplasm<br>Cytosol,"Pancreatic cancer:3.86e-6 (unfavourable), Urothelial cancer:2.33e-5 (unfavourable)",Expressed in all,Mixed,,,parathyroid gland: 34.2,Cell line enhanced,,MOLT-4: 366.7;REH: 201.1
CDK7,"CAK, CAK1, CDKN7, MO15, STK1",ENSG00000134058,Cyclin dependent kinase 7,5,69234795-69277430,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004364, HPA007932",Enhanced,,,,"Renal cancer:9.42e-7 (unfavourable), Pancreatic cancer:3.09e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 23.7,Mixed,,
CDK8,K35,ENSG00000132964,Cyclin dependent kinase 8,13,26254104-26405238,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA044721,,,Approved,Nucleus,Stomach cancer:9.23e-4 (favourable),Expressed in all,Expressed in all,,,testis: 17.7,Mixed,,
CDK9,"C-2k, CDC2L4, PITALRE, TAK",ENSG00000136807,Cyclin dependent kinase 9,9,127785679-127790787,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004216, HPA006738",Supported,,Approved,Nucleoplasm<br>Cytoplasmic bodies,Renal cancer:8.92e-4 (unfavourable),Expressed in all,Expressed in all,,,ovary: 60.5,Expressed in all,,
CDKAL1,FLJ20342,ENSG00000145996,CDK5 regulatory subunit associated protein 1 like 1,6,20534457-21232404,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057474,,,Uncertain,Vesicles,Endometrial cancer:1.03e-4 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 16.0,Cell line enriched,6,SCLC-21H: 222.3
CDKL1,KKIALRE,ENSG00000100490,Cyclin dependent kinase like 1,14,50329404-50416461,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA059605, HPA065919",Uncertain,,Enhanced,Nucleoplasm<br>Vesicles,,Mixed,Mixed,,,fallopian tube: 34.5,Mixed,,
CDKL2,"KKIAMRE, P56",ENSG00000138769,Cyclin dependent kinase like 2,4,75578005-75630716,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040672,,,Approved,Nucleus<br>Centrosome,Renal cancer:6.88e-15 (favourable),Mixed,Tissue enhanced,,testis: 33.1,cerebral cortex: 9.8,Cell line enhanced,,A-431: 2.7;RPTEC TERT1: 3.3
CDKL3,NKIAMRE,ENSG00000006837,Cyclin dependent kinase like 3,5,134286350-134371047,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027751,,,Uncertain,Nucleoplasm<br>Vesicles,,Mixed,Tissue enriched,9,testis: 28.9,cerebral cortex: 3.2,Mixed,,
CDKL4,,ENSG00000205111,Cyclin dependent kinase like 4,2,39175646-39229588,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA067895,Uncertain,,,,,Not detected,Tissue enriched,8,testis: 5.3,"fallopian tube,placenta: 0.6",Cell line enhanced,,HL-60: 1.6;RT4: 1.1;SH-SY5Y: 2.8
CDKL5,"CFAP247, EIEE2, STK9",ENSG00000008086,Cyclin dependent kinase like 5,X,18425583-18653629,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002847, CAB011577",Supported,,Enhanced,Nucleoplasm,Renal cancer:5.54e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 31.0,testis: 14.4,Mixed,,
CDKN3,"CDI1, KAP",ENSG00000100526,Cyclin dependent kinase inhibitor 3,14,54396849-54420218,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005285, HPA039311, HPA058874",,,Enhanced,Cytosol,"Renal cancer:0.00e+0 (unfavourable), Lung cancer:4.52e-4 (unfavourable), Pancreatic cancer:7.46e-4 (unfavourable)",Expressed in all,Tissue enriched,11,testis: 342.6,lymph node: 31.7,Expressed in all,,
CDO1,,ENSG00000129596,Cysteine dioxygenase type 1,5,115804733-115816954,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036573, HPA057503",Enhanced,,Uncertain,Nucleoplasm,Liver cancer:1.91e-5 (favourable),Group enriched,Tissue enhanced,,epididymis: 137.5;liver: 209.9,adipose tissue: 104.0,Cell line enhanced,,AF22: 38.7;ASC diff: 32.4;HAP1: 14.4;NTERA-2: 14.5
CDS1,,ENSG00000163624,CDP-diacylglycerol synthase 1,4,84582979-84651338,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA036187, HPA064546",Enhanced,,Approved,Nucleus<br>Nuclear membrane,"Renal cancer:0.00e+0 (favourable), Colorectal cancer:5.22e-4 (favourable)",Expressed in all,Mixed,,,fallopian tube: 49.6,Cell line enhanced,,CAPAN-2: 39.2;hTCEpi: 39.6;SK-BR-3: 44.9
CDS2,,ENSG00000101290,CDP-diacylglycerol synthase 2,20,5126786-5197887,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA019698,Approved,,Approved,Endoplasmic reticulum<br>Cytosol,Renal cancer:3.53e-9 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 48.9,Expressed in all,,
CDY1,CDY1A,ENSG00000172288,Chromodomain Y-linked 1,Y,25622162-25624902,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,11,testis: 1.0,all non-specific tissues: 0.0,Not detected,,
CDY1B,,ENSG00000172352,Chromodomain Y-linked 1B,Y,24045229-24048019,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,40,testis: 4.0,all non-specific tissues: 0.0,Not detected,,
CDY2A,CDY2,ENSG00000182415,Chromodomain Y-linked 2A,Y,18025787-18028597,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,24,epididymis: 1.3;testis: 3.5,all non-specific tissues: 0.0,Not detected,,
CDY2B,CDY,ENSG00000129873,Chromodomain Y-linked 2B,Y,17877410-17880220,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Not detected,,,testis: 0.2,Not detected,,
CDYL,"CDYL1, DKFZP586C1622",ENSG00000153046,Chromodomain Y-like,6,4706159-4955551,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB012249, HPA035578",Enhanced,,Supported,Nuclear speckles,"Glioma:2.10e-4 (favourable), Liver cancer:2.20e-4 (unfavourable), Melanoma:7.52e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 27.7,Expressed in all,,
CECR1,"ADGF, IDGFL",ENSG00000093072,"Cat eye syndrome chromosome region, candidate 1",22,17178790-17221989,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007888,Approved,,,,"Pancreatic cancer:8.91e-4 (favourable), Ovarian cancer:9.26e-4 (favourable)",Expressed in all,Expressed in all,,,spleen: 161.4,Cell line enhanced,,CAPAN-2: 22.2;Karpas-707: 30.5;MOLT-4: 33.3;U-937: 32.1
CELA1,ELA1,ENSG00000139610,Chymotrypsin like elastase family member 1,12,51328443-51346679,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,adrenal gland: 2.5;pancreas: 1.3,lymph node: 0.9,Cell line enriched,6,BEWO: 5.2
CELA2A,ELA2A,ENSG00000142615,Chymotrypsin like elastase family member 2A,1,15456728-15472091,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,371,pancreas: 34335.1,ovary: 92.5,Cell line enhanced,,HMC-1: 1.1
CELA2B,"ELA2B, RP11-265F14.2",ENSG00000215704,Chymotrypsin like elastase family member 2B,1,15465909-15491400,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,262,pancreas: 4261.7,ovary: 16.2,Cell line enriched,5,U-138 MG: 3.8
CELA3A,"ELA3, ELA3A",ENSG00000142789,Chymotrypsin like elastase family member 3A,1,22001656-22012539,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA028086, HPA045650",Supported,,Approved,Cytosol,,Tissue enriched,Tissue enriched,352,pancreas: 56987.6,ovary: 161.9,Cell line enriched,24,MOLT-4: 20.6
CELA3B,"CBPP, ELA3B",ENSG00000219073,Chymotrypsin like elastase family member 3B,1,21977021-21998642,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA028086, HPA045650",Supported,,Approved,Cytosol,,Tissue enriched,Tissue enriched,296,pancreas: 10568.2,ovary: 35.6,Mixed,,
CEMIP,"HYBID, IR2155535, KIAA1199, TMEM2L",ENSG00000103888,Cell migration inducing hyaluronan binding protein,15,80779343-80951776,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Urothelial cancer:2.65e-4 (unfavourable),Expressed in all,Tissue enhanced,,endometrium: 53.2,appendix: 15.8,Cell line enhanced,,BJ: 172.4;BJ hTERT+: 260.3;fHDF/TERT166: 200.3;HSkMC: 122.9;U-138 MG: 89.3
CEPT1,,ENSG00000134255,Choline/ethanolamine phosphotransferase 1,1,111139627-111185102,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,Glioma:6.43e-4 (favourable),Expressed in all,Expressed in all,,,spleen: 37.1,Expressed in all,,
CERK,"dA59H18.2, dA59H18.3, DKFZp434E0211, FLJ21430, FLJ23239, hCERK, KIAA1646, LK4",ENSG00000100422,Ceramide kinase,22,46684411-46738261,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA064699,,,Approved,Vesicles,"Urothelial cancer:1.58e-4 (unfavourable), Pancreatic cancer:2.35e-4 (favourable), Endometrial cancer:4.75e-4 (unfavourable)",Expressed in all,Expressed in all,,,small intestine: 34.3,Mixed,,
CERS3,"LASS3, MGC27091",ENSG00000154227,Ceramide synthase 3,15,100400395-100544995,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA006092, HPA024356",Approved,,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,9,esophagus: 48.1;skin: 60.5;testis: 32.3;tonsil: 14.3,breast: 4.3,Cell line enriched,6,hTCEpi: 47.1
CERS5,"FLJ25304, LASS5, MGC45411, Trh4",ENSG00000139624,Ceramide synthase 5,12,50129306-50167533,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA026589,Approved,,Approved,Nucleus<br>Nucleoli,"Renal cancer:9.33e-11 (unfavourable), Liver cancer:4.63e-5 (unfavourable), Thyroid cancer:5.76e-5 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 36.4,Expressed in all,,
CES1,"CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1",ENSG00000198848,Carboxylesterase 1,16,55802851-55833337,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA012023, HPA046717",Enhanced,,Enhanced,Endoplasmic reticulum,Urothelial cancer:9.92e-4 (unfavourable),Tissue enriched,Group enriched,7,gallbladder: 399.2;liver: 1099.9;lung: 229.9,adipose tissue: 79.7,Group enriched,5,Hep G2: 414.0;THP-1: 439.1;U-937: 102.6
CES2,"CE-2, CES2A1, iCE",ENSG00000172831,Carboxylesterase 2,16,66934444-66945096,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA018897,Enhanced,,Approved,Golgi apparatus<br>Cytosol,Renal cancer:1.50e-5 (favourable),Expressed in all,Expressed in all,,,duodenum: 527.2,Expressed in all,,
CES3,"ES31, FLJ21736",ENSG00000172828,Carboxylesterase 3,16,66961237-66975148,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041008, HPA041307",Approved,,Approved,Nuclear membrane<br>Endoplasmic reticulum,Liver cancer:7.26e-5 (favourable),Mixed,Tissue enhanced,,colon: 37.2;duodenum: 30.5;rectum: 34.1,small intestine: 26.6,Cell line enhanced,,AN3-CA: 7.1
CES5A,"CAUXIN, CES4C1, CES5, CES7, FLJ31547",ENSG00000159398,Carboxylesterase 5A,16,55846154-55956031,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA047635,Uncertain,,,,,Tissue enhanced,Tissue enriched,40,epididymis: 79.9,liver: 1.9,Cell line enriched,29,U-266/70: 5.8
CFB,"BF, BFD, H2-Bf",ENSG00000243649,Complement factor B,6,31945650-31952084,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA000951, HPA001817, HPA001832, CAB016381",Supported,,Approved,Endoplasmic reticulum<br>Vesicles<br>Cell Junctions,"Renal cancer:1.53e-5 (unfavourable), Breast cancer:2.76e-5 (favourable)",Expressed in all,Tissue enriched,21,liver: 285.9,stomach: 13.8,Cell line enhanced,,CAPAN-2: 6.6;fHDF/TERT166: 9.6;HSkMC: 14.1
CFD,"ADN, DF, PFD",ENSG00000197766,Complement factor D,19,859643-863630,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA052799,,,Uncertain,Plasma membrane,"Pancreatic cancer:1.77e-4 (favourable), Renal cancer:7.09e-4 (unfavourable)",Expressed in all,Tissue enriched,7,adipose tissue: 378.5,breast: 52.5,Group enriched,6,ASC diff: 82.6;THP-1: 121.6
CFI,"C3b-INA, FI, IF, KAF",ENSG00000205403,Complement factor I,4,109740694-109802179,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA001143, CAB016777, HPA024061",Supported,,,,Urothelial cancer:6.06e-4 (unfavourable),Expressed in all,Tissue enhanced,,liver: 524.7,kidney: 221.8,Cell line enhanced,,CAPAN-2: 112.1;Hep G2: 117.9;HSkMC: 48.7;RPTEC TERT1: 139.4
CFLAR,"c-FLIP, CASH, CASP8AP1, Casper, CLARP, FLAME, FLIP, I-FLICE, MRIT",ENSG00000003402,CASP8 and FADD like apoptosis regulator,2,201116104-201176687,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019044, CAB022157, CAB025216",Uncertain,,Supported,Nucleus<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,Head and neck cancer:2.79e-4 (favourable),Expressed in all,Expressed in all,,,bone marrow: 159.9,Expressed in all,,
CFTR,"ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR",ENSG00000001626,Cystic fibrosis transmembrane conductance regulator,7,117465784-117715971,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB001951, HPA021939",Enhanced,,,,Liver cancer:9.44e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,gallbladder: 89.3,rectum: 49.0,Group enriched,19,CACO-2: 26.2;MOLT-4: 97.6;U-266/70: 47.9
CH25H,,ENSG00000138135,Cholesterol 25-hydroxylase,10,89205629-89207314,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Expressed in all,Mixed,,,gallbladder: 23.0,Cell line enhanced,,ASC diff: 6.0;fHDF/TERT166: 25.5;HSkMC: 6.0
CHAT,,ENSG00000070748,Choline O-acetyltransferase,10,49609095-49665104,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB002313, HPA048547",Supported,,,,,Not detected,Tissue enriched,8,placenta: 7.2,duodenum: 0.8,Cell line enriched,9,NB-4: 7.2
CHD1,,ENSG00000153922,Chromodomain helicase DNA binding protein 1,5,98853985-98928957,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA022236,Approved,,Supported,Nucleus<br>Nucleoli fibrillar center,Renal cancer:7.25e-6 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 44.3,Expressed in all,,
CHD1L,ALC1,ENSG00000131778,Chromodomain helicase DNA binding protein 1 like,1,147242641-147295766,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027789, HPA028670",Enhanced,,Supported,Nucleoplasm,"Renal cancer:1.31e-9 (unfavourable), Liver cancer:3.07e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 48.4,Expressed in all,,
CHD2,"DKFZp547I1315, DKFZp686E01200, DKFZp781D1727, FLJ38614",ENSG00000173575,Chromodomain helicase DNA binding protein 2,15,92900189-93028005,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA060744, HPA060960",Enhanced,,Enhanced,Nucleus,,Expressed in all,Expressed in all,,,bone marrow: 48.3,Mixed,,
CHD3,"Mi-2a, Mi2-ALPHA, ZFH",ENSG00000170004,Chromodomain helicase DNA binding protein 3,17,7884806-7912760,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043368, HPA076524",Supported,,Approved,Nucleus<br>Nucleoli<br>Microtubule organizing center,"Endometrial cancer:7.68e-5 (favourable), Colorectal cancer:2.43e-4 (unfavourable), Pancreatic cancer:8.36e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 85.1,Expressed in all,,
CHD4,"Mi-2b, Mi2-BETA",ENSG00000111642,Chromodomain helicase DNA binding protein 4,12,6570083-6607476,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA012008,Supported,,Enhanced,Nucleus,Liver cancer:6.03e-6 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 119.0,Expressed in all,,
CHD5,,ENSG00000116254,Chromodomain helicase DNA binding protein 5,1,6101793-6180123,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA015809, HPA055477",Supported,,Supported,Nucleoplasm<br>Nuclear speckles<br>Cytosol,,Mixed,Tissue enriched,7,cerebral cortex: 42.1,testis: 6.2,Cell line enhanced,,SCLC-21H: 16.0;U-2 OS: 6.3
CHD6,"CHD5, dJ620E11.1, FLJ22369, KIAA1335, RIGB",ENSG00000124177,Chromodomain helicase DNA binding protein 6,20,41402101-41618494,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA015543,,,Approved,Nucleus,Lung cancer:3.42e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 31.5,Expressed in all,,
CHD7,"CRG, FLJ20357, FLJ20361, KIAA1416",ENSG00000171316,Chromodomain helicase DNA binding protein 7,8,60678778-60868028,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA053075,,,Supported,Nucleoplasm<br>Nucleoli,Endometrial cancer:5.34e-5 (unfavourable),Expressed in all,Mixed,,,parathyroid gland: 14.6,Cell line enhanced,,AF22: 50.9;SCLC-21H: 55.1
CHD8,"DUPLIN, HELSNF1, KIAA1564",ENSG00000100888,Chromodomain helicase DNA binding protein 8,14,21385194-21456126,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA052186,,,Supported,Nucleoplasm,"Liver cancer:4.94e-4 (unfavourable), Ovarian cancer:8.35e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 47.1,Expressed in all,,
CHD9,"BC022889, FLJ12178, KIAA0308",ENSG00000177200,Chromodomain helicase DNA binding protein 9,16,53055033-53329150,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042053, HPA049420",Approved,,Approved,Plasma membrane<br>Cytosol,Renal cancer:1.84e-4 (favourable),Expressed in all,Mixed,,,parathyroid gland: 28.2,Expressed in all,,
CHDH,,ENSG00000016391,Choline dehydrogenase,3,53812335-53846390,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036633, HPA058130",Enhanced,,,,Renal cancer:1.88e-8 (favourable),Mixed,Tissue enhanced,,kidney: 40.1,small intestine: 16.4,Cell line enhanced,,CACO-2: 9.5;Hep G2: 24.3;T-47d: 10.6
CHEK1,CHK1,ENSG00000149554,Checkpoint kinase 1,11,125625136-125676255,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA044364,,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.04e-8 (unfavourable), Pancreatic cancer:3.10e-6 (unfavourable), Liver cancer:3.70e-6 (unfavourable), Colorectal cancer:3.62e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 62.5;seminal vesicle: 52.6,testis: 22.1,Expressed in all,,
CHEK2,"bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53",ENSG00000183765,Checkpoint kinase 2,22,28687743-28742422,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA001878, CAB002030",Enhanced,,Supported,Nucleoplasm<br>Golgi apparatus,Renal cancer:7.80e-9 (unfavourable),Expressed in all,Mixed,,,testis: 13.4,Expressed in all,,
CHFR,"FLJ10796, RNF196",ENSG00000072609,Checkpoint with forkhead and ring finger domains,12,132822187-132956304,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA045768, HPA073826",Approved,,Uncertain,Nuclear bodies<br>Microtubules,Renal cancer:4.21e-9 (unfavourable),Expressed in all,Expressed in all,,,testis: 22.8,Mixed,,
CHIA,"AMCase, CHIT2, TSA1902",ENSG00000134216,"Chitinase, acidic",1,111290862-111320566,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA059193,Approved,,,,,Tissue enhanced,Group enriched,11,lung: 15.6;stomach: 8.2,endometrium: 1.1,Cell line enhanced,,ASC diff: 1.1
CHIT1,"CHI3, CHIT",ENSG00000133063,Chitinase 1,1,203212827-203273641,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA010575,Approved,,,,Cervical cancer:2.02e-4 (favourable),Tissue enhanced,Group enriched,14,"bone marrow: 31.3;breast: 10.9;cervix, uterine: 13.5;lung: 53.2;lymph node: 21.0","prostate,thyroid gland: 1.8",Not detected,,
CHKA,"CHK, CKI",ENSG00000110721,Choline kinase alpha,11,68052859-68121444,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA024153, CAB072803",Approved,,Approved,Endoplasmic reticulum,Liver cancer:7.75e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 136.1,Expressed in all,,
CHKB,"CHETK, CHKL",ENSG00000100288,Choline kinase beta,22,50578949-50601455,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA018797,Approved,,Approved,Cytosol,"Renal cancer:1.56e-5 (unfavourable), Cervical cancer:4.66e-4 (favourable)",Expressed in all,Mixed,,,testis: 15.1,Mixed,,
CHPF,"CHSY2, CSS2",ENSG00000123989,Chondroitin polymerizing factor,2,219538947-219543787,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA035123,Approved,,Supported,Vesicles<br>Centrosome<br>Cytosol,"Cervical cancer:1.57e-4 (unfavourable), Head and neck cancer:1.68e-4 (unfavourable), Urothelial cancer:2.96e-4 (unfavourable), Glioma:9.56e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 77.2,Mixed,,
CHPF2,"ChSy-3, CSGlcA-T, KIAA1402",ENSG00000033100,Chondroitin polymerizing factor 2,7,151232489-151238827,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA020992,Approved,,Approved,Nucleoplasm<br>Cytosol,"Pancreatic cancer:2.51e-4 (favourable), Liver cancer:9.47e-4 (unfavourable)",Expressed in all,Expressed in all,,,"gallbladder,spleen: 23.5",Expressed in all,,
CHPT1,CPT1,ENSG00000111666,Choline phosphotransferase 1,12,101696947-101744140,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA067643,Approved,,Approved,Vesicles,Thyroid cancer:7.41e-4 (favourable),Expressed in all,Expressed in all,,,breast: 125.6,Expressed in all,,
CHST1,"C6ST, KSGal6ST",ENSG00000175264,Carbohydrate sulfotransferase 1,11,45648877-45665622,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:4.64e-7 (unfavourable), Liver cancer:3.95e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 49.0;parathyroid gland: 19.1,thyroid gland: 9.9,Cell line enhanced,,HUVEC TERT2: 11.4;TIME: 10.8;WM-115: 35.6
CHST11,"C4ST, C4St-1, C4ST1, HSA269537",ENSG00000171310,Carbohydrate sulfotransferase 11,12,104455295-104762014,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA052828,Approved,,Approved,Golgi apparatus,"Renal cancer:7.59e-11 (unfavourable), Urothelial cancer:8.42e-4 (unfavourable)",Expressed in all,Mixed,,,appendix: 27.6,Mixed,,
CHST12,"C4S-2, C4ST2",ENSG00000136213,Carbohydrate sulfotransferase 12,7,2403560-2448483,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA041680,Approved,,Approved,Golgi apparatus,Pancreatic cancer:1.32e-5 (favourable),Expressed in all,Expressed in all,,,spleen: 16.1,Cell line enhanced,,U-266/70: 68.5
CHST13,C4ST3,ENSG00000180767,Carbohydrate sulfotransferase 13,3,126524283-126543291,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,liver: 5.9;testis: 6.3,spleen: 2.9,Group enriched,6,CACO-2: 13.9;Hep G2: 20.6;NB-4: 12.8;THP-1: 7.9
CHST14,"D4ST-1, D4ST1, HD4ST",ENSG00000169105,Carbohydrate sulfotransferase 14,15,40470998-40474571,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA057697, HPA071601",Approved,,Approved,Vesicles,,Expressed in all,Expressed in all,,,placenta: 38.8,Expressed in all,,
CHST15,"BRAG, GALNAC4S-6ST, KIAA0598",ENSG00000182022,Carbohydrate sulfotransferase 15,10,124007666-124093607,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017584,Approved,,Approved,Centrosome<br>Cytosol,Renal cancer:2.22e-7 (unfavourable),Expressed in all,Expressed in all,,,ovary: 45.6,Cell line enhanced,,REH: 82.5
CHST3,"C6ST, C6ST1",ENSG00000122863,Carbohydrate sulfotransferase 3,10,71964365-72013564,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA047523, HPA055704",Enhanced,,Approved,Golgi apparatus<br>Cytosol,,Expressed in all,Mixed,,,testis: 30.7,Mixed,,
CHST7,"C6ST-2, C6ST2",ENSG00000147119,Carbohydrate sulfotransferase 7,X,46573784-46598408,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA003919,Approved,,,,Cervical cancer:7.20e-4 (favourable),Expressed in all,Mixed,,,spleen: 12.8,Cell line enhanced,,EFO-21: 22.4;NTERA-2: 21.4
CHSY1,"CSS1, KIAA0990",ENSG00000131873,Chondroitin sulfate synthase 1,15,101175723-101251932,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA048902,Uncertain,,,,Renal cancer:6.33e-5 (unfavourable),Expressed in all,Expressed in all,,,placenta: 64.8,Expressed in all,,
CHSY3,"CHSY-2, CSS3",ENSG00000198108,Chondroitin sulfate synthase 3,5,129904472-130186634,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA044612,Uncertain,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 7.2",gallbladder: 4.5,Cell line enhanced,,ASC diff: 9.0;ASC TERT1: 8.1;U-138 MG: 14.0
CHUK,"IkBKA, IKK-alpha, IKK1, IKKA, NFKBIKA, TCF16",ENSG00000213341,Conserved helix-loop-helix ubiquitous kinase,10,100188298-100229619,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA001402, CAB004240, CAB018564",Approved,,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:1.27e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 23.1,Expressed in all,,
CIITA,"C2TA, MHC2TA, NLRA",ENSG00000179583,Class II major histocompatibility complex transactivator,16,10866222-10932281,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,CAB016084,Enhanced,,Approved,Nucleoplasm,,Expressed in all,Mixed,,,"lymph node,spleen: 59.2",Cell line enhanced,,HDLM-2: 44.9;REH: 81.4
CIT,"CITK, CRIK, KIAA0949, STK21",ENSG00000122966,Citron rho-interacting serine/threonine kinase,12,119685790-119877291,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA019082, HPA048812, HPA075506",Uncertain,,Approved,Cytosol,,Mixed,Mixed,,,cerebral cortex: 10.4,Mixed,,
CKB,CKBB,ENSG00000166165,Creatine kinase B,14,103519659-103523111,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001254, CAB047313",Enhanced,,Supported,Cytosol,Renal cancer:4.02e-8 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 475.1,Cell line enhanced,,CACO-2: 340.9;HEK 293: 940.9;SCLC-21H: 678.1
CKM,CKMM,ENSG00000104879,"Creatine kinase, M-type",19,45306414-45322977,"Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA047859,Enhanced,,,,,Group enriched,Tissue enriched,17,skeletal muscle: 23798.9,heart muscle: 1418.8,Cell line enriched,6,SCLC-21H: 75.4
CKMT1A,CKMT1,ENSG00000223572,"Creatine kinase, mitochondrial 1A",15,43692886-43699222,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,HPA043491,Uncertain,,,,,Mixed,Mixed,,,rectum: 73.8,Cell line enhanced,,HaCaT: 113.0;SCLC-21H: 52.4;SK-BR-3: 74.4;T-47d: 83.6
CKMT1B,"CKMT, CKMT1, UMTCK",ENSG00000237289,"Creatine kinase, mitochondrial 1B",15,43593054-43604901,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,HPA043491,Uncertain,,,,Endometrial cancer:2.55e-5 (unfavourable),Mixed,Tissue enhanced,,colon: 78.0;rectum: 68.4,duodenum: 63.0,Cell line enhanced,,HaCaT: 120.7;SCLC-21H: 60.9;SK-BR-3: 124.3;T-47d: 91.0
CKMT2,SMTCK,ENSG00000131730,"Creatine kinase, mitochondrial 2",5,81233285-81266397,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051880,Enhanced,,,,,Mixed,Group enriched,22,heart muscle: 710.7;skeletal muscle: 505.3,adrenal gland: 27.9,Cell line enhanced,,BEWO: 3.3;T-47d: 5.1
CLK1,,ENSG00000013441,CDC like kinase 1,2,200853009-200864744,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB033141, HPA062405",Approved,,Supported,Nucleoplasm<br>Nuclear membrane,Urothelial cancer:2.28e-4 (favourable),Expressed in all,Expressed in all,,,bone marrow: 113.5,Expressed in all,,
CLK2,clk2,ENSG00000176444,CDC like kinase 2,1,155262868-155278491,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA055366, HPA059507",Approved,,Enhanced,Nucleoplasm<br>Nuclear bodies,"Renal cancer:2.95e-9 (unfavourable), Liver cancer:2.82e-4 (unfavourable), Colorectal cancer:3.77e-4 (unfavourable), Urothelial cancer:5.43e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 26.8,Expressed in all,,
CLK3,clk3,ENSG00000179335,CDC like kinase 3,15,74598500-74645414,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046817,Approved,,Supported,Nucleoplasm<br>Intermediate filaments,"Colorectal cancer:2.05e-6 (unfavourable), Prostate cancer:5.92e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 71.7,Expressed in all,,
CLK4,,ENSG00000113240,CDC like kinase 4,5,178602664-178630615,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA043746,Approved,,Approved,Actin filaments,,Expressed in all,Expressed in all,,,testis: 22.5,Expressed in all,,
CLOCK,"bHLHe8, KAT13D, KIAA0334",ENSG00000134852,Clock circadian regulator,4,55427903-55547138,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001867, HPA027565",Supported,,Enhanced,Nucleoplasm,,Expressed in all,Mixed,,,testis: 26.4,Expressed in all,,
CLP1,"hClp1, HEAB",ENSG00000172409,Cleavage and polyadenylation factor I subunit 1,11,57648992-57661868,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA057770,Supported,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,bone marrow: 17.0,Expressed in all,,
CLPB,"ANKCLB, FLJ13152, HSP78, SKD3",ENSG00000162129,"ClpB homolog, mitochondrial AAA ATPase chaperonin",11,72292425-72434680,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA039005, HPA039006, HPA064571",Enhanced,,,,Renal cancer:8.36e-8 (favourable),Expressed in all,Tissue enriched,10,testis: 176.6,parathyroid gland: 18.5,Expressed in all,,
CLPP,,ENSG00000125656,Caseinolytic mitochondrial matrix peptidase proteolytic subunit,19,6361452-6368908,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA010649,Supported,,Enhanced,Mitochondria,Pancreatic cancer:6.50e-4 (favourable),Expressed in all,Expressed in all,,,appendix: 48.3,Expressed in all,,
CLYBL,CLB,ENSG00000125246,Citrate lyase beta like,13,99606669-99897134,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039959, HPA040691",Enhanced,,Approved,Cytosol,Renal cancer:6.66e-16 (favourable),Expressed in all,Expressed in all,,,kidney: 67.5,Cell line enhanced,,SCLC-21H: 62.6
CMA1,,ENSG00000092009,Chymase 1,14,24505353-24508265,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000363, HPA052634",Enhanced,,,,,Mixed,Tissue enhanced,,breast: 23.8,esophagus: 11.4,Not detected,,
CMAS,,ENSG00000111726,Cytidine monophosphate N-acetylneuraminic acid synthetase,12,22046174-22065674,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA039905,Supported,,Uncertain,Nucleoli<br>Cytosol,Renal cancer:7.19e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 127.9,Expressed in all,,
CMPK1,"CMPK, UMP-CMPK",ENSG00000162368,Cytidine/uridine monophosphate kinase 1,1,47333797-47378839,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA053730, HPA058604",Approved,,Supported,Nucleus,Glioma:8.67e-4 (favourable),Expressed in all,Expressed in all,,,small intestine: 169.1,Expressed in all,,
CMPK2,"NDK, TYKi, UMP-CMPK2",ENSG00000134326,Cytidine/uridine monophosphate kinase 2,2,6840570-6866635,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041430,Approved,,Approved,Mitochondria,Endometrial cancer:4.71e-4 (unfavourable),Expressed in all,Mixed,,,spleen: 5.5,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 16.8;BJ hTERT+ SV40 Large T+ RasG12V: 15.8;HEL: 23.9;MOLT-4: 11.9
CMTR1,"FTSJD2, ISG95, KIAA0082, MTr1",ENSG00000137200,Cap methyltransferase 1,6,37433219-37482827,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA029954, HPA029979, HPA029980",Enhanced,,Enhanced,Nucleoplasm<br>Cytosol,Endometrial cancer:1.73e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 85.5,Expressed in all,,
CMTR2,"AFT, FLJ11171, FTSJD1, MTr2",ENSG00000180917,Cap methyltransferase 2,16,71281389-71289715,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041700, HPA048265",Uncertain,,Approved,Nuclear speckles<br>Cell Junctions,Renal cancer:4.97e-5 (favourable),Expressed in all,Expressed in all,,,testis: 18.9,Expressed in all,,
CNDP1,"CN1, CPGL2, HsT2308, MGC10825",ENSG00000150656,Carnosine dipeptidase 1,18,74534440-74587212,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008933,Enhanced,,,,,Group enriched,Group enriched,12,cerebral cortex: 101.7;liver: 23.0,duodenum: 5.1,Cell line enriched,68,U-266/84: 57.1
CNDP2,"CN2, CPGL, FLJ10830, HsT2298, PEPA",ENSG00000133313,CNDP dipeptidase 2 (metallopeptidase M20 family),18,74495816-74523454,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB026196, HPA036898, HPA036899",Enhanced,,Enhanced,Nucleoplasm<br>Cytosol,Renal cancer:3.50e-6 (favourable),Expressed in all,Expressed in all,,,kidney: 342.2,Expressed in all,,
CNOT4,"CLONE243, NOT4, NOT4H",ENSG00000080802,CCR4-NOT transcription complex subunit 4,7,135361795-135510127,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA005737,Approved,,,,"Renal cancer:7.67e-6 (favourable), Liver cancer:1.19e-4 (unfavourable), Ovarian cancer:1.61e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 33.3,Expressed in all,,
CNOT6,"CCR4, Ccr4a, KIAA1194",ENSG00000113300,CCR4-NOT transcription complex subunit 6,5,180494412-180578405,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044568,Approved,,Approved,Cytosol,Liver cancer:3.61e-7 (unfavourable),Expressed in all,Expressed in all,,,testis: 25.1,Expressed in all,,
CNOT6L,"Ccr4b, DKFZp434K098",ENSG00000138767,CCR4-NOT transcription complex subunit 6 like,4,77713387-77819615,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA042688,Uncertain,,Supported,Cytosol,Renal cancer:1.69e-4 (favourable),Expressed in all,Expressed in all,,,lymph node: 43.7,Expressed in all,,
CNOT7,CAF1,ENSG00000198791,CCR4-NOT transcription complex subunit 7,8,17224964-17246878,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA069543,,,Supported,Nuclear bodies,Colorectal cancer:4.99e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 112.7,Expressed in all,,
CNOT8,"CAF1, CALIF, hCAF1, POP2",ENSG00000155508,CCR4-NOT transcription complex subunit 8,5,154857553-154876793,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051398,Approved,,,,"Liver cancer:5.33e-4 (unfavourable), Urothelial cancer:6.41e-4 (favourable)",Expressed in all,Expressed in all,,,bone marrow: 74.6,Expressed in all,,
CNP,,ENSG00000173786,"2',3'-cyclic nucleotide 3' phosphodiesterase",17,41966741-41977731,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002672, HPA023266, HPA023278, HPA023280, HPA023338",Enhanced,Supported,Enhanced,Nucleus<br>Cytosol,,Expressed in all,Tissue enriched,11,cerebral cortex: 614.8,prostate: 54.9,Expressed in all,,
COASY,"CoASY, DPCK, NBP, PPAT",ENSG00000068120,Coenzyme A synthase,17,42561467-42566277,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA022875, HPA022912, HPA023273",Approved,,Approved,Nucleoplasm<br>Cytosol,"Liver cancer:7.54e-5 (unfavourable), Endometrial cancer:2.15e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 60.1,Expressed in all,,
COLGALT1,"FLJ22329, GLT25D1",ENSG00000130309,Collagen beta(1-O)galactosyltransferase 1,19,17555594-17583162,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA047821,Approved,,Approved,Vesicles,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.65e-5 (unfavourable), Pancreatic cancer:1.92e-4 (unfavourable), Urothelial cancer:3.83e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 58.0,Expressed in all,,
COLGALT2,"C1orf17, GLT25D2, KIAA0584",ENSG00000198756,Collagen beta(1-O)galactosyltransferase 2,1,183929854-184037729,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA031749, HPA031750",Approved,,Approved,Nucleus<br>Vesicles,,Tissue enhanced,Tissue enriched,5,cerebral cortex: 46.4,prostate: 8.8,Cell line enhanced,,Hep G2: 11.7;SK-MEL-30: 14.3;U-251 MG: 14.6;WM-115: 22.1
COMT,,ENSG00000093010,Catechol-O-methyltransferase,22,19941607-19969975,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA001169, CAB011233",Enhanced,,Approved,Endoplasmic reticulum<br>Vesicles,"Endometrial cancer:3.68e-4 (favourable), Prostate cancer:5.67e-4 (favourable), Renal cancer:9.76e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 172.6,Expressed in all,,
COPS5,"CSN5, JAB1, MOV-34, SGN5",ENSG00000121022,COP9 signalosome subunit 5,8,67043079-67083783,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004242, HPA004845, HPA051531",Supported,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,testis: 92.4,Expressed in all,,
COPS6,"CSN6, MOV34-34KD",ENSG00000168090,COP9 signalosome subunit 6,7,100088954-100092200,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA044315,Approved,,Supported,Nucleoplasm,Renal cancer:6.72e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 129.6,Expressed in all,,
COQ2,"CL640, FLJ26072",ENSG00000173085,"Coenzyme Q2, polyprenyltransferase",4,83261536-83284914,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA056599, HPA068727",Approved,,Approved,Cytosol,,Expressed in all,Expressed in all,,,adrenal gland: 18.4,Expressed in all,,
COQ3,bA9819.1,ENSG00000132423,"Coenzyme Q3, methyltransferase",6,99369400-99394204,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA031273, HPA031274",Enhanced,,Approved,Nucleoplasm<br>Mitochondria,Renal cancer:6.86e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 20.8,Expressed in all,,
COQ5,MGC4767,ENSG00000110871,"Coenzyme Q5, methyltransferase",12,120503274-120534434,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA049487,Approved,,Approved,Nucleoli<br>Mitochondria,,Expressed in all,Expressed in all,,,thyroid gland: 42.1,Expressed in all,,
COQ8A,"ADCK3, CABC1, COQ8, SCAR9",ENSG00000163050,Coenzyme Q8A,1,226897536-226987545,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA061662,,,Supported,Mitochondria,,Expressed in all,Tissue enriched,6,skeletal muscle: 401.8,adrenal gland: 68.1,Cell line enhanced,,HEK 293: 75.6
COQ8B,"ADCK4, COQ8, FLJ12229",ENSG00000123815,Coenzyme Q8B,19,40691529-40718207,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA027229, HPA027277, HPA027279, HPA028303",Enhanced,,Enhanced,Mitochondria,,Expressed in all,Expressed in all,,,fallopian tube: 41.1,Expressed in all,,
CORIN,"ATC2, CRN, Lrp4, PRSC, TMPRSS10",ENSG00000145244,"Corin, serine peptidase",4,47593998-47838106,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA070941,,,Approved,Nuclear bodies<br>Plasma membrane<br>Actin filaments,,Mixed,Tissue enhanced,,heart muscle: 38.6,skin: 9.4,Group enriched,6,ASC diff: 7.2;ASC TERT1: 31.6
CP,,ENSG00000047457,Ceruloplasmin,3,149162410-149222055,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001834, CAB008591",Supported,,,,Renal cancer:1.14e-7 (unfavourable),Tissue enhanced,Tissue enriched,9,liver: 916.0,"cervix, uterine: 99.1",Cell line enriched,12,EFO-21: 273.0
CPA1,CPA,ENSG00000091704,Carboxypeptidase A1,7,130380339-130388114,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA021836, CAB025197, HPA052215",Enhanced,,,,,Tissue enriched,Tissue enriched,367,pancreas: 48856.8,ovary: 133.1,Cell line enhanced,,AN3-CA: 10.9;SCLC-21H: 2.5;U-2 OS: 1.7
CPA2,,ENSG00000158516,Carboxypeptidase A2,7,130266827-130289798,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA020342, HPA021317",Enhanced,,,,,Tissue enriched,Tissue enriched,104,pancreas: 9283.9,stomach: 89.6,Cell line enhanced,,AN3-CA: 2.0;CACO-2: 3.0;RH-30: 2.8;SCLC-21H: 1.9
CPA3,,ENSG00000163751,Carboxypeptidase A3,3,148865256-148897196,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA006479, HPA008689, CAB020712",Enhanced,,,,,Mixed,Tissue enhanced,,gallbladder: 173.9,lung: 126.9,Cell line enriched,46,HEL: 265.9
CPA4,CPA3,ENSG00000128510,Carboxypeptidase A4,7,130293134-130324180,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA021030,Uncertain,,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,Urothelial cancer:1.31e-4 (unfavourable),Tissue enhanced,Tissue enriched,7,skin: 67.8,esophagus: 10.0,Cell line enhanced,,LHCN-M2: 238.0;U-2 OS: 159.5;U-87 MG: 268.2
CPA5,,ENSG00000158525,Carboxypeptidase A5,7,130344816-130368730,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA020322,,,Approved,Nucleus,,Not detected,Tissue enriched,18,testis: 47.4,spleen: 2.6,Cell line enhanced,,RH-30: 7.1;RT4: 2.7;U-266/84: 4.1
CPA6,CPAH,ENSG00000165078,Carboxypeptidase A6,8,67422038-67746385,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,prostate: 4.9;rectum: 2.9,colon: 1.7,Cell line enhanced,,CACO-2: 2.9;EFO-21: 1.8;Hep G2: 3.6
CPB1,,ENSG00000153002,Carboxypeptidase B1,3,148791102-148860187,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB026158, HPA038069, HPA046340",Enhanced,,,,,Group enriched,Tissue enriched,312,pancreas: 47292.1,ovary: 151.6,Cell line enhanced,,HDLM-2: 1.0;U-2 OS: 1.7
CPB2,"CPU, PCPB, TAFI",ENSG00000080618,Carboxypeptidase B2,13,46053186-46105076,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA004146,Approved,,,,Liver cancer:2.06e-4 (favourable),Tissue enriched,Tissue enriched,28,liver: 755.5,lung: 26.5,Cell line enriched,66,Hep G2: 117.8
CPD,GP180,ENSG00000108582,Carboxypeptidase D,17,30378905-30469989,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA052796, HPA055465",Approved,,Approved,Nucleoplasm<br>Nuclear membrane<br>Nuclear speckles,,Expressed in all,Expressed in all,,,thyroid gland: 94.8,Expressed in all,,
CPE,,ENSG00000109472,Carboxypeptidase E,4,165361194-165498320,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA003819, CAB024907",Supported,,Approved,Nucleoplasm<br>Vesicles<br>Centrosome,"Urothelial cancer:2.12e-4 (unfavourable), Renal cancer:2.60e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 1560.8,Group enriched,5,Hep G2: 211.8;SCLC-21H: 493.5;SH-SY5Y: 147.0;SiHa: 668.1
CPM,,ENSG00000135678,Carboxypeptidase M,12,68842197-68971570,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA002657, HPA077243",Uncertain,,Uncertain,Vesicles,Endometrial cancer:1.00e-4 (favourable),Expressed in all,Tissue enhanced,,adipose tissue: 164.0,placenta: 101.2,Cell line enhanced,,ASC diff: 48.8;ASC TERT1: 35.1;HSkMC: 66.3;SiHa: 73.7
CPN1,,ENSG00000120054,Carboxypeptidase N subunit 1,10,100042193-100081877,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA040323,,,Approved,Nucleus<br>Nucleoli,,Group enriched,Tissue enriched,22,liver: 37.1,testis: 1.7,Cell line enriched,16,SK-MEL-30: 110.4
CPO,,ENSG00000144410,Carboxypeptidase O,2,206939554-206969474,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,14,small intestine: 131.5,epididymis: 9.3,Not detected,,
CPOX,"CPO, CPX, HCP",ENSG00000080819,Coproporphyrinogen oxidase,3,98521132-98593723,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA015736, HPA054448",,,Enhanced,Mitochondria,Renal cancer:1.04e-5 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 25.5,Expressed in all,,
CPPED1,"CSTP1, FLJ11151",ENSG00000103381,Calcineurin like phosphoesterase domain containing 1,16,12659799-12804017,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040938, HPA041970",Uncertain,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:1.62e-9 (favourable), Breast cancer:9.72e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 41.0,Cell line enhanced,,Hep G2: 97.8;HMC-1: 114.2
CPQ,"LDP, PGCP",ENSG00000104324,Carboxypeptidase Q,8,96645227-97149654,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA023235, HPA024490",Enhanced,,Supported,Golgi apparatus<br>Vesicles,"Renal cancer:5.40e-5 (favourable), Glioma:9.75e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 382.5,Cell line enhanced,,ASC TERT1: 92.2
CPS1,,ENSG00000021826,Carbamoyl-phosphate synthase 1,2,210477682-210679107,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB003781, HPA021400",Enhanced,,Approved,Nucleoli,Liver cancer:6.93e-5 (favourable),Tissue enriched,Group enriched,23,duodenum: 234.5;liver: 697.8;small intestine: 144.1,testis: 15.3,Cell line enhanced,,HeLa: 249.1;SK-BR-3: 84.1
CPT1A,"CPT1, CPT1-L, L-CPT1",ENSG00000110090,Carnitine palmitoyltransferase 1A,11,68754620-68844410,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008835,Enhanced,,Supported,Mitochondria,"Renal cancer:2.67e-7 (favourable), Breast cancer:3.84e-4 (unfavourable)",Expressed in all,Expressed in all,,,small intestine: 78.9,Mixed,,
CPT1B,"CPT1-M, M-CPT1",ENSG00000205560,Carnitine palmitoyltransferase 1B,22,50568861-50578465,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA029583,Approved,,,,,Mixed,Expressed in all,,,heart muscle: 106.5,Mixed,,
CPT1C,"CPT1P, CPTIC, FLJ23809",ENSG00000169169,Carnitine palmitoyltransferase 1C,19,49690898-49713731,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA014529, HPA063621",Approved,,Approved,Centrosome,Pancreatic cancer:1.84e-4 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 34.2,adrenal gland: 7.0,Cell line enhanced,,AF22: 39.0;SH-SY5Y: 74.9
CPT2,"CPT1, CPTASE",ENSG00000157184,Carnitine palmitoyltransferase 2,1,53196429-53214197,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA028201, HPA028202, HPA028214",Enhanced,,Supported,Nucleoplasm<br>Nucleoli<br>Mitochondria,"Renal cancer:1.46e-12 (favourable), Colorectal cancer:5.27e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 25.9,Expressed in all,,
CPVL,,ENSG00000106066,"Carboxypeptidase, vitellogenic like",7,28995231-29195451,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB003697, HPA045715, HPA056466",Enhanced,,Supported,Endoplasmic reticulum,"Endometrial cancer:8.56e-6 (unfavourable), Urothelial cancer:4.99e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 301.8,Cell line enhanced,,BEWO: 183.9;RPTEC TERT1: 604.1
CPXM1,"CPX-1, CPX1, CPXM",ENSG00000088882,"Carboxypeptidase X, M14 family member 1",20,2794069-2800637,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:4.62e-10 (unfavourable),Expressed in all,Tissue enhanced,,endometrium: 130.4;gallbladder: 132.2,urinary bladder: 75.0,Group enriched,5,AF22: 158.5;HSkMC: 62.0;NB-4: 92.9;NTERA-2: 34.2;REH: 136.3;SH-SY5Y: 113.9
CPXM2,"CPX2, UNQ676",ENSG00000121898,"Carboxypeptidase X, M14 family member 2",10,123706207-123940267,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048375,Uncertain,,,,Renal cancer:9.02e-4 (favourable),Expressed in all,Tissue enhanced,,epididymis: 72.6;smooth muscle: 80.7,urinary bladder: 34.4,Group enriched,15,BJ: 15.4;fHDF/TERT166: 55.4
CPZ,,ENSG00000109625,Carboxypeptidase Z,4,8592660-8619759,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,ovary: 121.5,placenta: 58.0,Cell line enhanced,,BEWO: 63.6;BJ: 32.8;BJ hTERT+: 42.2;RH-30: 54.5;U-2197: 38.2
CRAT,CAT1,ENSG00000095321,Carnitine O-acetyltransferase,9,129094810-129111189,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA019230, HPA020260, HPA022815",Enhanced,,Approved,Nucleoplasm<br>Nuclear membrane,"Renal cancer:0.00e+0 (favourable), Endometrial cancer:2.36e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 116.0,Mixed,,
CREBBP,"CBP, KAT3A, RSTS, RTS",ENSG00000005339,CREB binding protein,16,3725054-3880726,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004212, HPA055861",Enhanced,,Enhanced,Nucleoplasm<br>Nuclear bodies,Renal cancer:6.24e-5 (favourable),Expressed in all,Expressed in all,,,testis: 61.7,Expressed in all,,
CRLS1,"C20orf155, CLS1, dJ967N21.6, GCD10",ENSG00000088766,Cardiolipin synthase 1,20,6006090-6040053,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Urothelial cancer:8.02e-4 (favourable),Expressed in all,Expressed in all,,,liver: 87.0,Expressed in all,,
CROT,COT,ENSG00000005469,Carnitine O-octanoyltransferase,7,87345681-87399795,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA019052, HPA019364, HPA019365",Enhanced,,Supported,Vesicles,"Renal cancer:2.55e-6 (favourable), Urothelial cancer:4.02e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 68.4,Cell line enhanced,,RT4: 57.9
CRYL1,"GDH, lambda-CRY, MGC149525, MGC149526",ENSG00000165475,Crystallin lambda 1,13,20403667-20525857,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA040403,Enhanced,,Approved,Nucleus<br>Nucleoli<br>Golgi apparatus<br>Plasma membrane,"Renal cancer:2.30e-9 (favourable), Endometrial cancer:1.76e-5 (favourable)",Expressed in all,Expressed in all,,,kidney: 338.1,Mixed,,
CRYM,DFNA40,ENSG00000103316,Crystallin mu,16,21238874-21303083,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA019086, HPA030619",Enhanced,,Supported,Cytosol,,Tissue enhanced,Group enriched,6,cerebral cortex: 51.1;heart muscle: 47.8;kidney: 28.4;prostate: 24.7;urinary bladder: 14.8,lung: 5.7,Cell line enhanced,,HEL: 9.4;RPTEC TERT1: 32.9;U-87 MG: 8.7
CRYZ,,ENSG00000116791,Crystallin zeta,1,74705482-74733408,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021921, HPA023290",Approved,,Supported,Cytosol,,Expressed in all,Expressed in all,,,kidney: 345.5,Expressed in all,,
CS,,ENSG00000062485,Citrate synthase,12,56271699-56300392,"Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038460, HPA038461, CAB075750, CAB075751, CAB075752, CAB075753, CAB075754",Enhanced,,Enhanced,Mitochondria,Renal cancer:1.17e-4 (favourable),Expressed in all,Expressed in all,,,heart muscle: 190.9,Expressed in all,,
CSAD,"CSD, PCAP",ENSG00000139631,Cysteine sulfinic acid decarboxylase,12,53157663-53180909,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA039487,Approved,,,,"Renal cancer:1.93e-6 (unfavourable), Urothelial cancer:6.81e-6 (favourable), Liver cancer:1.37e-4 (favourable), Pancreatic cancer:3.39e-4 (favourable), Head and neck cancer:6.33e-4 (favourable), Colorectal cancer:9.50e-4 (unfavourable)",Expressed in all,Expressed in all,,,skin: 70.7,Cell line enhanced,,ASC diff: 57.9;T-47d: 49.5
CSF1R,"C-FMS, CD115, CSFR, FMS",ENSG00000182578,Colony stimulating factor 1 receptor,5,150053291-150113372,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB008970, HPA012323",Uncertain,,Supported,Vesicles<br>Plasma membrane,"Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable)",Expressed in all,Mixed,,,spleen: 147.7,Group enriched,6,BEWO: 118.6;SK-BR-3: 35.4
CSGALNACT1,"ChGn, CSGalNAcT-1, FLJ11264",ENSG00000147408,Chondroitin sulfate N-acetylgalactosaminyltransferase 1,8,19404161-19758029,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA061336,,,Supported,Actin filaments,,Expressed in all,Expressed in all,,,thyroid gland: 145.2,Cell line enhanced,,A549: 52.2;BJ hTERT+: 26.0;RPTEC TERT1: 29.9;U-2197: 33.6;U-87 MG: 25.2
CSGALNACT2,"GALNACT-2, GALNACT2, MGC40204, PRO0082",ENSG00000169826,Chondroitin sulfate N-acetylgalactosaminyltransferase 2,10,43138486-43185308,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031540,Approved,,Approved,Endoplasmic reticulum,Renal cancer:3.53e-7 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 87.2,Expressed in all,,
CSK,,ENSG00000103653,C-src tyrosine kinase,15,74782057-74803198,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB011203, HPA026488, HPA028425",Approved,Approved,Approved,Vesicles<br>Cytosol,"Cervical cancer:5.14e-5 (favourable), Stomach cancer:1.07e-4 (favourable), Renal cancer:1.74e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 195.2,Expressed in all,,
CSNK1A1,"CK1, CK1a, CK1alpha, CKIa, CKIalpha",ENSG00000113712,Casein kinase 1 alpha 1,5,149492197-149551552,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB016680, HPA051334",Uncertain,,Approved,Cytosol,"Colorectal cancer:1.15e-4 (favourable), Pancreatic cancer:5.79e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 219.6,Expressed in all,,
CSNK1A1L,MGC33182,ENSG00000180138,Casein kinase 1 alpha 1 like,13,37103259-37105664,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA051334,,,Approved,Cytosol,,Not detected,Tissue enriched,16,testis: 6.4,bone marrow: 0.3,Not detected,,
CSNK1D,"CKID, CKIdelta, HCKID",ENSG00000141551,Casein kinase 1 delta,17,82239023-82273731,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,CAB015410,Approved,,Supported,Nucleus<br>Nucleoli fibrillar center,"Liver cancer:2.38e-6 (unfavourable), Pancreatic cancer:9.62e-5 (favourable), Endometrial cancer:7.04e-4 (unfavourable), Renal cancer:8.34e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 66.9,Expressed in all,,
CSNK1E,"CKIE, CKIepsilon, HCKIE",ENSG00000213923,Casein kinase 1 epsilon,22,38290691-38318084,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009626, HPA026288",Approved,,Approved,Nucleus<br>Cytosol,"Renal cancer:4.67e-6 (unfavourable), Liver cancer:8.20e-5 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 171.1,Expressed in all,,
CSNK1G1,CK1gamma1,ENSG00000169118,Casein kinase 1 gamma 1,15,64165517-64356259,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA018209,,,Supported,Cytosol,,Expressed in all,Tissue enhanced,,testis: 59.9,thyroid gland: 13.9,Expressed in all,,
CSNK1G2,CK1g2,ENSG00000133275,Casein kinase 1 gamma 2,19,1941149-1981338,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA034868, HPA056572",Uncertain,,Approved,Vesicles,,Expressed in all,Expressed in all,,,testis: 76.8,Expressed in all,,
CSNK1G3,,ENSG00000151292,Casein kinase 1 gamma 3,5,123512099-123617045,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027010,Approved,,,,Colorectal cancer:9.90e-5 (favourable),Expressed in all,Expressed in all,,,testis: 28.4,Mixed,,
CSNK2A1,,ENSG00000101266,Casein kinase 2 alpha 1,20,473591-543821,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB020680, HPA059206, HPA061698, CAB069395",Enhanced,,Supported,Nucleoplasm,Liver cancer:4.11e-6 (unfavourable),Expressed in all,Expressed in all,,,testis: 129.5,Expressed in all,,
CSNK2A2,"CK2alpha', CSNK2A1",ENSG00000070770,Casein kinase 2 alpha 2,16,58157907-58197920,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA077719,,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Head and neck cancer:1.40e-5 (unfavourable), Liver cancer:1.80e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 237.6,Expressed in all,,
CSNK2A3,CSNK2A1P,ENSG00000254598,Casein kinase 2 alpha 3,11,11351942-11353357,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA059206, HPA061698",Uncertain,,Approved,Nucleoplasm,,Mixed,Not detected,,,testis: 0.5,Cell line enhanced,,A-431: 2.1
CTDNEP1,"DULLARD, HSA011916, NET56",ENSG00000175826,CTD nuclear envelope phosphatase 1,17,7243591-7252491,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA037439, HPA066466",Uncertain,,Supported,Lipid droplets,"Pancreatic cancer:1.81e-4 (favourable), Endometrial cancer:6.45e-4 (favourable)",Expressed in all,Expressed in all,,,skeletal muscle: 190.1,Expressed in all,,
CTDP1,FCP1,ENSG00000060069,CTD phosphatase subunit 1,18,79679801-79756623,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB032641, HPA040394, HPA070389",Supported,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:5.51e-5 (favourable), Endometrial cancer:6.43e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 19.6,Expressed in all,,
CTDSP1,"NLIIF, SCP1",ENSG00000144579,CTD small phosphatase 1,2,218398256-218405941,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA062654,,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,placenta: 106.8,Expressed in all,,
CTDSP2,"OS4, PSR2, SCP2",ENSG00000175215,CTD small phosphatase 2,12,57819927-57846739,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA052607,Uncertain,,Uncertain,Nucleoplasm,,Expressed in all,Expressed in all,,,lung: 170.1,Cell line enriched,7,RH-30: 1169.3
CTDSPL,"C3orf8, HYA22, PSR1, RBSP3, SCP3",ENSG00000144677,CTD small phosphatase like,3,37861960-37984469,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA048325,Approved,,Approved,Nucleoplasm<br>Vesicles,Renal cancer:6.22e-14 (favourable),Expressed in all,Expressed in all,,,skin: 65.7,Mixed,,
CTH,,ENSG00000116761,Cystathionine gamma-lyase,1,70411218-70439851,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021591, HPA023300",Enhanced,,,,Liver cancer:8.69e-4 (favourable),Group enriched,Expressed in all,,,liver: 73.2,Cell line enhanced,,Karpas-707: 52.3;SK-MEL-30: 75.8
CTPS1,CTPS,ENSG00000171793,CTP synthase 1,1,40979335-41012565,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB017111, HPA051322",Enhanced,,Supported,Actin filaments<br>Cytosol,,Expressed in all,Expressed in all,,,smooth muscle: 80.2,Expressed in all,,
CTPS2,,ENSG00000047230,CTP synthase 2,X,16588003-16712936,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA017437,Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Liver cancer:2.37e-5 (unfavourable), Urothelial cancer:4.56e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 27.4,Mixed,,
CTRB1,CTRB,ENSG00000168925,Chymotrypsinogen B1,16,75219000-75224924,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enriched,376,pancreas: 48923.8,ovary: 130.0,Cell line enhanced,,EFO-21: 2.9;HDLM-2: 2.3;U-2 OS: 2.4;U-266/84: 1.0
CTRB2,,ENSG00000168928,Chymotrypsinogen B2,16,75204096-75207185,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,392,pancreas: 29060.0,ovary: 74.0,Cell line enhanced,,EFO-21: 3.0;U-2 OS: 6.8;U-251 MG: 1.5;U-266/84: 1.9
CTRC,"CLCR, ELA4",ENSG00000162438,Chymotrypsin C,1,15438439-15449242,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA046920,Enhanced,,,,,Tissue enriched,Tissue enriched,361,pancreas: 18186.4,ovary: 50.3,Not detected,,
CTRL,,ENSG00000141086,Chymotrypsin like,16,67927640-67932414,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA034504, HPA034505",Enhanced,,Uncertain,Nucleoplasm,,Not detected,Tissue enriched,209,pancreas: 1629.9,ovary: 7.8,Mixed,,
CTSA,"GSL, PPGB",ENSG00000064601,Cathepsin A,20,45890144-45898820,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB024930, HPA031068",Enhanced,,Enhanced,Vesicles,Liver cancer:1.95e-4 (unfavourable),Expressed in all,Expressed in all,,,adrenal gland: 243.4,Expressed in all,,
CTSB,,ENSG00000164733,Cathepsin B,8,11842524-11869448,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000457, HPA018156",Uncertain,,Supported,Nucleoli<br>Vesicles,"Thyroid cancer:5.76e-4 (favourable), Urothelial cancer:9.02e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 2894.5,Expressed in all,,
CTSC,"DPP1, PALS, PLS",ENSG00000109861,Cathepsin C,11,88293592-88337787,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025364, HPA066610, HPA068434",Enhanced,,Supported,Vesicles,"Liver cancer:9.30e-5 (unfavourable), Renal cancer:4.80e-4 (favourable)",Expressed in all,Expressed in all,,,lung: 390.4,Expressed in all,,
CTSD,"CLN10, CPSD",ENSG00000117984,Cathepsin D,11,1752752-1764573,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000109, HPA003001",Enhanced,,,,"Renal cancer:4.93e-5 (favourable), Colorectal cancer:2.46e-4 (unfavourable)",Expressed in all,Expressed in all,,,lung: 1026.9,Expressed in all,,
CTSE,,ENSG00000196188,Cathepsin E,1,206009264-206023909,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA012940, CAB032687",Enhanced,,,,Urothelial cancer:5.26e-5 (favourable),Group enriched,Group enriched,9,duodenum: 229.1;stomach: 1121.8,lung: 74.6,Group enriched,7,BEWO: 20.3;RT4: 32.6
CTSF,"CATSF, CLN13",ENSG00000174080,Cathepsin F,11,66563463-66568841,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB002141, HPA031431, HPA055610",Approved,,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Renal cancer:8.92e-7 (favourable),Expressed in all,Expressed in all,,,ovary: 140.6,Cell line enhanced,,SK-MEL-30: 123.6
CTSG,CG,ENSG00000100448,Cathepsin G,14,24573522-24576260,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000110, HPA047737",Enhanced,,,,"Head and neck cancer:1.57e-4 (favourable), Urothelial cancer:8.91e-4 (unfavourable)",Mixed,Tissue enriched,84,bone marrow: 3457.0,gallbladder: 41.2,Cell line enriched,6,THP-1: 6055.4
CTSH,"ACC-4, ACC-5, ACC4, ACC5, CPSB",ENSG00000103811,Cathepsin H,15,78921058-78949574,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000458, HPA003524",Enhanced,,Supported,Vesicles<br>Cytosol<br>Cytoplasmic bodies,Endometrial cancer:6.90e-4 (favourable),Expressed in all,Expressed in all,,,lung: 570.6,Cell line enhanced,,CAPAN-2: 219.5;HaCaT: 161.7;RT4: 558.6
CTSK,"CTSO, CTSO2, PKND, PYCD",ENSG00000143387,Cathepsin K,1,150796208-150808323,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA050346,,,Supported,Vesicles,Renal cancer:7.12e-5 (unfavourable),Expressed in all,Expressed in all,,,"cervix, uterine: 575.0",Group enriched,6,ASC diff: 1592.3;ASC TERT1: 590.6;BJ hTERT+: 1576.7
CTSL,"CTSL1, FLJ31037",ENSG00000135047,Cathepsin L,9,87725519-87731393,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,CAB000459,Enhanced,,,,"Lung cancer:5.15e-5 (unfavourable), Renal cancer:4.34e-4 (favourable), Glioma:4.94e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 748.5,Cell line enhanced,,ASC TERT1: 1401.5
CTSO,CTSO1,ENSG00000256043,Cathepsin O,4,155924118-155953917,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA002041,Approved,,,,,Expressed in all,Expressed in all,,,gallbladder: 32.4,Cell line enhanced,,HSkMC: 15.9;Karpas-707: 30.6
CTSS,,ENSG00000163131,Cathepsin S,1,150730196-150765957,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000460, HPA002988",Supported,,Approved,Vesicles,,Expressed in all,Expressed in all,,,spleen: 374.8,Cell line enhanced,,HMC-1: 238.0;U-698: 410.8
CTSV,"CTSL2, CTSU",ENSG00000136943,Cathepsin V,9,97029679-97039643,"Enzymes, Predicted secreted proteins",Evidence at protein level,CAB017112,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Liver cancer:2.83e-5 (unfavourable), Urothelial cancer:2.39e-4 (unfavourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:8.41e-4 (favourable)",Mixed,Tissue enhanced,,"cervix, uterine: 69.3;skin: 64.2;testis: 131.8",placenta: 25.9,Cell line enriched,7,BEWO: 563.7
CTSW,,ENSG00000172543,Cathepsin W,11,65879809-65883741,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,CAB016345,Enhanced,,,,"Endometrial cancer:8.36e-6 (favourable), Renal cancer:8.84e-6 (unfavourable), Breast cancer:3.06e-4 (favourable), Head and neck cancer:9.89e-4 (favourable)",Expressed in all,Tissue enhanced,,bone marrow: 70.6;spleen: 60.4,lung: 36.5,Group enriched,20,HEL: 149.5;NB-4: 242.5
CTSZ,CTSX,ENSG00000101160,Cathepsin Z,20,58995185-59007247,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB025114, HPA049876, HPA053504",Supported,,Supported,Vesicles,Renal cancer:5.72e-5 (unfavourable),Expressed in all,Expressed in all,,,lung: 476.8,Cell line enhanced,,fHDF/TERT166: 693.2
CWC27,"NY-CO-10, SDCCAG-10, SDCCAG10",ENSG00000153015,CWC27 spliceosome associated protein homolog,5,64768930-65018763,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA020344, HPA024149, HPA065809",Approved,,Enhanced,Nucleoplasm,Liver cancer:5.27e-6 (unfavourable),Expressed in all,Expressed in all,,,testis: 31.1,Expressed in all,,
CYB5R1,"humb5R2, NQO3A2",ENSG00000159348,Cytochrome b5 reductase 1,1,202961869-202967280,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA010641, HPA014147",Enhanced,,Uncertain,Nucleoli<br>Mitochondria<br>Cytosol,Endometrial cancer:1.14e-4 (favourable),Expressed in all,Expressed in all,,,skeletal muscle: 183.8,Expressed in all,,
CYB5R2,,ENSG00000166394,Cytochrome b5 reductase 2,11,7665100-7677222,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038962, HPA061707",Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus,,Mixed,Tissue enhanced,,testis: 227.5,parathyroid gland: 72.2,Cell line enhanced,,BJ hTERT+: 101.1;BJ hTERT+ SV40 Large T+: 61.1;BJ hTERT+ SV40 Large T+ RasG12V: 57.7;NTERA-2: 69.5;WM-115: 94.6
CYB5R3,DIA1,ENSG00000100243,Cytochrome b5 reductase 3,22,42617840-42649568,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA001566,Approved,,Enhanced,Endoplasmic reticulum,Liver cancer:2.13e-5 (unfavourable),Expressed in all,Expressed in all,,,seminal vesicle: 339.4,Expressed in all,,
CYB5R4,"b5+b5R, dJ676J13.1, NCB5OR",ENSG00000065615,Cytochrome b5 reductase 4,6,83859643-83967424,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA018992,Approved,,,,,Expressed in all,Expressed in all,,,testis: 22.4,Expressed in all,,
CYB5RL,LOC606495,ENSG00000215883,Cytochrome b5 reductase like,1,54169651-54200036,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042671, HPA060463",Approved,,Enhanced,Nucleoplasm,,Mixed,Mixed,,,ovary: 5.3,Expressed in all,,
CYLD,"CYLD1, KIAA0849, USPL2",ENSG00000083799,CYLD lysine 63 deubiquitinase,16,50742050-50801935,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB011713, HPA050095",Approved,,Supported,Nucleoplasm<br>Microtubule organizing center,,Expressed in all,Expressed in all,,,testis: 70.2,Expressed in all,,
CYP11A1,"CYP11A, P450SCC",ENSG00000140459,Cytochrome P450 family 11 subfamily A member 1,15,74337759-74367740,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA016436,Enhanced,,,,,Mixed,Tissue enriched,11,adrenal gland: 748.5,testis: 68.5,Group enriched,25,BEWO: 102.7;HEL: 79.0;SiHa: 23.2
CYP11B1,"CPN1, CYP11B, FHI, P450C11",ENSG00000160882,Cytochrome P450 family 11 subfamily B member 1,8,142872356-142879846,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA049171, HPA056348, HPA057752",Supported,,,,,Not detected,Tissue enriched,916,adrenal gland: 1871.2,testis: 2.0,Not detected,,
CYP11B2,"ALDOS, CPN2, CYP11B, CYP11BL, P-450C18, P450aldo",ENSG00000179142,Cytochrome P450 family 11 subfamily B member 2,8,142910559-142917843,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA049171, HPA056348, HPA057752",Supported,,,,,Not detected,Tissue enriched,1057,adrenal gland: 126.3,testis: 0.1,Not detected,,
CYP17A1,"CPT7, CYP17, P450C17, S17AH",ENSG00000148795,Cytochrome P450 family 17 subfamily A member 1,10,102830531-102837533,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA048533,Enhanced,,,,Renal cancer:5.43e-7 (favourable),Tissue enriched,Tissue enriched,25,adrenal gland: 3751.4,testis: 152.4,Cell line enhanced,,HMC-1: 2.6;SCLC-21H: 1.3
CYP19A1,"ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM",ENSG00000137869,Cytochrome P450 family 19 subfamily A member 1,15,51208057-51338610,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000355, HPA051194",Enhanced,,Approved,Mitochondria,,Mixed,Tissue enriched,15,placenta: 174.5,adrenal gland: 11.9,Group enriched,6,ASC TERT1: 65.0;HDLM-2: 16.2;HSkMC: 22.8
CYP1A1,"CP11, CYP1, P1-450, P450-C, P450DX",ENSG00000140465,Cytochrome P450 family 1 subfamily A member 1,15,74719542-74725610,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB018654,Uncertain,,,,,Group enriched,Group enriched,8,liver: 33.9;small intestine: 20.5;urinary bladder: 80.8,breast: 5.7,Cell line enhanced,,CACO-2: 30.3;hTCEpi: 14.0;HUVEC TERT2: 15.7
CYP1A2,"CP12, P3-450",ENSG00000140505,Cytochrome P450 family 1 subfamily A member 2,15,74748844-74756202,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,CAB016531,Enhanced,,,,,Group enriched,Tissue enriched,170,liver: 268.6,thyroid gland: 1.5,Mixed,,
CYP1B1,"CP1B, GLC3A",ENSG00000138061,Cytochrome P450 family 1 subfamily B member 1,2,38066973-38109902,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB011705, HPA026863",Approved,,Uncertain,Mitochondria,"Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:2.76e-4 (unfavourable)",Expressed in all,Mixed,,,fallopian tube: 76.1,Cell line enhanced,,HSkMC: 400.2;SiHa: 283.9;U-87 MG: 138.5
CYP21A2,"CA21H, CAH1, CPS1, CYP21, CYP21B, P450c21B",ENSG00000231852,Cytochrome P450 family 21 subfamily A member 2,6,32038265-32041670,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA048979, HPA053371",Enhanced,,,,,Tissue enhanced,Tissue enriched,257,adrenal gland: 266.4,epididymis: 1.0,Group enriched,5,HDLM-2: 6.1;Karpas-707: 1.2
CYP24A1,"CP24, CYP24, P450-CC24",ENSG00000019186,Cytochrome P450 family 24 subfamily A member 1,20,54153449-54173973,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA022261, HPA063771",Enhanced,,Supported,Nucleoplasm<br>Plasma membrane<br>Mitochondria,,Mixed,Tissue enhanced,,endometrium: 24.8;urinary bladder: 50.8,placenta: 14.1,Group enriched,13,A549: 372.2;Hep G2: 83.4
CYP27A1,"CP27, CTX, CYP27",ENSG00000135929,Cytochrome P450 family 27 subfamily A member 1,2,218781749-218815293,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA059155,Enhanced,,Enhanced,Mitochondria,"Liver cancer:8.62e-6 (favourable), Breast cancer:1.05e-4 (favourable)",Expressed in all,Tissue enhanced,,liver: 279.5,lung: 98.4,Cell line enhanced,,Hep G2: 187.0;RPTEC TERT1: 50.8;SK-MEL-30: 86.7;WM-115: 42.3
CYP27B1,"CYP1, P450c1, PDDR, VDD1",ENSG00000111012,Cytochrome P450 family 27 subfamily B member 1,12,57762334-57768986,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,Thyroid cancer:6.79e-4 (unfavourable),Mixed,Tissue enhanced,,kidney: 4.3;thyroid gland: 3.9,appendix: 1.2,Cell line enriched,8,RH-30: 47.8
CYP2A13,"CPAD, CYP2A",ENSG00000197838,Cytochrome P450 family 2 subfamily A member 13,19,41088472-41096195,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA046713, HPA047262",Supported,,,,,Tissue enriched,Not detected,,,"liver,testis: 0.3",Not detected,,
CYP2A7,CYP2A,ENSG00000198077,Cytochrome P450 family 2 subfamily A member 7,19,40875439-40882752,"Enzymes, Predicted secreted proteins",Evidence at protein level,"CAB033510, HPA046713, HPA047262",Enhanced,,,,,Group enriched,Tissue enriched,123,liver: 60.9,breast: 0.4,Not detected,,
CYP2C18,"CPCI, CYP2C, CYP2C17, P450IIC17",ENSG00000108242,Cytochrome P450 family 2 subfamily C member 18,10,94683621-94736190,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,11,duodenum: 103.1;esophagus: 24.6;gallbladder: 24.5;liver: 97.8;small intestine: 88.1;stomach: 62.2,tonsil: 6.2,Cell line enhanced,,BEWO: 3.0
CYP2C19,"CPCJ, CYP2C, P450IIC19",ENSG00000165841,Cytochrome P450 family 2 subfamily C member 19,10,94762624-94853260,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA015066,Supported,,,,,Not detected,Tissue enhanced,,duodenum: 48.3;liver: 125.6,small intestine: 20.7,Not detected,,
CYP2C8,CPC8,ENSG00000138115,Cytochrome P450 family 2 subfamily C member 8,10,95036772-95069497,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA013547, HPA013970, HPA015066",Enhanced,,,,Pancreatic cancer:9.82e-4 (favourable),Tissue enriched,Tissue enriched,154,liver: 1124.1,gallbladder: 7.3,Not detected,,
CYP2C9,"CYP2C10, P450IIC9",ENSG00000138109,Cytochrome P450 family 2 subfamily C member 9,10,94938658-94989390,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA015066, CAB016123",Enhanced,,,,Liver cancer:2.83e-6 (favourable),Tissue enriched,Tissue enriched,7,liver: 963.1,duodenum: 136.8,Not detected,,
CYP2D6,"CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D",ENSG00000100197,Cytochrome P450 family 2 subfamily D member 6,22,42126499-42130906,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045223,Enhanced,,Approved,Golgi apparatus,,Tissue enriched,Group enriched,5,duodenum: 3.7;liver: 10.0;small intestine: 13.0,testis: 1.7,Cell line enhanced,,Hep G2: 1.2;HMC-1: 2.2;REH: 1.4;U-266/70: 1.3
CYP2E1,CYP2E,ENSG00000130649,Cytochrome P450 family 2 subfamily E member 1,10,133520406-133561220,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA009128, HPA029564",Enhanced,,,,,Tissue enriched,Tissue enriched,177,liver: 5332.2,tonsil: 30.1,Cell line enhanced,,HaCaT: 9.7;NB-4: 15.1
CYP2F1,CYP2F,ENSG00000197446,Cytochrome P450 family 2 subfamily F member 1,19,41114432-41128366,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,8,lung: 2.4;testis: 1.9,"bone marrow,esophagus,tonsil: 0.2",Group enriched,16,HMC-1: 4.7;K-562: 4.5
CYP2J2,,ENSG00000134716,Cytochrome P450 family 2 subfamily J member 2,1,59893308-59926790,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:5.54e-7 (unfavourable),Mixed,Tissue enhanced,,liver: 74.4;small intestine: 92.3,heart muscle: 57.5,Cell line enhanced,,RT4: 48.3;SK-BR-3: 12.0
CYP2R1,,ENSG00000186104,Cytochrome P450 family 2 subfamily R member 1,11,14877440-14892252,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042949,Approved,,,,Renal cancer:2.86e-4 (unfavourable),Expressed in all,Mixed,,,skin: 8.1,Cell line enhanced,,Karpas-707: 18.6
CYP2S1,,ENSG00000167600,Cytochrome P450 family 2 subfamily S member 1,19,41193049-41207539,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA049227, HPA069248",Approved,,Approved,Endoplasmic reticulum,Renal cancer:1.60e-6 (unfavourable),Expressed in all,Tissue enhanced,,duodenum: 96.7;small intestine: 68.6;stomach: 111.7,colon: 25.9,Cell line enhanced,,A549: 83.4;CACO-2: 39.6;HaCaT: 43.5;NTERA-2: 68.5
CYP2U1,SPG49,ENSG00000155016,Cytochrome P450 family 2 subfamily U member 1,4,107931369-107953457,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA041622, HPA046754, HPA064827",Uncertain,,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,"Renal cancer:2.75e-5 (favourable), Stomach cancer:6.97e-4 (unfavourable)",Expressed in all,Mixed,,,prostate: 15.7,Mixed,,
CYP39A1,,ENSG00000146233,Cytochrome P450 family 39 subfamily A member 1,6,46549580-46652830,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:1.86e-4 (favourable),Tissue enhanced,Tissue enhanced,,liver: 56.8,epididymis: 28.9,Cell line enhanced,,hTCEpi: 11.0;SiHa: 9.9;U-698: 7.7
CYP3A4,CYP3A3,ENSG00000160868,Cytochrome P450 family 3 subfamily A member 4,7,99756960-99784265,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB033671, HPA072245",Enhanced,,Uncertain,Cytosol,,Tissue enriched,Group enriched,199,duodenum: 826.8;liver: 2451.8;small intestine: 971.1,adrenal gland: 7.1,Cell line enhanced,,BEWO: 1.8;NB-4: 1.3;RPMI-8226: 2.2;SCLC-21H: 1.4;SH-SY5Y: 2.4
CYP3A43,,ENSG00000021461,Cytochrome P450 family 3 subfamily A member 43,7,99828013-99866102,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA066463, HPA072245",Supported,,Uncertain,Cytosol,Liver cancer:3.41e-4 (favourable),Tissue enriched,Tissue enriched,15,liver: 22.7,testis: 1.5,Not detected,,
CYP3A5,"CP35, P450PCN3, PCN3",ENSG00000106258,Cytochrome P450 family 3 subfamily A member 5,7,99648194-99679998,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA072245,,,Uncertain,Cytosol,Liver cancer:3.72e-5 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 114.8;liver: 93.2;small intestine: 187.6,stomach: 77.7,Cell line enhanced,,A549: 2.5;CACO-2: 7.9;CAPAN-2: 5.7;Hep G2: 5.0
CYP3A7,"CP37, P450-HFLA",ENSG00000160870,Cytochrome P450 family 3 subfamily A member 7,7,99705037-99735196,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA072245,,,Uncertain,Cytosol,,Tissue enriched,Tissue enriched,15,liver: 143.3,kidney: 9.8,Cell line enhanced,,Hep G2: 1.6;HHSteC: 1.0
CYP3A7-CYP3A51P,,ENSG00000282301,CYP3A7-CYP3A51P readthrough,7,99684957-99735102,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA072245,,,Uncertain,Cytosol,,,Tissue enhanced,,liver: 7.4,gallbladder: 1.9,Not detected,,
CYP46A1,CYP46,ENSG00000036530,Cytochrome P450 family 46 subfamily A member 1,14,99684304-99727301,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA040702,Uncertain,,,,,Tissue enriched,Tissue enriched,21,cerebral cortex: 64.1,heart muscle: 3.0,Group enriched,5,AF22: 2.4;U-937: 5.4
CYP4A11,"CYP4A2, CYP4AII",ENSG00000187048,Cytochrome P450 family 4 subfamily A member 11,1,46929177-46941484,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,183,kidney: 232.3;liver: 448.3,gallbladder: 1.8,Not detected,,
CYP4A22,,ENSG00000162365,Cytochrome P450 family 4 subfamily A member 22,1,47137435-47149741,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,16,kidney: 33.5;liver: 109.1,epididymis: 4.5,Cell line enriched,5,RH-30: 1.2
CYP4B1,,ENSG00000142973,Cytochrome P450 family 4 subfamily B member 1,1,46757838-46819413,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA004331,Approved,,Supported,Vesicles,Cervical cancer:5.99e-4 (favourable),Tissue enhanced,Tissue enhanced,,lung: 382.2,fallopian tube: 79.0,Cell line enriched,9,RT4: 234.9
CYP4F11,,ENSG00000171903,Cytochrome P450 family 4 subfamily F member 11,19,15912367-15934867,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA017265, CAB033648, HPA058960",Enhanced,,,,"Breast cancer:4.05e-4 (favourable), Pancreatic cancer:9.28e-4 (unfavourable)",Mixed,Tissue enhanced,,gallbladder: 29.5;liver: 32.7;small intestine: 26.3,epididymis: 20.0,Cell line enhanced,,A-431: 11.4;CAPAN-2: 44.2;EFO-21: 17.4;Hep G2: 17.0;RT4: 12.1
CYP4F2,,ENSG00000186115,Cytochrome P450 family 4 subfamily F member 2,19,15878023-15898120,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA014048, HPA017265, HPA058960",Supported,,,,,Tissue enriched,Group enriched,6,duodenum: 78.2;epididymis: 28.0;kidney: 39.3;liver: 84.6;small intestine: 84.3,prostate: 10.4,Cell line enhanced,,Hep G2: 2.5
CYP4F3,"CYP4F, LTB4H",ENSG00000186529,Cytochrome P450 family 4 subfamily F member 3,19,15640897-15662825,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA058960,Approved,,,,,Tissue enhanced,Tissue enhanced,,bone marrow: 53.1;liver: 98.0,kidney: 29.4,Group enriched,7,A549: 6.6;CAPAN-2: 28.8;HaCaT: 13.3;Hep G2: 12.4
CYP4F8,,ENSG00000186526,Cytochrome P450 family 4 subfamily F member 8,19,15615218-15630638,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058960,Approved,,,,,Group enriched,Tissue enriched,54,seminal vesicle: 147.7,breast: 2.7,Not detected,,
CYP4V2,CYP4AH1,ENSG00000145476,Cytochrome P450 family 4 subfamily V member 2,4,186191520-186213456,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA029122,Approved,,Approved,Nuclear speckles,"Renal cancer:1.49e-7 (favourable), Liver cancer:1.85e-4 (favourable), Endometrial cancer:5.86e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 65.1,liver: 47.4,Cell line enhanced,,SK-MEL-30: 19.3
CYP4X1,MGC40051,ENSG00000186377,Cytochrome P450 family 4 subfamily X member 1,1,47023568-47050751,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA017661,Approved,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 52.7",breast: 18.7,Cell line enhanced,,CACO-2: 3.6;NTERA-2: 2.0;SCLC-21H: 3.0;T-47d: 8.7
CYP4Z1,CYP4A20,ENSG00000186160,Cytochrome P450 family 4 subfamily Z member 1,1,47067488-47118319,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,breast: 6.9,lung: 1.5,Group enriched,43,HDLM-2: 8.5;SK-BR-3: 2.8
CYP51A1,"CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1",ENSG00000001630,Cytochrome P450 family 51 subfamily A member 1,7,92112151-92142952,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041325, HPA043508",Enhanced,,Enhanced,Endoplasmic reticulum,Cervical cancer:6.12e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 174.1,Expressed in all,,
CYP7A1,CYP7,ENSG00000167910,Cytochrome P450 family 7 subfamily A member 1,8,58490178-58500236,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Liver cancer:3.19e-4 (favourable),Tissue enriched,Tissue enriched,61,liver: 26.0,duodenum: 0.4,Not detected,,
CYP7B1,SPG5A,ENSG00000172817,Cytochrome P450 family 7 subfamily B member 1,8,64587763-64798761,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA017761,Uncertain,,,,,Mixed,Tissue enhanced,,parathyroid gland: 40.3,thyroid gland: 22.4,Cell line enhanced,,HSkMC: 11.3;SH-SY5Y: 6.2;WM-115: 11.7
CYP8B1,CYP12,ENSG00000180432,Cytochrome P450 family 8 subfamily B member 1,3,42856005-42876165,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,14,liver: 190.6,kidney: 13.7,Cell line enhanced,,BEWO: 2.2
DAO,DAMOX,ENSG00000110887,D-amino acid oxidase,12,108858932-108901043,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA038653, HPA038654",Enhanced,,,,Renal cancer:4.11e-4 (favourable),Tissue enriched,Group enriched,36,kidney: 89.8;liver: 74.1,rectum: 2.2,Not detected,,
DAPK1,DAPK,ENSG00000196730,Death associated protein kinase 1,9,87497228-87708633,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,"CAB037302, HPA040472, HPA048436",Approved,,Approved,Centrosome,Colorectal cancer:2.48e-5 (unfavourable),Expressed in all,Mixed,,,lung: 56.3,Cell line enhanced,,HMC-1: 85.8
DAPK2,"DRP-1, MGC119312",ENSG00000035664,Death associated protein kinase 2,15,63907036-64072033,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA071581,,,Supported,Golgi apparatus<br>Vesicles,Lung cancer:5.63e-4 (favourable),Tissue enriched,Tissue enhanced,,thyroid gland: 49.1,lung: 29.9,Cell line enhanced,,HMC-1: 16.0
DAPK3,"ZIP, ZIPK",ENSG00000167657,Death associated protein kinase 3,19,3958453-3971123,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA028569, HPA064809",Approved,,Approved,Nucleus,"Endometrial cancer:2.01e-5 (favourable), Renal cancer:6.49e-4 (unfavourable)",Expressed in all,Expressed in all,,,endometrium: 76.3,Expressed in all,,
DARS,,ENSG00000115866,Aspartyl-tRNA synthetase,2,135906677-135986100,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020451, HPA029804, HPA029805",Enhanced,,Enhanced,Cytosol,"Liver cancer:2.39e-6 (unfavourable), Renal cancer:1.24e-5 (unfavourable), Pancreatic cancer:6.54e-4 (unfavourable), Melanoma:7.57e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 91.0,Expressed in all,,
DARS2,FLJ10514,ENSG00000117593,"Aspartyl-tRNA synthetase 2, mitochondrial",1,173824503-173858546,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026506, HPA026528",Enhanced,,Supported,Nucleus<br>Mitochondria,Renal cancer:1.74e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 24.9,Expressed in all,,
DBH,DBM,ENSG00000123454,Dopamine beta-hydroxylase,9,133636360-133659344,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA002130, HPA005960, HPA070789",Enhanced,,Enhanced,Endoplasmic reticulum<br>Vesicles,,Mixed,Tissue enriched,28,adrenal gland: 356.8,liver: 12.6,Cell line enriched,370,SH-SY5Y: 1924.2
DBT,,ENSG00000137992,Dihydrolipoamide branched chain transacylase E2,1,100186919-100249834,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026481, HPA026485, HPA026533",Enhanced,,Supported,Mitochondria,Renal cancer:8.79e-12 (favourable),Expressed in all,Expressed in all,,,kidney: 19.7,Expressed in all,,
DCAF1,"KIAA0800, MGC102804, VPRBP",ENSG00000145041,DDB1 and CUL4 associated factor 1,3,51395867-51500002,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036142, HPA052445, HPA053203",Approved,,Enhanced,Nucleus<br>Nucleoli fibrillar center,Renal cancer:7.45e-5 (favourable),Expressed in all,Expressed in all,,,testis: 96.8,Expressed in all,,
DCK,,ENSG00000156136,Deoxycytidine kinase,4,70992538-71030914,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA059609, HPA062773",Approved,,Supported,Nucleus,Liver cancer:6.90e-7 (unfavourable),Expressed in all,Expressed in all,,,lymph node: 93.9,Expressed in all,,
DCLK1,"DCAMKL1, DCDC3A, DCLK, KIAA0369",ENSG00000133083,Doublecortin like kinase 1,13,35768652-36131306,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB012405, HPA015040, HPA015655",Enhanced,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:4.42e-4 (unfavourable),Tissue enhanced,Tissue enriched,5,cerebral cortex: 140.5,smooth muscle: 27.3,Cell line enhanced,,ASC diff: 19.8;ASC TERT1: 19.0;fHDF/TERT166: 18.2;HAP1: 18.4;HSkMC: 18.4;NTERA-2: 36.7
DCLK2,"DCAMKL2, DCDC3, DCDC3B, DCK2, MGC45428",ENSG00000170390,Doublecortin like kinase 2,4,150078274-150257457,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA015770,Enhanced,,,,"Pancreatic cancer:2.48e-4 (favourable), Ovarian cancer:3.25e-4 (favourable)",Tissue enriched,Tissue enriched,10,cerebral cortex: 82.6,heart muscle: 7.9,Cell line enhanced,,AF22: 23.3;BJ hTERT+: 20.2
DCLK3,"DCAMKL3, DCDC3C, KIAA1765",ENSG00000163673,Doublecortin like kinase 3,3,36712422-36764349,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA040685,Approved,,,,,Tissue enhanced,Tissue enhanced,,testis: 4.9,cerebral cortex: 1.1,Cell line enhanced,,SCLC-21H: 1.0
DCP2,NUDT20,ENSG00000172795,Decapping mRNA 2,5,112976702-113020970,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB011677, HPA057676",Approved,,Approved,Nucleoplasm<br>Cell Junctions<br>Cytoplasmic bodies,"Renal cancer:2.66e-5 (unfavourable), Liver cancer:4.84e-4 (unfavourable)",Expressed in all,Mixed,,,placenta: 18.9,Expressed in all,,
DCPS,"HINT-5, HSL1, HSPC015",ENSG00000110063,"Decapping enzyme, scavenger",11,126303752-126345749,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA039632, HPA058597",Supported,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,lymph node: 24.5,Expressed in all,,
DCT,TYRP2,ENSG00000080166,Dopachrome tautomerase,13,94436808-94479682,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA010743, HPA010800, CAB017634",Enhanced,,,,,Tissue enriched,Tissue enriched,31,skin: 126.8,breast: 4.0,Cell line enriched,177,SK-MEL-30: 202.8
DCTD,,ENSG00000129187,DCMP deaminase,4,182890060-182917936,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA035894,Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:1.81e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 167.0,Expressed in all,,
DCTPP1,"CDA03, MGC5627, RS21C6, XTP3TPA",ENSG00000179958,DCTP pyrophosphatase 1,16,30423619-30430075,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA002832,Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:9.71e-9 (favourable), Breast cancer:1.64e-5 (unfavourable), Liver cancer:6.28e-4 (unfavourable)",Expressed in all,Expressed in all,,,rectum: 64.1,Expressed in all,,
DCXR,"DCR, KIDCR, SDR20C1",ENSG00000169738,Dicarbonyl and L-xylulose reductase,17,82035136-82037732,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA023371, HPA023863",Enhanced,,Uncertain,Nucleoli<br>Microtubules,"Renal cancer:2.13e-4 (favourable), Pancreatic cancer:4.70e-4 (favourable)",Expressed in all,Group enriched,6,epididymis: 297.5;kidney: 217.3;liver: 640.9;prostate: 137.5,adipose tissue: 56.7,Expressed in all,,
DDAH1,DDAH,ENSG00000153904,Dimethylarginine dimethylaminohydrolase 1,1,85318481-85578363,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006308,Enhanced,,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:5.21e-6 (favourable), Colorectal cancer:5.99e-4 (favourable)",Expressed in all,Mixed,,,kidney: 121.4,Cell line enhanced,,SH-SY5Y: 122.6
DDAH2,G6A,ENSG00000213722,Dimethylarginine dimethylaminohydrolase 2,6,31727038-31730617,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA012509,Uncertain,,Uncertain,Microtubule organizing center<br>Cytosol,,Expressed in all,Mixed,,,thyroid gland: 22.3,Cell line enhanced,,EFO-21: 23.0;U-2 OS: 18.9
DDC,AADC,ENSG00000132437,Dopa decarboxylase,7,50458436-50565457,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA017742,Enhanced,,Approved,Actin filaments,,Mixed,Tissue enhanced,,duodenum: 155.2;kidney: 320.9;small intestine: 180.5,adrenal gland: 63.8,Group enriched,9,CACO-2: 44.3;Hep G2: 32.3;SCLC-21H: 154.0;SH-SY5Y: 144.1
DDO,,ENSG00000203797,D-aspartate oxidase,6,110391771-110415562,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA037525, HPA037526",Enhanced,,Supported,Cytosol,Renal cancer:8.69e-5 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 24.3,heart muscle: 12.2,Cell line enhanced,,RPMI-8226: 10.9;U-937: 13.6
DDR1,"CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6",ENSG00000204580,Discoidin domain receptor tyrosine kinase 1,6,30876421-30900156,"CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB010162, CAB025656, HPA057194",Approved,,Approved,Nucleoplasm<br>Cell Junctions,Renal cancer:3.31e-10 (favourable),Expressed in all,Mixed,,,cerebral cortex: 51.6,Cell line enhanced,,HaCaT: 80.3;RT4: 74.6;T-47d: 96.8
DDR2,"NTRKR3, TKT, TYRO10",ENSG00000162733,Discoidin domain receptor tyrosine kinase 2,1,162631373-162787400,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA070112,,,Supported,Plasma membrane<br>Actin filaments,Renal cancer:1.73e-7 (unfavourable),Expressed in all,Mixed,,,adrenal gland: 93.5,Cell line enhanced,,ASC diff: 203.0;ASC TERT1: 203.2;BJ hTERT+: 181.9
DDT,DDCT,ENSG00000099977,D-dopachrome tautomerase,22,23971365-23980469,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049871,Approved,,Approved,Mitochondria,,Expressed in all,Expressed in all,,,liver: 109.9,Expressed in all,,
DDX1,DBP-RB,ENSG00000079785,DEAD-box helicase 1,2,15591178-15631111,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012280, HPA034502, HPA034503",Enhanced,,Enhanced,Nucleoplasm<br>Cytosol,"Liver cancer:9.09e-9 (unfavourable), Renal cancer:9.69e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 145.1,Expressed in all,,
DDX10,HRH-J8,ENSG00000178105,DEAD-box helicase 10,11,108665025-108940930,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004691,Approved,,Approved,Nucleoli,"Renal cancer:2.14e-5 (favourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:5.75e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 29.2,Expressed in all,,
DDX11,"CHL1, CHLR1, KRG2, WABS",ENSG00000013573,DEAD/H-box helicase 11,12,31073845-31104791,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA065197,Supported,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Centrosome,"Renal cancer:5.23e-8 (unfavourable), Liver cancer:2.40e-4 (unfavourable)",Expressed in all,Expressed in all,,,skin: 19.3,Expressed in all,,
DDX17,P72,ENSG00000100201,DEAD-box helicase 17,22,38483440-38507660,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB024908, HPA063142",Enhanced,,Enhanced,Nuclear speckles,Lung cancer:6.06e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 336.0,Expressed in all,,
DDX18,MrDb,ENSG00000088205,DEAD-box helicase 18,2,117814650-117832379,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035400, HPA041056",Approved,,Enhanced,Nucleoli,"Endometrial cancer:2.64e-4 (unfavourable), Liver cancer:3.07e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 49.6,Expressed in all,,
DDX19A,"DDX19L, FLJ11126",ENSG00000168872,DEAD-box helicase 19A,16,70346829-70373383,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA045252, HPA066668",Approved,,Uncertain,Nucleoplasm,"Liver cancer:8.05e-5 (unfavourable), Head and neck cancer:2.38e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 51.3,Expressed in all,,
DDX19B,"DBP5, DDX19",ENSG00000157349,DEAD-box helicase 19B,16,70289663-70335283,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB037229, CAB037284, HPA046380, HPA066668",Approved,,Uncertain,Nucleoplasm,,Expressed in all,Expressed in all,,,testis: 82.8,Mixed,,
DDX20,"DP103, GEMIN3",ENSG00000064703,DEAD-box helicase 20,1,111755245-111768016,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA005516, CAB015427",Enhanced,,Supported,Nucleoplasm<br>Nuclear bodies<br>Cytosol,"Liver cancer:6.35e-6 (unfavourable), Colorectal cancer:9.85e-5 (favourable)",Expressed in all,Tissue enriched,10,testis: 130.7,parathyroid gland: 12.6,Expressed in all,,
DDX21,"GURDB, RH-II/GU",ENSG00000165732,DExD-box helicase 21,10,68956128-68985073,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036592, HPA036593",Enhanced,,Enhanced,Nucleus<br>Nucleoli,Pancreatic cancer:3.12e-4 (unfavourable),Expressed in all,Expressed in all,,,appendix: 71.2,Expressed in all,,
DDX23,"prp28, PRPF28, SNRNP100, U5-100K",ENSG00000174243,DEAD-box helicase 23,12,48829764-48852842,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038680, HPA039037",Approved,,Supported,Nucleus<br>Nucleoli,Liver cancer:3.03e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 58.2,Expressed in all,,
DDX24,,ENSG00000089737,DEAD-box helicase 24,14,94048291-94081245,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA002554,Uncertain,,Approved,Nucleoli<br>Cytosol,"Renal cancer:3.06e-9 (favourable), Stomach cancer:2.89e-4 (unfavourable)",Expressed in all,Tissue enhanced,,epididymis: 45.3,testis: 26.5,Mixed,,
DDX25,GRTH,ENSG00000109832,DEAD-box helicase 25,11,125903348-125943702,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA020137,Enhanced,,,,,Tissue enhanced,Group enriched,12,cerebral cortex: 34.6;testis: 163.8,thyroid gland: 8.0,Cell line enhanced,,NTERA-2: 10.8;SCLC-21H: 10.2
DDX27,"dJ686N3.1, DRS1",ENSG00000124228,DEAD-box helicase 27,20,49219295-49244077,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047087,Uncertain,,Approved,Nucleoli,"Liver cancer:6.70e-7 (unfavourable), Endometrial cancer:1.44e-5 (unfavourable), Renal cancer:1.73e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 46.2,Expressed in all,,
DDX28,"FLJ11282, MDDX28",ENSG00000182810,DEAD-box helicase 28,16,68021274-68023442,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA041911, HPA053585",Approved,,Supported,Nucleoli<br>Mitochondria<br>Cytosol,Renal cancer:2.07e-10 (favourable),Expressed in all,Expressed in all,,,bone marrow: 11.2,Expressed in all,,
DDX31,"FLJ13633, FLJ14578, FLJ23349, PPP1R25",ENSG00000125485,DEAD-box helicase 31,9,132592997-132670401,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA020891,,,Supported,Nucleoli<br>Golgi apparatus<br>Vesicles,Liver cancer:1.68e-7 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 23.0,Expressed in all,,
DDX39A,"BAT1L, DDX39, DDXL, URH49",ENSG00000123136,DExD-box helicase 39A,19,14408819-14419383,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA055334,Approved,,Approved,Nuclear speckles,"Renal cancer:1.50e-10 (unfavourable), Cervical cancer:6.86e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 209.7,Expressed in all,,
DDX39B,"BAT1, D6S81E, UAP56",ENSG00000198563,DExD-box helicase 39B,6,31530219-31542448,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB034012, HPA055334, HPA058450",Enhanced,,Enhanced,Nuclear speckles,"Renal cancer:1.11e-6 (unfavourable), Urothelial cancer:1.43e-5 (favourable)",Expressed in all,Expressed in all,,,epididymis: 45.0,Expressed in all,,
DDX3X,"DBX, DDX14, DDX3, HLP2",ENSG00000215301,"DEAD-box helicase 3, X-linked",X,41333348-41364472,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA001648, HPA005631, HPA059585",Supported,Approved,Approved,Nucleus<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 274.6,Expressed in all,,
DDX3Y,DBY,ENSG00000067048,"DEAD-box helicase 3, Y-linked",Y,12904108-12920478,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001648, HPA005631",Uncertain,Approved,Supported,Nucleus<br>Cytosol,Head and neck cancer:4.70e-5 (favourable),Mixed,Tissue enhanced,,testis: 128.6,prostate: 54.0,Cell line enhanced,,HEL: 139.0
DDX4,VASA,ENSG00000152670,DEAD-box helicase 4,5,55738017-55817157,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB026170, HPA037763, HPA037764",Enhanced,,,,,Tissue enriched,Tissue enriched,526,testis: 270.5,tonsil: 0.5,Cell line enhanced,,BEWO: 1.8
DDX41,"ABS, MGC8828",ENSG00000183258,DEAD-box helicase 41,5,177511577-177517469,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA017911, HPA048803",Enhanced,,Supported,Nucleus,Renal cancer:2.21e-6 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 52.6,Expressed in all,,
DDX42,"RHELP, RNAHP, SF3b125, SF3B8",ENSG00000198231,DEAD-box helicase 42,17,63773603-63819317,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA023447, HPA023571, HPA025941",Enhanced,,Enhanced,Nuclear speckles,"Liver cancer:2.84e-4 (unfavourable), Renal cancer:9.26e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 75.1,Expressed in all,,
DDX43,"CT13, DKFZp434H2114, HAGE",ENSG00000080007,DEAD-box helicase 43,6,73394748-73417569,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031381,Enhanced,,,,,Tissue enriched,Tissue enriched,5,testis: 34.6,placenta: 6.8,Cell line enhanced,,BEWO: 7.5;CAPAN-2: 11.7;HHSteC: 3.0;U-2 OS: 8.7
DDX46,"FLJ25329, KIAA0801, Prp5, PRPF5",ENSG00000145833,DEAD-box helicase 46,5,134758771-134855133,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036554, HPA057501",Supported,,Enhanced,Nuclear speckles,Colorectal cancer:9.01e-6 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 36.4,Expressed in all,,
DDX47,"DKFZp564O176, FLJ30012, HQ0256, RRP3",ENSG00000213782,DEAD-box helicase 47,12,12813316-12829981,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA014855,Approved,,Enhanced,Nucleoli,,Mixed,Expressed in all,,,thyroid gland: 55.8,Expressed in all,,
DDX49,FLJ10432,ENSG00000105671,DEAD-box helicase 49,19,18919675-18928633,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041870, HPA048093",Enhanced,,Approved,Nucleoli<br>Mitochondria,"Cervical cancer:2.01e-6 (favourable), Renal cancer:7.44e-5 (unfavourable), Liver cancer:7.05e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 24.3,Expressed in all,,
DDX5,"G17P1, HLR1, p68",ENSG00000108654,DEAD-box helicase 5,17,64499616-64508199,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005868, HPA020043",Supported,,Enhanced,Nucleoplasm,Colorectal cancer:2.12e-4 (favourable),Expressed in all,Expressed in all,,,smooth muscle: 599.5,Expressed in all,,
DDX50,"GU2, GUB, MGC3199, RH-II/GuB",ENSG00000107625,DExD-box helicase 50,10,68901278-68946847,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA037388, HPA037389, HPA058196",Approved,,Enhanced,Nucleoli,,Expressed in all,Expressed in all,,,testis: 47.0,Expressed in all,,
DDX51,,ENSG00000185163,DEAD-box helicase 51,12,132136594-132144335,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039503,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Cytosol,Liver cancer:4.73e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 11.4,Expressed in all,,
DDX52,ROK1,ENSG00000278053,DExD-box helicase 52,17,37609739-37643464,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA056173,Uncertain,,Supported,Nucleus<br>Nucleoli,"Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:9.41e-4 (favourable)",Expressed in all,Mixed,,,epididymis: 4.6,Mixed,,
DDX53,"CAGE, CT26",ENSG00000184735,DEAD-box helicase 53,X,22999961-23003589,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,100,testis: 10.0,all non-specific tissues: 0.0,Cell line enhanced,,K-562: 4.1;RPMI-8226: 1.6;U-2197: 1.3;U-266/84: 7.3
DDX54,"APR-5, DP97, MGC2835",ENSG00000123064,DEAD-box helicase 54,12,113157174-113185479,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA028244, HPA070786",Approved,,Approved,Nucleus<br>Nucleoli<br>Golgi apparatus,Liver cancer:1.39e-4 (unfavourable),Expressed in all,Expressed in all,,,appendix: 38.8,Expressed in all,,
DDX55,KIAA1595,ENSG00000111364,DEAD-box helicase 55,12,123602077-123620941,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039962, HPA044101",Approved,,Supported,Nucleus<br>Nucleoli<br>Cytosol,"Renal cancer:8.97e-12 (unfavourable), Liver cancer:2.11e-9 (unfavourable)",Expressed in all,Expressed in all,,,skin: 16.4,Expressed in all,,
DDX56,NOH61,ENSG00000136271,DEAD-box helicase 56,7,44565417-44575051,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019749, CAB037320",Uncertain,,,,"Renal cancer:8.41e-7 (unfavourable), Liver cancer:1.38e-5 (unfavourable)",Expressed in all,Expressed in all,,,"parathyroid gland,skin: 5.6",Expressed in all,,
DDX58,"DKFZp434J1111, FLJ13599, RIG-I",ENSG00000107201,DExD/H-box helicase 58,9,32455705-32526324,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB012643, HPA047193",Uncertain,,Supported,Cytosol,"Renal cancer:4.66e-4 (unfavourable), Endometrial cancer:5.46e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 19.8,Group enriched,6,BJ hTERT+ SV40 Large T+: 118.2;BJ hTERT+ SV40 Large T+ RasG12V: 128.1
DDX59,"DKFZP564B1023, ZNHIT5",ENSG00000118197,DEAD-box helicase 59,1,200623896-200669969,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA047166,Approved,,Approved,Nucleus<br>Actin filaments,Renal cancer:9.02e-4 (unfavourable),Expressed in all,Expressed in all,,,breast: 33.4,Expressed in all,,
DDX6,"HLR2, RCK",ENSG00000110367,DEAD-box helicase 6,11,118747766-118791149,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004668, HPA024201, HPA026644",Approved,,Supported,Cytosol<br>Cytoplasmic bodies,Liver cancer:6.56e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 65.6,Expressed in all,,
DDX60,FLJ20035,ENSG00000137628,DExD/H-box helicase 60,4,168216293-168318807,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046952,Approved,,Supported,Intermediate filaments<br>Cytosol,Pancreatic cancer:3.35e-4 (unfavourable),Expressed in all,Mixed,,,stomach: 45.7,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 35.0;BJ hTERT+ SV40 Large T+ RasG12V: 35.2
DDX60L,FLJ31033,ENSG00000181381,DEAD-box helicase 60-like,4,168356735-168537786,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA043211, HPA055501",Approved,,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:3.04e-5 (unfavourable), Renal cancer:2.94e-4 (unfavourable)",Expressed in all,Mixed,,,bone marrow: 33.7,Mixed,,
DECR1,"DECR, SDR18C1",ENSG00000104325,"2,4-dienoyl-CoA reductase 1",8,90001405-90052092,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA023160, HPA023162, HPA023238",Enhanced,,Supported,Mitochondria<br>Cytosol,"Renal cancer:1.79e-7 (favourable), Breast cancer:1.49e-4 (unfavourable), Urothelial cancer:6.06e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 262.9,Expressed in all,,
DECR2,"PDCR, SDR17C1",ENSG00000242612,"2,4-dienoyl-CoA reductase 2",16,401826-412487,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047631,,,Approved,Peroxisomes,,Expressed in all,Mixed,,,duodenum: 10.5,Mixed,,
DEGS1,"DEGS-1, Des-1, DES1, FADS7, MLD",ENSG00000143753,"Delta 4-desaturase, sphingolipid 1",1,224175756-224193441,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA076422,,,Supported,Mitochondria,"Renal cancer:6.83e-7 (unfavourable), Liver cancer:4.29e-5 (unfavourable), Endometrial cancer:7.74e-5 (unfavourable), Urothelial cancer:2.53e-4 (unfavourable)",Expressed in all,Expressed in all,,,skin: 616.3,Expressed in all,,
DEGS2,"C14orf66, DES2, FADS8",ENSG00000168350,"Delta 4-desaturase, sphingolipid 2",14,100143957-100160163,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046644,,,Approved,Nucleus<br>Nucleoli,"Renal cancer:7.94e-7 (favourable), Urothelial cancer:1.66e-4 (favourable)",Mixed,Tissue enhanced,,skin: 31.4;small intestine: 38.7,duodenum: 24.8,Cell line enriched,16,T-47d: 98.2
DERA,"CGI-26, DEOC",ENSG00000023697,Deoxyribose-phosphate aldolase,12,15911172-16037282,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA055897,,,Supported,Nucleus,"Thyroid cancer:3.64e-5 (favourable), Pancreatic cancer:1.32e-4 (unfavourable)",Expressed in all,Expressed in all,,,kidney: 74.7,Expressed in all,,
DGAT1,"ARGP1, DGAT",ENSG00000185000,Diacylglycerol O-acyltransferase 1,8,144314584-144326910,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,CAB032853,Enhanced,,Approved,Nucleoli<br>Endoplasmic reticulum,,Expressed in all,Tissue enhanced,,duodenum: 71.3;small intestine: 75.1,adipose tissue: 20.0,Cell line enhanced,,PC-3: 35.6
DGAT2,,ENSG00000062282,Diacylglycerol O-acyltransferase 2,11,75759512-75801535,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Endometrial cancer:2.84e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,adipose tissue: 493.2;liver: 170.9,skin: 116.1,Cell line enhanced,,ASC diff: 55.2;HDLM-2: 57.8
DGKA,"DAGK, DAGK1, DGK-alpha",ENSG00000065357,Diacylglycerol kinase alpha,12,55927319-55954027,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041645, HPA045462",Approved,,Approved,Nucleoplasm<br>Vesicles<br>Mitochondria,Renal cancer:1.66e-5 (unfavourable),Expressed in all,Mixed,,,skin: 97.4,Cell line enhanced,,HBEC3-KT: 93.1;hTERT-HME1: 102.8
DGKB,"DAGK2, DGK, DGK-BETA, KIAA0718",ENSG00000136267,Diacylglycerol kinase beta,7,14145049-14974777,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA020321,,Supported,,,,Tissue enriched,Tissue enriched,6,cerebral cortex: 34.2,endometrium: 5.6,Cell line enhanced,,AF22: 1.2;fHDF/TERT166: 2.0;SCLC-21H: 1.5;U-266/70: 2.5
DGKD,"DGKdelta, KIAA0145",ENSG00000077044,Diacylglycerol kinase delta,2,233354507-233472104,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027530, HPA049101",Approved,,Supported,Cytosol,"Renal cancer:4.07e-8 (unfavourable), Liver cancer:1.69e-5 (unfavourable)",Expressed in all,Mixed,,,testis: 20.8,Expressed in all,,
DGKE,"DAGK6, DGK",ENSG00000153933,Diacylglycerol kinase epsilon,17,56834099-56869567,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017167,Approved,,Approved,Nucleus<br>Cytosol,Endometrial cancer:3.92e-5 (favourable),Mixed,Mixed,,,testis: 12.1,Cell line enhanced,,Karpas-707: 61.4
DGKG,DAGK3,ENSG00000058866,Diacylglycerol kinase gamma,3,186105668-186362237,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA036577,Approved,,Approved,Vesicles<br>Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 21.4,placenta: 11.3,Cell line enhanced,,HDLM-2: 22.1;U-87 MG: 13.9
DGKH,DGKeta,ENSG00000102780,Diacylglycerol kinase eta,13,42040036-42256578,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039533, HPA040355",Uncertain,,,,,Mixed,Mixed,,,epididymis: 8.4,Mixed,,
DGKI,DGK-IOTA,ENSG00000157680,Diacylglycerol kinase iota,7,137381037-137847092,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021924,,,Approved,Nucleoplasm,,Mixed,Group enriched,11,cerebral cortex: 9.3;thyroid gland: 33.0,"heart muscle,smooth muscle: 1.8",Cell line enhanced,,SCLC-21H: 7.5;U-2197: 16.4;U-87 MG: 6.3
DGKK,,ENSG00000274588,Diacylglycerol kinase kappa,X,50365409-50470738,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,7,adrenal gland: 4.5,cerebral cortex: 0.6,Cell line enriched,14,Hep G2: 23.8
DGKQ,"DAGK, DAGK4, DAGK7",ENSG00000145214,Diacylglycerol kinase theta,4,958887-986895,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA026797, CAB033835",Uncertain,,,,,Expressed in all,Expressed in all,,,small intestine: 26.0,Mixed,,
DGKZ,"DAGK5, DAGK6, DGK-ZETA, hDGKzeta",ENSG00000149091,Diacylglycerol kinase zeta,11,46332905-46380554,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051336,Supported,,Supported,Nuclear speckles,Renal cancer:4.74e-5 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 132.6,Expressed in all,,
DGUOK,dGK,ENSG00000114956,Deoxyguanosine kinase,2,73926826-73958961,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA034766, HPA057246",Approved,,,,"Renal cancer:8.69e-7 (unfavourable), Urothelial cancer:7.47e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 56.6,Expressed in all,,
DHCR24,"DCE, KIAA0018, seladin-1",ENSG00000116133,24-dehydrocholesterol reductase,1,54849633-54887218,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA017981, CAB037247, HPA063005",Approved,,,,Endometrial cancer:1.05e-5 (unfavourable),Expressed in all,Expressed in all,,,adrenal gland: 1094.6,Mixed,,
DHCR7,SLOS,ENSG00000172893,7-dehydrocholesterol reductase,11,71428193-71452868,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA044280,Approved,,Supported,Endoplasmic reticulum<br>Cytosol,"Renal cancer:6.93e-7 (favourable), Urothelial cancer:5.67e-4 (unfavourable)",Expressed in all,Expressed in all,,,adrenal gland: 115.2,Expressed in all,,
DHDDS,"DS, FLJ13102, HDS, RP59",ENSG00000117682,Dehydrodolichyl diphosphate synthase subunit,1,26432282-26471294,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026721, HPA026727",Uncertain,,Uncertain,Plasma membrane,Renal cancer:4.08e-7 (favourable),Expressed in all,Expressed in all,,,adipose tissue: 54.5,Expressed in all,,
DHDH,HUM2DD,ENSG00000104808,Dihydrodiol dehydrogenase,19,48933682-48944969,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044131,Approved,,Approved,Nucleoplasm<br>Actin filaments,"Renal cancer:3.15e-4 (favourable), Endometrial cancer:9.91e-4 (unfavourable)",Expressed in all,Group enriched,5,duodenum: 10.2;kidney: 17.8;prostate: 5.1;small intestine: 18.6,testis: 2.5,Cell line enhanced,,SCLC-21H: 2.5
DHFR,,ENSG00000228716,Dihydrofolate reductase,5,80626228-80654983,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB037129, HPA051465",Uncertain,,Supported,Mitochondria,,Expressed in all,Mixed,,,lymph node: 49.6,Expressed in all,,
DHFR2,"DHFRL1, DHFRP4, FLJ16119",ENSG00000178700,Dihydrofolate reductase 2,3,94047836-94063389,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA051465,Uncertain,,Supported,Mitochondria,Renal cancer:2.30e-6 (favourable),Expressed in all,Mixed,,,parathyroid gland: 16.2,Mixed,,
DHODH,,ENSG00000102967,Dihydroorotate dehydrogenase (quinone),16,72008588-72027664,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA010123, HPA011942",Approved,,Supported,Nucleoplasm<br>Mitochondria,,Expressed in all,Mixed,,,liver: 21.4,Expressed in all,,
DHPS,MIG13,ENSG00000095059,Deoxyhypusine synthase,19,12675717-12681902,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA014461, HPA029413",Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,fallopian tube: 64.5,Expressed in all,,
DHRS3,"RDH17, retSDR1, Rsdr1, SDR1, SDR16C1",ENSG00000162496,Dehydrogenase/reductase 3,1,12567910-12617731,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010844,Supported,,Approved,Nucleoli<br>Mitochondria,Thyroid cancer:2.65e-4 (favourable),Expressed in all,Expressed in all,,,adipose tissue: 99.9,Cell line enhanced,,CAPAN-2: 219.3;WM-115: 228.2
DHRS4,"FLJ11008, humNRDR, SCAD-SRL, SDR-SRL, SDR25C2",ENSG00000157326,Dehydrogenase/reductase 4,14,23953586-23969279,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023972,Uncertain,,Approved,Nuclear membrane<br>Vesicles,Renal cancer:4.55e-6 (favourable),Expressed in all,Expressed in all,,,kidney: 149.0,Mixed,,
DHTKD1,"CMT2Q, DKFZP762M115, KIAA1630, MGC3090",ENSG00000181192,Dehydrogenase E1 and transketolase domain containing 1,10,12068972-12123225,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA037949, HPA037950, HPA066098",Approved,,Supported,Mitochondria,Renal cancer:3.43e-4 (favourable),Expressed in all,Expressed in all,,,liver: 66.5,Expressed in all,,
DHX15,"DBP1, DDX15, HRH2, PRP43, PRPF43, PrPp43p",ENSG00000109606,DEAH-box helicase 15,4,24517441-24584550,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA047047,Approved,,Enhanced,Nuclear speckles,Colorectal cancer:5.74e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 102.7,Expressed in all,,
DHX16,"DBP2, DDX16, Prp2, PRPF2",ENSG00000204560,DEAH-box helicase 16,6,30653119-30673037,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA051455,Enhanced,,Supported,Nucleoplasm,,Expressed in all,Mixed,,,testis: 11.5,Expressed in all,,
DHX29,DDX29,ENSG00000067248,DExH-box helicase 29,5,55256245-55307722,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA038317, HPA038318",Approved,,Approved,Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 39.2,Expressed in all,,
DHX30,"DDX30, FLJ11214, KIAA0890",ENSG00000132153,DExH-box helicase 30,3,47802909-47850195,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA034806,Supported,,Supported,Mitochondria<br>Cytosol,Renal cancer:1.37e-6 (favourable),Expressed in all,Expressed in all,,,testis: 46.2,Expressed in all,,
DHX32,"DDX32, DHLP1, FLJ10694, FLJ10889",ENSG00000089876,DEAH-box helicase 32 (putative),10,125836337-125896436,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA048872,Approved,,,,"Pancreatic cancer:9.49e-5 (unfavourable), Prostate cancer:6.34e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 59.8,Mixed,,
DHX33,"DDX33, DKFZp762F2011, FLJ21972",ENSG00000005100,DEAH-box helicase 33,17,5440912-5469060,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA073875,,,Supported,Nucleoli,Prostate cancer:6.10e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 13.6,Expressed in all,,
DHX34,"DDX34, KIAA0134",ENSG00000134815,DExH-box helicase 34,19,47349281-47382704,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042159, HPA043558",Uncertain,,Uncertain,Nucleus<br>Intermediate filaments,"Renal cancer:3.16e-6 (unfavourable), Liver cancer:8.63e-6 (unfavourable)",Expressed in all,Mixed,,,testis: 20.8,Expressed in all,,
DHX35,"C20orf15, DDX35, FLJ22759, KAIA0875",ENSG00000101452,DEAH-box helicase 35,20,38962299-39039723,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA054451, HPA062700",Uncertain,,Approved,Nucleus<br>Nuclear bodies<br>Centrosome,"Liver cancer:5.63e-6 (unfavourable), Endometrial cancer:4.25e-5 (unfavourable)",Expressed in all,Mixed,,,endometrium: 14.9,Expressed in all,,
DHX36,"DDX36, KIAA1488, MLEL1",ENSG00000174953,DEAH-box helicase 36,3,154272546-154324497,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA035399,Approved,,Supported,Nucleus<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 63.3,Expressed in all,,
DHX37,"DDX37, KIAA1517, MGC2695, MGC4322",ENSG00000150990,DEAH-box helicase 37,12,124946825-124989122,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047607,Enhanced,,Approved,Nuclear membrane,Liver cancer:9.54e-10 (unfavourable),Expressed in all,Mixed,,,bone marrow: 10.0,Expressed in all,,
DHX38,"DDX38, hPrp16, KIAA0224, PRP16, PRPF16",ENSG00000140829,DEAH-box helicase 38,16,72093562-72112912,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041347, HPA041604",Uncertain,,Supported,Nucleus,,Expressed in all,Expressed in all,,,parathyroid gland: 50.0,Expressed in all,,
DHX40,"ARG147, DDX40, FLJ22060, PAD",ENSG00000108406,DEAH-box helicase 40,17,59565525-59608345,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044350,Uncertain,,Supported,Nucleus,Colorectal cancer:4.05e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 89.6,Expressed in all,,
DHX57,DDX57,ENSG00000163214,DExH-box helicase 57,2,38797729-38875934,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036160,Uncertain,,Approved,Nucleoli<br>Intermediate filaments<br>Microtubules<br>Cytosol,Liver cancer:3.32e-6 (unfavourable),Expressed in all,Mixed,,,testis: 30.8,Expressed in all,,
DHX58,"D11LGP2, LGP2",ENSG00000108771,DExH-box helicase 58,17,42101404-42112733,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA018670, HPA019570",Approved,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,Breast cancer:3.45e-4 (favourable),Expressed in all,Expressed in all,,,spleen: 24.9,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 42.1;BJ hTERT+ SV40 Large T+ RasG12V: 51.2
DHX8,"DDX8, HRH1, PRP22, PRPF22",ENSG00000067596,DEAH-box helicase 8,17,43483865-43544463,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049285,Approved,,Supported,Nucleoplasm<br>Nuclear bodies,,Expressed in all,Expressed in all,,,parathyroid gland: 55.0,Expressed in all,,
DHX9,"DDX9, LKP, RHA",ENSG00000135829,DExH-box helicase 9,1,182839369-182887751,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB011819, HPA028050, HPA055684",Supported,,Enhanced,Nucleus,"Liver cancer:3.17e-4 (unfavourable), Melanoma:6.04e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 137.9,Expressed in all,,
DICER1,"Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1",ENSG00000100697,"Dicer 1, ribonuclease III",14,95086228-95158010,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000694, CAB068185",Approved,,Supported,Cytosol,,Expressed in all,Expressed in all,,,placenta: 32.6,Expressed in all,,
DIMT1,"DIMT1L, HSA9761",ENSG00000086189,DIM1 dimethyladenosine transferase 1 homolog,5,62387254-62403939,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA042944,Approved,,Approved,Nucleus<br>Nucleoli<br>Cytosol,"Renal cancer:8.90e-12 (unfavourable), Liver cancer:6.93e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 33.7,Expressed in all,,
DIO1,TXDI1,ENSG00000211452,Iodothyronine deiodinase 1,1,53891239-53911086,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Thyroid cancer:5.44e-4 (unfavourable),Group enriched,Group enriched,30,kidney: 147.5;liver: 94.9;thyroid gland: 434.9,fallopian tube: 7.5,Group enriched,20,Hep G2: 23.0;SK-BR-3: 59.3
DIO2,"SelY, TXDI2",ENSG00000211448,Iodothyronine deiodinase 2,14,80197527-80387757,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA029544, HPA048002",,,Supported,Nucleoplasm<br>Cytosol,"Endometrial cancer:4.62e-6 (favourable), Colorectal cancer:1.67e-4 (favourable)",Tissue enhanced,Group enriched,6,"cervix, uterine: 269.4;thyroid gland: 601.2",esophagus: 70.3,Cell line enhanced,,BJ: 70.1;HeLa: 63.5;SiHa: 184.0
DIO3,TXDI3,ENSG00000197406,Iodothyronine deiodinase 3,14,101561351-101563452,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 27.8;placenta: 25.4",ovary: 6.2,Cell line enriched,37,AF22: 53.5
DLAT,"DLTA, PDC-E2",ENSG00000150768,Dihydrolipoamide S-acetyltransferase,11,112024814-112064390,"Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003782, HPA040786, HPA062766",Enhanced,,Enhanced,Mitochondria,"Renal cancer:1.95e-14 (favourable), Colorectal cancer:6.19e-6 (favourable), Liver cancer:7.49e-5 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 31.0,Expressed in all,,
DLD,"DLDH, GCSL, LAD",ENSG00000091140,Dihydrolipoamide dehydrogenase,7,107890970-107931730,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA044849,Enhanced,,Supported,Mitochondria,Renal cancer:7.58e-9 (favourable),Expressed in all,Expressed in all,,,heart muscle: 174.7,Expressed in all,,
DLST,DLTS,ENSG00000119689,Dihydrolipoamide S-succinyltransferase,14,74881891-74903745,"Citric acid cycle related proteins, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003010,Supported,,,,Renal cancer:1.13e-12 (favourable),Expressed in all,Expressed in all,,,kidney: 106.7,Expressed in all,,
DMGDH,,ENSG00000132837,Dimethylglycine dehydrogenase,5,78997606-79236038,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036441, HPA036442, HPA077849",Enhanced,,Supported,Mitochondria,"Renal cancer:1.17e-5 (favourable), Liver cancer:5.32e-5 (favourable)",Group enriched,Group enriched,11,kidney: 179.1;liver: 146.2,epididymis: 14.9,Cell line enhanced,,BJ hTERT+: 2.9;Hep G2: 5.2
DMPK,"DM, DM1, DM1PK, DMK, MDPK, MT-PK",ENSG00000104936,Dystrophia myotonica protein kinase,19,45769717-45782552,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007164, HPA008905",Enhanced,,Approved,Vesicles<br>Cytosol,Pancreatic cancer:9.39e-5 (favourable),Expressed in all,Expressed in all,,,smooth muscle: 97.3,Cell line enhanced,,RH-30: 99.0
DNA2,"DNA2L, KIAA0083",ENSG00000138346,DNA replication helicase/nuclease 2,10,68414064-68472121,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA037487, HPA057526",Approved,,Supported,Mitochondria,,Mixed,Mixed,,,lymph node: 6.3,Mixed,,
DNAJC6,"KIAA0473, PARK19",ENSG00000116675,DnaJ heat shock protein family (Hsp40) member C6,1,65248219-65415869,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA031182, HPA054917",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:2.81e-4 (favourable),Tissue enhanced,Tissue enriched,10,cerebral cortex: 162.8,adrenal gland: 15.6,Cell line enhanced,,HDLM-2: 58.7;HEL: 150.3;K-562: 59.3
DNASE1,DNL1,ENSG00000213918,Deoxyribonuclease 1,16,3611728-3680143,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA010703,Enhanced,,Supported,Vesicles,Urothelial cancer:1.14e-4 (favourable),Expressed in all,Tissue enhanced,,small intestine: 37.8,duodenum: 29.9,Mixed,,
DNASE2,"DNL, DNL2",ENSG00000105612,"Deoxyribonuclease 2, lysosomal",19,12875211-12881468,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA066185,Enhanced,,,,,Expressed in all,Expressed in all,,,thyroid gland: 59.0,Expressed in all,,
DNASE2B,DLAD,ENSG00000137976,Deoxyribonuclease 2 beta,1,84398532-84415018,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enriched,7,salivary gland: 73.0,prostate: 10.5,Not detected,,
DNM1,DNM,ENSG00000106976,Dynamin 1,9,128191655-128255248,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005920, HPA049910, HPA061801",Enhanced,,Supported,Nucleoplasm,,Mixed,Tissue enriched,14,cerebral cortex: 364.2,"cervix, uterine: 25.6",Cell line enhanced,,A549: 114.8
DNM1L,"DRP1, DVLP, DYMPLE, HDYNIV, VPS1",ENSG00000087470,Dynamin 1 like,12,32679200-32745650,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB009952, HPA039324",Enhanced,,Enhanced,Vesicles<br>Cytosol,Liver cancer:6.27e-6 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 88.1,Expressed in all,,
DNM2,"CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII",ENSG00000079805,Dynamin 2,19,10718079-10833488,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA054246,Enhanced,,Approved,Golgi apparatus<br>Cytosol,"Liver cancer:3.63e-4 (unfavourable), Head and neck cancer:8.91e-4 (favourable)",Expressed in all,Expressed in all,,,colon: 103.9,Expressed in all,,
DNM3,KIAA0820,ENSG00000197959,Dynamin 3,1,171841498-172418466,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA064121,,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,cerebral cortex: 41.1,adrenal gland: 15.6,Cell line enhanced,,HEL: 20.5;RPTEC TERT1: 14.4;U-251 MG: 11.7
DNMT1,"CXXC9, DNMT, MCMT",ENSG00000130816,DNA methyltransferase 1,19,10133345-10231286,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA002694, CAB005876",Enhanced,,Enhanced,Nucleoplasm,Liver cancer:1.46e-4 (unfavourable),Expressed in all,Expressed in all,,,placenta: 51.2,Expressed in all,,
DNMT3A,,ENSG00000119772,DNA methyltransferase 3 alpha,2,25227855-25342590,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB009469, HPA026588",Approved,,Supported,Nucleoplasm,"Pancreatic cancer:1.18e-4 (favourable), Endometrial cancer:1.55e-4 (unfavourable), Liver cancer:1.58e-4 (unfavourable), Renal cancer:2.49e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 22.8,Cell line enhanced,,NTERA-2: 59.7;SH-SY5Y: 76.5
DNMT3B,,ENSG00000088305,DNA methyltransferase 3 beta,20,32762385-32809356,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001595, CAB069896",Enhanced,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.87e-7 (unfavourable), Endometrial cancer:5.04e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,testis: 9.2,skin: 4.5,Cell line enhanced,,BEWO: 236.9;NTERA-2: 333.3
DNPEP,"ASPEP, DAP",ENSG00000123992,Aspartyl aminopeptidase,2,219373546-219400022,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036398, HPA044860",Enhanced,,Supported,Cytosol,,Expressed in all,Expressed in all,,,testis: 65.4,Expressed in all,,
DNTT,TDT,ENSG00000107447,DNA nucleotidylexotransferase,10,96304396-96338564,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA044194,,,Approved,Nucleoplasm<br>Cytosol,,Not detected,Tissue enriched,8,bone marrow: 18.3,tonsil: 2.1,Group enriched,518,MOLT-4: 325.2;REH: 1262.7
DOHH,"HLRC1, MGC4293",ENSG00000129932,Deoxyhypusine hydroxylase,19,3490821-3500940,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041953,Approved,,Approved,Nucleus<br>Cytosol,"Endometrial cancer:2.24e-4 (favourable), Pancreatic cancer:3.58e-4 (favourable)",Expressed in all,Mixed,,,duodenum: 17.8,Expressed in all,,
DOLK,"DK1, KIAA1094, TMEM15",ENSG00000175283,Dolichol kinase,9,128945530-128947619,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA066767, HPA068706",,,Supported,Nucleus<br>Nucleoli,"Thyroid cancer:6.88e-5 (favourable), Renal cancer:5.53e-4 (favourable)",Expressed in all,Mixed,,,parathyroid gland: 24.7,Expressed in all,,
DOLPP1,LSFR2,ENSG00000167130,Dolichyldiphosphatase 1,9,129081100-129090438,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA019179,Approved,,Approved,Vesicles<br>Intermediate filaments,,Expressed in all,Expressed in all,,,duodenum: 25.8,Expressed in all,,
DOT1L,"DOT1, KIAA1814, KMT4",ENSG00000104885,DOT1 like histone lysine methyltransferase,19,2164149-2232578,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA011875, HPA071217",,,Enhanced,Nucleoplasm,"Endometrial cancer:1.69e-4 (favourable), Head and neck cancer:6.00e-4 (favourable)",Expressed in all,Tissue enriched,7,testis: 92.3,"appendix,bone marrow: 14.0",Expressed in all,,
DPAGT1,"ALG7, CDG-Ij, D11S366, DGPT, DPAGT, DPAGT2, GPT",ENSG00000172269,Dolichyl-phosphate N-acetylglucosaminephosphotransferase 1,11,119096503-119108331,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA053878,Approved,,,,Liver cancer:2.03e-5 (unfavourable),Expressed in all,Mixed,,,parathyroid gland: 25.5,Expressed in all,,
DPEP1,,ENSG00000015413,Dipeptidase 1 (renal),16,89613308-89638456,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,"HPA009426, HPA012783",Enhanced,,Approved,Nucleus<br>Cell Junctions,Renal cancer:6.84e-4 (favourable),Tissue enriched,Tissue enhanced,,kidney: 262.6;small intestine: 418.9,pancreas: 92.8,Cell line enhanced,,Hep G2: 22.4;HHSteC: 11.8;U-937: 36.5
DPEP2,,ENSG00000167261,Dipeptidase 2,16,67987394-68000586,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035644,Approved,,,,Testis cancer:8.47e-4 (unfavourable),Mixed,Tissue enhanced,,spleen: 38.7,lung: 27.9,Cell line enhanced,,HEL: 3.7;HMC-1: 16.1;U-937: 4.9
DPEP3,,ENSG00000141096,Dipeptidase 3,16,67975663-67980829,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA031870, HPA058607",Enhanced,,,,,Group enriched,Tissue enriched,25,testis: 56.9,spleen: 2.3,Not detected,,
DPH1,"DPH2L, DPH2L1, OVCA1",ENSG00000108963,Diphthamide biosynthesis 1,17,2030110-2043430,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA069750,,,Approved,Nucleoplasm<br>Cell Junctions,Pancreatic cancer:1.78e-5 (favourable),Expressed in all,Expressed in all,,,fallopian tube: 31.5,Expressed in all,,
DPH2,DPH2L2,ENSG00000132768,DPH2 homolog,1,43970000-43973369,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045796,Uncertain,,Approved,Nucleus,"Liver cancer:1.17e-8 (unfavourable), Stomach cancer:1.37e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 14.3,Expressed in all,,
DPH5,CGI-30,ENSG00000117543,Diphthamide biosynthesis 5,1,100989623-101026088,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA046439, HPA076234",Approved,,Approved,Golgi apparatus,,Expressed in all,Expressed in all,,,ovary: 52.1,Expressed in all,,
DPH6,"ATPBD4, MGC14798",ENSG00000134146,Diphthamine biosynthesis 6,15,35217345-35546193,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042976, HPA055496",Approved,,Enhanced,Nucleus<br>Nucleoli,,Expressed in all,Expressed in all,,,thyroid gland: 18.1,Expressed in all,,
DPH7,"C9orf112, FLJ90634, RRT2, WDR85",ENSG00000148399,Diphthamide biosynthesis 7,9,137554904-137578935,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA022911,Uncertain,,Approved,Nuclear bodies,"Renal cancer:1.52e-5 (unfavourable), Urothelial cancer:3.23e-4 (favourable), Pancreatic cancer:6.52e-4 (favourable)",Expressed in all,Expressed in all,,,fallopian tube: 18.1,Expressed in all,,
DPM1,"CDGIE, MPDS",ENSG00000000419,"Dolichyl-phosphate mannosyltransferase subunit 1, catalytic",20,50934867-50958555,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA051818,Approved,,,,Liver cancer:1.94e-6 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 80.5,Expressed in all,,
DPP10,"DPL2, DPPY, DPRP3",ENSG00000175497,Dipeptidyl peptidase like 10,2,114442299-115845752,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA048767,Uncertain,,Approved,Nucleus<br>Vesicles<br>Cytosol,,Mixed,Group enriched,7,adrenal gland: 14.1;cerebral cortex: 34.7,pancreas: 3.6,Cell line enhanced,,AF22: 4.1;HAP1: 6.4;HMC-1: 3.8;NTERA-2: 3.7;RT4: 5.3;SCLC-21H: 11.4;SH-SY5Y: 4.1
DPP3,,ENSG00000254986,Dipeptidyl peptidase 3,11,66480013-66509657,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035780, HPA035781",Approved,,Enhanced,Nuclear speckles<br>Plasma membrane<br>Cytosol,Stomach cancer:1.34e-4 (favourable),Expressed in all,Expressed in all,,,colon: 29.7,Expressed in all,,
DPP4,"ADCP2, CD26, DPPIV",ENSG00000197635,Dipeptidyl peptidase 4,2,161992241-162074542,"CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB045970,Enhanced,,,,"Renal cancer:1.35e-6 (favourable), Prostate cancer:1.98e-4 (unfavourable), Thyroid cancer:4.99e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 550.6,placenta: 169.1,Cell line enhanced,,ASC diff: 115.0;ASC TERT1: 118.1;BJ hTERT+: 131.1;RPTEC TERT1: 175.8
DPP6,"DPL1, DPPX",ENSG00000130226,Dipeptidyl peptidase like 6,7,153887097-154894285,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA050509,Enhanced,Supported,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 51.1;endometrium: 27.6,smooth muscle: 15.4,Cell line enriched,9,NTERA-2: 5.5
DPP7,"DPP2, DPPII",ENSG00000176978,Dipeptidyl peptidase 7,9,137110542-137115177,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA021282, CAB025541, HPA059381",Supported,,Enhanced,Golgi apparatus<br>Vesicles,"Colorectal cancer:6.07e-6 (unfavourable), Pancreatic cancer:8.31e-5 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 70.7,Mixed,,
DPP8,"DP8, DPRP1, FLJ14920, FLJ20283, MGC26191, MSTP141",ENSG00000074603,Dipeptidyl peptidase 8,15,65442463-65517704,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA008706,Approved,,Supported,Cytosol,,Expressed in all,Expressed in all,,,testis: 48.0,Expressed in all,,
DPP9,,ENSG00000142002,Dipeptidyl peptidase 9,19,4675224-4724673,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036059,Approved,,Supported,Cytosol,"Renal cancer:3.38e-8 (unfavourable), Endometrial cancer:6.21e-5 (favourable), Stomach cancer:7.72e-5 (favourable), Breast cancer:4.96e-4 (favourable)",Expressed in all,Expressed in all,,,appendix: 33.1,Expressed in all,,
DPYD,DPD,ENSG00000188641,Dihydropyrimidine dehydrogenase,1,97077743-97921049,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB033241, HPA045210",Uncertain,,,,Pancreatic cancer:6.27e-4 (unfavourable),Expressed in all,Expressed in all,,,lung: 44.1,Mixed,,
DPYS,DHPase,ENSG00000147647,Dihydropyrimidinase,8,104330324-104467053,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA024785,Enhanced,,,,,Group enriched,Group enriched,22,kidney: 200.4;liver: 246.2,gallbladder: 10.1,Not detected,,
DQX1,FLJ23757,ENSG00000144045,DEAQ-box RNA dependent ATPase 1,2,74518131-74526336,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039158,Enhanced,,Approved,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,duodenum: 14.4;small intestine: 13.5,colon: 5.5,Cell line enhanced,,HBEC3-KT: 4.2;Hep G2: 11.5;hTCEpi: 4.3
DROSHA,"Etohi2, HSA242976, RN3, RNASE3L, RNASEN",ENSG00000113360,Drosha ribonuclease III,5,31400497-31532196,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Liver cancer:1.39e-4 (unfavourable), Endometrial cancer:6.79e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 30.5,Expressed in all,,
DSE,"DSEPI, SART2",ENSG00000111817,Dermatan sulfate epimerase,6,116254173-116444860,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA014764, HPA052151",Uncertain,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:1.50e-4 (unfavourable), Cervical cancer:3.36e-4 (unfavourable), Ovarian cancer:6.34e-4 (unfavourable)",Mixed,Mixed,,,appendix: 36.2,Mixed,,
DSTYK,"DustyPK, KIAA0472, RIP5, RIPK5",ENSG00000133059,Dual serine/threonine and tyrosine protein kinase,1,205142505-205211566,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA044140,Uncertain,,Uncertain,Nuclear speckles<br>Intermediate filaments,Urothelial cancer:8.73e-5 (unfavourable),Expressed in all,Mixed,,,parathyroid gland: 28.8,Expressed in all,,
DTX1,hDx-1,ENSG00000135144,Deltex E3 ubiquitin ligase 1,12,113056709-113098028,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA051249, HPA055275",Approved,,Supported,Nucleoplasm<br>Nuclear bodies<br>Cytosol,Renal cancer:3.02e-5 (unfavourable),Expressed in all,Tissue enhanced,,lymph node: 13.4,spleen: 11.4,Group enriched,9,Daudi: 77.9;REH: 41.0;U-698: 75.9
DTX2,"KIAA1528, RNF58",ENSG00000091073,Deltex E3 ubiquitin ligase 2,7,76461676-76505995,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA042931,Approved,,Supported,Nucleoplasm<br>Nuclear membrane,"Renal cancer:1.13e-8 (unfavourable), Glioma:7.25e-4 (unfavourable)",Expressed in all,Expressed in all,,,esophagus: 37.2,Expressed in all,,
DTX3,"FLJ34766, RNF154",ENSG00000178498,Deltex E3 ubiquitin ligase 3,12,57604622-57609804,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA059654,Approved,,Approved,Nucleus<br>Nucleoli<br>Golgi apparatus,"Pancreatic cancer:1.44e-4 (favourable), Lung cancer:9.87e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 102.8,Mixed,,
DTX3L,BBAP,ENSG00000163840,Deltex E3 ubiquitin ligase 3L,3,122564238-122575203,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA010570,Uncertain,,Supported,Nucleoplasm<br>Cytosol,Pancreatic cancer:8.99e-4 (unfavourable),Expressed in all,Expressed in all,,,spleen: 36.1,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 83.9;BJ hTERT+ SV40 Large T+ RasG12V: 107.7
DTX4,"KIAA0937, RNF155",ENSG00000110042,Deltex E3 ubiquitin ligase 4,11,59171430-59208587,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA056760, HPA059294",Uncertain,Approved,Approved,Vesicles,"Thyroid cancer:5.81e-4 (favourable), Renal cancer:8.94e-4 (unfavourable)",Expressed in all,Mixed,,,lung: 27.3,Cell line enhanced,,BEWO: 63.2;RT4: 80.7
DTYMK,"CDC8, TMPK, TYMK",ENSG00000168393,Deoxythymidylate kinase,2,241675742-241686991,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042593, HPA042719",Approved,,Approved,Mitochondria,"Liver cancer:1.73e-5 (unfavourable), Renal cancer:1.22e-4 (unfavourable)",Expressed in all,Expressed in all,,,lymph node: 24.0,Expressed in all,,
DUOX1,"LNOX1, NOXEF1, THOX1",ENSG00000137857,Dual oxidase 1,15,45129933-45165576,"Enzymes, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA023544,Approved,,,,Cervical cancer:4.31e-6 (favourable),Tissue enhanced,Tissue enhanced,,skin: 96.9;thyroid gland: 92.6,esophagus: 73.2,Cell line enhanced,,HaCaT: 56.9;hTCEpi: 22.1;RT4: 29.0
DUOX2,"LNOX2, P138-TOX, P138(TOX), THOX2",ENSG00000140279,Dual oxidase 2,15,45092650-45114344,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,gallbladder: 446.7;thyroid gland: 124.8,urinary bladder: 87.1,Cell line enriched,8,HaCaT: 5.5
DUPD1,DUSP27,ENSG00000188716,Dual specificity phosphatase and pro isomerase domain containing 1,10,75037836-75058514,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA042964,Uncertain,,,,,Not detected,Tissue enriched,30,skeletal muscle: 24.4,prostate: 0.8,Not detected,,
DUSP1,"CL100, HVH1, MKP-1, PTPN10",ENSG00000120129,Dual specificity phosphatase 1,5,172768090-172771195,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB018554, HPA069577",Approved,,Approved,Nucleoli<br>Cytosol,Stomach cancer:3.11e-5 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 1027.0,Expressed in all,,
DUSP10,"MKP-5, MKP5",ENSG00000143507,Dual specificity phosphatase 10,1,221701424-221742176,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA016758,Approved,,Supported,Nucleoplasm<br>Golgi apparatus<br>Cytosol,"Renal cancer:3.69e-4 (unfavourable), Liver cancer:5.42e-4 (favourable)",Expressed in all,Mixed,,,liver: 16.7,Cell line enhanced,,HaCaT: 86.1
DUSP12,"DUSP1, YVH1",ENSG00000081721,Dual specificity phosphatase 12,1,161749758-161757238,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA008840,Uncertain,,Supported,Nucleus,"Renal cancer:1.55e-7 (unfavourable), Liver cancer:1.99e-5 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 20.3,Expressed in all,,
DUSP13,"BEDP, DUSP13A, DUSP13B, FLJ32450, TMDP",ENSG00000079393,Dual specificity phosphatase 13,10,75094432-75109221,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,6,skeletal muscle: 84.9;testis: 47.5,heart muscle: 10.9,Cell line enhanced,,BEWO: 4.2;EFO-21: 4.7;Hep G2: 7.4;K-562: 3.8;LHCN-M2: 7.9;RH-30: 7.7
DUSP14,"MKP-L, MKP6",ENSG00000276023,Dual specificity phosphatase 14,17,37489831-37513501,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019911,Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:6.97e-9 (unfavourable),Expressed in all,Tissue enhanced,,fallopian tube: 5.1,skin: 2.7,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 15.2;HBF TERT88: 21.7;WM-115: 13.0
DUSP15,"bA243J16.5, bA243J16.6, C20orf57, FLJ20645, VHY",ENSG00000149599,Dual specificity phosphatase 15,20,31847637-31870747,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA076649,Enhanced,,Approved,Plasma membrane<br>Cytosol,Renal cancer:5.40e-7 (favourable),Mixed,Tissue enhanced,,testis: 77.1,parathyroid gland: 16.1,Cell line enhanced,,REH: 14.6;SH-SY5Y: 4.6
DUSP16,"KIAA1700, MKP-7, MKP7",ENSG00000111266,Dual specificity phosphatase 16,12,12474210-12562383,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA020326,Approved,,Supported,Nucleoplasm,Head and neck cancer:1.01e-4 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 33.2,Cell line enhanced,,NTERA-2: 39.3
DUSP18,DUSP20,ENSG00000167065,Dual specificity phosphatase 18,22,30652051-30667890,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB034070, HPA051349",Approved,,Supported,Nucleoplasm,,Mixed,Mixed,,,testis: 22.3,Expressed in all,,
DUSP19,"DUSP17, SKRP1",ENSG00000162999,Dual specificity phosphatase 19,2,183078559-183100005,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021501,Approved,,Approved,Nucleoplasm,,Mixed,Mixed,,,testis: 5.5,Mixed,,
DUSP2,PAC-1,ENSG00000158050,Dual specificity phosphatase 2,2,96143166-96145440,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA071920,,,Supported,Nucleus<br>Nuclear membrane,Renal cancer:4.97e-5 (unfavourable),Expressed in all,Tissue enhanced,,bone marrow: 78.9;seminal vesicle: 86.2,lymph node: 50.7,Cell line enhanced,,RT4: 27.2;SCLC-21H: 34.8;U-698: 28.6
DUSP21,,ENSG00000189037,Dual specificity phosphatase 21,X,44844004-44844888,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,41,testis: 9.9,small intestine: 0.2,Not detected,,
DUSP22,"JKAP, JSP1, MKPX, VHX",ENSG00000112679,Dual specificity phosphatase 22,6,291630-351355,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031394,Approved,,Approved,Nucleoplasm<br>Vesicles,,Expressed in all,Expressed in all,,,testis: 85.1,Expressed in all,,
DUSP23,"DUSP25, FLJ20442",ENSG00000158716,Dual specificity phosphatase 23,1,159780932-159782543,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028211, HPA045792",Approved,,Supported,Nucleoplasm,"Renal cancer:2.59e-5 (unfavourable), Liver cancer:3.06e-4 (unfavourable)",Expressed in all,Expressed in all,,,adrenal gland: 40.4,Mixed,,
DUSP26,"DUSP24, MGC1136",ENSG00000133878,Dual specificity phosphatase 26,8,33591332-33600106,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA018221,Approved,,Supported,Nucleus,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 47.1;skeletal muscle: 138.7,ovary: 39.6,Group enriched,29,SCLC-21H: 110.0;SH-SY5Y: 23.6
DUSP28,"DUSP26, VHP",ENSG00000188542,Dual specificity phosphatase 28,2,240560054-240564014,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047456, CAB069448",Uncertain,,Uncertain,Nuclear speckles<br>Cytosol,Pancreatic cancer:1.84e-4 (favourable),Expressed in all,Mixed,,,skeletal muscle: 3.9,Mixed,,
DUSP3,VHR,ENSG00000108861,Dual specificity phosphatase 3,17,43766121-43778988,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA063616,,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:5.49e-5 (favourable), Head and neck cancer:3.00e-4 (unfavourable), Glioma:9.23e-4 (unfavourable)",Expressed in all,Expressed in all,,,seminal vesicle: 100.8,Mixed,,
DUSP4,"HVH2, MKP-2, TYP",ENSG00000120875,Dual specificity phosphatase 4,8,29333064-29350668,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA061967,,,Supported,Nucleoplasm,Renal cancer:4.19e-4 (unfavourable),Expressed in all,Tissue enhanced,,breast: 29.6,stomach: 28.2,Cell line enhanced,,A549: 90.3;SK-MEL-30: 120.4;WM-115: 120.9
DUSP5,HVH3,ENSG00000138166,Dual specificity phosphatase 5,10,110497838-110511544,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Lung cancer:8.30e-6 (unfavourable),Expressed in all,Mixed,,,esophagus: 100.1,Cell line enhanced,,hTERT-HME1: 303.0;U-266/70: 167.5
DUSP6,"MKP-3, PYST1",ENSG00000139318,Dual specificity phosphatase 6,12,89347232-89353271,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB017566, HPA053188",Approved,,Uncertain,Nucleoplasm<br>Cytosol,Endometrial cancer:7.21e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 141.2,Cell line enhanced,,AN3-CA: 428.0
DUSP7,"MKP-X, PYST2",ENSG00000164086,Dual specificity phosphatase 7,3,52048919-52056550,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Renal cancer:8.84e-6 (unfavourable),Expressed in all,Expressed in all,,,skin: 45.1,Expressed in all,,
DUSP8,"C11orf81, FLJ42958, HB5, HVH-5",ENSG00000184545,Dual specificity phosphatase 8,11,1554044-1571920,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA020071,Approved,,Approved,Cytosol,Renal cancer:2.75e-6 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 5.1,smooth muscle: 2.3,Cell line enhanced,,MCF7: 1.9;SH-SY5Y: 2.2
DUSP9,"MKP-4, MKP4",ENSG00000130829,Dual specificity phosphatase 9,X,153642492-153651326,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003336,Enhanced,,Approved,Endoplasmic reticulum,Endometrial cancer:1.60e-4 (unfavourable),Mixed,Group enriched,35,kidney: 29.0;placenta: 103.3,testis: 1.8,Cell line enriched,6,Hep G2: 251.7
DUT,dUTPase,ENSG00000128951,Deoxyuridine triphosphatase,15,48331011-48343373,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA054422, HPA060360",Enhanced,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,lymph node: 114.3,Expressed in all,,
DYRK1A,"DYRK, DYRK1, MNBH",ENSG00000157540,Dual specificity tyrosine phosphorylation regulated kinase 1A,21,37365790-37517450,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA015323, HPA015810",Approved,,Approved,Nucleoli fibrillar center<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 61.3,Expressed in all,,
DYRK1B,MIRK,ENSG00000105204,Dual specificity tyrosine phosphorylation regulated kinase 1B,19,39825350-39834201,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA028522, HPA028786",Uncertain,,Approved,Nucleus,Renal cancer:8.83e-4 (favourable),Expressed in all,Tissue enhanced,,skeletal muscle: 37.4,testis: 33.6,Cell line enhanced,,SCLC-21H: 15.0;SH-SY5Y: 15.3
DYRK2,,ENSG00000127334,Dual specificity tyrosine phosphorylation regulated kinase 2,12,67648338-67665406,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA027230, HPA056902",Approved,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,small intestine: 31.0,Expressed in all,,
DYRK3,"hYAK3-2, RED, REDK",ENSG00000143479,Dual specificity tyrosine phosphorylation regulated kinase 3,1,206635536-206684419,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA075041,,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:9.41e-7 (unfavourable),Expressed in all,Tissue enhanced,,testis: 86.7,gallbladder: 23.2,Cell line enhanced,,hTERT-HME1: 56.1
DYRK4,,ENSG00000010219,Dual specificity tyrosine phosphorylation regulated kinase 4,12,4562204-4615302,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028065, HPA056073",Enhanced,,Enhanced,Vesicles,Renal cancer:6.52e-6 (unfavourable),Expressed in all,Tissue enhanced,,testis: 66.2,epididymis: 20.7,Mixed,,
DZIP3,"hRUL138, PPP1R66",ENSG00000198919,DAZ interacting zinc finger protein 3,3,108589682-108694846,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA035066, HPA049232",Approved,,Approved,Vesicles,Renal cancer:3.65e-4 (favourable),Expressed in all,Expressed in all,,,testis: 65.7,Mixed,,
E4F1,E4F,ENSG00000167967,E4F transcription factor 1,16,2223566-2235742,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA052042, HPA071325",,,Enhanced,Nucleoplasm,"Head and neck cancer:1.10e-4 (favourable), Renal cancer:5.50e-4 (unfavourable), Cervical cancer:9.13e-4 (favourable)",Expressed in all,Expressed in all,,,skin: 12.8,Expressed in all,,
EARS2,"KIAA1970, MSE1",ENSG00000103356,"Glutamyl-tRNA synthetase 2, mitochondrial",16,23522014-23557731,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA043289, HPA043633",Approved,,Supported,Nucleoplasm<br>Mitochondria,"Renal cancer:3.16e-6 (favourable), Pancreatic cancer:7.20e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 32.9,Expressed in all,,
EBP,"CDPX2, CHO2, CPX, CPXD",ENSG00000147155,Emopamil binding protein (sterol isomerase),X,48521158-48528716,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA003130,Approved,,Supported,Endoplasmic reticulum,,Expressed in all,Expressed in all,,,liver: 91.3,Expressed in all,,
ECE1,ECE,ENSG00000117298,Endothelin converting enzyme 1,1,21217247-21345504,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA001490, HPA013616",Approved,,,,,Expressed in all,Expressed in all,,,parathyroid gland: 436.1,Expressed in all,,
ECE2,"KIAA0604, MGC2408",ENSG00000145194,Endothelin converting enzyme 2,3,184249650-184293031,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043346, HPA062215",Enhanced,,Approved,Nucleus<br>Cytosol,"Endometrial cancer:8.41e-5 (unfavourable), Liver cancer:5.80e-4 (unfavourable)",Expressed in all,Mixed,,,adrenal gland: 15.4,Expressed in all,,
ECEL1,"DINE, XCE",ENSG00000171551,Endothelin converting enzyme like 1,2,232479827-232487828,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA067560, HPA069756",,Supported,Approved,Nucleoplasm<br>Nuclear membrane<br>Nucleoli,,Tissue enhanced,Tissue enriched,25,ovary: 111.9,spleen: 4.4,Group enriched,7,AN3-CA: 40.8;HeLa: 15.2
ECHDC1,dJ351K20.2,ENSG00000093144,Ethylmalonyl-CoA decarboxylase 1,6,127288710-127343609,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA035445, HPA035446",Uncertain,,Approved,Vesicles,,Expressed in all,Expressed in all,,,adipose tissue: 98.5,Mixed,,
ECHS1,SCEH,ENSG00000127884,"Enoyl-CoA hydratase, short chain 1",10,133362480-133373689,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003783, HPA021995, HPA022476",Enhanced,,Enhanced,Mitochondria,Renal cancer:8.57e-5 (favourable),Expressed in all,Expressed in all,,,liver: 438.0,Expressed in all,,
ECI1,DCI,ENSG00000167969,Enoyl-CoA delta isomerase 1,16,2239395-2252300,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041746, HPA043227",Enhanced,,,,"Renal cancer:8.99e-8 (favourable), Cervical cancer:3.04e-5 (favourable), Liver cancer:1.07e-4 (favourable)",Expressed in all,Expressed in all,,,skeletal muscle: 69.3,Expressed in all,,
ECI2,"ACBD2, DRS1, HCA88, PECI",ENSG00000198721,Enoyl-CoA delta isomerase 2,6,4115689-4135597,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA022130, HPA031626",Enhanced,,Enhanced,Peroxisomes,"Renal cancer:2.04e-6 (favourable), Head and neck cancer:2.85e-4 (unfavourable)",Expressed in all,Expressed in all,,,kidney: 238.6,Expressed in all,,
EDEM3,C1orf22,ENSG00000116406,ER degradation enhancing alpha-mannosidase like protein 3,1,184690231-184754913,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA025754, HPA025755, HPA027297",Approved,,Approved,Endoplasmic reticulum,Renal cancer:1.63e-6 (unfavourable),Expressed in all,Expressed in all,,,stomach: 34.4,Expressed in all,,
EEF2K,eEF-2K,ENSG00000103319,Eukaryotic elongation factor 2 kinase,16,22206282-22288732,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB007818, HPA056061",Approved,,Approved,Nucleoplasm,Renal cancer:2.38e-4 (unfavourable),Expressed in all,Expressed in all,,,skin: 54.3,Expressed in all,,
EGFR,"ERBB, ERBB1",ENSG00000146648,Epidermal growth factor receptor,7,55019021-55211628,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB000035, HPA001200, HPA018530, CAB068186, CAB073534",Enhanced,,Enhanced,Plasma membrane,Urothelial cancer:2.04e-5 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 100.0,skin: 58.7,Cell line enriched,15,A-431: 4682.9
EGLN1,"C1orf12, HIFPH2, PHD2, SM-20, ZMYND6",ENSG00000135766,Egl-9 family hypoxia inducible factor 1,1,231363751-231425044,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA022129,Approved,,Approved,Cytosol,Cervical cancer:2.99e-7 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 29.9,Expressed in all,,
EGLN2,"HIFPH1, PHD1",ENSG00000269858,Egl-9 family hypoxia inducible factor 2,19,40798996-40808433,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA056649,,,Supported,Nucleoplasm,"Cervical cancer:2.88e-4 (favourable), Pancreatic cancer:4.81e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 205.1,Expressed in all,,
EGLN3,"HIFPH3, PHD3",ENSG00000129521,Egl-9 family hypoxia inducible factor 3,14,33924231-34462774,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA064895,,,Approved,Cytosol,"Liver cancer:2.14e-5 (unfavourable), Renal cancer:2.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 98.0,heart muscle: 62.0,Cell line enhanced,,RH-30: 43.2;RT4: 97.7
EHHADH,ECHD,ENSG00000113790,Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase,3,185190624-185281990,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036401, HPA042021",Enhanced,,,,Renal cancer:1.28e-5 (favourable),Group enriched,Group enriched,7,kidney: 148.6;liver: 173.1,duodenum: 21.4,Mixed,,
EHMT1,"bA188C12.1, Eu-HMTase1, FLJ12879, KIAA1876, KMT1D",ENSG00000181090,Euchromatic histone lysine methyltransferase 1,9,137618963-137870016,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA060022,,,Supported,Nucleoplasm<br>Nuclear bodies,"Endometrial cancer:6.56e-4 (favourable), Head and neck cancer:8.91e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 65.0,Expressed in all,,
EHMT2,"BAT8, C6orf30, Em:AF134726.3, G9A, KMT1C, NG36/G9a",ENSG00000204371,Euchromatic histone lysine methyltransferase 2,6,31879759-31897687,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA050550, HPA060259",Supported,,Supported,Nucleoplasm<br>Nuclear speckles,Liver cancer:1.79e-4 (unfavourable),Expressed in all,Mixed,,,cerebral cortex: 4.7,Cell line enhanced,,NTERA-2: 19.2
EIF2AK1,"HRI, KIAA1369",ENSG00000086232,Eukaryotic translation initiation factor 2 alpha kinase 1,7,6022244-6059230,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA016496, CAB022082, HPA061675",Approved,,Supported,Nucleus<br>Cytosol,Liver cancer:6.99e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 129.4,Expressed in all,,
EIF2AK2,"EIF2AK1, PKR, PPP1R83, PRKR",ENSG00000055332,Eukaryotic translation initiation factor 2 alpha kinase 2,2,37099210-37157065,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB003845, HPA019795, HPA063893",Approved,,Enhanced,Cytosol,"Pancreatic cancer:2.08e-4 (unfavourable), Endometrial cancer:3.77e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 25.4,Mixed,,
EIF2AK3,"PEK, PERK",ENSG00000172071,Eukaryotic translation initiation factor 2 alpha kinase 3,2,88556741-88627576,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"CAB009204, HPA015737",Enhanced,,,,,Expressed in all,Mixed,,,parathyroid gland: 37.3,Expressed in all,,
EIF2AK4,"GCN2, KIAA1338",ENSG00000128829,Eukaryotic translation initiation factor 2 alpha kinase 4,15,39934146-40035591,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA011811,Approved,,Approved,Cytosol,,Expressed in all,Expressed in all,,,endometrium: 54.3,Expressed in all,,
EIF3F,"eIF3-epsilon, eIF3-p47, eIF3f, EIF3S5",ENSG00000175390,Eukaryotic translation initiation factor 3 subunit F,11,7970251-8001862,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA049250,Approved,,Uncertain,Nucleoli<br>Cytosol,Liver cancer:6.86e-4 (unfavourable),Expressed in all,Expressed in all,,,ovary: 178.4,Expressed in all,,
EIF4A1,"DDX2A, EIF-4A, EIF4A",ENSG00000161960,Eukaryotic translation initiation factor 4A1,17,7572706-7579005,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB011689, HPA068286",Uncertain,,Approved,Cytosol,Renal cancer:1.76e-8 (unfavourable),Expressed in all,Expressed in all,,,smooth muscle: 458.2,Expressed in all,,
EIF4A2,"BM-010, DDX2B, EIF4A, EIF4F",ENSG00000156976,Eukaryotic translation initiation factor 4A2,3,186783205-186789900,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB011690, HPA068286",Uncertain,,Approved,Cytosol,,Expressed in all,Expressed in all,,,ovary: 726.0,Expressed in all,,
EIF4A3,"DDX48, EIF4AIII, KIAA0111",ENSG00000141543,Eukaryotic translation initiation factor 4A3,17,80135214-80147183,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA021878,Enhanced,,Supported,Nucleoplasm,"Liver cancer:1.68e-5 (unfavourable), Colorectal cancer:3.57e-5 (favourable), Lung cancer:1.87e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 112.1,Expressed in all,,
EIF5B,"DKFZp434I036, FLJ10524, IF2, KIAA0741",ENSG00000158417,Eukaryotic translation initiation factor 5B,2,99337353-99401326,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034648, HPA040095",Approved,,Approved,Plasma membrane<br>Cytosol,"Liver cancer:7.15e-10 (unfavourable), Renal cancer:1.42e-6 (unfavourable), Ovarian cancer:8.99e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 67.5,Expressed in all,,
ELAC1,D29,ENSG00000141642,ElaC ribonuclease Z 1,18,50967991-50988121,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040867, HPA066483",Approved,,Supported,Nucleus<br>Cytosol,Renal cancer:8.43e-8 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 17.8,Expressed in all,,
ELAC2,"FLJ10530, HPC2",ENSG00000006744,ElaC ribonuclease Z 2,17,12992391-13018187,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA019535,Approved,,Enhanced,Nucleoplasm,Endometrial cancer:3.24e-6 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 55.1,Expressed in all,,
ELANE,"ELA2, HLE, HNE, NE",ENSG00000197561,"Elastase, neutrophil expressed",19,851014-856247,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB015409, HPA066836",Enhanced,,,,,Group enriched,Tissue enriched,320,bone marrow: 1199.6,skin: 3.7,Cell line enriched,56,THP-1: 1171.3
ELOVL1,Ssc1,ENSG00000066322,ELOVL fatty acid elongase 1,1,43363397-43368074,"Enzymes, Predicted membrane proteins",Evidence at protein level,"CAB033426, HPA056557",Approved,,Approved,Endoplasmic reticulum,"Liver cancer:2.79e-7 (unfavourable), Cervical cancer:3.63e-5 (unfavourable), Pancreatic cancer:8.51e-4 (unfavourable)",Expressed in all,Expressed in all,,,skin: 156.7,Expressed in all,,
ELOVL2,Ssc2,ENSG00000197977,ELOVL fatty acid elongase 2,6,10980759-11044314,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Breast cancer:6.73e-5 (favourable),Group enriched,Tissue enhanced,,liver: 27.6;parathyroid gland: 36.7;placenta: 50.2,cerebral cortex: 22.8,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 29.1;HBF TERT88: 28.0;RH-30: 30.7
ELOVL3,CIG-30,ENSG00000119915,ELOVL fatty acid elongase 3,10,102226328-102229589,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA036236,Supported,,Approved,Vesicles<br>Cytosol,Endometrial cancer:6.25e-5 (unfavourable),Tissue enhanced,Tissue enhanced,,adipose tissue: 3.6;breast: 4.4;skin: 3.4,testis: 2.3,Cell line enhanced,,HSkMC: 10.4;SiHa: 24.5
ELOVL4,"CT118, SCA34, STGD2, STGD3",ENSG00000118402,ELOVL fatty acid elongase 4,6,79914812-79947580,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,Urothelial cancer:6.27e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 24.0;skin: 50.7,parathyroid gland: 15.7,Cell line enhanced,,MOLT-4: 25.9
ELOVL5,"dJ483K16.1, HELO1, SCA38",ENSG00000012660,ELOVL fatty acid elongase 5,6,53267398-53349179,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB017042, HPA047752, HPA054197",Enhanced,,Enhanced,Endoplasmic reticulum,"Renal cancer:1.94e-6 (unfavourable), Thyroid cancer:6.80e-4 (unfavourable)",Expressed in all,Expressed in all,,,adipose tissue: 257.0,Expressed in all,,
ELOVL6,"FLJ23378, LCE, MGC5487",ENSG00000170522,ELOVL fatty acid elongase 6,4,110045846-110199199,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA042355,Uncertain,,,,Colorectal cancer:6.74e-4 (favourable),Expressed in all,Mixed,,,liver: 27.9,Mixed,,
ELOVL7,FLJ23563,ENSG00000164181,ELOVL fatty acid elongase 7,5,60751791-60844389,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA036337,Approved,,,,"Renal cancer:1.54e-9 (favourable), Endometrial cancer:3.87e-5 (unfavourable)",Expressed in all,Mixed,,,prostate: 35.8,Cell line enhanced,,HEL: 33.1
ELP3,"FLJ10422, KAT9",ENSG00000134014,Elongator acetyltransferase complex subunit 3,8,28089673-28191156,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA025812,Uncertain,,,,"Renal cancer:1.31e-5 (favourable), Colorectal cancer:9.25e-4 (favourable)",Expressed in all,Expressed in all,,,"cervix, uterine: 37.6",Expressed in all,,
ENGASE,FLJ21865,ENSG00000167280,Endo-beta-N-acetylglucosaminidase,17,79074939-79088599,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021551,Approved,,Approved,Centrosome<br>Cytosol,"Renal cancer:8.97e-6 (unfavourable), Urothelial cancer:8.73e-5 (favourable), Pancreatic cancer:2.60e-4 (favourable)",Expressed in all,Expressed in all,,,spleen: 28.1,Mixed,,
ENO1,"ENO1L1, MBP-1, MPB1, PPH",ENSG00000074800,Enolase 1,1,8861002-8879249,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB018614, HPA068284, HPA068721, CAB069394",Enhanced,,Enhanced,Plasma membrane<br>Cytosol,"Liver cancer:1.30e-8 (unfavourable), Glioma:2.12e-4 (unfavourable)",Expressed in all,Expressed in all,,,appendix: 768.2,Expressed in all,,
ENO2,,ENSG00000111674,Enolase 2,12,6913745-6923698,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000063, HPA068284, HPA068721, CAB073539, CAB079023",Enhanced,Supported,Supported,Plasma membrane<br>Cytosol,"Renal cancer:7.89e-11 (unfavourable), Liver cancer:5.15e-4 (unfavourable), Colorectal cancer:6.96e-4 (unfavourable)",Expressed in all,Tissue enriched,7,cerebral cortex: 431.0,parathyroid gland: 64.8,Cell line enhanced,,U-87 MG: 368.8
ENO3,,ENSG00000108515,Enolase 3,17,4948092-4957131,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000793, HPA068284, HPA068721",Enhanced,,Supported,Plasma membrane<br>Cytosol,Colorectal cancer:7.33e-4 (unfavourable),Expressed in all,Tissue enriched,17,skeletal muscle: 5974.6,heart muscle: 350.1,Expressed in all,,
ENO4,"AC023283.3, C10orf134",ENSG00000188316,Enolase family member 4,10,116849512-116911788,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA037938, HPA061509",Enhanced,,,,,Mixed,Tissue enhanced,,fallopian tube: 9.2;testis: 6.8,thyroid gland: 3.4,Cell line enhanced,,MCF7: 3.0;T-47d: 2.3
ENOPH1,"E1, MASA, mtnC",ENSG00000145293,Enolase-phosphatase 1,4,82430562-82461091,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004985, HPA044607",Enhanced,,Approved,Nucleoplasm<br>Nuclear bodies,Liver cancer:1.74e-5 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 98.3,Expressed in all,,
ENOSF1,"HSRTSBETA, rTS, TYMSAS",ENSG00000132199,Enolase superfamily member 1,18,670324-712676,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047829,Enhanced,,,,Breast cancer:2.27e-4 (favourable),Expressed in all,Mixed,,,kidney: 38.9,Expressed in all,,
ENPEP,"CD249, gp160",ENSG00000138792,Glutamyl aminopeptidase,4,110365733-110565285,"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA002821, HPA005128",Enhanced,,Approved,Endoplasmic reticulum,,Tissue enriched,Group enriched,5,duodenum: 36.5;kidney: 94.3;parathyroid gland: 160.7;small intestine: 180.3,placenta: 21.5,Cell line enhanced,,BEWO: 2.6;HEK 293: 6.8;MOLT-4: 1.4
ENPP1,"M6S1, NPPS, PC-1, PCA1, PDNP1",ENSG00000197594,Ectonucleotide pyrophosphatase/phosphodiesterase 1,6,131808016-131895155,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"CAB032904, HPA062066",Enhanced,,,,,Expressed in all,Tissue enhanced,,parathyroid gland: 54.3;placenta: 62.9,thyroid gland: 34.1,Cell line enhanced,,ASC diff: 23.4;U-138 MG: 27.3
ENPP2,"ATX, PD-IALPHA, PDNP2",ENSG00000136960,Ectonucleotide pyrophosphatase/phosphodiesterase 2,8,119557086-119673453,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA023700, HPA053652",Approved,,Approved,Nucleus<br>Golgi apparatus<br>Actin filaments,Pancreatic cancer:2.07e-5 (favourable),Expressed in all,Expressed in all,,,placenta: 376.2,Cell line enhanced,,ASC TERT1: 231.1;BJ hTERT+: 160.8
ENPP3,"B10, CD203c, gp130RB13-6, PD-IBETA, PDNP3",ENSG00000154269,Ectonucleotide pyrophosphatase/phosphodiesterase 3,6,131628442-131747418,"CD markers, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043772,Enhanced,,,,Renal cancer:1.96e-4 (unfavourable),Tissue enriched,Tissue enhanced,,"cervix, uterine: 45.4;small intestine: 49.9",seminal vesicle: 22.0,Group enriched,15,HEL: 3.9;Hep G2: 9.9;HMC-1: 5.4
ENPP4,"KIAA0879, NPP4",ENSG00000001561,Ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative),6,46129993-46146699,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA016594,Approved,,,,Renal cancer:6.95e-7 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 38.4,Cell line enhanced,,SCLC-21H: 21.1
ENPP6,MGC33971,ENSG00000164303,Ectonucleotide pyrophosphatase/phosphodiesterase 6,4,184088706-184221230,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042740,Approved,,Approved,Golgi apparatus,,Tissue enriched,Tissue enhanced,,kidney: 30.6;ovary: 15.0,cerebral cortex: 8.6,Cell line enhanced,,Karpas-707: 2.3;SH-SY5Y: 3.8;U-266/70: 2.2;U-266/84: 1.1
ENPP7,"alk-SMase, NPP7",ENSG00000182156,Ectonucleotide pyrophosphatase/phosphodiesterase 7,17,79730919-79742222,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA024603,Approved,,,,,Tissue enriched,Group enriched,22,duodenum: 45.7;small intestine: 110.2,kidney: 3.5,Cell line enhanced,,Karpas-707: 1.4;U-266/70: 2.1
ENTPD1,"ATPDase, CD39, NTPDase-1, SPG64",ENSG00000138185,Ectonucleoside triphosphate diphosphohydrolase 1,10,95711779-95869695,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"CAB002494, HPA014067",Enhanced,,Uncertain,Microtubules,"Renal cancer:5.33e-5 (unfavourable), Thyroid cancer:7.89e-4 (favourable)",Expressed in all,Mixed,,,smooth muscle: 98.8,Group enriched,7,HDLM-2: 179.7;Karpas-707: 112.9
ENTPD3,"CD39L3, HB6, NTPDase-3",ENSG00000168032,Ectonucleoside triphosphate diphosphohydrolase 3,3,40387156-40428619,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA071802,,,Approved,Cytosol,,Mixed,Tissue enhanced,,"cervix, uterine: 33.6",urinary bladder: 14.7,Cell line enhanced,,HBEC3-KT: 9.3;hTCEpi: 6.3;RT4: 15.1
ENTPD4,"KIAA0392, LALP70, LAP70, LYSAL1, NTPDase-4, UDPase",ENSG00000197217,Ectonucleoside triphosphate diphosphohydrolase 4,8,23385783-23457695,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017655,Supported,,Supported,Vesicles,,Expressed in all,Expressed in all,,,parathyroid gland: 47.3,Expressed in all,,
ENTPD5,"CD39L4, NTPDase-5, PCPH",ENSG00000187097,Ectonucleoside triphosphate diphosphohydrolase 5,14,73958010-74019399,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA002927,Enhanced,,Approved,Cytosol,Renal cancer:3.95e-5 (favourable),Expressed in all,Tissue enhanced,,liver: 130.4,rectum: 111.3,Expressed in all,,
ENTPD6,"CD39L2, dJ738P15.3, IL6ST2, NTPDase-6",ENSG00000197586,Ectonucleoside triphosphate diphosphohydrolase 6 (putative),20,25195693-25226729,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015491, HPA069555",Approved,,Supported,Golgi apparatus,,Expressed in all,Expressed in all,,,cerebral cortex: 105.7,Expressed in all,,
ENTPD8,"NTPDase-8, UNQ2492",ENSG00000188833,Ectonucleoside triphosphate diphosphohydrolase 8,9,137434364-137441816,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA021509,Enhanced,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Stomach cancer:7.17e-4 (favourable),Mixed,Tissue enhanced,,colon: 21.7;duodenum: 28.7;small intestine: 31.6,rectum: 12.5,Cell line enhanced,,CAPAN-2: 4.8;RPMI-8226: 3.7;T-47d: 2.7
EOGT,"AER61, C3orf64, FLJ33770",ENSG00000163378,EGF domain specific O-linked N-acetylglucosamine transferase,3,68975214-69013961,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA019460,Approved,,Approved,Nucleoplasm<br>Nuclear membrane<br>Cytosol,Renal cancer:8.97e-5 (unfavourable),Expressed in all,Expressed in all,,,seminal vesicle: 50.3,Mixed,,
EP300,"KAT3B, p300",ENSG00000100393,E1A binding protein p300,22,41091786-41180079,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB000146, HPA003128, HPA004112",Supported,,Enhanced,Nucleoplasm,Renal cancer:7.45e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 46.2,Expressed in all,,
EPHA1,"EPH, EPHT, EPHT1",ENSG00000146904,EPH receptor A1,7,143390289-143408892,"Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,CAB026144,Uncertain,,,,Renal cancer:1.14e-6 (favourable),Mixed,Tissue enriched,24,parathyroid gland: 877.3,esophagus: 36.2,Cell line enhanced,,CACO-2: 29.0;HaCaT: 28.6;NTERA-2: 106.2
EPHA10,"FLJ16103, FLJ33655",ENSG00000183317,EPH receptor A10,1,37713880-37765133,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA027497,Uncertain,,,,,Mixed,Tissue enhanced,,testis: 20.4,colon: 7.9,Cell line enhanced,,BEWO: 4.7;HDLM-2: 18.1;SCLC-21H: 10.2
EPHA2,ECK,ENSG00000142627,EPH receptor A2,1,16124337-16156087,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,CAB010464,,,Supported,Nuclear speckles<br>Golgi apparatus<br>Plasma membrane<br>Cell Junctions,,Expressed in all,Tissue enhanced,,esophagus: 86.8,gallbladder: 44.5,Cell line enhanced,,PC-3: 211.2;WM-115: 253.0
EPHA3,"ETK, ETK1, HEK, HEK4, TYRO4",ENSG00000044524,EPH receptor A3,3,89107524-89482134,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB010462,Approved,,Uncertain,Nucleoplasm<br>Golgi apparatus<br>Cytosol,Renal cancer:3.28e-7 (unfavourable),Mixed,Tissue enhanced,,prostate: 51.9,gallbladder: 29.8,Cell line enriched,7,AF22: 192.5
EPHA4,"Hek8, TYRO1",ENSG00000116106,EPH receptor A4,2,221418027-221574202,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB028368,Enhanced,,,,"Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 41.6,testis: 22.2,Cell line enhanced,,AF22: 77.5;CACO-2: 49.0;U-2197: 35.7
EPHA5,"CEK7, EHK1, Hek7, TYRO4",ENSG00000145242,EPH receptor A5,4,65319563-65670495,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,5,cerebral cortex: 18.0,"cervix, uterine: 3.3",Cell line enhanced,,PC-3: 8.7;TIME: 10.3;U-138 MG: 25.1;U-2197: 14.6;U-251 MG: 17.0
EPHA6,FLJ35246,ENSG00000080224,EPH receptor A6,3,96814581-97752460,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007397, HPA058047",Uncertain,,Enhanced,Nucleoplasm,,Mixed,Tissue enhanced,,ovary: 7.7;testis: 15.1,cerebral cortex: 3.6,Cell line enhanced,,HEK 293: 8.5;U-266/70: 21.4
EPHA7,Hek11,ENSG00000135333,EPH receptor A7,6,93240020-93419547,"Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB010496,Approved,,,,,Tissue enhanced,Tissue enriched,13,parathyroid gland: 253.5,prostate: 20.2,Cell line enhanced,,AF22: 15.6;HEK 293: 41.9;RH-30: 41.8;THP-1: 25.7
EPHA8,"EEK, Hek3",ENSG00000070886,EPH receptor A8,1,22563564-22603594,"Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB009660, HPA031433",Uncertain,,,,,Mixed,Tissue enhanced,,adrenal gland: 4.7;spleen: 2.6;testis: 1.9,cerebral cortex: 1.3,Cell line enriched,14,SCLC-21H: 70.4
EPHB1,"EPHT2, Hek6",ENSG00000154928,EPH receptor B1,3,134597801-135260467,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA067740,Enhanced,,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,,Tissue enriched,Tissue enhanced,,cerebral cortex: 23.7;testis: 20.5,thyroid gland: 11.9,Cell line enhanced,,HDLM-2: 59.3;HMC-1: 31.7
EPHB2,"DRT, EPHT3, ERK, Hek5, Tyro5",ENSG00000133216,EPH receptor B2,1,22710839-22921500,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB013647, HPA071200",Approved,,Supported,Nucleus<br>Plasma membrane,"Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable)",Tissue enhanced,Mixed,,,rectum: 27.3,Cell line enhanced,,HUVEC TERT2: 71.2;TIME: 69.5
EPHB3,"ETK2, Hek2, Tyro6",ENSG00000182580,EPH receptor B3,3,184561784-184582409,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA007698, HPA008184, CAB034350",Enhanced,,,,Renal cancer:7.88e-5 (unfavourable),Expressed in all,Tissue enhanced,,skin: 45.4,stomach: 18.1,Cell line enhanced,,BEWO: 27.9;HaCaT: 35.7;SK-BR-3: 23.1;T-47d: 19.3
EPHB4,"HTK, Tyro11",ENSG00000196411,EPH receptor B4,7,100802565-100827521,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB013537,Uncertain,,,,"Colorectal cancer:4.33e-4 (unfavourable), Breast cancer:8.56e-4 (unfavourable), Urothelial cancer:8.84e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 50.6,Mixed,,
EPHX1,EPHX,ENSG00000143819,Epoxide hydrolase 1,1,225810092-225845563,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020593, HPA048847",Enhanced,,,,"Lung cancer:7.02e-5 (favourable), Prostate cancer:1.32e-4 (favourable)",Tissue enriched,Expressed in all,,,adrenal gland: 1085.6,Cell line enhanced,,ASC diff: 821.1;SiHa: 629.7
EPHX2,,ENSG00000120915,Epoxide hydrolase 2,8,27490779-27545564,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA023094, HPA023660",Approved,,Enhanced,Cytosol,"Renal cancer:1.98e-10 (favourable), Cervical cancer:2.45e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 171.7,Cell line enhanced,,K-562: 46.0
EPM2A,"LD, LDE",ENSG00000112425,"EPM2A, laforin glucan phosphatase",6,145382535-145736023,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA053643, HPA055468",,,Enhanced,Nucleoplasm,Renal cancer:4.08e-7 (favourable),Expressed in all,Mixed,,,skeletal muscle: 26.8,Mixed,,
EPRS,"EARS, GLUPRORS, PARS, QARS, QPRS",ENSG00000136628,Glutamyl-prolyl-tRNA synthetase,1,219968601-220046658,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA026490, HPA030052",Enhanced,,Enhanced,Cytosol,"Urothelial cancer:2.62e-4 (unfavourable), Breast cancer:7.25e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 120.4,Expressed in all,,
EPX,"EPO, EPP, EPX-PEN",ENSG00000121053,Eosinophil peroxidase,17,58192737-58205174,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA050507,Approved,,,,,Not detected,Tissue enriched,24,bone marrow: 20.5,cerebral cortex: 0.8,Cell line enriched,55,NB-4: 157.0
ERAP1,"A-LAP, ARTS-1, ERAAP1, KIAA0525, PILS-AP",ENSG00000164307,Endoplasmic reticulum aminopeptidase 1,5,96760810-96808100,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025095, HPA042317",Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,placenta: 68.0,Expressed in all,,
ERAP2,"L-RAP, LRAP",ENSG00000164308,Endoplasmic reticulum aminopeptidase 2,5,96875939-96919716,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025618, HPA034498, HPA064360",Enhanced,,Approved,Golgi apparatus,Pancreatic cancer:1.20e-4 (unfavourable),Expressed in all,Mixed,,,lymph node: 49.3,Cell line enhanced,,CAPAN-2: 155.3;hTEC/SVTERT24-B: 83.9;TIME: 152.1
ERBB2,"CD340, HER-2, HER2, NEU, NGL",ENSG00000141736,Erb-b2 receptor tyrosine kinase 2,17,39687914-39730426,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555",Enhanced,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 124.5,Cell line enriched,22,SK-BR-3: 2343.7
ERBB3,"HER3, LCCS2",ENSG00000065361,Erb-b2 receptor tyrosine kinase 3,12,56079857-56103505,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB025331, HPA045396",Uncertain,,Approved,Plasma membrane<br>Actin filaments,,Expressed in all,Mixed,,,small intestine: 86.8,Cell line enhanced,,Hep G2: 79.5;SK-BR-3: 77.6;SK-MEL-30: 109.7;T-47d: 108.2;WM-115: 145.7
ERBB4,"ALS19, HER4",ENSG00000178568,Erb-b2 receptor tyrosine kinase 4,2,211375717-212538841,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB000276, HPA012016, CAB025522",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,fallopian tube: 17.8,cerebral cortex: 7.6,Group enriched,5,AF22: 6.8;EFO-21: 4.8;HEK 293: 3.5;RPTEC TERT1: 4.2;SCLC-21H: 3.7;T-47d: 4.8
ERCC2,"EM9, MAG, MGC102762, MGC126218, MGC126219, TFIIH, XPD",ENSG00000104884,"ERCC excision repair 2, TFIIH core complex helicase subunit",19,45349837-45370918,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005375, HPA038057, HPA069266",Approved,,Supported,Nucleoplasm,Pancreatic cancer:3.26e-4 (favourable),Expressed in all,Expressed in all,,,testis: 16.1,Expressed in all,,
ERCC3,"BTF2, GTF2H, RAD25, TFIIH, XPB",ENSG00000163161,"ERCC excision repair 3, TFIIH core complex helicase subunit",2,127257290-127294176,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB037153, HPA046077",Approved,,Enhanced,Nucleoplasm,"Liver cancer:1.62e-7 (unfavourable), Renal cancer:4.30e-6 (unfavourable)",Expressed in all,Expressed in all,,,testis: 55.1,Expressed in all,,
ERCC6L,"FLJ20105, PICH, RAD26L",ENSG00000186871,"ERCC excision repair 6 like, spindle assembly checkpoint helicase",X,72204657-72239047,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA050492,Approved,,Supported,Nucleoplasm<br>Centrosome<br>Cytosol,Breast cancer:1.80e-4 (unfavourable),Tissue enhanced,Mixed,,,lymph node: 2.8,Mixed,,
ERMP1,"FLJ23309, FXNA, KIAA1815",ENSG00000099219,Endoplasmic reticulum metallopeptidase 1,9,5765076-5833117,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA020584,Uncertain,,Approved,Nucleus<br>Nucleoli,Renal cancer:5.83e-10 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 124.7,thyroid gland: 44.0,Cell line enhanced,,RT4: 122.7
ERN1,"IRE1, IRE1P",ENSG00000178607,Endoplasmic reticulum to nucleus signaling 1,17,64039142-64130819,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB009495, HPA027730",Supported,,,,Renal cancer:1.68e-4 (unfavourable),Expressed in all,Expressed in all,,,adrenal gland: 53.4,Cell line enhanced,,Karpas-707: 74.5;U-266/70: 74.0
ERN2,IRE1b,ENSG00000134398,Endoplasmic reticulum to nucleus signaling 2,16,23690326-23713500,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA016558,Uncertain,,,,,Mixed,Group enriched,7,"cervix, uterine: 27.6;colon: 27.5;duodenum: 12.3;gallbladder: 25.1;rectum: 23.2;small intestine: 9.9;stomach: 49.1",appendix: 3.8,Cell line enriched,8,CAPAN-2: 5.9
ESD,,ENSG00000139684,Esterase D,13,46771256-46797232,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA039700,Approved,,Approved,Golgi apparatus<br>Cytosol,"Head and neck cancer:2.16e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 245.7,Expressed in all,,
ESPL1,"ESP1, KIAA0165, SEPA",ENSG00000135476,"Extra spindle pole bodies like 1, separase",12,53268299-53293643,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB012185,Uncertain,,Supported,Nucleoplasm<br>Vesicles,"Liver cancer:2.01e-5 (unfavourable), Endometrial cancer:5.32e-5 (unfavourable), Stomach cancer:7.10e-4 (favourable), Lung cancer:7.14e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 11.4;testis: 10.6,lymph node: 4.8,Mixed,,
ETFDH,ETFQO,ENSG00000171503,Electron transfer flavoprotein dehydrogenase,4,158672125-158709623,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA041978,Enhanced,,,,Renal cancer:5.76e-10 (favourable),Expressed in all,Expressed in all,,,liver: 99.7,Expressed in all,,
ETHE1,"HSCO, YF13H12",ENSG00000105755,"ETHE1, persulfide dioxygenase",19,43506719-43527244,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA028360, HPA029028, HPA029029",Enhanced,,Enhanced,Mitochondria,Lung cancer:9.58e-4 (unfavourable),Expressed in all,Expressed in all,,,colon: 240.2,Mixed,,
ETNK1,"EKI, EKI1",ENSG00000139163,Ethanolamine kinase 1,12,22625075-22690665,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA010712, HPA029407",Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Urothelial cancer:1.75e-4 (favourable), Liver cancer:5.85e-4 (unfavourable)",Expressed in all,Expressed in all,,,stomach: 45.6,Expressed in all,,
ETNK2,"EKI2, FLJ10761",ENSG00000143845,Ethanolamine kinase 2,1,204131062-204152003,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA057167,Enhanced,,,,"Glioma:3.43e-4 (unfavourable), Renal cancer:6.50e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 110.6;liver: 120.7;testis: 143.1,ovary: 43.4,Mixed,,
ETNPPL,AGXT2L1,ENSG00000164089,Ethanolamine-phosphate phospho-lyase,4,108742040-108763054,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA044546, HPA072938",Approved,,Approved,Nucleus,Glioma:1.31e-4 (favourable),Group enriched,Group enriched,8,cerebral cortex: 141.2;liver: 98.6,stomach: 15.2,Cell line enhanced,,HeLa: 3.8;Hep G2: 1.5;NTERA-2: 1.1
EXD2,"C14orf114, EXDL2, FLJ10738",ENSG00000081177,Exonuclease 3'-5' domain containing 2,14,69191511-69244020,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA002906, HPA005848",Uncertain,,Approved,Intermediate filaments<br>Mitochondria,"Renal cancer:2.08e-9 (favourable), Liver cancer:8.47e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 36.6,Mixed,,
EXT1,"LGCR, LGS, ttv",ENSG00000182197,Exostosin glycosyltransferase 1,8,117794490-118111853,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA044394,Uncertain,,,,"Lung cancer:1.20e-5 (unfavourable), Thyroid cancer:4.64e-4 (unfavourable), Cervical cancer:7.04e-4 (unfavourable)",Expressed in all,Mixed,,,duodenum: 31.6,Cell line enhanced,,BJ hTERT+: 193.5;fHDF/TERT166: 189.8
EXT2,SOTV,ENSG00000151348,Exostosin glycosyltransferase 2,11,44095549-44245429,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA078409,,,Supported,Golgi apparatus,"Renal cancer:5.36e-6 (unfavourable), Head and neck cancer:2.50e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 90.7,Expressed in all,,
EXTL1,"EXTL, MGC70794",ENSG00000158008,Exostosin like glycosyltransferase 1,1,26019884-26036464,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA037749,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 11.2,skeletal muscle: 4.3,Cell line enriched,10,WM-115: 148.7
EXTL2,,ENSG00000162694,Exostosin like glycosyltransferase 2,1,100872372-100895998,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB020716, HPA068921",Approved,,Approved,Nucleus<br>Cytosol,Liver cancer:1.64e-5 (unfavourable),Expressed in all,Expressed in all,,,placenta: 34.1,Expressed in all,,
EXTL3,"botv, REGR",ENSG00000012232,Exostosin like glycosyltransferase 3,8,28600469-28755599,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB025387,Approved,,,,"Liver cancer:1.14e-5 (unfavourable), Renal cancer:2.47e-5 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 36.8,Expressed in all,,
EYA1,BOR,ENSG00000104313,EYA transcriptional coactivator and phosphatase 1,8,71197433-71362232,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA028917,,,Supported,Nucleoplasm<br>Nuclear bodies,,Mixed,Tissue enhanced,,parathyroid gland: 81.7;prostate: 21.2,cerebral cortex: 10.7,Cell line enhanced,,AN3-CA: 28.1;RH-30: 23.1;SH-SY5Y: 57.2
EYA2,EAB1,ENSG00000064655,EYA transcriptional coactivator and phosphatase 2,20,46894624-47188844,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027024, HPA059291",Uncertain,,Supported,Cytosol,Endometrial cancer:4.30e-5 (favourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 76.3",fallopian tube: 50.0,Cell line enhanced,,HBEC3-KT: 28.0;SCLC-21H: 68.4;U-266/70: 82.5;U-266/84: 98.8
EYA3,DKFZp686C132,ENSG00000158161,EYA transcriptional coactivator and phosphatase 3,1,27970344-28088696,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA052432, HPA062889",Uncertain,,Enhanced,Nucleoplasm,"Renal cancer:3.15e-6 (favourable), Head and neck cancer:5.11e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 20.8,Expressed in all,,
EYA4,"CMD1J, DFNA10",ENSG00000112319,EYA transcriptional coactivator and phosphatase 4,6,133240598-133532120,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004805, HPA038771, HPA038772",Enhanced,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,seminal vesicle: 16.0,fallopian tube: 11.5,Cell line enhanced,,A549: 22.1;HeLa: 45.5;RH-30: 22.5;U-87 MG: 23.4
EZH1,"KIAA0388, KMT6B",ENSG00000108799,Enhancer of zeste 1 polycomb repressive complex 2 subunit,17,42700275-42745049,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA005478, HPA077684",Supported,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,ovary: 58.7,Expressed in all,,
EZH2,"ENX-1, EZH1, KMT6, KMT6A",ENSG00000106462,Enhancer of zeste 2 polycomb repressive complex 2 subunit,7,148807383-148884321,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,CAB009589,Enhanced,,Supported,Nucleoplasm,"Renal cancer:8.18e-12 (unfavourable), Liver cancer:2.11e-6 (unfavourable), Melanoma:1.96e-4 (unfavourable), Stomach cancer:6.97e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 50.5,bone marrow: 30.0,Expressed in all,,
F10,,ENSG00000126218,Coagulation factor X,13,113122814-113149529,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Pancreatic cancer:1.82e-5 (favourable), Renal cancer:5.14e-5 (unfavourable)",Tissue enriched,Tissue enhanced,,liver: 67.5,"cervix, uterine: 51.6",Cell line enhanced,,BJ: 12.5;Hep G2: 40.8;SH-SY5Y: 30.0
F11,FXI,ENSG00000088926,Coagulation factor XI,4,186265945-186288806,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA039808,,,Approved,Vesicles,Liver cancer:3.29e-5 (favourable),Tissue enriched,Tissue enhanced,,liver: 180.1,kidney: 44.7,Cell line enriched,8,Hep G2: 6.0
F12,,ENSG00000131187,Coagulation factor XII,5,177402140-177409576,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA003825,Approved,,,,"Liver cancer:4.63e-5 (favourable), Renal cancer:7.09e-4 (unfavourable)",Tissue enriched,Tissue enriched,78,liver: 141.6,bone marrow: 1.8,Cell line enhanced,,HDLM-2: 6.4;MCF7: 6.7;PC-3: 5.8;SH-SY5Y: 4.5
F13A1,F13A,ENSG00000124491,Coagulation factor XIII A chain,6,6144085-6321013,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001804, CAB002155",Enhanced,,,,Renal cancer:6.61e-6 (unfavourable),Expressed in all,Expressed in all,,,placenta: 670.5,Cell line enhanced,,AF22: 22.5;LHCN-M2: 7.1;RH-30: 41.4
F2,,ENSG00000180210,"Coagulation factor II, thrombin",11,46719180-46739506,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016780, CAB018650, HPA051476, HPA054698",Enhanced,,,,Renal cancer:6.75e-12 (unfavourable),Tissue enriched,Tissue enriched,1472,liver: 627.3,testis: 0.4,Cell line enriched,18,Hep G2: 186.7
F7,,ENSG00000057593,Coagulation factor VII,13,113105788-113120681,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA004826,,,Approved,Mitochondria,,Tissue enriched,Tissue enriched,44,liver: 65.0,testis: 1.4,Group enriched,7,CACO-2: 11.8;Hep G2: 6.1
F9,FIX,ENSG00000101981,Coagulation factor IX,X,139530758-139563458,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Liver cancer:6.69e-4 (favourable),Tissue enriched,Tissue enriched,2258,liver: 365.0,kidney: 0.1,Not detected,,
FAAH,FAAH-1,ENSG00000117480,Fatty acid amide hydrolase,1,46394265-46413848,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA007425,Approved,,Uncertain,Cytosol,"Stomach cancer:3.63e-5 (favourable), Renal cancer:4.25e-5 (favourable), Endometrial cancer:1.51e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 60.0,Cell line enhanced,,BEWO: 34.8;RT4: 31.9
FAAH2,"AMDD, FAAH-2, FLJ31204, RP11-479E16.1",ENSG00000165591,Fatty acid amide hydrolase 2,X,57286706-57489196,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:2.47e-13 (favourable), Urothelial cancer:6.83e-5 (favourable), Thyroid cancer:2.66e-4 (favourable), Ovarian cancer:5.99e-4 (favourable)",Mixed,Mixed,,,parathyroid gland: 20.2,Cell line enhanced,,CAPAN-2: 12.2;HDLM-2: 12.0;RPMI-8226: 18.0;U-266/70: 15.9
FADS2,"D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13",ENSG00000134824,Fatty acid desaturase 2,11,61792980-61867354,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006741,Approved,,,,"Renal cancer:1.00e-7 (unfavourable), Urothelial cancer:3.42e-4 (unfavourable)",Expressed in all,Expressed in all,,,adrenal gland: 414.3,Expressed in all,,
FAH,,ENSG00000103876,Fumarylacetoacetate hydrolase,15,80152490-80186946,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA041370, HPA044093",Enhanced,,Approved,Cytosol,Head and neck cancer:8.51e-4 (unfavourable),Expressed in all,Expressed in all,,,liver: 151.9,Cell line enhanced,,HHSteC: 261.9
FAHD1,"C16orf36, DKFZP566J2046",ENSG00000180185,Fumarylacetoacetate hydrolase domain containing 1,16,1826941-1840207,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB025530, HPA043226, HPA043534",Enhanced,,Enhanced,Nucleus<br>Mitochondria,"Renal cancer:2.80e-14 (favourable), Colorectal cancer:8.27e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 66.1,Expressed in all,,
FAM105A,"FLJ11127, NET20",ENSG00000145569,Family with sequence similarity 105 member A,5,14581775-14615007,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA046638,Uncertain,,Approved,Nucleoli<br>Cytosol,"Pancreatic cancer:1.02e-4 (favourable), Testis cancer:7.62e-4 (unfavourable)",Expressed in all,Mixed,,,bone marrow: 35.5,Cell line enhanced,,HMC-1: 87.0;U-937: 38.0
FAM20C,"DKFZp547D065, DMP4, G-CK, IMAGE:4942737",ENSG00000177706,"FAM20C, golgi associated secretory pathway kinase",7,192969-260745,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA019823,,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,"Ovarian cancer:9.40e-6 (unfavourable), Cervical cancer:8.89e-4 (unfavourable)",Expressed in all,Expressed in all,,,kidney: 38.3,Cell line enhanced,,HSkMC: 118.8;U-87 MG: 99.8
FAM213B,"C1orf93, MGC26818",ENSG00000157870,Family with sequence similarity 213 member B,1,2586491-2591469,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006403,Approved,Approved,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:1.28e-4 (favourable), Liver cancer:1.62e-4 (unfavourable)",Expressed in all,Mixed,,,small intestine: 14.6,Mixed,,
FAN1,"KIAA1018, MTMR15",ENSG00000198690,FANCD2 and FANCI associated nuclease 1,15,30903852-30943108,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA048198,,,Supported,Nucleoplasm<br>Cytokinetic bridge<br>Cytosol,Renal cancer:1.42e-6 (favourable),Expressed in all,Expressed in all,,,epididymis: 11.4,Expressed in all,,
FANCL,"FAAP43, FLJ10335, PHF9, Pog",ENSG00000115392,Fanconi anemia complementation group L,2,58159243-58241372,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB033842, HPA036685, HPA036686",Supported,,Approved,Nuclear bodies<br>Vesicles,"Renal cancer:1.12e-7 (unfavourable), Liver cancer:2.81e-7 (unfavourable), Urothelial cancer:7.80e-5 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 44.6,Expressed in all,,
FANCM,"FAAP250, KIAA1596",ENSG00000187790,Fanconi anemia complementation group M,14,45135940-45200890,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA055144,,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 14.0,endometrium: 4.3,Mixed,,
FAP,DPPIV,ENSG00000078098,Fibroblast activation protein alpha,2,162170684-162245151,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA059739,Approved,,,,Head and neck cancer:4.82e-4 (unfavourable),Mixed,Tissue enhanced,,endometrium: 50.7,smooth muscle: 38.5,Cell line enhanced,,ASC diff: 128.1;ASC TERT1: 137.8;BJ hTERT+: 131.5;U-138 MG: 159.0
FAR1,"FLJ22728, MLSTD2, SDR10E1",ENSG00000197601,Fatty acyl-CoA reductase 1,11,13668670-13732346,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017322,Approved,,Enhanced,Peroxisomes,Colorectal cancer:2.27e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 58.9,Mixed,,
FAR2,"FLJ10462, MLSTD1, SDR10E2",ENSG00000064763,Fatty acyl-CoA reductase 2,12,29149103-29340980,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA015884,Approved,,Approved,Nucleoli<br>Golgi apparatus,Renal cancer:4.93e-4 (unfavourable),Expressed in all,Mixed,,,epididymis: 43.9,Cell line enhanced,,HUVEC TERT2: 69.5
FARS2,"dJ236A3.1, FARS1",ENSG00000145982,"Phenylalanyl-tRNA synthetase 2, mitochondrial",6,5261044-5771580,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA018148, HPA028836",Approved,,Approved,Plasma membrane,"Renal cancer:1.24e-6 (favourable), Colorectal cancer:5.14e-4 (favourable)",Expressed in all,Expressed in all,,,fallopian tube: 24.5,Expressed in all,,
FARSA,"CML33, FARSL, FARSLA",ENSG00000179115,Phenylalanyl-tRNA synthetase alpha subunit,19,12922479-12934037,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001911,Approved,,Supported,Cytosol,"Cervical cancer:8.23e-4 (favourable), Stomach cancer:8.32e-4 (favourable), Endometrial cancer:9.22e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 67.2,Expressed in all,,
FARSB,"FARSLB, FRSB, PheHB",ENSG00000116120,Phenylalanyl-tRNA synthetase beta subunit,2,222570536-222656337,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036677, HPA036678, HPA061398",Enhanced,,Supported,Nucleus<br>Cytosol,"Liver cancer:6.45e-10 (unfavourable), Renal cancer:3.21e-5 (unfavourable), Urothelial cancer:1.25e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 34.4,Expressed in all,,
FASN,"FAS, SDR27X1",ENSG00000169710,Fatty acid synthase,17,82078333-82098332,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005192, HPA006461, CAB015417, HPA056108",Enhanced,,Enhanced,Plasma membrane<br>Cytosol,"Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable)",Expressed in all,Expressed in all,,,adipose tissue: 290.7,Expressed in all,,
FASTK,FAST,ENSG00000164896,Fas activated serine/threonine kinase,7,151076593-151080866,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA031621, CAB032539",Approved,,Approved,Nuclear speckles<br>Mitochondria,"Pancreatic cancer:3.99e-4 (favourable), Colorectal cancer:4.73e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 41.7,Expressed in all,,
FBP1,FBP,ENSG00000165140,Fructose-bisphosphatase 1,9,94603133-94640249,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA005857, HPA012513, CAB033869",Enhanced,,Uncertain,Mitochondria,"Renal cancer:6.86e-7 (favourable), Urothelial cancer:1.64e-5 (favourable), Liver cancer:1.79e-4 (favourable), Endometrial cancer:5.16e-4 (favourable)",Expressed in all,Tissue enhanced,,liver: 443.9,duodenum: 329.6,Cell line enhanced,,HaCaT: 66.7;MCF7: 184.8;RT4: 124.5;U-698: 78.4
FBP2,,ENSG00000130957,Fructose-bisphosphatase 2,9,94558720-94593793,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA012513, HPA055286",Uncertain,,Approved,Nucleoplasm<br>Plasma membrane,,Mixed,Tissue enriched,8,skeletal muscle: 266.1,stomach: 32.7,Cell line enhanced,,BEWO: 3.9;MCF7: 2.4;SiHa: 3.0
FBXO18,"FBH1, Fbx18, FLJ14590",ENSG00000134452,"F-box protein, helicase, 18",10,5890203-5937594,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA002844,Supported,,,,Liver cancer:7.73e-7 (unfavourable),Expressed in all,Expressed in all,,,fallopian tube: 46.8,Expressed in all,,
FDFT1,,ENSG00000079459,Farnesyl-diphosphate farnesyltransferase 1,8,11795573-11839309,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008874,Approved,,Supported,Endoplasmic reticulum,"Renal cancer:6.59e-9 (favourable), Colorectal cancer:4.92e-5 (favourable)",Expressed in all,Expressed in all,,,testis: 215.0,Expressed in all,,
FDPS,,ENSG00000160752,Farnesyl diphosphate synthase,1,155308748-155320666,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA028200,Approved,,Approved,Nucleoplasm<br>Cytosol,Liver cancer:7.35e-4 (unfavourable),Expressed in all,Expressed in all,,,liver: 186.4,Expressed in all,,
FDXR,ADXR,ENSG00000161513,Ferredoxin reductase,17,74862497-74873031,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB008597, CAB009818, HPA044393, HPA053673",Enhanced,,Enhanced,Mitochondria,Endometrial cancer:2.38e-4 (favourable),Expressed in all,Tissue enriched,6,adrenal gland: 232.0,testis: 39.1,Expressed in all,,
FECH,,ENSG00000066926,Ferrochelatase,18,57548283-57586772,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA044100, HPA048177",Approved,,,,Renal cancer:2.38e-10 (favourable),Expressed in all,Expressed in all,,,bone marrow: 93.3,Expressed in all,,
FER,"PPP1R74, TYK3",ENSG00000151422,FER tyrosine kinase,5,108747822-109196841,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA007641, CAB022464",Approved,,Supported,Cytosol,Renal cancer:5.55e-4 (favourable),Expressed in all,Mixed,,,parathyroid gland: 19.4,Cell line enhanced,,RPMI-8226: 62.9
FES,FPS,ENSG00000182511,"FES proto-oncogene, tyrosine kinase",15,90883695-90895776,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA001376,Approved,,Approved,Nucleus<br>Vesicles<br>Cytosol,Colorectal cancer:5.78e-4 (unfavourable),Expressed in all,Expressed in all,,,spleen: 96.5,Cell line enhanced,,HEL: 56.3;HL-60: 45.0;HMC-1: 100.9;NB-4: 46.6;THP-1: 73.8
FGFR1,"BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM",ENSG00000077782,Fibroblast growth factor receptor 1,8,38411138-38468834,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB033614, HPA056402, HPA076274",Approved,,Supported,Nucleoli,,Expressed in all,Expressed in all,,,"cervix, uterine: 109.5",Cell line enhanced,,AN3-CA: 602.2
FGFR2,"BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25",ENSG00000066468,Fibroblast growth factor receptor 2,10,121478334-121598458,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB010886, HPA035305, HPA056562",Uncertain,,Approved,Vesicles,"Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)",Expressed in all,Mixed,,,skin: 129.4,Cell line enhanced,,AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4
FGFR3,"ACH, CD333, CEK2, JTK4",ENSG00000068078,Fibroblast growth factor receptor 3,4,1793307-1808872,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB004231, HPA067204",Enhanced,,Supported,Endoplasmic reticulum,Endometrial cancer:3.77e-4 (unfavourable),Expressed in all,Tissue enriched,7,skin: 333.1,cerebral cortex: 49.4,Cell line enhanced,,CACO-2: 41.4;Hep G2: 56.1;NTERA-2: 37.4;RT4: 81.0
FGFR4,"CD334, JTK2",ENSG00000160867,Fibroblast growth factor receptor 4,5,177086886-177098144,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB005196, HPA027273, HPA027369, HPA028251",Approved,,,,,Mixed,Tissue enhanced,,lung: 38.9,duodenum: 21.4,Cell line enhanced,,CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0
FGR,"c-fgr, p55c-fgr, SRC2",ENSG00000000938,"FGR proto-oncogene, Src family tyrosine kinase",1,27612064-27635277,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002024,Enhanced,,Approved,Plasma membrane<br>Aggresome,,Expressed in all,Tissue enhanced,,appendix: 85.6;bone marrow: 137.0;spleen: 90.6,lung: 56.3,Cell line enhanced,,Daudi: 61.4;HMC-1: 25.8;U-266/70: 116.7
FH,fumarase,ENSG00000091483,Fumarate hydratase,1,241497603-241519761,"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB017785, HPA025770, HPA025948, HPA027341",Enhanced,Approved,Enhanced,Mitochondria,Renal cancer:2.76e-7 (favourable),Expressed in all,Expressed in all,,,liver: 142.2,Expressed in all,,
FHIT,"AP3Aase, FRA3B",ENSG00000189283,Fragile histidine triad,3,59749310-61251459,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB002684, HPA018840, HPA018909",Enhanced,,Approved,Nucleoli fibrillar center<br>Plasma membrane,Renal cancer:1.36e-4 (favourable),Mixed,Expressed in all,,,kidney: 26.8,Cell line enhanced,,U-266/70: 27.6
FICD,"HIP13, HYPE",ENSG00000198855,FIC domain containing,12,108515185-108525837,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA021390, HPA071134",Approved,,Approved,Nucleus,Endometrial cancer:4.61e-5 (favourable),Expressed in all,Mixed,,,thyroid gland: 17.7,Mixed,,
FKBP10,"FKBP6, FLJ20683, FLJ22041, FLJ23833, hFKBP65",ENSG00000141756,FK506 binding protein 10,17,41812680-41823217,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA051171, HPA057021",Enhanced,,Approved,Vesicles,"Renal cancer:0.00e+0 (unfavourable), Thyroid cancer:3.43e-5 (unfavourable), Cervical cancer:4.16e-4 (unfavourable), Urothelial cancer:4.99e-4 (unfavourable)",Expressed in all,Mixed,,,placenta: 84.7,Mixed,,
FKBP11,FKBP19,ENSG00000134285,FK506 binding protein 11,12,48921518-48926474,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA041709,Enhanced,,Approved,Centrosome,"Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:7.09e-4 (favourable)",Expressed in all,Mixed,,,pancreas: 60.7,Mixed,,
FKBP14,"FKBP22, FLJ20731",ENSG00000106080,FK506 binding protein 14,7,30010587-30026684,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA013329, HPA026829",Uncertain,,Approved,Nucleus<br>Golgi apparatus<br>Cytosol,"Breast cancer:1.60e-4 (unfavourable), Urothelial cancer:4.25e-4 (unfavourable), Stomach cancer:4.57e-4 (unfavourable), Liver cancer:6.87e-4 (unfavourable)",Expressed in all,Mixed,,,smooth muscle: 20.3,Mixed,,
FKBP1A,"FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE",ENSG00000088832,FK506 binding protein 1A,20,1368978-1393172,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB004639, HPA051798",Uncertain,,,,"Liver cancer:3.44e-7 (unfavourable), Renal cancer:6.69e-5 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 369.7,Expressed in all,,
FKBP1B,"FKBP12.6, FKBP1L, FKBP9, OTK4, PPIase",ENSG00000119782,FK506 binding protein 1B,2,24049701-24063681,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA045572, HPA051798",Uncertain,,Approved,Vesicles,,Expressed in all,Tissue enhanced,,cerebral cortex: 24.4,duodenum: 18.6,Cell line enhanced,,Hep G2: 30.2;NTERA-2: 41.7;SH-SY5Y: 31.9;TIME: 30.3
FKBP2,"FKBP-13, PPIase",ENSG00000173486,FK506 binding protein 2,11,64241003-64244132,"Enzymes, Predicted secreted proteins",Evidence at protein level,"CAB025561, HPA049405",Enhanced,,Approved,Plasma membrane,,Expressed in all,Expressed in all,,,epididymis: 399.2,Expressed in all,,
FKBP3,"FKBP-25, PPIase",ENSG00000100442,FK506 binding protein 3,14,45115600-45135319,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000864, CAB012232, CAB012520",Supported,,Supported,Cytosol,,Expressed in all,Expressed in all,,,skeletal muscle: 143.3,Expressed in all,,
FKBP4,"FKBP52, FKBP59",ENSG00000004478,FK506 binding protein 4,12,2794953-2805423,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006148, CAB017441, HPA062857",Enhanced,,Enhanced,Nucleoplasm<br>Cytosol,"Liver cancer:6.12e-5 (unfavourable), Lung cancer:1.44e-4 (unfavourable), Endometrial cancer:7.65e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 107.4,Expressed in all,,
FKBP5,"FKBP51, FKBP54, P54, PPIase, Ptg-10",ENSG00000096060,FK506 binding protein 5,6,35573585-35728583,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009315, HPA031092, HPA031093, HPA031095",Enhanced,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,adipose tissue: 415.3,Cell line enhanced,,ASC diff: 517.9;HHSteC: 495.2;HSkMC: 518.9
FKBP7,FKBP23,ENSG00000079150,FK506 binding protein 7,2,178463664-178478600,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA008707,Approved,Supported,Supported,Endoplasmic reticulum,Renal cancer:4.61e-6 (unfavourable),Expressed in all,Tissue enhanced,,ovary: 60.2,endometrium: 44.1,Cell line enhanced,,ASC diff: 104.3;ASC TERT1: 65.6
FKBP8,"FKBP38, FKBPr38",ENSG00000105701,FK506 binding protein 8,19,18531751-18544077,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB025346, HPA045177",Supported,,Supported,Endoplasmic reticulum<br>Mitochondria<br>Cytosol,"Colorectal cancer:1.24e-4 (unfavourable), Pancreatic cancer:7.76e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 354.7,Expressed in all,,
FKBP9,"FKBP60, FKBP63",ENSG00000122642,FK506 binding protein 9,7,32957404-33006931,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA012595, HPA055256",Approved,,Supported,Golgi apparatus<br>Vesicles<br>Mitochondria,"Urothelial cancer:7.02e-6 (unfavourable), Head and neck cancer:2.02e-4 (unfavourable), Cervical cancer:4.22e-4 (unfavourable), Glioma:8.06e-4 (unfavourable), Liver cancer:8.69e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 110.4,Mixed,,
FLAD1,"FAD1, PP591",ENSG00000160688,Flavin adenine dinucleotide synthetase 1,1,154983338-154993111,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA028476, HPA028486, HPA028563",Approved,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:2.55e-6 (unfavourable), Liver cancer:3.04e-4 (unfavourable)",Expressed in all,Expressed in all,,,skin: 28.5,Expressed in all,,
FLT1,"FLT, VEGFR1",ENSG00000102755,Fms related tyrosine kinase 1,13,28300344-28495145,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA011740, HPA014290, CAB068189, CAB068190",Enhanced,,Supported,Plasma membrane<br>Actin filaments,Renal cancer:2.19e-4 (unfavourable),Expressed in all,Tissue enriched,8,placenta: 622.5,thyroid gland: 81.9,Cell line enhanced,,BJ: 61.1;HMC-1: 308.1;WM-115: 126.2
FLT3,"CD135, FLK2, STK1",ENSG00000122025,Fms related tyrosine kinase 3,13,28003274-28100592,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA047539,,,Approved,Endoplasmic reticulum,,Tissue enhanced,Tissue enhanced,,lymph node: 7.0;spleen: 7.7,appendix: 3.9,Group enriched,14,REH: 38.7;THP-1: 17.4
FLT4,"PCL, VEGFR3",ENSG00000037280,Fms related tyrosine kinase 4,5,180601506-180649624,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB000099, HPA046519, HPA067906",Approved,,Enhanced,Nuclear speckles<br>Plasma membrane<br>Cell Junctions,,Expressed in all,Mixed,,,spleen: 18.3,Cell line enhanced,,BEWO: 11.8;HEK 293: 14.1;T-47d: 13.7;TIME: 12.7
FMO1,,ENSG00000010932,Flavin containing monooxygenase 1,1,171248471-171285978,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA023680,Uncertain,,,,Renal cancer:2.81e-4 (favourable),Tissue enriched,Tissue enriched,9,kidney: 203.2,small intestine: 22.8,Cell line enriched,8,HSkMC: 14.8
FMO2,,ENSG00000094963,Flavin containing monooxygenase 2,1,171185208-171211230,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA028261,Approved,,,,,Mixed,Tissue enhanced,,adipose tissue: 98.3;esophagus: 102.9;lung: 158.2,breast: 55.8,Group enriched,48,ASC diff: 27.9;ASC TERT1: 12.9;HSkMC: 35.2
FMO3,,ENSG00000007933,Flavin containing monooxygenase 3,1,171090877-171117819,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA013750,Enhanced,,,,"Lung cancer:5.60e-5 (favourable), Renal cancer:1.13e-4 (unfavourable), Liver cancer:3.46e-4 (favourable)",Tissue enriched,Tissue enriched,24,liver: 556.7,fallopian tube: 22.8,Group enriched,13,ASC diff: 23.4;ASC TERT1: 17.9;HSkMC: 5.1
FMO4,FMO2,ENSG00000076258,Flavin containing monooxygenase 4,1,171314208-171342084,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA049100,Uncertain,,,,"Liver cancer:1.09e-4 (favourable), Renal cancer:6.96e-4 (favourable), Lung cancer:7.45e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 48.2;liver: 30.1,parathyroid gland: 10.9,Cell line enhanced,,EFO-21: 5.2
FMO5,,ENSG00000131781,Flavin containing monooxygenase 5,1,147175351-147243050,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012373,Enhanced,,Supported,Endoplasmic reticulum<br>Cytosol,Renal cancer:1.34e-6 (favourable),Tissue enriched,Tissue enhanced,,liver: 324.7,small intestine: 75.4,Cell line enhanced,,Hep G2: 26.6;HMC-1: 7.7;THP-1: 6.7
FNTA,"FPTA, PGGT1A, PTAR2",ENSG00000168522,"Farnesyltransferase, CAAX box, alpha",8,43034194-43085788,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB010149, HPA018830",Approved,,Approved,Cytosol,Renal cancer:2.94e-12 (unfavourable),Expressed in all,Expressed in all,,,placenta: 63.4,Expressed in all,,
FNTB,FPTB,ENSG00000257365,"Farnesyltransferase, CAAX box, beta",14,64986720-65062652,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA062743,Approved,,Approved,Centrosome,Liver cancer:6.03e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 17.7,Expressed in all,,
FOLH1,"FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA",ENSG00000086205,Folate hydrolase 1,11,49146635-49208670,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB001451, HPA010593",Enhanced,,,,"Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable)",Tissue enriched,Group enriched,6,duodenum: 298.8;prostate: 136.6;small intestine: 90.8,cerebral cortex: 31.0,Mixed,,
FPGS,,ENSG00000136877,Folylpolyglutamate synthase,9,127794597-127814327,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA050488,Approved,,,,Endometrial cancer:9.08e-4 (favourable),Expressed in all,Expressed in all,,,"fallopian tube,ovary: 26.1",Expressed in all,,
FPGT,GFPP,ENSG00000254685,Fucose-1-phosphate guanylyltransferase,1,74198212-74234086,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA072331,,,Uncertain,Vesicles,Liver cancer:2.30e-4 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 32.8,Expressed in all,,
FRK,"GTK, PTK5, RAK",ENSG00000111816,Fyn related Src family tyrosine kinase,6,115931149-116060758,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB025217, HPA030479",Approved,,Supported,Nucleus<br>Cytosol,Renal cancer:9.66e-7 (favourable),Mixed,Mixed,,,kidney: 10.0,Mixed,,
FTCD,,ENSG00000160282,Formimidoyltransferase cyclodeaminase,21,46136262-46155567,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020073, HPA030928, HPA030929, HPA036114",Enhanced,,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable)",Tissue enriched,Group enriched,18,kidney: 100.2;liver: 184.7,testis: 7.7,Cell line enriched,24,Hep G2: 62.7
FTH1,"FHC, FTH, FTHL6, PIG15, PLIF",ENSG00000167996,Ferritin heavy chain 1,11,61959718-61967660,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB008623,Approved,,Approved,Microtubules,"Renal cancer:5.20e-5 (unfavourable), Head and neck cancer:7.56e-5 (unfavourable), Liver cancer:6.18e-4 (unfavourable)",Expressed in all,Expressed in all,,,appendix: 4962.3,Expressed in all,,
FTMT,MtF,ENSG00000181867,Ferritin mitochondrial,5,121851955-121852833,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,471,testis: 47.1,all non-specific tissues: 0.0,Not detected,,
FTSJ1,"CDLIV, JM23, MRX44, MRX9, SPB1, TRM7, TRMT7",ENSG00000068438,FtsJ RNA methyltransferase homolog 1 (E. coli),X,48476021-48486364,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002718,Approved,,Approved,Cytosol,"Renal cancer:5.24e-10 (unfavourable), Liver cancer:1.74e-5 (unfavourable)",Expressed in all,Expressed in all,,,"cervix, uterine: 24.7",Expressed in all,,
FUCA1,,ENSG00000179163,"Fucosidase, alpha-L- 1, tissue",1,23845077-23868294,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA046542, HPA056371",Enhanced,,,,"Renal cancer:5.70e-13 (favourable), Endometrial cancer:2.45e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 185.6,Cell line enhanced,,CAPAN-2: 144.5
FUCA2,"dJ20N2.5, MGC1314",ENSG00000001036,"Fucosidase, alpha-L- 2, plasma",6,143494811-143511690,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA031659, HPA031660, HPA031661",Uncertain,,,,Liver cancer:2.70e-9 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 154.2,Mixed,,
FUK,FLJ39408,ENSG00000157353,Fucokinase,16,70454421-70480274,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041971,Approved,,Approved,Vesicles,"Urothelial cancer:8.38e-4 (favourable), Renal cancer:8.91e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 13.9,Mixed,,
FUOM,"C10orf125, FLJ26016, FucM, FucU",ENSG00000148803,Fucose mutarotase,10,133355154-133358035,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039207,Uncertain,,,,,Expressed in all,Tissue enhanced,,liver: 74.9,duodenum: 50.9,Mixed,,
FURIN,"FUR, PACE, PCSK3, SPC1",ENSG00000140564,"Furin, paired basic amino acid cleaving enzyme",15,90868592-90883458,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB009499,Approved,,Supported,Nucleoplasm<br>Golgi apparatus,Lung cancer:1.58e-4 (unfavourable),Expressed in all,Expressed in all,,,salivary gland: 92.8,Expressed in all,,
FUT1,"H, HSC",ENSG00000174951,Fucosyltransferase 1 (H blood group),19,48748011-48755390,"Blood group antigen proteins, Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:3.99e-4 (favourable),Mixed,Mixed,,,stomach: 7.1,Cell line enhanced,,HEL: 8.6;SCLC-21H: 8.1
FUT2,"SE, Se2, SEC2, sej",ENSG00000176920,Fucosyltransferase 2,19,48695971-48705950,"Blood group antigen proteins, Enzymes, Predicted membrane proteins",Evidence at protein level,HPA014402,Uncertain,,Uncertain,Plasma membrane<br>Cytosol,Head and neck cancer:5.83e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 51.4,stomach: 32.2,Cell line enriched,6,CAPAN-2: 68.6
FUT3,"CD174, LE",ENSG00000171124,Fucosyltransferase 3 (Lewis blood group),19,5842888-5851474,"Blood group antigen proteins, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046966,Supported,,,,"Renal cancer:8.22e-7 (favourable), Breast cancer:6.86e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,colon: 68.0;esophagus: 83.0;small intestine: 63.1,rectum: 49.4,Group enriched,5,A-431: 40.5;RH-30: 14.4
FUT5,FUC-TV,ENSG00000130383,Fucosyltransferase 5,19,5865826-5870540,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA046966,Uncertain,,,,,Not detected,Not detected,,,"bone marrow,testis: 0.3",Not detected,,
FUT6,"FCT3A, FLJ40754, FT1A, FucT-VI",ENSG00000156413,Fucosyltransferase 6,19,5830610-5839731,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043707, HPA046966",Approved,,Supported,Golgi apparatus,"Renal cancer:3.17e-8 (favourable), Head and neck cancer:2.12e-4 (favourable)",Mixed,Tissue enhanced,,esophagus: 49.8;kidney: 34.5,small intestine: 30.6,Group enriched,5,Hep G2: 7.2;RPMI-8226: 2.7
FUT8,,ENSG00000033170,Fucosyltransferase 8,14,65410592-65744121,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB017129, HPA040863, HPA043410",Enhanced,,Enhanced,Golgi apparatus<br>Cytosol,,Expressed in all,Mixed,,,cerebral cortex: 31.5,Expressed in all,,
FXN,"CyaY, FA, FARR, FRDA, X25",ENSG00000165060,Frataxin,9,69035259-69100178,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB022164, HPA068304",Supported,,Supported,Mitochondria<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 34.1,Expressed in all,,
FYN,"MGC45350, SLK, SYN",ENSG00000010810,"FYN proto-oncogene, Src family tyrosine kinase",6,111660332-111873452,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005034, CAB018387, HPA023887, HPA063770",Approved,,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:1.43e-4 (unfavourable), Liver cancer:1.84e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 166.1,Cell line enhanced,,U-2197: 500.5
G2E3,"FLJ20333, KIAA1333, PHF7B",ENSG00000092140,G2/M-phase specific E3 ubiquitin protein ligase,14,30559123-30620063,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001601,Approved,,Supported,Vesicles<br>Cytosol,,Expressed in all,Tissue enriched,6,testis: 80.4,thyroid gland: 12.9,Mixed,,
G3BP1,"G3BP, HDH-VIII",ENSG00000145907,G3BP stress granule assembly factor 1,5,151771045-151812785,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA004052, CAB037068",Supported,,Enhanced,Cytosol,Renal cancer:3.33e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 91.0,Expressed in all,,
G6PC,"G6PT, GSD1a",ENSG00000131482,Glucose-6-phosphatase catalytic subunit,17,42900797-42913369,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA052324,Enhanced,,,,"Renal cancer:3.79e-5 (favourable), Liver cancer:5.42e-5 (favourable)",Tissue enriched,Tissue enhanced,,kidney: 89.1;liver: 147.3,small intestine: 33.2,Not detected,,
G6PC2,IGRP,ENSG00000152254,Glucose-6-phosphatase catalytic subunit 2,2,168901240-168910000,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,12,pancreas: 2.9,testis: 0.2,Not detected,,
G6PC3,UGRP,ENSG00000141349,Glucose-6-phosphatase catalytic subunit 3,17,44070735-44076344,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA067052,,,Supported,Endoplasmic reticulum,"Endometrial cancer:1.11e-4 (favourable), Liver cancer:9.61e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 84.3,Expressed in all,,
G6PD,G6PD1,ENSG00000160211,Glucose-6-phosphate dehydrogenase,X,154531391-154547572,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000247, HPA000834",Enhanced,,Approved,Vesicles<br>Microtubule organizing center<br>Cytosol,Liver cancer:9.45e-13 (unfavourable),Expressed in all,Expressed in all,,,testis: 107.0,Expressed in all,,
GAA,,ENSG00000171298,"Glucosidase alpha, acid",17,80101556-80119879,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA026970, HPA029126",Enhanced,,,,Colorectal cancer:7.66e-4 (unfavourable),Expressed in all,Expressed in all,,,placenta: 69.7,Mixed,,
GAD1,GAD,ENSG00000128683,Glutamate decarboxylase 1,2,170813213-170861151,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004415, HPA031949, HPA058412, CAB078176",Enhanced,Supported,Approved,Vesicles,"Cervical cancer:7.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)",Tissue enhanced,Tissue enriched,6,cerebral cortex: 75.3,parathyroid gland: 11.8,Cell line enhanced,,HEL: 55.7
GAD2,GAD65,ENSG00000136750,Glutamate decarboxylase 2,10,26216307-26304558,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA044637, CAB078177",Enhanced,,,,,Group enriched,Tissue enriched,17,cerebral cortex: 22.9,pancreas: 1.3,Group enriched,13,MOLT-4: 2.4;SCLC-21H: 7.4
GADL1,,ENSG00000144644,Glutamate decarboxylase like 1,3,30726200-30894765,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039160, HPA040229",Uncertain,,Approved,Plasma membrane<br>Cytosol,,Not detected,Tissue enhanced,,skeletal muscle: 9.0,thyroid gland: 2.5,Cell line enhanced,,HAP1: 5.0
GAK,DNAJC26,ENSG00000178950,Cyclin G associated kinase,4,849276-932373,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027405, HPA027459, HPA027463",Approved,,Enhanced,Golgi apparatus<br>Vesicles,"Renal cancer:1.70e-6 (favourable), Urothelial cancer:7.41e-4 (favourable)",Expressed in all,Expressed in all,,,duodenum: 51.5,Expressed in all,,
GAL3ST1,CST,ENSG00000128242,Galactose-3-O-sulfotransferase 1,22,30554635-30574587,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA001220,Approved,,Approved,Vesicles,Renal cancer:1.79e-4 (unfavourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 18.0;duodenum: 23.2;small intestine: 27.0,kidney: 10.1,Cell line enhanced,,A549: 25.1;EFO-21: 13.7
GALC,,ENSG00000054983,Galactosylceramidase,14,87837820-87993665,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB022196,Approved,,,,,Expressed in all,Expressed in all,,,testis: 44.0,Cell line enhanced,,CAPAN-2: 72.3;HMC-1: 67.2
GALE,SDR1E1,ENSG00000117308,UDP-galactose-4-epimerase,1,23795599-23800804,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007340,Approved,,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Thyroid cancer:2.68e-4 (favourable),Expressed in all,Expressed in all,,,stomach: 112.8,Expressed in all,,
GALK1,GALK,ENSG00000108479,Galactokinase 1,17,75751594-75765711,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA007094, HPA016960",Approved,,Approved,Golgi apparatus<br>Cytosol,"Renal cancer:1.55e-6 (unfavourable), Urothelial cancer:1.62e-5 (unfavourable)",Expressed in all,Expressed in all,,,liver: 23.4,Expressed in all,,
GALK2,GK2,ENSG00000156958,Galactokinase 2,15,49155656-49367869,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA043564, HPA048267",Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:1.88e-5 (favourable), Endometrial cancer:7.31e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 31.8,Expressed in all,,
GALM,,ENSG00000143891,Galactose mutarotase,2,38665910-38741237,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035472, HPA035473, HPA064835",Enhanced,,Approved,Nucleoplasm,"Renal cancer:9.06e-5 (favourable), Urothelial cancer:1.32e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 118.1,Mixed,,
GALNS,"GALNAC6S, GAS",ENSG00000141012,Galactosamine (N-acetyl)-6-sulfatase,16,88813734-88856970,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB026404, HPA042433",Enhanced,,Approved,Cytosol,Liver cancer:3.66e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 29.7,Expressed in all,,
GALNT1,GalNAc-T1,ENSG00000141429,Polypeptide N-acetylgalactosaminyltransferase 1,18,35581117-35711834,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012628,Uncertain,,,,,Expressed in all,Expressed in all,,,urinary bladder: 85.6,Expressed in all,,
GALNT10,GalNAc-T10,ENSG00000164574,Polypeptide N-acetylgalactosaminyltransferase 10,5,154190730-154420984,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA007525,Approved,,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane,"Endometrial cancer:3.33e-6 (favourable), Ovarian cancer:5.69e-4 (unfavourable)",Expressed in all,Expressed in all,,,ovary: 81.7,Mixed,,
GALNT11,GalNAc-T11,ENSG00000178234,Polypeptide N-acetylgalactosaminyltransferase 11,7,152025674-152122347,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA039330,Uncertain,,,,"Renal cancer:2.24e-6 (favourable), Glioma:8.42e-4 (unfavourable)",Expressed in all,Expressed in all,,,kidney: 242.9,Mixed,,
GALNT12,GalNAc-T12,ENSG00000119514,Polypeptide N-acetylgalactosaminyltransferase 12,9,98807699-98850081,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA048292,Enhanced,,,,Renal cancer:3.24e-4 (favourable),Mixed,Tissue enhanced,,epididymis: 92.1,rectum: 61.4,Cell line enhanced,,U-2197: 151.4
GALNT13,"GalNAc-T13, KIAA1918",ENSG00000144278,Polypeptide N-acetylgalactosaminyltransferase 13,2,153871913-154453849,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA060775,Approved,,,,,Tissue enriched,Group enriched,6,adrenal gland: 6.6;cerebral cortex: 32.7,prostate: 3.5,Cell line enhanced,,SH-SY5Y: 46.7;WM-115: 33.1
GALNT14,"FLJ12691, GalNac-T10, GalNac-T14",ENSG00000158089,Polypeptide N-acetylgalactosaminyltransferase 14,2,30910467-31155202,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030138,,,Approved,Nucleus<br>Golgi apparatus,,Tissue enriched,Tissue enhanced,,kidney: 40.3,parathyroid gland: 12.8,Cell line enhanced,,RPTEC TERT1: 29.5;RT4: 23.6;SCLC-21H: 25.2
GALNT15,"GALNT7, GALNTL2, pp-GalNAc-T15",ENSG00000131386,Polypeptide N-acetylgalactosaminyltransferase 15,3,16174649-16231992,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA017076,Uncertain,,Approved,Golgi apparatus<br>Cytosol,,Tissue enriched,Tissue enhanced,,adipose tissue: 36.3;cerebral cortex: 41.2;placenta: 43.0,breast: 18.3,Group enriched,11,ASC diff: 91.0;ASC TERT1: 90.9;HSkMC: 72.4;U-2197: 22.3
GALNT16,"GalNAc-T16, GALNTL1, KIAA1130",ENSG00000100626,Polypeptide N-acetylgalactosaminyltransferase 16,14,69259277-69357033,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA059136,Approved,,Approved,Nucleus,Renal cancer:5.23e-6 (favourable),Mixed,Mixed,,,cerebral cortex: 28.5,Cell line enhanced,,AF22: 9.0;hTEC/SVTERT24-B: 17.0;SCLC-21H: 10.5;U-2 OS: 21.2
GALNT18,"GalNAc-T18, GALNT15, GALNTL4, MGC71806",ENSG00000110328,Polypeptide N-acetylgalactosaminyltransferase 18,11,11270876-11622005,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA012955,Approved,,Approved,Mitochondria,Endometrial cancer:1.29e-4 (unfavourable),Expressed in all,Tissue enhanced,,thyroid gland: 59.3,lung: 43.2,Cell line enhanced,,A-431: 36.5;HaCaT: 46.1;PC-3: 33.7;SK-BR-3: 35.3;U-87 MG: 32.9
GALNT2,GalNAc-T2,ENSG00000143641,Polypeptide N-acetylgalactosaminyltransferase 2,1,230057990-230282124,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA011222,Supported,,Enhanced,Golgi apparatus,"Renal cancer:2.79e-13 (unfavourable), Lung cancer:8.48e-8 (unfavourable), Cervical cancer:1.22e-6 (unfavourable)",Expressed in all,Expressed in all,,,ovary: 48.5,Expressed in all,,
GALNT3,"GalNAc-T3, HFTC, HHS",ENSG00000115339,Polypeptide N-acetylgalactosaminyltransferase 3,2,165747591-165794682,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA007613,Enhanced,,Supported,Golgi apparatus,"Cervical cancer:2.08e-4 (unfavourable), Head and neck cancer:4.10e-4 (unfavourable)",Expressed in all,Mixed,,,stomach: 86.1,Cell line enhanced,,CAPAN-2: 92.9;HaCaT: 108.1;hTCEpi: 82.6
GALNT4,GalNAc-T4,ENSG00000257594,Polypeptide N-acetylgalactosaminyltransferase 4,12,89519408-89524806,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA076116,,,Supported,Golgi apparatus<br>Vesicles,,Mixed,Mixed,,,stomach: 31.0,Cell line enhanced,,PC-3: 20.4
GALNT5,GalNAc-T5,ENSG00000136542,Polypeptide N-acetylgalactosaminyltransferase 5,2,157257598-157314211,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA008963, HPA009035",Approved,,Approved,Nucleoli<br>Golgi apparatus<br>Vesicles<br>Cytosol,,Mixed,Tissue enhanced,,lung: 18.4;rectum: 19.7;stomach: 16.8,colon: 13.9,Cell line enhanced,,A-431: 60.2;BJ hTERT+: 63.9;fHDF/TERT166: 72.0;HaCaT: 69.5;LHCN-M2: 65.2
GALNT6,GalNAc-T6,ENSG00000139629,Polypeptide N-acetylgalactosaminyltransferase 6,12,51351247-51392867,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA011762, HPA017086",Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus,"Ovarian cancer:5.40e-4 (favourable), Endometrial cancer:9.85e-4 (favourable)",Mixed,Tissue enhanced,,stomach: 61.5,"cervix, uterine: 49.5",Mixed,,
GALNT8,GALNAC-T8,ENSG00000130035,Polypeptide N-acetylgalactosaminyltransferase 8,12,4720341-4851927,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA012638, HPA014418, HPA073461",Approved,,Approved,Vesicles,,Tissue enhanced,Group enriched,7,cerebral cortex: 19.4;colon: 17.6;duodenum: 8.1;rectum: 40.6;small intestine: 18.9;testis: 26.5,appendix: 3.2,Cell line enhanced,,Karpas-707: 24.5;NTERA-2: 12.1;U-2 OS: 4.6;U-266/84: 7.3
GALNT9,GALNAC-T9,ENSG00000182870,Polypeptide N-acetylgalactosaminyltransferase 9,12,132196372-132329349,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA075016,,,Approved,Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 29.4,thyroid gland: 6.3,Cell line enriched,6,U-87 MG: 30.6
GALNTL6,"GalNAc-T6L, GALNT17",ENSG00000174473,Polypeptide N-acetylgalactosaminyltransferase-like 6,4,171812254-173041559,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA031019,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 5.4;testis: 4.5,spleen: 1.9,Not detected,,
GALT,,ENSG00000213930,Galactose-1-phosphate uridylyltransferase,9,34638133-34651035,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004868, HPA005729",Enhanced,,Approved,Cytosol,"Renal cancer:6.25e-6 (favourable), Pancreatic cancer:3.11e-5 (favourable)",Expressed in all,Expressed in all,,,liver: 25.7,Mixed,,
GAMT,"PIG2, TP53I2",ENSG00000130005,Guanidinoacetate N-methyltransferase,19,1397026-1401570,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051806,Approved,,,,Stomach cancer:6.57e-4 (unfavourable),Tissue enriched,Group enriched,5,epididymis: 173.0;liver: 158.9;skeletal muscle: 425.6,pancreas: 48.1,Mixed,,
GANAB,"G2AN, GIIA, GluII, KIAA0088",ENSG00000089597,Glucosidase II alpha subunit,11,62624826-62646726,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA026874, HPA061426",Enhanced,,Approved,Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol,"Liver cancer:1.27e-5 (unfavourable), Urothelial cancer:9.54e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 295.2,Expressed in all,,
GANC,,ENSG00000214013,"Glucosidase alpha, neutral C",15,42273233-42356935,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA016949,Approved,,Approved,Nucleoplasm<br>Actin filaments,Lung cancer:9.76e-4 (favourable),Expressed in all,Expressed in all,,,lung: 29.8,Expressed in all,,
GAPDH,GAPD,ENSG00000111640,Glyceraldehyde-3-phosphate dehydrogenase,12,6533927-6538374,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005197, CAB016392, HPA040067, HPA061280",Supported,,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:6.25e-10 (unfavourable), Liver cancer:1.79e-6 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 9869.6,Expressed in all,,
GAPDHS,"GAPD2, GAPDH-2, GAPDS",ENSG00000105679,"Glyceraldehyde-3-phosphate dehydrogenase, spermatogenic",19,35533412-35545316,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA042666,Enhanced,,Approved,Nucleoplasm<br>Centrosome,,Tissue enriched,Tissue enriched,13,testis: 242.8,thyroid gland: 19.0,Mixed,,
GARS,"CMT2D, DSMAV, GlyRS, SMAD1",ENSG00000106105,Glycyl-tRNA synthetase,7,30594681-30634033,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA017896, HPA019097",Enhanced,,Supported,Cytosol,"Renal cancer:1.70e-5 (unfavourable), Urothelial cancer:3.04e-5 (unfavourable), Liver cancer:8.95e-5 (unfavourable), Breast cancer:1.02e-4 (unfavourable), Endometrial cancer:8.48e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 96.0,Expressed in all,,
GART,"PGFT, PRGS",ENSG00000159131,"Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase",21,33503931-33543491,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA002119, HPA005779",Approved,,Uncertain,Nucleoplasm<br>Mitochondria<br>Cytosol,"Renal cancer:3.95e-6 (unfavourable), Head and neck cancer:5.05e-5 (unfavourable), Liver cancer:9.82e-5 (unfavourable), Pancreatic cancer:2.19e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 55.1,Expressed in all,,
GATM,AGAT,ENSG00000171766,Glycine amidinotransferase,15,45361124-45402327,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA026077,Enhanced,,Supported,Mitochondria,Renal cancer:1.38e-4 (favourable),Expressed in all,Group enriched,6,kidney: 1904.2;liver: 1291.1;pancreas: 573.9,ovary: 195.7,Cell line enhanced,,RH-30: 190.4;U-266/70: 92.4;U-266/84: 115.1
GBA,"GBA1, GLUC",ENSG00000177628,Glucosylceramidase beta,1,155234452-155244699,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA006667, CAB037171, CAB037289",Supported,,,,,Expressed in all,Expressed in all,,,parathyroid gland: 276.1,Expressed in all,,
GBA2,"AD035, DKFZp762K054, KIAA1605, SPG46",ENSG00000070610,Glucosylceramidase beta 2,9,35736866-35749228,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA024026,Approved,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,"Renal cancer:1.24e-11 (favourable), Pancreatic cancer:6.00e-4 (favourable), Urothelial cancer:6.60e-4 (favourable)",Expressed in all,Expressed in all,,,small intestine: 64.2,Expressed in all,,
GBE1,,ENSG00000114480,"1,4-alpha-glucan branching enzyme 1",3,81489699-81762161,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038073, HPA038074, HPA038075",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,adipose tissue: 79.6,Expressed in all,,
GCAT,KBL,ENSG00000100116,Glycine C-acetyltransferase,22,37807905-37817176,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA020460,Uncertain,,Supported,Nucleoplasm<br>Mitochondria,,Expressed in all,Expressed in all,,,prostate: 30.0,Expressed in all,,
GCDH,ACAD5,ENSG00000105607,Glutaryl-CoA dehydrogenase,19,12891026-12914207,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA043252, HPA048492",Enhanced,,Supported,Mitochondria,"Renal cancer:6.79e-8 (favourable), Liver cancer:7.28e-5 (favourable), Lung cancer:3.35e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 42.9,Expressed in all,,
GCH1,"DYT14, DYT5, DYT5a, GCH, GTPCH1",ENSG00000131979,GTP cyclohydrolase 1,14,54842008-54902852,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA028612,Approved,,Supported,Nucleoplasm<br>Nuclear membrane<br>Cytosol,"Pancreatic cancer:1.41e-4 (favourable), Urothelial cancer:6.67e-4 (favourable), Ovarian cancer:8.69e-4 (favourable)",Expressed in all,Tissue enhanced,,bone marrow: 22.6,liver: 18.8,Cell line enhanced,,SH-SY5Y: 48.2
GCK,"HK4, MODY2",ENSG00000106633,Glucokinase,7,44144271-44198170,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA007034, HPA007093",Approved,,Approved,Golgi apparatus<br>Cytosol,,Tissue enhanced,Mixed,,,cerebral cortex: 2.5,Cell line enriched,6,SCLC-21H: 7.7
GCLC,"GCS, GLCL, GLCLC",ENSG00000001084,Glutamate-cysteine ligase catalytic subunit,6,53497341-53616970,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009569, HPA036359, HPA036360",Approved,,Approved,Nucleus<br>Nucleoli<br>Cytosol,"Renal cancer:3.83e-6 (favourable), Thyroid cancer:8.24e-4 (unfavourable)",Expressed in all,Expressed in all,,,fallopian tube: 80.9,Expressed in all,,
GCNT1,"C2GNT, NACGT2, NAGCT2",ENSG00000187210,"Glucosaminyl (N-acetyl) transferase 1, core 2",9,76419850-76507416,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003522, HPA003523, HPA031151",Uncertain,,Supported,Nuclear speckles,"Urothelial cancer:4.96e-4 (unfavourable), Endometrial cancer:8.44e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 186.4,duodenum: 50.1,Cell line enhanced,,HHSteC: 38.9
GCNT2,"bA360O19.2, bA421M1.1, CCAT, GCNT5, IGNT, II, NACGT1, NAGCT1, ULG3",ENSG00000111846,"Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)",6,10492223-10629368,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA026776,Approved,,Supported,Golgi apparatus,,Mixed,Tissue enhanced,,prostate: 55.7,breast: 13.9,Cell line enhanced,,CACO-2: 39.6;EFO-21: 67.0
GCNT3,"C2/4GnT, C2GnT-M, C2GnT2",ENSG00000140297,"Glucosaminyl (N-acetyl) transferase 3, mucin type",15,59594875-59640239,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA011154,Enhanced,,Approved,Golgi apparatus<br>Vesicles,"Liver cancer:6.49e-5 (unfavourable), Endometrial cancer:1.78e-4 (favourable)",Tissue enhanced,Tissue enhanced,,colon: 142.2;gallbladder: 118.0;rectum: 134.6;small intestine: 138.4,duodenum: 97.7,Cell line enriched,6,A549: 133.3
GCNT4,C2GNT3,ENSG00000176928,"Glucosaminyl (N-acetyl) transferase 4, core 2",5,75025346-75030899,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037431,Approved,,Supported,Nucleoplasm<br>Golgi apparatus,Renal cancer:1.93e-7 (favourable),Mixed,Mixed,,,duodenum: 21.4,Cell line enriched,5,RT4: 25.9
GDA,,ENSG00000119125,Guanine deaminase,9,72114595-72257193,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019352, HPA024099, HPA030387",Enhanced,,Approved,Nucleus,Renal cancer:2.66e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 102.2;duodenum: 95.2;small intestine: 104.1,kidney: 43.6,Cell line enhanced,,A-431: 31.0;EFO-21: 125.3;HeLa: 32.0;hTCEpi: 45.2
GDE1,MIR16,ENSG00000006007,Glycerophosphodiester phosphodiesterase 1,16,19501689-19522145,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA074747,,,Approved,Nucleus<br>Nucleoli<br>Vesicles,"Renal cancer:3.12e-5 (favourable), Liver cancer:7.52e-5 (unfavourable), Colorectal cancer:3.12e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 67.9,Expressed in all,,
GDPD2,"FLJ20207, GDE3, OBDPF",ENSG00000130055,Glycerophosphodiester phosphodiesterase domain containing 2,X,70423031-70433390,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,skin: 50.8;spleen: 60.0,small intestine: 20.0,Group enriched,8,AF22: 8.8;NTERA-2: 19.3
GDPGP1,C15orf58,ENSG00000183208,GDP-D-glucose phosphorylase 1,15,90233808-90245811,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA048189, HPA059841",Approved,,Approved,Cytosol,Breast cancer:6.32e-4 (favourable),Expressed in all,Mixed,,,parathyroid gland: 9.6,Mixed,,
GFER,"ALR, ERV1, HERV1, HPO1, HPO2, HSS",ENSG00000127554,"Growth factor, augmenter of liver regeneration",16,1984207-1987749,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA041227, HPA063553",Approved,,Enhanced,Mitochondria<br>Cytosol,Renal cancer:4.06e-4 (favourable),Expressed in all,Expressed in all,,,small intestine: 50.0,Expressed in all,,
GFPT1,"GFA, GFAT, GFAT1, GFPT",ENSG00000198380,Glutamine--fructose-6-phosphate transaminase 1,2,69319769-69387254,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA047240,,,Approved,Nucleus<br>Nucleoli,Colorectal cancer:7.13e-5 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 81.8,Expressed in all,,
GFPT2,GFAT2,ENSG00000131459,Glutamine-fructose-6-phosphate transaminase 2,5,180300690-180353387,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA056892, HPA059910",Uncertain,,Supported,Vesicles,"Renal cancer:2.58e-14 (unfavourable), Lung cancer:2.95e-4 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable), Cervical cancer:9.09e-4 (unfavourable)",Expressed in all,Tissue enhanced,,adipose tissue: 90.9,appendix: 25.7,Cell line enhanced,,ASC TERT1: 138.7;hTEC/SVTERT24-B: 242.9;U-87 MG: 409.1
GGACT,A2LD1,ENSG00000134864,Gamma-glutamylamine cyclotransferase,13,100530164-100589528,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA065320,Enhanced,,,,,Expressed in all,Tissue enriched,6,kidney: 75.9,testis: 11.8,Cell line enriched,8,SCLC-21H: 157.1
GGCT,"C7orf24, CRF21, GCTG, Ggc, MGC3077",ENSG00000006625,Gamma-glutamylcyclotransferase,7,30496621-30504844,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA020735, HPA029914",Approved,,,,"Liver cancer:7.23e-4 (unfavourable), Breast cancer:7.68e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 125.5,Expressed in all,,
GGCX,VKCFD1,ENSG00000115486,Gamma-glutamyl carboxylase,2,85544723-85561547,"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA018284,Approved,,,,Endometrial cancer:1.82e-6 (unfavourable),Expressed in all,Expressed in all,,,liver: 61.3,Expressed in all,,
GGH,,ENSG00000137563,Gamma-glutamyl hydrolase,8,63015079-63039171,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB019296, HPA025226",Approved,,,,"Endometrial cancer:3.99e-7 (unfavourable), Lung cancer:1.65e-4 (unfavourable)",Expressed in all,Tissue enhanced,,kidney: 90.0,liver: 63.2,Mixed,,
GGPS1,GGPPS1,ENSG00000152904,Geranylgeranyl diphosphate synthase 1,1,235327350-235344532,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA029472,Enhanced,,,,Liver cancer:6.69e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 90.1,Expressed in all,,
GGT1,"CD224, D22S672, D22S732, GGT",ENSG00000100031,Gamma-glutamyltransferase 1,22,24583750-24629005,"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA045635, HPA047534, HPA065444",Supported,,Approved,Vesicles,"Renal cancer:4.83e-4 (favourable), Ovarian cancer:7.44e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 161.2,small intestine: 95.9,Cell line enhanced,,HDLM-2: 148.2;Karpas-707: 162.6;RPMI-8226: 159.9;RPTEC TERT1: 155.8
GGT5,"GGT-REL, GGTLA1",ENSG00000099998,Gamma-glutamyltransferase 5,22,24219654-24245142,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA008121, CAB032489",Uncertain,,Approved,Nucleoli fibrillar center,"Renal cancer:6.36e-5 (unfavourable), Stomach cancer:4.06e-4 (unfavourable), Testis cancer:6.97e-4 (unfavourable)",Expressed in all,Mixed,,,adipose tissue: 67.3,Cell line enhanced,,ASC diff: 113.5;ASC TERT1: 87.8;HHSteC: 197.7;HSkMC: 197.7;TIME: 90.0
GGT6,FLJ90165,ENSG00000167741,Gamma-glutamyltransferase 6,17,4556927-4560818,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA023362, HPA027213",Approved,,,,"Renal cancer:9.42e-7 (favourable), Lung cancer:4.35e-4 (favourable)",Mixed,Mixed,,,colon: 54.8,Group enriched,8,RT4: 48.3;SK-BR-3: 15.2;T-47d: 59.4
GGT7,"D20S101, dJ18C9.2, GGTL3, GGTL5",ENSG00000131067,Gamma-glutamyltransferase 7,20,34844720-34872860,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA013204, HPA013339",Approved,,Approved,Nucleus<br>Vesicles,Endometrial cancer:1.26e-5 (unfavourable),Expressed in all,Expressed in all,,,"cerebral cortex,parathyroid gland: 50.0",Mixed,,
GK,"GK1, GKD",ENSG00000198814,Glycerol kinase,X,30653359-30731456,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA060687,Supported,,,,Renal cancer:3.24e-9 (favourable),Expressed in all,Tissue enhanced,,kidney: 111.0,small intestine: 98.6,Mixed,,
GK2,"GKP2, GKTA",ENSG00000196475,Glycerol kinase 2,4,79406352-79408293,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA060687,Uncertain,,,,,Not detected,Tissue enriched,1527,testis: 152.6,all non-specific tissues: 0.0,Cell line enriched,45,SCLC-21H: 4.4
GK3P,"GKP3, GKTB",ENSG00000229894,Glycerol kinase 3 pseudogene,4,165277812-165279679,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA060687,Uncertain,,,,,Not detected,Tissue enriched,79,testis: 23.9,bone marrow: 0.3,Not detected,,
GK5,MGC40579,ENSG00000175066,Glycerol kinase 5 (putative),3,142157527-142225607,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042606, HPA057998",Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Mixed,,,prostate: 13.6,Expressed in all,,
GLA,GALA,ENSG00000102393,Galactosidase alpha,X,101397803-101407925,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA000237, HPA000966",Enhanced,,,,"Liver cancer:5.62e-5 (unfavourable), Stomach cancer:6.16e-4 (favourable)",Expressed in all,Expressed in all,,,seminal vesicle: 59.2,Expressed in all,,
GLB1,"EBP, ELNR1",ENSG00000170266,Galactosidase beta 1,3,32996608-33097230,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB008382, HPA040610, HPA069503",Enhanced,,Supported,Golgi apparatus<br>Vesicles,Renal cancer:1.14e-5 (favourable),Expressed in all,Expressed in all,,,epididymis: 122.5,Cell line enriched,5,BEWO: 804.9
GLCE,"HSEPI, KIAA0836",ENSG00000138604,Glucuronic acid epimerase,15,69160584-69272217,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA040481, HPA048216",Uncertain,,Approved,Mitochondria,,Expressed in all,Mixed,,,placenta: 19.1,Cell line enhanced,,HUVEC TERT2: 99.7
GLDC,"GCSP, NKH",ENSG00000178445,Glycine decarboxylase,9,6532464-6645783,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002318, HPA052887",Enhanced,,Supported,Nucleus<br>Mitochondria,"Endometrial cancer:5.24e-5 (unfavourable), Renal cancer:3.50e-4 (favourable)",Tissue enhanced,Tissue enhanced,,kidney: 30.3;liver: 19.9;placenta: 20.1,cerebral cortex: 10.6,Cell line enhanced,,BEWO: 206.9;RPTEC TERT1: 67.4
GLO1,GLOD1,ENSG00000124767,Glyoxalase I,6,38675925-38703141,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB040541, CAB040542, HPA059791",Enhanced,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:5.21e-4 (unfavourable),Expressed in all,Expressed in all,,,prostate: 274.2,Cell line enriched,5,HMC-1: 2266.7
GLS,"GLS1, KIAA0838",ENSG00000115419,Glutaminase,2,190880827-190965552,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA036223,Enhanced,,Supported,Mitochondria,Endometrial cancer:3.45e-4 (unfavourable),Expressed in all,Expressed in all,,,kidney: 333.2,Expressed in all,,
GLS2,"GA, GLS, hLGA, LGA",ENSG00000135423,Glutaminase 2,12,56470944-56488414,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA038608,Uncertain,,,,,Tissue enhanced,Tissue enriched,11,liver: 80.4,cerebral cortex: 7.2,Cell line enhanced,,Daudi: 22.6;SCLC-21H: 10.1
GLUD1,"GDH, GLUD",ENSG00000148672,Glutamate dehydrogenase 1,10,87050486-87094866,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA042492, HPA044839, HPA061369",Approved,,Supported,Mitochondria,"Renal cancer:1.44e-6 (favourable), Pancreatic cancer:1.76e-5 (unfavourable), Glioma:5.08e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 457.9,Expressed in all,,
GLUD2,GLUDP1,ENSG00000182890,Glutamate dehydrogenase 2,X,121047588-121050080,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042492, HPA044839, HPA061369",Uncertain,,Supported,Mitochondria,Renal cancer:1.98e-4 (favourable),Mixed,Tissue enriched,11,testis: 46.5,epididymis: 4.1,Cell line enhanced,,HAP1: 7.6;K-562: 7.6;SK-MEL-30: 8.3;WM-115: 11.7
GLUL,GLNS,ENSG00000135821,Glutamate-ammonia ligase,1,182381704-182392206,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA007316, HPA007571, CAB008636",Approved,,Supported,Mitochondria<br>Cytosol,Breast cancer:4.81e-4 (favourable),Expressed in all,Expressed in all,,,adipose tissue: 851.0,Cell line enhanced,,ASC diff: 791.8;ASC TERT1: 567.1;HSkMC: 512.4
GLYAT,"ACGNAT, GAT",ENSG00000149124,Glycine-N-acyltransferase,11,58640426-58731974,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040251, HPA044094",Enhanced,,,,Renal cancer:1.31e-6 (favourable),Group enriched,Group enriched,10,kidney: 584.9;liver: 355.3,adipose tissue: 47.4,Mixed,,
GLYATL1,"FLJ34646, MGC15397",ENSG00000166840,Glycine-N-acyltransferase like 1,11,58905398-59043527,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039501,Supported,,Uncertain,Golgi apparatus<br>Cytosol,"Renal cancer:3.03e-5 (favourable), Liver cancer:3.69e-4 (favourable)",Group enriched,Group enriched,13,kidney: 145.2;liver: 298.1,prostate: 17.4,Cell line enhanced,,CACO-2: 1.6;Daudi: 3.5;RPTEC TERT1: 1.2;U-2197: 1.1
GLYATL2,"BXMAS2-10, MGC24009",ENSG00000156689,Glycine-N-acyltransferase like 2,11,58834065-58904215,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA060292, HPA065454",Uncertain,,Approved,Mitochondria,Endometrial cancer:9.05e-7 (favourable),Tissue enhanced,Group enriched,6,"breast: 14.3;cervix, uterine: 27.5;gallbladder: 11.0",salivary gland: 3.0,Cell line enhanced,,BJ hTERT+: 4.1;HAP1: 5.9;SK-BR-3: 10.2;U-2197: 6.0
GLYCTK,"HBEBP2, HBEBP4",ENSG00000168237,Glycerate kinase,3,52287089-52293476,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA006913,Approved,,Approved,Golgi apparatus<br>Cytosol<br>Rods & Rings,Head and neck cancer:1.64e-4 (favourable),Tissue enriched,Tissue enhanced,,duodenum: 38.3;liver: 60.6,small intestine: 31.8,Expressed in all,,
GMDS,"GMD, SDR3E1",ENSG00000112699,"GDP-mannose 4,6-dehydratase",6,1623806-2245692,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031528,Enhanced,,,,"Endometrial cancer:5.89e-4 (favourable), Renal cancer:5.93e-4 (favourable)",Expressed in all,Mixed,,,duodenum: 106.3,Expressed in all,,
GMPPB,KIAA1851,ENSG00000173540,GDP-mannose pyrophosphorylase B,3,49716844-49723951,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA014657,Uncertain,,Supported,Nucleus,"Endometrial cancer:6.19e-6 (favourable), Renal cancer:3.17e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 42.0,Expressed in all,,
GMPR,,ENSG00000137198,Guanosine monophosphate reductase,6,16238580-16295549,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000904, HPA021476",Uncertain,,,,"Renal cancer:2.94e-5 (favourable), Ovarian cancer:2.06e-4 (favourable), Lung cancer:8.07e-4 (favourable)",Expressed in all,Expressed in all,,,skeletal muscle: 105.7,Cell line enhanced,,HEL: 171.8;HMC-1: 275.3
GMPR2,,ENSG00000100938,Guanosine monophosphate reductase 2,14,24232422-24239242,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000904, HPA067884, HPA068782",Uncertain,,Approved,Nucleoplasm<br>Nucleoli,Renal cancer:2.21e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 144.2,Expressed in all,,
GMPS,,ENSG00000163655,Guanine monophosphate synthase,3,155870536-155944026,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA046630,,,Approved,Cytosol,"Liver cancer:8.73e-7 (unfavourable), Endometrial cancer:5.54e-5 (unfavourable), Pancreatic cancer:1.04e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 181.7,Expressed in all,,
GNE,"IBM2, Uae1",ENSG00000159921,Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,9,36214441-36277056,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007045, HPA027258",Approved,,Supported,Cytosol,Renal cancer:9.28e-11 (favourable),Expressed in all,Expressed in all,,,rectum: 53.4,Cell line enhanced,,RPTEC TERT1: 82.9
GNMT,,ENSG00000124713,Glycine N-methyltransferase,6,42960758-42963880,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA027501,Enhanced,,Approved,Cytosol,Liver cancer:1.86e-4 (favourable),Group enriched,Group enriched,9,liver: 155.0;pancreas: 55.8;prostate: 32.7,breast: 9.4,Cell line enhanced,,Hep G2: 5.7;SCLC-21H: 11.3;T-47d: 5.8
GNPAT,"DAP-AT, DAPAT, DHAPAT",ENSG00000116906,Glyceronephosphate O-acyltransferase,1,231241207-231277973,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,Renal cancer:8.29e-6 (unfavourable),Expressed in all,Expressed in all,,,testis: 59.7,Expressed in all,,
GNPDA1,"GNPDA, GNPI, GPI, HLN, KIAA0060",ENSG00000113552,Glucosamine-6-phosphate deaminase 1,5,141991749-142013041,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000499, HPA046891",Uncertain,,Approved,Golgi apparatus<br>Vesicles,Liver cancer:2.60e-6 (unfavourable),Expressed in all,Expressed in all,,,kidney: 77.6,Mixed,,
GNPDA2,SB52,ENSG00000163281,Glucosamine-6-phosphate deaminase 2,4,44682200-44726595,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000499, HPA046891",Uncertain,,Approved,Golgi apparatus<br>Vesicles,,Expressed in all,Expressed in all,,,thyroid gland: 32.4,Mixed,,
GNPNAT1,"FLJ10607, Gpnat1",ENSG00000100522,Glucosamine-phosphate N-acetyltransferase 1,14,52775194-52791668,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044647,Approved,,,,Pancreatic cancer:8.52e-5 (unfavourable),Expressed in all,Expressed in all,,,liver: 39.4,Expressed in all,,
GNPTAB,"GNPTA, KIAA1208, MGC4170",ENSG00000111670,N-acetylglucosamine-1-phosphate transferase alpha and beta subunits,12,101745497-101830938,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA014558, HPA042343",Approved,,Supported,Golgi apparatus,Endometrial cancer:8.48e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 63.1,Expressed in all,,
GNS,,ENSG00000135677,Glucosamine (N-acetyl)-6-sulfatase,12,64713445-64759447,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA013695, CAB026011, HPA048508",Enhanced,,,,"Liver cancer:1.94e-5 (unfavourable), Glioma:4.17e-4 (unfavourable)",Expressed in all,Expressed in all,,,adrenal gland: 172.9,Expressed in all,,
GOT1,AST1,ENSG00000120053,Glutamic-oxaloacetic transaminase 1,10,99396870-99430624,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA064532, HPA072629",Enhanced,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:3.72e-13 (favourable), Cervical cancer:6.23e-4 (favourable)",Expressed in all,Expressed in all,,,heart muscle: 321.5,Expressed in all,,
GOT2,"KAT4, KATIV, KYAT4, mitAAT",ENSG00000125166,Glutamic-oxaloacetic transaminase 2,16,58707131-58734357,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA018139,Enhanced,,,,"Renal cancer:2.90e-9 (favourable), Liver cancer:5.75e-5 (favourable), Head and neck cancer:1.61e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 240.2,Expressed in all,,
GPAM,"GPAT1, KIAA1560, MGC26846",ENSG00000119927,"Glycerol-3-phosphate acyltransferase, mitochondrial",10,112149864-112215377,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA046339, HPA060090",Approved,,Approved,Mitochondria,Renal cancer:4.54e-6 (favourable),Tissue enriched,Expressed in all,,,adipose tissue: 315.8,Expressed in all,,
GPAT2,CT123,ENSG00000186281,"Glycerol-3-phosphate acyltransferase 2, mitochondrial",2,96021946-96039451,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA036841,Uncertain,,Approved,Mitochondria,,Mixed,Mixed,,,testis: 7.2,Cell line enhanced,,BJ: 6.9;BJ hTERT+ SV40 Large T+: 18.2;BJ hTERT+ SV40 Large T+ RasG12V: 11.3;U-2 OS: 11.7
GPAT3,"AGPAT10, AGPAT9, HMFN0839, LPAAT-theta, MAG1, MGC11324",ENSG00000138678,Glycerol-3-phosphate acyltransferase 3,4,83535914-83605875,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA029414, CAB033749",Approved,,Uncertain,Plasma membrane<br>Cytosol,"Renal cancer:2.71e-9 (favourable), Urothelial cancer:8.21e-4 (unfavourable)",Mixed,Tissue enhanced,,kidney: 89.9,duodenum: 40.7,Cell line enhanced,,CAPAN-2: 141.3;U-87 MG: 67.1;WM-115: 52.9
GPAT4,"AGPAT6, DKFZp586M1819, LPAAT-zeta, TSARG7",ENSG00000158669,Glycerol-3-phosphate acyltransferase 4,8,41577187-41625001,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA016471,Approved,,,,"Ovarian cancer:2.20e-4 (unfavourable), Prostate cancer:4.15e-4 (favourable), Urothelial cancer:5.65e-4 (favourable), Endometrial cancer:9.37e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 80.3,Expressed in all,,
GPCPD1,"GDE5, GDPD6, KIAA1434",ENSG00000125772,Glycerophosphocholine phosphodiesterase 1,20,5544404-5611026,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039556, HPA042987",Uncertain,,Approved,Nucleoplasm,"Endometrial cancer:1.30e-4 (favourable), Renal cancer:3.73e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 46.5,Mixed,,
GPD1,,ENSG00000167588,Glycerol-3-phosphate dehydrogenase 1,12,50103819-50111319,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA044620,Enhanced,,,,,Mixed,Tissue enhanced,,adipose tissue: 636.1;skeletal muscle: 195.7,kidney: 148.1,Cell line enhanced,,ASC diff: 86.3;CACO-2: 22.1;Hep G2: 17.0;RPMI-8226: 20.7
GPD1L,KIAA0089,ENSG00000152642,Glycerol-3-phosphate dehydrogenase 1-like,3,32105689-32168713,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:3.33e-15 (favourable), Liver cancer:1.35e-5 (unfavourable), Lung cancer:5.71e-5 (favourable), Colorectal cancer:7.05e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 92.5,Expressed in all,,
GPD2,,ENSG00000115159,Glycerol-3-phosphate dehydrogenase 2,2,156435290-156613735,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA008012, HPA045506",Enhanced,,,,Liver cancer:1.44e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 45.7,Mixed,,
GPHN,KIAA1385,ENSG00000171723,Gephyrin,14,66507407-67181803,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA003116, CAB004419, HPA024694",Enhanced,,Uncertain,Cytoplasmic bodies,"Renal cancer:5.25e-12 (favourable), Urothelial cancer:4.61e-5 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 30.5,Mixed,,
GPI,"AMF, NLK",ENSG00000105220,Glucose-6-phosphate isomerase,19,34359480-34402156,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB018655, HPA024305, CAB040563, HPA052171",Enhanced,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 314.1,Expressed in all,,
GPLD1,,ENSG00000112293,Glycosylphosphatidylinositol specific phospholipase D1,6,24424565-24495205,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB008625, HPA012500",Uncertain,,,,Liver cancer:1.12e-4 (favourable),Tissue enriched,Tissue enhanced,,liver: 23.6,skin: 9.0,Cell line enhanced,,Daudi: 5.7;U-698: 5.6
GPT,"ALT1, GPT1",ENSG00000167701,Glutamic--pyruvic transaminase,8,144502973-144507174,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA031059, HPA031060, CAB032997, CAB032999",Enhanced,,,,"Liver cancer:1.47e-5 (favourable), Renal cancer:2.19e-4 (favourable)",Tissue enriched,Mixed,,,liver: 25.0,Mixed,,
GPT2,ALT2,ENSG00000166123,Glutamic--pyruvic transaminase 2,16,46884378-46931297,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA051514,Approved,,Approved,Mitochondria,Ovarian cancer:3.17e-4 (favourable),Expressed in all,Expressed in all,,,esophagus: 85.0,Mixed,,
GPX1,,ENSG00000233276,Glutathione peroxidase 1,3,49357176-49358600,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB011582, HPA044758",Approved,,Supported,Cytosol,Endometrial cancer:7.78e-4 (favourable),Expressed in all,Expressed in all,,,adipose tissue: 276.3,Mixed,,
GPX2,GSHPX-GI,ENSG00000176153,Glutathione peroxidase 2,14,64939152-64942905,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003545,Enhanced,,Approved,Nucleoplasm<br>Cytosol,Head and neck cancer:5.10e-4 (unfavourable),Mixed,Tissue enhanced,,gallbladder: 696.1;rectum: 461.1,stomach: 334.9,Group enriched,20,A549: 930.0;HaCaT: 249.8;Hep G2: 659.7;RT4: 543.6;SCLC-21H: 352.2
GPX3,,ENSG00000211445,Glutathione peroxidase 3,5,151020438-151028993,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB069456,Uncertain,,,,Stomach cancer:1.65e-4 (unfavourable),Expressed in all,Expressed in all,,,kidney: 11674.4,Cell line enriched,11,ASC diff: 5265.2
GPX4,"MCSP, PHGPx",ENSG00000167468,Glutathione peroxidase 4,19,1103926-1106791,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB008630, HPA047224, HPA058546",Enhanced,,Supported,Nucleoplasm<br>Mitochondria,"Endometrial cancer:1.84e-5 (favourable), Cervical cancer:7.18e-4 (favourable), Pancreatic cancer:7.72e-4 (favourable), Renal cancer:8.61e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 1140.7,Expressed in all,,
GPX5,,ENSG00000224586,Glutathione peroxidase 5,6,28525925-28534952,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,30,epididymis: 12.2,seminal vesicle: 0.4,Not detected,,
GPX6,GPXP3,ENSG00000198704,Glutathione peroxidase 6,6,28503296-28528215,"Enzymes, Predicted secreted proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enriched,12,epididymis: 4.0,testis: 0.3,Not detected,,
GPX7,"FLJ14777, GPX6, NPGPx",ENSG00000116157,Glutathione peroxidase 7,1,52602372-52609051,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA025829,,,Approved,Nucleoli,Renal cancer:2.26e-5 (unfavourable),Expressed in all,Expressed in all,,,placenta: 42.1,Cell line enhanced,,REH: 69.6;RPMI-8226: 89.3;THP-1: 68.1
GPX8,"EPLA847, UNQ847",ENSG00000164294,Glutathione peroxidase 8 (putative),5,55160118-55167071,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036720,Enhanced,,Supported,Actin filaments<br>Cytosol,"Renal cancer:5.13e-9 (unfavourable), Stomach cancer:7.96e-4 (unfavourable)",Expressed in all,Mixed,,,"cervix, uterine: 48.0",Mixed,,
GRHPR,"GLXR, PH2",ENSG00000137106,Glyoxylate and hydroxypyruvate reductase,9,37422666-37436990,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA022971,Approved,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:5.39e-9 (favourable), Breast cancer:7.00e-5 (favourable)",Expressed in all,Expressed in all,,,liver: 323.3,Expressed in all,,
GRK1,"GPRK1, RHOK, RK",ENSG00000185974,G protein-coupled receptor kinase 1,13,113667155-113737735,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035200, HPA059376",Enhanced,,,,,Tissue enhanced,Not detected,,,thyroid gland: 0.8,Not detected,,
GRK2,"ADRBK1, BARK1",ENSG00000173020,G protein-coupled receptor kinase 2,11,67266410-67286556,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005021, CAB037248, HPA048330",Approved,,Approved,Vesicles,Renal cancer:1.25e-4 (unfavourable),Expressed in all,Expressed in all,,,spleen: 127.3,Expressed in all,,
GRK3,"ADRBK2, BARK2",ENSG00000100077,G protein-coupled receptor kinase 3,22,25564849-25729294,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000804,Uncertain,,Approved,Nucleus<br>Plasma membrane,Urothelial cancer:1.29e-4 (favourable),Expressed in all,Mixed,,,adipose tissue: 32.7,Cell line enhanced,,HDLM-2: 40.3;SH-SY5Y: 39.9
GRK4,"GPRK2L, GPRK4",ENSG00000125388,G protein-coupled receptor kinase 4,4,2963608-3040747,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028737, HPA057023",Approved,,Supported,Vesicles,,Expressed in all,Tissue enriched,9,testis: 74.7,cerebral cortex: 8.1,Cell line enhanced,,SCLC-21H: 18.6
GRK5,GPRK5,ENSG00000198873,G protein-coupled receptor kinase 5,10,119207589-119459742,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB025579, HPA046838",Approved,,Supported,Nuclear membrane<br>Nuclear speckles<br>Plasma membrane,Renal cancer:2.38e-7 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 78.5,Cell line enhanced,,BJ hTERT+: 68.5;HUVEC TERT2: 55.7
GRK6,GPRK6,ENSG00000198055,G protein-coupled receptor kinase 6,5,177403204-177442901,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA015327, HPA018903",Approved,,Approved,Mitochondria,"Liver cancer:5.66e-6 (unfavourable), Pancreatic cancer:1.22e-4 (favourable)",Expressed in all,Expressed in all,,,bone marrow: 87.5,Expressed in all,,
GRK7,GPRK7,ENSG00000114124,G protein-coupled receptor kinase 7,3,141778148-141818490,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Not detected,,,"skin,testis: 0.2",Not detected,,
GSG2,haspin,ENSG00000177602,"Germ cell associated 2, haspin",17,3723903-3726699,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027422, HPA030698",Approved,,Supported,Nucleus,,Mixed,Tissue enhanced,,testis: 13.2,lymph node: 5.0,Mixed,,
GSK3A,,ENSG00000105723,Glycogen synthase kinase 3 alpha,19,42230186-42242625,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004422, HPA028423",Approved,,Approved,Cytosol,"Liver cancer:1.13e-4 (unfavourable), Endometrial cancer:4.02e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 74.5,Expressed in all,,
GSK3B,,ENSG00000082701,Glycogen synthase kinase 3 beta,3,119821323-120094417,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB016263, HPA028017",Approved,,Enhanced,Nucleus,"Liver cancer:8.20e-5 (unfavourable), Renal cancer:1.52e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 47.4,Expressed in all,,
GSR,,ENSG00000104687,Glutathione-disulfide reductase,8,30678061-30727926,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001538, CAB008632",Approved,,Supported,Plasma membrane<br>Cytosol,"Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 79.3,Expressed in all,,
GSS,,ENSG00000100983,Glutathione synthetase,20,34928430-34955817,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA054508, HPA059315",Enhanced,,Supported,Nucleus,"Renal cancer:7.31e-6 (favourable), Liver cancer:7.21e-5 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 105.8,Expressed in all,,
GSTA1,,ENSG00000243955,Glutathione S-transferase alpha 1,6,52791664-52803910,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA004342, HPA048934, HPA053817",Supported,,Supported,Cytosol,"Renal cancer:3.71e-4 (unfavourable), Lung cancer:8.66e-4 (favourable)",Group enriched,Tissue enhanced,,adrenal gland: 1136.4;kidney: 1310.9;liver: 1757.6,small intestine: 1002.9,Cell line enriched,11,Hep G2: 245.8
GSTA2,GST2,ENSG00000244067,Glutathione S-transferase alpha 2,6,52750089-52763569,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA004342, HPA048934, HPA053817",Supported,,Supported,Cytosol,Renal cancer:1.17e-4 (unfavourable),Group enriched,Group enriched,5,kidney: 651.7;liver: 986.1,gallbladder: 155.6,Group enriched,17,CACO-2: 19.6;Hep G2: 12.5
GSTA3,,ENSG00000174156,Glutathione S-transferase alpha 3,6,52896639-52909685,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA004342, HPA048934, HPA053817",Approved,,Supported,Cytosol,,Mixed,Tissue enhanced,,adrenal gland: 56.1;fallopian tube: 102.0,placenta: 32.1,Not detected,,
GSTA4,,ENSG00000170899,Glutathione S-transferase alpha 4,6,52977948-52995378,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA048934,Approved,,,,,Expressed in all,Expressed in all,,,adrenal gland: 390.0,Cell line enhanced,,AF22: 92.3
GSTA5,,ENSG00000182793,Glutathione S-transferase alpha 5,6,52831655-52846095,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA004342, HPA048934, HPA053817",Uncertain,,Approved,Cytosol,,Not detected,Not detected,,,testis: 0.1,Not detected,,
GSTK1,GST13,ENSG00000197448,Glutathione S-transferase kappa 1,7,143244093-143270854,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006311, HPA022904",Enhanced,,Supported,Peroxisomes,"Renal cancer:2.10e-6 (favourable), Breast cancer:4.41e-6 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 377.4,Expressed in all,,
GSTM1,"GST1, H-B, MU",ENSG00000134184,Glutathione S-transferase mu 1,1,109687814-109709039,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB022669, CAB047357, HPA048652, HPA055972, HPA055973",Approved,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,liver: 317.1,parathyroid gland: 233.1,Cell line enhanced,,HEL: 78.7;HeLa: 68.9;HHSteC: 66.1;hTEC/SVTERT24-B: 72.9;MOLT-4: 92.2
GSTM2,GST4,ENSG00000213366,Glutathione S-transferase mu 2,1,109668022-109709551,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB040547, HPA055972, HPA055973",Approved,,Enhanced,Cytosol,Lung cancer:9.70e-5 (favourable),Mixed,Expressed in all,,,ovary: 201.1,Cell line enhanced,,ASC TERT1: 82.2;HSkMC: 85.0
GSTM3,GST5,ENSG00000134202,Glutathione S-transferase mu 3,1,109733932-109741038,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB017130, HPA035190, CAB040583, HPA055972",Enhanced,,Supported,Cytosol,Melanoma:1.89e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 722.1,Cell line enhanced,,T-47d: 462.4
GSTM4,,ENSG00000168765,Glutathione S-transferase mu 4,1,109656081-109674836,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA048652, HPA055972, HPA055973",Approved,,Approved,Cytokinetic bridge<br>Cytosol,Breast cancer:9.96e-5 (favourable),Expressed in all,Expressed in all,,,duodenum: 149.7,Mixed,,
GSTM5,,ENSG00000134201,Glutathione S-transferase mu 5,1,109712255-109775428,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA048652, HPA055972, HPA055973",Approved,,Approved,Cytokinetic bridge<br>Cytosol,,Mixed,Group enriched,6,breast: 845.2;ovary: 221.0,fallopian tube: 84.6,Group enriched,8,fHDF/TERT166: 12.9;HHSteC: 5.7;HSkMC: 5.3
GSTO1,"GSTTLp28, P28",ENSG00000148834,Glutathione S-transferase omega 1,10,104235356-104267459,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA037603, HPA037604",Enhanced,,,,"Renal cancer:2.11e-4 (unfavourable), Breast cancer:6.95e-4 (favourable), Head and neck cancer:8.83e-4 (unfavourable)",Expressed in all,Expressed in all,,,liver: 266.3,Expressed in all,,
GSTO2,,ENSG00000065621,Glutathione S-transferase omega 2,10,104268873-104304945,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA048141,Approved,,Approved,Nucleus<br>Nucleoli,Renal cancer:7.10e-7 (favourable),Mixed,Mixed,,,testis: 36.1,Cell line enhanced,,CAPAN-2: 45.6;hTCEpi: 32.1;hTERT-HME1: 36.7;T-47d: 36.0
GSTP1,"FAEES3, GST3, GSTP",ENSG00000084207,Glutathione S-transferase pi 1,11,67583595-67586660,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019779, HPA019869",Enhanced,,Supported,Mitochondria<br>Cytosol,,Expressed in all,Expressed in all,,,esophagus: 1059.9,Expressed in all,,
GSTT2B,GSTT2P,ENSG00000133433,Glutathione S-transferase theta 2B (gene/pseudogene),22,23957414-23961186,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000750,Uncertain,,Supported,Nucleoplasm<br>Cytosol,Breast cancer:5.06e-4 (favourable),Expressed in all,Tissue enriched,7,breast: 411.1,adrenal gland: 60.8,Cell line enhanced,,AN3-CA: 53.0;HHSteC: 68.3;T-47d: 60.4
GSTZ1,"GSTZ1-1, MAAI, MAI",ENSG00000100577,Glutathione S-transferase zeta 1,14,77320884-77331597,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004701,Approved,,Approved,Nucleus<br>Cytosol,"Renal cancer:1.12e-7 (favourable), Ovarian cancer:3.73e-4 (favourable), Breast cancer:4.93e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 134.5,Expressed in all,,
GTF2F2,"BTF4, RAP30, TFIIF",ENSG00000188342,General transcription factor IIF subunit 2,13,45120515-45284909,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006912,Supported,,Supported,Nucleus<br>Microtubules,Head and neck cancer:1.65e-5 (unfavourable),Expressed in all,Expressed in all,,,skin: 26.3,Expressed in all,,
GTF3C4,"KAT12, TFIIIC90",ENSG00000125484,General transcription factor IIIC subunit 4,9,132670035-132694955,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA069369,,,Supported,Nucleus,Renal cancer:2.99e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 17.0,Expressed in all,,
GUCY1A2,"GC-SA2, GUC1A2",ENSG00000152402,Guanylate cyclase 1 soluble subunit alpha 2,11,106674012-107018524,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,CAB009534,Uncertain,,,,Renal cancer:3.02e-5 (unfavourable),Mixed,Tissue enhanced,,placenta: 25.6,endometrium: 21.1,Cell line enhanced,,BJ hTERT+: 9.5;BJ hTERT+ SV40 Large T+ RasG12V: 13.1;HBF TERT88: 6.9
GUCY1A3,"GC-SA3, GUC1A3",ENSG00000164116,Guanylate cyclase 1 soluble subunit alpha,4,155666711-155732349,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB010887, HPA056004, HPA058617",Uncertain,,Supported,Nucleus,"Lung cancer:2.38e-4 (favourable), Testis cancer:3.59e-4 (unfavourable), Renal cancer:7.59e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 136.7,smooth muscle: 43.8,Cell line enhanced,,HAP1: 7.2;Karpas-707: 7.1;MOLT-4: 15.2;RPTEC TERT1: 9.3;RT4: 11.7;SH-SY5Y: 9.5
GUCY1B3,"GC-S-beta-1, GC-SB3, GUC1B3",ENSG00000061918,Guanylate cyclase 1 soluble subunit beta,4,155758992-155807591,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB010890, HPA020870",Approved,,Approved,Cytosol,"Renal cancer:2.42e-4 (unfavourable), Testis cancer:3.23e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 177.3,Cell line enhanced,,HEL: 42.7;MOLT-4: 24.5;RPTEC TERT1: 35.1
GUCY2C,"GUC2C, STAR",ENSG00000070019,Guanylate cyclase 2C,12,14612632-14696585,"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA037655, HPA073759",Uncertain,,Uncertain,Vesicles,Liver cancer:1.37e-5 (unfavourable),Group enriched,Group enriched,13,colon: 37.0;duodenum: 68.7;rectum: 45.4;small intestine: 73.2,appendix: 4.4,Cell line enhanced,,AN3-CA: 1.2;CAPAN-2: 1.4;SiHa: 1.6
GUCY2D,"CORD6, CYGD, GUC1A4, GUC2D, LCA, LCA1, retGC, RETGC-1, ROS-GC1",ENSG00000132518,"Guanylate cyclase 2D, retinal",17,8002594-8020339,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,testis: 1.4,lymph node: 0.3,Cell line enriched,6,HMC-1: 1.1
GUCY2F,"CYGF, GC-F, GUC2DL, RetGC-2, ROS-GC2",ENSG00000101890,"Guanylate cyclase 2F, retinal",X,109372906-109482072,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Not detected,,,"fallopian tube,testis: 0.4",Not detected,,
GUK1,,ENSG00000143774,Guanylate kinase 1,1,228139962-228148984,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028118, HPA048587",Approved,,Uncertain,Nucleoplasm<br>Cytosol,Renal cancer:8.85e-5 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 264.8,Expressed in all,,
GUSB,,ENSG00000169919,Glucuronidase beta,7,65960684-65982314,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA036322, HPA036323",Approved,,Supported,Vesicles,,Expressed in all,Expressed in all,,,breast: 95.9,Expressed in all,,
GXYLT1,"FLJ43151, GLT8D3",ENSG00000151233,Glucoside xylosyltransferase 1,12,42081845-42144879,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,Urothelial cancer:3.91e-4 (favourable),Expressed in all,Mixed,,,testis: 17.8,Expressed in all,,
GXYLT2,GLT8D4,ENSG00000172986,Glucoside xylosyltransferase 2,3,72888073-72998138,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA068429,Uncertain,,Approved,Nucleoplasm<br>Cytokinetic bridge<br>Midbody ring,"Renal cancer:1.46e-7 (unfavourable), Urothelial cancer:2.42e-5 (unfavourable)",Mixed,Mixed,,,ovary: 20.6,Cell line enhanced,,MOLT-4: 29.2
GYG1,GYG,ENSG00000163754,Glycogenin 1,3,148991341-149027668,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA030497,Approved,,Supported,Vesicles,Liver cancer:6.15e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 210.0,Mixed,,
GYG2,GN-2,ENSG00000056998,Glycogenin 2,X,2828788-2882820,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA005495, HPA064686",Enhanced,,Approved,Nucleus<br>Nucleoli<br>Cytosol,Pancreatic cancer:3.01e-5 (favourable),Expressed in all,Tissue enriched,13,adipose tissue: 173.1,breast: 13.2,Cell line enhanced,,AF22: 39.5;NTERA-2: 39.5;SK-MEL-30: 68.1
GYS1,"GSY, GYS",ENSG00000104812,Glycogen synthase 1,19,48968125-48993310,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB007793, HPA041598",Enhanced,,Approved,Microtubules<br>Cytosol,Renal cancer:3.46e-4 (unfavourable),Expressed in all,Expressed in all,,,skeletal muscle: 109.7,Expressed in all,,
GYS2,,ENSG00000111713,Glycogen synthase 2,12,21536189-21604847,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA039482,Approved,,,,Liver cancer:7.62e-5 (favourable),Tissue enriched,Tissue enriched,23,liver: 91.8,adipose tissue: 3.9,Cell line enhanced,,CACO-2: 1.0
GZMA,"CTLA3, HFSP",ENSG00000145649,Granzyme A,5,55102648-55110252,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA054134,Uncertain,,,,"Renal cancer:1.26e-6 (unfavourable), Endometrial cancer:6.44e-6 (favourable), Breast cancer:7.27e-4 (favourable)",Expressed in all,Mixed,,,spleen: 70.9,Cell line enhanced,,HL-60: 3.2
GZMB,"CCPI, CGL-1, CGL1, CSP-B, CSPB, CTLA1, CTSGL1, HLP, SECT",ENSG00000100453,Granzyme B,14,24630954-24634267,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000376, HPA003418",Enhanced,,,,"Renal cancer:1.10e-7 (unfavourable), Endometrial cancer:1.58e-5 (favourable), Breast cancer:7.27e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 40.1,"bone marrow,spleen: 36.2",Cell line enriched,6,HMC-1: 17.4
GZMH,"CCP-X, CGL-2, CSP-C, CTLA1, CTSGL2",ENSG00000100450,Granzyme H,14,24606480-24609699,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA029200,Enhanced,,,,"Renal cancer:1.74e-6 (unfavourable), Endometrial cancer:2.00e-6 (favourable)",Expressed in all,Tissue enhanced,,spleen: 35.3,lymph node: 25.3,Not detected,,
GZMK,"PRSS, TRYP2",ENSG00000113088,Granzyme K,5,55024253-55034570,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA063181,Enhanced,,,,"Renal cancer:1.06e-4 (unfavourable), Breast cancer:8.68e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 103.9,spleen: 41.9,Not detected,,
GZMM,"LMET1, MET1",ENSG00000197540,Granzyme M,19,544034-549924,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA015624,Enhanced,,,,"Head and neck cancer:1.87e-7 (favourable), Renal cancer:1.21e-4 (unfavourable), Endometrial cancer:1.89e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 20.9;spleen: 19.7,appendix: 13.0,Cell line enhanced,,EFO-21: 1.9;HDLM-2: 1.6;HMC-1: 1.8;MOLT-4: 1.1
H6PD,GDH,ENSG00000049239,Hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase,1,9234775-9271337,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA004824, HPA005440",Approved,,Uncertain,Cytosol,,Expressed in all,Expressed in all,,,ovary: 42.8,Mixed,,
HAAO,,ENSG00000162882,"3-hydroxyanthranilate 3,4-dioxygenase",2,42767089-42792593,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036394, HPA042024",Enhanced,,,,Liver cancer:5.77e-4 (favourable),Group enriched,Tissue enhanced,,liver: 152.2,small intestine: 45.5,Cell line enhanced,,CACO-2: 11.2;Hep G2: 32.9;REH: 9.2
HABP2,"FSAP, HABP, HGFAL, PHBP",ENSG00000148702,Hyaluronan binding protein 2,10,113550837-113589602,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA019518,Approved,,,,,Tissue enriched,Group enriched,12,gallbladder: 55.8;liver: 225.6,stomach: 11.3,Cell line enriched,5,RPTEC TERT1: 38.3
HACD1,"CAP, PTPLA",ENSG00000165996,3-hydroxyacyl-CoA dehydratase 1,10,17589032-17617377,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,heart muscle: 42.0,smooth muscle: 36.3,Mixed,,
HACD2,PTPLB,ENSG00000206527,3-hydroxyacyl-CoA dehydratase 2,3,123490820-123585185,"Enzymes, Predicted membrane proteins",Evidence at protein level,CAB019282,Approved,,,,Pancreatic cancer:9.59e-5 (unfavourable),Expressed in all,Expressed in all,,,adipose tissue: 68.9,Expressed in all,,
HACD3,"B-ind1, HSPC121, PTPLAD1",ENSG00000074696,3-hydroxyacyl-CoA dehydratase 3,15,65530418-65578352,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA014837, HPA060347",Enhanced,,Enhanced,Nuclear membrane<br>Endoplasmic reticulum<br>Mitochondria<br>Cytosol,Renal cancer:3.09e-5 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 138.9,Expressed in all,,
HACD4,"Em:AL662879.1, PTPLAD2",ENSG00000188921,3-hydroxyacyl-CoA dehydratase 4,9,20999515-21031636,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA058666,Uncertain,,,,"Ovarian cancer:3.14e-4 (favourable), Renal cancer:6.77e-4 (unfavourable)",Mixed,Mixed,,,lung: 12.6,Cell line enhanced,,BJ hTERT+: 14.0;HDLM-2: 10.0;U-937: 10.5
HACE1,KIAA1320,ENSG00000085382,HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1,6,104728093-104859919,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA046071,,,Supported,Nuclear bodies<br>Endoplasmic reticulum,"Renal cancer:1.17e-5 (unfavourable), Thyroid cancer:7.50e-4 (unfavourable)",Mixed,Tissue enhanced,,placenta: 44.1,testis: 19.1,Mixed,,
HADH,"HADH1, HADHSC, SCHAD",ENSG00000138796,Hydroxyacyl-CoA dehydrogenase,4,107989714-108035175,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA039588, HPA043888",Supported,,Supported,Mitochondria,Renal cancer:0.00e+0 (favourable),Expressed in all,Expressed in all,,,adipose tissue: 154.5,Expressed in all,,
HADHA,"GBP, LCEH, LCHAD, MTPA",ENSG00000084754,"Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit",2,26190635-26244726,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA015536, HPA056070",Approved,,Enhanced,Mitochondria,Renal cancer:3.68e-5 (favourable),Expressed in all,Expressed in all,,,duodenum: 235.3,Expressed in all,,
HADHB,MTPB,ENSG00000138029,"Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit",2,26243170-26290468,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA037539, HPA037540, HPA066099",Enhanced,,Supported,Mitochondria,Renal cancer:1.37e-9 (favourable),Expressed in all,Expressed in all,,,heart muscle: 300.8,Expressed in all,,
HAGH,"GLO2, GLXII, HAGH1",ENSG00000063854,Hydroxyacylglutathione hydrolase,16,1795620-1827194,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043041, HPA061143",Approved,,,,"Renal cancer:1.81e-6 (favourable), Liver cancer:5.33e-6 (favourable), Cervical cancer:5.82e-5 (favourable), Urothelial cancer:5.19e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 124.4,Expressed in all,,
HAL,HIS,ENSG00000084110,Histidine ammonia-lyase,12,95972662-95996365,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038547, HPA038548",Enhanced,,Uncertain,Cytosol,,Tissue enriched,Group enriched,8,liver: 51.2;skin: 72.5,bone marrow: 7.4,Cell line enhanced,,BEWO: 2.1;THP-1: 7.4
HAO1,"GOX, GOX1",ENSG00000101323,Hydroxyacid oxidase 1,20,7882981-7940474,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA049552,Enhanced,,,,,Tissue enriched,Tissue enriched,305,liver: 308.6,kidney: 1.0,Not detected,,
HAO2,"GIG16, HAOX2",ENSG00000116882,Hydroxyacid oxidase 2,1,119368779-119394130,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Renal cancer:4.92e-4 (favourable),Group enriched,Group enriched,300,kidney: 317.5;liver: 219.8,"adrenal gland,breast: 0.8",Not detected,,
HARS,,ENSG00000170445,Histidyl-tRNA synthetase,5,140673173-140692024,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA036539,Approved,,Enhanced,Cytosol,Liver cancer:1.96e-7 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 71.1,Expressed in all,,
HARS2,"HARSL, HARSR, HO3",ENSG00000112855,"Histidyl-tRNA synthetase 2, mitochondrial",5,140691426-140699291,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA035941,Approved,,Approved,Cytosol,"Liver cancer:2.92e-4 (unfavourable), Colorectal cancer:6.19e-4 (favourable), Breast cancer:6.49e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 36.5,Expressed in all,,
HAS1,HAS,ENSG00000105509,Hyaluronan synthase 1,19,51713112-51723994,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA067602,Approved,,Supported,Nucleoplasm<br>Plasma membrane,,Mixed,Tissue enhanced,,adipose tissue: 27.0,appendix: 8.9,Group enriched,12,hTEC/SVTERT24-B: 27.0;U-87 MG: 110.6
HAS2,,ENSG00000170961,Hyaluronan synthase 2,8,121612116-121641390,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA052060,,,Approved,Nuclear speckles,,Mixed,Tissue enhanced,,adipose tissue: 27.9,gallbladder: 12.7,Cell line enhanced,,HBF TERT88: 154.7;hTEC/SVTERT24-B: 155.8;LHCN-M2: 174.3;U-138 MG: 396.2;U-251 MG: 103.0
HAS3,,ENSG00000103044,Hyaluronan synthase 3,16,69105564-69118719,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA031554, CAB033850",Supported,,Approved,Microtubules,Pancreatic cancer:5.36e-4 (unfavourable),Group enriched,Tissue enhanced,,lung: 29.9;urinary bladder: 36.4,stomach: 11.8,Cell line enhanced,,HaCaT: 46.5;PC-3: 257.9;RT4: 89.2
HAT1,KAT1,ENSG00000128708,Histone acetyltransferase 1,2,171922448-171983682,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036788, CAB037191",Enhanced,,Enhanced,Nucleoplasm,Liver cancer:5.72e-5 (unfavourable),Expressed in all,Expressed in all,,,lymph node: 56.3,Expressed in all,,
HCCS,"CCHL, MLS",ENSG00000004961,Holocytochrome c synthase,X,11111301-11123078,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA002946,Approved,,Enhanced,Mitochondria,"Renal cancer:6.17e-8 (favourable), Liver cancer:1.35e-5 (unfavourable), Breast cancer:8.69e-5 (unfavourable)",Expressed in all,Expressed in all,,,heart muscle: 31.5,Expressed in all,,
HCK,JTK9,ENSG00000101336,"HCK proto-oncogene, Src family tyrosine kinase",20,32052188-32101856,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005195, HPA063768",Approved,,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:1.66e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 149.6;spleen: 113.2,lung: 74.1,Group enriched,8,THP-1: 48.4;U-937: 161.1
HDAC1,"GON-10, HD1, RPD3L1",ENSG00000116478,Histone deacetylase 1,1,32292086-32333635,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005017, HPA029693, CAB068191",Enhanced,,Enhanced,Nucleoplasm,"Liver cancer:5.76e-7 (unfavourable), Renal cancer:1.04e-5 (unfavourable)",Expressed in all,Expressed in all,,,lymph node: 139.0,Expressed in all,,
HDAC10,DKFZP761B039,ENSG00000100429,Histone deacetylase 10,22,50245183-50251405,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB045977, HPA056514",Supported,,Approved,Nucleoli fibrillar center,"Renal cancer:4.74e-11 (unfavourable), Endometrial cancer:2.45e-5 (favourable), Cervical cancer:4.46e-4 (favourable), Pancreatic cancer:9.25e-4 (favourable)",Expressed in all,Mixed,,,spleen: 9.8,Mixed,,
HDAC11,,ENSG00000163517,Histone deacetylase 11,3,13479724-13506424,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:7.88e-10 (favourable), Liver cancer:1.20e-5 (unfavourable)",Expressed in all,Mixed,,,cerebral cortex: 66.7,Cell line enhanced,,T-47d: 39.9
HDAC2,"RPD3, YAF1",ENSG00000196591,Histone deacetylase 2,6,113933028-114011308,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005054, HPA011727",Supported,,Enhanced,Nucleus,"Liver cancer:5.39e-10 (unfavourable), Breast cancer:7.07e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 141.1,Expressed in all,,
HDAC3,"HD3, RPD3, RPD3-2",ENSG00000171720,Histone deacetylase 3,5,141620876-141636870,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005583, HPA052052",Supported,,Supported,Nucleoplasm<br>Golgi apparatus,"Renal cancer:2.65e-6 (unfavourable), Colorectal cancer:3.39e-4 (favourable), Pancreatic cancer:3.95e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 52.1,Expressed in all,,
HDAC4,"BDMR, HA6116, HD4, HDAC-4, HDAC-A, HDACA, KIAA0288",ENSG00000068024,Histone deacetylase 4,2,239048168-239401654,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004431, HPA048723",Approved,,Supported,Nucleoplasm<br>Cytosol,"Pancreatic cancer:1.13e-4 (favourable), Ovarian cancer:6.33e-4 (unfavourable)",Expressed in all,Mixed,,,cerebral cortex: 19.3,Cell line enhanced,,MOLT-4: 40.5
HDAC5,"FLJ90614, KIAA0600, NY-CO-9",ENSG00000108840,Histone deacetylase 5,17,44076746-44123702,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB019400, HPA030991",Approved,,Supported,Nuclear speckles<br>Golgi apparatus<br>Cytosol,"Liver cancer:3.12e-5 (unfavourable), Renal cancer:3.30e-5 (favourable), Cervical cancer:6.14e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 60.0,Mixed,,
HDAC6,"FLJ16239, HD6, JM21, KIAA0901, PPP1R90",ENSG00000094631,Histone deacetylase 6,X,48801377-48824982,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA003714, CAB004236, HPA026321",Approved,,Supported,Nucleoplasm,Urothelial cancer:3.34e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 51.4,Expressed in all,,
HDAC7,"DKFZP586J0917, HDAC7A",ENSG00000061273,Histone deacetylase 7,12,47782722-47833132,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA004775,,,Supported,Cytosol,"Urothelial cancer:4.65e-4 (favourable), Melanoma:5.16e-4 (unfavourable), Renal cancer:8.25e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 43.9,Expressed in all,,
HDAC8,"HDACL1, MRXS6, RPD3, WTS",ENSG00000147099,Histone deacetylase 8,X,72329516-72573103,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA048560,Supported,,Supported,Nucleus<br>Plasma membrane,,Expressed in all,Expressed in all,,,epididymis: 27.1,Expressed in all,,
HDAC9,"HD7, HDAC, HDAC7B, KIAA0744, MITR",ENSG00000048052,Histone deacetylase 9,7,18086949-19002416,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA028926,Uncertain,,Approved,Nucleoplasm,,Mixed,Mixed,,,spleen: 24.6,Cell line enhanced,,HAP1: 176.1;SH-SY5Y: 71.2
HDC,,ENSG00000140287,Histidine decarboxylase,15,50241947-50266026,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA038891,Approved,,,,,Mixed,Tissue enhanced,,epididymis: 53.2,gallbladder: 17.3,Group enriched,6,HEL: 392.3;HMC-1: 885.1
HDDC3,MGC45386,ENSG00000184508,HD domain containing 3,15,90929964-90932569,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040895,Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,adrenal gland: 16.2,Expressed in all,,
HECTD1,KIAA1131,ENSG00000092148,HECT domain E3 ubiquitin protein ligase 1,14,31100112-31207804,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA002929, HPA054461",Approved,,Supported,Nucleus<br>Nucleoli,Renal cancer:1.20e-6 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 109.5,Expressed in all,,
HECTD2,FLJ37306,ENSG00000165338,HECT domain E3 ubiquitin protein ligase 2,10,91409280-91514829,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037767,Approved,,Approved,Nucleoplasm,Renal cancer:1.67e-5 (unfavourable),Mixed,Mixed,,,prostate: 28.1,Mixed,,
HECTD3,FLJ21156,ENSG00000126107,HECT domain E3 ubiquitin protein ligase 3,1,45002540-45011329,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027467,Approved,,,,"Thyroid cancer:1.85e-6 (favourable), Liver cancer:2.14e-5 (unfavourable)",Expressed in all,Expressed in all,,,"duodenum,parathyroid gland: 47.3",Expressed in all,,
HECW1,"KIAA0322, NEDL1",ENSG00000002746,"HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1",7,43112599-43566001,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007203, HPA007593, HPA007609",Approved,,Supported,Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 10.9;kidney: 8.2,testis: 3.4,Cell line enhanced,,A549: 3.9;U-266/70: 9.1
HECW2,"KIAA1301, NEDL2",ENSG00000138411,"HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2",2,196194370-196593692,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA034609,Uncertain,,Approved,Nucleoli fibrillar center<br>Endoplasmic reticulum,Renal cancer:5.18e-5 (unfavourable),Mixed,Mixed,,,placenta: 15.8,Cell line enhanced,,HDLM-2: 59.6;HUVEC TERT2: 24.5;SCLC-21H: 45.1;TIME: 32.0
HELB,,ENSG00000127311,DNA helicase B,12,66302545-66347645,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Mixed,,,lymph node: 3.5,Mixed,,
HELQ,Hel308,ENSG00000163312,"Helicase, POLQ-like",4,83407343-83455856,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036852, HPA036853",Approved,,Approved,Nucleoplasm<br>Nuclear speckles,"Renal cancer:2.76e-4 (favourable), Pancreatic cancer:9.07e-4 (favourable)",Expressed in all,Mixed,,,adrenal gland: 11.9,Expressed in all,,
HENMT1,"C1orf59, FLJ30525, HEN1",ENSG00000162639,HEN1 methyltransferase homolog 1,1,108648290-108661526,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028464, HPA028497",Uncertain,,Approved,Plasma membrane<br>Focal adhesion sites,"Renal cancer:2.48e-5 (unfavourable), Cervical cancer:2.56e-4 (favourable), Colorectal cancer:9.95e-4 (favourable)",Expressed in all,Tissue enriched,9,testis: 128.3,lymph node: 14.8,Cell line enhanced,,U-937: 75.4
HERC1,"p532, p619",ENSG00000103657,HECT and RLD domain containing E3 ubiquitin protein ligase family member 1,15,63608618-63833942,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA049749,Uncertain,,,,"Renal cancer:1.36e-6 (favourable), Head and neck cancer:4.87e-5 (favourable), Pancreatic cancer:3.66e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 58.6,Expressed in all,,
HERC2,"D15F37S1, jdf2, p528",ENSG00000128731,HECT and RLD domain containing E3 ubiquitin protein ligase 2,15,28111040-28322152,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB017188, HPA048389",Approved,,Approved,Vesicles,Renal cancer:1.41e-7 (favourable),Expressed in all,Mixed,,,parathyroid gland: 12.1,Cell line enhanced,,HEL: 48.6
HERC3,KIAA0032,ENSG00000138641,HECT and RLD domain containing E3 ubiquitin protein ligase 3,4,88521048-88708542,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039170,Approved,,Approved,Cytosol,Renal cancer:5.65e-7 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 61.0,Mixed,,
HERC4,"DKFZP564G092, KIAA1593",ENSG00000148634,HECT and RLD domain containing E3 ubiquitin protein ligase 4,10,67921899-68075348,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA045453, HPA070301",Uncertain,,Supported,Nucleoli fibrillar center<br>Cytosol,Renal cancer:3.86e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 32.5,Expressed in all,,
HERC6,FLJ20637,ENSG00000138642,HECT and RLD domain containing E3 ubiquitin protein ligase family member 6,4,88378739-88443111,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA035846,Uncertain,,Approved,Nucleus<br>Cytosol,Renal cancer:7.14e-5 (favourable),Expressed in all,Expressed in all,,,esophagus: 22.8,Group enriched,5,BJ hTERT+ SV40 Large T+: 108.0;BJ hTERT+ SV40 Large T+ RasG12V: 83.5
HEXA,,ENSG00000213614,Hexosaminidase subunit alpha,15,72340919-72376476,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA054583,Supported,,,,Endometrial cancer:5.63e-8 (favourable),Expressed in all,Expressed in all,,,epididymis: 200.6,Mixed,,
HEXB,,ENSG00000049860,Hexosaminidase subunit beta,5,74640023-74722647,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA055409, HPA056010",Enhanced,,,,Liver cancer:3.36e-8 (unfavourable),Expressed in all,Expressed in all,,,placenta: 440.8,Mixed,,
HEXDC,FLJ23825,ENSG00000169660,Hexosaminidase D,17,82418318-82442645,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA022834, HPA023379, HPA027844",Uncertain,,Approved,Nucleoli fibrillar center<br>Mitochondria,"Urothelial cancer:2.52e-5 (favourable), Head and neck cancer:2.71e-4 (favourable), Pancreatic cancer:5.57e-4 (favourable), Cervical cancer:7.70e-4 (favourable)",Expressed in all,Expressed in all,,,spleen: 24.4,Expressed in all,,
HFM1,"FLJ36760, FLJ39011, MER3, SEC63D1",ENSG00000162669,"HFM1, ATP dependent DNA helicase homolog",1,91260766-91404869,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035036, HPA035557",,,Supported,Golgi apparatus<br>Vesicles,,Tissue enhanced,Tissue enriched,5,testis: 25.0,ovary: 4.7,Cell line enhanced,,AF22: 5.1;AN3-CA: 2.6;K-562: 2.6;SCLC-21H: 2.1;SH-SY5Y: 2.3
HGD,"AKU, HGO",ENSG00000113924,"Homogentisate 1,2-dioxygenase",3,120628173-120682571,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA047374, HPA052359",Enhanced,,Supported,Golgi apparatus,Endometrial cancer:1.78e-4 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 175.8;liver: 324.3,gallbladder: 87.1,Group enriched,10,CACO-2: 38.8;EFO-21: 75.8;Hep G2: 110.3;RPTEC TERT1: 153.1
HGF,"DFNB39, F-TCF, HGFB, HPTA, SF",ENSG00000019991,Hepatocyte growth factor,7,81699006-81770438,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB010333, HPA040360, HPA044088",Approved,,Approved,Centrosome<br>Cytosol,Renal cancer:5.59e-4 (unfavourable),Mixed,Tissue enriched,16,placenta: 438.8,gallbladder: 27.5,Cell line enhanced,,ASC TERT1: 118.1;HHSteC: 111.7;HL-60: 63.0;hTEC/SVTERT24-B: 86.9;Karpas-707: 174.5;U-87 MG: 60.7
HGFAC,"HGFA, HGFAP",ENSG00000109758,HGF activator,4,3441887-3449495,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA058279, HPA059076",Enhanced,,,,Renal cancer:9.31e-4 (unfavourable),Tissue enriched,Tissue enriched,14,liver: 28.6,testis: 2.0,Cell line enriched,6,Hep G2: 3.6
HGSNAT,"FLJ32731, HGNAT, TMEM76",ENSG00000165102,Heparan-alpha-glucosaminide N-acetyltransferase,8,43140455-43202855,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA029578,Approved,,,,"Ovarian cancer:6.33e-5 (favourable), Glioma:7.02e-4 (unfavourable)",Expressed in all,Expressed in all,,,"cervix, uterine: 49.2",Expressed in all,,
HIBADH,NS5ATP1,ENSG00000106049,3-hydroxyisobutyrate dehydrogenase,7,27525442-27662995,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA019522, HPA021002",Enhanced,,,,Renal cancer:5.56e-11 (favourable),Expressed in all,Expressed in all,,,kidney: 113.0,Expressed in all,,
HIBCH,,ENSG00000198130,3-hydroxyisobutyryl-CoA hydrolase,2,190189735-190344193,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036540, HPA036541",Enhanced,,Approved,Nucleoplasm<br>Mitochondria,"Renal cancer:1.04e-10 (favourable), Ovarian cancer:1.22e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 180.6,Expressed in all,,
HIF1AN,"DKFZp762F1811, FIH1, FLJ20615, FLJ22027",ENSG00000166135,Hypoxia inducible factor 1 alpha subunit inhibitor,10,100529072-100559998,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA048742, HPA065302, CAB069903",Enhanced,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 25.7,Expressed in all,,
HIPK1,"KIAA0630, MGC26642, MGC33446, MGC33548, Myak, Nbak2",ENSG00000163349,Homeodomain interacting protein kinase 1,1,113929192-113977869,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA016664,Approved,,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,,Expressed in all,Expressed in all,,,bone marrow: 89.7,Expressed in all,,
HIPK2,,ENSG00000064393,Homeodomain interacting protein kinase 2,7,139561570-139777778,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA007611,Supported,,Supported,Nucleus,Renal cancer:9.99e-4 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 61.3,Cell line enhanced,,HDLM-2: 113.5
HIPK3,"DYRK6, FIST3, PKY, YAK1",ENSG00000110422,Homeodomain interacting protein kinase 3,11,33256672-33357023,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA028069,Approved,,Supported,Nuclear bodies<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 126.8,Expressed in all,,
HIPK4,FLJ32818,ENSG00000160396,Homeodomain interacting protein kinase 4,19,40379271-40390187,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027733,Uncertain,,,,,Not detected,Group enriched,29,cerebral cortex: 4.7;testis: 14.6,endometrium: 0.3,Not detected,,
HK1,,ENSG00000156515,Hexokinase 1,10,69269984-69401882,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA007043, HPA007044, CAB010052, HPA011956",Supported,,Enhanced,Mitochondria,Head and neck cancer:3.39e-6 (unfavourable),Expressed in all,Expressed in all,,,testis: 153.6,Cell line enhanced,,K-562: 491.8
HK2,,ENSG00000159399,Hexokinase 2,2,74833981-74893359,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA028587,Enhanced,,,,"Renal cancer:1.37e-4 (unfavourable), Liver cancer:3.65e-4 (unfavourable)",Expressed in all,Mixed,,,epididymis: 80.4,Cell line enhanced,,U-87 MG: 168.5
HK3,,ENSG00000160883,Hexokinase 3,5,176880869-176899332,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA056743,Enhanced,,,,Renal cancer:3.84e-8 (unfavourable),Mixed,Tissue enhanced,,bone marrow: 87.9,spleen: 27.9,Cell line enhanced,,SCLC-21H: 5.3;THP-1: 2.5;U-937: 16.3
HKDC1,"FLJ22761, FLJ37767",ENSG00000156510,Hexokinase domain containing 1,10,69220303-69267559,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA011956, HPA064198, HPA064230",Approved,,Enhanced,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 53.1;small intestine: 52.3,thyroid gland: 15.2,Group enriched,6,A549: 35.7;CACO-2: 46.7;CAPAN-2: 96.8;EFO-21: 31.5;Hep G2: 22.5;RPTEC TERT1: 61.4
HLCS,HCS,ENSG00000159267,Holocarboxylase synthetase,21,36750888-36990236,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA017379,Approved,,Supported,Cytosol,Breast cancer:7.72e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 33.7,Expressed in all,,
HLTF,"HIP116A, HLTF1, RNF80, SMARCA3, SNF2L3",ENSG00000071794,Helicase like transcription factor,3,149030127-149086554,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA015284, HPA049001",Uncertain,,Enhanced,Nucleus,Liver cancer:7.27e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 83.4,Expressed in all,,
HM13,"dJ324O17.1, H13, IMP1, IMPAS, PSENL3, PSL3, SPP, SPPL1",ENSG00000101294,Histocompatibility minor 13,20,31514428-31577923,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA045089, HPA056062",Approved,,Supported,Endoplasmic reticulum,"Renal cancer:4.64e-12 (unfavourable), Liver cancer:1.95e-5 (unfavourable)",Expressed in all,Expressed in all,,,"cervix, uterine: 154.2",Expressed in all,,
HMBS,"PBGD, PORC, UPS",ENSG00000256269,Hydroxymethylbilane synthase,11,119084866-119093549,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006114, HPA050659",Enhanced,,Approved,Lipid droplets,,Expressed in all,Tissue enriched,5,bone marrow: 52.8,parathyroid gland: 9.8,Expressed in all,,
HMGCL,HL,ENSG00000117305,3-hydroxymethyl-3-methylglutaryl-CoA lyase,1,23801885-23838620,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA004727,Enhanced,,,,"Renal cancer:5.07e-8 (favourable), Colorectal cancer:7.67e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 154.3,Expressed in all,,
HMGCLL1,"bA418P12.1, DKFZP434G1411",ENSG00000146151,3-hydroxymethyl-3-methylglutaryl-CoA lyase like 1,6,55434369-55579214,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 14.5;placenta: 9.0,prostate: 5.2,Cell line enriched,11,SCLC-21H: 7.1
HMGCR,,ENSG00000113161,3-hydroxy-3-methylglutaryl-CoA reductase,5,75336329-75362104,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA008338, CAB016797",Approved,,,,Renal cancer:9.42e-6 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 87.5,Expressed in all,,
HMGCS1,HMGCS,ENSG00000112972,3-hydroxy-3-methylglutaryl-CoA synthase 1,5,43289395-43313512,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB032907, HPA036913, HPA036914",Approved,,Supported,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:3.87e-6 (favourable),Expressed in all,Expressed in all,,,liver: 208.7,Expressed in all,,
HMGCS2,,ENSG00000134240,3-hydroxy-3-methylglutaryl-CoA synthase 2,1,119747996-119768905,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA027423, HPA027442, CAB032906",Enhanced,,Supported,Mitochondria,"Liver cancer:2.43e-7 (favourable), Renal cancer:3.43e-5 (favourable), Ovarian cancer:2.17e-4 (favourable)",Tissue enhanced,Tissue enhanced,,liver: 1270.5,colon: 363.4,Cell line enriched,15,RT4: 161.6
HMOX1,"bK286B10, HO-1",ENSG00000100292,Heme oxygenase 1,22,35380361-35394214,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000635, CAB017444",Enhanced,,Uncertain,Golgi apparatus<br>Plasma membrane,Liver cancer:1.59e-4 (unfavourable),Expressed in all,Expressed in all,,,spleen: 428.5,Cell line enhanced,,BEWO: 701.9;U-138 MG: 414.7;U-87 MG: 399.9
HMOX2,HO-2,ENSG00000103415,Heme oxygenase 2,16,4474690-4510347,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB025464, HPA040611",Supported,,Approved,Vesicles<br>Cytosol,"Renal cancer:8.98e-6 (favourable), Endometrial cancer:7.91e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 97.6,Expressed in all,,
HNMT,,ENSG00000150540,Histamine N-methyltransferase,2,137964020-138016364,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035480, HPA035481",Approved,,,,"Pancreatic cancer:3.41e-4 (unfavourable), Urothelial cancer:4.68e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 124.0,Cell line enhanced,,Hep G2: 152.7;RT4: 91.6
HOGA1,"C10orf65, DHDPS2, DHDPSL, FLJ37472, NPL2",ENSG00000241935,4-hydroxy-2-oxoglutarate aldolase 1,10,97584323-97612802,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA039466,Approved,,,,Renal cancer:9.08e-4 (favourable),Group enriched,Tissue enhanced,,kidney: 53.4;liver: 20.7,heart muscle: 8.5,Cell line enhanced,,EFO-21: 9.0;Hep G2: 17.6;RPTEC TERT1: 23.2
HP,,ENSG00000257017,Haptoglobin,16,72054592-72061055,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB003787, HPA047750",Enhanced,,Approved,Vesicles,Renal cancer:6.94e-13 (unfavourable),Tissue enriched,Tissue enriched,182,liver: 28407.0,bone marrow: 155.8,Cell line enhanced,,Hep G2: 153.5;HSkMC: 88.2
HPD,"4-HPPD, 4HPPD, GLOD3, PPD",ENSG00000158104,4-hydroxyphenylpyruvate dioxygenase,12,121839527-121863596,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038321, HPA038322",Enhanced,,Uncertain,Nuclear speckles,,Tissue enriched,Group enriched,86,kidney: 529.9;liver: 1293.2,seminal vesicle: 10.5,Cell line enriched,24,Hep G2: 349.1
HPGD,SDR36C1,ENSG00000164120,Hydroxyprostaglandin dehydrogenase 15-(NAD),4,174490177-174523154,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004919, HPA005679",Enhanced,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:3.20e-4 (favourable),Tissue enhanced,Tissue enhanced,,urinary bladder: 375.7,stomach: 181.5,Cell line enhanced,,A549: 128.2;HEL: 282.4;RT4: 385.2
HPGDS,"GSTS, GSTS1, GSTS1-1, H-PGDS, PGD2, PGDS",ENSG00000163106,Hematopoietic prostaglandin D synthase,4,94298535-94342876,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA024035,Enhanced,,,,,Mixed,Tissue enhanced,,placenta: 28.1,lung: 14.5,Group enriched,9,HEL: 43.7;HMC-1: 12.2
HPN,TMPRSS1,ENSG00000105707,Hepsin,19,35040506-35066571,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006804,Approved,,,,Renal cancer:5.45e-5 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 99.7;liver: 155.4,prostate: 31.6,Group enriched,7,EFO-21: 29.1;Hep G2: 31.2;T-47d: 20.3
HPR,,ENSG00000261701,Haptoglobin-related protein,16,72063224-72077246,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA047750,Supported,,Approved,Vesicles,,Tissue enriched,Tissue enriched,24,liver: 444.1,heart muscle: 18.7,Cell line enriched,14,Hep G2: 34.3
HPRT1,"HGPRT, HPRT",ENSG00000165704,Hypoxanthine phosphoribosyltransferase 1,X,134460153-134520513,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006360, CAB012200",Enhanced,,Supported,Cytosol,Head and neck cancer:1.35e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 139.1,Mixed,,
HPSE,"HPA, HPSE1, HSE1",ENSG00000173083,Heparanase,4,83292461-83335153,"Enzymes, Predicted secreted proteins",Evidence at protein level,"CAB009813, HPA055344",,,Enhanced,Nucleoplasm<br>Vesicles,,Mixed,Tissue enhanced,,parathyroid gland: 20.0,testis: 10.0,Cell line enhanced,,Karpas-707: 27.7
HS3ST1,3OST1,ENSG00000002587,Heparan sulfate-glucosamine 3-sulfotransferase 1,4,11393150-11429765,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA002237,Approved,,Approved,Vesicles,"Renal cancer:5.99e-8 (favourable), Endometrial cancer:7.73e-4 (favourable), Urothelial cancer:8.67e-4 (favourable)",Mixed,Tissue enhanced,,gallbladder: 13.9;ovary: 23.2,urinary bladder: 5.6,Cell line enhanced,,CAPAN-2: 12.2;RPTEC TERT1: 9.1;RT4: 8.0;SCLC-21H: 4.3
HS3ST2,3OST2,ENSG00000122254,Heparan sulfate-glucosamine 3-sulfotransferase 2,16,22814177-22916338,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA017736,Approved,,,,"Renal cancer:1.35e-4 (favourable), Glioma:2.22e-4 (unfavourable)",Mixed,Tissue enriched,30,cerebral cortex: 35.7,lung: 1.1,Group enriched,7,HaCaT: 8.5;SH-SY5Y: 17.7
HS3ST3A1,"30ST3A1, 3OST3A1",ENSG00000153976,Heparan sulfate-glucosamine 3-sulfotransferase 3A1,17,13495689-13601927,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA062518, HPA071530",Uncertain,,Approved,Microtubules,,Mixed,Tissue enhanced,,spleen: 9.1,seminal vesicle: 6.8,Cell line enhanced,,PC-3: 40.6;U-251 MG: 103.1;U-87 MG: 72.4
HS3ST3B1,"30ST3B1, 3OST3B1",ENSG00000125430,Heparan sulfate-glucosamine 3-sulfotransferase 3B1,17,14301083-14349404,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA064126,,,Approved,Vesicles,,Mixed,Tissue enhanced,,liver: 14.7,lymph node: 7.1,Cell line enhanced,,AF22: 20.5;BEWO: 14.3;HSkMC: 14.6;U-251 MG: 16.3
HS3ST4,3OST4,ENSG00000182601,Heparan sulfate-glucosamine 3-sulfotransferase 4,16,25692026-26137688,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enriched,7,cerebral cortex: 18.7,breast: 2.8,Cell line enhanced,,NTERA-2: 1.4
HS3ST5,3-OST-5,ENSG00000249853,Heparan sulfate-glucosamine 3-sulfotransferase 5,6,114055586-114343045,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021823, HPA064677",Approved,,,,,Not detected,Group enriched,5,cerebral cortex: 6.2;seminal vesicle: 2.2;skeletal muscle: 1.3,adrenal gland: 0.6,Cell line enhanced,,PC-3: 4.2;RT4: 6.8;SCLC-21H: 19.0
HS3ST6,HS3ST5,ENSG00000162040,Heparan sulfate-glucosamine 3-sulfotransferase 6,16,1911463-1918440,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Cervical cancer:3.73e-4 (favourable),Tissue enhanced,Tissue enriched,10,skin: 9.5,fallopian tube: 0.9,Not detected,,
HSD11B1,"HSD11, HSD11B, SDR26C1",ENSG00000117594,Hydroxysteroid 11-beta dehydrogenase 1,1,209686178-209734950,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA047729,Enhanced,,,,Renal cancer:1.97e-10 (unfavourable),Tissue enriched,Group enriched,9,liver: 492.5;placenta: 105.1,ovary: 31.6,Group enriched,6,ASC diff: 678.2;HHSteC: 173.0
HSD17B1,"EDH17B2, EDHB17, HSD17, MGC138140, SDR28C1",ENSG00000108786,Hydroxysteroid 17-beta dehydrogenase 1,17,42549214-42555213,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021032, HPA065296",Enhanced,,Supported,Cytosol,,Mixed,Tissue enriched,14,placenta: 98.3,cerebral cortex: 7.1,Cell line enriched,8,BEWO: 331.8
HSD17B10,"17b-HSD10, ABAD, CAMR, ERAB, HADH2, MHBD, MRPP2, MRXS10, SDR5C1",ENSG00000072506,Hydroxysteroid 17-beta dehydrogenase 10,X,53431258-53434373,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA001432,Approved,,,,Cervical cancer:2.80e-4 (favourable),Expressed in all,Expressed in all,,,liver: 126.6,Expressed in all,,
HSD17B11,"17-BETA-HSD11, 17-BETA-HSDXI, DHRS8, PAN1B, RetSDR2, SDR16C2",ENSG00000198189,Hydroxysteroid 17-beta dehydrogenase 11,4,87336610-87391386,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA021608,Approved,,Supported,Lipid droplets,,Expressed in all,Expressed in all,,,small intestine: 295.2,Cell line enhanced,,CAPAN-2: 236.8
HSD17B12,"KAR, SDR12C1",ENSG00000149084,Hydroxysteroid 17-beta dehydrogenase 12,11,43680558-43856617,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA016427,Approved,,,,"Renal cancer:2.10e-8 (favourable), Liver cancer:2.76e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 196.5,Expressed in all,,
HSD17B2,"HSD17, SDR9C2",ENSG00000086696,Hydroxysteroid 17-beta dehydrogenase 2,16,82035004-82098534,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA021826, HPA050235",Enhanced,,Approved,Endoplasmic reticulum,Urothelial cancer:3.83e-4 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 430.9;placenta: 552.6,small intestine: 199.4,Cell line enhanced,,BJ hTERT+: 47.0;Hep G2: 32.2;RT4: 77.0;TIME: 44.0
HSD17B3,SDR12C2,ENSG00000130948,Hydroxysteroid 17-beta dehydrogenase 3,9,96235306-96302152,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA056833,Enhanced,,Supported,Vesicles,,Mixed,Tissue enriched,15,testis: 74.9,thyroid gland: 4.8,Cell line enhanced,,HBEC3-KT: 2.6;HEL: 3.2;U-2 OS: 5.8
HSD17B4,"DBP, MFE-2, SDR8C1",ENSG00000133835,Hydroxysteroid 17-beta dehydrogenase 4,5,119452443-119637199,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021302, HPA021311, HPA021479",Enhanced,,Enhanced,Peroxisomes,"Renal cancer:6.31e-6 (favourable), Colorectal cancer:1.33e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 229.7,Expressed in all,,
HSD17B6,"HSE, RODH, SDR9C6",ENSG00000025423,Hydroxysteroid 17-beta dehydrogenase 6,12,56752161-56787790,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA059141,Enhanced,,Approved,Nucleus<br>Vesicles,Liver cancer:6.32e-4 (favourable),Tissue enriched,Tissue enriched,10,liver: 930.6,seminal vesicle: 96.0,Cell line enhanced,,SCLC-21H: 12.9
HSD17B7,"PRAP, SDR37C1",ENSG00000132196,Hydroxysteroid 17-beta dehydrogenase 7,1,162790702-162812817,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA047496,Approved,,,,Renal cancer:8.47e-5 (unfavourable),Expressed in all,Mixed,,,liver: 16.9,Expressed in all,,
HSD17B8,"D6S2245E, FABGL, H2-KE6, HKE6, KE6, RING2, SDR30C1",ENSG00000204228,Hydroxysteroid 17-beta dehydrogenase 8,6,33204642-33206831,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA042132,Enhanced,,,,"Renal cancer:2.18e-12 (favourable), Liver cancer:1.90e-5 (favourable), Breast cancer:9.99e-4 (favourable)",Expressed in all,Mixed,,,parathyroid gland: 9.9,Cell line enhanced,,RPMI-8226: 11.7;T-47d: 9.9;U-266/70: 12.1
HSD3B1,"HSD3B, HSDB3, SDR11E1",ENSG00000203857,"Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1",1,119507198-119515054,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043261, HPA043264, HPA044028",Supported,,,,Urothelial cancer:4.59e-5 (favourable),Tissue enhanced,Tissue enriched,13,placenta: 110.5,small intestine: 8.7,Cell line enriched,7,CACO-2: 52.9
HSD3B2,SDR11E2,ENSG00000203859,"Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2",1,119414931-119423035,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043261, HPA043264, HPA044028",Supported,,,,,Tissue enhanced,Tissue enriched,433,adrenal gland: 2384.5,testis: 5.5,Cell line enhanced,,SK-MEL-30: 1.2
HSD3B7,"C(27)-3BETA-HSD, SDR11E3",ENSG00000099377,"Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7",16,30985207-30989152,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA050521, HPA060847",Uncertain,,Supported,Lipid droplets,"Renal cancer:1.60e-6 (unfavourable), Colorectal cancer:5.95e-4 (unfavourable)",Expressed in all,Expressed in all,,,liver: 21.9,Cell line enhanced,,HDLM-2: 83.9;HMC-1: 85.9;U-2197: 89.0
HSPD1,"GroEL, HSP60, SPG13",ENSG00000144381,Heat shock protein family D (Hsp60) member 1,2,197486581-197516737,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001523, CAB002775, HPA050025, CAB072816",Supported,,Enhanced,Mitochondria,"Endometrial cancer:1.61e-4 (unfavourable), Liver cancer:2.25e-4 (unfavourable)",Expressed in all,Expressed in all,,,adrenal gland: 834.1,Expressed in all,,
HTRA1,"ARMD7, HtrA, IGFBP5-protease, PRSS11",ENSG00000166033,HtrA serine peptidase 1,10,122461525-122514908,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA036655,Enhanced,,Supported,Plasma membrane,"Renal cancer:7.90e-7 (unfavourable), Urothelial cancer:5.62e-6 (unfavourable), Glioma:8.66e-4 (unfavourable)",Expressed in all,Mixed,,,ovary: 503.4,Cell line enhanced,,ASC diff: 1649.0;HSkMC: 1139.5;LHCN-M2: 1027.1;U-87 MG: 974.2
HTRA2,"OMI, PARK13, PRSS25",ENSG00000115317,HtrA serine peptidase 2,2,74529377-74533348,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"CAB004004, HPA006602, HPA027366",Uncertain,,Supported,Mitochondria,Liver cancer:7.77e-8 (unfavourable),Expressed in all,Mixed,,,spleen: 9.0,Expressed in all,,
HTRA3,"Prsp, Tasp",ENSG00000170801,HtrA serine peptidase 3,4,8269765-8307111,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA021187, HPA063810",Approved,,Approved,Vesicles,"Renal cancer:1.61e-9 (unfavourable), Thyroid cancer:1.29e-4 (unfavourable)",Expressed in all,Mixed,,,ovary: 60.9,Cell line enriched,6,U-2197: 168.9
HTRA4,FLJ90724,ENSG00000169495,HtrA serine peptidase 4,8,38974164-38988662,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA045402,Enhanced,,,,,Tissue enhanced,Tissue enriched,20,placenta: 94.9,bone marrow: 4.7,Cell line enriched,160,BEWO: 219.1
HUNK,,ENSG00000142149,Hormonally up-regulated Neu-associated kinase,21,31873315-32044633,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027295, HPA027372",Approved,,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:7.48e-5 (favourable),Mixed,Mixed,,,placenta: 6.8,Cell line enhanced,,AF22: 13.3;BEWO: 15.9;RH-30: 17.7;SCLC-21H: 17.5;SiHa: 14.1
HUWE1,"Ib772, KIAA0312, UREB1",ENSG00000086758,"HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase",X,53532096-53686729,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA002548, CAB022718",Approved,,Enhanced,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 96.6,Expressed in all,,
HYAL1,"FUS2, HYAL-1, LUCA1, NAT6",ENSG00000114378,Hyaluronoglucosaminidase 1,3,50299889-50312381,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA002112,Uncertain,,,,"Renal cancer:1.56e-11 (favourable), Colorectal cancer:2.07e-4 (favourable)",Expressed in all,Tissue enhanced,,liver: 71.1;spleen: 69.3,kidney: 43.5,Cell line enhanced,,Hep G2: 66.6;SK-BR-3: 20.5
HYAL2,"LuCa-2, LUCA2",ENSG00000068001,Hyaluronoglucosaminidase 2,3,50317790-50322906,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA036436,Uncertain,,,,,Expressed in all,Expressed in all,,,spleen: 214.2,Expressed in all,,
HYAL3,"LUCA-3, LUCA14, Minna14",ENSG00000186792,Hyaluronoglucosaminidase 3,3,50292831-50299468,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049402,Uncertain,,,,Urothelial cancer:2.12e-5 (unfavourable),Expressed in all,Tissue enhanced,,bone marrow: 22.7,testis: 14.0,Expressed in all,,
HYAL4,,ENSG00000106302,Hyaluronoglucosaminidase 4,7,123828983-123877478,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029453,Uncertain,,,,,Tissue enriched,Tissue enhanced,,placenta: 5.9;testis: 4.0,"skin,spleen: 1.1",Cell line enhanced,,BEWO: 3.5;CAPAN-2: 5.2;RT4: 11.2
HYI,HT036,ENSG00000178922,Hydroxypyruvate isomerase (putative),1,43451003-43453989,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040092,Uncertain,,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Urothelial cancer:2.72e-5 (favourable), Renal cancer:2.75e-5 (unfavourable), Colorectal cancer:4.96e-4 (unfavourable), Liver cancer:5.55e-4 (unfavourable), Breast cancer:9.18e-4 (favourable)",Expressed in all,Expressed in all,,,seminal vesicle: 81.4,Mixed,,
HYKK,"AGPHD1, LOC123688",ENSG00000188266,Hydroxylysine kinase,15,78507564-78537372,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040706,Approved,,Approved,Vesicles<br>Aggresome,,Mixed,Mixed,,,kidney: 12.5,Cell line enhanced,,HEK 293: 20.5
IARS,"IARS1, ILRS",ENSG00000196305,Isoleucyl-tRNA synthetase,9,92210207-92293756,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA029806,Approved,,Supported,Cytosol,Liver cancer:4.98e-7 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 141.8,Expressed in all,,
IARS2,FLJ10326,ENSG00000067704,"Isoleucyl-tRNA synthetase 2, mitochondrial",1,220094102-220148041,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA024212, HPA024594, HPA024596",Enhanced,,Enhanced,Mitochondria,"Pancreatic cancer:9.24e-5 (unfavourable), Cervical cancer:1.04e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 144.3,Expressed in all,,
ICK,"KIAA0936, LCK2, MGC46090, MRK",ENSG00000112144,Intestinal cell kinase,6,53001279-53061802,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000791, HPA001113",Approved,,Approved,Nucleoli fibrillar center,,Expressed in all,Mixed,,,adrenal gland: 23.1,Expressed in all,,
ICMT,"HSTE14, PCCMT, PPMT",ENSG00000116237,Isoprenylcysteine carboxyl methyltransferase,1,6221193-6235972,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA032024, HPA032025",Uncertain,,,,Liver cancer:1.79e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 45.1,Expressed in all,,
IDE,,ENSG00000119912,Insulin degrading enzyme,10,92451684-92574076,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA063478,Approved,,,,"Endometrial cancer:3.53e-4 (favourable), Colorectal cancer:3.69e-4 (favourable)",Expressed in all,Expressed in all,,,skin: 63.4,Expressed in all,,
IDH1,,ENSG00000138413,"Isocitrate dehydrogenase (NADP(+)) 1, cytosolic",2,208236227-208266074,"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB033218, HPA035248, HPA057936, CAB062556",Enhanced,,Approved,Nuclear bodies<br>Cytosol,"Renal cancer:2.45e-5 (unfavourable), Liver cancer:6.93e-5 (unfavourable)",Expressed in all,Expressed in all,,,prostate: 338.1,Expressed in all,,
IDH2,,ENSG00000182054,"Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial",15,90083045-90102504,"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007831,Enhanced,,Supported,Mitochondria,Cervical cancer:5.15e-5 (favourable),Expressed in all,Expressed in all,,,skeletal muscle: 450.0,Expressed in all,,
IDH3A,,ENSG00000166411,Isocitrate dehydrogenase 3 (NAD(+)) alpha,15,78131498-78171949,"Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041465, HPA062971",Supported,,Enhanced,Mitochondria,Renal cancer:6.49e-8 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 44.1,Expressed in all,,
IDH3B,RP46,ENSG00000101365,Isocitrate dehydrogenase 3 (NAD(+)) beta,20,2658395-2664219,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA049387, HPA054180",Enhanced,,Enhanced,Mitochondria,"Renal cancer:6.78e-8 (favourable), Liver cancer:1.59e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 100.5,Expressed in all,,
IDH3G,,ENSG00000067829,Isocitrate dehydrogenase 3 (NAD(+)) gamma,X,153785766-153794523,"Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000425, HPA002017",Enhanced,,Enhanced,Mitochondria,Renal cancer:5.73e-6 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 64.9,Expressed in all,,
IDI1,,ENSG00000067064,Isopentenyl-diphosphate delta isomerase 1,10,1039908-1049170,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039169,Approved,,,,Renal cancer:1.46e-4 (favourable),Expressed in all,Expressed in all,,,breast: 244.8,Expressed in all,,
IDI2,IPPI2,ENSG00000148377,Isopentenyl-diphosphate delta isomerase 2,10,1018907-1025859,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,41,skeletal muscle: 76.3,heart muscle: 1.8,Not detected,,
IDNK,"bA522I20.2, C9orf103, hGntK",ENSG00000148057,"IDNK, gluconokinase",9,83623049-83644130,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA020378, HPA058429",Enhanced,,Approved,Mitochondria<br>Cytosol,Endometrial cancer:1.10e-6 (favourable),Expressed in all,Mixed,,,kidney: 50.5,Mixed,,
IDO1,"IDO, INDO",ENSG00000131203,"Indoleamine 2,3-dioxygenase 1",8,39902275-39928444,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA023072, HPA023149, HPA027772, CAB072820",Enhanced,,,,"Renal cancer:1.12e-7 (unfavourable), Ovarian cancer:3.32e-4 (favourable), Melanoma:5.27e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 149.4,lymph node: 57.3,Cell line enriched,7,EFO-21: 54.8
IDS,SIDS,ENSG00000010404,Iduronate 2-sulfatase,X,149476990-149521096,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enriched,5,cerebral cortex: 435.8,epididymis: 86.8,Expressed in all,,
IDUA,MPS1,ENSG00000127415,"Iduronidase, alpha-L-",4,986997-1004506,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025901, HPA046979, HPA054254",Enhanced,,Supported,Vesicles,"Renal cancer:7.87e-5 (unfavourable), Urothelial cancer:8.04e-5 (favourable), Colorectal cancer:3.13e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 16.5,Cell line enhanced,,U-266/70: 43.1
IFIH1,"Hlcd, IDDM19, MDA-5, MDA5",ENSG00000115267,Interferon induced with helicase C domain 1,2,162267079-162318703,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002656,Approved,,,,,Expressed in all,Mixed,,,spleen: 31.1,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 72.5;BJ hTERT+ SV40 Large T+ RasG12V: 93.7
IGF1R,"CD221, IGFIR, IGFR, JTK13, MGC18216",ENSG00000140443,Insulin like growth factor 1 receptor,15,98648971-98964530,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,"CAB010268, HPA045563",Uncertain,,Uncertain,Vesicles,Renal cancer:3.75e-7 (favourable),Expressed in all,Mixed,,,prostate: 25.0,Mixed,,
IGHMBP2,"CATF1, CMT2S, HCSA, HMN6, SMARD1, SMUBP2, ZFAND7",ENSG00000132740,Immunoglobulin mu binding protein 2,11,68903842-68940602,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA060994,,,Approved,Nucleus,"Renal cancer:1.29e-8 (unfavourable), Pancreatic cancer:5.89e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 27.9,Expressed in all,,
IKBKB,"IKK-beta, IKK2, IKKB, NFKBIKB",ENSG00000104365,Inhibitor of nuclear factor kappa B kinase subunit beta,8,42271302-42332653,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA001249, CAB004447",Enhanced,,Approved,Cytosol,Urothelial cancer:1.46e-6 (favourable),Expressed in all,Mixed,,,parathyroid gland: 18.7,Expressed in all,,
IKBKE,"IKK-i, IKKE, KIAA0151",ENSG00000263528,Inhibitor of nuclear factor kappa B kinase subunit epsilon,1,206470476-206496889,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA015788, CAB025983",Approved,,Supported,Cytosol,Renal cancer:5.34e-7 (unfavourable),Expressed in all,Mixed,,,lymph node: 27.4,Mixed,,
IL4I1,FIG1,ENSG00000104951,Interleukin 4 induced 1,19,49889654-49929539,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA045598,Enhanced,,,,"Renal cancer:1.23e-10 (unfavourable), Glioma:1.85e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 24.5;testis: 32.0,lymph node: 10.5,Cell line enhanced,,EFO-21: 31.1;HDLM-2: 55.9;Karpas-707: 33.8
ILK,,ENSG00000166333,Integrin linked kinase,11,6603708-6610874,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004041, HPA048437",Enhanced,,Enhanced,Cell Junctions<br>Focal adhesion sites,Renal cancer:2.44e-4 (favourable),Expressed in all,Expressed in all,,,seminal vesicle: 558.8,Expressed in all,,
ILKAP,"DKFZP434J2031, FLJ10181, PPM1O",ENSG00000132323,ILK associated serine/threonine phosphatase,2,238170401-238203729,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA004752, HPA056099",Uncertain,,Approved,Nucleoplasm,"Renal cancer:9.89e-6 (unfavourable), Liver cancer:1.04e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 28.0,Expressed in all,,
IMMP1L,"FLJ25059, IMMP1",ENSG00000148950,Inner mitochondrial membrane peptidase subunit 1,11,31432401-31509645,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA058308,Approved,,,,"Pancreatic cancer:6.72e-4 (favourable), Liver cancer:7.97e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 39.2,Expressed in all,,
IMMP2L,"IMMP2L-IT1, IMP2",ENSG00000184903,Inner mitochondrial membrane peptidase subunit 2,7,110663051-111562517,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA026711,Approved,,Approved,Mitochondria,Head and neck cancer:1.89e-5 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 39.4,Expressed in all,,
IMPA1,IMPA,ENSG00000133731,Inositol monophosphatase 1,8,81657961-81686693,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA037489,Approved,,Approved,Nucleoplasm<br>Mitochondria,,Expressed in all,Expressed in all,,,testis: 72.0,Expressed in all,,
IMPA2,,ENSG00000141401,Inositol monophosphatase 2,18,11981025-12030883,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA029561,Approved,,Approved,Nucleoplasm<br>Mitochondria,Renal cancer:0.00e+0 (favourable),Expressed in all,Expressed in all,,,skin: 129.8,Cell line enhanced,,BEWO: 240.8;SiHa: 163.4
IMPAD1,"FLJ20421, gPAPP, IMPA3",ENSG00000104331,Inositol monophosphatase domain containing 1,8,56957933-56993844,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA009411,Supported,,Supported,Nucleus<br>Golgi apparatus<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 52.7,Expressed in all,,
IMPDH1,"LCA11, RP10, sWSS2608",ENSG00000106348,Inosine monophosphate dehydrogenase 1,7,128392277-128410252,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA001400,Approved,,Supported,Cytosol<br>Rods & Rings,"Renal cancer:1.78e-12 (unfavourable), Liver cancer:1.12e-7 (unfavourable), Urothelial cancer:3.72e-5 (unfavourable), Glioma:1.17e-4 (unfavourable), Cervical cancer:3.87e-4 (unfavourable)",Expressed in all,Expressed in all,,,adipose tissue: 47.2,Expressed in all,,
IMPDH2,,ENSG00000178035,Inosine monophosphate dehydrogenase 2,3,49024325-49029408,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001400, CAB020717",Approved,,Enhanced,Cytosol<br>Rods & Rings,Liver cancer:3.22e-4 (unfavourable),Expressed in all,Expressed in all,,,ovary: 422.5,Expressed in all,,
INMT,,ENSG00000241644,Indolethylamine N-methyltransferase,7,30697985-30757602,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA061343,,,Approved,Golgi apparatus<br>Vesicles,Liver cancer:5.72e-4 (favourable),Tissue enhanced,Tissue enhanced,,lung: 144.8,seminal vesicle: 66.2,Group enriched,6,CACO-2: 13.8;HHSteC: 5.7
INO80,"hINO80, Ino80, INO80A, INOC1, KIAA1259",ENSG00000128908,INO80 complex subunit,15,40978880-41116354,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041417, HPA041484",,,Enhanced,Nucleoplasm<br>Nuclear bodies,Renal cancer:6.30e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 18.2,Expressed in all,,
INPP1,,ENSG00000151689,Inositol polyphosphate-1-phosphatase,2,190343470-190371665,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036698, HPA036699",Supported,,Approved,Vesicles,"Thyroid cancer:1.12e-5 (favourable), Urothelial cancer:5.70e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 73.6,Mixed,,
INPP4A,INPP4,ENSG00000040933,Inositol polyphosphate-4-phosphatase type I A,2,98444854-98594390,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA001628,Approved,,Approved,Nucleus<br>Nuclear membrane,Endometrial cancer:3.70e-6 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 38.7,Expressed in all,,
INPP4B,,ENSG00000109452,Inositol polyphosphate-4-phosphatase type II B,4,142023160-142847432,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA037681, HPA037682",Approved,,Approved,Centrosome,Pancreatic cancer:1.03e-4 (unfavourable),Mixed,Mixed,,,testis: 33.2,Cell line enhanced,,CAPAN-2: 132.1
INPP5A,5PTASE,ENSG00000068383,Inositol polyphosphate-5-phosphatase A,10,132537820-132783480,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA012285, HPA066549",Enhanced,,Approved,Cytosol,"Renal cancer:3.15e-4 (favourable), Breast cancer:7.47e-4 (unfavourable)",Expressed in all,Expressed in all,,,smooth muscle: 60.9,Expressed in all,,
INPP5B,,ENSG00000204084,Inositol polyphosphate-5-phosphatase B,1,37860697-37947057,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028803,Approved,,Approved,Cytosol,"Renal cancer:6.11e-5 (unfavourable), Head and neck cancer:1.11e-4 (favourable), Pancreatic cancer:5.33e-4 (favourable)",Expressed in all,Expressed in all,,,ovary: 26.3,Expressed in all,,
INPP5D,"hp51CN, SHIP, SHIP1",ENSG00000168918,Inositol polyphosphate-5-phosphatase D,2,233059967-233207903,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB016300, HPA070455",Uncertain,,Approved,Cytosol,Head and neck cancer:2.03e-5 (favourable),Expressed in all,Mixed,,,lymph node: 39.3,Cell line enhanced,,HEL: 84.8;HMC-1: 83.7;hTCEpi: 63.0;NB-4: 56.4
INPP5E,"CORS1, JBTS1, pharbin, PPI5PIV",ENSG00000148384,Inositol polyphosphate-5-phosphatase E,9,136428619-136439823,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA065758,Approved,,,,Pancreatic cancer:1.82e-4 (favourable),Expressed in all,Expressed in all,,,testis: 15.9,Expressed in all,,
INPP5F,"hSac2, KIAA0966, SAC2",ENSG00000198825,Inositol polyphosphate-5-phosphatase F,10,119726097-119829278,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Expressed in all,Expressed in all,,,cerebral cortex: 132.0,Expressed in all,,
INPP5J,"INPP5, PIB5PA, PIPP",ENSG00000185133,Inositol polyphosphate-5-phosphatase J,22,31122731-31134696,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA034539,,,Approved,Nucleoli<br>Cytosol,"Renal cancer:1.12e-7 (favourable), Lung cancer:1.47e-5 (favourable)",Tissue enriched,Group enriched,10,parathyroid gland: 215.4;thyroid gland: 242.1,small intestine: 22.4,Cell line enhanced,,HL-60: 15.5;SK-BR-3: 30.3;T-47d: 24.0
INPP5K,SKIP,ENSG00000132376,Inositol polyphosphate-5-phosphatase K,17,1494571-1516888,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031044,Uncertain,,,,"Pancreatic cancer:1.47e-6 (favourable), Endometrial cancer:2.33e-5 (favourable), Cervical cancer:3.91e-4 (favourable)",Expressed in all,Expressed in all,,,adipose tissue: 32.2,Expressed in all,,
INPPL1,SHIP2,ENSG00000165458,Inositol polyphosphate phosphatase like 1,11,72223701-72239105,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA037601,Approved,,Supported,Golgi apparatus<br>Cytosol,Liver cancer:7.37e-4 (unfavourable),Expressed in all,Expressed in all,,,spleen: 64.3,Expressed in all,,
INSR,CD220,ENSG00000171105,Insulin receptor,19,7112255-7294034,"CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,"HPA036302, HPA036303",Uncertain,,Approved,Vesicles,,Expressed in all,Expressed in all,,,ovary: 35.5,Cell line enhanced,,Karpas-707: 42.9
INSRR,IRR,ENSG00000027644,Insulin receptor related receptor,1,156840063-156859018,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA025285,Uncertain,,,,,Not detected,Tissue enhanced,,adrenal gland: 1.8;kidney: 1.4;testis: 2.2,prostate: 0.6,Group enriched,10,SCLC-21H: 5.5;SH-SY5Y: 17.2
IP6K1,"IHPK1, KIAA0263",ENSG00000176095,Inositol hexakisphosphate kinase 1,3,49724294-49786542,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040825,Approved,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Cytosol,"Renal cancer:5.77e-5 (favourable), Head and neck cancer:2.08e-4 (favourable), Pancreatic cancer:6.85e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 47.5,Expressed in all,,
IP6K2,IHPK2,ENSG00000068745,Inositol hexakisphosphate kinase 2,3,48688003-48740353,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007532, HPA070811",Approved,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions,"Breast cancer:1.25e-4 (favourable), Urothelial cancer:1.83e-4 (favourable), Lung cancer:2.95e-4 (favourable)",Expressed in all,Expressed in all,,,epididymis: 131.1,Expressed in all,,
IP6K3,"IHPK3, INSP6K3",ENSG00000161896,Inositol hexakisphosphate kinase 3,6,33721670-33746905,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA053644,Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:6.09e-4 (unfavourable),Mixed,Tissue enhanced,,skeletal muscle: 32.4;thyroid gland: 21.9,heart muscle: 9.1,Cell line enhanced,,HHSteC: 18.4;LHCN-M2: 30.1;RH-30: 15.3
IPMK,,ENSG00000151151,Inositol polyphosphate multikinase,10,58191517-58267934,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037837, HPA057542",Uncertain,,Enhanced,Nucleus,Renal cancer:9.96e-7 (unfavourable),Expressed in all,Mixed,,,parathyroid gland: 28.3,Mixed,,
IPPK,"C9orf12, FLJ13163, INSP5K2, IP5K, IPK1",ENSG00000127080,Inositol-pentakisphosphate 2-kinase,9,92613184-92670265,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA020603,Uncertain,,Approved,Cytosol,Urothelial cancer:1.28e-4 (unfavourable),Mixed,Mixed,,,skin: 34.2,Expressed in all,,
IRAK1,"IRAK, pelle",ENSG00000184216,Interleukin 1 receptor associated kinase 1,X,154010500-154019980,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004461, HPA054476",Supported,,Supported,Nucleus<br>Cytosol,"Renal cancer:2.06e-4 (unfavourable), Liver cancer:3.03e-4 (unfavourable)",Expressed in all,Expressed in all,,,appendix: 51.0,Expressed in all,,
IRAK2,,ENSG00000134070,Interleukin 1 receptor associated kinase 2,3,10164865-10243743,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB013483, HPA050520",Uncertain,,Approved,Vesicles,"Urothelial cancer:6.60e-5 (favourable), Pancreatic cancer:2.26e-4 (unfavourable), Liver cancer:8.35e-4 (unfavourable)",Expressed in all,Mixed,,,bone marrow: 14.6,Cell line enhanced,,BEWO: 31.5;BJ hTERT+: 28.0;CAPAN-2: 30.8;RT4: 38.6
IRAK3,IRAK-M,ENSG00000090376,Interleukin 1 receptor associated kinase 3,12,66188879-66254622,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA043097,Approved,,Approved,Vesicles,Renal cancer:6.23e-4 (unfavourable),Mixed,Tissue enhanced,,bone marrow: 51.0,adipose tissue: 19.3,Cell line enhanced,,HEL: 20.3;HL-60: 24.1;THP-1: 24.3;U-937: 20.5
IRAK4,NY-REN-64,ENSG00000198001,Interleukin 1 receptor associated kinase 4,12,43758944-43789543,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB016685, CAB022077",Uncertain,,Approved,Nucleoli<br>Microtubules<br>Cytosol,"Endometrial cancer:3.46e-5 (favourable), Urothelial cancer:4.42e-5 (favourable)",Expressed in all,Mixed,,,lymph node: 20.3,Expressed in all,,
IRF2BP1,"DKFZP434M154, IRF-2BP1",ENSG00000170604,Interferon regulatory factor 2 binding protein 1,19,45883607-45886170,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042164, HPA049480",Approved,,Supported,Nucleoplasm,"Renal cancer:3.85e-5 (favourable), Pancreatic cancer:2.32e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 13.2,Expressed in all,,
ISG20,"CD25, HEM45",ENSG00000172183,Interferon stimulated exonuclease gene 20,15,88636153-88656483,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:4.86e-8 (unfavourable), Ovarian cancer:1.85e-5 (favourable), Glioma:3.12e-5 (unfavourable)",Expressed in all,Tissue enhanced,,lymph node: 221.4,spleen: 136.2,Cell line enhanced,,Daudi: 151.0;SK-MEL-30: 543.4
ISYNA1,"Ino1, INOS, IPS",ENSG00000105655,Inositol-3-phosphate synthase 1,19,18434388-18438301,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007931, HPA008232, CAB020720",Enhanced,,Approved,Nucleus<br>Cytosol,Renal cancer:9.23e-4 (unfavourable),Expressed in all,Tissue enhanced,,testis: 117.3,placenta: 63.8,Cell line enhanced,,BEWO: 475.1
ITCH,AIP4,ENSG00000078747,Itchy E3 ubiquitin protein ligase,20,34363235-34511393,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021126, HPA049032",Supported,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,testis: 73.2,Expressed in all,,
ITK,"EMT, LYK, PSCTK2",ENSG00000113263,IL2 inducible T-cell kinase,5,157142933-157255191,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,appendix: 20.2;lymph node: 33.2;tonsil: 22.3,spleen: 14.0,Cell line enhanced,,HDLM-2: 3.2;HEL: 3.4;HMC-1: 3.8;MOLT-4: 18.7
ITPA,"C20orf37, dJ794I6.3, HLC14-06-P",ENSG00000125877,Inosine triphosphatase,20,3208868-3223870,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA022824,Approved,,Supported,Cytosol,Liver cancer:2.54e-5 (unfavourable),Expressed in all,Expressed in all,,,fallopian tube: 40.3,Expressed in all,,
ITPK1,,ENSG00000100605,Inositol-tetrakisphosphate 1-kinase,14,92936914-93116320,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA055230,Approved,,Approved,Mitochondria,Endometrial cancer:8.56e-4 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 93.1,Expressed in all,,
ITPKA,"IP3-3KA, IP3KA",ENSG00000137825,Inositol-trisphosphate 3-kinase A,15,41493393-41503551,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040454,Enhanced,Approved,Approved,Vesicles,"Renal cancer:3.76e-9 (unfavourable), Glioma:5.08e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 25.7;duodenum: 17.7;small intestine: 19.8,stomach: 8.9,Cell line enhanced,,Hep G2: 22.6
ITPKB,"IP3-3KB, IP3KB",ENSG00000143772,Inositol-trisphosphate 3-kinase B,1,226631690-226739323,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030273, HPA072923",Uncertain,,Approved,Nucleus,"Head and neck cancer:1.72e-5 (favourable), Lung cancer:6.65e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 61.6,Cell line enhanced,,SK-MEL-30: 36.3
ITPKC,"IP3-3KC, IP3KC",ENSG00000086544,Inositol-trisphosphate 3-kinase C,19,40717103-40740860,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA050760, HPA053003",Approved,,Supported,Nuclear speckles,Lung cancer:4.91e-4 (unfavourable),Expressed in all,Expressed in all,,,esophagus: 69.3,Mixed,,
IVD,ACAD2,ENSG00000128928,Isovaleryl-CoA dehydrogenase,15,40405795-40435947,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA041391, HPA044250",Enhanced,,Enhanced,Nucleoplasm<br>Mitochondria,"Renal cancer:2.91e-9 (favourable), Liver cancer:1.95e-5 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 151.7,Mixed,,
IYD,"C6orf71, DEHAL1, dJ422F24.1",ENSG00000009765,Iodotyrosine deiodinase,6,150368892-150405969,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA059627,Enhanced,,Supported,Plasma membrane,Liver cancer:6.22e-4 (favourable),Tissue enriched,Tissue enriched,28,thyroid gland: 794.5,kidney: 27.9,Cell line enhanced,,CACO-2: 1.1;SK-BR-3: 2.4
JADE2,"JADE-2, KIAA0239, PHF15",ENSG00000043143,Jade family PHD finger 2,5,134524312-134583230,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA025959, HPA055789",Uncertain,,Enhanced,Nucleoplasm,"Renal cancer:5.36e-6 (favourable), Ovarian cancer:4.42e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 48.6,Mixed,,
JAK1,"JAK1A, JAK1B, JTK3",ENSG00000162434,Janus kinase 1,1,64833229-64966504,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB013088,Approved,,,,"Renal cancer:2.67e-4 (favourable), Colorectal cancer:2.81e-4 (favourable), Breast cancer:9.63e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 115.6,Expressed in all,,
JAK2,JTK10,ENSG00000096968,Janus kinase 2,9,4984390-5128183,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB013089, HPA040820, HPA043870",Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites,,Expressed in all,Mixed,,,appendix: 28.1,Group enriched,6,ASC diff: 34.8;HDLM-2: 71.3;HEL: 140.3
JAK3,"JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK",ENSG00000105639,Janus kinase 3,19,17824780-17848071,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA070314,Enhanced,,,,"Renal cancer:2.89e-14 (unfavourable), Cervical cancer:6.42e-5 (favourable)",Expressed in all,Tissue enhanced,,appendix: 48.4;lymph node: 46.6,tonsil: 27.2,Cell line enhanced,,HDLM-2: 33.0;Karpas-707: 28.7;U-266/84: 17.1;U-937: 18.8
JOSD1,KIAA0063,ENSG00000100221,Josephin domain containing 1,22,38685543-38701556,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001168,Uncertain,,,,Liver cancer:4.50e-4 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 56.4,Expressed in all,,
JOSD2,SBBI54,ENSG00000161677,Josephin domain containing 2,19,50505998-50511353,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Liver cancer:6.04e-5 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 16.8,Mixed,,
KALRN,"ARHGEF24, DUET, duo, HAPIP, Hs.8004, Kalirin, TRAD",ENSG00000160145,"Kalirin, RhoGEF kinase",3,124080023-124726325,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA011913, CAB026456",Approved,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 51.3,spleen: 11.8,Cell line enhanced,,CACO-2: 47.6;HEL: 31.9;SH-SY5Y: 16.9
KARS,"DFNB89, KARS1, KARS2",ENSG00000065427,Lysyl-tRNA synthetase,16,75627474-75648643,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA041345, HPA041550",Enhanced,,Supported,Cytosol,Head and neck cancer:8.84e-6 (unfavourable),Expressed in all,Expressed in all,,,testis: 178.6,Expressed in all,,
KAT2A,"GCN5, GCN5L2, PCAF-b",ENSG00000108773,Lysine acetyltransferase 2A,17,42113108-42121358,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA048958,Uncertain,,,,"Renal cancer:1.41e-8 (unfavourable), Pancreatic cancer:3.57e-4 (favourable)",Expressed in all,Expressed in all,,,skin: 10.9,Mixed,,
KAT2B,"GCN5, GCN5L, P/CAF, PCAF",ENSG00000114166,Lysine acetyltransferase 2B,3,20040023-20154404,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004526, HPA055839",Supported,,Approved,Nucleus,,Expressed in all,Expressed in all,,,parathyroid gland: 85.2,Mixed,,
KAT5,"cPLA2, ESA1, HTATIP, HTATIP1, PLIP, TIP60, ZC2HC5",ENSG00000172977,Lysine acetyltransferase 5,11,65711996-65719604,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA016953,Approved,,Supported,Nucleoplasm,Renal cancer:1.10e-13 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 84.4,Expressed in all,,
KAT6A,"MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220",ENSG00000083168,Lysine acetyltransferase 6A,8,41929479-42051990,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB017023, HPA063266, HPA065052",Supported,,Approved,Nucleoli<br>Nuclear speckles<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 34.5,Expressed in all,,
KAT6B,"Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B",ENSG00000156650,Lysine acetyltransferase 6B,10,74825582-75032622,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA006104,Supported,,Approved,Nucleus<br>Nuclear bodies,Renal cancer:4.82e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 17.3,Expressed in all,,
KAT7,"HBO1, HBOA, MYST2, ZC2HC7",ENSG00000136504,Lysine acetyltransferase 7,17,49788555-49835030,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA044470,Approved,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,testis: 107.0,Expressed in all,,
KAT8,"FLJ14040, hMOF, MOF, MYST1, ZC2HC8",ENSG00000103510,Lysine acetyltransferase 8,16,31115754-31131393,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA066324,,,Supported,Nucleoplasm,Lung cancer:6.34e-4 (favourable),Expressed in all,Expressed in all,,,ovary: 61.6,Expressed in all,,
KATNA1,,ENSG00000186625,Katanin catalytic subunit A1,6,149594873-149648972,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036207,Approved,,Supported,Nucleus<br>Microtubule organizing center,Liver cancer:3.57e-7 (unfavourable),Expressed in all,Expressed in all,,,testis: 80.2,Expressed in all,,
KATNAL1,MGC2599,ENSG00000102781,Katanin catalytic subunit A1 like 1,13,30202630-30307484,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046205,,,Uncertain,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 37.7,smooth muscle: 21.9,Mixed,,
KATNAL2,"DKFZP667C165, MGC33211",ENSG00000167216,Katanin catalytic subunit A1 like 2,18,46917492-47102243,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040712, HPA042029",Approved,,Approved,Nucleoplasm<br>Intermediate filaments,Renal cancer:1.24e-7 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 45.1;testis: 32.6,thyroid gland: 24.4,Mixed,,
KCMF1,"DEBT91, DKFZP434L1021, PCMF, ZZZ1",ENSG00000176407,Potassium channel modulatory factor 1,2,84971093-85059472,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030383, HPA030384",Enhanced,,Enhanced,Nucleoplasm<br>Cytosol,"Liver cancer:2.33e-7 (unfavourable), Renal cancer:4.18e-6 (unfavourable), Pancreatic cancer:6.10e-5 (unfavourable)",Expressed in all,Expressed in all,,,testis: 124.6,Expressed in all,,
KCTD11,"C17orf36, KCASH1, REN",ENSG00000213859,Potassium channel tetramerization domain containing 11,17,7351889-7354944,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA052035,Approved,,Approved,Nucleoplasm,"Ovarian cancer:5.02e-4 (unfavourable), Endometrial cancer:9.55e-4 (favourable)",Expressed in all,Mixed,,,esophagus: 39.8,Cell line enhanced,,HBEC3-KT: 38.4
KDM2A,"CXXC8, DKFZP434M1735, FBL11, FBL7, FBXL11, FLJ00115, JHDM1A, KIAA1004, LILINA",ENSG00000173120,Lysine demethylase 2A,11,67119269-67258087,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB012272, HPA044251",Supported,,Approved,Nucleus,,Expressed in all,Expressed in all,,,testis: 60.0,Expressed in all,,
KDM2B,"CXXC2, Fbl10, FBXL10, JHDM1B, PCCX2",ENSG00000089094,Lysine demethylase 2B,12,121429097-121581015,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA071257,,,Uncertain,Nucleoplasm,"Head and neck cancer:6.74e-6 (favourable), Pancreatic cancer:8.64e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 35.8,Expressed in all,,
KDM8,"FLJ13798, JMJD5",ENSG00000155666,Lysine demethylase 8,16,27203495-27221768,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026545,Uncertain,,Approved,Nucleoplasm<br>Cytosol,Pancreatic cancer:1.75e-4 (favourable),Expressed in all,Tissue enhanced,,liver: 24.2,small intestine: 13.8,Mixed,,
KDR,"CD309, FLK1, VEGFR, VEGFR2",ENSG00000128052,Kinase insert domain receptor,4,55078477-55125589,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,CAB004028,Enhanced,,Supported,Plasma membrane,Renal cancer:7.26e-4 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 119.2,thyroid gland: 54.7,Group enriched,9,HUVEC TERT2: 178.6;TIME: 148.0
KDSR,"DHSR, FVT1, SDR35C1",ENSG00000119537,3-ketodihydrosphingosine reductase,18,63327726-63367510,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB003673, HPA044884",Approved,,,,Renal cancer:9.53e-6 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 45.5,Expressed in all,,
KEL,"CD238, ECE3",ENSG00000197993,"Kell blood group, metallo-endopeptidase",7,142941114-142962681,"Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,bone marrow: 14.5;testis: 19.5,lymph node: 6.4,Group enriched,14,HEL: 12.2;K-562: 10.7
KHK,,ENSG00000138030,Ketohexokinase,2,27086747-27100772,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007040,Enhanced,,Approved,Cytosol,Endometrial cancer:7.62e-8 (unfavourable),Group enriched,Group enriched,11,duodenum: 113.1;kidney: 111.2;liver: 97.3;small intestine: 133.2,cerebral cortex: 10.1,Cell line enhanced,,Hep G2: 32.5
KIT,"C-Kit, CD117, PBT, SCFR",ENSG00000157404,KIT proto-oncogene receptor tyrosine kinase,4,54657918-54740715,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,"CAB003288, HPA004471, CAB068253, CAB072867, HPA073252",Enhanced,Supported,Supported,Plasma membrane,Renal cancer:5.63e-4 (favourable),Mixed,Tissue enhanced,,breast: 133.6,thyroid gland: 78.7,Group enriched,14,HEL: 220.1;HMC-1: 434.1
KL,,ENSG00000133116,Klotho,13,33016433-33066145,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,"Renal cancer:1.29e-9 (favourable), Pancreatic cancer:4.44e-4 (favourable)",Group enriched,Group enriched,5,kidney: 136.6;parathyroid gland: 346.4,placenta: 44.1,Cell line enhanced,,HMC-1: 2.1;SK-BR-3: 3.4
KLK1,Klk6,ENSG00000167748,Kallikrein 1,19,50819148-50823787,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Group enriched,Group enriched,36,pancreas: 1994.7;salivary gland: 2549.9,colon: 63.5,Cell line enriched,18,RPMI-8226: 26.9
KLK10,"NES1, PRSSL1",ENSG00000129451,Kallikrein related peptidase 10,19,51012739-51020175,"Cancer-related genes, Enzymes, Predicted secreted proteins",Evidence at protein level,HPA017195,,,Uncertain,Plasma membrane<br>Cytosol,"Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable)",Mixed,Tissue enhanced,,esophagus: 138.2;skin: 52.7,tonsil: 45.8,Group enriched,5,CAPAN-2: 200.9;HaCaT: 307.2
KLK11,"PRSS20, TLSP",ENSG00000167757,Kallikrein related peptidase 11,19,51022216-51028039,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB026340,Approved,,,,"Endometrial cancer:3.78e-4 (favourable), Pancreatic cancer:4.17e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 225.7;skin: 214.5,prostate: 104.9,Cell line enhanced,,CAPAN-2: 5.6;EFO-21: 12.3;HaCaT: 36.6
KLK12,KLK-L5,ENSG00000186474,Kallikrein related peptidase 12,19,51029092-51035230,"Enzymes, Predicted secreted proteins",Evidence at protein level,CAB025473,Uncertain,,,,Thyroid cancer:8.01e-4 (favourable),Tissue enhanced,Tissue enhanced,,esophagus: 32.4,tonsil: 8.1,Not detected,,
KLK13,KLK-L4,ENSG00000167759,Kallikrein related peptidase 13,19,51056206-51065114,"Cancer-related genes, Enzymes, Predicted secreted proteins",Evidence at protein level,HPA062136,Enhanced,,,,,Tissue enhanced,Tissue enriched,9,esophagus: 402.2,tonsil: 45.0,Cell line enriched,10,HaCaT: 16.8
KLK14,KLK-L6,ENSG00000129437,Kallikrein related peptidase 14,19,51077495-51084245,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,CAB026228,Uncertain,,,,,Tissue enhanced,Tissue enriched,5,skin: 10.4,breast: 2.0,Cell line enhanced,,HaCaT: 8.7;U-266/84: 3.7
KLK15,"ACO, HSRNASPH, prostinogen",ENSG00000174562,Kallikrein related peptidase 15,19,50825289-50837213,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA019802,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,colon: 3.2;salivary gland: 2.4,adrenal gland: 1.8,Cell line enriched,5,RPMI-8226: 1.7
KLK2,,ENSG00000167751,Kallikrein related peptidase 2,19,50861568-50880567,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA000764,Supported,,,,,Tissue enriched,Tissue enriched,192,prostate: 867.2,testis: 4.5,Cell line enhanced,,NB-4: 3.6
KLK3,"APS, PSA",ENSG00000142515,Kallikrein related peptidase 3,19,50854915-50860764,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000070, HPA000764",Enhanced,,,,,Tissue enriched,Tissue enriched,365,prostate: 12913.0,seminal vesicle: 35.3,Group enriched,165,BEWO: 30.5;NB-4: 17.7;RPMI-8226: 12.8;SH-SY5Y: 11.1;U-2197: 10.1
KLK4,"EMSP, EMSP1, KLK-L1, PRSS17, PSTS",ENSG00000167749,Kallikrein related peptidase 4,19,50906352-50910738,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA051839,Enhanced,,,,,Tissue enriched,Tissue enriched,37,prostate: 406.5,skin: 10.8,Cell line enhanced,,CAPAN-2: 5.7;HaCaT: 7.0
KLK5,"KLK-L2, SCTE",ENSG00000167754,Kallikrein related peptidase 5,19,50943303-50953093,"Cancer-related genes, Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA014343, CAB025503, CAB026341",Enhanced,,,,"Urothelial cancer:3.85e-6 (unfavourable), Endometrial cancer:2.33e-4 (unfavourable), Lung cancer:9.79e-4 (unfavourable)",Tissue enhanced,Tissue enriched,6,skin: 213.5,breast: 37.8,Group enriched,41,A-431: 414.4;HaCaT: 396.7
KLK6,"Bssp, Klk7, neurosin, PRSS18, PRSS9",ENSG00000167755,Kallikrein related peptidase 6,19,50958631-50969673,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA051837,,,Supported,Nucleoplasm<br>Nuclear membrane<br>Cytokinetic bridge,"Endometrial cancer:1.38e-5 (unfavourable), Urothelial cancer:1.27e-4 (unfavourable), Pancreatic cancer:7.82e-4 (unfavourable), Lung cancer:8.85e-4 (unfavourable)",Tissue enhanced,Group enriched,5,cerebral cortex: 78.6;esophagus: 63.0;fallopian tube: 44.9;tonsil: 31.3,kidney: 10.2,Group enriched,15,A-431: 496.5;CAPAN-2: 1158.9
KLK7,"PRSS6, SCCE",ENSG00000169035,Kallikrein related peptidase 7,19,50976482-50984099,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA018994, CAB026342, HPA062126",Enhanced,,Supported,Nuclear membrane<br>Plasma membrane,"Endometrial cancer:8.06e-5 (unfavourable), Pancreatic cancer:1.16e-4 (unfavourable)",Tissue enhanced,Group enriched,5,esophagus: 68.7;skin: 219.6,fallopian tube: 27.9,Group enriched,6,CAPAN-2: 7.1;HaCaT: 28.1
KLK8,"HNP, neuropsin, ovasin, PRSS19, TADG14",ENSG00000129455,Kallikrein related peptidase 8,19,50996007-51002711,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB019393, HPA035761",Enhanced,,Approved,Vesicles,"Pancreatic cancer:1.10e-4 (unfavourable), Endometrial cancer:2.31e-4 (unfavourable), Lung cancer:5.72e-4 (unfavourable), Urothelial cancer:6.17e-4 (unfavourable)",Tissue enhanced,Group enriched,6,esophagus: 77.9;fallopian tube: 20.9;skin: 96.8,breast: 11.0,Group enriched,7,A-431: 76.9;CAPAN-2: 98.5;HaCaT: 73.3
KLK9,KLK-L3,ENSG00000213022,Kallikrein related peptidase 9,19,51003111-51009634,"Cancer-related genes, Enzymes, Predicted secreted proteins",Evidence at transcript level,CAB025049,Uncertain,,,,,Tissue enriched,Not detected,,,"skin,tonsil: 0.8",Not detected,,
KLKB1,KLK3,ENSG00000164344,Kallikrein B1,4,186208979-186258471,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,45,liver: 155.0,"gallbladder,kidney: 3.4",Cell line enhanced,,NTERA-2: 2.9;SCLC-21H: 2.3
KMO,,ENSG00000117009,Kynurenine 3-monooxygenase,1,241532134-241595642,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA031115, HPA056942",Enhanced,,,,Renal cancer:6.49e-8 (unfavourable),Mixed,Tissue enhanced,,kidney: 32.3;liver: 47.7,spleen: 10.8,Cell line enhanced,,RPMI-8226: 6.1;RPTEC TERT1: 16.3;SK-BR-3: 8.4;U-698: 6.4
KMT2A,"ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1",ENSG00000118058,Lysine methyltransferase 2A,11,118436490-118526832,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB017794, CAB024270, HPA044910",Enhanced,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 31.0,Expressed in all,,
KMT2B,"CXXC10, HRX2, KIAA0304, MLL1B, MLL2, MLL4, TRX2, WBP7",ENSG00000272333,Lysine methyltransferase 2B,19,35718019-35738878,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA006487,,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 28.8,Expressed in all,,
KMT2C,"HALR, KIAA1506, MLL3",ENSG00000055609,Lysine methyltransferase 2C,7,152134922-152436005,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA074736,,,Supported,Nucleoplasm,Renal cancer:8.01e-6 (favourable),Expressed in all,Expressed in all,,,skin: 25.0,Expressed in all,,
KMT2D,"ALR, CAGL114, MLL2, MLL4, TNRC21",ENSG00000167548,Lysine methyltransferase 2D,12,49018975-49059774,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA035977,Approved,,Approved,Nucleus<br>Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 46.6,Expressed in all,,
KMT2E,"HDCMC04P, MLL5",ENSG00000005483,Lysine methyltransferase 2E,7,105014179-105114361,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA022812, HPA056125",Approved,Approved,,,Renal cancer:3.80e-5 (unfavourable),Expressed in all,Expressed in all,,,endometrium: 51.7,Expressed in all,,
KMT5A,"PR-Set7, SET07, SET8, SETD8",ENSG00000183955,Lysine methyltransferase 5A,12,123383773-123409358,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA064495,,,Approved,Nucleus<br>Cytosol,Liver cancer:6.21e-7 (unfavourable),Expressed in all,Expressed in all,,,prostate: 36.8,Expressed in all,,
KMT5B,"CGI-85, SUV420H1",ENSG00000110066,Lysine methyltransferase 5B,11,68154863-68213828,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA063648,,,Supported,Nucleus,Urothelial cancer:9.30e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 52.2,Expressed in all,,
KMT5C,"MGC2705, SUV420H2",ENSG00000133247,Lysine methyltransferase 5C,19,55339853-55348120,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA052294,Uncertain,,Approved,Nucleoplasm,Renal cancer:1.05e-8 (unfavourable),Expressed in all,Mixed,,,skin: 4.8,Cell line enhanced,,SCLC-21H: 21.9
KSR1,"KSR, RSU2",ENSG00000141068,Kinase suppressor of ras 1,17,27456714-27626438,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB009623, HPA011215",Uncertain,,,,Renal cancer:6.54e-4 (unfavourable),Expressed in all,Expressed in all,,,placenta: 75.6,Cell line enhanced,,HDLM-2: 562.3;HEL: 176.9
KSR2,FLJ25965,ENSG00000171435,Kinase suppressor of ras 2,12,117453012-117968983,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA035536,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 4.1,adrenal gland: 1.2,Group enriched,6,HUVEC TERT2: 3.8;SCLC-21H: 3.8;TIME: 5.6
KYAT1,"CCBL1, GTK, KATI",ENSG00000171097,Kynurenine aminotransferase 1,9,128832942-128882494,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021176, HPA021177, HPA027736",Approved,,Enhanced,Nucleoplasm<br>Cytosol,,Expressed in all,Mixed,,,cerebral cortex: 17.0,Expressed in all,,
KYAT3,"CCBL2, KAT3, KATIII, RBM1, RP11-82K18.3",ENSG00000137944,Kynurenine aminotransferase 3,1,88935773-88992953,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026538, HPA027168",Enhanced,,Approved,Nucleoli<br>Cytosol,"Renal cancer:5.02e-6 (favourable), Breast cancer:3.19e-5 (favourable), Head and neck cancer:1.86e-4 (favourable), Ovarian cancer:2.80e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 42.8,Expressed in all,,
KYNU,,ENSG00000115919,Kynureninase,2,142877498-143055832,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA031686,Enhanced,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Mixed,,,liver: 45.9,Cell line enhanced,,A549: 168.9;HeLa: 138.9;hTEC/SVTERT24-B: 106.9;SiHa: 109.4;U-87 MG: 309.1
L2HGDH,"C14orf160, FLJ12618",ENSG00000087299,L-2-hydroxyglutarate dehydrogenase,14,50237563-50312548,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA065409, HPA069708",Approved,,Enhanced,Mitochondria,Renal cancer:9.75e-10 (favourable),Expressed in all,Mixed,,,kidney: 20.8,Expressed in all,,
L3HYPDH,"C14orf149, FLJ25436",ENSG00000126790,Trans-L-3-hydroxyproline dehydratase,14,59460363-59484430,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA056694,Approved,,Uncertain,Vesicles,Renal cancer:1.72e-9 (unfavourable),Expressed in all,Expressed in all,,,testis: 32.0,Expressed in all,,
LACTB,"FLJ14902, MRPL56",ENSG00000103642,Lactamase beta,15,63121800-63142061,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA036361, HPA036362",Enhanced,,Supported,Mitochondria,,Expressed in all,Expressed in all,,,testis: 39.7,Expressed in all,,
LAP3,"LAP, LAPEP, PEPS",ENSG00000002549,Leucine aminopeptidase 3,4,17577192-17607972,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA029606, HPA029607",Enhanced,,Supported,Nucleoplasm<br>Midbody<br>Cytosol,,Expressed in all,Expressed in all,,,appendix: 176.5,Mixed,,
LARS,"FLJ10595, FLJ21788, HSPC192, LARS1, LEUS, RNTLS",ENSG00000133706,Leucyl-tRNA synthetase,5,146113038-146182660,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036424, HPA040881",Supported,,Supported,Nuclear bodies<br>Cytosol,"Liver cancer:3.78e-5 (unfavourable), Thyroid cancer:2.98e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 70.8,Expressed in all,,
LARS2,"KIAA0028, LEURS, MGC26121, mtLeuRS",ENSG00000011376,"Leucyl-tRNA synthetase 2, mitochondrial",3,45388506-45549421,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035951, HPA045450, HPA066085",Approved,,Supported,Nucleoplasm<br>Mitochondria,"Renal cancer:1.32e-11 (favourable), Colorectal cancer:1.71e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 19.2,Expressed in all,,
LATS1,WARTS,ENSG00000131023,Large tumor suppressor kinase 1,6,149658153-149718256,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031804,Approved,,Uncertain,Nucleoplasm<br>Vesicles,,Expressed in all,Expressed in all,,,parathyroid gland: 23.6,Expressed in all,,
LATS2,,ENSG00000150457,Large tumor suppressor kinase 2,13,20973032-21061547,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039191, HPA049037",Approved,,Supported,Microtubule organizing center<br>Cytosol,Cervical cancer:3.26e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 25.8,Mixed,,
LCAT,,ENSG00000213398,Lecithin-cholesterol acyltransferase,16,67939750-67944131,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA044767,,,Approved,Nucleoplasm,"Liver cancer:4.21e-8 (favourable), Renal cancer:1.71e-4 (unfavourable), Colorectal cancer:8.50e-4 (unfavourable)",Expressed in all,Expressed in all,,,liver: 105.7,Cell line enhanced,,BEWO: 73.6
LCK,,ENSG00000182866,"LCK proto-oncogene, Src family tyrosine kinase",1,32251239-32286165,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA003494, CAB003816",Enhanced,,Approved,Golgi apparatus,"Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable)",Mixed,Tissue enhanced,,lymph node: 125.9;tonsil: 72.4,appendix: 66.3,Group enriched,7,MOLT-4: 429.5;U-698: 207.6
LCLAT1,"AGPAT8, ALCAT1, FLJ37965, LYCAT",ENSG00000172954,Lysocardiolipin acyltransferase 1,2,30447226-30644225,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA031880, HPA049217",Uncertain,,Supported,Endoplasmic reticulum<br>Cytosol,"Liver cancer:8.72e-4 (unfavourable), Head and neck cancer:9.67e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 18.8,Expressed in all,,
LCMT1,"CGI-68, PPMT1",ENSG00000205629,Leucine carboxyl methyltransferase 1,16,25111729-25178231,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041559, HPA043530",Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:7.53e-6 (favourable), Cervical cancer:2.78e-4 (favourable), Liver cancer:5.85e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 59.8,Expressed in all,,
LCMT2,"KIAA0547, MGC9534, PPM2, TYW4",ENSG00000168806,Leucine carboxyl methyltransferase 2,15,43323649-43330605,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039401, HPA048176",Approved,,Approved,Nucleoplasm<br>Vesicles,Renal cancer:5.69e-9 (favourable),Expressed in all,Mixed,,,parathyroid gland: 13.2,Mixed,,
LCT,,ENSG00000115850,Lactase,2,135787840-135837180,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,631,duodenum: 223.1;small intestine: 142.8,"appendix,lymph node: 0.2",Cell line enhanced,,MOLT-4: 3.9;RPMI-8226: 6.7
LDHA,,ENSG00000134333,Lactate dehydrogenase A,11,18394388-18408425,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB015336, CAB069404",Uncertain,,Supported,Vesicles<br>Cytosol,"Renal cancer:9.69e-9 (unfavourable), Liver cancer:3.26e-8 (unfavourable), Lung cancer:2.27e-6 (unfavourable), Pancreatic cancer:8.09e-6 (unfavourable), Cervical cancer:2.78e-5 (unfavourable)",Expressed in all,Expressed in all,,,adipose tissue: 503.4,Expressed in all,,
LDHAL6A,"LDH6A, MGC23940",ENSG00000166800,Lactate dehydrogenase A like 6A,11,18455824-18479600,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,13,testis: 17.5,skin: 1.3,Cell line enriched,6,HL-60: 8.8
LDHAL6B,"LDH6B, LDHAL6, LDHL",ENSG00000171989,Lactate dehydrogenase A like 6B,15,59206823-59208515,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA053962,Enhanced,,,,,Not detected,Tissue enriched,166,testis: 76.5,gallbladder: 0.4,Not detected,,
LDHB,,ENSG00000111716,Lactate dehydrogenase B,12,21635342-21757857,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004641, HPA019007",Enhanced,,Enhanced,Cytosol,Renal cancer:2.51e-4 (favourable),Expressed in all,Expressed in all,,,kidney: 1790.8,Expressed in all,,
LDHC,CT32,ENSG00000166796,Lactate dehydrogenase C,11,18412307-18452058,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045442,Enhanced,,,,,Mixed,Tissue enriched,402,testis: 472.9,thyroid gland: 1.1,Cell line enhanced,,U-2197: 4.8;U-266/70: 3.5;U-266/84: 3.0
LDHD,,ENSG00000166816,Lactate dehydrogenase D,16,75111860-75116771,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041766, HPA048639, HPA066148",Enhanced,,Approved,Cytosol,"Renal cancer:2.95e-14 (favourable), Liver cancer:5.61e-4 (favourable)",Expressed in all,Mixed,,,kidney: 34.0,Cell line enhanced,,HMC-1: 13.2;T-47d: 27.8;U-266/70: 8.9
LFNG,SCDO3,ENSG00000106003,LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase,7,2512529-2529177,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA069130,Approved,,,,Endometrial cancer:6.36e-4 (favourable),Expressed in all,Expressed in all,,,skin: 68.5,Cell line enhanced,,RH-30: 44.5;U-2 OS: 52.5
LGMN,"LGMN1, PRSC1",ENSG00000100600,Legumain,14,92703807-92748702,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA001426,Enhanced,,Approved,Nucleoplasm<br>Vesicles,Renal cancer:4.70e-4 (favourable),Expressed in all,Expressed in all,,,placenta: 360.0,Cell line enhanced,,RPMI-8226: 587.9;U-266/70: 339.8
LHPP,HDHD2B,ENSG00000107902,Phospholysine phosphohistidine inorganic pyrophosphate phosphatase,10,124461834-124617888,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA009163, HPA009269",Enhanced,,Supported,Nuclear speckles<br>Cytosol,,Expressed in all,Expressed in all,,,cerebral cortex: 70.6,Mixed,,
LIAS,LAS,ENSG00000121897,Lipoic acid synthetase,4,39458587-39485109,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA018842, HPA019076",Approved,Approved,Approved,Nucleoplasm<br>Mitochondria,Renal cancer:4.11e-7 (favourable),Expressed in all,Mixed,,,testis: 15.1,Expressed in all,,
LIG1,,ENSG00000105486,DNA ligase 1,19,48115445-48170603,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB037015, HPA041431, HPA048071",Approved,,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Renal cancer:5.75e-5 (unfavourable),Expressed in all,Mixed,,,bone marrow: 20.9,Mixed,,
LIG3,LIG2,ENSG00000005156,DNA ligase 3,17,34980494-35009743,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006723,Supported,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,testis: 38.7,Expressed in all,,
LIG4,,ENSG00000174405,DNA ligase 4,13,108207439-108218368,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001334, HPA057325",Supported,,Supported,Nucleoplasm<br>Cytoplasmic bodies,,Expressed in all,Mixed,,,parathyroid gland: 20.2,Expressed in all,,
LIMK1,LIMK,ENSG00000106683,LIM domain kinase 1,7,74082933-74122525,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA028064, HPA028516",Approved,,Supported,Nuclear speckles<br>Cytosol,"Renal cancer:6.63e-8 (unfavourable), Liver cancer:7.79e-6 (unfavourable), Colorectal cancer:4.95e-5 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 39.5,Expressed in all,,
LIMK2,,ENSG00000182541,LIM domain kinase 2,22,31212239-31280080,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA008183, CAB019313, HPA053882",Approved,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:4.57e-6 (unfavourable),Expressed in all,Expressed in all,,,skin: 70.8,Expressed in all,,
LIPA,"CESD, LAL",ENSG00000107798,"Lipase A, lysosomal acid type",10,89213569-89414557,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB034892, HPA057052",Enhanced,,Supported,Vesicles,,Expressed in all,Expressed in all,,,spleen: 496.6,Mixed,,
LIPC,"HL, HTGL",ENSG00000166035,"Lipase C, hepatic type",15,58410569-58569843,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enriched,14,liver: 86.4,kidney: 6.3,Cell line enhanced,,CACO-2: 6.9;EFO-21: 5.7;Hep G2: 16.4;HMC-1: 6.0;U-2197: 17.2
LIPE,HSL,ENSG00000079435,"Lipase E, hormone sensitive type",19,42401507-42427426,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006567, CAB017700",Enhanced,,Supported,Cytosol,Pancreatic cancer:1.15e-4 (favourable),Expressed in all,Tissue enriched,20,adipose tissue: 870.5,testis: 44.0,Cell line enriched,6,ASC diff: 94.1
LIPF,"HGL, HLAL",ENSG00000182333,"Lipase F, gastric type",10,88664441-88678814,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,HPA045930,Enhanced,,,,,Tissue enriched,Tissue enriched,86,stomach: 22415.5,duodenum: 259.5,Cell line enhanced,,HMC-1: 3.6;MOLT-4: 2.7;NTERA-2: 3.5;THP-1: 4.5;U-2 OS: 2.4;U-266/70: 2.4
LIPG,EDL,ENSG00000101670,"Lipase G, endothelial type",18,49560699-49599182,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA016966,Uncertain,,,,,Tissue enriched,Group enriched,11,placenta: 214.4;thyroid gland: 403.2,seminal vesicle: 29.1,Cell line enhanced,,AN3-CA: 113.7;HaCaT: 167.5;RPTEC TERT1: 93.8;TIME: 201.4
LIPT2,,ENSG00000175536,Lipoyl(octanoyl) transferase 2 (putative),11,74491712-74493733,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040249,Approved,,Approved,Vesicles<br>Centrosome,Ovarian cancer:1.63e-4 (favourable),Expressed in all,Mixed,,,testis: 14.5,Mixed,,
LMLN,"Gp63, Msp",ENSG00000185621,Leishmanolysin like peptidase,3,197960200-198043720,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA016481, HPA028844",Uncertain,,Supported,Focal adhesion sites<br>Cytosol,Endometrial cancer:6.77e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 18.6,epididymis: 13.0,Mixed,,
LMTK2,"AATYK2, BREK, cprk, KIAA1079, KPI-2, KPI2, LMR2, PPP1R100",ENSG00000164715,Lemur tyrosine kinase 2,7,98106885-98209633,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA010657, HPA041836",Uncertain,,Approved,Nuclear speckles<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol,"Renal cancer:1.12e-7 (favourable), Ovarian cancer:8.03e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 27.9,Expressed in all,,
LMTK3,"KIAA1883, LMR3, PPP1R101, TYKLM3",ENSG00000142235,Lemur tyrosine kinase 3,19,48485271-48513189,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA040203, HPA077070",Enhanced,,Approved,Nucleoplasm<br>Cell Junctions,Renal cancer:3.18e-8 (favourable),Mixed,Group enriched,6,cerebral cortex: 20.3;parathyroid gland: 4.9,duodenum: 2.2,Cell line enhanced,,HMC-1: 6.1;SK-BR-3: 6.2;U-266/70: 5.9
LNPEP,"CAP, IRAP, P-LAP, PLAP",ENSG00000113441,Leucyl and cystinyl aminopeptidase,5,96935394-97037515,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA043642,Approved,,,,,Expressed in all,Mixed,,,parathyroid gland: 23.3,Expressed in all,,
LNX1,"LNX, MPDZ, PDZRN2",ENSG00000072201,Ligand of numb-protein X 1,4,53459301-53701405,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA002235, HPA071091",Approved,,Supported,Cell Junctions<br>Cytosol,Renal cancer:3.08e-7 (favourable),Expressed in all,Mixed,,,placenta: 39.4,Mixed,,
LONP1,"hLON, LonHS, PIM1, PRSS15",ENSG00000196365,"Lon peptidase 1, mitochondrial",19,5691834-5720572,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002034, HPA002192",Supported,,Enhanced,Nucleus<br>Mitochondria,,Expressed in all,Expressed in all,,,adrenal gland: 140.4,Expressed in all,,
LONP2,"LONP, LONPL, MGC4840",ENSG00000102910,"Lon peptidase 2, peroxisomal",16,48244296-48363122,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA008862,Uncertain,,,,"Renal cancer:6.71e-7 (favourable), Cervical cancer:4.55e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 81.8,Expressed in all,,
LOX,,ENSG00000113083,Lysyl oxidase,5,122063195-122078360,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA043930,,,Supported,Endoplasmic reticulum,"Renal cancer:3.93e-8 (unfavourable), Urothelial cancer:3.32e-4 (unfavourable), Liver cancer:7.38e-4 (unfavourable)",Expressed in all,Mixed,,,adipose tissue: 29.6,Cell line enhanced,,BJ: 799.4;fHDF/TERT166: 1126.5;U-138 MG: 458.1
LOXL2,WS9-14,ENSG00000134013,Lysyl oxidase like 2,8,23297189-23425328,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025848, HPA036257, HPA056542",Approved,,Approved,Nucleoplasm,"Lung cancer:1.46e-7 (unfavourable), Renal cancer:2.91e-7 (unfavourable), Cervical cancer:9.83e-6 (unfavourable), Glioma:1.78e-4 (unfavourable), Pancreatic cancer:9.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,,smooth muscle: 59.8,placenta: 53.3,Cell line enhanced,,BJ: 809.1;U-87 MG: 911.1
LOXL3,,ENSG00000115318,Lysyl oxidase like 3,2,74532414-74555690,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA035281,Approved,,,,Renal cancer:7.97e-8 (unfavourable),Tissue enhanced,Mixed,,,placenta: 21.6,Cell line enhanced,,U-138 MG: 238.3;WM-115: 524.2
LPA,"LP, Lp(a)",ENSG00000198670,Lipoprotein(a),6,160531483-160664259,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016072, HPA060604",Supported,,,,,Tissue enriched,Tissue enriched,25,liver: 41.5,seminal vesicle: 1.6,Not detected,,
LPCAT1,"AGPAT10, AGPAT9, AYTL2, FLJ12443",ENSG00000153395,Lysophosphatidylcholine acyltransferase 1,5,1456480-1523977,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA012501, HPA022268",Enhanced,,Supported,Endoplasmic reticulum<br>Lipid droplets,"Liver cancer:1.88e-8 (unfavourable), Renal cancer:2.64e-7 (unfavourable), Pancreatic cancer:4.90e-5 (favourable), Cervical cancer:7.11e-5 (unfavourable), Endometrial cancer:3.67e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lung: 19.0;spleen: 14.7,cerebral cortex: 4.4,Cell line enhanced,,BEWO: 80.0;EFO-21: 74.7;PC-3: 52.0
LPCAT2,"AGPAT11, AYTL1, FLJ20481, LysoPAFAT",ENSG00000087253,Lysophosphatidylcholine acyltransferase 2,16,55508998-55586670,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007891, HPA008433",Enhanced,Supported,Enhanced,Endoplasmic reticulum<br>Lipid droplets,"Endometrial cancer:8.03e-6 (favourable), Colorectal cancer:3.43e-4 (favourable)",Expressed in all,Tissue enhanced,,thyroid gland: 142.6,bone marrow: 56.4,Cell line enhanced,,CAPAN-2: 100.9;HMC-1: 141.4;WM-115: 114.8
LPCAT3,"C3F, MBOAT5, nessy, OACT5",ENSG00000111684,Lysophosphatidylcholine acyltransferase 3,12,6976186-7018510,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:4.89e-5 (favourable),Expressed in all,Expressed in all,,,duodenum: 123.0,Expressed in all,,
LPCAT4,"AGPAT7, AYTL3, FLJ10257, LPAAT-eta, LPEAT2",ENSG00000176454,Lysophosphatidylcholine acyltransferase 4,15,34358618-34367278,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030719,Uncertain,,,,Liver cancer:9.99e-4 (unfavourable),Expressed in all,Mixed,,,rectum: 38.6,Expressed in all,,
LPIN1,KIAA0188,ENSG00000134324,Lipin 1,2,11677595-11827409,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA038021,Approved,,Approved,Nucleus<br>Nucleoli fibrillar center,,Expressed in all,Expressed in all,,,testis: 102.1,Expressed in all,,
LPIN2,KIAA0249,ENSG00000101577,Lipin 2,18,2916994-3013315,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB015223, HPA017857, HPA030550",Enhanced,,Supported,Plasma membrane<br>Actin filaments<br>Cytosol,Head and neck cancer:8.01e-4 (favourable),Expressed in all,Mixed,,,liver: 87.3,Mixed,,
LPIN3,"LIPN3L, SMP2",ENSG00000132793,Lipin 3,20,41340920-41360582,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA051466, HPA052667, HPA070640",Approved,,Supported,Cytosol,"Renal cancer:1.14e-5 (unfavourable), Ovarian cancer:1.74e-4 (unfavourable), Endometrial cancer:9.74e-4 (unfavourable)",Expressed in all,Mixed,,,skin: 48.5,Mixed,,
LPL,LIPD,ENSG00000175445,Lipoprotein lipase,8,19901717-19967258,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048749,,,Supported,Vesicles,Urothelial cancer:6.07e-4 (unfavourable),Expressed in all,Tissue enhanced,,adipose tissue: 976.8,heart muscle: 239.2,Cell line enriched,7,AF22: 363.8
LPO,SPO,ENSG00000167419,Lactoperoxidase,17,58218548-58268518,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA028688,Enhanced,Supported,,,,Not detected,Tissue enriched,221,salivary gland: 372.8,testis: 1.6,Cell line enriched,7,THP-1: 6.2
LRAT,LCA14,ENSG00000121207,Lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase),4,154626945-154753118,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA070726,,,Uncertain,Endoplasmic reticulum<br>Golgi apparatus,,Mixed,Tissue enhanced,,thyroid gland: 2.3,testis: 1.6,Cell line enriched,11,NTERA-2: 11.7
LRRK1,"FLJ23119, KIAA1790, RIPK6, Roco1",ENSG00000154237,Leucine rich repeat kinase 1,15,100919215-101078254,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA010537,Uncertain,,Supported,Mitochondria<br>Cytosol,Renal cancer:5.71e-5 (unfavourable),Mixed,Mixed,,,lymph node: 12.6,Cell line enhanced,,Daudi: 27.9
LRRK2,"DKFZp434H2111, FLJ45829, PARK8, RIPK7, ROCO2",ENSG00000188906,Leucine rich repeat kinase 2,12,40196744-40369285,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA014293, CAB037160",Approved,,Approved,Nucleus<br>Vesicles,Renal cancer:3.02e-6 (favourable),Group enriched,Expressed in all,,,lung: 95.4,Cell line enhanced,,A549: 7.4;ASC TERT1: 5.6;RPTEC TERT1: 6.7
LRSAM1,"CMT2P, FLJ31641",ENSG00000148356,Leucine rich repeat and sterile alpha motif containing 1,9,127451486-127503501,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021403, HPA021844, CAB037304",Supported,,Approved,Cytosol,"Pancreatic cancer:6.78e-6 (favourable), Renal cancer:5.72e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 20.8,Expressed in all,,
LRTOMT,"CFAP111, COMT2, DFNB63, LRRC51",ENSG00000184154,Leucine rich transmembrane and O-methyltransferase domain containing,11,72080331-72110782,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA039949,Approved,,Approved,Nucleoli<br>Microtubules,"Ovarian cancer:5.36e-4 (favourable), Endometrial cancer:7.70e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 136.6,Expressed in all,,
LSS,OSC,ENSG00000160285,Lanosterol synthase,21,46188141-46228824,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA032060, HPA032062, CAB034116",Supported,,Approved,Cytosol,"Urothelial cancer:3.07e-4 (unfavourable), Stomach cancer:6.80e-4 (unfavourable)",Expressed in all,Expressed in all,,,prostate: 38.7,Expressed in all,,
LTA4H,,ENSG00000111144,Leukotriene A4 hydrolase,12,96000828-96043520,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA008399, CAB015221, HPA017017",Supported,,Supported,Nucleoplasm<br>Cytosol,"Lung cancer:8.96e-4 (favourable), Breast cancer:9.79e-4 (favourable)",Expressed in all,Expressed in all,,,lung: 283.5,Expressed in all,,
LTC4S,MGC33147,ENSG00000213316,Leukotriene C4 synthase,5,179793980-179796647,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,fallopian tube: 3.7,"adipose tissue,adrenal gland: 2.0",Cell line enriched,6,HMC-1: 59.7
LTK,TYK1,ENSG00000062524,Leukocyte receptor tyrosine kinase,15,41503638-41513887,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA059545,Uncertain,,Approved,Vesicles,,Mixed,Mixed,,,placenta: 15.2,Cell line enhanced,,HEL: 4.4;NB-4: 6.1;RH-30: 4.4;THP-1: 9.9
LTN1,"C21orf10, C21orf98, FLJ11053, KIAA0714, LISTERIN, RNF160, ZNF294",ENSG00000198862,Listerin E3 ubiquitin protein ligase 1,21,28928144-28992956,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA029143, CAB034164, HPA055604",Uncertain,,Enhanced,Cytosol,,Expressed in all,Expressed in all,,,placenta: 26.6,Expressed in all,,
LVRN,"APQ, AQPEP, FLJ90650, TAQPEP",ENSG00000172901,Laeverin,5,115962454-116027619,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA053254,Enhanced,,,,,Not detected,Group enriched,22,adipose tissue: 11.8;placenta: 31.5,breast: 1.0,Not detected,,
LYN,JTK8,ENSG00000254087,"LYN proto-oncogene, Src family tyrosine kinase",8,55879813-56014168,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001231, CAB004492",Enhanced,,Supported,Golgi apparatus<br>Vesicles<br>Plasma membrane,Renal cancer:3.43e-4 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 161.1,appendix: 130.6,Cell line enhanced,,HEL: 215.0;HMC-1: 205.1
LYZ,,ENSG00000090382,Lysozyme,12,69348341-69354234,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"CAB000055, HPA048284, HPA066182",Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus<br>Actin filaments,Head and neck cancer:7.45e-4 (favourable),Expressed in all,Expressed in all,,,stomach: 9651.4,Group enriched,5,Hep G2: 633.5;THP-1: 321.5;U-937: 404.3
LYZL1,"LYC2, MGC33408",ENSG00000120563,Lysozyme like 1,10,29289061-29318328,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,480,testis: 53.4,parathyroid gland: 0.1,Not detected,,
LYZL2,,ENSG00000151033,Lysozyme like 2,10,30611779-30629762,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,670,testis: 67.0,all non-specific tissues: 0.0,Cell line enriched,6,SK-BR-3: 2.2
LYZL6,"LYC1, PRO1485, TKAL754",ENSG00000275722,Lysozyme like 6,17,35934518-35943699,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA025734, HPA053073",Supported,,,,,Not detected,Not detected,,,testis: 0.1,Not detected,,
MAK,"dJ417M14.2, RP62",ENSG00000111837,Male germ cell associated kinase,6,10762723-10838555,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,9,fallopian tube: 9.7;parathyroid gland: 10.2;testis: 20.4,lung: 1.4,Cell line enhanced,,HDLM-2: 1.4
MALT1,"MLT, PCASP1",ENSG00000172175,MALT1 paracaspase,18,58671386-58754477,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004494, HPA048432",Enhanced,,Supported,Nucleoli<br>Cytosol,,Expressed in all,Expressed in all,,,lymph node: 34.0,Expressed in all,,
MAN1A1,,ENSG00000111885,Mannosidase alpha class 1A member 1,6,119177209-119349761,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB037058, HPA053198, HPA063561",Uncertain,,Supported,Golgi apparatus,,Expressed in all,Expressed in all,,,placenta: 112.4,Cell line enhanced,,ASC diff: 187.5;Karpas-707: 157.8;U-266/70: 224.6
MAN1A2,MAN1B,ENSG00000198162,Mannosidase alpha class 1A member 2,1,117367449-117528872,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA034559, HPA057364",Enhanced,,Enhanced,Golgi apparatus,Ovarian cancer:4.08e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 44.3,Expressed in all,,
MAN1B1,"ERManI, MANA-ER, MRT15",ENSG00000177239,Mannosidase alpha class 1B member 1,9,137086927-137109187,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA051516,Approved,,Uncertain,Vesicles,Liver cancer:1.45e-4 (unfavourable),Expressed in all,Expressed in all,,,fallopian tube: 33.4,Expressed in all,,
MAN1C1,HMIC,ENSG00000117643,Mannosidase alpha class 1C member 1,1,25617468-25786207,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA048352,Uncertain,,Uncertain,Nucleus<br>Vesicles,"Pancreatic cancer:4.79e-4 (favourable), Lung cancer:7.55e-4 (favourable)",Expressed in all,Mixed,,,thyroid gland: 40.7,Cell line enhanced,,AF22: 28.0;HSkMC: 74.2
MAN2A1,"GOLIM7, MANA2",ENSG00000112893,Mannosidase alpha class 2A member 1,5,109689366-109869625,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB022377, HPA026896",Enhanced,,Supported,Golgi apparatus,,Expressed in all,Expressed in all,,,parathyroid gland: 40.5,Expressed in all,,
MAN2A2,"HsT19662, MANA2X",ENSG00000196547,Mannosidase alpha class 2A member 2,15,90902218-90922584,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA017226, HPA077930",Approved,,Approved,Cytoplasmic bodies,Renal cancer:8.95e-4 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 46.3,Expressed in all,,
MAN2B1,"LAMAN, MANB",ENSG00000104774,Mannosidase alpha class 2B member 1,19,12646511-12666742,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA041530, HPA053404",Supported,,Approved,Nucleoplasm<br>Vesicles,Renal cancer:1.94e-5 (unfavourable),Expressed in all,Expressed in all,,,spleen: 95.1,Expressed in all,,
MAN2B2,KIAA0935,ENSG00000013288,Mannosidase alpha class 2B member 2,4,6575175-6623362,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA037005,Uncertain,,,,Endometrial cancer:7.59e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 37.7,Expressed in all,,
MAN2C1,"MANA, MANA1",ENSG00000140400,Mannosidase alpha class 2C member 1,15,75355207-75368630,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040627, HPA067407",Uncertain,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,parathyroid gland: 46.7,Expressed in all,,
MANBA,,ENSG00000109323,Mannosidase beta,4,102631488-102760994,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA053478,Approved,,Supported,Vesicles,"Liver cancer:3.74e-6 (unfavourable), Glioma:1.06e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 37.4,Expressed in all,,
MANEA,"FLJ12838, mandaselin",ENSG00000172469,Mannosidase endo-alpha,6,95577543-95609457,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA011046, HPA011069",Enhanced,,Supported,Golgi apparatus,Colorectal cancer:3.04e-4 (favourable),Expressed in all,Mixed,,,thyroid gland: 19.4,Expressed in all,,
MAOA,,ENSG00000189221,Monoamine oxidase A,X,43654907-43746824,"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB009437, HPA054807, HPA059299",Enhanced,,Enhanced,Mitochondria,,Expressed in all,Mixed,,,small intestine: 248.3,Cell line enhanced,,ASC diff: 108.7;HHSteC: 249.1;hTCEpi: 61.9;RT4: 102.5
MAOB,,ENSG00000069535,Monoamine oxidase B,X,43766611-43882447,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"HPA002328, CAB037200",Enhanced,,Approved,Nucleoli<br>Mitochondria,,Expressed in all,Mixed,,,seminal vesicle: 215.4,Group enriched,9,Hep G2: 28.1;SiHa: 82.8
MAP2K1,"MAPKK1, MEK1, PRKMK1",ENSG00000169032,Mitogen-activated protein kinase kinase 1,15,66386817-66492312,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB003834, HPA026430",Approved,,Enhanced,Plasma membrane<br>Cytosol,Glioma:2.68e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 144.4,Expressed in all,,
MAP2K2,"MEK2, PRKMK2",ENSG00000126934,Mitogen-activated protein kinase kinase 2,19,4090321-4124129,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB003835, HPA051993",Supported,,Supported,Cytosol,"Stomach cancer:5.43e-5 (favourable), Cervical cancer:3.72e-4 (favourable), Head and neck cancer:7.98e-4 (favourable)",Expressed in all,Expressed in all,,,duodenum: 135.0,Expressed in all,,
MAP2K3,"MAPKK3, MEK3, MKK3, PRKMK3",ENSG00000034152,Mitogen-activated protein kinase kinase 3,17,21284672-21315240,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,CAB018548,Approved,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,bone marrow: 129.9,Expressed in all,,
MAP2K4,"JNKK1, MEK4, MKK4, PRKMK4, SERK1",ENSG00000065559,Mitogen-activated protein kinase kinase 4,17,12020824-12143830,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB007751, HPA060074",Enhanced,,Approved,Nucleoplasm<br>Cell Junctions,,Expressed in all,Expressed in all,,,cerebral cortex: 64.0,Expressed in all,,
MAP2K5,"HsT17454, MAPKK5, MEK5, PRKMK5",ENSG00000137764,Mitogen-activated protein kinase kinase 5,15,67542709-67807123,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB022094, HPA027347, HPA027755",Supported,,Approved,Nucleoli<br>Microtubules,Renal cancer:8.03e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 32.7,Expressed in all,,
MAP2K6,"MAPKK6, MEK6, MKK6, PRKMK6, SAPKK3",ENSG00000108984,Mitogen-activated protein kinase kinase 6,17,69414698-69543331,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB007744, HPA031134",Enhanced,,Supported,Nucleus<br>Cytosol,"Breast cancer:2.27e-6 (favourable), Pancreatic cancer:7.52e-4 (favourable)",Mixed,Mixed,,,"cervix, uterine: 39.1",Cell line enhanced,,A549: 36.5
MAP2K7,"Jnkk2, MKK7, PRKMK7",ENSG00000076984,Mitogen-activated protein kinase kinase 7,19,7903843-7914478,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001633, CAB004262, HPA064711",Supported,,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Head and neck cancer:8.54e-5 (favourable), Urothelial cancer:1.56e-4 (favourable)",Expressed in all,Expressed in all,,,spleen: 19.1,Expressed in all,,
MAP3K1,"MAPKKK1, MEKK, MEKK1",ENSG00000095015,Mitogen-activated protein kinase kinase kinase 1,5,56815574-56896152,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"CAB004500, HPA046509",Approved,,Approved,Cytosol,,Expressed in all,Mixed,,,spleen: 28.3,Cell line enhanced,,SH-SY5Y: 55.9
MAP3K10,"MEKK10, MLK2, MST",ENSG00000130758,Mitogen-activated protein kinase kinase kinase 10,19,40191744-40215575,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007039,Approved,,Approved,Nucleus<br>Actin filaments<br>Cytosol,"Urothelial cancer:2.13e-4 (favourable), Head and neck cancer:8.69e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 31.1,testis: 7.1,Mixed,,
MAP3K11,"MEKK11, MLK3, PTK1, SPRK",ENSG00000173327,Mitogen-activated protein kinase kinase kinase 11,11,65597755-65615382,"Enzymes, Predicted intracellular proteins",Evidence at protein level,CAB010165,Approved,,Supported,Microtubule organizing center<br>Cytosol,,Expressed in all,Expressed in all,,,spleen: 54.7,Expressed in all,,
MAP3K12,"DLK, MEKK12, MUK, ZPK, ZPKP1",ENSG00000139625,Mitogen-activated protein kinase kinase kinase 12,12,53479669-53500063,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039936, HPA071996",Approved,,Approved,Nucleus<br>Cell Junctions,"Renal cancer:5.43e-10 (unfavourable), Pancreatic cancer:1.51e-4 (favourable)",Mixed,Mixed,,,gallbladder: 23.9,Cell line enhanced,,HHSteC: 46.6
MAP3K13,"LZK, MEKK13",ENSG00000073803,Mitogen-activated protein kinase kinase kinase 13,3,185282941-185489097,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA016497, HPA036691, HPA036692",Uncertain,,Approved,Nucleoplasm<br>Microtubule organizing center<br>Cytosol,"Endometrial cancer:1.28e-5 (unfavourable), Pancreatic cancer:7.27e-5 (unfavourable), Ovarian cancer:1.11e-4 (favourable)",Expressed in all,Expressed in all,,,epididymis: 69.3,Mixed,,
MAP3K14,"FTDCR1B, HS, HSNIK, NIK",ENSG00000006062,Mitogen-activated protein kinase kinase kinase 14,17,45263121-45317040,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027269, HPA027270",Approved,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol,"Cervical cancer:5.27e-5 (favourable), Renal cancer:2.78e-4 (unfavourable)",Expressed in all,Expressed in all,,,lymph node: 22.8,Mixed,,
MAP3K15,"ASK3, bA723P2.3, FLJ16518",ENSG00000180815,Mitogen-activated protein kinase kinase kinase 15,X,19360056-19515261,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004006,,,Approved,Vesicles,,Mixed,Tissue enriched,6,adrenal gland: 14.3,spleen: 2.2,Cell line enhanced,,A549: 1.8;HAP1: 5.1;HEK 293: 3.8;REH: 2.4
MAP3K19,"FLJ23074, RCK, YSK4",ENSG00000176601,Mitogen-activated protein kinase kinase kinase 19,2,134964491-135047468,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA011388,,,Uncertain,Cytosol,,Tissue enhanced,Group enriched,8,fallopian tube: 28.5;testis: 7.8,lung: 2.2,Not detected,,
MAP3K2,"MEKK2, MEKK2B",ENSG00000169967,Mitogen-activated protein kinase kinase kinase 2,2,127298730-127388465,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021540,Approved,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,thyroid gland: 29.8,Expressed in all,,
MAP3K20,"MLK7, MLTK, MLTKalpha, MLTKbeta, MRK, ZAK",ENSG00000091436,Mitogen-activated protein kinase kinase kinase 20,2,173075435-173268010,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA017205,Approved,,Supported,Cytosol,Renal cancer:3.41e-6 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 133.3,Mixed,,
MAP3K21,"KIAA1804, MLK4",ENSG00000143674,Mitogen-activated protein kinase kinase kinase 21,1,233327768-233385148,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007636,Uncertain,,Approved,Plasma membrane<br>Cytosol,,Mixed,Mixed,,,testis: 17.8,Cell line enhanced,,HEK 293: 25.2
MAP3K3,"MAPKKK3, MEKK3",ENSG00000198909,Mitogen-activated protein kinase kinase kinase 3,17,63622415-63696303,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB007764, HPA035410, HPA035411",Uncertain,,Approved,Nucleoplasm,Endometrial cancer:1.13e-4 (unfavourable),Expressed in all,Expressed in all,,,spleen: 41.5,Expressed in all,,
MAP3K4,"KIAA0213, MAPKKK4, MEKK4, MTK1",ENSG00000085511,Mitogen-activated protein kinase kinase kinase 4,6,160991727-161117385,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007625,Uncertain,,Approved,Cytosol,,Expressed in all,Expressed in all,,,endometrium: 15.4,Expressed in all,,
MAP3K5,"ASK1, MAPKKK5, MEKK5",ENSG00000197442,Mitogen-activated protein kinase kinase kinase 5,6,136557047-136792518,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB007824, HPA063245, HPA064423",Approved,,Supported,Cytosol,"Pancreatic cancer:5.91e-4 (unfavourable), Head and neck cancer:6.08e-4 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 115.7,Mixed,,
MAP3K6,"ASK2, MAPKKK6, MEKK6",ENSG00000142733,Mitogen-activated protein kinase kinase kinase 6,1,27355184-27366892,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051192,Approved,,Approved,Nucleus<br>Plasma membrane<br>Actin filaments<br>Cytosol,"Glioma:1.73e-4 (unfavourable), Head and neck cancer:7.26e-4 (favourable), Liver cancer:8.76e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 114.9,esophagus: 41.2,Mixed,,
MAP3K7,"MEKK7, TAK1",ENSG00000135341,Mitogen-activated protein kinase kinase kinase 7,6,90513573-90587045,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007633,Approved,,Approved,Nuclear speckles<br>Cytosol,Liver cancer:3.51e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 29.0,Expressed in all,,
MAP3K8,"c-COT, COT, EST, ESTF, MEKK8, Tpl-2",ENSG00000107968,Mitogen-activated protein kinase kinase kinase 8,10,30433937-30461833,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB005120, HPA017962",Supported,,Supported,Cytosol,Renal cancer:8.76e-7 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 209.6,Mixed,,
MAP3K9,"MEKK9, MLK1, PRKE1",ENSG00000006432,Mitogen-activated protein kinase kinase kinase 9,14,70722526-70809534,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA000942,Approved,,Approved,Nucleus<br>Nucleoli,,Mixed,Mixed,,,testis: 10.1,Cell line enhanced,,A-431: 20.2
MAP4K1,HPK1,ENSG00000104814,Mitogen-activated protein kinase kinase kinase kinase 1,19,38587641-38618882,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007419, CAB007754",Enhanced,,Uncertain,Nucleoplasm<br>Plasma membrane,"Renal cancer:7.99e-10 (unfavourable), Cervical cancer:6.17e-5 (favourable), Head and neck cancer:3.26e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 37.3;spleen: 23.8;tonsil: 27.2,appendix: 19.2,Cell line enhanced,,Daudi: 34.0;HDLM-2: 44.1;Karpas-707: 34.0;U-266/70: 28.3;U-266/84: 27.3;U-698: 41.0
MAP4K2,"BL44, GCK, RAB8IP",ENSG00000168067,Mitogen-activated protein kinase kinase kinase kinase 2,11,64784914-64803241,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA007330,Enhanced,,Approved,Vesicles,Liver cancer:3.10e-5 (unfavourable),Expressed in all,Mixed,,,spleen: 22.9,Mixed,,
MAP4K3,"GLK, MAPKKKK3, RAB8IPL1",ENSG00000011566,Mitogen-activated protein kinase kinase kinase kinase 3,2,39249266-39437312,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA030380,Approved,,Approved,Centrosome,,Expressed in all,Expressed in all,,,thyroid gland: 40.9,Expressed in all,,
MAP4K4,"FLH21957, HGK, NIK",ENSG00000071054,Mitogen-activated protein kinase kinase kinase kinase 4,2,101696850-101894689,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA008476,Uncertain,,,,"Renal cancer:3.62e-6 (unfavourable), Lung cancer:1.57e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 154.6,Mixed,,
MAPK1,"ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2",ENSG00000100030,Mitogen-activated protein kinase 1,22,21754500-21867680,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA003995, CAB004229, HPA005700, HPA030069",Approved,,,,Liver cancer:4.95e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 132.4,Expressed in all,,
MAPK10,"JNK3, p493F12, p54bSAPK, PRKM10",ENSG00000109339,Mitogen-activated protein kinase 10,4,86010395-86594131,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,CAB022625,Approved,,,,"Renal cancer:3.11e-4 (favourable), Urothelial cancer:5.57e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 113.0,seminal vesicle: 38.6,Cell line enriched,16,AF22: 181.7
MAPK11,"p38-2, p38Beta, PRKM11, SAPK2",ENSG00000185386,Mitogen-activated protein kinase 11,22,50263713-50270767,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB012961, HPA045069",Approved,,Approved,Mitochondria,Renal cancer:6.02e-6 (unfavourable),Expressed in all,Mixed,,,cerebral cortex: 27.7,Mixed,,
MAPK12,"ERK6, p38gamma, PRKM12, SAPK-3, SAPK3",ENSG00000188130,Mitogen-activated protein kinase 12,22,50245450-50261825,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB025483, HPA054562",Enhanced,,Approved,Nuclear speckles<br>Cytosol,Renal cancer:5.00e-6 (unfavourable),Mixed,Tissue enriched,6,skeletal muscle: 91.5,cerebral cortex: 15.7,Mixed,,
MAPK13,"p38delta, PRKM13, SAPK4",ENSG00000156711,Mitogen-activated protein kinase 13,6,36127809-36144524,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007667, CAB025854",Enhanced,,Approved,Nucleus<br>Nucleoli<br>Cytosol,Renal cancer:9.00e-4 (favourable),Expressed in all,Mixed,,,skin: 93.7,Cell line enhanced,,HBEC3-KT: 107.0
MAPK14,"CSBP1, CSBP2, CSPB1, Mxi2, p38, PRKM14, PRKM15",ENSG00000112062,Mitogen-activated protein kinase 14,6,36027677-36111236,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB010285, CAB040578, HPA051825",Approved,,Supported,Nuclear speckles,,Expressed in all,Expressed in all,,,placenta: 63.2,Expressed in all,,
MAPK15,"ERK7, ERK8",ENSG00000181085,Mitogen-activated protein kinase 15,8,143716259-143722458,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA002704,,,Approved,Nucleoplasm<br>Cell Junctions<br>Cytosol,,Mixed,Tissue enhanced,,fallopian tube: 43.7,parathyroid gland: 13.2,Cell line enhanced,,CAPAN-2: 6.9;HeLa: 10.4;MCF7: 11.8;T-47d: 12.5
MAPK3,"ERK1, p44erk1, p44mapk, PRKM3",ENSG00000102882,Mitogen-activated protein kinase 3,16,30114105-30123506,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB002683, HPA003995, HPA005700, HPA030069",Approved,,Approved,Nucleoplasm,Liver cancer:1.11e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 133.7,Expressed in all,,
MAPK4,"Erk3-related, Erk4, PRKM4",ENSG00000141639,Mitogen-activated protein kinase 4,18,50560078-50731824,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,adrenal gland: 29.7;cerebral cortex: 33.4;parathyroid gland: 60.1,seminal vesicle: 13.9,Cell line enhanced,,SCLC-21H: 13.6;SH-SY5Y: 3.0
MAPK6,"ERK3, HsT17250, p97MAPK, PRKM6",ENSG00000069956,Mitogen-activated protein kinase 6,15,51952106-52067372,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB005184, HPA030262",Approved,Approved,Enhanced,Cytosol,,Expressed in all,Expressed in all,,,testis: 53.0,Expressed in all,,
MAPK7,"BMK1, ERK5, PRKM7",ENSG00000166484,Mitogen-activated protein kinase 7,17,19377721-19383544,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB018561, HPA031031",Uncertain,,Enhanced,Nucleus<br>Cytosol,Liver cancer:1.86e-4 (unfavourable),Expressed in all,Mixed,,,testis: 10.6,Mixed,,
MAPK8,"JNK, JNK1, PRKM8, SAPK1",ENSG00000107643,Mitogen-activated protein kinase 8,10,48306639-48439360,"Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004463, CAB069396",Approved,,,,"Liver cancer:8.66e-4 (unfavourable), Renal cancer:8.66e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 35.1,Expressed in all,,
MAPK9,"JNK2, p54a, PRKM9, SAPK",ENSG00000050748,Mitogen-activated protein kinase 9,5,180233143-180292099,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,CAB008910,Approved,,,,Colorectal cancer:1.11e-4 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 83.9,Expressed in all,,
MAPKAPK2,,ENSG00000162889,Mitogen-activated protein kinase-activated protein kinase 2,1,206684944-206734283,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,"CAB010297, HPA045556, HPA063708, HPA064435",Approved,,Supported,Nucleoplasm<br>Centrosome,"Renal cancer:4.58e-6 (unfavourable), Liver cancer:1.93e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 113.0,Expressed in all,,
MAPKAPK3,"3pK, MAPKAP3",ENSG00000114738,Mitogen-activated protein kinase-activated protein kinase 3,3,50611520-50649297,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058275,,,Supported,Nucleoplasm,"Renal cancer:1.90e-8 (favourable), Colorectal cancer:8.08e-5 (favourable)",Expressed in all,Expressed in all,,,heart muscle: 117.6,Expressed in all,,
MAPKAPK5,PRAK,ENSG00000089022,Mitogen-activated protein kinase-activated protein kinase 5,12,111841978-111902238,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB004546, HPA015515",Supported,,Supported,Nucleoplasm<br>Cytosol,Liver cancer:2.98e-8 (unfavourable),Expressed in all,Expressed in all,,,rectum: 33.8,Expressed in all,,
1-Mar,"FLJ20668, MARCH-I, RNF171",ENSG00000145416,Membrane associated ring-CH-type finger 1,4,163524298-164384050,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014600,Uncertain,,Supported,Mitochondria,,Mixed,Mixed,,,lymph node: 36.0,Mixed,,
10-Mar,"FLJ35757, MARCH-X, RNF190",ENSG00000173838,Membrane associated ring-CH-type finger 10,17,62701314-62808344,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023322,Enhanced,,Approved,Plasma membrane<br>Cytosol,,Mixed,Tissue enriched,7,testis: 144.4,fallopian tube: 20.5,Cell line enhanced,,BEWO: 2.5;EFO-21: 4.5;SCLC-21H: 9.7
11-Mar,MARCH-XI,ENSG00000183654,Membrane associated ring-CH-type finger 11,5,16067139-16180762,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,20,testis: 90.3,cerebral cortex: 4.5,Cell line enriched,13,SH-SY5Y: 89.2
2-Mar,"HSPC240, MARCH-II, RNF172",ENSG00000099785,Membrane associated ring-CH-type finger 2,19,8413270-8439017,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014063,Approved,,Approved,Cytosol,"Endometrial cancer:1.05e-5 (favourable), Pancreatic cancer:6.21e-4 (favourable), Colorectal cancer:6.48e-4 (unfavourable), Head and neck cancer:8.29e-4 (favourable)",Expressed in all,Expressed in all,,,epididymis: 64.8,Mixed,,
3-Mar,"MARCH-III, MGC48332, RNF173",ENSG00000173926,Membrane associated ring-CH-type finger 3,5,126867714-127030808,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA043406,Uncertain,,Supported,Vesicles,,Mixed,Mixed,,,testis: 10.9,Cell line enhanced,,hTEC/SVTERT24-B: 41.0;TIME: 27.2
4-Mar,"KIAA1399, MARCH-IV, RNF174",ENSG00000144583,Membrane associated ring-CH-type finger 4,2,216257865-216372027,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA014348,Approved,,,,,Mixed,Tissue enriched,6,cerebral cortex: 9.1,stomach: 1.6,Cell line enhanced,,BJ: 63.3;fHDF/TERT166: 37.3
5-Mar,"FLJ20445, MARCH-V, MITOL, RNF153",ENSG00000198060,Membrane associated ring-CH-type finger 5,10,92291163-92353964,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA056596,,,Supported,Mitochondria,,Expressed in all,Expressed in all,,,thyroid gland: 28.7,Expressed in all,,
6-Mar,"MARCH-VI, RNF176, TEB4",ENSG00000145495,Membrane associated ring-CH-type finger 6,5,10353703-10440388,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA040841, HPA063246",Approved,,Supported,Endoplasmic reticulum,,Expressed in all,Expressed in all,,,parathyroid gland: 96.8,Expressed in all,,
7-Mar,"AXOT, MARCH-VII, RNF177",ENSG00000136536,Membrane associated ring-CH-type finger 7,2,159712457-159771027,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA014275, HPA022152",Enhanced,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:1.84e-4 (unfavourable), Liver cancer:2.41e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 113.1,Expressed in all,,
8-Mar,"c-MIR, CMIR, MARCH-VIII, MIR, RNF178",ENSG00000165406,Membrane associated ring-CH-type finger 8,10,45454585-45594906,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014597,Approved,,,,"Pancreatic cancer:2.71e-4 (favourable), Renal cancer:6.64e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 104.6,Expressed in all,,
9-Mar,"FLJ36578, RNF179",ENSG00000139266,Membrane associated ring-CH-type finger 9,12,57755098-57760407,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,"Lung cancer:1.54e-5 (favourable), Renal cancer:2.98e-5 (favourable), Ovarian cancer:1.59e-4 (favourable), Endometrial cancer:3.07e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 30.3,Cell line enriched,16,RH-30: 498.8
MARK1,"MARK, PAR-1C",ENSG00000116141,Microtubule affinity regulating kinase 1,1,220528183-220664461,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA007421, HPA008061",Uncertain,,,,"Pancreatic cancer:2.23e-5 (favourable), Melanoma:2.63e-4 (unfavourable)",Mixed,Mixed,,,cerebral cortex: 21.1,Cell line enhanced,,RT4: 50.7
MARK2,"EMK1, PAR-1, PAR-1B, Par1b",ENSG00000072518,Microtubule affinity regulating kinase 2,11,63838928-63911019,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038790, HPA074905",Approved,,Supported,Nucleoplasm<br>Plasma membrane,"Liver cancer:1.30e-4 (unfavourable), Endometrial cancer:3.21e-4 (unfavourable)",Expressed in all,Expressed in all,,,skin: 46.1,Expressed in all,,
MARK3,"CTAK1, KP78, PAR-1A",ENSG00000075413,Microtubule affinity regulating kinase 3,14,103385392-103503831,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA024652,Approved,,Approved,Nuclear membrane,Melanoma:1.14e-4 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 64.0,Expressed in all,,
MARK4,"FLJ90097, KIAA1860, MARKL1, Nbla00650, PAR-1D",ENSG00000007047,Microtubule affinity regulating kinase 4,19,45079288-45305283,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA039186,Approved,,Approved,Cytosol,"Endometrial cancer:8.31e-8 (unfavourable), Head and neck cancer:3.05e-5 (unfavourable)",Expressed in all,Expressed in all,,,testis: 51.2,Expressed in all,,
MARS,"CMT2U, MetRS, SPG70",ENSG00000166986,Methionyl-tRNA synthetase,12,57475445-57517569,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA004125, CAB017097",Supported,Approved,Enhanced,Cytosol,"Liver cancer:4.55e-7 (unfavourable), Renal cancer:1.59e-4 (unfavourable), Breast cancer:1.73e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 66.7,Expressed in all,,
MARS2,"mtMetRS, SPAX3",ENSG00000247626,"Methionyl-tRNA synthetase 2, mitochondrial",2,197705369-197708387,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035589, HPA035590",Uncertain,,Approved,Intermediate filaments<br>Cytosol,"Renal cancer:6.14e-5 (favourable), Glioma:1.49e-4 (favourable), Endometrial cancer:3.50e-4 (unfavourable)",Expressed in all,Expressed in all,,,lymph node: 7.5,Expressed in all,,
MASP1,"CRARF, MASP, PRSS5",ENSG00000127241,Mannan binding lectin serine peptidase 1,3,187217285-187292022,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001617, HPA009641",Supported,,Supported,Nucleoplasm<br>Cytosol,Liver cancer:2.20e-4 (favourable),Group enriched,Tissue enhanced,,"cervix, uterine: 135.4",endometrium: 94.8,Group enriched,8,BJ: 107.2;BJ hTERT+: 389.0
MASP2,MASP1P1,ENSG00000009724,Mannan binding lectin serine peptidase 2,1,11026523-11047233,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA029313, HPA029314",Approved,,Supported,Golgi apparatus,Liver cancer:1.60e-4 (favourable),Tissue enriched,Tissue enriched,18,liver: 105.5,skin: 5.7,Cell line enhanced,,Hep G2: 12.9
MAST1,"KIAA0973, SAST",ENSG00000105613,Microtubule associated serine/threonine kinase 1,19,12833951-12874951,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA028181, HPA073106",Enhanced,,Approved,Vesicles,,Tissue enhanced,Tissue enriched,12,cerebral cortex: 35.2,testis: 3.0,Cell line enhanced,,AN3-CA: 21.6;SCLC-21H: 47.7;SH-SY5Y: 21.4
MAST2,"KIAA0807, MAST205",ENSG00000086015,Microtubule associated serine/threonine kinase 2,1,45786987-46036124,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA039722, HPA040155",Approved,,Approved,Cytosol,"Renal cancer:6.85e-13 (unfavourable), Liver cancer:4.31e-8 (unfavourable)",Expressed in all,Expressed in all,,,testis: 78.6,Expressed in all,,
MAST3,KIAA0561,ENSG00000099308,Microtubule associated serine/threonine kinase 3,19,18097793-18151692,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035061, HPA035062",Uncertain,,Approved,Nuclear speckles,"Head and neck cancer:2.97e-4 (favourable), Pancreatic cancer:7.01e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 51.5,Mixed,,
MAST4,KIAA0303,ENSG00000069020,Microtubule associated serine/threonine kinase family member 4,5,66596361-67169595,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000544,Approved,,Approved,Nucleoplasm<br>Cytosol,Head and neck cancer:5.18e-5 (favourable),Expressed in all,Mixed,,,parathyroid gland: 47.7,Cell line enhanced,,HDLM-2: 40.1
MASTL,"FLJ14813, Gwl, THC2",ENSG00000120539,Microtubule associated serine/threonine kinase like,10,27154824-27186924,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA027175, HPA054273",Approved,,Enhanced,Nucleoplasm,"Renal cancer:1.71e-6 (unfavourable), Liver cancer:2.52e-6 (unfavourable), Pancreatic cancer:4.81e-5 (unfavourable)",Expressed in all,Mixed,,,testis: 12.6,Expressed in all,,
MAT1A,"MAT, MATA1, SAMS, SAMS1",ENSG00000151224,Methionine adenosyltransferase 1A,10,80271820-80289684,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA048627,Supported,,,,,Tissue enriched,Tissue enriched,10,liver: 689.6,epididymis: 68.4,Cell line enriched,11,Hep G2: 64.0
MAT2A,"MATA2, MATII, SAMS2",ENSG00000168906,Methionine adenosyltransferase 2A,2,85539165-85545280,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009968, HPA043028",Approved,,Approved,Nucleoplasm<br>Cytosol,"Endometrial cancer:5.29e-5 (unfavourable), Melanoma:5.94e-5 (unfavourable), Liver cancer:4.87e-4 (unfavourable), Lung cancer:8.94e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 644.9,Expressed in all,,
MATK,"CHK, CTK, DKFZp434N1212, HHYLTK, HYL, HYLTK, Lsk, MGC1708, MGC2101",ENSG00000007264,Megakaryocyte-associated tyrosine kinase,19,3777970-3802129,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004847,Approved,,,,Breast cancer:5.27e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 22.0,spleen: 19.8,Cell line enhanced,,HL-60: 85.8;K-562: 43.3;NB-4: 47.4;SCLC-21H: 36.7
MB21D1,"C6orf150, cGAS",ENSG00000164430,Mab-21 domain containing 1,6,73413515-73452276,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA031700, HPA031702",Enhanced,,Approved,Microtubule organizing center<br>Cytosol,Renal cancer:2.27e-7 (unfavourable),Expressed in all,Mixed,,,bone marrow: 8.7,Cell line enhanced,,RH-30: 40.2
MBOAT1,"dJ434O11.1, LPEAT1, MGC44669, OACT1",ENSG00000172197,Membrane bound O-acyltransferase domain containing 1,6,20102145-20212399,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA052996,,,Approved,Mitochondria,Pancreatic cancer:9.15e-4 (unfavourable),Expressed in all,Mixed,,,fallopian tube: 55.7,Cell line enhanced,,HaCaT: 55.4;HEL: 47.2
MBOAT2,"FLJ14415, FLJ90298, OACT2",ENSG00000143797,Membrane bound O-acyltransferase domain containing 2,2,8852690-9003813,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA014836,Uncertain,,Approved,Vesicles,"Endometrial cancer:2.13e-9 (unfavourable), Urothelial cancer:5.32e-4 (unfavourable)",Mixed,Tissue enhanced,,parathyroid gland: 50.1,cerebral cortex: 29.7,Mixed,,
MBOAT7,"BB1, hMBOA-7, LENG4, LPIAT",ENSG00000125505,Membrane bound O-acyltransferase domain containing 7,19,54173412-54189882,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA055967,Approved,,Approved,Cytosol,"Liver cancer:5.55e-6 (unfavourable), Renal cancer:6.62e-5 (unfavourable), Urothelial cancer:4.31e-4 (favourable), Lung cancer:5.13e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 24.3,Cell line enhanced,,HMC-1: 150.7
MBTPS1,"KIAA0091, PCSK8, S1P, SKI-1",ENSG00000140943,"Membrane bound transcription factor peptidase, site 1",16,84053761-84116906,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA056109,Supported,,,,Renal cancer:2.21e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 118.5,Expressed in all,,
MBTPS2,"KFSD, S2P",ENSG00000012174,"Membrane bound transcription factor peptidase, site 2",X,21839636-21885424,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA005494, CAB009486",Approved,,Approved,Nucleoplasm<br>Mitochondria<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 19.3,Expressed in all,,
MCAT,"fabD, FASN2C, MCT, MCT1, MT, NET62",ENSG00000100294,Malonyl-CoA-acyl carrier protein transacylase,22,43132206-43143394,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003122, HPA035471",Approved,,Supported,Mitochondria,"Renal cancer:2.18e-4 (favourable), Stomach cancer:3.89e-4 (favourable), Endometrial cancer:5.53e-4 (favourable)",Expressed in all,Expressed in all,,,fallopian tube: 23.0,Expressed in all,,
MCCC1,MCCA,ENSG00000078070,Methylcrotonoyl-CoA carboxylase 1,3,183015218-183116075,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008310,Approved,,Enhanced,Mitochondria,Renal cancer:3.68e-4 (favourable),Expressed in all,Expressed in all,,,kidney: 57.9,Expressed in all,,
MCCC2,MCCB,ENSG00000131844,Methylcrotonoyl-CoA carboxylase 2,5,71587288-71658704,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038300, HPA038301, HPA061546",Enhanced,,Enhanced,Mitochondria,"Renal cancer:6.43e-8 (favourable), Liver cancer:1.70e-4 (favourable), Colorectal cancer:3.62e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 77.2,Mixed,,
MCEE,GLOD2,ENSG00000124370,Methylmalonyl-CoA epimerase,2,71109684-71130239,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA035196,,,Approved,Nucleoli,"Head and neck cancer:4.76e-4 (favourable), Liver cancer:5.78e-4 (favourable)",Expressed in all,Expressed in all,,,breast: 41.2,Expressed in all,,
MCM2,"BM28, CCNL1, cdc19, CDCL1, D3S3194, KIAA0030",ENSG00000073111,Minichromosome maintenance complex component 2,3,127598223-127622436,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB000303, HPA031495, HPA031496",Enhanced,,Supported,Nucleoplasm,"Liver cancer:1.51e-7 (unfavourable), Cervical cancer:4.66e-4 (favourable)",Expressed in all,Mixed,,,bone marrow: 38.5,Expressed in all,,
MCM3,,ENSG00000112118,Minichromosome maintenance complex component 3,6,52264009-52284881,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002162, HPA004789, HPA004790",Supported,,Enhanced,Nucleoplasm,"Thyroid cancer:3.13e-5 (favourable), Melanoma:4.40e-5 (unfavourable), Liver cancer:1.40e-4 (unfavourable), Cervical cancer:1.89e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 80.8,Expressed in all,,
MCM4,"CDC21, CDC54, hCdc21, MGC33310, P1-Cdc21",ENSG00000104738,Minichromosome maintenance complex component 4,8,47960185-47978160,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004497, HPA004873, HPA031052",Supported,,Enhanced,Nucleoplasm,"Endometrial cancer:2.84e-5 (unfavourable), Melanoma:1.15e-4 (unfavourable), Liver cancer:1.23e-4 (unfavourable), Colorectal cancer:2.19e-4 (favourable), Pancreatic cancer:2.38e-4 (unfavourable), Renal cancer:2.61e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 78.6,Expressed in all,,
MCM5,CDC46,ENSG00000100297,Minichromosome maintenance complex component 5,22,35400063-35425430,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000101, HPA000845, HPA052880",Enhanced,,Enhanced,Nucleoplasm,"Cervical cancer:2.81e-6 (favourable), Renal cancer:3.58e-5 (unfavourable), Liver cancer:1.78e-4 (unfavourable), Lung cancer:3.95e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 88.5,Expressed in all,,
MCM6,Mis5,ENSG00000076003,Minichromosome maintenance complex component 6,2,135839626-135876426,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA004818, CAB009577",Enhanced,,Enhanced,Nucleoplasm,"Renal cancer:8.29e-12 (unfavourable), Liver cancer:5.70e-7 (unfavourable), Melanoma:1.09e-5 (unfavourable)",Expressed in all,Mixed,,,lymph node: 40.7,Expressed in all,,
MCM7,"CDC47, MCM2, PPP1R104",ENSG00000166508,Minichromosome maintenance complex component 7,7,100092728-100101940,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002163, HPA003898, CAB016312",Enhanced,,Enhanced,Nucleoplasm,"Cervical cancer:1.28e-4 (favourable), Liver cancer:2.18e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 41.9,Expressed in all,,
MCM8,"C20orf154, dJ967N21.5, MGC119522, MGC119523, MGC12866, MGC4816, REC",ENSG00000125885,Minichromosome maintenance 8 homologous recombination repair factor,20,5950652-5998977,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA045141,,,Supported,Nucleoplasm,"Liver cancer:9.30e-8 (unfavourable), Pancreatic cancer:7.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 27.6,lymph node: 10.2,Expressed in all,,
MCM9,"C6orf61, dJ329L24.3, FLJ20170, MCMDC1, MGC35304",ENSG00000111877,Minichromosome maintenance 9 homologous recombination repair factor,6,118813442-118935162,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA031137,Approved,,Approved,Nucleoplasm,,Expressed in all,Mixed,,,epididymis: 15.5,Expressed in all,,
MDH1,,ENSG00000014641,Malate dehydrogenase 1,2,63588609-63607197,"Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027296, CAB047333, HPA054276",Uncertain,,Supported,Centrosome<br>Cytosol,"Endometrial cancer:7.13e-4 (unfavourable), Renal cancer:9.95e-4 (favourable)",Expressed in all,Expressed in all,,,heart muscle: 715.9,Expressed in all,,
MDH2,,ENSG00000146701,Malate dehydrogenase 2,7,76048051-76067508,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA019714, HPA019716, HPA019848, HPA026720",Enhanced,,Enhanced,Mitochondria,Renal cancer:1.49e-5 (favourable),Expressed in all,Expressed in all,,,skeletal muscle: 233.2,Expressed in all,,
MDM2,"HDM2, MGC5370",ENSG00000135679,MDM2 proto-oncogene,12,68808176-68850686,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB000086, CAB016303",Supported,,Supported,Nucleus,"Endometrial cancer:4.51e-7 (favourable), Cervical cancer:3.23e-4 (favourable)",Expressed in all,Expressed in all,,,rectum: 33.9,Expressed in all,,
MDP1,"FN6Pase, MGC5987",ENSG00000213920,Magnesium dependent phosphatase 1,14,24213937-24216070,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003064, HPA070338",Uncertain,,Approved,Nucleoplasm,Renal cancer:5.96e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 20.3,Mixed,,
ME1,,ENSG00000065833,Malic enzyme 1,6,83210389-83431071,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006493,Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:1.81e-7 (unfavourable), Liver cancer:4.57e-5 (unfavourable)",Expressed in all,Mixed,,,parathyroid gland: 54.1,Cell line enhanced,,CACO-2: 113.5
ME2,,ENSG00000082212,Malic enzyme 2,18,50878734-50954257,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA008247, HPA008880",Enhanced,,Enhanced,Mitochondria,Liver cancer:8.29e-8 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 39.2,Expressed in all,,
ME3,,ENSG00000151376,Malic enzyme 3,11,86441108-86672636,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA038473,Approved,,,,Urothelial cancer:3.86e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 38.7,Cell line enhanced,,CAPAN-2: 44.6;TIME: 30.7
MECR,"CGI-63, ETR1, FASN2B, NRBF1",ENSG00000116353,Mitochondrial trans-2-enoyl-CoA reductase,1,29192873-29230942,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA022018, HPA022030, HPA028740",Enhanced,,Supported,Mitochondria,"Renal cancer:5.81e-6 (favourable), Urothelial cancer:5.29e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 18.4,Expressed in all,,
MELK,KIAA0175,ENSG00000165304,Maternal embryonic leucine zipper kinase,9,36572862-36677683,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017214,Uncertain,,,,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.91e-7 (unfavourable), Lung cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.58e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 16.9,lymph node: 11.7,Expressed in all,,
MEP1A,PPHA,ENSG00000112818,Meprin A subunit alpha,6,46793390-46839782,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB025163, HPA029416",Enhanced,,,,,Tissue enriched,Group enriched,42,colon: 117.8;duodenum: 282.2;rectum: 114.3;small intestine: 538.5,appendix: 6.2,Cell line enhanced,,BEWO: 1.2;CACO-2: 2.4;RPMI-8226: 1.0
MEP1B,,ENSG00000141434,Meprin A subunit beta,18,32185069-32220404,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA029119,Enhanced,,,,,Group enriched,Group enriched,37,duodenum: 251.4;small intestine: 402.2,colon: 8.7,Cell line enhanced,,SCLC-21H: 6.6
MERTK,"c-Eyk, mer, RP38, Tyro12",ENSG00000153208,"MER proto-oncogene, tyrosine kinase",2,111898479-112029561,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036196, HPA075622",Approved,,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,"Renal cancer:4.43e-5 (favourable), Lung cancer:4.74e-4 (favourable)",Expressed in all,Mixed,,,adrenal gland: 77.2,Cell line enhanced,,CACO-2: 31.5;Hep G2: 27.2;HUVEC TERT2: 32.3
MET,"DFNB97, HGFR, RCCP2",ENSG00000105976,"MET proto-oncogene, receptor tyrosine kinase",7,116672390-116798386,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB005282, CAB018577, HPA055607",Uncertain,,Supported,Plasma membrane<br>Cytosol,"Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 39.0,Mixed,,
METAP1,"KIAA0094, MAP1A, MetAP1A",ENSG00000164024,Methionyl aminopeptidase 1,4,98995620-99062813,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB025485, HPA037997, HPA037998",Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:2.28e-5 (unfavourable), Liver cancer:3.08e-5 (unfavourable), Renal cancer:1.72e-4 (favourable), Colorectal cancer:7.22e-4 (favourable), Urothelial cancer:9.31e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 77.3,Expressed in all,,
METAP1D,"MAP1D, Metap1l",ENSG00000172878,"Methionyl aminopeptidase type 1D, mitochondrial",2,171999583-172082430,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030298, HPA030299",Uncertain,,Supported,Vesicles,,Expressed in all,Mixed,,,ovary: 9.3,Expressed in all,,
METAP2,"MAP2, MNPEP, p67",ENSG00000111142,Methionyl aminopeptidase 2,12,95473520-95515839,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB013025, HPA019095",Enhanced,,Supported,Plasma membrane<br>Cytosol,Liver cancer:4.51e-6 (unfavourable),Expressed in all,Expressed in all,,,seminal vesicle: 142.4,Expressed in all,,
METTL1,"C12orf1, TRM8, TRMT8",ENSG00000037897,Methyltransferase like 1,12,57768471-57772793,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA020914, HPA050450",Uncertain,,Enhanced,Nucleus,"Renal cancer:3.55e-6 (unfavourable), Liver cancer:4.25e-6 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 22.8,Cell line enriched,6,RH-30: 242.6
METTL11B,"C1orf184, HOMT1B",ENSG00000203740,Methyltransferase like 11B,1,170146001-170167790,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028049,Uncertain,,,,,Not detected,Tissue enhanced,,heart muscle: 1.5,"skeletal muscle,testis: 0.4",Cell line enriched,13,NTERA-2: 1.7
METTL14,KIAA1627,ENSG00000145388,Methyltransferase like 14,4,118685368-118715433,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA038002,Supported,,Supported,Nucleoplasm,Renal cancer:1.46e-5 (favourable),Expressed in all,Expressed in all,,,testis: 23.5,Expressed in all,,
METTL3,"M6A, MT-A70, Spo8",ENSG00000165819,Methyltransferase like 3,14,21498133-21511375,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,"Liver cancer:2.19e-5 (unfavourable), Pancreatic cancer:2.72e-4 (favourable), Ovarian cancer:2.78e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 35.5,Expressed in all,,
MEX3C,"FLJ38871, RKHD2, RNF194",ENSG00000176624,Mex-3 RNA binding family member C,18,51174550-51218304,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA040603,Uncertain,,Approved,Vesicles,Liver cancer:8.49e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 81.7,Expressed in all,,
MFNG,,ENSG00000100060,MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase,22,37469063-37486401,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA048936, HPA056479",Approved,,Uncertain,Actin filaments,"Renal cancer:3.31e-5 (unfavourable), Endometrial cancer:1.65e-4 (favourable), Colorectal cancer:5.12e-4 (unfavourable)",Expressed in all,Mixed,,,lymph node: 68.5,Cell line enhanced,,HL-60: 153.4;HMC-1: 213.3;HUVEC TERT2: 166.4;U-937: 134.0
MGAM,MGA,ENSG00000257335,Maltase-glucoamylase,7,141907813-142106747,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA002270,Enhanced,,,,Renal cancer:6.16e-5 (favourable),Tissue enriched,Tissue enhanced,,duodenum: 59.4;small intestine: 97.2,epididymis: 31.1,Cell line enhanced,,A549: 1.6;BJ hTERT+: 1.3;HL-60: 2.2;U-937: 3.4
MGAM2,,ENSG00000257743,Maltase-glucoamylase 2 (putative),7,142111749-142222324,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA055697,Enhanced,,Approved,Vesicles<br>Cytosol,,Group enriched,Group enriched,5,duodenum: 11.8;small intestine: 10.4,salivary gland: 2.1,Cell line enriched,7,RH-30: 1.1
MGAT1,"GLCNAC-TI, GLYT1, GNT-1, GnTI, MGAT",ENSG00000131446,"Mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase",5,180784782-180815652,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017432,Approved,,,,Renal cancer:8.65e-4 (unfavourable),Expressed in all,Expressed in all,,,spleen: 118.4,Expressed in all,,
MGAT2,GNT-II,ENSG00000168282,"Mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase",14,49620795-49623481,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA043721, HPA056824",Approved,,Supported,Golgi apparatus,Cervical cancer:3.22e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 45.0,Expressed in all,,
MGAT3,GNT-III,ENSG00000128268,"Mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase",22,39457344-39492194,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA017598,Approved,,,,Renal cancer:5.04e-8 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 38.6,small intestine: 32.5,Cell line enhanced,,BEWO: 65.1;HMC-1: 51.2;U-266/70: 57.7
MGAT4A,"GnT-4a, GnT-Iva",ENSG00000071073,"Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A",2,98619106-98731126,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007608,Enhanced,,Approved,Golgi apparatus,"Endometrial cancer:6.48e-8 (unfavourable), Breast cancer:4.30e-4 (unfavourable)",Expressed in all,Mixed,,,parathyroid gland: 84.1,Cell line enhanced,,BEWO: 122.6;TIME: 64.1
MGAT4B,GnT-Ivb,ENSG00000161013,"Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B",5,179797597-179806952,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA052134,Uncertain,,,,"Glioma:8.53e-5 (unfavourable), Renal cancer:5.78e-4 (favourable)",Expressed in all,Expressed in all,,,small intestine: 153.7,Expressed in all,,
MGAT4C,HGNT-IV-H,ENSG00000182050,MGAT4 family member C,12,85955666-86838904,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA016418,Approved,,,,,Tissue enriched,Group enriched,5,cerebral cortex: 5.9;epididymis: 6.7;testis: 5.5;thyroid gland: 15.9,adrenal gland: 1.6,Group enriched,13,NTERA-2: 8.7;SCLC-21H: 4.4
MGAT5,GNT-V,ENSG00000152127,"Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase",2,134119983-134454621,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA010919,Approved,,,,,Expressed in all,Mixed,,,parathyroid gland: 32.6,Expressed in all,,
MGAT5B,"FLJ25132, GnT-IX, GnT-VB",ENSG00000167889,"Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B",17,76868456-76950393,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA011082,,,Approved,Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle,,Group enriched,Tissue enriched,14,cerebral cortex: 23.1,testis: 1.6,Cell line enhanced,,A549: 28.7;SCLC-21H: 18.6;U-138 MG: 18.3;U-2 OS: 21.0
MGEA5,"MEA5, NCOAT, OGA",ENSG00000198408,Meningioma expressed antigen 5 (hyaluronidase),10,101784443-101818465,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036141, HPA076501",Approved,,Supported,Cytosol,Colorectal cancer:8.69e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 129.4,Expressed in all,,
MGLL,"HU-K5, MGL",ENSG00000074416,Monoglyceride lipase,3,127689062-127823250,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA011348, HPA011993, HPA011994",Enhanced,,Supported,Nucleoplasm,Pancreatic cancer:6.41e-4 (unfavourable),Expressed in all,Expressed in all,,,adipose tissue: 188.3,Cell line enhanced,,BJ hTERT+: 193.8
MGMT,,ENSG00000170430,O-6-methylguanine-DNA methyltransferase,10,129467184-129768007,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002786, HPA032135, HPA032136, HPA069497, CAB069881",Supported,,Enhanced,Nucleoplasm,"Liver cancer:1.54e-4 (favourable), Cervical cancer:9.42e-4 (favourable)",Expressed in all,Expressed in all,,,fallopian tube: 26.1,Mixed,,
MGRN1,"KIAA0544, RNF156",ENSG00000102858,Mahogunin ring finger 1,16,4616493-4690974,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007653,Approved,,,,,Expressed in all,Expressed in all,,,cerebral cortex: 56.4,Expressed in all,,
MGST1,"GST12, MGST-I",ENSG00000008394,Microsomal glutathione S-transferase 1,12,16347142-16609259,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA044840,Enhanced,,Approved,Endoplasmic reticulum<br>Mitochondria,"Thyroid cancer:1.97e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)",Expressed in all,Expressed in all,,,liver: 1602.4,Cell line enhanced,,ASC diff: 3718.8
MGST2,MGST-II,ENSG00000085871,Microsomal glutathione S-transferase 2,4,139665768-139740745,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA010707,Approved,,Approved,Nucleoplasm,"Renal cancer:3.22e-9 (favourable), Endometrial cancer:5.26e-5 (favourable)",Expressed in all,Expressed in all,,,liver: 178.3,Mixed,,
MGST3,GST-III,ENSG00000143198,Microsomal glutathione S-transferase 3,1,165630861-165661796,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA053311,,,Approved,Nucleus,,Expressed in all,Expressed in all,,,epididymis: 629.7,Expressed in all,,
MIB1,"DIP-1, KIAA1323, MIB, ZZANK2, ZZZ6",ENSG00000101752,Mindbomb E3 ubiquitin protein ligase 1,18,21704957-21870957,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA019100, CAB037044",Approved,,Approved,Nuclear membrane<br>Vesicles<br>Plasma membrane,,Expressed in all,Expressed in all,,,thyroid gland: 24.2,Expressed in all,,
MIB2,"FLJ39787, skeletrophin, ZZANK1, ZZZ5",ENSG00000197530,Mindbomb E3 ubiquitin protein ligase 2,1,1615415-1630610,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA068322,Enhanced,,,,,Expressed in all,Tissue enhanced,,skeletal muscle: 12.4,cerebral cortex: 4.4,Cell line enhanced,,SCLC-21H: 18.4
MICAL1,"DKFZp434B1517, FLJ11937, FLJ21739, MICAL, NICAL",ENSG00000135596,"Microtubule associated monooxygenase, calponin and LIM domain containing 1",6,109444062-109465968,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030175, HPA030176, HPA030178",Approved,,,,"Pancreatic cancer:2.63e-7 (favourable), Renal cancer:6.71e-7 (unfavourable)",Expressed in all,Mixed,,,bone marrow: 39.5,Cell line enhanced,,THP-1: 95.6
MICAL2,KIAA0750,ENSG00000133816,"Microtubule associated monooxygenase, calponin and LIM domain containing 2",11,12094008-12263789,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030437,Approved,,Approved,Golgi apparatus,Renal cancer:3.63e-5 (unfavourable),Expressed in all,Mixed,,,testis: 79.8,Cell line enhanced,,U-138 MG: 131.4
MICAL3,KIAA0819,ENSG00000243156,"Microtubule associated monooxygenase, calponin and LIM domain containing 3",22,17787649-18024559,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000639, HPA003421, HPA034882",Uncertain,,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 71.2,Expressed in all,,
MID1,"FXY, OS, RNF59, TRIM18",ENSG00000101871,Midline 1,X,10445310-10833654,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA003715,Approved,,,,Liver cancer:3.06e-4 (unfavourable),Expressed in all,Mixed,,,seminal vesicle: 20.7,Cell line enhanced,,A549: 168.3;AF22: 136.2
MID2,"FXY2, MRX101, RNF60, TRIM1",ENSG00000080561,Midline 2,X,107825755-107927193,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,Stomach cancer:3.73e-4 (unfavourable),Expressed in all,Mixed,,,smooth muscle: 23.4,Cell line enhanced,,HUVEC TERT2: 34.7;Karpas-707: 25.8
MIF,"GIF, GLIF",ENSG00000240972,Macrophage migration inhibitory factor (glycosylation-inhibiting factor),22,23894004-23895227,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003868, CAB005284",Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,prostate: 41.3,Expressed in all,,
MINDY1,"FAM63A, FLJ11280, MINDY-1",ENSG00000143409,MINDY lysine 48 deubiquitinase 1,1,150996086-151008375,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028351, HPA028358, HPA061086",Approved,,Supported,Nucleoplasm,Renal cancer:3.43e-8 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 79.1,Cell line enhanced,,T-47d: 46.6
MINDY2,"FAM63B, KIAA1164",ENSG00000128923,MINDY lysine 48 deubiquitinase 2,15,58771192-58861900,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA051103, HPA063669",Approved,,Enhanced,Nucleoplasm,Renal cancer:3.00e-8 (favourable),Expressed in all,Mixed,,,thyroid gland: 16.3,Expressed in all,,
MINDY3,"C10orf97, CARP, DERP5, FAM188A, FLJ13397, my042",ENSG00000148481,MINDY lysine 48 deubiquitinase 3,10,15778170-15860520,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038400, HPA038406",Uncertain,,Supported,Nucleoplasm<br>Nuclear membrane,,Expressed in all,Expressed in all,,,testis: 39.2,Expressed in all,,
MINDY4,"C7orf67, FAM188B, FLJ22374",ENSG00000106125,MINDY lysine 48 deubiquitinase 4,7,30771417-30892387,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019475, HPA030129, HPA030130",Approved,,Supported,Vesicles<br>Cytosol,,Mixed,Mixed,,,fallopian tube: 18.6,Cell line enhanced,,K-562: 17.1
MINK1,"B55, MAP4K6, MINK, YSK2, ZC3",ENSG00000141503,Misshapen like kinase 1,17,4833388-4898061,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA056296,Approved,,,,"Pancreatic cancer:2.77e-4 (favourable), Liver cancer:3.00e-4 (unfavourable), Prostate cancer:9.27e-4 (unfavourable)",Expressed in all,Expressed in all,,,skin: 72.5,Expressed in all,,
MINPP1,MIPP,ENSG00000107789,Multiple inositol-polyphosphate phosphatase 1,10,87504875-87553460,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA026859,Approved,,,,Renal cancer:6.98e-5 (unfavourable),Expressed in all,Expressed in all,,,placenta: 27.6,Mixed,,
MIOX,ALDRL6,ENSG00000100253,Myo-inositol oxygenase,22,50486784-50490648,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039451, HPA039562",Enhanced,,,,Renal cancer:2.60e-6 (favourable),Tissue enriched,Tissue enriched,30,kidney: 821.5,thyroid gland: 26.9,Cell line enhanced,,HDLM-2: 23.3;Karpas-707: 9.3;U-266/70: 5.9
MIPEP,MIP,ENSG00000027001,Mitochondrial intermediate peptidase,13,23730189-23889419,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA030676, HPA031669, HPA031670",Approved,,Enhanced,Mitochondria,Renal cancer:7.66e-12 (favourable),Expressed in all,Expressed in all,,,fallopian tube: 27.4,Expressed in all,,
MKNK1,MNK1,ENSG00000079277,MAP kinase interacting serine/threonine kinase 1,1,46557408-46616843,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB027355, CAB037310, HPA071293",Approved,,Supported,Nucleoplasm,"Liver cancer:1.24e-5 (unfavourable), Renal cancer:1.51e-5 (unfavourable), Cervical cancer:7.05e-4 (favourable)",Expressed in all,Expressed in all,,,appendix: 35.8,Expressed in all,,
MKNK2,"GPRK7, MNK2",ENSG00000099875,MAP kinase interacting serine/threonine kinase 2,19,2037465-2051244,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021875, CAB037253, HPA070499",Enhanced,,Supported,Nuclear bodies,"Endometrial cancer:4.86e-5 (favourable), Stomach cancer:4.01e-4 (favourable)",Expressed in all,Expressed in all,,,skeletal muscle: 174.3,Expressed in all,,
MKRN1,RNF61,ENSG00000133606,Makorin ring finger protein 1,7,140453040-140479569,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000567,,,Approved,Nucleus<br>Nuclear membrane<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 224.7,Expressed in all,,
MKRN2,"HSPC070, RNF62",ENSG00000075975,Makorin ring finger protein 2,3,12557014-12583713,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037559, HPA037560",Enhanced,,Approved,Nucleoplasm<br>Cytosol,"Liver cancer:1.58e-4 (unfavourable), Renal cancer:6.04e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 100.1,Expressed in all,,
MKRN3,"D15S9, MGC88288, RNF63, ZFP127, ZNF127",ENSG00000179455,Makorin ring finger protein 3,15,23565678-23630075,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA029494,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Glioma:9.23e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 5.9;placenta: 4.1;testis: 3.6,epididymis: 1.1,Cell line enhanced,,K-562: 22.8
MLKL,FLJ34389,ENSG00000168404,Mixed lineage kinase domain like pseudokinase,16,74671855-74700960,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,,,,,,Endometrial cancer:2.16e-4 (favourable),Expressed in all,Mixed,,,spleen: 28.9,Mixed,,
MLYCD,"hMCD, MCD",ENSG00000103150,Malonyl-CoA decarboxylase,16,83899126-83927026,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA031625,Enhanced,,,,Renal cancer:2.61e-7 (favourable),Expressed in all,Mixed,,,heart muscle: 3.2,Mixed,,
MMAB,"cblB, CFAP23",ENSG00000139428,Methylmalonic aciduria (cobalamin deficiency) cblB type,12,109553737-109573874,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA039017,Approved,,Approved,Mitochondria,Renal cancer:1.55e-4 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 32.5,Expressed in all,,
MME,"CALLA, CD10, NEP",ENSG00000196549,Membrane metalloendopeptidase,3,155024124-155183729,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000013, HPA052583, HPA056072",Enhanced,,,,,Mixed,Tissue enhanced,,duodenum: 428.2;kidney: 384.2;small intestine: 401.5,prostate: 162.5,Cell line enhanced,,ASC TERT1: 595.9;BJ hTERT+: 1084.7;HSkMC: 604.7
MMEL1,"MMEL2, NEPII, NL1, NL2, SEP",ENSG00000142606,Membrane metalloendopeptidase like 1,1,2590639-2632990,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007876, HPA008205, CAB020786",Uncertain,,,,,Mixed,Tissue enhanced,,testis: 5.4,stomach: 2.5,Cell line enhanced,,CAPAN-2: 2.1;EFO-21: 2.4;MCF7: 1.9;SK-BR-3: 10.6
MMP1,CLG,ENSG00000196611,Matrix metallopeptidase 1,11,102789920-102798160,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA004920,,,Approved,Vesicles,"Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,appendix: 39.2;gallbladder: 126.4,urinary bladder: 29.1,Cell line enhanced,,BJ hTERT+: 921.1;HBF TERT88: 1061.5;HUVEC TERT2: 2464.5;WM-115: 1436.5
MMP10,STMY2,ENSG00000166670,Matrix metallopeptidase 10,11,102770503-102780628,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,CAB002159,Uncertain,,Approved,Plasma membrane<br>Cytosol,Urothelial cancer:7.12e-4 (favourable),Tissue enhanced,Tissue enriched,40,endometrium: 443.1,appendix: 11.1,Cell line enhanced,,BJ: 10.0;HUVEC TERT2: 12.6;SCLC-21H: 5.6
MMP11,STMY3,ENSG00000099953,Matrix metallopeptidase 11,22,23768226-23784316,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,"CAB002593, HPA068864",Approved,,,,Renal cancer:2.62e-4 (unfavourable),Expressed in all,Group enriched,9,"cervix, uterine: 31.6;endometrium: 123.1;placenta: 28.0",smooth muscle: 6.9,Cell line enhanced,,AN3-CA: 17.4;REH: 7.4
MMP12,HME,ENSG00000262406,Matrix metallopeptidase 12,11,102862736-102875034,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,Liver cancer:1.42e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 54.6;urinary bladder: 28.7,tonsil: 17.3,Group enriched,11,BJ: 2.7;fHDF/TERT166: 8.5;hTEC/SVTERT24-B: 6.1
MMP13,CLG3,ENSG00000137745,Matrix metallopeptidase 13,11,102942995-102955734,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,lung: 1.5;urinary bladder: 1.3,appendix: 0.3,Cell line enhanced,,HaCaT: 15.8;PC-3: 6.2
MMP14,MT1-MMP,ENSG00000157227,Matrix metallopeptidase 14,14,22836557-22849027,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB009918, HPA051432",Approved,,Approved,Intermediate filaments<br>Cytosol,"Renal cancer:1.34e-4 (unfavourable), Ovarian cancer:9.48e-4 (unfavourable)",Expressed in all,Mixed,,,endometrium: 236.6,Cell line enhanced,,HHSteC: 664.7
MMP15,"MT2-MMP, MTMMP2, SMCP-2",ENSG00000102996,Matrix metallopeptidase 15,16,58025566-58046901,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002611, HPA040390",Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable)",Expressed in all,Tissue enhanced,,thyroid gland: 70.1,placenta: 39.3,Cell line enhanced,,BEWO: 86.0;WM-115: 73.7
MMP16,"C8orf57, DKFZp761D112, MT3-MMP",ENSG00000156103,Matrix metallopeptidase 16,8,88032009-88328025,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA023693,Uncertain,,Approved,Vesicles<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.6,gallbladder: 4.2,Cell line enhanced,,AN3-CA: 27.2;SH-SY5Y: 17.2;WM-115: 28.4
MMP17,MT4-MMP,ENSG00000198598,Matrix metallopeptidase 17,12,131828393-131851783,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 24.0,skin: 8.2,Group enriched,5,REH: 53.0;SK-MEL-30: 109.1;WM-115: 201.0
MMP19,"MMP18, RASI-1",ENSG00000123342,Matrix metallopeptidase 19,12,55835433-55842966,"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,HPA070804,,,Approved,Endoplasmic reticulum<br>Vesicles,Renal cancer:8.56e-9 (unfavourable),Expressed in all,Tissue enhanced,,adipose tissue: 64.2;gallbladder: 97.3,placenta: 28.2,Cell line enriched,7,BEWO: 141.1
MMP2,"CLG4, CLG4A, TBE-1",ENSG00000087245,Matrix metallopeptidase 2,16,55389700-55506691,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001939, CAB002788",Approved,,Uncertain,Vesicles<br>Cytosol,,Expressed in all,Tissue enhanced,,gallbladder: 1682.1,urinary bladder: 910.7,Cell line enhanced,,ASC diff: 3859.6;U-138 MG: 1525.4;U-87 MG: 1772.5
MMP20,,ENSG00000137674,Matrix metallopeptidase 20,11,102576835-102625332,"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,6,testis: 1.1,"appendix,breast,kidney,tonsil: 0.1",Not detected,,
MMP21,,ENSG00000154485,Matrix metallopeptidase 21,10,125766453-125775821,"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,27,epididymis: 59.2,ovary: 2.1,Not detected,,
MMP23B,"MIFR, MIFR-1, MMP22",ENSG00000189409,Matrix metallopeptidase 23B,1,1632095-1635263,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Mixed,,,"gallbladder,placenta: 4.1",Cell line enhanced,,HHSteC: 3.5;NTERA-2: 1.8;U-266/70: 2.5
MMP24,MT5-MMP,ENSG00000125966,Matrix metallopeptidase 24,20,35226654-35277000,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at transcript level,HPA049280,,,Approved,Nucleoli<br>Plasma membrane,Renal cancer:8.17e-11 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 10.6,lung: 7.0,Cell line enhanced,,A549: 32.8;CACO-2: 46.1;RPTEC TERT1: 18.5;U-2 OS: 18.9
MMP25,"MMP20, MMPL1, MT6-MMP",ENSG00000008516,Matrix metallopeptidase 25,16,3046681-3060726,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB025177,Uncertain,,,,Head and neck cancer:1.09e-5 (favourable),Tissue enhanced,Tissue enhanced,,appendix: 23.3;bone marrow: 24.7;spleen: 20.7,adipose tissue: 6.4,Cell line enriched,11,HMC-1: 95.7
MMP26,"endometase, MGC126590, MGC126592",ENSG00000167346,Matrix metallopeptidase 26,11,4704927-4992429,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at transcript level,,,,,,,Group enriched,Tissue enriched,63,endometrium: 23.9,"prostate,testis: 0.3",Not detected,,
MMP27,,ENSG00000137675,Matrix metallopeptidase 27,11,102691487-102705806,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,HPA069097,Approved,,,,,Not detected,Group enriched,5,breast: 6.0;skin: 2.8,bone marrow: 0.8,Not detected,,
MMP28,"EPILYSIN, MM28, MMP-25, MMP-28",ENSG00000271447,Matrix metallopeptidase 28,17,35756249-35795707,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Pancreatic cancer:6.28e-6 (unfavourable),Mixed,Tissue enhanced,,testis: 6.5,adipose tissue: 4.2,Cell line enriched,9,HaCaT: 32.1
MMP3,"STMY, STMY1",ENSG00000149968,Matrix metallopeptidase 3,11,102835801-102843803,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007875,Uncertain,,Supported,Vesicles,"Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,appendix: 26.5;endometrium: 58.6,urinary bladder: 9.0,Group enriched,15,BJ: 1172.2;BJ hTERT+: 3041.4;fHDF/TERT166: 1276.8
MMP7,"MPSL1, PUMP-1",ENSG00000137673,Matrix metallopeptidase 7,11,102520508-102530753,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB025869, HPA051358",Supported,,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 820.8,breast: 201.7,Cell line enhanced,,A549: 133.0;CAPAN-2: 715.3;EFO-21: 178.3;RPTEC TERT1: 262.4
MMP8,CLG1,ENSG00000118113,Matrix metallopeptidase 8,11,102711795-102727050,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA021221, HPA022935",Enhanced,,,,,Tissue enriched,Tissue enriched,103,bone marrow: 335.8,endometrium: 3.2,Cell line enriched,10,WM-115: 69.6
MMP9,CLG4B,ENSG00000100985,Matrix metallopeptidase 9,20,46008908-46016561,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201",Enhanced,,Approved,Cytosol,"Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable)",Expressed in all,Tissue enhanced,,bone marrow: 252.6;lymph node: 117.7,appendix: 82.8,Cell line enriched,8,NB-4: 227.3
MOCOS,"FLJ20733, HMCS, MOS",ENSG00000075643,Molybdenum cofactor sulfurase,18,36187519-36272157,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA039412, HPA047958",Uncertain,,Supported,Mitochondria<br>Cytosol,"Renal cancer:3.03e-12 (unfavourable), Pancreatic cancer:1.29e-4 (unfavourable), Lung cancer:3.55e-4 (unfavourable)",Mixed,Mixed,,,adrenal gland: 11.4,Cell line enhanced,,hTERT-HME1: 38.4;SiHa: 58.4;SK-MEL-30: 30.1
MOCS1,MOCOD,ENSG00000124615,Molybdenum cofactor synthesis 1,6,39899578-39934551,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA045783, HPA058177, HPA075505",Uncertain,,Approved,Plasma membrane<br>Cytosol,"Cervical cancer:1.07e-5 (unfavourable), Pancreatic cancer:6.07e-5 (favourable)",Expressed in all,Mixed,,,placenta: 60.3,Cell line enhanced,,CACO-2: 38.2
MOCS2,MOCO1,ENSG00000164172,Molybdenum cofactor synthesis 2,5,53095679-53110063,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA037679, HPA037680",Approved,,Approved,Nucleus<br>Cytosol,Renal cancer:3.68e-6 (favourable),Expressed in all,Expressed in all,,,kidney: 106.4,Expressed in all,,
MOCS3,"dJ914P20.3, UBA4",ENSG00000124217,Molybdenum cofactor synthesis 3,20,50958826-50963931,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027556,Uncertain,,,,"Liver cancer:1.39e-4 (unfavourable), Endometrial cancer:5.82e-4 (unfavourable), Renal cancer:7.55e-4 (favourable)",Expressed in all,Mixed,,,testis: 5.2,Expressed in all,,
MOGAT1,"DGAT2L, DGAT2L1, MGAT1",ENSG00000124003,Monoacylglycerol O-acyltransferase 1,2,222671786-222709930,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA049944,Uncertain,,,,,Tissue enhanced,Tissue enriched,10,gallbladder: 30.7,parathyroid gland: 2.9,Not detected,,
MOGAT2,"DGAT2L5, FLJ22644, MGAT2",ENSG00000166391,Monoacylglycerol O-acyltransferase 2,11,75717819-75732958,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA028834,Uncertain,,,,,Tissue enhanced,Group enriched,12,colon: 12.5;duodenum: 37.2;liver: 12.1;rectum: 12.5;small intestine: 43.6,appendix: 1.9,Group enriched,6,Hep G2: 2.7;RPMI-8226: 1.8
MOGAT3,"DC7, DGAT2L2, MGAT3",ENSG00000106384,Monoacylglycerol O-acyltransferase 3,7,101195007-101201021,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA011940,Uncertain,,Approved,Centrosome,,Tissue enhanced,Group enriched,6,colon: 11.3;duodenum: 30.4;rectum: 11.9;small intestine: 33.6,liver: 3.4,Cell line enhanced,,CACO-2: 2.9;Hep G2: 8.1
MOGS,"CWH41, DER7, GCS1",ENSG00000115275,Mannosyl-oligosaccharide glucosidase,2,74461057-74465410,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA011322, HPA011969",Approved,,Enhanced,Endoplasmic reticulum,"Renal cancer:2.79e-8 (unfavourable), Liver cancer:2.34e-6 (unfavourable), Colorectal cancer:5.33e-4 (unfavourable)",Expressed in all,Expressed in all,,,duodenum: 63.1,Expressed in all,,
MOK,"RAGE, RAGE1, STK30",ENSG00000080823,MOK protein kinase,14,102224500-102305200,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027292,,,Supported,Endoplasmic reticulum,,Mixed,Tissue enhanced,,testis: 71.8,fallopian tube: 34.3,Cell line enhanced,,HBF TERT88: 143.8;hTEC/SVTERT24-B: 382.7;NB-4: 315.3;U-138 MG: 197.5
MOS,,ENSG00000172680,"MOS proto-oncogene, serine/threonine kinase",8,56112942-56113982,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040424,Uncertain,,,,,Not detected,Not detected,,,testis: 0.8,Not detected,,
MOV10,"fSAP113, gb110, MGC2948",ENSG00000155363,Mov10 RISC complex RNA helicase,1,112673141-112700746,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA031627,,,Approved,Cytosol,"Renal cancer:1.48e-11 (unfavourable), Liver cancer:3.44e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 33.9,Mixed,,
MOV10L1,"CHAMP, DJ402G11.8, DKFZp434B0717",ENSG00000073146,Mov10 RISC complex RNA helicase like 1,22,50089879-50161690,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA019034,Approved,,,,,Mixed,Tissue enriched,9,testis: 39.9,endometrium: 4.2,Group enriched,6,HHSteC: 2.1;HUVEC TERT2: 10.4;TIME: 4.7
MPG,MDG,ENSG00000103152,N-methylpurine DNA glycosylase,16,77007-85853,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006531,Approved,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:2.82e-5 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 49.0,Expressed in all,,
MPI,,ENSG00000178802,Mannose phosphate isomerase,15,74890005-74902219,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007200,Approved,,Approved,Plasma membrane<br>Cytosol,Head and neck cancer:2.39e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 52.3,Expressed in all,,
MPND,FLJ14981,ENSG00000008382,MPN domain containing,19,4343527-4360086,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA043274, HPA045475",Approved,,Approved,Nucleus<br>Nucleoli,"Lung cancer:1.55e-4 (favourable), Cervical cancer:2.99e-4 (favourable), Endometrial cancer:6.12e-4 (favourable), Renal cancer:7.04e-4 (favourable)",Expressed in all,Expressed in all,,,duodenum: 30.9,Expressed in all,,
MPO,,ENSG00000005381,Myeloperoxidase,17,58269856-58280935,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000059, HPA021147, HPA061464",Enhanced,,Supported,Nucleus<br>Vesicles,,Tissue enhanced,Tissue enriched,82,bone marrow: 2499.6,salivary gland: 30.6,Group enriched,98,HL-60: 2786.8;NB-4: 2892.7
MPST,"MST, TST2, TUM1",ENSG00000128309,Mercaptopyruvate sulfurtransferase,22,37019635-37029822,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA001240,Enhanced,,Approved,Mitochondria<br>Cytosol,Urothelial cancer:5.89e-4 (favourable),Expressed in all,Mixed,,,duodenum: 108.8,Expressed in all,,
MRI1,"MGC3207, MRDI, mtnA, Ypr118w",ENSG00000037757,Methylthioribose-1-phosphate isomerase 1,19,13764532-13774282,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042744, CAB045988",Approved,,Supported,Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol,,Expressed in all,Expressed in all,,,placenta: 23.1,Mixed,,
MRPL58,"DS-1, ICT1",ENSG00000167862,Mitochondrial ribosomal protein L58,17,75012670-75021261,"Enzymes, Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,HPA003634,Approved,,Supported,Nucleoplasm<br>Mitochondria,Renal cancer:2.09e-4 (unfavourable),Expressed in all,Expressed in all,,,kidney: 36.1,Expressed in all,,
MSMO1,"DESP4, ERG25, SC4MOL",ENSG00000052802,Methylsterol monooxygenase 1,4,165327623-165343160,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA056127,Approved,,,,"Cervical cancer:2.97e-4 (unfavourable), Renal cancer:9.21e-4 (favourable)",Expressed in all,Expressed in all,,,liver: 297.1,Expressed in all,,
MSRA,,ENSG00000175806,Methionine sulfoxide reductase A,8,10054268-10428891,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA023804, HPA053069",Approved,,Enhanced,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,kidney: 113.1,Mixed,,
MST1R,"CD136, CDw136, PTK8, RON",ENSG00000164078,Macrophage stimulating 1 receptor,3,49887002-49903873,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007657, HPA008180, CAB008972",Enhanced,,Approved,Cytosol,Urothelial cancer:2.33e-5 (favourable),Mixed,Tissue enhanced,,skin: 69.4,stomach: 37.2,Cell line enhanced,,CAPAN-2: 84.1;HaCaT: 46.9;HBEC3-KT: 41.5;hTCEpi: 57.4;RT4: 49.8
MT-CO1,"COI, COX1, MTCO1",ENSG00000198804,Mitochondrially encoded cytochrome c oxidase I,MT,5904-7445,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB016241, HPA069328",Enhanced,,Supported,Mitochondria,Liver cancer:2.29e-4 (favourable),Expressed in all,Expressed in all,,,heart muscle: 79421.5,Expressed in all,,
MT-ND1,"MTND1, NAD1, ND1",ENSG00000198888,Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1,MT,3307-4262,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,CAB033779,Approved,,,,"Pancreatic cancer:3.26e-4 (favourable), Breast cancer:3.63e-4 (favourable)",Expressed in all,Expressed in all,,,skeletal muscle: 23817.4,Expressed in all,,
MT-ND2,"MTND2, NAD2, ND2",ENSG00000198763,Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2,MT,4470-5511,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Expressed in all,Expressed in all,,,heart muscle: 24880.0,Expressed in all,,
MT-ND3,"MTND3, NAD3, ND3",ENSG00000198840,Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3,MT,10059-10404,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA063296,Enhanced,,Approved,Cytosol,Liver cancer:4.63e-5 (favourable),Expressed in all,Expressed in all,,,heart muscle: 30083.4,Expressed in all,,
MT-ND4,"LHON, MTND4, NAD4, ND4",ENSG00000198886,Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4,MT,10760-12137,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA053928,Approved,,,,Ovarian cancer:1.76e-4 (favourable),Expressed in all,Expressed in all,,,heart muscle: 36982.3,Expressed in all,,
MT-ND4L,"MTND4L, NAD4L, ND4L",ENSG00000212907,Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L,MT,10470-10766,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA075648,,,Supported,Mitochondria,Liver cancer:4.47e-4 (favourable),Expressed in all,Expressed in all,,,kidney: 23320.0,Expressed in all,,
MT-ND5,"MTND5, NAD5, ND5",ENSG00000198786,Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5,MT,12337-14148,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:7.31e-5 (favourable),Expressed in all,Expressed in all,,,heart muscle: 13037.2,Expressed in all,,
MT-ND6,"MTND6, NAD6, ND6",ENSG00000198695,Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6,MT,14149-14673,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:8.91e-6 (favourable),Expressed in all,Expressed in all,,,heart muscle: 22714.1,Expressed in all,,
MTAP,"c86fus, MSAP",ENSG00000099810,Methylthioadenosine phosphorylase,9,21802543-21937651,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA046915,,,Supported,Cytosol,Liver cancer:4.68e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 15.7,Mixed,,
MTFMT,FMT1,ENSG00000103707,Mitochondrial methionyl-tRNA formyltransferase,15,65001512-65029639,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA040710,Uncertain,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:3.31e-8 (favourable),Expressed in all,Mixed,,,smooth muscle: 2.7,Mixed,,
MTHFD1,"MTHFC, MTHFD",ENSG00000100714,"Methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1",14,64388031-64463457,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000704, HPA001290, HPA015006, HPA050052",Approved,,Enhanced,Cytosol,"Renal cancer:5.93e-5 (favourable), Pancreatic cancer:6.96e-4 (unfavourable)",Expressed in all,Expressed in all,,,liver: 198.5,Expressed in all,,
MTHFD1L,"DKFZP586G1517, FLJ21145, FTHFSDC1",ENSG00000120254,Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like,6,150865549-151101887,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015006, HPA029040, HPA029041, HPA050052, HPA074911",Approved,,Supported,Mitochondria,"Cervical cancer:1.68e-5 (unfavourable), Liver cancer:8.33e-5 (unfavourable), Urothelial cancer:8.69e-5 (unfavourable), Head and neck cancer:5.10e-4 (unfavourable), Endometrial cancer:7.28e-4 (unfavourable)",Expressed in all,Mixed,,,placenta: 20.6,Expressed in all,,
MTHFD2,,ENSG00000065911,"Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase",2,74198562-74217565,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB003684, HPA049657",Approved,,,,"Renal cancer:1.11e-16 (unfavourable), Endometrial cancer:2.07e-5 (unfavourable), Glioma:8.47e-5 (favourable)",Expressed in all,Expressed in all,,,appendix: 39.6,Expressed in all,,
MTHFD2L,MGC72244,ENSG00000163738,Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like,4,74114174-74303099,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA035434,Uncertain,,,,,Mixed,Mixed,,,adrenal gland: 4.8,Mixed,,
MTHFR,,ENSG00000177000,Methylenetetrahydrofolate reductase,1,11785723-11806920,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA063389,,,Approved,Cell Junctions,"Head and neck cancer:3.97e-5 (favourable), Pancreatic cancer:4.81e-5 (favourable), Liver cancer:1.19e-4 (unfavourable), Renal cancer:2.12e-4 (favourable)",Expressed in all,Expressed in all,,,epididymis: 64.9,Expressed in all,,
MTHFS,HsT19268,ENSG00000136371,Methenyltetrahydrofolate synthetase,15,79833585-79897379,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA008067, HPA054177",Approved,,Supported,Cytosol,"Liver cancer:1.29e-6 (favourable), Renal cancer:2.04e-4 (favourable), Glioma:6.94e-4 (unfavourable)",Expressed in all,Expressed in all,,,liver: 116.1,Expressed in all,,
MTM1,,ENSG00000171100,Myotubularin 1,X,150568619-150673322,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA010008, HPA010665",Approved,,Supported,Plasma membrane,Renal cancer:7.40e-7 (favourable),Expressed in all,Mixed,,,parathyroid gland: 27.3,Expressed in all,,
MTMR1,,ENSG00000063601,Myotubularin related protein 1,X,150692971-150765103,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA002977, HPA018502",Approved,,Approved,Microtubule organizing center,,Expressed in all,Expressed in all,,,parathyroid gland: 26.6,Mixed,,
MTMR2,"CMT4B, KIAA1073",ENSG00000087053,Myotubularin related protein 2,11,95832882-95925315,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA049831,Approved,,Supported,Vesicles,"Liver cancer:1.61e-8 (unfavourable), Pancreatic cancer:3.60e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 57.8,Expressed in all,,
MTMR3,"FYVE-DSP1, KIAA0371, ZFYVE10",ENSG00000100330,Myotubularin related protein 3,22,29883155-30030866,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034515, HPA034516, HPA061399",Uncertain,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Expressed in all,,,bone marrow: 52.3,Expressed in all,,
MTMR4,"KIAA0647, ZFYVE11",ENSG00000108389,Myotubularin related protein 4,17,58489529-58517905,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:1.53e-5 (unfavourable), Pancreatic cancer:5.09e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 35.2,Expressed in all,,
MTOR,"FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1",ENSG00000198793,Mechanistic target of rapamycin,1,11106535-11262507,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB069425, HPA071227",Approved,,Approved,Vesicles<br>Cytosol,Renal cancer:1.49e-5 (favourable),Expressed in all,Expressed in all,,,testis: 62.2,Expressed in all,,
MTPAP,"FLJ10486, mtPAP, PAPD1, SPAX4",ENSG00000107951,Mitochondrial poly(A) polymerase,10,30309801-30374448,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038620, HPA058232",Approved,,Supported,Mitochondria,Liver cancer:4.20e-6 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 22.7,Expressed in all,,
MTR,cblG,ENSG00000116984,5-methyltetrahydrofolate-homocysteine methyltransferase,1,236795281-236903981,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA044474, HPA054915",Approved,,Supported,Cytosol,Thyroid cancer:5.75e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 28.7,Expressed in all,,
MTRR,cblE,ENSG00000124275,5-methyltetrahydrofolate-homocysteine methyltransferase reductase,5,7851186-7906025,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA038113,Supported,,Approved,Nucleoplasm<br>Intermediate filaments<br>Cytosol,Liver cancer:6.60e-4 (unfavourable),Expressed in all,Expressed in all,,,kidney: 20.5,Expressed in all,,
MUL1,"C1orf166, FLJ12875, GIDE, MAPL, MULAN, RNF218",ENSG00000090432,Mitochondrial E3 ubiquitin protein ligase 1,1,20499448-20508161,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA026827,,,Approved,Nucleoplasm<br>Mitochondria<br>Cytosol,Renal cancer:6.15e-14 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 39.7,Expressed in all,,
MUSK,,ENSG00000030304,Muscle associated receptor tyrosine kinase,9,110668771-110801620,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Mixed,,,testis: 3.0,Group enriched,19,LHCN-M2: 20.0;RH-30: 23.3
MUT,,ENSG00000146085,Methylmalonyl-CoA mutase,6,49430360-49463191,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035971, HPA035972",Enhanced,,Approved,Mitochondria<br>Cytosol,Renal cancer:8.71e-13 (favourable),Expressed in all,Expressed in all,,,liver: 104.1,Expressed in all,,
MVD,MPD,ENSG00000167508,Mevalonate diphosphate decarboxylase,16,88651935-88663161,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041404, HPA048250",Uncertain,,Approved,Cell Junctions<br>Cytosol,Endometrial cancer:2.17e-4 (favourable),Expressed in all,Expressed in all,,,duodenum: 33.9,Expressed in all,,
MVK,"LRBP, MK",ENSG00000110921,Mevalonate kinase,12,109573255-109598117,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA016961,Approved,,,,,Expressed in all,Expressed in all,,,testis: 31.6,Expressed in all,,
MYCBP2,"FLJ10106, KIAA0916, PAM",ENSG00000005810,"MYC binding protein 2, E3 ubiquitin protein ligase",13,77044655-77327050,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA058807,,,Supported,Nucleus<br>Vesicles,Renal cancer:5.01e-5 (favourable),Expressed in all,Expressed in all,,,skin: 82.7,Expressed in all,,
MYLIP,"IDOL, MIR",ENSG00000007944,Myosin regulatory light chain interacting protein,6,16129125-16148248,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,"Lung cancer:6.44e-6 (favourable), Urothelial cancer:4.11e-5 (favourable), Renal cancer:3.67e-4 (favourable)",Expressed in all,Expressed in all,,,placenta: 119.3,Mixed,,
MYLK,"MLCK, MLCK1, MYLK1, smMLCK",ENSG00000065534,Myosin light chain kinase,3,123610049-123884331,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB020789, HPA031677, HPA048055",Enhanced,,Enhanced,Plasma membrane<br>Actin filaments,"Renal cancer:2.04e-6 (unfavourable), Urothelial cancer:4.46e-4 (unfavourable)",Expressed in all,Expressed in all,,,smooth muscle: 3002.5,Cell line enhanced,,BJ: 144.8;BJ hTERT+: 209.1;fHDF/TERT166: 165.3;RPTEC TERT1: 207.7
MYLK2,"KMLC, MLCK2, skMLCK",ENSG00000101306,Myosin light chain kinase 2,20,31819308-31834689,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA059704, HPA059890",Enhanced,,Supported,Endoplasmic reticulum,Glioma:5.74e-4 (favourable),Tissue enhanced,Tissue enriched,49,skeletal muscle: 253.1,esophagus: 5.1,Cell line enhanced,,RH-30: 10.2;RPMI-8226: 6.2
MYLK3,"caMLCK, MLCK",ENSG00000140795,Myosin light chain kinase 3,16,46703369-46790407,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA073447,Enhanced,,,,,Not detected,Tissue enhanced,,heart muscle: 69.4;skeletal muscle: 16.9,testis: 11.7,Cell line enhanced,,BEWO: 12.5;HEL: 36.3;K-562: 5.8;SK-BR-3: 6.2
MYLK4,SgK085,ENSG00000145949,Myosin light chain kinase family member 4,6,2663629-2750966,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA015860,Uncertain,,,,,Mixed,Tissue enhanced,,skeletal muscle: 9.8,kidney: 3.1,Cell line enriched,7,HEL: 6.4
MYO3A,DFNB30,ENSG00000095777,Myosin IIIA,10,25934267-26212527,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA048951, HPA051893",Approved,,Supported,Plasma membrane<br>Actin filaments<br>Cytoplasmic bodies,,Mixed,Tissue enriched,9,testis: 6.8,skin: 0.8,Cell line enhanced,,CAPAN-2: 2.0;HEK 293: 2.2;SCLC-21H: 2.3;U-2 OS: 3.7;U-698: 8.6
MYO3B,,ENSG00000071909,Myosin IIIB,2,170178145-170655171,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045483,Approved,,,,,Mixed,Group enriched,5,epididymis: 11.8;kidney: 4.8;parathyroid gland: 15.3;urinary bladder: 4.2,thyroid gland: 1.6,Group enriched,11,HDLM-2: 8.9;HEL: 7.8;RT4: 7.8
MYSM1,KIAA1915,ENSG00000162601,"Myb like, SWIRM and MPN domains 1",1,58654739-58700092,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA054291, HPA067133",Approved,,Supported,Nucleoplasm<br>Plasma membrane,Head and neck cancer:5.09e-5 (favourable),Expressed in all,Mixed,,,parathyroid gland: 11.2,Mixed,,
NAA10,"ARD1, ARD1A, DXS707, TE2",ENSG00000102030,"N(alpha)-acetyltransferase 10, NatA catalytic subunit",X,153929242-153935223,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB006269, HPA030711",Supported,,Enhanced,Nucleoli<br>Cytosol,Renal cancer:3.29e-8 (unfavourable),Expressed in all,Expressed in all,,,smooth muscle: 25.7,Expressed in all,,
NAA11,"ARD1B, ARD2, hARD2",ENSG00000156269,"N(alpha)-acetyltransferase 11, NatA catalytic subunit",4,79225694-79326050,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA035922,Approved,,,,,Tissue enhanced,Group enriched,37,placenta: 6.1;testis: 11.4,"cerebral cortex,endometrium,parathyroid gland,smooth muscle,thyroid gland: 0.2",Cell line enhanced,,K-562: 11.1;U-266/70: 25.3;U-266/84: 8.0
NAA20,"dJ1002M8.1, NAT3, NAT5",ENSG00000173418,"N(alpha)-acetyltransferase 20, NatB catalytic subunit",20,20017116-20033655,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA063344,,,Supported,Cytosol,Head and neck cancer:1.96e-4 (unfavourable),Expressed in all,Expressed in all,,,esophagus: 82.5,Expressed in all,,
NAA30,"C14orf35, FLJ35355, MAK3, Mak3p, NAT12",ENSG00000139977,"N(alpha)-acetyltransferase 30, NatC catalytic subunit",14,57390544-57415917,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA057824,Uncertain,,Supported,Cytosol,Renal cancer:1.25e-8 (favourable),Expressed in all,Expressed in all,,,testis: 34.2,Expressed in all,,
NAA40,"FLJ13848, NAT11",ENSG00000110583,"N(alpha)-acetyltransferase 40, NatD catalytic subunit",11,63938959-63957328,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037816,Uncertain,,Approved,Nuclear bodies,Liver cancer:1.43e-7 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 27.1,Expressed in all,,
NAA50,"FLJ13194, MAK3, NAT13, NAT5, San",ENSG00000121579,"N(alpha)-acetyltransferase 50, NatE catalytic subunit",3,113716460-113746300,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Liver cancer:1.51e-5 (unfavourable), Pancreatic cancer:7.92e-5 (unfavourable), Endometrial cancer:2.32e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 111.8,Expressed in all,,
NAA60,"FLJ14154, NAT15",ENSG00000122390,"N(alpha)-acetyltransferase 60, NatF catalytic subunit",16,3443611-3486963,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040916,Approved,,Uncertain,Actin filaments<br>Cytosol,"Endometrial cancer:3.14e-4 (favourable), Pancreatic cancer:4.30e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 86.3,Expressed in all,,
NAALAD2,"GCPIII, NAALADASE2",ENSG00000077616,N-acetylated alpha-linked acidic dipeptidase 2,11,90131515-90192894,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA060820, HPA065419",Approved,,Approved,Nucleus,,Tissue enhanced,Tissue enhanced,,testis: 27.2,adrenal gland: 13.7,Group enriched,5,CACO-2: 31.5;SH-SY5Y: 13.2
NAALADL1,,ENSG00000168060,N-acetylated alpha-linked acidic dipeptidase like 1,11,65044818-65058549,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA047123,Enhanced,,Uncertain,Cytosol,,Expressed in all,Tissue enriched,5,small intestine: 104.2,duodenum: 20.1,Cell line enhanced,,fHDF/TERT166: 6.0;HHSteC: 17.2;HSkMC: 9.8;SCLC-21H: 12.7
NAALADL2,,ENSG00000177694,N-acetylated alpha-linked acidic dipeptidase like 2,3,174438573-175810552,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012413, HPA017425, CAB025586",Approved,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,parathyroid gland: 28.0,"cervix, uterine: 9.9",Cell line enhanced,,ASC TERT1: 10.1;fHDF/TERT166: 5.0;WM-115: 5.8
NADK,FLJ13052,ENSG00000008130,NAD kinase,1,1751232-1780457,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA048909, HPA053368",Uncertain,,Approved,Nucleoplasm<br>Vesicles,,Expressed in all,Expressed in all,,,spleen: 77.4,Expressed in all,,
NADK2,"C5orf33, FLJ30596, MNADK, NADKD1",ENSG00000152620,"NAD kinase 2, mitochondrial",5,36192592-36242279,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038366, HPA038367, HPA061492",Enhanced,,,,,Expressed in all,Expressed in all,,,liver: 173.0,Expressed in all,,
NADSYN1,FLJ10631,ENSG00000172890,NAD synthetase 1,11,71453109-71524107,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB017798, HPA038523, HPA038524",Approved,,Enhanced,Cytosol,"Liver cancer:5.17e-6 (unfavourable), Renal cancer:8.72e-5 (unfavourable), Urothelial cancer:5.10e-4 (favourable)",Expressed in all,Expressed in all,,,bone marrow: 41.7,Expressed in all,,
NAGA,D22S674,ENSG00000198951,Alpha-N-acetylgalactosaminidase,22,42058354-42070842,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA000649,Enhanced,,,,,Expressed in all,Expressed in all,,,parathyroid gland: 63.7,Expressed in all,,
NAGK,GNK,ENSG00000124357,N-acetylglucosamine kinase,2,71064344-71079805,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035206, HPA035207",Enhanced,,Approved,Nucleus<br>Cytosol,"Renal cancer:4.35e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable), Endometrial cancer:6.88e-4 (unfavourable)",Expressed in all,Expressed in all,,,esophagus: 148.0,Expressed in all,,
NAGLU,NAG,ENSG00000108784,N-acetyl-alpha-glucosaminidase,17,42536172-42544449,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA038815,Supported,Approved,,,"Renal cancer:2.58e-6 (favourable), Glioma:3.43e-4 (unfavourable), Endometrial cancer:4.17e-4 (favourable), Pancreatic cancer:6.90e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 47.5,Expressed in all,,
NAGPA,"APAA, UCE",ENSG00000103174,N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase,16,5024844-5034141,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA064055,Approved,,,,"Renal cancer:2.67e-5 (unfavourable), Liver cancer:4.67e-4 (unfavourable)",Expressed in all,Mixed,,,cerebral cortex: 9.6,Mixed,,
NAGS,"AGAS, ARGA, NAT7",ENSG00000161653,N-acetylglutamate synthase,17,44004546-44009063,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA027300,,,Supported,Mitochondria,,Expressed in all,Tissue enhanced,,duodenum: 14.8;small intestine: 13.6,liver: 5.0,Cell line enhanced,,HHSteC: 4.0;TIME: 5.0;U-87 MG: 8.7
NAMPT,"PBEF, PBEF1",ENSG00000105835,Nicotinamide phosphoribosyltransferase,7,106248285-106286326,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB034349, HPA047776, HPA057722",Approved,,Approved,Nuclear speckles<br>Cell Junctions,"Renal cancer:2.49e-6 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable), Cervical cancer:4.78e-4 (unfavourable), Head and neck cancer:8.81e-4 (unfavourable)",Expressed in all,Expressed in all,,,appendix: 778.1,Expressed in all,,
NANP,"C20orf147, dJ694B14.3, HDHD4, MGC26833",ENSG00000170191,N-acetylneuraminic acid phosphatase,20,25612935-25624175,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA050342,Uncertain,,Approved,Nuclear membrane,Liver cancer:9.01e-6 (unfavourable),Expressed in all,Mixed,,,testis: 4.9,Expressed in all,,
NANS,SAS,ENSG00000095380,N-acetylneuraminate synthase,9,98056739-98083075,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA019223,Approved,,Approved,Nucleoplasm,"Endometrial cancer:1.71e-4 (favourable), Liver cancer:6.42e-4 (unfavourable)",Expressed in all,Expressed in all,,,prostate: 148.2,Expressed in all,,
NAPEPLD,"C7orf18, FMP30, NAPE-PLD",ENSG00000161048,N-acyl phosphatidylethanolamine phospholipase D,7,103099776-103149560,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019832, HPA024338",Approved,,Enhanced,Cytosol,Renal cancer:7.32e-6 (favourable),Expressed in all,Mixed,,,cerebral cortex: 11.2,Mixed,,
NAPRT,"NAPRT1, PP3856",ENSG00000147813,Nicotinate phosphoribosyltransferase,8,143574785-143578649,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA023739, HPA024017, CAB068206, CAB068207",Enhanced,,Approved,Nucleus<br>Golgi apparatus<br>Cytosol,Renal cancer:6.28e-4 (favourable),Expressed in all,Tissue enhanced,,duodenum: 21.4;small intestine: 20.7,bone marrow: 9.6,Cell line enhanced,,CAPAN-2: 33.3;SK-BR-3: 30.1
NAPSA,"KAP, Kdap, NAP1, NAPA",ENSG00000131400,Napsin A aspartic peptidase,19,50358477-50365830,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB009591, HPA045280, HPA047236, HPA047744",Enhanced,,,,Renal cancer:1.21e-4 (favourable),Tissue enriched,Tissue enriched,14,lung: 1412.2,kidney: 101.4,Cell line enriched,23,U-698: 27.1
NARS,NARS1,ENSG00000134440,Asparaginyl-tRNA synthetase,18,57600656-57622213,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB034257, HPA040017",Enhanced,,Approved,Cytosol,"Liver cancer:1.23e-7 (unfavourable), Renal cancer:1.73e-7 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 154.1,Expressed in all,,
NARS2,"DFNB94, FLJ23441, SLM5",ENSG00000137513,"Asparaginyl-tRNA synthetase 2, mitochondrial (putative)",11,78435961-78574874,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA026793,Supported,,Approved,Nucleoplasm<br>Mitochondria<br>Cytosol,"Renal cancer:1.22e-6 (favourable), Ovarian cancer:1.39e-5 (favourable)",Expressed in all,Expressed in all,,,kidney: 19.8,Expressed in all,,
NAT1,AAC1,ENSG00000171428,N-acetyltransferase 1,8,18170477-18223689,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB017782, HPA043704",Approved,,,,Colorectal cancer:5.07e-4 (favourable),Tissue enriched,Mixed,,,epididymis: 18.4,Mixed,,
NAT2,AAC2,ENSG00000156006,N-acetyltransferase 2,8,18391245-18401218,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043704,Uncertain,,,,Colorectal cancer:4.61e-5 (favourable),Tissue enhanced,Group enriched,13,colon: 14.4;duodenum: 32.7;liver: 62.4;rectum: 14.0;small intestine: 27.1,smooth muscle: 2.3,Cell line enhanced,,RT4: 1.2;SCLC-21H: 2.5;SK-BR-3: 1.0
NAT8,"ATase2, GLA, Hcml1, TSC501",ENSG00000144035,N-acetyltransferase 8 (putative),2,73640832-73642393,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA067855, HPA074519",Enhanced,,Approved,Endoplasmic reticulum,,Tissue enriched,Tissue enriched,18,kidney: 891.8,liver: 49.4,Cell line enriched,12,Hep G2: 8.7
NAT8L,"FLJ37478, Hcml3",ENSG00000185818,N-acetyltransferase 8 like,4,2059512-2069089,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040677,,,Supported,Mitochondria,Endometrial cancer:1.01e-5 (unfavourable),Group enriched,Group enriched,7,adipose tissue: 48.6;cerebral cortex: 64.9;testis: 19.0,kidney: 6.7,Cell line enhanced,,SCLC-21H: 32.4
NAV2,"FLJ10633, FLJ11030, FLJ23707, HELAD1, KIAA1419, POMFIL2, RAINB1",ENSG00000166833,Neuron navigator 2,11,19350724-20121598,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA011755, HPA011891",Approved,,Supported,Nucleoplasm,,Expressed in all,Mixed,,,heart muscle: 39.2,Cell line enhanced,,hTERT-HME1: 69.3;SH-SY5Y: 87.7
NAXD,"CARKD, FLJ10769, LP3298",ENSG00000213995,NAD(P)HX dehydratase,13,110615460-110639993,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA010551,Uncertain,,,,"Renal cancer:4.63e-5 (favourable), Endometrial cancer:3.15e-4 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 26.9,Mixed,,
NAXE,"AIBP, APOA1BP, MGC119143, MGC119144, MGC119145, YJEFN1",ENSG00000163382,NAD(P)HX epimerase,1,156591762-156594299,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA043766, HPA048164",Enhanced,,Enhanced,Nucleoplasm<br>Cytosol,Endometrial cancer:4.94e-4 (unfavourable),Expressed in all,Expressed in all,,,epididymis: 112.2,Expressed in all,,
NCOA1,"bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1",ENSG00000084676,Nuclear receptor coactivator 1,2,24491914-24770702,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB019402, HPA070213, HPA070520",Enhanced,,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 59.0,Expressed in all,,
NCOA3,"ACTR, AIB1, bHLHe42, CAGH16, KAT13B, p/CIP, RAC3, SRC-3, SRC3, TNRC16, TRAM-1",ENSG00000124151,Nuclear receptor coactivator 3,20,47501902-47656877,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB009800, HPA024210",Supported,,Supported,Nucleoplasm<br>Cytosol,Liver cancer:8.09e-4 (unfavourable),Expressed in all,Expressed in all,,,lymph node: 44.8,Expressed in all,,
NDST1,"HSST, NST1",ENSG00000070614,N-deacetylase and N-sulfotransferase 1,5,150485818-150558211,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA060532,Approved,,,,"Ovarian cancer:5.13e-4 (unfavourable), Endometrial cancer:6.99e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 59.7,Expressed in all,,
NDST2,"HSST2, NST2",ENSG00000166507,N-deacetylase and N-sulfotransferase 2,10,73801911-73811798,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA051515,Approved,,Approved,Cytosol,,Mixed,Expressed in all,,,spleen: 44.9,Expressed in all,,
NDST3,HSST3,ENSG00000164100,N-deacetylase and N-sulfotransferase 3,4,118033618-118258648,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA056189,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 3.0;spleen: 2.8,"cervix, uterine: 0.7",Cell line enriched,16,MOLT-4: 13.3
NDST4,,ENSG00000138653,N-deacetylase and N-sulfotransferase 4,4,114827763-115113876,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA011129,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.4;ovary: 1.8,spleen: 1.0,Cell line enhanced,,AF22: 2.8;CACO-2: 2.4;RH-30: 14.2;T-47d: 3.1
NDUFAF7,"C2orf56, MidA, PRO1853",ENSG00000003509,NADH:ubiquinone oxidoreductase complex assembly factor 7,2,37231631-37253403,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045217,Uncertain,,,,"Liver cancer:1.48e-4 (unfavourable), Lung cancer:3.08e-4 (favourable)",Expressed in all,Tissue enriched,5,testis: 69.1,adrenal gland: 12.9,Expressed in all,,
NDUFS1,CI-75k,ENSG00000023228,NADH:ubiquinone oxidoreductase core subunit S1,2,206114817-206159603,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA064605, CAB070844",Approved,,Supported,Mitochondria,"Renal cancer:1.47e-12 (favourable), Breast cancer:3.85e-4 (unfavourable)",Expressed in all,Expressed in all,,,heart muscle: 71.1,Expressed in all,,
NDUFS2,CI-49,ENSG00000158864,NADH:ubiquinone oxidoreductase core subunit S2,1,161197104-161214395,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA055140, HPA061953",Enhanced,,Enhanced,Nucleoplasm<br>Mitochondria,Renal cancer:2.32e-4 (favourable),Expressed in all,Expressed in all,,,heart muscle: 124.0,Expressed in all,,
NDUFS3,CI-30,ENSG00000213619,NADH:ubiquinone oxidoreductase core subunit S3,11,47565336-47584562,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA004484,Approved,,Supported,Nuclear bodies<br>Mitochondria,Renal cancer:2.61e-6 (favourable),Expressed in all,Expressed in all,,,skeletal muscle: 127.2,Expressed in all,,
NDUFS7,"CI-20, FLJ45860, FLJ46880, PSST",ENSG00000115286,NADH:ubiquinone oxidoreductase core subunit S7,19,1383527-1395589,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:4.90e-7 (favourable), Cervical cancer:2.03e-4 (favourable)",Expressed in all,Tissue enhanced,,skeletal muscle: 96.7,duodenum: 40.7,Mixed,,
NDUFS8,"CI-23k, TYKY",ENSG00000110717,NADH:ubiquinone oxidoreductase core subunit S8,11,68030617-68036644,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA018524,Approved,,Supported,Mitochondria,Renal cancer:3.27e-8 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 152.6,Expressed in all,,
NDUFV1,CI-51K,ENSG00000167792,NADH:ubiquinone oxidoreductase core subunit V1,11,67606852-67612535,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA045211, HPA075051",Approved,,Supported,Mitochondria<br>Cytosol,Renal cancer:7.49e-10 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 222.1,Expressed in all,,
NDUFV2,CI-24k,ENSG00000178127,NADH:ubiquinone oxidoreductase core subunit V2,18,9102630-9134345,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003404, HPA077896",Supported,Approved,Supported,Mitochondria,,Expressed in all,Expressed in all,,,skeletal muscle: 190.8,Expressed in all,,
NEDD4,"KIAA0093, MGC176705, NEDD4-1, RPF1",ENSG00000069869,"Neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase",15,55826922-55993746,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB001991, HPA039883, CAB072833",Approved,,Approved,Cytosol,"Renal cancer:3.74e-6 (unfavourable), Lung cancer:5.14e-4 (unfavourable)",Expressed in all,Mixed,,,placenta: 22.4,Mixed,,
NEDD4L,"KIAA0439, NEDD4-2, RSP5",ENSG00000049759,"Neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase",18,58044367-58401540,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA024618, HPA064730",Approved,,Approved,Focal adhesion sites,Renal cancer:6.55e-15 (favourable),Expressed in all,Expressed in all,,,prostate: 71.5,Mixed,,
NEIL1,"FLJ22402, FPG1, hFPG1, NEI1",ENSG00000140398,Nei like DNA glycosylase 1,15,75346955-75357114,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA054084,Approved,,Supported,Nucleoplasm,Pancreatic cancer:2.09e-4 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 10.6,Mixed,,
NEIL2,"FLJ31644, MGC2832, MGC4505, NEH2",ENSG00000154328,Nei like DNA glycosylase 2,8,11769639-11787346,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA073029, HPA073916",,,Enhanced,Nucleoplasm<br>Vesicles,,Expressed in all,Expressed in all,,,testis: 45.4,Mixed,,
NEIL3,"FLJ10858, FPG2, hFPG2, hNEI3, ZGRF3",ENSG00000109674,Nei like DNA glycosylase 3,4,177309836-177362943,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA065761,,,Enhanced,Nucleoplasm,"Lung cancer:1.16e-4 (unfavourable), Endometrial cancer:5.45e-4 (unfavourable)",Mixed,Mixed,,,bone marrow: 4.3,Mixed,,
NEK1,"KIAA1901, NY-REN-55",ENSG00000137601,NIMA related kinase 1,4,169392857-169612629,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020873, HPA040413",Approved,,Approved,Nuclear membrane<br>Nucleoli,Renal cancer:1.42e-4 (favourable),Expressed in all,Mixed,,,testis: 21.8,Expressed in all,,
NEK10,FLJ32685,ENSG00000163491,NIMA related kinase 10,3,27110085-27369460,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA038941,Uncertain,,Approved,Nucleoplasm<br>Vesicles,Breast cancer:4.20e-4 (favourable),Tissue enriched,Tissue enhanced,,testis: 65.9,breast: 18.6,Cell line enhanced,,LHCN-M2: 6.8;U-2 OS: 7.1
NEK11,FLJ23495,ENSG00000114670,NIMA related kinase 11,3,131026850-131350465,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA016908,Approved,,Supported,Nucleoplasm,"Renal cancer:5.92e-6 (favourable), Cervical cancer:7.10e-4 (favourable)",Mixed,Tissue enhanced,,fallopian tube: 34.6,testis: 28.0,Mixed,,
NEK2,"NEK2A, NLK1, PPP1R111, RP67",ENSG00000117650,NIMA related kinase 2,1,211658657-211675630,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB017530, HPA064967",Enhanced,,Supported,Nucleus<br>Centrosome,"Liver cancer:9.47e-6 (unfavourable), Lung cancer:9.11e-4 (unfavourable)",Mixed,Tissue enriched,11,testis: 121.2,bone marrow: 11.2,Mixed,,
NEK3,"HSPK36, MGC29949",ENSG00000136098,NIMA related kinase 3,13,52132639-52159861,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019062, HPA043230",Enhanced,,Approved,Microtubules,,Expressed in all,Expressed in all,,,testis: 29.6,Mixed,,
NEK4,"NRK2, pp12301, STK2",ENSG00000114904,NIMA related kinase 4,3,52708449-52770949,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA015750, HPA058543",Approved,,Supported,Cytosol,Colorectal cancer:2.69e-5 (favourable),Expressed in all,Expressed in all,,,testis: 84.3,Expressed in all,,
NEK5,,ENSG00000197168,NIMA related kinase 5,13,52033611-52129078,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035565, HPA041399",Enhanced,,,,,Mixed,Group enriched,8,fallopian tube: 12.2;testis: 18.7,lung: 1.9,Cell line enhanced,,T-47d: 1.0
NEK6,SID6-1512,ENSG00000119408,NIMA related kinase 6,9,124257606-124353307,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB045993, HPA056828",Approved,,Supported,Nucleoplasm<br>Microtubule organizing center<br>Cytosol,Testis cancer:7.66e-4 (unfavourable),Expressed in all,Expressed in all,,,appendix: 44.3,Cell line enhanced,,HMC-1: 219.5
NEK7,,ENSG00000151414,NIMA related kinase 7,1,198156963-198322420,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA015520, HPA018193",Approved,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,heart muscle: 93.3,Expressed in all,,
NEK8,NPHP9,ENSG00000160602,NIMA related kinase 8,17,28725897-28743455,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA040661, HPA040679",Approved,,,,"Lung cancer:4.52e-4 (favourable), Colorectal cancer:6.98e-4 (unfavourable)",Expressed in all,Mixed,,,thyroid gland: 9.7,Mixed,,
NEK9,"DKFZp434D0935, MGC16714, Nek8, NERCC",ENSG00000119638,NIMA related kinase 9,14,75079353-75127344,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA001405,Approved,,Approved,Mitochondria,Pancreatic cancer:5.63e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 29.9,Mixed,,
NEU1,NEU,ENSG00000204386,Neuraminidase 1,6,31857659-31862906,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA015634, HPA021506",Approved,,Supported,Vesicles<br>Cell Junctions,,Expressed in all,Mixed,,,thyroid gland: 14.3,Expressed in all,,
NEU2,SIAL2,ENSG00000115488,Neuraminidase 2,2,233032672-233035057,"Enzymes, Predicted intracellular proteins",Evidence at protein level,CAB022336,Uncertain,,,,,Not detected,Tissue enriched,13,skin: 1.4,breast: 0.1,Not detected,,
NEU3,,ENSG00000162139,Neuraminidase 3,11,74988134-75018893,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038729, HPA038730, HPA070381",Uncertain,,Supported,Nucleoplasm<br>Vesicles,Pancreatic cancer:5.98e-4 (favourable),Expressed in all,Mixed,,,parathyroid gland: 25.4,Expressed in all,,
NEU4,,ENSG00000204099,Neuraminidase 4,2,241808825-241817413,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037394, HPA037395",Uncertain,,,,,Group enriched,Group enriched,6,bone marrow: 2.4;cerebral cortex: 6.3;colon: 8.3;duodenum: 5.6;liver: 4.1;rectum: 3.7;small intestine: 5.3,"fallopian tube,gallbladder: 0.7",Group enriched,20,Hep G2: 26.3;HMC-1: 45.5
NEURL1,"h-neu, neu-1, NEURL, RNF67",ENSG00000107954,Neuralized E3 ubiquitin protein ligase 1,10,103493979-103592552,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA044204,Uncertain,,,,,Mixed,Tissue enhanced,,skeletal muscle: 50.9,cerebral cortex: 30.1,Cell line enhanced,,BEWO: 13.2;SCLC-21H: 20.2;SiHa: 9.4
NEURL1B,"DKFZP761M1511, Neur2",ENSG00000214357,Neuralized E3 ubiquitin protein ligase 1B,5,172641266-172691540,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037612,Approved,,Supported,Vesicles,Renal cancer:3.00e-6 (unfavourable),Expressed in all,Mixed,,,seminal vesicle: 45.0,Cell line enhanced,,REH: 39.9
NEURL3,"Lincr, LOC93082",ENSG00000163121,Neuralized E3 ubiquitin protein ligase 3,2,96497643-96508109,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,,,,,,Liver cancer:6.46e-4 (unfavourable),Mixed,Tissue enhanced,,salivary gland: 13.9,pancreas: 4.2,Cell line enhanced,,BEWO: 3.6;CAPAN-2: 13.6;RPMI-8226: 6.9;RT4: 3.7
NFS1,"IscS, NifS",ENSG00000244005,"NFS1, cysteine desulfurase",20,35668055-35699359,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB034314, HPA051801, HPA054755",Enhanced,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:4.72e-6 (favourable),Expressed in all,Expressed in all,,,kidney: 43.7,Expressed in all,,
NGLY1,"FLJ11005, PNG1",ENSG00000151092,N-glycanase 1,3,25718944-25790039,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA036825,Approved,,,,"Liver cancer:1.96e-6 (unfavourable), Colorectal cancer:1.17e-5 (favourable)",Expressed in all,Expressed in all,,,testis: 116.0,Expressed in all,,
NHLRC1,"bA204B7.2, EPM2B, malin",ENSG00000187566,NHL repeat containing E3 ubiquitin protein ligase 1,6,18120440-18122687,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA066030,,,Uncertain,Vesicles,"Urothelial cancer:5.30e-4 (favourable), Endometrial cancer:9.01e-4 (unfavourable)",Expressed in all,Mixed,,,skin: 4.5,Cell line enhanced,,EFO-21: 6.4;SCLC-21H: 7.2
NIM1K,"MGC42105, NIM1",ENSG00000177453,NIM1 serine/threonine protein kinase,5,43192071-43280850,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA007695,Uncertain,,Approved,Cytosol,,Tissue enriched,Tissue enriched,8,cerebral cortex: 16.3,lung: 2.0,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 1.9;HDLM-2: 2.1;PC-3: 2.4;U-87 MG: 2.6
NIT2,,ENSG00000114021,Nitrilase family member 2,3,100334701-100361635,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA036999,Approved,,Supported,Centrosome<br>Cytosol,Endometrial cancer:4.62e-4 (unfavourable),Expressed in all,Mixed,,,kidney: 19.0,Expressed in all,,
NKTR,p104,ENSG00000114857,Natural killer cell triggering receptor,3,42600614-42648741,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA022120, HPA051576",Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Urothelial cancer:1.05e-5 (favourable), Head and neck cancer:1.26e-4 (favourable), Renal cancer:5.02e-4 (unfavourable), Prostate cancer:6.01e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 24.3,Expressed in all,,
NLK,,ENSG00000087095,Nemo like kinase,17,28041737-28196381,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA018192, HPA056511",Approved,,Supported,Nucleus<br>Nucleoli<br>Cell Junctions,,Expressed in all,Expressed in all,,,cerebral cortex: 52.4,Expressed in all,,
NLN,"AGTBP, KIAA1226",ENSG00000123213,Neurolysin,5,65722196-65871725,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA031862,Approved,,Approved,Mitochondria,"Renal cancer:5.58e-7 (favourable), Pancreatic cancer:7.51e-4 (unfavourable)",Expressed in all,Mixed,,,cerebral cortex: 8.2,Expressed in all,,
NME1,"NDPKA, NM23, NM23-H1",ENSG00000239672,NME/NM23 nucleoside diphosphate kinase 1,17,51153536-51162428,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA008467, CAB040571, HPA041113",Supported,,Enhanced,Nucleoplasm<br>Cytosol,"Renal cancer:2.07e-9 (unfavourable), Liver cancer:2.60e-5 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 89.3,Expressed in all,,
NME2,"NDPKB, NM23-H2",ENSG00000243678,NME/NM23 nucleoside diphosphate kinase 2,17,51165435-51171747,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041113,Approved,,,,"Renal cancer:1.55e-6 (unfavourable), Cervical cancer:4.74e-4 (unfavourable), Liver cancer:7.09e-4 (unfavourable)",Expressed in all,Expressed in all,,,breast: 512.0,Expressed in all,,
NME3,"DR-nm23, NDPKC, NM23-H3",ENSG00000103024,NME/NM23 nucleoside diphosphate kinase 3,16,1770286-1771730,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041113, HPA052733",Approved,,Approved,Nucleoplasm<br>Cytosol,Breast cancer:6.81e-5 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 36.1,Cell line enhanced,,HEK 293: 64.8
NME4,"NDPKD, nm23-H4, NM23H4",ENSG00000103202,NME/NM23 nucleoside diphosphate kinase 4,16,396725-410367,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB045997, HPA072588",Approved,,Supported,Mitochondria,"Renal cancer:1.61e-7 (unfavourable), Cervical cancer:6.53e-4 (unfavourable)",Expressed in all,Expressed in all,,,prostate: 167.2,Mixed,,
NME6,"IPIA-ALPHA, NM23-H6",ENSG00000172113,NME/NM23 nucleoside diphosphate kinase 6,3,48293264-48301685,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA017909,Approved,,Approved,Vesicles,"Liver cancer:2.17e-7 (unfavourable), Renal cancer:3.18e-5 (favourable)",Expressed in all,Expressed in all,,,fallopian tube: 27.7,Expressed in all,,
NME7,"CFAP67, FLJ37194, NM23-H7",ENSG00000143156,NME/NM23 family member 7,1,169132531-169367967,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038014, HPA054289",Uncertain,,Approved,Mitochondria,Liver cancer:3.24e-5 (unfavourable),Expressed in all,Expressed in all,,,fallopian tube: 39.0,Expressed in all,,
NMNAT1,"LCA9, NMNAT, PNAT1",ENSG00000173614,Nicotinamide nucleotide adenylyltransferase 1,1,9943428-9985501,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA059447,Approved,,Supported,Nucleoplasm<br>Nuclear bodies,Renal cancer:3.85e-14 (favourable),Expressed in all,Mixed,,,thyroid gland: 12.5,Mixed,,
NMNAT2,"C1orf15, KIAA0479, PNAT2",ENSG00000157064,Nicotinamide nucleotide adenylyltransferase 2,1,183248237-183418602,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA061714,Enhanced,,,,,Mixed,Tissue enriched,6,cerebral cortex: 73.5,testis: 13.3,Cell line enhanced,,SCLC-21H: 91.4;U-2197: 42.4;U-87 MG: 34.4
NMNAT3,PNAT3,ENSG00000163864,Nicotinamide nucleotide adenylyltransferase 3,3,139560180-139678017,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039077, HPA057402",Approved,,Supported,Mitochondria,"Renal cancer:1.95e-5 (favourable), Pancreatic cancer:7.29e-5 (favourable), Cervical cancer:9.67e-4 (favourable)",Mixed,Mixed,,,ovary: 20.5,Cell line enhanced,,HEL: 22.9;THP-1: 8.5;U-266/70: 11.9
NMRK1,"bA235O14.2, C9orf95, FLJ20559, NRK1",ENSG00000106733,Nicotinamide riboside kinase 1,9,75060573-75088217,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA049795,Approved,,Approved,Nucleoplasm<br>Cytosol,"Endometrial cancer:3.70e-6 (favourable), Renal cancer:5.60e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 120.8,Cell line enhanced,,HDLM-2: 70.8
NMRK2,"ITGB1BP3, MIBP, NRK2",ENSG00000077009,Nicotinamide riboside kinase 2,19,3933103-3942416,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049909, HPA054792, HPA072450",Approved,,Enhanced,Nucleoplasm<br>Vesicles,Renal cancer:1.19e-4 (favourable),Tissue enhanced,Group enriched,49,heart muscle: 374.4;skeletal muscle: 218.4,esophagus: 6.1,Group enriched,9,BEWO: 28.1;NTERA-2: 24.3
NMT1,NMT,ENSG00000136448,N-myristoyltransferase 1,17,45051610-45109016,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA022949, HPA022963",Enhanced,,Supported,Plasma membrane<br>Cytosol,Liver cancer:4.94e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 58.6,Expressed in all,,
NMT2,,ENSG00000152465,N-myristoyltransferase 2,10,15102584-15168693,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001303,Approved,,Supported,Golgi apparatus<br>Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 39.4,Cell line enhanced,,TIME: 123.2
NNMT,,ENSG00000166741,Nicotinamide N-methyltransferase,11,114257787-114313285,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA059180,Approved,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,"Renal cancer:1.02e-6 (unfavourable), Stomach cancer:1.75e-4 (unfavourable), Head and neck cancer:2.07e-4 (unfavourable)",Expressed in all,Tissue enhanced,,liver: 197.2,adipose tissue: 107.8,Cell line enhanced,,HSkMC: 300.0;RPTEC TERT1: 491.7
NNT,,ENSG00000112992,Nicotinamide nucleotide transhydrogenase,5,43602692-43707405,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA004829, CAB004975",Enhanced,,Enhanced,Mitochondria,Renal cancer:1.22e-15 (favourable),Expressed in all,Expressed in all,,,heart muscle: 130.6,Expressed in all,,
NOCT,"Ccr4c, CCR4L, CCRN4L, NOC",ENSG00000151014,Nocturnin,4,139015789-139045939,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA012287, HPA053714",Uncertain,,Supported,Nucleoplasm<br>Nuclear bodies<br>Cytosol,"Renal cancer:1.05e-5 (unfavourable), Lung cancer:5.28e-5 (unfavourable), Urothelial cancer:6.23e-4 (unfavourable)",Expressed in all,Tissue enhanced,,bone marrow: 21.2,gallbladder: 8.4,Expressed in all,,
NOS1,"nNOS, NOS",ENSG00000089250,Nitric oxide synthase 1,12,117208142-117452170,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002167, HPA058312",Uncertain,,Supported,Nucleoplasm<br>Plasma membrane,,Mixed,Tissue enhanced,,skeletal muscle: 12.9,cerebral cortex: 3.0,Cell line enhanced,,HaCaT: 4.0;RH-30: 9.0;RPTEC TERT1: 4.4
NOS2,"HEP-NOS, iNOS, NOS, NOS2A",ENSG00000007171,Nitric oxide synthase 2,17,27756766-27800499,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB002014,Approved,,,,,Tissue enhanced,Group enriched,5,appendix: 18.9;colon: 7.0;duodenum: 12.3;rectum: 9.8;small intestine: 24.1;urinary bladder: 6.5,smooth muscle: 2.5,Group enriched,8,CACO-2: 13.0;SCLC-21H: 14.7
NOS3,"ECNOS, eNOS",ENSG00000164867,Nitric oxide synthase 3,7,150990995-151014588,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB002168,Enhanced,,,,Renal cancer:3.63e-4 (unfavourable),Expressed in all,Tissue enriched,7,spleen: 71.8,adipose tissue: 10.6,Cell line enhanced,,BEWO: 22.3;HUVEC TERT2: 37.6;TIME: 67.7
NOSIP,CGI-25,ENSG00000142546,Nitric oxide synthase interacting protein,19,49555711-49590262,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA043464, HPA062132",Approved,,Enhanced,Nucleus,,Expressed in all,Expressed in all,,,testis: 97.6,Expressed in all,,
NOTUM,,ENSG00000185269,"NOTUM, palmitoleoyl-protein carboxylesterase",17,81952507-81961840,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enriched,56,placenta: 192.5,liver: 3.4,Cell line enriched,16,Hep G2: 284.8
NPEPL1,"bA261P9.2, FLJ11583",ENSG00000215440,Aminopeptidase-like 1,20,58689131-58719238,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004986, CAB017025, HPA036356",Approved,,Approved,Nucleoplasm,"Renal cancer:1.87e-9 (unfavourable), Urothelial cancer:5.73e-4 (favourable)",Expressed in all,Expressed in all,,,spleen: 24.7,Cell line enhanced,,MCF7: 78.7
NPEPPS,"MP100, PSA",ENSG00000141279,Aminopeptidase puromycin sensitive,17,47522942-47623276,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021453, HPA045649",Uncertain,,Supported,Cytosol,"Colorectal cancer:3.39e-5 (favourable), Liver cancer:3.67e-5 (unfavourable)",Expressed in all,Expressed in all,,,esophagus: 106.9,Expressed in all,,
NPL,"C1orf13, DHDPS1, NPL1",ENSG00000135838,N-acetylneuraminate pyruvate lyase,1,182789293-182830384,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028345,,,Approved,Vesicles<br>Plasma membrane,"Renal cancer:6.63e-4 (unfavourable), Liver cancer:8.05e-4 (unfavourable)",Expressed in all,Mixed,,,placenta: 63.8,Mixed,,
NPR1,"ANPa, ANPRA, GUCY2A, NPRA",ENSG00000169418,Natriuretic peptide receptor 1,1,153678637-153693992,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA031087,,,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,"Pancreatic cancer:2.49e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,,adipose tissue: 72.0;fallopian tube: 58.2,placenta: 25.4,Cell line enriched,6,ASC diff: 107.2
NPR2,"AMDM, ANPb, ANPRB, GUCY2B, NPRB",ENSG00000159899,Natriuretic peptide receptor 2,9,35792154-35809732,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Expressed in all,Mixed,,,endometrium: 31.1,Cell line enhanced,,ASC diff: 37.7
NQO1,"DHQU, DIA4, DTD, NMOR1, QR1",ENSG00000181019,NAD(P)H quinone dehydrogenase 1,16,69706996-69726951,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007308, CAB012421",Enhanced,,Enhanced,Cytosol,Head and neck cancer:1.45e-4 (unfavourable),Expressed in all,Tissue enhanced,,breast: 379.3;stomach: 556.0,gallbladder: 320.2,Expressed in all,,
NQO2,"DHQV, DIA6, NMOR2, QR2",ENSG00000124588,N-ribosyldihydronicotinamide:quinone reductase 2,6,2987987-3028869,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA021283, HPA021332",Enhanced,,Supported,Nucleoplasm<br>Cytosol,Liver cancer:8.40e-4 (unfavourable),Expressed in all,Expressed in all,,,kidney: 201.0,Expressed in all,,
NRBP1,"BCON3, MADM, MUDPNP, NRBP",ENSG00000115216,Nuclear receptor binding protein 1,2,27427790-27442259,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA029527, CAB033078",Supported,,Supported,Cytosol,"Liver cancer:2.22e-5 (unfavourable), Renal cancer:5.84e-5 (unfavourable)",Expressed in all,Expressed in all,,,testis: 125.8,Expressed in all,,
NRBP2,DKFZp434P086,ENSG00000185189,Nuclear receptor binding protein 2,8,143833594-143840974,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB020944, HPA029051, HPA029052",Approved,,Approved,Cytosol,Renal cancer:2.01e-5 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 55.2,Mixed,,
NRDC,"hNRD1, hNRD2, NRD1",ENSG00000078618,Nardilysin convertase,1,51789191-51878937,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA053661,,,Approved,Nucleoplasm,"Renal cancer:2.12e-9 (unfavourable), Liver cancer:5.49e-6 (unfavourable)",Expressed in all,Expressed in all,,,testis: 167.5,Expressed in all,,
NRK,DKFZp686A17109,ENSG00000123572,Nik related kinase,X,105822543-105958610,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017238,Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Tissue enriched,Tissue enhanced,,ovary: 39.8;placenta: 34.3,adrenal gland: 21.0,Cell line enhanced,,fHDF/TERT166: 45.0;RH-30: 12.4;RPTEC TERT1: 26.3
NSD1,"ARA267, FLJ22263, KMT3B, STO",ENSG00000165671,Nuclear receptor binding SET domain protein 1,5,177133025-177300215,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA048431, HPA070333, HPA073705",Supported,,Supported,Nucleus<br>Plasma membrane,,Expressed in all,Expressed in all,,,testis: 43.2,Mixed,,
NSD2,"KMT3G, MMSET, WHSC1",ENSG00000109685,Nuclear receptor binding SET domain protein 2,4,1871424-1982207,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA015801, CAB068246, CAB068247",Enhanced,,Supported,Nucleus,"Liver cancer:2.61e-4 (unfavourable), Renal cancer:7.19e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 66.6,Expressed in all,,
NSD3,"FLJ20353, KMT3F, WHISTLE, WHSC1L1",ENSG00000147548,Nuclear receptor binding SET domain protein 3,8,38269697-38382272,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA005659, CAB013721, HPA018893",Uncertain,,Approved,Nucleoplasm<br>Mitochondria,Pancreatic cancer:7.48e-4 (unfavourable),Expressed in all,Expressed in all,,,placenta: 47.8,Expressed in all,,
NSDHL,"H105e3, SDR31E1, XAP104",ENSG00000147383,NAD(P) dependent steroid dehydrogenase-like,X,152830967-152869729,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000248, HPA000571",Enhanced,,Enhanced,Endoplasmic reticulum<br>Lipid droplets,"Renal cancer:6.09e-5 (favourable), Liver cancer:5.04e-4 (unfavourable), Cervical cancer:5.65e-4 (favourable)",Expressed in all,Expressed in all,,,epididymis: 54.1,Expressed in all,,
NSF,SKD2,ENSG00000073969,"N-ethylmaleimide sensitive factor, vesicle fusing ATPase",17,46590669-46757464,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA003154, CAB009324, CAB013645, HPA071089",Enhanced,,Supported,Cytosol,,Expressed in all,Tissue enriched,5,cerebral cortex: 134.3,parathyroid gland: 25.6,Mixed,,
NSUN2,"FLJ20303, Misu, MRT5, TRM4",ENSG00000037474,NOP2/Sun RNA methyltransferase family member 2,5,6599239-6633291,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA037896,Enhanced,,Supported,Nucleus,Renal cancer:5.69e-5 (unfavourable),Expressed in all,Expressed in all,,,breast: 44.2,Expressed in all,,
NT5C1A,"CN-I, CN-IA, CN1, CN1A, MGC119199, MGC119201",ENSG00000116981,"5'-nucleotidase, cytosolic IA",1,39659121-39672038,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA050283, HPA054158",Supported,,,,,Not detected,Tissue enhanced,,heart muscle: 7.5;skeletal muscle: 24.9,cerebral cortex: 4.8,Cell line enriched,20,SH-SY5Y: 18.9
NT5C1B,"AIRP, CN-IB",ENSG00000185013,"5'-nucleotidase, cytosolic IB",2,18562872-18589572,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at transcript level,HPA056683,Uncertain,,,,,Not detected,Tissue enriched,43,testis: 57.5,skin: 1.3,Mixed,,
NT5C2,"cN-II, GMP, NT5B, PNT5, SPG65",ENSG00000076685,"5'-nucleotidase, cytosolic II",10,103088017-103193306,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA003751,Approved,,,,,Expressed in all,Expressed in all,,,thyroid gland: 119.6,Expressed in all,,
NT5C3A,"cN-III, hUMP1, NT5C3, p36, P5'N-1, PN-I, POMP, PSN1, UMPH, UMPH1",ENSG00000122643,"5'-nucleotidase, cytosolic IIIA",7,33014114-33062797,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA010630, HPA029058",Uncertain,,,,"Renal cancer:1.70e-4 (unfavourable), Liver cancer:2.42e-4 (unfavourable)",Expressed in all,Expressed in all,,,rectum: 46.5,Expressed in all,,
NT5C3B,"cN-IIIB, MGC20781, NT5C3L",ENSG00000141698,"5'-nucleotidase, cytosolic IIIB",17,41825181-41836263,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030786, HPA057095",Approved,,,,"Liver cancer:8.11e-5 (unfavourable), Pancreatic cancer:2.67e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 79.2,Mixed,,
NT5E,"CALJA, CD73, eN, eNT, NT5",ENSG00000135318,5'-nucleotidase ecto,6,85449584-85495791,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA017357,Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 172.7",smooth muscle: 106.3,Cell line enhanced,,LHCN-M2: 772.3;U-87 MG: 800.0
NTHL1,"NTH1, OCTS3",ENSG00000065057,Nth like DNA glycosylase 1,16,2039815-2047866,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,CAB025152,Supported,,,,,Expressed in all,Expressed in all,,,fallopian tube: 21.3,Expressed in all,,
NTMT1,"AD-003, C9orf32, HOMT1A, METTL11A, NRMT, NRMT1",ENSG00000148335,N-terminal Xaa-Pro-Lys N-methyltransferase 1,9,129608884-129636131,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA020092, HPA058420",Uncertain,,Enhanced,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 90.5,Expressed in all,,
NTPCR,"C1orf57, HCR-NTPase, MGC13186",ENSG00000135778,"Nucleoside-triphosphatase, cancer-related",1,232950605-232983882,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028125, HPA054304",Uncertain,,Approved,Cytosol,,Expressed in all,Mixed,,,parathyroid gland: 11.4,Mixed,,
NTRK1,"MTC, TRK, TRKA",ENSG00000198400,Neurotrophic receptor tyrosine kinase 1,1,156815640-156881850,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB004606, HPA035799, HPA076570",Approved,,Uncertain,Vesicles<br>Cytosol,,Tissue enhanced,Tissue enriched,6,adrenal gland: 9.5,testis: 1.6,Cell line enhanced,,HDLM-2: 10.4;HEL: 11.9;HMC-1: 69.1;SH-SY5Y: 19.1
NTRK2,TRKB,ENSG00000148053,Neurotrophic receptor tyrosine kinase 2,9,84668551-85027070,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA007637, CAB010346",Enhanced,,Approved,Cytosol,,Group enriched,Tissue enhanced,,cerebral cortex: 439.6;thyroid gland: 215.7,breast: 82.1,Group enriched,5,AF22: 9.4;HaCaT: 3.1;RPTEC TERT1: 8.1;SH-SY5Y: 12.9;WM-115: 2.8
NTRK3,TRKC,ENSG00000140538,Neurotrophic receptor tyrosine kinase 3,15,87859751-88256768,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009233, HPA027484, HPA048065",Enhanced,,Supported,Nuclear membrane<br>Nucleoli,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 39.6,testis: 15.2,Cell line enriched,8,U-138 MG: 99.2
NUAK1,"ARK5, KIAA0537, NuaK1",ENSG00000074590,NUAK family kinase 1,12,106063340-106140033,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA057143,,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Microtubules,"Stomach cancer:4.27e-4 (unfavourable), Endometrial cancer:9.83e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 47.0;parathyroid gland: 42.5,skin: 21.0,Cell line enhanced,,AF22: 50.0;EFO-21: 47.3;RH-30: 70.1
NUAK2,"FLJ90349, SNARK",ENSG00000163545,NUAK family kinase 2,1,205302059-205321791,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA008958,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cytosol,"Endometrial cancer:3.01e-7 (unfavourable), Pancreatic cancer:7.94e-6 (favourable)",Expressed in all,Mixed,,,esophagus: 22.0,Cell line enhanced,,BEWO: 42.0;RPTEC TERT1: 30.2
NUDT1,MTH1,ENSG00000106268,Nudix hydrolase 1,7,2242222-2251146,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA012636,Approved,,Approved,Cytosol,"Renal cancer:1.30e-7 (unfavourable), Liver cancer:4.44e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 50.4,Expressed in all,,
NUDT10,"DIPP3a, hDIPP3alpha",ENSG00000122824,Nudix hydrolase 10,X,51332231-51337525,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047027, HPA057684",Approved,,Approved,Cytosol,,Group enriched,Tissue enhanced,,testis: 49.7,prostate: 24.8,Group enriched,8,AF22: 7.4;HAP1: 14.7;HEK 293: 9.7;NTERA-2: 25.9;SH-SY5Y: 6.0;U-2 OS: 13.4
NUDT11,"DIPP3b, FLJ10628, hDIPP3beta",ENSG00000196368,Nudix hydrolase 11,X,51490011-51496596,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047027, HPA057684",Approved,,Approved,Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 40.1;testis: 67.7,"prostate,seminal vesicle: 14.7",Cell line enhanced,,HAP1: 71.2;NTERA-2: 42.7
NUDT12,DKFZP761I172,ENSG00000112874,Nudix hydrolase 12,5,103548855-103562793,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045449,Supported,,,,Renal cancer:2.86e-5 (favourable),Expressed in all,Mixed,,,parathyroid gland: 45.1,Mixed,,
NUDT14,UGPP,ENSG00000183828,Nudix hydrolase 14,14,105172938-105181323,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA046755, HPA058759",Approved,,Approved,Nucleoli<br>Microtubules,"Renal cancer:1.18e-5 (favourable), Ovarian cancer:1.66e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 24.7,Mixed,,
NUDT15,"FLJ10956, MTH2",ENSG00000136159,Nudix hydrolase 15,13,48037567-48047222,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038968, HPA038969",Approved,,Supported,Nucleoplasm,Melanoma:1.25e-5 (unfavourable),Expressed in all,Expressed in all,,,prostate: 22.8,Expressed in all,,
NUDT16,FLJ31265,ENSG00000198585,Nudix hydrolase 16,3,131381671-131388830,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA060452, HPA062492",Uncertain,,Supported,Nucleus<br>Nucleoli,"Renal cancer:1.05e-7 (favourable), Cervical cancer:9.39e-5 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 54.8,Mixed,,
NUDT18,"FLJ22494, MTH3",ENSG00000275074,Nudix hydrolase 18,8,22106872-22109419,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028581, HPA030125",Approved,,Supported,Nucleoplasm<br>Golgi apparatus,"Endometrial cancer:2.49e-6 (favourable), Cervical cancer:1.43e-4 (favourable), Pancreatic cancer:2.47e-4 (favourable), Renal cancer:8.30e-4 (favourable)",Expressed in all,Mixed,,,epididymis: 16.2,Mixed,,
NUDT2,APAH1,ENSG00000164978,Nudix hydrolase 2,9,34329506-34343713,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004684, HPA044903, HPA058623, HPA067639",Uncertain,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,epididymis: 43.6,Expressed in all,,
NUDT3,DIPP,ENSG00000272325,Nudix hydrolase 3,6,34279679-34392674,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047027, HPA055953",Uncertain,,Approved,Cytosol,Cervical cancer:5.29e-4 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 77.5,Expressed in all,,
NUDT4,"DIPP2, DIPP2alpha, DIPP2beta, HDCMB47P, KIAA0487",ENSG00000173598,Nudix hydrolase 4,12,93377883-93408146,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA017593, HPA047027, HPA057684",Approved,,Approved,Cytosol,Renal cancer:1.27e-4 (favourable),Expressed in all,Expressed in all,,,ovary: 184.7,Expressed in all,,
NUDT5,"hYSAH1, YSA1H",ENSG00000165609,Nudix hydrolase 5,10,12165325-12196144,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019827,Approved,,Approved,Nucleus<br>Vesicles<br>Centrosome,Renal cancer:7.14e-12 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 45.6,Expressed in all,,
NUDT9,MGC3037,ENSG00000170502,Nudix hydrolase 9,4,87422582-87459454,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA036917, HPA044866",Approved,,,,"Renal cancer:8.00e-11 (favourable), Endometrial cancer:7.43e-5 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 85.9,Expressed in all,,
NUS1,"C6orf68, MGC7199, NgBR, TANGO14",ENSG00000153989,NUS1 dehydrodolichyl diphosphate synthase subunit,6,117675502-117710640,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA027504,Supported,,Approved,Vesicles<br>Plasma membrane,Cervical cancer:6.99e-4 (unfavourable),Expressed in all,Expressed in all,,,"cervix, uterine: 92.2",Expressed in all,,
NXN,"FLJ12614, NRX",ENSG00000167693,Nucleoredoxin,17,799313-979770,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023566,Approved,,Supported,Golgi apparatus<br>Cytosol,,Expressed in all,Mixed,,,endometrium: 42.7,Mixed,,
OAS1,"IFI-4, OIAS, OIASI",ENSG00000089127,2'-5'-oligoadenylate synthetase 1,12,112906777-112933222,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003657, CAB021104",Uncertain,,Approved,Cytosol,"Urothelial cancer:6.12e-6 (favourable), Pancreatic cancer:3.02e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 90.1,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 266.2;BJ hTERT+ SV40 Large T+ RasG12V: 396.9;U-266/70: 307.4;U-266/84: 229.8
OAS2,,ENSG00000111335,2'-5'-oligoadenylate synthetase 2,12,112978395-113011723,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB024984, HPA045947",Approved,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:4.31e-6 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)",Expressed in all,Mixed,,,spleen: 59.7,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 292.1;BJ hTERT+ SV40 Large T+ RasG12V: 247.3;SK-MEL-30: 98.7
OAS3,,ENSG00000111331,2'-5'-oligoadenylate synthetase 3,12,112938352-112973249,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041253, HPA041372",Uncertain,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:2.23e-5 (unfavourable),Expressed in all,Mixed,,,spleen: 33.4,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 251.3;BJ hTERT+ SV40 Large T+ RasG12V: 285.0
OAT,HOGA,ENSG00000065154,Ornithine aminotransferase,10,124397303-124418976,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB033576, HPA040098, HPA064742",Enhanced,,Supported,Nucleoplasm<br>Mitochondria,,Expressed in all,Expressed in all,,,small intestine: 859.8,Mixed,,
OBSCN,"ARHGEF30, KIAA1556, KIAA1639, UNC89",ENSG00000154358,"Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF",1,228208130-228378874,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA021186,Enhanced,,Approved,Plasma membrane<br>Cytosol,Endometrial cancer:1.64e-4 (unfavourable),Mixed,Tissue enriched,7,skeletal muscle: 301.1,heart muscle: 45.7,Mixed,,
OCRL,OCRL1,ENSG00000122126,"OCRL, inositol polyphosphate-5-phosphatase",X,129539849-129592561,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA012495,Approved,,Approved,Microtubules<br>Cytosol,Breast cancer:2.93e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 65.3,Mixed,,
ODC1,ODC,ENSG00000115758,Ornithine decarboxylase 1,2,10439968-10448504,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001536, CAB035996",Approved,,Approved,Plasma membrane<br>Cytosol,Liver cancer:3.07e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 242.0,Expressed in all,,
OGDH,E1k,ENSG00000105953,Oxoglutarate dehydrogenase,7,44606572-44709066,"Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019514, HPA020347",Supported,,Enhanced,Mitochondria,Renal cancer:2.22e-14 (favourable),Expressed in all,Expressed in all,,,heart muscle: 147.8,Expressed in all,,
OGG1,"HMMH, HOGG1, MUTM, OGH1",ENSG00000114026,8-oxoguanine DNA glycosylase,3,9749944-9788219,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA027514, CAB047301",Approved,,Enhanced,Nucleoplasm,"Liver cancer:5.77e-5 (unfavourable), Renal cancer:2.65e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 30.5,Expressed in all,,
OGT,"FLJ23071, HRNT1, MGC22921, O-GLCNAC",ENSG00000147162,O-linked N-acetylglucosamine (GlcNAc) transferase,X,71533083-71575897,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA030751, HPA030752, HPA030753, HPA030754, CAB034099",Approved,,Supported,Nucleoplasm<br>Plasma membrane,"Urothelial cancer:6.85e-7 (favourable), Renal cancer:2.36e-6 (unfavourable), Head and neck cancer:1.97e-4 (favourable), Endometrial cancer:8.33e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 83.2,Expressed in all,,
OLAH,"FLJ11106, SAST, THEDC1",ENSG00000152463,Oleoyl-ACP hydrolase,10,15032227-15073852,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037947, HPA037948",Enhanced,,,,,Group enriched,Tissue enriched,7,testis: 46.0,breast: 6.2,Cell line enhanced,,hTCEpi: 3.3;LHCN-M2: 3.0;SK-BR-3: 4.2
OMA1,"FLJ33782, MPRP-1, YKR087C, ZMPOMA1",ENSG00000162600,OMA1 zinc metallopeptidase,1,58415384-58546802,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA055120,Approved,,Approved,Nucleoplasm<br>Mitochondria,"Breast cancer:1.63e-4 (favourable), Colorectal cancer:7.70e-4 (favourable), Lung cancer:8.52e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 31.9,Expressed in all,,
OPA1,"FLJ12460, KIAA0567, MGM1, NPG, NTG",ENSG00000198836,"OPA1, mitochondrial dynamin like GTPase",3,193593144-193697823,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA036926, HPA036927",Enhanced,,Supported,Nucleoplasm<br>Mitochondria,"Pancreatic cancer:8.44e-5 (unfavourable), Renal cancer:1.84e-4 (favourable), Endometrial cancer:8.61e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 56.2,Expressed in all,,
OPLAH,"5-Opase, OPLA",ENSG00000178814,5-oxoprolinase (ATP-hydrolysing),8,144051266-144063965,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026562, HPA028260, HPA052429",Uncertain,,Approved,Nucleoli fibrillar center,Renal cancer:1.53e-6 (favourable),Expressed in all,Tissue enhanced,,testis: 58.2,duodenum: 13.8,Cell line enhanced,,AN3-CA: 31.2;BEWO: 20.2;PC-3: 24.2
OSGEP,"GCPL1, KAE1, OSGEP1, PRSMG1",ENSG00000092094,O-sialoglycoprotein endopeptidase,14,20446411-20455105,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039751,Uncertain,,Supported,Nucleoplasm<br>Plasma membrane,"Renal cancer:4.64e-6 (unfavourable), Breast cancer:1.48e-4 (favourable)",Expressed in all,Mixed,,,thyroid gland: 12.7,Expressed in all,,
OSGEPL1,"OSGEPL, Qri7",ENSG00000128694,O-sialoglycoprotein endopeptidase like 1,2,189746660-189763227,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA030693,Uncertain,,Enhanced,Mitochondria,"Ovarian cancer:3.19e-4 (favourable), Liver cancer:3.71e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 12.2,Expressed in all,,
OTC,,ENSG00000036473,Ornithine carbamoyltransferase,X,38352545-38421450,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000243, HPA000570",Enhanced,,Supported,Mitochondria,,Tissue enriched,Group enriched,26,duodenum: 114.4;liver: 195.4;small intestine: 96.9,colon: 5.3,Not detected,,
OTUB1,"FLJ20113, FLJ40710",ENSG00000167770,"OTU deubiquitinase, ubiquitin aldehyde binding 1",11,63985853-64001811,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039176, CAB072836",Approved,Supported,Approved,Nucleus<br>Cytosol,Head and neck cancer:3.05e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 116.0,Expressed in all,,
OTUB2,"C14orf137, FLJ21916, MGC3102",ENSG00000089723,"OTU deubiquitinase, ubiquitin aldehyde binding 2",14,94026329-94048930,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA002329,Enhanced,,,,,Mixed,Tissue enhanced,,testis: 9.7,skin: 4.7,Cell line enhanced,,Karpas-707: 12.8;RPTEC TERT1: 8.5
OTUD1,"DUBA7, OTDC1",ENSG00000165312,OTU deubiquitinase 1,10,23439458-23442390,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038503, HPA038504",Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus,"Renal cancer:6.61e-7 (favourable), Endometrial cancer:4.59e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 43.3,Cell line enhanced,,CAPAN-2: 37.8;HaCaT: 36.0;SiHa: 28.0
OTUD3,"DUBA4, KIAA0459",ENSG00000169914,OTU deubiquitinase 3,1,19882513-19912945,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028543, HPA028544",Approved,,Approved,Nucleoplasm<br>Intermediate filaments<br>Cytosol,,Expressed in all,Mixed,,,testis: 19.4,Expressed in all,,
OTUD4,"DUBA6, HSHIN1, KIAA1046",ENSG00000164164,OTU deubiquitinase 4,4,145110838-145180161,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036623,Uncertain,,Approved,Cytosol,,Expressed in all,Expressed in all,,,testis: 72.7,Expressed in all,,
OTUD5,"DKFZp761A052, DUBA",ENSG00000068308,OTU deubiquitinase 5,X,48922028-48958386,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA017375,Approved,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cytosol,"Lung cancer:1.48e-4 (favourable), Pancreatic cancer:8.20e-4 (favourable), Cervical cancer:9.57e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 69.9,Group enriched,8,U-266/70: 1128.2;U-266/84: 277.1
OTUD6A,"DUBA2, FLJ25831, HSHIN6",ENSG00000189401,OTU deubiquitinase 6A,X,70062491-70064179,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA053304,Enhanced,,,,,Tissue enriched,Tissue enriched,14,testis: 9.5,thyroid gland: 0.7,Not detected,,
OTUD6B,"CGI-77, DUBA5",ENSG00000155100,OTU domain containing 6B,8,91070196-91087095,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA024046, HPA024503, HPA024772",Enhanced,Approved,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,Breast cancer:7.50e-4 (unfavourable),Expressed in all,Mixed,,,cerebral cortex: 17.2,Expressed in all,,
OTUD7A,"C15orf16, CEZANNE2, OTUD7",ENSG00000169918,OTU deubiquitinase 7A,15,31475398-31870789,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044554,Uncertain,,Approved,Nucleoli<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 13.5,testis: 5.1,Cell line enhanced,,SCLC-21H: 6.3;SH-SY5Y: 2.7
OTUD7B,"CEZANNE, ZA20D1",ENSG00000264522,OTU deubiquitinase 7B,1,149937812-150010676,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027045,Supported,,Approved,Nucleoplasm<br>Microtubules,"Melanoma:5.09e-5 (favourable), Endometrial cancer:7.47e-4 (favourable)",Expressed in all,Mixed,,,parathyroid gland: 23.7,Mixed,,
OTULIN,"FAM105B, FLJ34884",ENSG00000154124,OTU deubiquitinase with linear linkage specificity,5,14664664-14699711,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA051074,Uncertain,,Approved,Plasma membrane<br>Mitochondria,Renal cancer:2.59e-7 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 17.1,Expressed in all,,
OVCH1,OVCH,ENSG00000187950,Ovochymase 1,12,29412474-29497686,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA040253,Uncertain,,,,,Not detected,Group enriched,5,lung: 6.8;testis: 4.3;thyroid gland: 1.7,spleen: 0.8,Group enriched,6,Daudi: 3.9;HEL: 1.0
OXCT1,"OXCT, SCOT",ENSG00000083720,3-oxoacid CoA-transferase 1,5,41730065-41870519,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA012047, HPA061425",Enhanced,,Enhanced,Mitochondria,"Renal cancer:1.86e-8 (favourable), Liver cancer:1.03e-4 (unfavourable)",Expressed in all,Tissue enhanced,,heart muscle: 162.3,cerebral cortex: 98.7,Cell line enhanced,,SiHa: 338.4
OXCT2,"FKSG25, FLJ00030, SCOT-T",ENSG00000198754,3-oxoacid CoA-transferase 2,1,39769523-39771348,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA075423,Enhanced,,,,,Not detected,Tissue enriched,12,testis: 37.4,thyroid gland: 3.0,Cell line enhanced,,Karpas-707: 5.4;THP-1: 5.6
OXSM,"CEM1, FASN2D, FLJ20604, KS",ENSG00000151093,"3-oxoacyl-ACP synthase, mitochondrial",3,25782917-25794534,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021293, HPA021300, HPA021337",Enhanced,,Approved,Mitochondria<br>Cytosol,"Renal cancer:4.18e-9 (favourable), Colorectal cancer:1.35e-4 (favourable), Endometrial cancer:5.51e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 17.4,Mixed,,
OXSR1,"KIAA1101, OSR1",ENSG00000172939,Oxidative stress responsive 1,3,38165089-38255488,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA008237, CAB017181",Enhanced,,Enhanced,Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 43.0,Expressed in all,,
P3H1,"GROS1, LEPRE1, LEPRECAN, MGC117314",ENSG00000117385,Prolyl 3-hydroxylase 1,1,42746335-42767084,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA012113, HPA016980",Approved,,Approved,Nucleoli<br>Vesicles,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.95e-7 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 53.5,smooth muscle: 28.8,Expressed in all,,
P3H2,"FLJ10718, LEPREL1, MLAT4",ENSG00000090530,Prolyl 3-hydroxylase 2,3,189956728-190122437,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA007890, HPA013355",Approved,,,,,Expressed in all,Mixed,,,prostate: 60.8,Cell line enhanced,,HaCaT: 97.1;RPTEC TERT1: 83.3
P3H3,"GRCB, HSU47926, LEPREL2",ENSG00000110811,Prolyl 3-hydroxylase 3,12,6828410-6839851,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA043695,Approved,,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:1.64e-4 (unfavourable), Pancreatic cancer:4.91e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 11.7,endometrium: 6.2,Cell line enhanced,,BJ: 33.3
P4HA1,"C-P4Halpha(I), P4HA",ENSG00000122884,Prolyl 4-hydroxylase subunit alpha 1,10,73007217-73096974,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA007599, HPA026593",Enhanced,,Supported,Endoplasmic reticulum<br>Vesicles<br>Mitochondria,"Renal cancer:9.40e-9 (unfavourable), Head and neck cancer:1.19e-5 (unfavourable), Cervical cancer:3.19e-5 (unfavourable), Pancreatic cancer:2.85e-4 (unfavourable), Lung cancer:5.10e-4 (unfavourable), Breast cancer:9.01e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 91.7,Expressed in all,,
P4HA2,C-P4Halpha(II),ENSG00000072682,Prolyl 4-hydroxylase subunit alpha 2,5,132191838-132295315,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA016997, HPA027824, CAB062557",Enhanced,,Enhanced,Endoplasmic reticulum<br>Vesicles,"Renal cancer:2.77e-7 (unfavourable), Cervical cancer:1.24e-5 (unfavourable), Urothelial cancer:3.12e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 95.3,Mixed,,
P4HA3,C-P4Halpha(III),ENSG00000149380,Prolyl 4-hydroxylase subunit alpha 3,11,74235801-74311657,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA007897,Approved,,,,"Renal cancer:3.34e-9 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable)",Mixed,Tissue enhanced,,smooth muscle: 14.5,gallbladder: 8.9,Cell line enhanced,,BJ: 16.3;HUVEC TERT2: 31.5;TIME: 22.1
P4HB,"DSI, ERBA2L, GIT, P4Hbeta, PDI, PDIA1, PO4DB, PO4HB, PROHB",ENSG00000185624,Prolyl 4-hydroxylase subunit beta,17,81843159-81860694,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB012463, HPA018884",Enhanced,,Supported,Endoplasmic reticulum,Renal cancer:2.30e-11 (unfavourable),Expressed in all,Expressed in all,,,small intestine: 504.4,Expressed in all,,
PA2G4,,ENSG00000170515,Proliferation-associated 2G4,12,56104319-56113907,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB011711, CAB012428, HPA016484",Supported,,Approved,Cytosol,"Renal cancer:4.59e-7 (unfavourable), Liver cancer:6.31e-7 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 138.1,Expressed in all,,
PADI1,"HPAD10, PAD1, PDI, PDI1",ENSG00000142623,Peptidyl arginine deiminase 1,1,17205126-17246005,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA062294,Enhanced,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:8.34e-11 (unfavourable),Tissue enhanced,Tissue enriched,7,esophagus: 37.1,skin: 5.4,Cell line enhanced,,CAPAN-2: 4.5;EFO-21: 2.3;HaCaT: 1.3;LHCN-M2: 1.6;RPTEC TERT1: 1.9
PADI2,"KIAA0994, PDI2",ENSG00000117115,Peptidyl arginine deiminase 2,1,17066761-17119435,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047735,Enhanced,,,,,Mixed,Tissue enhanced,,cerebral cortex: 85.0;colon: 89.8;rectum: 99.9;skeletal muscle: 108.6,breast: 48.8,Group enriched,5,A549: 10.4;RPTEC TERT1: 25.1;SK-BR-3: 38.1;T-47d: 13.1
PADI3,PDI3,ENSG00000142619,Peptidyl arginine deiminase 3,1,17249098-17284233,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA043739,Uncertain,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.55e-11 (unfavourable), Endometrial cancer:3.22e-4 (unfavourable)",Tissue enhanced,Group enriched,10,esophagus: 3.7;seminal vesicle: 4.9;urinary bladder: 10.2,epididymis: 0.6,Cell line enhanced,,EFO-21: 13.2;RT4: 13.9;T-47d: 12.0
PADI4,"PAD, PADI5, PDI4, PDI5",ENSG00000159339,Peptidyl arginine deiminase 4,1,17308195-17364004,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA017007, HPA042825",Enhanced,,,,,Not detected,Tissue enriched,12,bone marrow: 71.8,spleen: 5.9,Cell line enhanced,,HEL: 1.1;RPMI-8226: 1.0
PADI6,,ENSG00000276747,Peptidyl arginine deiminase 6,1,17372196-17401699,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
PAFAH1B2,,ENSG00000168092,Platelet activating factor acetylhydrolase 1b catalytic subunit 2,11,117144267-117176894,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA051836,Approved,,Supported,Nucleoli<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:7.79e-5 (unfavourable), Lung cancer:3.07e-4 (unfavourable), Ovarian cancer:4.25e-4 (favourable), Liver cancer:9.44e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 68.2,Expressed in all,,
PAFAH1B3,,ENSG00000079462,Platelet activating factor acetylhydrolase 1b catalytic subunit 3,19,42297033-42303546,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA035639,Uncertain,,Approved,Intermediate filaments,"Renal cancer:2.07e-4 (unfavourable), Liver cancer:8.74e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 36.7,Mixed,,
PAFAH2,HSD-PLA2,ENSG00000158006,Platelet activating factor acetylhydrolase 2,1,25959767-25998157,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA018157,Approved,,,,"Renal cancer:0.00e+0 (favourable), Endometrial cancer:3.28e-6 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 29.1,Expressed in all,,
PAH,PH,ENSG00000171759,Phenylalanine hydroxylase,12,102836885-102958410,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA028407, HPA031642",Enhanced,,Approved,Endoplasmic reticulum<br>Vesicles,Liver cancer:4.30e-4 (favourable),Tissue enriched,Tissue enhanced,,kidney: 504.6;liver: 722.4,gallbladder: 125.9,Cell line enriched,26,Hep G2: 161.3
PAICS,"ADE2H1, AIRC, PAIS",ENSG00000128050,Phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase,4,56435741-56464579,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035895, HPA041538",Uncertain,,Approved,Cytosol,"Renal cancer:5.85e-5 (unfavourable), Liver cancer:1.50e-4 (unfavourable), Thyroid cancer:2.41e-4 (unfavourable), Ovarian cancer:8.44e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 74.0,Expressed in all,,
PAK1,,ENSG00000149269,P21 (RAC1) activated kinase 1,11,77321707-77474635,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA003565, CAB005312",Enhanced,Supported,Enhanced,Plasma membrane<br>Cytosol,"Glioma:9.48e-5 (unfavourable), Colorectal cancer:5.87e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 184.2,Mixed,,
PAK2,"PAK65, PAKgamma",ENSG00000180370,P21 (RAC1) activated kinase 2,3,196739857-196832647,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,CAB007794,Approved,,Enhanced,Nucleus<br>Vesicles,"Pancreatic cancer:3.36e-4 (unfavourable), Prostate cancer:9.58e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 60.1,Expressed in all,,
PAK3,"bPAK, hPAK3, MRX30, MRX47",ENSG00000077264,P21 (RAC1) activated kinase 3,X,110944285-111227361,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA044791, HPA060219",Approved,,Approved,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 34.3,thyroid gland: 10.4,Cell line enhanced,,EFO-21: 10.2;HAP1: 10.2;HDLM-2: 11.9;NTERA-2: 9.6;SCLC-21H: 14.7;U-251 MG: 11.1
PAK4,,ENSG00000130669,P21 (RAC1) activated kinase 4,19,39125770-39182816,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB025747, CAB044670, HPA070175, HPA072220",Uncertain,,Supported,Plasma membrane<br>Cell Junctions,"Renal cancer:5.29e-5 (favourable), Prostate cancer:9.85e-4 (unfavourable)",Expressed in all,Expressed in all,,,prostate: 47.8,Expressed in all,,
PAK5,"KIAA1264, PAK7",ENSG00000101349,P21 (RAC1) activated kinase 5,20,9537389-9839041,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA020444,Approved,,Approved,Nucleoplasm,,Mixed,Tissue enriched,5,cerebral cortex: 13.4,adrenal gland: 2.6,Group enriched,10,SCLC-21H: 5.6;SH-SY5Y: 1.8
PAK6,PAK5,ENSG00000137843,P21 (RAC1) activated kinase 6,15,40238759-40277487,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA031124,Approved,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions,,Not detected,Mixed,,,cerebral cortex: 28.6,Cell line enhanced,,CACO-2: 17.4;HaCaT: 28.5;hTCEpi: 13.9
PAM,"PAL, PHM",ENSG00000145730,Peptidylglycine alpha-amidating monooxygenase,5,102753981-103031105,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB026119, HPA042260",Enhanced,,Approved,Golgi apparatus<br>Cytosol,"Endometrial cancer:1.63e-4 (favourable), Liver cancer:6.20e-4 (unfavourable)",Expressed in all,Expressed in all,,,heart muscle: 947.8,Cell line enhanced,,fHDF/TERT166: 553.5
PAMR1,"DKFZP586H2123, RAMP",ENSG00000149090,Peptidase domain containing associated with muscle regeneration 1,11,35431823-35530300,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:5.08e-5 (unfavourable), Stomach cancer:6.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 87.0;endometrium: 92.2",placenta: 76.1,Cell line enhanced,,ASC TERT1: 233.7;BJ hTERT+: 274.9;HSkMC: 84.2;U-87 MG: 78.6
PAN2,"hPAN2, KIAA0710, USP52",ENSG00000135473,PAN2 poly(A) specific ribonuclease subunit,12,56316223-56334053,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Renal cancer:2.77e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 33.0,Expressed in all,,
PAN3,,ENSG00000152520,PAN3 poly(A) specific ribonuclease subunit,13,28138506-28295335,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028817,Approved,,,,,Expressed in all,Expressed in all,,,spleen: 28.7,Expressed in all,,
PANK1,"MGC24596, PANK, PANK1a, PANK1b",ENSG00000152782,Pantothenate kinase 1,10,89579497-89645572,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:1.55e-10 (favourable), Liver cancer:1.50e-4 (favourable)",Mixed,Tissue enhanced,,kidney: 46.6;liver: 55.1,duodenum: 20.6,Mixed,,
PANK2,"C20orf48, FLJ11729, HARP, HSS, NBIA1, PKAN",ENSG00000125779,Pantothenate kinase 2,20,3888839-3929882,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA008440,Approved,,Supported,Cytosol,Liver cancer:1.20e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 51.9,Expressed in all,,
PANK3,FLJ12899,ENSG00000120137,Pantothenate kinase 3,5,168548495-168579600,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA062358,,,Approved,Nucleoplasm<br>Golgi apparatus,Colorectal cancer:3.94e-4 (favourable),Expressed in all,Expressed in all,,,duodenum: 40.8,Expressed in all,,
PANK4,FLJ10782,ENSG00000157881,Pantothenate kinase 4,1,2508533-2526628,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA011723, HPA012036, HPA027961",Uncertain,,Approved,Cytosol,Renal cancer:1.57e-5 (favourable),Expressed in all,Tissue enhanced,,appendix: 3.2,skin: 2.9,Mixed,,
PAOX,PAO,ENSG00000148832,Polyamine oxidase,10,133379234-133391694,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047782,,,Uncertain,Nucleoplasm<br>Centrosome,"Head and neck cancer:1.38e-5 (favourable), Cervical cancer:6.07e-5 (favourable), Renal cancer:9.49e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 7.6,cerebral cortex: 3.2,Cell line enhanced,,A-431: 5.2;U-266/70: 12.5
PAPD4,"FLJ38499, GLD2, TUT2",ENSG00000164329,"Poly(A) RNA polymerase D4, non-canonical",5,79612120-79686648,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA054468,,,Approved,Cytosol,,Expressed in all,Expressed in all,,,spleen: 38.4,Expressed in all,,
PAPD5,TRF4-2,ENSG00000121274,"Poly(A) RNA polymerase D5, non-canonical",16,50152918-50235310,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042968, HPA048225",Uncertain,,,,Renal cancer:1.85e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 27.5,Expressed in all,,
PAPD7,"LAK-1, POLK, POLS, TRF4, TRF4-1",ENSG00000112941,"Poly(A) RNA polymerase D7, non-canonical",5,6713007-6757048,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA045487, HPA046742",Enhanced,,Supported,Nucleoplasm<br>Nuclear membrane<br>Golgi apparatus,"Renal cancer:7.99e-5 (unfavourable), Urothelial cancer:8.55e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 19.1,Expressed in all,,
PAPOLA,PAP,ENSG00000090060,Poly(A) polymerase alpha,14,96501433-96567111,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA001788,Supported,,Enhanced,Nucleoplasm,Liver cancer:2.41e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 166.9,Expressed in all,,
PAPOLB,PAPT,ENSG00000218823,Poly(A) polymerase beta,7,4857733-4861994,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enriched,539,testis: 53.9,all non-specific tissues: 0.0,Not detected,,
PAPOLG,FLJ12972,ENSG00000115421,Poly(A) polymerase gamma,2,60756230-60802085,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB017795, HPA035349, HPA035350",Approved,,Enhanced,Nucleoplasm,Renal cancer:4.21e-4 (unfavourable),Expressed in all,Mixed,,,thyroid gland: 22.2,Expressed in all,,
PAPPA,"ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1",ENSG00000182752,Pappalysin 1,9,116153804-116402322,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001667, CAB016724",Enhanced,,Uncertain,Plasma membrane<br>Cytosol,,Mixed,Tissue enriched,7,placenta: 104.5,parathyroid gland: 14.8,Cell line enhanced,,ASC diff: 34.3;HSkMC: 99.9;U-138 MG: 35.8
PAPPA2,"PAPP-A2, PAPPE, PLAC3",ENSG00000116183,Pappalysin 2,1,176463171-176845605,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA018412, HPA018430",Enhanced,,Approved,Endoplasmic reticulum<br>Vesicles,,Mixed,Tissue enriched,8,placenta: 82.7,"cervix, uterine: 10.8",Cell line enriched,6,U-87 MG: 19.4
PAPSS1,"ATPSK1, PAPSS",ENSG00000138801,3'-phosphoadenosine 5'-phosphosulfate synthase 1,4,107590276-107720452,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA049781,Approved,,Approved,Nucleus<br>Nucleoli,"Liver cancer:2.70e-5 (unfavourable), Endometrial cancer:8.58e-4 (favourable), Colorectal cancer:9.14e-4 (favourable)",Expressed in all,Expressed in all,,,endometrium: 73.7,Expressed in all,,
PAPSS2,ATPSK2,ENSG00000198682,3'-phosphoadenosine 5'-phosphosulfate synthase 2,10,87659613-87747705,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA071224,,,Approved,Mitochondria,"Melanoma:1.33e-6 (unfavourable), Thyroid cancer:3.21e-5 (unfavourable), Pancreatic cancer:6.58e-4 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 157.6,Cell line enhanced,,fHDF/TERT166: 365.8
PARG,,ENSG00000227345,Poly(ADP-ribose) glycohydrolase,10,49818279-49970203,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021819, HPA053007",Enhanced,,Enhanced,Nucleus<br>Vesicles,Liver cancer:5.57e-5 (unfavourable),Expressed in all,Mixed,,,parathyroid gland: 16.9,Expressed in all,,
PARK7,"DJ-1, DJ1",ENSG00000116288,Parkinsonism associated deglycase,1,7954291-7985505,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004190, CAB005870",Enhanced,,Supported,Nucleus<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 515.7,Expressed in all,,
PARL,"PRO2207, PSARL, PSARL1, RHBDS1",ENSG00000175193,Presenilin associated rhomboid like,3,183829271-183884933,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA019545,Approved,,Approved,Mitochondria,Urothelial cancer:9.11e-5 (favourable),Expressed in all,Expressed in all,,,epididymis: 71.1,Expressed in all,,
PARN,DAN,ENSG00000140694,Poly(A)-specific ribonuclease,16,14435701-14632728,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006314, CAB011673, HPA012010",Enhanced,,Approved,Nucleoli<br>Nuclear speckles,Head and neck cancer:4.64e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 28.0,Expressed in all,,
PARP1,"ADPRT, PARP, PPOL",ENSG00000143799,Poly(ADP-ribose) polymerase 1,1,226360691-226408079,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727",Supported,Supported,Enhanced,Nucleus,"Renal cancer:1.35e-5 (unfavourable), Liver cancer:3.40e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 198.4,Expressed in all,,
PARP10,FLJ14464,ENSG00000178685,Poly(ADP-ribose) polymerase family member 10,8,143977153-144012772,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028122, HPA052427",Approved,,Supported,Nucleoli<br>Cytosol,,Expressed in all,Expressed in all,,,spleen: 56.4,Mixed,,
PARP11,C12orf6,ENSG00000111224,Poly(ADP-ribose) polymerase family member 11,12,3791047-3873448,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026895,Uncertain,,,,,Expressed in all,Mixed,,,testis: 17.6,Mixed,,
PARP12,"FLJ22693, PARP-12, ZC3H1, ZC3HDC1",ENSG00000059378,Poly(ADP-ribose) polymerase family member 12,7,140023744-140063721,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003584, HPA063872",Approved,,Approved,Nucleus,"Renal cancer:4.12e-7 (unfavourable), Liver cancer:1.63e-4 (unfavourable)",Expressed in all,Mixed,,,skin: 13.8,Mixed,,
PARP14,"KIAA1268, pART8",ENSG00000173193,Poly(ADP-ribose) polymerase family member 14,3,122680618-122730840,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA008846, HPA012063",Supported,,Enhanced,Cytosol,Renal cancer:1.79e-4 (unfavourable),Expressed in all,Expressed in all,,,spleen: 51.1,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 67.0;BJ hTERT+ SV40 Large T+ RasG12V: 107.2
PARP15,"FLJ40597, pART7",ENSG00000173200,Poly(ADP-ribose) polymerase family member 15,3,122577602-122639047,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA035757,,,Approved,Mitochondria,,Mixed,Tissue enhanced,,lymph node: 55.0;spleen: 60.4;tonsil: 48.1,appendix: 35.3,Cell line enhanced,,HEL: 7.8;TIME: 8.4
PARP16,"C15orf30, FLJ20509, FLJ25281, pART15",ENSG00000138617,Poly(ADP-ribose) polymerase family member 16,15,65234460-65300618,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA017081,Approved,,,,,Expressed in all,Expressed in all,,,ovary: 13.0,Expressed in all,,
PARP2,ADPRTL2,ENSG00000129484,Poly(ADP-ribose) polymerase 2,14,20343582-20357905,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA052003,Approved,,Approved,Nucleus<br>Nucleoli,Liver cancer:6.48e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 46.3,Expressed in all,,
PARP3,"ADPRT3, ADPRTL3, hPARP-3, IRT1, pADPRT-3",ENSG00000041880,Poly(ADP-ribose) polymerase family member 3,3,51942345-51948867,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA067657,Supported,,,,"Renal cancer:1.25e-8 (favourable), Breast cancer:6.39e-5 (favourable)",Expressed in all,Mixed,,,parathyroid gland: 53.0,Expressed in all,,
PARP4,"ADPRTL1, p193, VAULT3, VPARP, VWA5C",ENSG00000102699,Poly(ADP-ribose) polymerase family member 4,13,24420926-24512810,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA011739,Approved,,Supported,Cytosol,Renal cancer:1.21e-5 (favourable),Expressed in all,Expressed in all,,,gallbladder: 46.0,Expressed in all,,
PARP6,pART17,ENSG00000137817,Poly(ADP-ribose) polymerase family member 6,15,72241181-72272999,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026991,Approved,,Approved,Plasma membrane,"Renal cancer:8.02e-8 (unfavourable), Cervical cancer:3.17e-5 (favourable), Colorectal cancer:3.37e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 46.9,Mixed,,
PARP8,"FLJ21308, pART16",ENSG00000151883,Poly(ADP-ribose) polymerase family member 8,5,50665899-50846522,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA049183,Approved,,Approved,Nucleoplasm<br>Cell Junctions<br>Midbody ring<br>Cytosol,Urothelial cancer:1.12e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 72.9,Cell line enhanced,,THP-1: 65.6
PARP9,"BAL, BAL1",ENSG00000138496,Poly(ADP-ribose) polymerase family member 9,3,122527924-122564577,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA066708,,,Supported,Nucleoplasm<br>Mitochondria<br>Cytosol,Ovarian cancer:6.65e-4 (favourable),Expressed in all,Expressed in all,,,spleen: 60.9,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 89.2;BJ hTERT+ SV40 Large T+ RasG12V: 110.6
PARS2,DKFZp727A071,ENSG00000162396,"Prolyl-tRNA synthetase 2, mitochondrial (putative)",1,54756898-54764514,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028308, HPA028314, HPA028518",Uncertain,,Approved,Nucleoli fibrillar center<br>Mitochondria,"Renal cancer:1.24e-6 (favourable), Colorectal cancer:1.26e-5 (favourable), Liver cancer:2.34e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 8.0,Mixed,,
PASK,"KIAA0135, PASKIN, STK37",ENSG00000115687,PAS domain containing serine/threonine kinase,2,241106099-241150264,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA016450, HPA021079",Uncertain,,Supported,Cytosol,,Expressed in all,Tissue enhanced,,testis: 25.5,prostate: 16.3,Mixed,,
PBK,"CT84, FLJ14385, Nori-3, SPK, TOPK",ENSG00000168078,PDZ binding kinase,8,27809620-27838095,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA005753, HPA050656",Enhanced,Supported,Approved,Cytosol,"Renal cancer:1.18e-12 (unfavourable), Liver cancer:8.29e-5 (unfavourable), Pancreatic cancer:6.56e-4 (unfavourable)",Expressed in all,Tissue enriched,8,testis: 108.8,lymph node: 13.3,Mixed,,
PC,PCB,ENSG00000173599,Pyruvate carboxylase,11,66848233-66958376,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB033742, HPA043922, HPA058765",Uncertain,,Enhanced,Mitochondria,"Ovarian cancer:7.86e-5 (unfavourable), Renal cancer:8.22e-5 (favourable)",Expressed in all,Expressed in all,,,adipose tissue: 63.8,Mixed,,
PCBD1,"DCOH, PCBD, PCD",ENSG00000166228,Pterin-4 alpha-carbinolamine dehydratase 1,10,70882280-70888784,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA037575, HPA061723",Approved,,Enhanced,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,liver: 157.7,Mixed,,
PCBD2,"DCOH2, DCOHM",ENSG00000132570,Pterin-4 alpha-carbinolamine dehydratase 2,5,134904906-135007959,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036428,Uncertain,,Approved,Plasma membrane,,Expressed in all,Expressed in all,,,parathyroid gland: 16.1,Expressed in all,,
PCCA,,ENSG00000175198,Propionyl-CoA carboxylase alpha subunit,13,100089015-100530437,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA041716, HPA047792",Enhanced,,,,Renal cancer:0.00e+0 (favourable),Expressed in all,Expressed in all,,,epididymis: 266.0,Cell line enhanced,,RPTEC TERT1: 124.8;SCLC-21H: 107.6;U-937: 103.1
PCCB,,ENSG00000114054,Propionyl-CoA carboxylase beta subunit,3,136250306-136337896,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA036939, HPA036940",Enhanced,,,,Renal cancer:6.47e-7 (favourable),Expressed in all,Expressed in all,,,liver: 103.1,Expressed in all,,
PCK1,PEPCK-C,ENSG00000124253,Phosphoenolpyruvate carboxykinase 1,20,57561080-57568112,"Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006277, HPA006507, CAB017027",Approved,,,,Renal cancer:1.47e-5 (favourable),Tissue enriched,Tissue enhanced,,kidney: 425.9;liver: 319.7,small intestine: 157.6,Cell line enriched,9,ASC diff: 14.0
PCK2,"PEPCK, PEPCK2",ENSG00000100889,"Phosphoenolpyruvate carboxykinase 2, mitochondrial",14,24094053-24110598,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB018734, HPA051162, HPA053502",Enhanced,,Enhanced,Mitochondria,Liver cancer:2.81e-4 (favourable),Expressed in all,Group enriched,6,duodenum: 367.6;kidney: 192.2;liver: 258.6;small intestine: 276.5,colon: 47.0,Expressed in all,,
PCMT1,,ENSG00000120265,Protein-L-isoaspartate (D-aspartate) O-methyltransferase,6,149749443-149811420,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA003239,Approved,,Supported,Cytosol,"Breast cancer:4.02e-7 (unfavourable), Head and neck cancer:1.88e-4 (unfavourable), Liver cancer:2.58e-4 (unfavourable), Endometrial cancer:4.27e-4 (unfavourable), Urothelial cancer:6.38e-4 (unfavourable), Cervical cancer:9.58e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 194.7,Expressed in all,,
PCSK1,"NEC1, PC1, PC3, SPC3",ENSG00000175426,Proprotein convertase subtilisin/kexin type 1,5,96390415-96434143,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048564,Approved,,,,Glioma:1.31e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 33.6,adrenal gland: 8.3,Group enriched,6,SCLC-21H: 26.6;U-138 MG: 18.8;U-87 MG: 15.5
PCSK2,"NEC2, PC2, SPC2",ENSG00000125851,Proprotein convertase subtilisin/kexin type 2,20,17226107-17484578,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049627,Enhanced,,Approved,Vesicles,,Group enriched,Tissue enhanced,,adrenal gland: 37.5;cerebral cortex: 31.7,skin: 16.5,Group enriched,6,AF22: 59.2;SCLC-21H: 18.5
PCSK4,"DKFZp434B217, MGC34749, PC4, SPC5",ENSG00000115257,Proprotein convertase subtilisin/kexin type 4,19,1481428-1490752,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA005572,Uncertain,,,,Endometrial cancer:9.45e-5 (favourable),Expressed in all,Tissue enriched,9,testis: 41.3,fallopian tube: 4.8,Cell line enhanced,,AN3-CA: 6.5;HMC-1: 3.2;U-266/70: 5.8
PCSK5,"PC5, PC6, SPC6",ENSG00000099139,Proprotein convertase subtilisin/kexin type 5,9,75890644-76362339,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA031072,Enhanced,,Supported,Golgi apparatus,Renal cancer:9.61e-5 (unfavourable),Mixed,Mixed,,,small intestine: 28.1,Cell line enhanced,,BEWO: 31.5;HaCaT: 41.2;RPTEC TERT1: 32.1;U-2 OS: 68.5
PCSK6,"PACE4, SPC4",ENSG00000140479,Proprotein convertase subtilisin/kexin type 6,15,101297142-101525202,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004774,Uncertain,,,,"Renal cancer:7.06e-7 (unfavourable), Breast cancer:9.99e-4 (favourable)",Mixed,Tissue enhanced,,liver: 90.3;spleen: 124.6,placenta: 53.9,Cell line enhanced,,BEWO: 57.8;HEK 293: 58.5;Hep G2: 39.9
PCSK7,"LPC, PC7, PC8, SPC7",ENSG00000160613,Proprotein convertase subtilisin/kexin type 7,11,117204337-117232525,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043181, HPA052957",,,Uncertain,Nucleus<br>Nuclear membrane<br>Nucleoli,,Expressed in all,Expressed in all,,,endometrium: 75.4,Expressed in all,,
PCSK9,"FH3, HCHOLA3, NARC-1",ENSG00000169174,Proprotein convertase subtilisin/kexin type 9,1,55039548-55064852,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Urothelial cancer:2.40e-4 (unfavourable),Mixed,Tissue enhanced,,liver: 6.1;lung: 11.1,colon: 3.4,Cell line enhanced,,A-431: 72.0;HaCaT: 94.8;HeLa: 62.7;RPTEC TERT1: 39.4
PCYOX1,"KIAA0908, PCL1",ENSG00000116005,Prenylcysteine oxidase 1,2,70257386-70281191,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA035193,Approved,,,,Renal cancer:1.89e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 141.1,Expressed in all,,
PCYT1A,"CT, CTPCT, PCYT1",ENSG00000161217,"Phosphate cytidylyltransferase 1, choline, alpha",3,196214222-196287957,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA035428,Approved,,Approved,Nucleus,Liver cancer:8.65e-5 (unfavourable),Expressed in all,Expressed in all,,,duodenum: 66.9,Expressed in all,,
PCYT1B,"CCT-beta, CTB",ENSG00000102230,"Phosphate cytidylyltransferase 1, choline, beta",X,24558087-24672677,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006367,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 21.9;testis: 17.4,"fallopian tube,smooth muscle: 4.7",Cell line enhanced,,AF22: 11.6;CACO-2: 21.4;HEL: 28.7;NTERA-2: 13.3;SCLC-21H: 10.7
PCYT2,ET,ENSG00000185813,"Phosphate cytidylyltransferase 2, ethanolamine",17,81900965-81911464,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA023033, HPA023034",Enhanced,,Supported,Intermediate filaments<br>Centrosome,Renal cancer:4.29e-6 (favourable),Expressed in all,Expressed in all,,,testis: 241.6,Expressed in all,,
PDDC1,FLJ34283,ENSG00000177225,Parkinson disease 7 domain containing 1,11,767220-777488,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008812,Uncertain,,Supported,Nucleoplasm,"Renal cancer:3.79e-5 (favourable), Liver cancer:3.98e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 31.7,Expressed in all,,
PDE10A,,ENSG00000112541,Phosphodiesterase 10A,6,165327287-165986603,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB045998, HPA047200",Supported,,,,Renal cancer:4.44e-7 (unfavourable),Mixed,Tissue enhanced,,thyroid gland: 14.5,testis: 12.2,Cell line enhanced,,LHCN-M2: 14.4;SH-SY5Y: 11.1;TIME: 14.8
PDE11A,,ENSG00000128655,Phosphodiesterase 11A,2,177623252-178108339,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA034560,Approved,,,,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 10.5;prostate: 8.8,testis: 6.4,Cell line enhanced,,fHDF/TERT166: 2.2;Hep G2: 2.0
PDE12,"2'-PDE, DKFZp667B1218",ENSG00000174840,Phosphodiesterase 12,3,57556276-57566844,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043171,Approved,,,,"Renal cancer:3.63e-8 (favourable), Colorectal cancer:2.85e-5 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 15.9,Expressed in all,,
PDE1A,,ENSG00000115252,Phosphodiesterase 1A,2,182140036-182523192,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA022151,Approved,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,thyroid gland: 76.5,testis: 63.0,Cell line enhanced,,ASC diff: 25.5;HHSteC: 18.5;HSkMC: 34.2
PDE1B,PDES1B,ENSG00000123360,Phosphodiesterase 1B,12,54549350-54579239,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA018492,Approved,,,,Renal cancer:4.77e-6 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 18.4,parathyroid gland: 11.9,Cell line enhanced,,HDLM-2: 10.6;HL-60: 5.1;HMC-1: 10.2;NB-4: 5.1;THP-1: 5.1;U-937: 5.0
PDE1C,Hcam3,ENSG00000154678,Phosphodiesterase 1C,7,31751179-32299329,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021751, HPA052375",Uncertain,,Approved,Nucleus,,Tissue enhanced,Tissue enhanced,,heart muscle: 37.2,cerebral cortex: 20.8,Cell line enhanced,,fHDF/TERT166: 114.5;U-251 MG: 66.4;WM-115: 102.6
PDE2A,,ENSG00000186642,Phosphodiesterase 2A,11,72576141-72674591,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB009752, HPA031192",Enhanced,,Supported,Cytosol,Liver cancer:1.76e-6 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 141.8;spleen: 184.3,adipose tissue: 62.1,Cell line enriched,6,HeLa: 340.7
PDE3A,CGI-PDE,ENSG00000172572,Phosphodiesterase 3A,12,20369245-20684381,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA014492,Uncertain,,Supported,Cytosol,Renal cancer:1.72e-6 (unfavourable),Expressed in all,Mixed,,,heart muscle: 35.4,Group enriched,8,AF22: 15.4;HEL: 26.9;HeLa: 53.3;HUVEC TERT2: 11.9;SH-SY5Y: 31.0;U-138 MG: 22.1
PDE3B,HcGIP1,ENSG00000152270,Phosphodiesterase 3B,11,14643723-14872044,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA056111,,,Approved,Endoplasmic reticulum,Pancreatic cancer:7.91e-4 (favourable),Mixed,Tissue enhanced,,adipose tissue: 65.4,testis: 17.4,Mixed,,
PDE4A,DPDE2,ENSG00000065989,Phosphodiesterase 4A,19,10416773-10469631,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB017632, HPA043310, HPA076091",Uncertain,,Supported,Plasma membrane,,Expressed in all,Mixed,,,parathyroid gland: 34.0,Cell line enhanced,,HMC-1: 32.2
PDE4B,DPDE4,ENSG00000184588,Phosphodiesterase 4B,1,65792514-66374579,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003005,Uncertain,,Approved,Golgi apparatus<br>Cytosol,Renal cancer:5.04e-4 (unfavourable),Expressed in all,Mixed,,,cerebral cortex: 67.0,Cell line enhanced,,AN3-CA: 57.3;HUVEC TERT2: 77.6;NTERA-2: 56.0
PDE4C,DPDE1,ENSG00000105650,Phosphodiesterase 4C,19,18207961-18255419,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA048975,Enhanced,,,,,Mixed,Mixed,,,endometrium: 7.4,Cell line enhanced,,BEWO: 3.8;U-87 MG: 5.5
PDE4D,DPDE3,ENSG00000113448,Phosphodiesterase 4D,5,58969038-60522120,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA045895,Approved,,Approved,Nuclear membrane<br>Plasma membrane<br>Cytosol,Renal cancer:4.00e-5 (favourable),Mixed,Mixed,,,bone marrow: 47.7,Cell line enhanced,,A549: 56.1;AN3-CA: 65.2;HeLa: 68.4
PDE5A,,ENSG00000138735,Phosphodiesterase 5A,4,119494395-119628991,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004729, HPA012873",Approved,,Approved,Cytosol,"Urothelial cancer:1.17e-4 (unfavourable), Cervical cancer:5.20e-4 (favourable)",Expressed in all,Mixed,,,prostate: 97.7,Cell line enhanced,,BJ hTERT+: 38.5;HHSteC: 55.3
PDE6A,"PDEA, RP43",ENSG00000132915,Phosphodiesterase 6A,5,149857955-149944793,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA016970, HPA074677",Enhanced,,,,,Not detected,Tissue enriched,8,epididymis: 20.2,testis: 2.4,Cell line enhanced,,CACO-2: 2.1
PDE6B,"CSNB3, CSNBAD2, PDEB, rd1, RP40",ENSG00000133256,Phosphodiesterase 6B,4,625584-670782,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA054148, HPA059929",Supported,,Approved,Cytosol,Lung cancer:5.34e-4 (favourable),Mixed,Mixed,,,cerebral cortex: 22.3,Cell line enhanced,,MOLT-4: 25.1;REH: 15.3;SCLC-21H: 23.8;SH-SY5Y: 12.6;U-266/84: 16.5
PDE6C,"ACHM5, COD4, PDEA2",ENSG00000095464,Phosphodiesterase 6C,10,93612588-93666010,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Not detected,,,skin: 0.6,Not detected,,
PDE6G,"PDEG, RP57",ENSG00000185527,Phosphodiesterase 6G,17,81650459-81663112,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA045118,Supported,,,,,Tissue enhanced,Tissue enhanced,,lymph node: 26.1;spleen: 33.3,placenta: 18.9,Cell line enhanced,,NTERA-2: 10.5;REH: 11.5
PDE6H,,ENSG00000139053,Phosphodiesterase 6H,12,14973022-14981865,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA045118,Supported,,,,,Not detected,Tissue enhanced,,bone marrow: 2.4;placenta: 1.3,adrenal gland: 0.5,Not detected,,
PDE7A,HCP1,ENSG00000205268,Phosphodiesterase 7A,8,65717510-65842322,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB018770, HPA027340",Approved,,,,"Renal cancer:1.35e-4 (unfavourable), Liver cancer:5.64e-4 (unfavourable)",Expressed in all,Expressed in all,,,lymph node: 68.9,Expressed in all,,
PDE7B,,ENSG00000171408,Phosphodiesterase 7B,6,135851696-136195574,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA023967,Uncertain,,Approved,Nucleoplasm,Renal cancer:1.59e-4 (favourable),Mixed,Mixed,,,ovary: 16.2,Cell line enhanced,,EFO-21: 15.3;HSkMC: 16.3;U-2197: 10.6
PDE8A,HsT19550,ENSG00000073417,Phosphodiesterase 8A,15,84980440-85139145,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007722,Approved,,Approved,Golgi apparatus,,Expressed in all,Expressed in all,,,parathyroid gland: 30.2,Expressed in all,,
PDE8B,,ENSG00000113231,Phosphodiesterase 8B,5,77210449-77429807,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036911, HPA036912",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Tissue enriched,Tissue enriched,6,thyroid gland: 293.7,cerebral cortex: 53.0,Cell line enhanced,,BJ hTERT+: 14.6;HeLa: 32.2;SK-BR-3: 10.4
PDE9A,,ENSG00000160191,Phosphodiesterase 9A,21,42653636-42775509,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA011380,Enhanced,,Approved,Nucleoplasm<br>Vesicles,,Expressed in all,Tissue enhanced,,prostate: 56.8,spleen: 25.5,Cell line enhanced,,AF22: 29.5;EFO-21: 28.2;NTERA-2: 41.2;SCLC-21H: 26.8
PDF,,ENSG00000258429,Peptide deformylase (mitochondrial),16,69328621-69330595,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA063409,Approved,,Approved,Nucleoplasm<br>Mitochondria,"Head and neck cancer:2.73e-4 (unfavourable), Cervical cancer:4.63e-4 (unfavourable), Renal cancer:6.11e-4 (favourable), Lung cancer:7.35e-4 (unfavourable)",Expressed in all,Expressed in all,,,kidney: 7.8,Expressed in all,,
PDGFRA,"CD140a, GAS9, PDGFR2",ENSG00000134853,Platelet derived growth factor receptor alpha,4,54229097-54298247,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA004947, CAB018143",Supported,,Supported,Nucleus<br>Plasma membrane<br>Cell Junctions,"Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)",Expressed in all,Expressed in all,,,ovary: 222.6,Cell line enhanced,,ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0
PDGFRB,"CD140b, JTK12, PDGFR, PDGFR1",ENSG00000113721,Platelet derived growth factor receptor beta,5,150113837-150155872,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB003842, CAB018144, HPA028499",Enhanced,,Supported,Golgi apparatus<br>Vesicles,"Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable)",Expressed in all,Mixed,,,gallbladder: 193.8,Cell line enhanced,,ASC diff: 923.6;ASC TERT1: 324.4
PDHA1,PDHA,ENSG00000131828,Pyruvate dehydrogenase (lipoamide) alpha 1,X,19343893-19361705,"Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA047487, HPA047864, HPA063053",Approved,,Supported,Mitochondria,Renal cancer:1.13e-7 (favourable),Expressed in all,Expressed in all,,,heart muscle: 222.0,Expressed in all,,
PDHA2,PDHAL,ENSG00000163114,Pyruvate dehydrogenase (lipoamide) alpha 2,4,95840019-95841474,"Citric acid cycle related proteins, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047487, HPA047864, HPA063053",Approved,,Supported,Mitochondria,,Not detected,Tissue enriched,1010,testis: 101.0,all non-specific tissues: 0.0,Not detected,,
PDHB,,ENSG00000168291,Pyruvate dehydrogenase (lipoamide) beta,3,58427630-58433857,"Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB033794, HPA036744, HPA036745",Enhanced,,Supported,Nucleoplasm<br>Mitochondria,Renal cancer:2.79e-8 (favourable),Expressed in all,Expressed in all,,,heart muscle: 112.0,Expressed in all,,
PDIA2,"PDA2, PDI, PDIP, PDIR",ENSG00000185615,Protein disulfide isomerase family A member 2,16,283152-287215,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA051692, HPA053492",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Tissue enriched,Tissue enriched,7,pancreas: 523.1,stomach: 71.9,Cell line enhanced,,HAP1: 4.0;HEK 293: 7.9;Hep G2: 4.4;MCF7: 3.6;SH-SY5Y: 3.9
PDIA3,"ERp57, ERp60, ERp61, GRP57, GRP58, HsT17083, P58, PI-PLC",ENSG00000167004,Protein disulfide isomerase family A member 3,15,43746392-43773279,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA002645, HPA003230, CAB011199, CAB075744",Enhanced,,Enhanced,Endoplasmic reticulum,"Renal cancer:2.11e-8 (unfavourable), Head and neck cancer:8.95e-5 (unfavourable), Endometrial cancer:2.05e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 91.5,Expressed in all,,
PDIA4,"ERP70, ERP72",ENSG00000155660,Protein disulfide isomerase family A member 4,7,149003062-149028641,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA006139, HPA006140, CAB017368",Supported,,Supported,Endoplasmic reticulum,"Renal cancer:5.20e-9 (unfavourable), Glioma:8.61e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 372.1,Expressed in all,,
PDIA5,"FLJ30401, PDIR",ENSG00000065485,Protein disulfide isomerase family A member 5,3,123067062-123225227,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA030353, HPA030355",Enhanced,,Supported,Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus,"Renal cancer:8.09e-11 (unfavourable), Endometrial cancer:4.55e-4 (favourable)",Expressed in all,Mixed,,,placenta: 70.8,Mixed,,
PDIA6,"ERp5, P5, TXNDC7",ENSG00000143870,Protein disulfide isomerase family A member 6,2,10783391-10837977,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB034347, HPA034652, HPA034653",Enhanced,,Supported,Endoplasmic reticulum<br>Cytosol,"Renal cancer:2.51e-6 (unfavourable), Liver cancer:3.63e-5 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable), Cervical cancer:1.80e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 591.9,Expressed in all,,
PDIK1L,CLIK1L,ENSG00000175087,PDLIM1 interacting kinase 1 like,1,26111165-26125543,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA064157,,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,thyroid gland: 27.4,Expressed in all,,
PDK1,,ENSG00000152256,Pyruvate dehydrogenase kinase 1,2,172555373-172608669,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017554, HPA027376, HPA059083",Approved,,Approved,Nucleoli<br>Mitochondria,"Renal cancer:1.10e-8 (unfavourable), Cervical cancer:7.30e-5 (unfavourable)",Expressed in all,Expressed in all,,,testis: 22.2,Expressed in all,,
PDK2,PDHK2,ENSG00000005882,Pyruvate dehydrogenase kinase 2,17,50094737-50112152,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA008287,Supported,,Supported,Nucleoplasm<br>Mitochondria,"Renal cancer:9.59e-5 (favourable), Cervical cancer:5.87e-4 (favourable)",Expressed in all,Expressed in all,,,epididymis: 151.5,Mixed,,
PDK3,,ENSG00000067992,Pyruvate dehydrogenase kinase 3,X,24465221-24539837,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA046583, HPA072492",Approved,,Supported,Nucleoli<br>Mitochondria,Liver cancer:2.76e-4 (unfavourable),Expressed in all,Mixed,,,testis: 24.9,Mixed,,
PDK4,,ENSG00000004799,Pyruvate dehydrogenase kinase 4,7,95583499-95596491,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA056731,Approved,,,,Stomach cancer:1.80e-4 (unfavourable),Expressed in all,Expressed in all,,,seminal vesicle: 763.0,Cell line enriched,7,ASC diff: 333.3
PDP1,"PDH, PDP, PPM2A, PPM2C",ENSG00000164951,Pyruvate dehyrogenase phosphatase catalytic subunit 1,8,93857807-93926066,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA018483, HPA019081, HPA021152",Uncertain,,Supported,Nucleoplasm<br>Mitochondria<br>Cytosol,"Renal cancer:8.42e-9 (favourable), Breast cancer:8.61e-5 (unfavourable), Ovarian cancer:5.60e-4 (unfavourable)",Expressed in all,Expressed in all,,,adrenal gland: 82.3,Expressed in all,,
PDP2,"KIAA1348, PPM2B, PPM2C2",ENSG00000172840,Pyruvate dehyrogenase phosphatase catalytic subunit 2,16,66878589-66895754,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019950, HPA062059",Approved,,Supported,Mitochondria,Renal cancer:9.75e-7 (favourable),Expressed in all,Mixed,,,thyroid gland: 15.5,Expressed in all,,
PDPK1,PDK1,ENSG00000140992,3-phosphoinositide dependent protein kinase 1,16,2537964-2603188,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004272, HPA035199, HPA068961",Supported,,Approved,Vesicles,Renal cancer:1.29e-14 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 52.0,Expressed in all,,
PDSS1,"COQ1, TPRT, TPT",ENSG00000148459,Decaprenyl diphosphate synthase subunit 1,10,26697659-26746798,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038032, HPA042741",Uncertain,,Approved,Cytosol,"Liver cancer:1.25e-5 (unfavourable), Endometrial cancer:1.66e-4 (unfavourable)",Expressed in all,Mixed,,,duodenum: 18.4,Expressed in all,,
PDSS2,"bA59I9.3, C6orf210",ENSG00000164494,Decaprenyl diphosphate synthase subunit 2,6,107152557-107459564,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA029685, HPA029686",Approved,,Enhanced,Cytosol,"Renal cancer:3.75e-7 (favourable), Breast cancer:1.34e-5 (unfavourable), Colorectal cancer:5.74e-5 (favourable)",Expressed in all,Expressed in all,,,prostate: 23.4,Expressed in all,,
PDXK,"C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79",ENSG00000160209,Pyridoxal kinase,21,43719094-43762307,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030196, HPA030197, HPA030198, CAB033918",Approved,,Enhanced,Nucleus,,Expressed in all,Expressed in all,,,cerebral cortex: 47.5,Expressed in all,,
PDXP,"CIN, dJ37E16.5, FLJ32703",ENSG00000241360,Pyridoxal phosphatase,22,37658727-37666934,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000531,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 135.9,testis: 30.5,Mixed,,
PDZRN3,"KIAA1095, LNX3, SEMACAP3",ENSG00000121440,PDZ domain containing ring finger 3,3,73382433-73624940,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038822, HPA061420",Approved,,Supported,Nucleus<br>Cytosol,"Renal cancer:3.65e-7 (favourable), Endometrial cancer:3.35e-5 (favourable), Pancreatic cancer:4.93e-4 (favourable)",Mixed,Mixed,,,ovary: 85.7,Cell line enhanced,,AF22: 31.7;ASC diff: 39.1;BJ hTERT+: 34.1;HSkMC: 30.3
PEAK1,"KIAA2002, sgk269",ENSG00000173517,Pseudopodium enriched atypical kinase 1,15,77100656-77420144,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026313, HPA026517",Approved,,,,,Expressed in all,Mixed,,,spleen: 40.6,Expressed in all,,
PECR,"HSA250303, SDR29C1, TERP",ENSG00000115425,Peroxisomal trans-2-enoyl-CoA reductase,2,215996329-216082955,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021593, HPA022539",Enhanced,,Supported,Peroxisomes,Renal cancer:1.36e-5 (favourable),Expressed in all,Expressed in all,,,liver: 82.8,Mixed,,
PELI1,,ENSG00000197329,Pellino E3 ubiquitin protein ligase 1,2,64092652-64144454,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA053182,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Intermediate filaments,"Renal cancer:5.67e-6 (unfavourable), Endometrial cancer:5.33e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 143.9,Cell line enhanced,,U-698: 99.2
PELI2,,ENSG00000139946,Pellino E3 ubiquitin protein ligase family member 2,14,56117814-56301526,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA053182,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Intermediate filaments,Renal cancer:1.53e-6 (favourable),Mixed,Mixed,,,testis: 18.8,Cell line enhanced,,HMC-1: 29.1;MOLT-4: 31.6;SCLC-21H: 20.6
PELI3,MGC35521,ENSG00000174516,Pellino E3 ubiquitin protein ligase family member 3,11,66466327-66477337,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB033750, HPA038875, HPA062281",Uncertain,,Approved,Nucleus<br>Nucleoli<br>Vesicles,Renal cancer:8.19e-4 (favourable),Expressed in all,Mixed,,,parathyroid gland: 23.7,Mixed,,
PEMT,"PEMPT, PEMT2",ENSG00000133027,Phosphatidylethanolamine N-methyltransferase,17,17505563-17591708,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA042375,Approved,,Approved,Cytosol,Endometrial cancer:6.77e-6 (favourable),Expressed in all,Expressed in all,,,epididymis: 208.8,Expressed in all,,
PEPD,,ENSG00000124299,Peptidase D,19,33386950-33521794,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA015599, HPA072045",Approved,,Supported,Nucleoplasm,Renal cancer:6.50e-9 (favourable),Expressed in all,Expressed in all,,,kidney: 342.6,Expressed in all,,
PFAS,"FGARAT, KIAA0361, PURL",ENSG00000178921,Phosphoribosylformylglycinamidine synthase,17,8247618-8270491,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA022140, HPA022886",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane,Liver cancer:9.19e-4 (unfavourable),Expressed in all,Expressed in all,,,lymph node: 11.6,Expressed in all,,
PFKFB1,PFRX,ENSG00000158571,"6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1",X,54932961-54998534,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,8,adipose tissue: 30.1;liver: 18.7;skeletal muscle: 39.3,breast: 3.8,Cell line enhanced,,ASC diff: 5.9;Hep G2: 2.4
PFKFB2,,ENSG00000123836,"6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2",1,207034366-207081024,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049975, HPA063575",Uncertain,,Enhanced,Nucleus,"Renal cancer:3.23e-7 (favourable), Thyroid cancer:8.63e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 86.2,Mixed,,
PFKFB3,,ENSG00000170525,"6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3",10,6144934-6254644,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA008266, CAB020795, HPA043889",Uncertain,,Enhanced,Nucleoplasm,Renal cancer:1.87e-7 (unfavourable),Expressed in all,Expressed in all,,,adipose tissue: 345.8,Expressed in all,,
PFKFB4,,ENSG00000114268,"6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4",3,48517684-48562015,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047719, HPA066058",Uncertain,,Approved,Nucleoli,"Renal cancer:3.91e-8 (unfavourable), Cervical cancer:3.04e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 31.7,small intestine: 22.7,Cell line enhanced,,U-87 MG: 80.8;WM-115: 72.6
PFKL,,ENSG00000141959,"Phosphofructokinase, liver type",21,44300051-44327376,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA030047,Approved,,Approved,Nucleoli<br>Mitochondria,Ovarian cancer:4.41e-4 (unfavourable),Expressed in all,Expressed in all,,,small intestine: 101.7,Expressed in all,,
PFKM,"PFK-1, PFKX, PPP1R122",ENSG00000152556,"Phosphofructokinase, muscle",12,48105139-48146404,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002117,Approved,,Approved,Endoplasmic reticulum,"Renal cancer:2.28e-7 (favourable), Endometrial cancer:5.85e-6 (unfavourable), Head and neck cancer:7.91e-5 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 549.3,Expressed in all,,
PFKP,"PFK-C, PFKF",ENSG00000067057,"Phosphofructokinase, platelet",10,3066333-3137712,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA018257, HPA056484",Uncertain,,Supported,Cytosol,"Liver cancer:8.72e-6 (unfavourable), Head and neck cancer:1.55e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 285.1,Mixed,,
PGA3,,ENSG00000229859,"Pepsinogen 3, group I (pepsinogen A)",11,61203307-61213098,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB026358, HPA046875",Enhanced,,,,,Tissue enriched,Tissue enriched,716,stomach: 6775.4,cerebral cortex: 9.4,Group enriched,5,HMC-1: 7.5;THP-1: 1.9
PGA4,,ENSG00000229183,"Pepsinogen 4, group I (pepsinogen A)",11,61222216-61231927,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA046875,Supported,,,,,Not detected,Tissue enriched,2994,stomach: 34510.3,cerebral cortex: 11.5,Group enriched,7,BJ hTERT+: 12.2;THP-1: 5.2
PGA5,,ENSG00000256713,"Pepsinogen 5, group I (pepsinogen A)",11,61241042-61251448,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA046875,Supported,,,,,Tissue enriched,Tissue enriched,684,stomach: 3513.1,cerebral cortex: 5.1,Cell line enriched,13,BJ hTERT+: 23.3
PGAM1,"PGAM-B, PGAMA",ENSG00000171314,Phosphoglycerate mutase 1,10,97426160-97433441,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042528, HPA060483",Approved,,Approved,Nucleoplasm,"Breast cancer:2.04e-4 (unfavourable), Cervical cancer:3.86e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 421.2,Expressed in all,,
PGAM2,PGAM-M,ENSG00000164708,Phosphoglycerate mutase 2,7,44062727-44065587,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA050314, HPA060173",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Not detected,Group enriched,8,heart muscle: 521.3;skeletal muscle: 1459.5,testis: 126.6,Cell line enriched,10,SCLC-21H: 77.0
PGAM4,"dJ1000K24.1, PGAM-B, PGAM1, PGAM3",ENSG00000226784,Phosphoglycerate mutase family member 4,X,77968874-77969638,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042528, HPA060483",Uncertain,,Approved,Nucleoplasm,,Mixed,Not detected,,,appendix: 0.5,Cell line enhanced,,A-431: 1.9
PGAM5,"BXLBv68, MGC5352",ENSG00000247077,"PGAM family member 5, mitochondrial serine/threonine protein phosphatase",12,132710819-132722734,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA036978, HPA036979, CAB068215",Enhanced,,Supported,Mitochondria,Liver cancer:1.13e-6 (unfavourable),Expressed in all,Expressed in all,,,testis: 28.3,Expressed in all,,
PGC,,ENSG00000096088,Progastricsin,6,41736711-41754109,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA031717, HPA031718",Enhanced,,Supported,Nucleus,,Tissue enhanced,Tissue enriched,17,stomach: 22276.5,duodenum: 1302.2,Cell line enriched,11,Hep G2: 171.0
PGD,,ENSG00000142657,Phosphogluconate dehydrogenase,1,10398592-10420144,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA031314, HPA031315",Enhanced,Supported,Approved,Intermediate filaments<br>Cytosol,Liver cancer:3.98e-4 (unfavourable),Expressed in all,Expressed in all,,,esophagus: 486.8,Expressed in all,,
PGGHG,"ATHL1, FLJ22635",ENSG00000142102,Protein-glucosylgalactosylhydroxylysine glucosidase,11,289135-296107,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039383, HPA058829",Uncertain,,Enhanced,Cytosol,Urothelial cancer:5.12e-4 (favourable),Expressed in all,Expressed in all,,,lymph node: 73.6,Mixed,,
PGGT1B,"BGGI, GGTI",ENSG00000164219,Protein geranylgeranyltransferase type I subunit beta,5,115204012-115262872,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA030646,Uncertain,,Approved,Nucleoplasm<br>Endoplasmic reticulum<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 19.0,Expressed in all,,
PGK1,,ENSG00000102144,Phosphoglycerate kinase 1,X,78065188-78129296,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB010065, HPA045385, HPA073644, HPA073656",Approved,,,,"Breast cancer:7.05e-8 (unfavourable), Head and neck cancer:2.65e-6 (unfavourable), Cervical cancer:2.69e-5 (unfavourable), Liver cancer:2.74e-4 (unfavourable), Pancreatic cancer:8.34e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 118.2,Expressed in all,,
PGK2,"PGK-2, PGKPS",ENSG00000170950,Phosphoglycerate kinase 2,6,49785651-49787307,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA045385, HPA073644, HPA073656",Supported,,,,,Not detected,Tissue enriched,774,testis: 346.1,epididymis: 0.4,Not detected,,
PGLS,6PGL,ENSG00000130313,6-phosphogluconolactonase,19,17511629-17521288,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040744, HPA042032",Approved,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,fallopian tube: 46.7,Expressed in all,,
PGLYRP2,"PGLYRPL, PGRP-L, PGRPL, tagL, tagL-alpha, tagl-beta, TAGL-like",ENSG00000161031,Peptidoglycan recognition protein 2,19,15468645-15498956,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB033468, HPA043568, HPA046311, HPA075237",Approved,,Approved,Cell Junctions,,Tissue enriched,Tissue enriched,17,liver: 133.2,testis: 7.8,Group enriched,8,MCF7: 5.7;T-47d: 6.8
PGM1,,ENSG00000079739,Phosphoglucomutase 1,1,63593276-63660245,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004666, HPA024190, HPA024637, HPA046329",Approved,,Enhanced,Actin filaments,Pancreatic cancer:8.74e-5 (unfavourable),Expressed in all,Expressed in all,,,skeletal muscle: 512.9,Mixed,,
PGM2,FLJ10983,ENSG00000169299,Phosphoglucomutase 2,4,37826633-37862937,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040676,Uncertain,,Approved,Intermediate filaments,Colorectal cancer:2.14e-5 (favourable),Expressed in all,Mixed,,,esophagus: 36.5,Expressed in all,,
PGM2L1,"BM32A, FLJ32029",ENSG00000165434,Phosphoglucomutase 2 like 1,11,74330318-74398473,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA056995, HPA060948",Enhanced,,Approved,Mitochondria,,Mixed,Tissue enriched,9,cerebral cortex: 64.1,endometrium: 7.3,Cell line enhanced,,RH-30: 18.2
PGM3,"AGM1, DKFZP434B187, PAGM",ENSG00000013375,Phosphoglucomutase 3,6,83161150-83193936,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004998, HPA029759, HPA029760",Enhanced,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:2.39e-7 (unfavourable), Cervical cancer:5.67e-4 (unfavourable), Breast cancer:8.78e-4 (unfavourable), Ovarian cancer:9.96e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 82.2,Expressed in all,,
PGP,,ENSG00000184207,Phosphoglycolate phosphatase,16,2211997-2214807,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA043096, HPA046739",Approved,,Approved,Nuclear bodies,"Urothelial cancer:6.42e-4 (favourable), Renal cancer:7.05e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 28.1,Expressed in all,,
PGPEP1,"Pcp, PGP, PGP-I, PGPI",ENSG00000130517,Pyroglutamyl-peptidase I,19,18340587-18369950,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035368, HPA055277",Approved,,Approved,Golgi apparatus,"Renal cancer:3.71e-8 (favourable), Pancreatic cancer:1.71e-4 (favourable), Melanoma:6.80e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 29.3,Cell line enhanced,,HMC-1: 51.6
PGPEP1L,,ENSG00000183571,Pyroglutamyl-peptidase I-like,15,98968230-99007795,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA041781,Uncertain,,,,,Not detected,Group enriched,6,heart muscle: 2.4;skeletal muscle: 10.5;testis: 3.8,"breast,esophagus: 0.9",Cell line enhanced,,U-2 OS: 1.1
PGS1,DKFZP762M186,ENSG00000087157,Phosphatidylglycerophosphate synthase 1,17,78378640-78425114,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA022526,Approved,,Approved,Vesicles<br>Cell Junctions<br>Intermediate filaments,"Renal cancer:1.16e-5 (unfavourable), Pancreatic cancer:7.33e-5 (favourable), Liver cancer:1.37e-4 (unfavourable), Prostate cancer:9.94e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 26.7,Expressed in all,,
PHEX,"HPDR, HPDR1, HYP, HYP1, PEX, XLH",ENSG00000102174,"Phosphate regulating endopeptidase homolog, X-linked",X,22032441-22251310,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,Thyroid cancer:2.51e-4 (favourable),Tissue enhanced,Tissue enhanced,,endometrium: 3.5,lung: 2.9,Cell line enhanced,,PC-3: 2.8;U-87 MG: 6.5;WM-115: 2.8
PHF8,"JHDM1F, KDM7B, KIAA1111, ZNF422",ENSG00000172943,PHD finger protein 8,X,53936676-54048958,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038779, HPA062015",Approved,,Supported,Nucleus,Urothelial cancer:3.74e-5 (favourable),Expressed in all,Expressed in all,,,epididymis: 85.8,Expressed in all,,
PHGDH,"PDG, PGDH, SERA",ENSG00000092621,Phosphoglycerate dehydrogenase,1,119659798-119744215,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003681, HPA021241, HPA024031, CAB068216",Enhanced,,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Endometrial cancer:1.48e-4 (unfavourable), Glioma:2.26e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 216.7,skin: 115.9,Mixed,,
PHKG1,PHKG,ENSG00000164776,Phosphorylase kinase catalytic subunit gamma 1,7,56080283-56092996,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012057,Enhanced,,,,,Tissue enriched,Tissue enriched,7,skeletal muscle: 100.5,cerebral cortex: 14.2,Mixed,,
PHKG2,,ENSG00000156873,Phosphorylase kinase catalytic subunit gamma 2,16,30748270-30761176,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA065618, HPA068751",,,Supported,Cytosol,"Lung cancer:1.90e-4 (favourable), Cervical cancer:7.90e-4 (favourable), Pancreatic cancer:8.02e-4 (favourable), Colorectal cancer:9.92e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 149.4,Expressed in all,,
PHLPP1,"KIAA0606, PHLPP, PLEKHE1, PPM3A, SCOP",ENSG00000081913,PH domain and leucine rich repeat protein phosphatase 1,18,62715450-62980433,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA020200,Uncertain,,,,Renal cancer:5.35e-8 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 40.9,Mixed,,
PHLPP2,"KIAA0931, PHLPPL, PPM3B",ENSG00000040199,PH domain and leucine rich repeat protein phosphatase 2,16,71637835-71724701,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA048598,Approved,,Approved,Vesicles,,Expressed in all,Mixed,,,small intestine: 24.2,Expressed in all,,
PHOSPHO1,,ENSG00000173868,Phosphoethanolamine/phosphocholine phosphatase,17,49223362-49230766,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA053016, HPA065025",Uncertain,,Approved,Plasma membrane<br>Actin filaments,,Mixed,Tissue enhanced,,spleen: 20.4;testis: 41.1,bone marrow: 12.4,Cell line enhanced,,Daudi: 4.3;EFO-21: 3.6;HDLM-2: 4.0
PHOSPHO2,MGC22679,ENSG00000144362,"Phosphatase, orphan 2",2,169694454-169701708,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA034726, HPA034727",Uncertain,,Approved,Vesicles,"Liver cancer:3.82e-6 (unfavourable), Renal cancer:9.53e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 23.0,Expressed in all,,
PHPT1,"bA216L13.10, CGI-202, DKFZp564M173, HSPC141, PHP14",ENSG00000054148,Phosphohistidine phosphatase 1,9,136848724-136851027,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB013584, HPA020952",Approved,,Approved,Nuclear bodies<br>Cytosol,,Expressed in all,Expressed in all,,,heart muscle: 73.8,Expressed in all,,
PHYH,"PAHX, PHYH1, RD",ENSG00000107537,Phytanoyl-CoA 2-hydroxylase,10,13277796-13302412,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA007598, HPA011796",Enhanced,,,,Renal cancer:7.28e-12 (favourable),Expressed in all,Expressed in all,,,liver: 334.1,Mixed,,
PHYKPL,"AGXT2L2, MGC15875",ENSG00000175309,5-phosphohydroxy-L-lysine phospho-lyase,5,178208497-178232791,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036461, HPA063608",Approved,,Approved,Mitochondria,Renal cancer:3.82e-5 (unfavourable),Expressed in all,Expressed in all,,,rectum: 34.5,Expressed in all,,
PI4K2A,"DKFZP761G1923, PI4KII, PIK42A",ENSG00000155252,Phosphatidylinositol 4-kinase type 2 alpha,10,97640686-97676434,"Enzymes, Predicted intracellular proteins",Evidence at protein level,CAB030649,Approved,,,,Colorectal cancer:4.21e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 31.3,Expressed in all,,
PI4K2B,"FLJ11105, PI4KIIB, PIK42B",ENSG00000038210,Phosphatidylinositol 4-kinase type 2 beta,4,25233975-25279092,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004099,Approved,,Supported,Cytosol,Colorectal cancer:9.64e-5 (favourable),Expressed in all,Mixed,,,thyroid gland: 33.9,Expressed in all,,
PI4KA,"PI4K-ALPHA, pi4K230, PIK4CA",ENSG00000241973,Phosphatidylinositol 4-kinase alpha,22,20707691-20859417,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009092, HPA075515",Approved,,Approved,Nucleoplasm<br>Plasma membrane,"Renal cancer:7.22e-5 (favourable), Lung cancer:5.24e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 113.6,Expressed in all,,
PI4KB,"PI4K-BETA, pi4K92, PIK4CB",ENSG00000143393,Phosphatidylinositol 4-kinase beta,1,151291797-151327715,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006280, HPA006281, CAB022071",Approved,,Supported,Golgi apparatus,"Pancreatic cancer:1.25e-5 (favourable), Liver cancer:2.97e-4 (unfavourable), Renal cancer:3.23e-4 (unfavourable), Thyroid cancer:6.78e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 102.7,Expressed in all,,
PIAS4,"FLJ12419, Piasg, PIASY, ZMIZ6",ENSG00000105229,Protein inhibitor of activated STAT 4,19,4007646-4039386,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA010598,Approved,,Approved,Nucleoplasm,"Endometrial cancer:1.18e-5 (favourable), Pancreatic cancer:7.04e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 29.3,Expressed in all,,
PIF1,"C15orf20, FLJ22692",ENSG00000140451,PIF1 5'-to-3' DNA helicase,15,64815632-64825668,"Enzymes, Predicted intracellular proteins",Evidence at protein level,CAB018701,Supported,,Supported,Nucleoplasm,Melanoma:5.22e-4 (unfavourable),Tissue enhanced,Mixed,,,lymph node: 5.3,Mixed,,
PIGA,GPI3,ENSG00000165195,Phosphatidylinositol glycan anchor biosynthesis class A,X,15319451-15335580,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA001174,Approved,,,,Pancreatic cancer:7.64e-4 (unfavourable),Expressed in all,Mixed,,,lung: 9.8,Expressed in all,,
PIGC,,ENSG00000135845,Phosphatidylinositol glycan anchor biosynthesis class C,1,172370189-172444086,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA036663,Uncertain,,,,"Renal cancer:1.43e-8 (unfavourable), Liver cancer:4.49e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 47.7,Expressed in all,,
PIGH,GPI-H,ENSG00000100564,Phosphatidylinositol glycan anchor biosynthesis class H,14,67581955-67600287,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA031624,Approved,,,,Renal cancer:2.68e-7 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 107.3,Expressed in all,,
PIGK,"GPI8, hGPI8",ENSG00000142892,Phosphatidylinositol glycan anchor biosynthesis class K,1,77088990-77219430,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA056383, HPA057040",Uncertain,,,,Liver cancer:4.68e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 28.4,Expressed in all,,
PIGL,,ENSG00000108474,Phosphatidylinositol glycan anchor biosynthesis class L,17,16217191-16351797,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA012739,Approved,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:1.47e-4 (unfavourable), Prostate cancer:2.57e-4 (unfavourable)",Expressed in all,Expressed in all,,,"epididymis,thyroid gland: 14.7",Mixed,,
PIGP,"DCRC, DSCR5, DSRC",ENSG00000185808,Phosphatidylinositol glycan anchor biosynthesis class P,21,37059170-37073170,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA026921,Uncertain,,Approved,Vesicles,,Expressed in all,Expressed in all,,,epididymis: 125.7,Expressed in all,,
PIGQ,"GPI1, hGPI1",ENSG00000007541,Phosphatidylinositol glycan anchor biosynthesis class Q,16,566995-584136,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039105, HPA039828, HPA061414",Approved,,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Renal cancer:2.53e-6 (favourable),Expressed in all,Expressed in all,,,bone marrow: 17.5,Expressed in all,,
PIK3C2A,PI3K-C2alpha,ENSG00000011405,Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha,11,17077730-17207983,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037641, HPA037642",Uncertain,,Supported,Nucleus,Renal cancer:1.66e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 94.6,Expressed in all,,
PIK3C2B,"C2-PI3K, PI3K-C2beta",ENSG00000133056,Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta,1,204422628-204494724,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030515, HPA050360",Approved,,Approved,Nucleoplasm<br>Cytosol,"Urothelial cancer:1.16e-4 (favourable), Liver cancer:5.42e-4 (unfavourable)",Expressed in all,Mixed,,,lymph node: 28.2,Cell line enhanced,,BEWO: 67.8;RT4: 60.2
PIK3C2G,,ENSG00000139144,Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma,12,18247614-18648416,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,Pancreatic cancer:3.50e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,epididymis: 20.4;stomach: 20.0,parathyroid gland: 17.3,Group enriched,6,BEWO: 1.2;HaCaT: 1.8;hTERT-HME1: 2.9
PIK3C3,Vps34,ENSG00000078142,Phosphatidylinositol 3-kinase catalytic subunit type 3,18,41955206-42087830,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040718,Approved,,,,Renal cancer:4.97e-4 (favourable),Expressed in all,Expressed in all,,,testis: 32.9,Expressed in all,,
PIK3CA,PI3K,ENSG00000121879,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha",3,179148114-179240093,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA009985, CAB017804",Approved,,Approved,Cytosol,,Expressed in all,Mixed,,,parathyroid gland: 23.8,Expressed in all,,
PIK3CB,PIK3C1,ENSG00000051382,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta",3,138652699-138834938,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB031938, HPA064207",Approved,,Approved,Nucleoplasm<br>Nucleoli<br>Midbody,"Pancreatic cancer:3.99e-5 (unfavourable), Liver cancer:6.42e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 88.9,Expressed in all,,
PIK3CD,p110D,ENSG00000171608,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta",1,9651732-9729114,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB015420, HPA044953",Enhanced,,Approved,Vesicles<br>Cytokinetic bridge,,Expressed in all,Tissue enhanced,,lymph node: 56.4,spleen: 51.2,Cell line enhanced,,HDLM-2: 146.7;REH: 64.7;U-937: 63.7
PIK3CG,,ENSG00000105851,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma",7,106865278-106907145,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA069976,,,Supported,Plasma membrane,,Mixed,Tissue enhanced,,bone marrow: 28.1,lymph node: 22.0,Cell line enhanced,,HMC-1: 30.6;MOLT-4: 44.8;U-266/70: 53.9;U-937: 40.5
PIK3R4,"p150, VPS15",ENSG00000196455,Phosphoinositide-3-kinase regulatory subunit 4,3,130678935-130746829,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036032, HPA036033",Approved,,Approved,Vesicles<br>Microtubules,Renal cancer:4.40e-6 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 46.6,Expressed in all,,
PIKFYVE,"FAB1, KIAA0981, MGC40423, p235, PIKfyve, PIP5K, PIP5K3, ZFYVE29",ENSG00000115020,"Phosphoinositide kinase, FYVE-type zinc finger containing",2,208266267-208358751,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA042604,Uncertain,,Uncertain,Nuclear speckles,Head and neck cancer:6.81e-4 (favourable),Expressed in all,Expressed in all,,,testis: 25.8,Expressed in all,,
PIM1,PIM,ENSG00000137193,"Pim-1 proto-oncogene, serine/threonine kinase",6,37170203-37175426,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003941, CAB017040",Uncertain,,Supported,Nucleoli<br>Cytosol,Endometrial cancer:9.73e-4 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 133.9,Expressed in all,,
PIM2,,ENSG00000102096,"Pim-2 proto-oncogene, serine/threonine kinase",X,48913182-48919024,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA000285,,,Approved,Cytosol,"Renal cancer:1.17e-11 (unfavourable), Cervical cancer:4.05e-5 (favourable)",Tissue enriched,Mixed,,,lymph node: 128.7,Expressed in all,,
PIM3,,ENSG00000198355,"Pim-3 proto-oncogene, serine/threonine kinase",22,49960513-49964080,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA068758,,,Supported,Cytosol,"Renal cancer:8.09e-4 (favourable), Ovarian cancer:9.68e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 61.2,Expressed in all,,
PIN1,dod,ENSG00000127445,"Peptidylprolyl cis/trans isomerase, NIMA-interacting 1",19,9835257-9849682,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004528, CAB009326, HPA068650",Approved,,Enhanced,Nucleoplasm<br>Cytosol,"Renal cancer:7.80e-5 (favourable), Pancreatic cancer:3.25e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 136.9,Expressed in all,,
PIN4,"EPVH, PAR14, PAR17",ENSG00000102309,"Peptidylprolyl cis/trans isomerase, NIMA-interacting 4",X,72181353-72302926,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA054483, HPA064504",Approved,,Supported,Nucleus<br>Nucleoli,"Testis cancer:2.58e-4 (favourable), Urothelial cancer:2.66e-4 (favourable), Lung cancer:6.37e-4 (favourable)",Expressed in all,Expressed in all,,,epididymis: 24.3,Expressed in all,,
PINK1,PARK6,ENSG00000158828,PTEN induced putative kinase 1,1,20633455-20651511,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001931, CAB026191",Uncertain,,,,Renal cancer:1.11e-16 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 145.5,Expressed in all,,
PIP4K2A,"PIP5K2A, PIP5KIIA, PIP5KIIalpha",ENSG00000150867,Phosphatidylinositol-5-phosphate 4-kinase type 2 alpha,10,22534849-22714555,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA065440, HPA068771",Supported,,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:1.46e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 144.3,Expressed in all,,
PIP4K2B,"PIP5K2B, PIP5KIIB, PIP5KIIbeta",ENSG00000276293,Phosphatidylinositol-5-phosphate 4-kinase type 2 beta,17,38765689-38800126,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047875, HPA062220",Approved,,Supported,Nucleoplasm,"Thyroid cancer:1.36e-4 (favourable), Liver cancer:4.54e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 51.6,Expressed in all,,
PIP4K2C,"FLJ22055, PIP5K2C",ENSG00000166908,Phosphatidylinositol-5-phosphate 4-kinase type 2 gamma,12,57591174-57603418,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028658, HPA058551",Approved,,Approved,Vesicles,"Renal cancer:2.06e-6 (favourable), Liver cancer:7.98e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 109.1,Mixed,,
PIP5K1A,,ENSG00000143398,Phosphatidylinositol-4-phosphate 5-kinase type 1 alpha,1,151197949-151249536,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA029366,Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:4.16e-7 (unfavourable),Expressed in all,Expressed in all,,,testis: 67.8,Expressed in all,,
PIP5K1B,"MSS4, STM7",ENSG00000107242,Phosphatidylinositol-4-phosphate 5-kinase type 1 beta,9,68705414-69009176,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA009687,Uncertain,,Approved,Nucleus<br>Vesicles,Renal cancer:1.03e-9 (favourable),Mixed,Mixed,,,testis: 50.3,Cell line enhanced,,AF22: 47.6;HEL: 16.8;U-266/70: 14.2
PIP5K1C,"KIAA0589, LCCS3, PIP5Kgamma",ENSG00000186111,Phosphatidylinositol-4-phosphate 5-kinase type 1 gamma,19,3630183-3700479,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA017168,Approved,,Approved,Nucleoplasm<br>Cytosol,"Endometrial cancer:7.28e-5 (favourable), Cervical cancer:1.79e-4 (favourable), Pancreatic cancer:2.32e-4 (favourable), Renal cancer:3.00e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 52.9,Expressed in all,,
PIP5KL1,"bA203J24.5, MGC46424",ENSG00000167103,Phosphatidylinositol-4-phosphate 5-kinase like 1,9,127920879-127930797,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA056240,Uncertain,,Supported,Cytosol,,Mixed,Tissue enhanced,,parathyroid gland: 3.8,skin: 2.2,Cell line enhanced,,Karpas-707: 32.1;RPMI-8226: 21.0
PIPOX,LPIPOX,ENSG00000179761,Pipecolic acid and sarcosine oxidase,17,28950513-29057220,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,Pancreatic cancer:1.49e-4 (favourable),Group enriched,Group enriched,7,kidney: 137.9;liver: 235.9,epididymis: 26.0,Group enriched,5,AF22: 30.7;Hep G2: 65.9;NTERA-2: 61.7;RH-30: 85.6
PIR,,ENSG00000087842,Pirin,X,15384799-15493564,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA000697,Enhanced,,Supported,Cytosol,"Renal cancer:6.11e-7 (unfavourable), Cervical cancer:2.78e-4 (favourable), Ovarian cancer:4.94e-4 (favourable)",Expressed in all,Mixed,,,urinary bladder: 22.6,Cell line enhanced,,HUVEC TERT2: 565.7;SK-MEL-30: 201.8
PISD,"dJ858B16.2, PSDC",ENSG00000241878,Phosphatidylserine decarboxylase,22,31618491-31662432,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA031090, HPA031091",Approved,,Approved,Golgi apparatus<br>Cytosol,Urothelial cancer:5.27e-5 (favourable),Expressed in all,Expressed in all,,,adipose tissue: 35.9,Expressed in all,,
PITRM1,"hMP1, KIAA1104, MP1, PreP",ENSG00000107959,Pitrilysin metallopeptidase 1,10,3137728-3172841,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006753, HPA006754",Enhanced,,Supported,Mitochondria,,Expressed in all,Expressed in all,,,testis: 86.6,Expressed in all,,
PJA1,"FLJ11830, RNF70",ENSG00000181191,Praja ring finger ubiquitin ligase 1,X,69160851-69165793,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000595,Enhanced,,Approved,Nucleus<br>Nucleoli,Renal cancer:7.44e-5 (favourable),Expressed in all,Expressed in all,,,epididymis: 181.5,Cell line enhanced,,HAP1: 88.6
PJA2,"KIAA0438, Neurodap1, RNF131",ENSG00000198961,Praja ring finger ubiquitin ligase 2,5,109334709-109409994,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040347, HPA057636",Enhanced,,Supported,Intermediate filaments,Ovarian cancer:8.02e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 254.4,Expressed in all,,
PKDCC,"SgK493, Vlk",ENSG00000162878,"Protein kinase domain containing, cytoplasmic",2,42048020-42058528,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA026427, HPA026442, HPA026526",Uncertain,,,,,Expressed in all,Mixed,,,adipose tissue: 27.4,Cell line enhanced,,AN3-CA: 72.7;ASC diff: 41.5;CACO-2: 78.1;HHSteC: 43.5
PKLR,,ENSG00000143627,"Pyruvate kinase, liver and RBC",1,155289839-155301434,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006653, CAB034376, CAB034378",Enhanced,,Approved,Endoplasmic reticulum<br>Golgi apparatus,,Tissue enriched,Tissue enhanced,,kidney: 14.0;liver: 26.4,bone marrow: 7.8,Cell line enriched,16,K-562: 72.0
PKM,"OIP3, PK3, PKM2, THBP1",ENSG00000067225,"Pyruvate kinase, muscle",15,72199029-72231822,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB019421, HPA029501",Uncertain,,Enhanced,Cytosol,"Liver cancer:2.74e-6 (unfavourable), Pancreatic cancer:5.17e-5 (unfavourable), Head and neck cancer:1.30e-4 (unfavourable), Lung cancer:2.85e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 1492.3,Expressed in all,,
PKMYT1,"MYT1, PPP1R126",ENSG00000127564,"Protein kinase, membrane associated tyrosine/threonine 1",16,2968024-2980539,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA068860,,,Supported,Nucleus<br>Nucleoli<br>Golgi apparatus,"Lung cancer:3.37e-4 (unfavourable), Liver cancer:8.33e-4 (unfavourable)",Mixed,Tissue enhanced,,bone marrow: 17.0;testis: 27.7,lymph node: 9.7,Mixed,,
PKN1,"DBK, MGC46204, PAK1, PKN, PRK1, PRKCL1",ENSG00000123143,Protein kinase N1,19,14433053-14471867,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003982, CAB010278",Approved,,Supported,Nucleus<br>Nuclear bodies<br>Cytosol,,Expressed in all,Expressed in all,,,spleen: 85.9,Expressed in all,,
PKN2,"Pak-2, PRK2, PRKCL2, STK7",ENSG00000065243,Protein kinase N2,1,88684222-88836255,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA034861, HPA057913",Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Intermediate filaments<br>Cytosol,Colorectal cancer:5.67e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 48.8,Expressed in all,,
PKN3,"PKNbeta, UTDP4-1",ENSG00000160447,Protein kinase N3,9,128702523-128720918,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA045390, HPA058305",Uncertain,,Approved,Vesicles,,Expressed in all,Mixed,,,adipose tissue: 7.6,Cell line enhanced,,HeLa: 45.8
PLA2G10,GXPLA2,ENSG00000069764,Phospholipase A2 group X,16,14672545-14694669,"Enzymes, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA041893,Uncertain,,,,Endometrial cancer:5.74e-5 (favourable),Mixed,Tissue enhanced,,colon: 6.9;rectum: 6.5;stomach: 10.4,duodenum: 2.2,Cell line enhanced,,CAPAN-2: 1.3
PLA2G12A,PLA2G12,ENSG00000123739,Phospholipase A2 group XIIA,4,109709989-109730077,"Enzymes, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA035908, HPA035909",Approved,,,,Renal cancer:2.54e-9 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 34.0,Expressed in all,,
PLA2G16,"AdPLA, H-REV107-1, HRASLS3, HREV107, HREV107-3, MGC118754.",ENSG00000176485,Phospholipase A2 group XVI,11,63573195-63616883,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,HPA058997,Uncertain,,Approved,Mitochondria,"Pancreatic cancer:5.58e-6 (unfavourable), Thyroid cancer:2.54e-5 (favourable)",Expressed in all,Expressed in all,,,adipose tissue: 327.7,Cell line enhanced,,CAPAN-2: 206.7
PLA2G1B,"PLA2, PLA2A, PPLA2",ENSG00000170890,Phospholipase A2 group IB,12,120322111-120327789,"Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB022329, HPA047822, HPA060803",Enhanced,,Enhanced,Cytosol,,Tissue enriched,Tissue enriched,246,pancreas: 23843.3,ovary: 96.9,Cell line enhanced,,Hep G2: 1.7;U-2 OS: 1.8
PLA2G2A,"PLA2B, PLA2L",ENSG00000188257,Phospholipase A2 group IIA,1,19975431-19980416,"Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA015236,Enhanced,,Uncertain,Nucleus<br>Nucleoli,Melanoma:1.49e-4 (favourable),Expressed in all,Tissue enhanced,,colon: 108.4;rectum: 177.5;small intestine: 233.7,duodenum: 85.7,Group enriched,11,Hep G2: 50.2;RT4: 53.3
PLA2G2D,sPLA2S,ENSG00000117215,Phospholipase A2 group IID,1,20111939-20119566,"Enzymes, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,,,,,,"Cervical cancer:8.15e-5 (favourable), Breast cancer:4.35e-4 (favourable), Endometrial cancer:9.74e-4 (favourable)",Tissue enriched,Tissue enhanced,,lymph node: 118.5;tonsil: 54.0,appendix: 20.5,Cell line enriched,6,RPMI-8226: 5.9
PLA2G2E,,ENSG00000188784,Phospholipase A2 group IIE,1,19920009-19923617,"Enzymes, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA064085,Uncertain,,,,,Not detected,Tissue enriched,11,tonsil: 2.3,small intestine: 0.2,Not detected,,
PLA2G2F,,ENSG00000158786,Phospholipase A2 group IIF,1,20139326-20150386,"Enzymes, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,,,,,,Urothelial cancer:3.86e-4 (favourable),Tissue enriched,Group enriched,11,skin: 11.3;tonsil: 7.2;urinary bladder: 3.9,gallbladder: 0.6,Cell line enriched,57,RT4: 110.7
PLA2G3,GIII-SPLA2,ENSG00000100078,Phospholipase A2 group III,22,31134809-31140607,"Enzymes, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA021016,Uncertain,,,,Head and neck cancer:4.47e-4 (favourable),Mixed,Tissue enhanced,,esophagus: 4.4;lung: 3.6;skin: 10.2,parathyroid gland: 1.5,Group enriched,6,AF22: 14.3;AN3-CA: 13.6;NTERA-2: 7.5;SCLC-21H: 13.2
PLA2G4A,"cPLA2-alpha, PLA2G4",ENSG00000116711,Phospholipase A2 group IVA,1,186828953-186988981,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010050, HPA050062, HPA054206",Approved,,Supported,Cytosol,"Endometrial cancer:2.85e-4 (favourable), Breast cancer:9.07e-4 (favourable)",Mixed,Tissue enhanced,,parathyroid gland: 200.5,seminal vesicle: 68.3,Cell line enhanced,,RPMI-8226: 50.7;U-2197: 61.7
PLA2G4B,"cPLA2-beta, HsT16992",ENSG00000243708,Phospholipase A2 group IVB,15,41837775-41848147,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,skin: 36.3,esophagus: 14.1,Cell line enhanced,,RT4: 5.9
PLA2G4C,cPLA2-gamma,ENSG00000105499,Phospholipase A2 group IVC,19,48047843-48110817,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA043083,Approved,,Approved,Cytosol,,Mixed,Mixed,,,parathyroid gland: 29.7,Cell line enhanced,,HHSteC: 12.1;TIME: 17.1
PLA2G4D,cPLA2delta,ENSG00000159337,Phospholipase A2 group IVD,15,42067009-42094554,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,29,prostate: 34.2;skin: 16.5,esophagus: 0.8,Cell line enriched,30,RPMI-8226: 12.2
PLA2G4E,FLJ45651,ENSG00000188089,Phospholipase A2 group IVE,15,41981582-42051190,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA041105,Enhanced,,,,,Tissue enhanced,Tissue enriched,10,skin: 20.4,"esophagus,tonsil: 2.0",Not detected,,
PLA2G4F,PLA2G4F/Z,ENSG00000168907,Phospholipase A2 group IVF,15,42139034-42156636,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA042713, HPA056752",Enhanced,,Approved,Nucleus<br>Vesicles,Endometrial cancer:2.00e-4 (unfavourable),Mixed,Tissue enriched,5,skin: 92.5,lung: 18.4,Cell line enhanced,,hTCEpi: 1.4;RT4: 6.6
PLA2G5,,ENSG00000127472,Phospholipase A2 group V,1,20028179-20091190,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA053361,Approved,,,,,Group enriched,Tissue enhanced,,heart muscle: 48.6,seminal vesicle: 19.8,Cell line enhanced,,U-138 MG: 1.0;U-2197: 2.1
PLA2G6,"iPLA2, iPLA2beta, NBIA2, PARK14, PNPLA9",ENSG00000184381,Phospholipase A2 group VI,22,38111495-38205690,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,HPA001171,Approved,,Approved,Microtubule organizing center<br>Cytosol,"Urothelial cancer:1.55e-4 (favourable), Cervical cancer:7.29e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 60.2,Cell line enhanced,,HEL: 55.1
PLA2G7,"LDL-PLA2, PAFAH",ENSG00000146070,Phospholipase A2 group VII,6,46704201-46735693,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA035916,,,Uncertain,Vesicles,,Expressed in all,Mixed,,,spleen: 37.5,Cell line enhanced,,NTERA-2: 1.7;PC-3: 3.2;RT4: 1.3;U-2 OS: 1.7
PLAT,,ENSG00000104368,"Plasminogen activator, tissue type",8,42175233-42207724,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA003412, CAB009335",Supported,,Approved,Actin filaments,"Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable)",Expressed in all,Tissue enriched,5,parathyroid gland: 709.4,urinary bladder: 135.9,Cell line enhanced,,CAPAN-2: 590.7;HMC-1: 372.4;U-2197: 417.3;WM-115: 889.6
PLAU,"UPA, URK",ENSG00000122861,"Plasminogen activator, urokinase",10,73909177-73917497,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008719,Approved,,,,"Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable)",Expressed in all,Expressed in all,,,appendix: 60.3,Cell line enhanced,,CAPAN-2: 757.8;LHCN-M2: 690.9;RPTEC TERT1: 2356.8;U-251 MG: 715.9
PLB1,"FLJ30866, PLB",ENSG00000163803,Phospholipase B1,2,28457145-28643788,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014045,,,Approved,Cytosol,,Mixed,Group enriched,7,skin: 9.4;small intestine: 45.7,testis: 4.2,Cell line enhanced,,BEWO: 3.5
PLCB1,"KIAA0581, PLC-I, PLC154",ENSG00000182621,Phospholipase C beta 1,20,8077251-8968360,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004275, CAB005334, HPA034743, HPA057910",Enhanced,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 68.3;parathyroid gland: 121.3,placenta: 28.2,Cell line enhanced,,Hep G2: 46.8
PLCB2,FLJ38135,ENSG00000137841,Phospholipase C beta 2,15,40278176-40307935,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009443, HPA041298",Approved,,Approved,Cytosol,"Renal cancer:7.20e-5 (unfavourable), Head and neck cancer:3.00e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 55.9,appendix: 38.2,Cell line enhanced,,HEL: 70.2;HMC-1: 82.2;U-937: 41.8
PLCB3,,ENSG00000149782,Phospholipase C beta 3,11,64251523-64269150,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009257, HPA039279, HPA043907",Enhanced,,Enhanced,Nucleoplasm,"Renal cancer:4.31e-5 (unfavourable), Liver cancer:1.39e-4 (unfavourable)",Expressed in all,Expressed in all,,,duodenum: 114.9,Expressed in all,,
PLCB4,,ENSG00000101333,Phospholipase C beta 4,20,9068763-9481242,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007951,Supported,,Approved,Nucleoplasm<br>Microtubules,Endometrial cancer:2.11e-4 (favourable),Tissue enhanced,Tissue enhanced,,thyroid gland: 58.5,epididymis: 30.5,Cell line enhanced,,fHDF/TERT166: 87.3;LHCN-M2: 74.5;RPTEC TERT1: 85.5
PLCD1,,ENSG00000187091,Phospholipase C delta 1,3,38007496-38029762,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB009913, HPA020107, HPA021677",Approved,,Approved,Microtubules,Renal cancer:9.25e-11 (favourable),Expressed in all,Mixed,,,testis: 38.3,Mixed,,
PLCD3,,ENSG00000161714,Phospholipase C delta 3,17,45108967-45133354,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA025711, HPA053665",Approved,,Approved,Plasma membrane,"Lung cancer:2.89e-6 (unfavourable), Thyroid cancer:4.28e-4 (favourable)",Expressed in all,Mixed,,,skeletal muscle: 29.7,Mixed,,
PLCD4,,ENSG00000115556,Phospholipase C delta 4,2,218607765-218637184,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009914, HPA038139, HPA038140",Enhanced,,Approved,Nuclear membrane<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,skeletal muscle: 38.4,testis: 9.7,Cell line enhanced,,SH-SY5Y: 21.8
PLCE1,"KIAA1516, NPHS3, PLCE",ENSG00000138193,Phospholipase C epsilon 1,10,94030812-94332823,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA015597, HPA015598",Enhanced,,Supported,Cytosol,,Expressed in all,Mixed,,,endometrium: 21.6,Cell line enhanced,,RT4: 17.8;U-2 OS: 13.5
PLCG1,"NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1",ENSG00000124181,Phospholipase C gamma 1,20,41136960-41196801,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004277, HPA036681, HPA036682",Approved,,Supported,Cytosol,Pancreatic cancer:4.72e-4 (favourable),Expressed in all,Expressed in all,,,endometrium: 47.6,Expressed in all,,
PLCG2,,ENSG00000197943,Phospholipase C gamma 2,16,81739097-81962693,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004280, HPA020099, HPA020100",Enhanced,,Approved,Vesicles,"Renal cancer:4.88e-4 (favourable), Head and neck cancer:6.71e-4 (favourable)",Expressed in all,Tissue enhanced,,lymph node: 78.9,tonsil: 65.8,Cell line enhanced,,Daudi: 130.7;HMC-1: 74.1;U-698: 278.1
PLCH1,"DKFZp434C1372, KIAA1069, MGC117152, PLCeta1, PLCL3",ENSG00000114805,Phospholipase C eta 1,3,155375580-155745067,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036176, HPA057978",Uncertain,,Enhanced,Vesicles,Renal cancer:3.03e-5 (favourable),Mixed,Tissue enhanced,,testis: 20.6,fallopian tube: 13.0,Cell line enhanced,,AF22: 38.5;NTERA-2: 20.8
PLCH2,"KIAA0450, PLC-eta2, PLCeta2, PLCL4, RP3-395M20.1",ENSG00000149527,Phospholipase C eta 2,1,2425980-2505530,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA072705,Approved,,,,,Mixed,Tissue enhanced,,skin: 58.5,esophagus: 14.0,Cell line enhanced,,HBEC3-KT: 91.6;hTCEpi: 42.6;hTERT-HME1: 26.9
PLCZ1,"NYD-SP27, PLCzeta",ENSG00000139151,Phospholipase C zeta 1,12,18683169-18738057,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,23,testis: 48.5,skin: 2.1,Not detected,,
PLD1,,ENSG00000075651,Phospholipase D1,3,171600405-171810950,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004527, HPA042396",Enhanced,,Approved,Plasma membrane,Urothelial cancer:4.76e-6 (unfavourable),Expressed in all,Tissue enhanced,,gallbladder: 138.3,small intestine: 49.2,Cell line enhanced,,HUVEC TERT2: 49.2;TIME: 42.2
PLD2,,ENSG00000129219,Phospholipase D2,17,4807096-4823434,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA013397,Approved,,,,,Expressed in all,Expressed in all,,,esophagus: 42.5,Mixed,,
PLD3,HU-K4,ENSG00000105223,Phospholipase D family member 3,19,40348456-40380439,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012800, CAB020812",Approved,,,,"Renal cancer:2.21e-4 (favourable), Pancreatic cancer:6.44e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 494.9,Expressed in all,,
PLD4,C14orf175,ENSG00000166428,Phospholipase D family member 4,14,104924816-104937790,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA051512,Approved,,,,,Mixed,Mixed,,,lymph node: 13.9,Cell line enhanced,,HMC-1: 99.3;RPMI-8226: 58.9;THP-1: 143.6
PLG,,ENSG00000122194,Plasminogen,6,160702238-160753315,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000668, CAB016678, HPA021602, HPA048823, HPA053770",Supported,,Uncertain,Vesicles,Renal cancer:4.22e-4 (favourable),Tissue enriched,Tissue enriched,6,liver: 1749.3,kidney: 313.4,Cell line enhanced,,RH-30: 1.0
PLK1,PLK,ENSG00000166851,Polo like kinase 1,16,23677656-23690367,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA051638, HPA053229",Approved,,,,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.70e-7 (unfavourable), Lung cancer:2.28e-5 (unfavourable), Pancreatic cancer:4.12e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 44.2,lymph node: 32.8,Expressed in all,,
PLK2,SNK,ENSG00000145632,Polo like kinase 2,5,58453982-58460260,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009624, HPA069329",Approved,,Approved,Nucleoplasm<br>Mitochondria<br>Cytosol,Renal cancer:2.08e-4 (unfavourable),Expressed in all,Expressed in all,,,spleen: 96.0,Cell line enhanced,,T-47d: 343.8
PLK3,"CNK, FNK, PRK",ENSG00000173846,Polo like kinase 3,1,44800225-44805990,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA060318,Enhanced,,,,Renal cancer:1.75e-4 (unfavourable),Expressed in all,Mixed,,,gallbladder: 24.3,Mixed,,
PLK4,"Sak, STK18",ENSG00000142731,Polo like kinase 4,4,127880861-127899195,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA017327, HPA035026, HPA043198",Approved,,Supported,Centrosome<br>Cytosol,"Colorectal cancer:7.46e-5 (favourable), Lung cancer:5.13e-4 (unfavourable), Pancreatic cancer:5.14e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 40.9,bone marrow: 13.9,Mixed,,
PLK5,"PLK5P, SgK384ps",ENSG00000185988,Polo like kinase 5,19,1524074-1535456,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA035024,Enhanced,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 4.5;endometrium: 4.7;testis: 6.9",epididymis: 3.3,Not detected,,
PLOD1,"LH1, LLH, PLOD",ENSG00000083444,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",1,11934205-11975538,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA049137, HPA055799",Uncertain,,Uncertain,Nucleoplasm<br>Vesicles,"Renal cancer:1.91e-12 (unfavourable), Urothelial cancer:2.43e-4 (unfavourable), Liver cancer:2.79e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 122.3,Expressed in all,,
PLOD2,LH2,ENSG00000152952,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2",3,146069440-146163653,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB025898, HPA069126",Approved,,Uncertain,Nucleoli<br>Cytosol,"Renal cancer:4.99e-11 (unfavourable), Liver cancer:7.64e-10 (unfavourable), Lung cancer:1.42e-4 (unfavourable), Cervical cancer:1.97e-4 (unfavourable), Stomach cancer:2.83e-4 (unfavourable)",Expressed in all,Mixed,,,thyroid gland: 150.8,Cell line enhanced,,HBF TERT88: 615.2;U-87 MG: 554.9
PLOD3,LH3,ENSG00000106397,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3",7,101205977-101218420,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA001236,Uncertain,,,,"Cervical cancer:1.91e-5 (unfavourable), Colorectal cancer:3.26e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 48.1,Expressed in all,,
PLPP1,"LPP1, PAP-2a, PPAP2A",ENSG00000067113,Phospholipid phosphatase 1,5,55424854-55535050,"Enzymes, Predicted membrane proteins",Evidence at protein level,"CAB033331, HPA047815",Enhanced,,Supported,Plasma membrane,"Stomach cancer:5.77e-4 (unfavourable), Liver cancer:6.06e-4 (favourable)",Expressed in all,Mixed,,,prostate: 339.9,Cell line enhanced,,ASC diff: 295.0;HMC-1: 201.8
PLPP2,"LPP2, PAP-2c, PPAP2C",ENSG00000141934,Phospholipid phosphatase 2,19,281040-291504,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA055540,Uncertain,,Approved,Mitochondria,"Endometrial cancer:3.21e-8 (favourable), Breast cancer:4.55e-4 (unfavourable)",Expressed in all,Tissue enhanced,,fallopian tube: 128.6,"cervix, uterine: 92.0",Cell line enhanced,,A549: 122.2;CAPAN-2: 128.0
PLPP3,"LPP3, PAP-2b, PPAP2B",ENSG00000162407,Phospholipid phosphatase 3,1,56494747-56645301,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA028892, HPA072751",Uncertain,,Supported,Golgi apparatus,Renal cancer:4.59e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 546.5,Group enriched,8,ASC diff: 484.3;ASC TERT1: 245.1;HSkMC: 316.7;U-138 MG: 173.1;U-2197: 610.0
PLPP4,"DPPL2, PPAPDC1, PPAPDC1A",ENSG00000203805,Phospholipid phosphatase 4,10,120456954-120589855,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045188,Approved,,Approved,Nucleus<br>Nucleoli,,Mixed,Tissue enhanced,,cerebral cortex: 17.1;gallbladder: 10.4;testis: 12.7,kidney: 7.8,Cell line enhanced,,BJ: 30.3;U-251 MG: 92.6
PLPP5,"DPPL1, HTPAP, PPAPDC1B",ENSG00000147535,Phospholipid phosphatase 5,8,38263130-38269243,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA055777,,,Approved,Vesicles,"Renal cancer:8.33e-10 (unfavourable), Endometrial cancer:1.48e-5 (favourable), Ovarian cancer:2.42e-5 (favourable), Lung cancer:8.72e-5 (favourable)",Expressed in all,Expressed in all,,,prostate: 120.8,Mixed,,
PLPPR2,"LPPR2, PRG-4",ENSG00000105520,Phospholipid phosphatase related 2,19,11355386-11365698,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA048973,Uncertain,,Approved,Nucleoplasm,"Renal cancer:7.46e-11 (unfavourable), Colorectal cancer:6.45e-4 (unfavourable), Pancreatic cancer:6.82e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 77.2,Cell line enhanced,,U-2197: 88.4
PLPPR3,"FLJ11535, LPPR3, PRG-2, PRG2",ENSG00000129951,Phospholipid phosphatase related 3,19,812488-821977,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA052293, HPA057034",Uncertain,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,,Tissue enhanced,Tissue enhanced,,bone marrow: 6.1;cerebral cortex: 9.6;fallopian tube: 8.9,testis: 2.1,Cell line enhanced,,NB-4: 38.6;THP-1: 86.0
PLPPR4,"KIAA0455, LPPR4, PHP1, PRG-1",ENSG00000117600,Phospholipid phosphatase related 4,1,99263953-99309590,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,10,cerebral cortex: 88.6,testis: 9.0,Cell line enhanced,,BJ hTERT+: 21.8;BJ hTERT+ SV40 Large T+ RasG12V: 10.0;SH-SY5Y: 21.1;U-138 MG: 9.8;U-87 MG: 16.4
PM20D1,"Cps1, FLJ32569",ENSG00000162877,Peptidase M20 domain containing 1,1,205828022-205850132,"Enzymes, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,kidney: 6.0;pancreas: 16.6,skin: 3.9,Cell line enriched,10,Karpas-707: 1.3
PM20D2,"ACY1L2, bA63L7.3",ENSG00000146281,Peptidase M20 domain containing 2,6,89146050-89165565,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030325, HPA030326, HPA030327",Approved,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,prostate: 41.1,Mixed,,
PMM1,Sec53,ENSG00000100417,Phosphomannomutase 1,22,41576894-41589890,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA030712,Uncertain,,,,"Endometrial cancer:6.09e-6 (favourable), Pancreatic cancer:2.05e-4 (favourable), Cervical cancer:5.92e-4 (favourable)",Expressed in all,Expressed in all,,,ovary: 54.9,Expressed in all,,
PMM2,"CDG1, CDG1a, CDGS, PMI, PMI1",ENSG00000140650,Phosphomannomutase 2,16,8788823-8849331,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA040852, HPA063649",Approved,,Approved,Nucleus<br>Cytosol,"Renal cancer:8.97e-6 (unfavourable), Colorectal cancer:1.04e-4 (favourable)",Expressed in all,Expressed in all,,,rectum: 28.3,Expressed in all,,
PMPCA,"Alpha-MPP, INPP5E, KIAA0123",ENSG00000165688,"Peptidase, mitochondrial processing alpha subunit",9,136410570-136423761,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021648, HPA063735",Enhanced,,Enhanced,Mitochondria,"Renal cancer:2.14e-6 (favourable), Pancreatic cancer:8.00e-5 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 38.6,Expressed in all,,
PMPCB,"MPPB, MPPP52",ENSG00000105819,"Peptidase, mitochondrial processing beta subunit",7,103297422-103329511,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040674, HPA074168",Approved,,Supported,Mitochondria,"Renal cancer:2.95e-8 (favourable), Breast cancer:2.79e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 70.0,Expressed in all,,
PMVK,"HUMPMKI, PMK, PMKA",ENSG00000163344,Phosphomevalonate kinase,1,154924734-154936991,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA029900,Approved,,,,"Renal cancer:4.96e-4 (favourable), Ovarian cancer:9.70e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 56.5,Expressed in all,,
PNCK,"CaMK1b, MGC45419",ENSG00000130822,Pregnancy up-regulated nonubiquitous CaM kinase,X,153669730-153689010,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007458,Approved,,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:1.04e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 40.5;seminal vesicle: 52.3,smooth muscle: 22.4,Cell line enriched,7,AN3-CA: 29.8
PNKP,PNK,ENSG00000039650,Polynucleotide kinase 3'-phosphatase,19,49859882-49878351,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA006782,Supported,,Supported,Nucleus<br>Nucleoli,Breast cancer:9.18e-4 (favourable),Expressed in all,Expressed in all,,,spleen: 38.1,Expressed in all,,
PNLDC1,"dJ195P10.2, FLJ40240",ENSG00000146453,"PARN like, ribonuclease domain containing 1",6,159800249-159820704,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA052026,Uncertain,,,,,Mixed,Tissue enriched,5,testis: 12.2,fallopian tube: 2.4,Not detected,,
PNLIP,PL,ENSG00000175535,Pancreatic lipase,10,116545931-116567855,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA062430, HPA062494",Enhanced,,,,,Tissue enriched,Tissue enriched,325,pancreas: 93703.0,ovary: 288.0,Cell line enhanced,,U-2 OS: 1.3
PNLIPRP3,,ENSG00000203837,Pancreatic lipase related protein 3,10,116427867-116477957,"Enzymes, Predicted secreted proteins",Evidence at transcript level,"HPA046202, HPA052009",Uncertain,,,,,Tissue enhanced,Tissue enhanced,,breast: 12.0;skin: 5.4,esophagus: 1.8,Cell line enriched,14,hTCEpi: 233.8
PNMT,PENT,ENSG00000141744,Phenylethanolamine N-methyltransferase,17,39667981-39670475,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017029, HPA043412, HPA051005",Enhanced,,,,Endometrial cancer:3.95e-5 (unfavourable),Tissue enhanced,Tissue enriched,8,adrenal gland: 226.6,seminal vesicle: 29.2,Cell line enhanced,,HEL: 4.8;K-562: 10.4;NB-4: 14.5;SCLC-21H: 7.0;SH-SY5Y: 5.8
PNP,"NP, PUNP",ENSG00000198805,Purine nucleoside phosphorylase,14,20468954-20477094,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA001625,Enhanced,,Supported,Cytosol,"Renal cancer:2.24e-4 (favourable), Liver cancer:4.43e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 698.2,Expressed in all,,
PNPLA2,"ATGL, desnutrin, FP17548, iPLA2zeta, TTS-2.2",ENSG00000177666,Patatin like phospholipase domain containing 2,11,818902-825573,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA055173, HPA062602",,,Enhanced,Nucleoplasm<br>Lipid droplets,,Expressed in all,Tissue enriched,13,adipose tissue: 420.0,skeletal muscle: 33.4,Expressed in all,,
PNPLA3,"adiponutrin, ADPN, C22orf20, dJ796I17.1, FLJ22012, iPLA2epsilon",ENSG00000100344,Patatin like phospholipase domain containing 3,22,43923739-43964488,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA058058,Approved,,Approved,Nucleoli<br>Mitochondria<br>Cytosol,,Tissue enhanced,Tissue enhanced,,liver: 16.2,kidney: 4.7,Mixed,,
PNPLA4,"DXS1283E, GS2, iPLA2eta",ENSG00000006757,Patatin like phospholipase domain containing 4,X,7898247-7927739,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA003656,Approved,,,,"Renal cancer:2.23e-12 (favourable), Glioma:4.67e-4 (unfavourable), Head and neck cancer:5.37e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 50.2,Mixed,,
PNPLA6,"iPLA2delta, NTE, SPG39, sws",ENSG00000032444,Patatin like phospholipase domain containing 6,19,7534004-7561764,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA007522,Uncertain,,,,"Pancreatic cancer:3.51e-5 (favourable), Head and neck cancer:5.25e-4 (favourable), Renal cancer:7.53e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 49.1,Expressed in all,,
PNPLA8,"IPLA2-2, IPLA2G, iPLA2gamma",ENSG00000135241,Patatin like phospholipase domain containing 8,7,108470422-108569666,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA020083,Approved,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,Renal cancer:1.86e-6 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 63.1,Expressed in all,,
PNPO,PDXPO,ENSG00000108439,Pyridoxamine 5'-phosphate oxidase,17,47941506-47948288,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA023204, HPA027776",Enhanced,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,liver: 51.3,Mixed,,
PNPT1,"DFNB70, old-35, OLD35, PNPase",ENSG00000138035,Polyribonucleotide nucleotidyltransferase 1,2,55634265-55693910,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB033424, HPA034602, HPA034603",Supported,,Enhanced,Mitochondria,"Liver cancer:1.95e-7 (unfavourable), Pancreatic cancer:5.44e-5 (unfavourable), Endometrial cancer:5.57e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 9.9,Expressed in all,,
POFUT1,"FUT12, KIAA0180, O-Fuc-T, O-FUT",ENSG00000101346,Protein O-fucosyltransferase 1,20,32207880-32238667,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA054519, HPA059935",Approved,,Approved,Centrosome,,Expressed in all,Expressed in all,,,parathyroid gland: 35.7,Expressed in all,,
POFUT2,"C21orf80, FUT13, KIAA0958",ENSG00000186866,Protein O-fucosyltransferase 2,21,45263928-45287898,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA044297,Uncertain,,,,"Renal cancer:8.66e-12 (unfavourable), Colorectal cancer:4.55e-7 (unfavourable), Liver cancer:2.78e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 24.3,Expressed in all,,
POGLUT1,"9630046K23Rik, C3orf9, hCLP46, KDELCL1, KTELC1, MDS010, MDSRP, MGC32995, Rumi",ENSG00000163389,Protein O-glucosyltransferase 1,3,119468938-119494708,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA037855, HPA037856",Approved,,,,"Renal cancer:7.02e-7 (unfavourable), Urothelial cancer:2.23e-4 (favourable)",Expressed in all,Mixed,,,seminal vesicle: 16.5,Expressed in all,,
POLA1,"NSX, p180, POLA",ENSG00000101868,"DNA polymerase alpha 1, catalytic subunit",X,24693919-24996986,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002947, CAB012274",Enhanced,,Supported,Nucleoplasm<br>Cytosol,Liver cancer:4.80e-5 (unfavourable),Expressed in all,Mixed,,,lymph node: 8.7,Expressed in all,,
POLB,,ENSG00000070501,DNA polymerase beta,8,42338454-42371808,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB011616, HPA049104",Enhanced,,Approved,Vesicles,"Renal cancer:2.15e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Urothelial cancer:5.65e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 92.7,Expressed in all,,
POLD1,"CDC2, POLD",ENSG00000062822,"DNA polymerase delta 1, catalytic subunit",19,50384204-50418018,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004375, HPA046524",Enhanced,,Supported,Nucleoplasm,Liver cancer:2.87e-6 (unfavourable),Expressed in all,Mixed,,,bone marrow: 21.4,Expressed in all,,
POLE,POLE1,ENSG00000177084,"DNA polymerase epsilon, catalytic subunit",12,132623753-132687365,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA058210, HPA067385",,,Enhanced,Nucleus<br>Plasma membrane,"Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 22.1,Expressed in all,,
POLE2,DPE2,ENSG00000100479,"DNA polymerase epsilon 2, accessory subunit",14,49643555-49688422,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA027555,Uncertain,,Supported,Nucleoplasm<br>Nuclear bodies<br>Vesicles,,Expressed in all,Mixed,,,bone marrow: 10.7,Mixed,,
POLE3,"CHARAC17, CHRAC17, p17, Ybl1",ENSG00000148229,"DNA polymerase epsilon 3, accessory subunit",9,113407235-113410672,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA047945,Uncertain,,Approved,Nucleus<br>Nucleoli,Liver cancer:8.35e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 76.4,Expressed in all,,
POLE4,p12,ENSG00000115350,"DNA polymerase epsilon 4, accessory subunit",2,74958492-74970128,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA054979, HPA071815",Approved,,Approved,Nucleus<br>Cytosol,Liver cancer:6.49e-4 (unfavourable),Expressed in all,Expressed in all,,,"cervix, uterine: 12.8",Mixed,,
POLG,"POLG1, POLGA",ENSG00000140521,"DNA polymerase gamma, catalytic subunit",15,89305198-89334861,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA056821,Approved,,,,Prostate cancer:5.73e-4 (unfavourable),Expressed in all,Expressed in all,,,spleen: 19.7,Expressed in all,,
POLG2,"HP55, MTPOLB",ENSG00000256525,"DNA polymerase gamma 2, accessory subunit",17,64477785-64497036,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB017030, HPA023202",Approved,,Approved,Nuclear bodies<br>Mitochondria,"Liver cancer:1.39e-6 (unfavourable), Renal cancer:1.17e-5 (unfavourable), Prostate cancer:6.59e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 20.2,Expressed in all,,
POLH,"RAD30A, XP-V",ENSG00000170734,DNA polymerase eta,6,43576150-43615660,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006721, HPA026762",Approved,,Enhanced,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 20.8,Expressed in all,,
POLI,"RAD30B, RAD3OB",ENSG00000101751,DNA polymerase iota,18,54269404-54321266,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA012000, HPA064696",Enhanced,,Supported,Nuclear speckles<br>Cytoplasmic bodies,,Expressed in all,Expressed in all,,,testis: 69.7,Expressed in all,,
POLK,"DINB1, DINP, POLQ",ENSG00000122008,DNA polymerase kappa,5,75511756-75601144,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA012035, HPA057303, HPA068117, HPA069375",,,Enhanced,Nucleoplasm<br>Nuclear bodies,,Expressed in all,Mixed,,,thyroid gland: 12.8,Mixed,,
POLL,,ENSG00000166169,DNA polymerase lambda,10,101578882-101588270,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA066704,,,Enhanced,Nucleus<br>Golgi apparatus,,Expressed in all,Expressed in all,,,testis: 49.9,Mixed,,
POLM,Tdt-N,ENSG00000122678,DNA polymerase mu,7,44072247-44082540,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA058900, HPA066007",,,Supported,Nucleus,,Expressed in all,Expressed in all,,,spleen: 10.9,Cell line enhanced,,HBEC3-KT: 47.1
POLN,,ENSG00000130997,DNA polymerase nu,4,2071918-2242121,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035939, HPA035940",,,Enhanced,Nucleoplasm,,Mixed,Tissue enhanced,,adipose tissue: 3.0;testis: 4.4,"epididymis,prostate: 1.0",Mixed,,
POLQ,POLH,ENSG00000051341,DNA polymerase theta,3,121431427-121546641,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA048931, HPA053359",,,Uncertain,Nucleus<br>Golgi apparatus<br>Cytosol,"Endometrial cancer:5.46e-5 (unfavourable), Stomach cancer:1.04e-4 (favourable)",Mixed,Mixed,,,testis: 4.0,Mixed,,
POLR1A,"DKFZP586M0122, FLJ21915, RPA1, RPO1-4",ENSG00000068654,RNA polymerase I subunit A,2,86020216-86106155,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB010145, HPA031513, HPA049700",Supported,,Supported,Nucleus<br>Nucleoli fibrillar center,"Liver cancer:3.70e-9 (unfavourable), Ovarian cancer:3.37e-4 (unfavourable), Thyroid cancer:8.41e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 12.3,Expressed in all,,
POLR1B,"FLJ10816, FLJ21921, RPA2, Rpo1-2",ENSG00000125630,RNA polymerase I subunit B,2,112541915-112577150,"Enzymes, Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins",Evidence at protein level,HPA037528,,,Supported,Nucleoli<br>Cytosol,"Endometrial cancer:2.71e-5 (unfavourable), Pancreatic cancer:5.52e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 24.0,Expressed in all,,
POLR2A,"POLR2, POLRA, RPB1",ENSG00000181222,RNA polymerase II subunit A,17,7484366-7514616,"Enzymes, Predicted intracellular proteins, RNA polymerase related proteins",Evidence at protein level,"CAB012226, CAB016388, HPA021563, CAB022311, HPA053012",Enhanced,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,testis: 117.6,Expressed in all,,
POLR2B,RPB2,ENSG00000047315,RNA polymerase II subunit B,4,56977722-57031168,"Enzymes, Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins",Evidence at protein level,HPA037506,Supported,,Supported,Nucleoplasm,Renal cancer:7.17e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 86.2,Expressed in all,,
POLR3A,"hRPC155, RPC1, RPC155",ENSG00000148606,RNA polymerase III subunit A,10,77969251-78029545,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RNA polymerase related proteins",Evidence at protein level,HPA037926,Uncertain,,Supported,Nucleoplasm,Liver cancer:3.64e-6 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 17.9,Expressed in all,,
POLR3B,"FLJ10388, RPC2",ENSG00000013503,RNA polymerase III subunit B,12,106357658-106510198,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RNA polymerase related proteins",Evidence at protein level,HPA036466,Supported,,Approved,Nuclear speckles,Renal cancer:1.21e-4 (favourable),Expressed in all,Mixed,,,parathyroid gland: 24.1,Expressed in all,,
POLRMT,"APOLMT, h-mtRPOL, MTRNAP, MTRPOL",ENSG00000099821,RNA polymerase mitochondrial,19,617224-633604,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006366,Uncertain,,Supported,Mitochondria,Endometrial cancer:4.50e-4 (favourable),Expressed in all,Expressed in all,,,testis: 46.8,Expressed in all,,
POMK,"FLJ23356, SgK196",ENSG00000185900,Protein-O-mannose kinase,8,43093506-43123434,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA013321,Uncertain,,Approved,Nucleus<br>Cytosol,,Mixed,Mixed,,,cerebral cortex: 6.2,Expressed in all,,
POMT1,LGMD2K,ENSG00000130714,Protein O-mannosyltransferase 1,9,131502902-131523806,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA065252,,,Approved,Golgi apparatus,"Pancreatic cancer:3.90e-5 (favourable), Renal cancer:4.68e-5 (favourable)",Expressed in all,Expressed in all,,,testis: 62.7,Expressed in all,,
POMT2,LGMD2N,ENSG00000009830,Protein O-mannosyltransferase 2,14,77274956-77320884,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA003663,Uncertain,,,,Liver cancer:2.40e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 28.9,Expressed in all,,
PON1,"ESA, PON",ENSG00000005421,Paraoxonase 1,7,95297676-95324707,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters",Evidence at protein level,HPA001610,Uncertain,,,,Liver cancer:7.24e-7 (favourable),Tissue enriched,Tissue enriched,69,liver: 233.6,adrenal gland: 3.3,Not detected,,
PON2,,ENSG00000105854,Paraoxonase 2,7,95404863-95435329,"Candidate cardiovascular disease genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025430, HPA029193",Enhanced,,,,"Renal cancer:4.30e-8 (unfavourable), Cervical cancer:1.43e-5 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 226.2,Mixed,,
PON3,,ENSG00000105852,Paraoxonase 3,7,95359944-95396368,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA014848, CAB025250",Enhanced,,,,,Group enriched,Tissue enriched,8,liver: 328.5,breast: 43.4,Cell line enhanced,,A549: 26.6;CACO-2: 7.9;Hep G2: 22.5;T-47d: 17.0
POP1,,ENSG00000104356,"POP1 homolog, ribonuclease P/MRP subunit",8,98117297-98159834,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA066194,,,Supported,Nucleoli,"Liver cancer:1.26e-6 (unfavourable), Breast cancer:2.54e-4 (unfavourable), Renal cancer:5.97e-4 (unfavourable), Lung cancer:9.88e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 6.0,Expressed in all,,
POP4,RPP29,ENSG00000105171,"POP4 homolog, ribonuclease P/MRP subunit",19,29604017-29617237,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA042748,Approved,,,,Liver cancer:3.31e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 15.2,Expressed in all,,
POP5,,ENSG00000167272,"POP5 homolog, ribonuclease P/MRP subunit",12,120578764-120581398,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047598, HPA069204",Approved,,Approved,Nucleus<br>Nucleoli,"Cervical cancer:2.68e-5 (favourable), Renal cancer:4.85e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 51.8,Expressed in all,,
POP7,"RPP2, RPP20",ENSG00000172336,"POP7 homolog, ribonuclease P/MRP subunit",7,100706053-100707495,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021007,Uncertain,,Supported,Nucleoli<br>Vesicles,"Liver cancer:4.99e-5 (unfavourable), Renal cancer:6.02e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 41.1,Expressed in all,,
POR,"CYPOR, FLJ26468",ENSG00000127948,Cytochrome p450 oxidoreductase,7,75899200-75986855,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB004372, HPA010136",Enhanced,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Glioma:5.23e-4 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 220.8,Expressed in all,,
PPA1,"IOPPP, PP, PP1, Ppase, SID6-8061",ENSG00000180817,Pyrophosphatase (inorganic) 1,10,70202830-70233911,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019878, HPA020096",Supported,,Supported,Vesicles,,Expressed in all,Expressed in all,,,breast: 226.6,Expressed in all,,
PPA2,FLJ20459,ENSG00000138777,Pyrophosphatase (inorganic) 2,4,105369077-105474081,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA030888, HPA031671, HPA031672",Supported,,Approved,Nucleus<br>Mitochondria,"Renal cancer:1.27e-11 (favourable), Breast cancer:2.98e-4 (unfavourable), Colorectal cancer:6.60e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 21.3,Expressed in all,,
PPAT,"GPAT, PRAT",ENSG00000128059,Phosphoribosyl pyrophosphate amidotransferase,4,56393362-56435615,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036091, HPA036092",Approved,,Approved,Midbody ring,"Liver cancer:1.14e-8 (unfavourable), Endometrial cancer:5.15e-5 (unfavourable), Thyroid cancer:1.95e-4 (unfavourable), Renal cancer:8.34e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 16.1,Expressed in all,,
PPCDC,"FLJ14585, MDS018",ENSG00000138621,Phosphopantothenoylcysteine decarboxylase,15,75023555-75117462,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045667,Approved,,Approved,Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 22.4,Expressed in all,,
PPCS,FLJ11838,ENSG00000127125,Phosphopantothenoylcysteine synthetase,1,42456117-42473385,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA031361, HPA031363",Approved,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Mitochondria,Liver cancer:5.96e-5 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 110.6,Expressed in all,,
PPEF1,"PPEF, PPP7CA",ENSG00000086717,Protein phosphatase with EF-hand domain 1,X,18675909-18827921,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA034577,Uncertain,,Uncertain,Plasma membrane<br>Cytokinetic bridge,,Mixed,Tissue enriched,7,testis: 26.4,cerebral cortex: 3.6,Cell line enhanced,,A549: 1.0;HeLa: 1.1
PPEF2,PPP7CB,ENSG00000156194,Protein phosphatase with EF-hand domain 2,4,75859864-75902571,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Not detected,,,testis: 0.4,Not detected,,
PPIA,CYPA,ENSG00000196262,Peptidylprolyl isomerase A,7,44796680-44824564,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004655, HPA058345",Uncertain,,,,Liver cancer:2.27e-6 (unfavourable),Expressed in all,Expressed in all,,,breast: 1679.8,Expressed in all,,
PPIAL4A,"COAS2, PPIAL4, PPIAL4B",ENSG00000263353,Peptidylprolyl isomerase A like 4A,1,120889746-120890405,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA058345,Uncertain,,,,,Not detected,Not detected,,,cerebral cortex: 0.4,Mixed,,
PPIAL4C,,ENSG00000263464,Peptidylprolyl isomerase A like 4C,1,149583865-149584464,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA058345,Uncertain,,,,,Not detected,Mixed,,,duodenum: 3.9,Mixed,,
PPIAL4D,,ENSG00000256374,Peptidylprolyl isomerase A like 4D,1,145241630-145242124,"Enzymes, Predicted intracellular proteins",No evidence,HPA058345,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
PPIAL4E,,ENSG00000271567,Peptidylprolyl isomerase A like 4E,1,144372875-144373659,"Enzymes, Predicted intracellular proteins",No evidence,HPA058345,Uncertain,,,,,Not detected,Not detected,,,bone marrow: 0.3,Not detected,,
PPIAL4F,,ENSG00000279782,Peptidylprolyl isomerase A like 4F,1,144592868-144593527,"Enzymes, Predicted intracellular proteins",No evidence,HPA058345,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
PPIAL4G,,ENSG00000236334,Peptidylprolyl isomerase A like 4G,1,148479824-148483679,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA058345,Uncertain,,,,,Not detected,Not detected,,,skeletal muscle: 0.9,Not detected,,
PPIB,"CYPB, OI9",ENSG00000166794,Peptidylprolyl isomerase B,15,64155812-64163205,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"CAB011487, HPA012720",Enhanced,,Supported,Nucleus<br>Endoplasmic reticulum,"Renal cancer:2.02e-11 (unfavourable), Endometrial cancer:1.56e-5 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 855.2,Expressed in all,,
PPIC,CYPC,ENSG00000168938,Peptidylprolyl isomerase C,5,123023250-123036741,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA039163,Approved,,,,Liver cancer:4.78e-4 (unfavourable),Expressed in all,Mixed,,,thyroid gland: 77.6,Mixed,,
PPID,CYP-40,ENSG00000171497,Peptidylprolyl isomerase D,4,158709134-158723396,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019520, HPA019692",Approved,,Supported,Nucleus<br>Nucleoli<br>Cytosol,,Expressed in all,Expressed in all,,,duodenum: 50.9,Expressed in all,,
PPIE,"CyP-33, MGC111222, MGC3736",ENSG00000084072,Peptidylprolyl isomerase E,1,39692182-39763914,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019357, HPA020131",Approved,,Supported,Nuclear speckles,"Renal cancer:5.05e-5 (unfavourable), Liver cancer:1.76e-4 (unfavourable)",Expressed in all,Expressed in all,,,fallopian tube: 67.3,Expressed in all,,
PPIF,"Cyp-D, hCyP3",ENSG00000108179,Peptidylprolyl isomerase F,10,79347469-79355337,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA077416,,,Supported,Mitochondria,,Expressed in all,Expressed in all,,,adrenal gland: 188.4,Expressed in all,,
PPIG,"CARS-Cyp, SCAF10, SRCyp",ENSG00000138398,Peptidylprolyl isomerase G,2,169584340-169641406,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021788, HPA057469",Supported,,Supported,Nuclear speckles<br>Cytosol,Renal cancer:4.56e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 84.6,Expressed in all,,
PPIH,"CYP-20, CYPH, MGC5016, SnuCyp-20, USA-CYP",ENSG00000171960,Peptidylprolyl isomerase H,1,42658425-42676758,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA059019,Approved,,,,"Renal cancer:1.78e-9 (unfavourable), Liver cancer:1.55e-5 (unfavourable)",Expressed in all,Expressed in all,,,testis: 60.1,Expressed in all,,
PPIL1,CYPL1,ENSG00000137168,Peptidylprolyl isomerase like 1,6,36854827-36875024,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA062916,,,Approved,Nucleoli,"Liver cancer:1.28e-5 (unfavourable), Ovarian cancer:4.90e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 42.0,Expressed in all,,
PPIL2,"CYC4, Cyp-60, UBOX7",ENSG00000100023,Peptidylprolyl isomerase like 2,22,21666009-21700015,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035344, HPA055637",Supported,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,thyroid gland: 31.5,Expressed in all,,
PPIL3,CyPJ,ENSG00000240344,Peptidylprolyl isomerase like 3,2,200870907-200889303,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA040765, HPA062187",Approved,,Supported,Nucleus,"Ovarian cancer:1.19e-4 (favourable), Renal cancer:5.16e-4 (unfavourable)",Expressed in all,Expressed in all,,,ovary: 45.3,Expressed in all,,
PPIL4,,ENSG00000131013,Peptidylprolyl isomerase like 4,6,149504733-149546038,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA031599, HPA031600",Approved,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,thyroid gland: 48.0,Expressed in all,,
PPIL6,"bA425D10.6, dJ919F19.1, MGC41939, RSPH12",ENSG00000185250,Peptidylprolyl isomerase like 6,6,109390215-109441171,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA036717,Approved,,Approved,Nucleus<br>Golgi apparatus<br>Cytosol,,Mixed,Tissue enhanced,,fallopian tube: 53.2;testis: 32.6,thyroid gland: 17.7,Cell line enhanced,,AN3-CA: 5.4;ASC diff: 6.2;ASC TERT1: 7.8
PPIP5K1,"HISPPD2A, IPS1, KIAA0377, VIP1",ENSG00000168781,Diphosphoinositol pentakisphosphate kinase 1,15,43533462-43590253,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039380,Approved,,Supported,Cytosol,"Renal cancer:7.14e-8 (favourable), Ovarian cancer:8.57e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 53.1,Expressed in all,,
PPIP5K2,"CFAP160, HISPPD1, KIAA0433, VIP2",ENSG00000145725,Diphosphoinositol pentakisphosphate kinase 2,5,103120149-103212799,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037895, HPA038442",Approved,,Approved,Vesicles,Thyroid cancer:1.12e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 34.3,Expressed in all,,
PPM1A,"MGC9201, PP2CA, PP2Calpha",ENSG00000100614,"Protein phosphatase, Mg2+/Mn2+ dependent 1A",14,60245752-60299087,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA029209,Approved,,Supported,Plasma membrane<br>Cytosol,Renal cancer:1.57e-9 (favourable),Expressed in all,Expressed in all,,,testis: 100.1,Expressed in all,,
PPM1B,"PP2CB, PP2CBETA, PPC2BETAX",ENSG00000138032,"Protein phosphatase, Mg2+/Mn2+ dependent 1B",2,44167969-44244384,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA016745,Approved,,Approved,Nucleoli<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 82.3,Expressed in all,,
PPM1D,"PP2C-DELTA, Wip1",ENSG00000170836,"Protein phosphatase, Mg2+/Mn2+ dependent 1D",17,60600183-60666280,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA022277,Uncertain,,Approved,Endoplasmic reticulum,"Colorectal cancer:3.52e-4 (favourable), Liver cancer:4.27e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 9.6,Expressed in all,,
PPM1E,"CaMKP-N, KIAA1072, POPX1, PP2CH",ENSG00000175175,"Protein phosphatase, Mg2+/Mn2+ dependent 1E",17,58755869-58985176,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA018462, HPA019263",Approved,,Approved,Nucleus<br>Nucleoli,,Tissue enhanced,Group enriched,5,adrenal gland: 7.3;cerebral cortex: 20.5;testis: 12.1,fallopian tube: 2.4,Cell line enhanced,,AF22: 12.1;HAP1: 20.6;SCLC-21H: 10.7;SH-SY5Y: 19.9
PPM1F,"CAMKP, CaMKPase, FEM-2, KIAA0015, POPX2",ENSG00000100034,"Protein phosphatase, Mg2+/Mn2+ dependent 1F",22,21919420-21952837,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030989, HPA030990",Approved,,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:6.03e-5 (unfavourable),Expressed in all,Expressed in all,,,placenta: 38.9,Expressed in all,,
PPM1G,"PP2CG, PP2Cgamma",ENSG00000115241,"Protein phosphatase, Mg2+/Mn2+ dependent 1G",2,27381194-27409687,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035530, HPA035531",Enhanced,,Enhanced,Nucleoplasm,"Liver cancer:3.14e-7 (unfavourable), Ovarian cancer:6.08e-5 (favourable)",Expressed in all,Tissue enriched,5,testis: 337.3,lymph node: 65.2,Expressed in all,,
PPM1H,"ARHCL1, FLJ13253, KIAA1157, NERPP-2C",ENSG00000111110,"Protein phosphatase, Mg2+/Mn2+ dependent 1H",12,62643982-62935037,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB020694, HPA044244, HPA058777",Approved,,Supported,Nucleoplasm,Renal cancer:2.72e-5 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 54.2,cerebral cortex: 23.0,Cell line enhanced,,CACO-2: 67.4;HMC-1: 56.0
PPM1J,"DKFZp434P1514, FLJ35951, MGC19531, PP2Czeta, PPP2CZ",ENSG00000155367,"Protein phosphatase, Mg2+/Mn2+ dependent 1J",1,112709994-112715477,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046045,Uncertain,,Approved,Vesicles,,Mixed,Group enriched,6,epididymis: 22.8;skeletal muscle: 24.1;skin: 21.4;testis: 46.5,heart muscle: 4.7,Cell line enhanced,,T-47d: 18.2
PPM1K,"BDP, DKFZp761G058, hPTMP, PP2Ckappa, PP2Cm",ENSG00000163644,"Protein phosphatase, Mg2+/Mn2+ dependent 1K",4,88257620-88284769,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020066, HPA020862, HPA023891",Approved,,Supported,Mitochondria,,Expressed in all,Expressed in all,,,heart muscle: 61.4,Mixed,,
PPM1L,PP2CE,ENSG00000163590,"Protein phosphatase, Mg2+/Mn2+ dependent 1L",3,160755602-161078907,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA019891, HPA019953",Approved,,Approved,Nucleoplasm<br>Cytosol,Breast cancer:4.90e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 39.6,cerebral cortex: 27.9,Group enriched,5,HDLM-2: 73.7;U-266/70: 57.7
PPM1M,"FLJ32332, PP2Ceta",ENSG00000164088,"Protein phosphatase, Mg2+/Mn2+ dependent 1M",3,52245793-52250597,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036905, HPA062291",Uncertain,,Approved,Nuclear bodies,"Renal cancer:1.61e-5 (unfavourable), Lung cancer:6.69e-4 (favourable), Cervical cancer:7.73e-4 (favourable)",Expressed in all,Expressed in all,,,lung: 35.0,Mixed,,
PPM1N,FLJ40125,ENSG00000213889,"Protein phosphatase, Mg2+/Mn2+ dependent 1N (putative)",19,45488777-45502510,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043577,,,Supported,Vesicles,,Tissue enhanced,Tissue enriched,5,skeletal muscle: 69.9,spleen: 12.9,Cell line enhanced,,RT4: 24.0
PPME1,PME-1,ENSG00000214517,Protein phosphatase methylesterase 1,11,74171099-74254703,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004541, HPA043900, HPA064396",Uncertain,,Supported,Nucleus<br>Nuclear bodies,"Liver cancer:4.45e-6 (unfavourable), Renal cancer:2.76e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 156.1,Expressed in all,,
PPOX,"PPO, VP",ENSG00000143224,Protoporphyrinogen oxidase,1,161166410-161178013,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA030123,Uncertain,,Approved,Mitochondria<br>Cytosol,Renal cancer:9.89e-4 (unfavourable),Expressed in all,Expressed in all,,,fallopian tube: 38.9,Expressed in all,,
PPP1CA,"PP-1A, PP1A, PP1alpha, PPP1A",ENSG00000172531,Protein phosphatase 1 catalytic subunit alpha,11,67398183-67421183,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB004545, HPA046833",Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Thyroid cancer:1.17e-4 (favourable),Expressed in all,Expressed in all,,,lymph node: 166.4,Expressed in all,,
PPP1CB,"PP-1B, PP1B, PP1beta",ENSG00000213639,Protein phosphatase 1 catalytic subunit beta,2,28751640-28802940,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB022558, HPA065425, CAB069426",Supported,,Enhanced,Nucleus<br>Plasma membrane,Liver cancer:6.52e-6 (unfavourable),Expressed in all,Expressed in all,,,esophagus: 273.8,Expressed in all,,
PPP1CC,"PP1C, PP1gamma",ENSG00000186298,Protein phosphatase 1 catalytic subunit gamma,12,110719680-110742939,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB022645,Uncertain,,,,"Liver cancer:2.75e-6 (unfavourable), Cervical cancer:7.44e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 257.5,Expressed in all,,
PPP2CA,"PP2AC, PP2Calpha",ENSG00000113575,Protein phosphatase 2 catalytic subunit alpha,5,134194334-134226142,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB003848, HPA043236",Approved,,,,Liver cancer:7.33e-5 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 126.6,Expressed in all,,
PPP2CB,PP2Abeta,ENSG00000104695,Protein phosphatase 2 catalytic subunit beta,8,30774457-30814314,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB018600, HPA043236",Approved,,Supported,Nucleoplasm,Renal cancer:5.82e-7 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 207.5,Expressed in all,,
PPP3CA,"CALN, CALNA, CNA1, PPP2B",ENSG00000138814,Protein phosphatase 3 catalytic subunit alpha,4,101023409-101348278,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA012778, CAB018581",Enhanced,,Enhanced,Nucleoplasm<br>Cytosol,Pancreatic cancer:3.82e-4 (unfavourable),Tissue enriched,Expressed in all,,,cerebral cortex: 164.3,Expressed in all,,
PPP3CB,"CALNA2, CALNB, CNA2, PP2Bbeta",ENSG00000107758,Protein phosphatase 3 catalytic subunit beta,10,73436428-73496024,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA008233, HPA008823",Uncertain,,Approved,Mitochondria,"Pancreatic cancer:6.96e-5 (favourable), Liver cancer:9.59e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 153.2,Expressed in all,,
PPP3CC,"CALNA3, PP2Bgamma",ENSG00000120910,Protein phosphatase 3 catalytic subunit gamma,8,22440819-22541142,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA023396, CAB024950",Approved,,Approved,Vesicles,Lung cancer:6.80e-5 (favourable),Expressed in all,Expressed in all,,,testis: 101.2,Expressed in all,,
PPP4C,"PP4, PPX",ENSG00000149923,Protein phosphatase 4 catalytic subunit,16,30075978-30085377,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043837,Enhanced,,Supported,Nucleus<br>Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 78.0,Expressed in all,,
PPP5C,"PP5, PPP5",ENSG00000011485,Protein phosphatase 5 catalytic subunit,19,46346994-46392981,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB022641, HPA029065, HPA056933",Approved,,Supported,Vesicles<br>Cytosol,Liver cancer:3.45e-6 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 44.3,Expressed in all,,
PPP6C,PP6,ENSG00000119414,Protein phosphatase 6 catalytic subunit,9,125146573-125189939,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA050940,Uncertain,,,,Renal cancer:4.50e-6 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 52.7,Expressed in all,,
PPT1,"CLN1, INCL, PPT",ENSG00000131238,Palmitoyl-protein thioesterase 1,1,40072705-40097703,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA021546,Supported,,,,Liver cancer:6.98e-8 (unfavourable),Expressed in all,Expressed in all,,,spleen: 193.0,Expressed in all,,
PPTC7,TA-PP2C,ENSG00000196850,PTC7 protein phosphatase homolog,12,110533245-110583320,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039335, HPA040614",Approved,,Approved,Plasma membrane<br>Cytosol,"Ovarian cancer:1.43e-5 (unfavourable), Renal cancer:4.48e-5 (favourable), Pancreatic cancer:6.76e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 34.4,Expressed in all,,
PPWD1,KIAA0073,ENSG00000113593,Peptidylprolyl isomerase domain and WD repeat containing 1,5,65563236-65587549,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019353, HPA019360",Enhanced,,Supported,Nuclear bodies,"Liver cancer:2.19e-4 (unfavourable), Renal cancer:6.72e-4 (unfavourable)",Expressed in all,Expressed in all,,,lymph node: 31.6,Expressed in all,,
PRAG1,"DKFZp761P0423, NACK, PEAK2, PRAGMIN, SgK223",ENSG00000275342,PEAK1 related kinase activating pseudokinase 1,8,8317736-8386498,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA012066,Uncertain,,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,Renal cancer:4.81e-4 (favourable),Expressed in all,Tissue enhanced,,thyroid gland: 28.3,small intestine: 12.2,Cell line enhanced,,A549: 45.2
PRCP,"HUMPCP, PCP",ENSG00000137509,Prolylcarboxypeptidase,11,82823502-82970584,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA017065,Approved,,,,Renal cancer:2.65e-6 (favourable),Expressed in all,Expressed in all,,,placenta: 222.7,Expressed in all,,
PRDM2,"HUMHOXY1, KMT8, KMT8A, MTB-ZF, RIZ, RIZ1, RIZ2",ENSG00000116731,PR/SET domain 2,1,13700198-13825079,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA005809,Approved,,Approved,Nucleus<br>Golgi apparatus,,Expressed in all,Expressed in all,,,bone marrow: 51.2,Expressed in all,,
PRDM6,"KMT8C, PRISM",ENSG00000061455,PR/SET domain 6,5,123089121-123194266,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA030322, HPA030324",Uncertain,,Uncertain,Nucleoplasm,,Mixed,Tissue enhanced,,gallbladder: 5.2;placenta: 5.9,lung: 4.0,Cell line enhanced,,BEWO: 3.5;HEK 293: 4.7
PRDM7,ZNF910,ENSG00000126856,PR/SET domain 7,16,90056566-90092072,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA059944,Approved,,Uncertain,Nuclear speckles,,Tissue enriched,Tissue enriched,11,testis: 1.1,all non-specific tissues: 0.0,Group enriched,30,REH: 3.8;SK-MEL-30: 2.1
PRDM9,"KMT8B, MSBP3, PFM6, ZNF899",ENSG00000164256,PR/SET domain 9,5,23443586-23528597,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA059555,Uncertain,,,,,Not detected,Group enriched,7,epididymis: 1.7;testis: 7.1,bone marrow: 0.6,Cell line enriched,7,U-266/70: 5.0
PRDX1,"NKEFA, PAGA",ENSG00000117450,Peroxiredoxin 1,1,45511036-45523047,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004682, HPA007730",Approved,,Supported,Mitochondria,"Liver cancer:1.17e-5 (unfavourable), Urothelial cancer:2.89e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 1209.9,Expressed in all,,
PRDX2,"MGC4104, NKEFB, PRP, PRX2, PRXII, TDPX1, TSA",ENSG00000167815,Peroxiredoxin 2,19,12796820-12801859,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB008713,Approved,,,,Renal cancer:5.66e-11 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 468.9,Mixed,,
PRDX3,"AOP-1, AOP1, MER5, SP-22",ENSG00000165672,Peroxiredoxin 3,10,119167703-119178833,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB008656, HPA041488",Enhanced,,,,,Expressed in all,Expressed in all,,,adrenal gland: 429.1,Expressed in all,,
PRDX4,AOE37-2,ENSG00000123131,Peroxiredoxin 4,X,23664262-23686399,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB008659, CAB027389, CAB047362",Enhanced,,Supported,Endoplasmic reticulum<br>Cytosol,Renal cancer:1.33e-6 (unfavourable),Expressed in all,Expressed in all,,,pancreas: 239.5,Expressed in all,,
PRDX5,"ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10",ENSG00000126432,Peroxiredoxin 5,11,64318088-64321811,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB008661, HPA037915, HPA037916",Enhanced,,Enhanced,Mitochondria<br>Cytosol,Renal cancer:1.24e-5 (favourable),Expressed in all,Expressed in all,,,fallopian tube: 606.1,Expressed in all,,
PRDX6,"1-Cys, aiPLA2, AOP2, KIAA0106, MGC46173, NSGPx, p29, PRX",ENSG00000117592,Peroxiredoxin 6,1,173477266-173488807,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006983, CAB008663",Supported,,Supported,Plasma membrane<br>Cytosol,"Head and neck cancer:1.23e-5 (unfavourable), Renal cancer:9.51e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 370.1,Expressed in all,,
PREP,,ENSG00000085377,Prolyl endopeptidase,6,105277565-105403084,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB025414, HPA031388, HPA031389, HPA031390",Enhanced,,Enhanced,Cytosol,Head and neck cancer:3.33e-4 (unfavourable),Expressed in all,Expressed in all,,,rectum: 53.9,Expressed in all,,
PREPL,KIAA0436,ENSG00000138078,Prolyl endopeptidase-like,2,44316281-44361862,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA063238,Approved,,,,,Expressed in all,Expressed in all,,,cerebral cortex: 257.4,Expressed in all,,
PRKAA1,AMPKa1,ENSG00000132356,Protein kinase AMP-activated catalytic subunit alpha 1,5,40759379-40798374,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005050, HPA035409, HPA064946",Supported,,Supported,Nuclear speckles,,Expressed in all,Expressed in all,,,testis: 74.4,Expressed in all,,
PRKAA2,"AMPK, AMPKa2, PRKAA",ENSG00000162409,Protein kinase AMP-activated catalytic subunit alpha 2,1,56645322-56715335,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA044540,Approved,,Supported,Nuclear speckles<br>Golgi apparatus,"Renal cancer:4.95e-5 (favourable), Endometrial cancer:4.80e-4 (unfavourable), Liver cancer:5.30e-4 (unfavourable)",Mixed,Tissue enhanced,,heart muscle: 26.5,parathyroid gland: 15.0,Cell line enhanced,,RPTEC TERT1: 10.7
PRKACA,PKACa,ENSG00000072062,Protein kinase cAMP-activated catalytic subunit alpha,19,14091688-14118084,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010361, HPA071185",Approved,,Approved,Cytosol,"Cervical cancer:6.28e-6 (favourable), Endometrial cancer:6.26e-5 (unfavourable), Pancreatic cancer:6.47e-4 (favourable)",Expressed in all,Expressed in all,,,heart muscle: 200.4,Expressed in all,,
PRKACB,PKACb,ENSG00000142875,Protein kinase cAMP-activated catalytic subunit beta,1,84078062-84238498,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010363, HPA029754, HPA071185",Approved,,Approved,Cytosol,"Renal cancer:1.89e-6 (favourable), Liver cancer:9.49e-4 (unfavourable)",Expressed in all,Tissue enriched,5,cerebral cortex: 316.3,adrenal gland: 63.1,Mixed,,
PRKACG,PKACg,ENSG00000165059,Protein kinase cAMP-activated catalytic subunit gamma,9,69012529-69014113,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004530, HPA071185",Supported,,Approved,Cytosol,,Not detected,Tissue enriched,302,testis: 30.1,all non-specific tissues: 0.0,Not detected,,
PRKCA,PKCA,ENSG00000154229,Protein kinase C alpha,17,66302636-66810743,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB003844, HPA006563, HPA006564, CAB016290",Enhanced,Approved,Enhanced,Plasma membrane<br>Cytosol,,Expressed in all,Mixed,,,cerebral cortex: 45.0,Cell line enhanced,,U-87 MG: 157.3
PRKCB,"PKCB, PRKCB1, PRKCB2",ENSG00000166501,Protein kinase C beta,16,23836001-24220611,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB003843, HPA048321, HPA054203",Approved,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 125.4,spleen: 64.5,Cell line enhanced,,HEL: 145.7;HMC-1: 137.9;K-562: 211.8
PRKCD,,ENSG00000163932,Protein kinase C delta,3,53156009-53192717,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001863, HPA001890, CAB010469, CAB013225",Enhanced,,Enhanced,Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol,"Liver cancer:2.24e-4 (unfavourable), Lung cancer:9.01e-4 (favourable)",Expressed in all,Mixed,,,adrenal gland: 70.4,Expressed in all,,
PRKCE,,ENSG00000171132,Protein kinase C epsilon,2,45651345-46187990,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB001948, HPA044496, HPA054252",Enhanced,,Approved,Vesicles,"Renal cancer:2.63e-7 (favourable), Endometrial cancer:2.42e-4 (unfavourable), Lung cancer:9.62e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 48.3,parathyroid gland: 20.5,Mixed,,
PRKCG,"MGC57564, PKCC, PKCG, SCA14",ENSG00000126583,Protein kinase C gamma,19,53879190-53907652,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB013051, HPA047870, HPA054560",Supported,,,,,Mixed,Tissue enriched,9,cerebral cortex: 40.9,testis: 4.7,Cell line enhanced,,A549: 2.0;SH-SY5Y: 1.5
PRKCH,"PKC-L, PKCL, PRKCL",ENSG00000027075,Protein kinase C eta,14,61187559-61550976,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026294, HPA053709",Approved,,Approved,Plasma membrane<br>Cytosol,Head and neck cancer:8.55e-6 (favourable),Expressed in all,Expressed in all,,,lymph node: 61.7,Cell line enhanced,,BEWO: 78.7;HUVEC TERT2: 90.5;MOLT-4: 60.3;TIME: 58.5
PRKCI,"DXS1179E, PKCI",ENSG00000163558,Protein kinase C iota,3,170222365-170305981,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026574, HPA038635",Approved,,Enhanced,Microtubules<br>Cytokinetic bridge<br>Cytosol,"Endometrial cancer:3.93e-6 (unfavourable), Pancreatic cancer:1.22e-4 (unfavourable), Liver cancer:3.02e-4 (unfavourable), Renal cancer:3.10e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 39.9,Expressed in all,,
PRKCQ,,ENSG00000065675,Protein kinase C theta,10,6427143-6580301,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA065279, HPA073098",,,Enhanced,Microtubule organizing center,Thyroid cancer:5.27e-4 (unfavourable),Mixed,Tissue enhanced,,skeletal muscle: 43.0,thyroid gland: 25.0,Cell line enhanced,,HEL: 50.9;MOLT-4: 34.7
PRKCZ,PKC2,ENSG00000067606,Protein kinase C zeta,1,2050470-2185395,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA021851,Enhanced,,Approved,Plasma membrane<br>Cytosol,Renal cancer:1.64e-9 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 99.7,placenta: 62.3,Cell line enhanced,,BEWO: 45.1
PRKD1,"PKC-mu, PKCM, PKD, PRKCM",ENSG00000184304,Protein kinase D1,14,29576479-30191898,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB018367, HPA029834",Uncertain,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:2.44e-5 (favourable), Thyroid cancer:2.91e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 50.3,prostate: 28.5,Mixed,,
PRKD2,"DKFZP586E0820, HSPC187, PKD2",ENSG00000105287,Protein kinase D2,19,46674275-46717127,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021490, HPA056727",Enhanced,,Supported,Nucleoplasm<br>Cytosol,Urothelial cancer:9.15e-4 (favourable),Expressed in all,Expressed in all,,,spleen: 60.3,Expressed in all,,
PRKD3,"EPK2, PRKCN",ENSG00000115825,Protein kinase D3,2,37250502-37324808,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA029529,Uncertain,,Supported,Nucleoplasm<br>Cytosol,"Liver cancer:3.47e-4 (unfavourable), Colorectal cancer:4.84e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 44.4,Expressed in all,,
PRKDC,"DNA-PKcs, DNAPK, DNPK1, HYRC, HYRC1, p350, XRCC7",ENSG00000253729,"Protein kinase, DNA-activated, catalytic polypeptide",8,47773108-47960183,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005167, HPA035174",Supported,,Enhanced,Nucleoplasm,Endometrial cancer:1.03e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 30.6,Expressed in all,,
PRKG1,"PGK, PKG, PRKG1B, PRKGR1B",ENSG00000185532,"Protein kinase, cGMP-dependent, type I",10,50991358-52298350,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA007699, CAB009629",Enhanced,,Approved,Vesicles<br>Cytosol,,Mixed,Mixed,,,smooth muscle: 25.1,Cell line enhanced,,AN3-CA: 19.3;BJ hTERT+: 17.6;fHDF/TERT166: 13.4
PRKG2,"cGKII, PRKGR2",ENSG00000138669,"Protein kinase, cGMP-dependent, type II",4,81087370-81215117,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007386, CAB018739",Approved,,,,,Tissue enhanced,Tissue enhanced,,prostate: 15.3;small intestine: 14.4,duodenum: 9.7,Cell line enhanced,,HEL: 18.8;SCLC-21H: 7.3
PRKX,PKX1,ENSG00000183943,"Protein kinase, X-linked",X,3604370-3713608,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA015324,Supported,,Supported,Nucleus,,Expressed in all,Tissue enhanced,,thyroid gland: 58.0,fallopian tube: 31.8,Cell line enhanced,,HMC-1: 67.0
PRMT1,"ANM1, HCP1, HRMT1L2",ENSG00000126457,Protein arginine methyltransferase 1,19,49675786-49689029,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB022550, HPA069769, HPA072136",Enhanced,,Supported,Nucleoplasm,Liver cancer:8.04e-5 (unfavourable),Expressed in all,Expressed in all,,,fallopian tube: 181.1,Expressed in all,,
PRMT2,"HRMT1L1, MGC111373",ENSG00000160310,Protein arginine methyltransferase 2,21,46635167-46665124,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA018976, HPA029591",Uncertain,,Enhanced,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,ovary: 98.6,Expressed in all,,
PRMT5,"HRMT1L5, SKB1, SKB1Hs",ENSG00000100462,Protein arginine methyltransferase 5,14,22920511-22929585,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA005525, CAB012459, HPA064708",Approved,,Approved,Nucleus<br>Cytosol,"Liver cancer:4.77e-5 (unfavourable), Urothelial cancer:1.04e-4 (unfavourable), Head and neck cancer:1.82e-4 (unfavourable), Pancreatic cancer:2.61e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 72.8,Expressed in all,,
PRMT6,"FLJ10559, HRMT1L6",ENSG00000198890,Protein arginine methyltransferase 6,1,107056679-107059294,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA059424,Approved,,Supported,Nucleus<br>Nucleoli,Endometrial cancer:3.05e-4 (unfavourable),Expressed in all,Mixed,,,parathyroid gland: 17.2,Cell line enhanced,,MCF7: 235.5
PRMT7,"FLJ10640, KIAA1933",ENSG00000132600,Protein arginine methyltransferase 7,16,68310974-68358563,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA044241,Supported,,Supported,Nucleoplasm<br>Nucleoli fibrillar center,Endometrial cancer:2.31e-5 (favourable),Expressed in all,Expressed in all,,,fallopian tube: 25.0,Expressed in all,,
PROC,,ENSG00000115718,"Protein C, inactivator of coagulation factors Va and VIIIa",2,127418427-127429246,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA005550, CAB016721, CAB016792",Supported,,,,,Tissue enriched,Tissue enriched,12,liver: 140.4,kidney: 12.0,Cell line enriched,12,Hep G2: 105.5
PRODH,"HSPOX2, PIG6, PRODH1, PRODH2, TP53I6",ENSG00000100033,Proline dehydrogenase 1,22,18912777-18936553,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA020361,Uncertain,,,,Cervical cancer:1.54e-4 (favourable),Tissue enhanced,Tissue enhanced,,small intestine: 25.2,duodenum: 5.7,Cell line enriched,6,RPTEC TERT1: 28.5
PRODH2,HSPOX1,ENSG00000250799,Proline dehydrogenase 2,19,35799988-35813299,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA051287,Approved,,Supported,Nucleoplasm<br>Cytosol,,Group enriched,Group enriched,96,kidney: 132.8;liver: 45.1,testis: 0.9,Cell line enriched,14,Hep G2: 21.4
PROZ,PZ,ENSG00000126231,"Protein Z, vitamin K dependent plasma glycoprotein",13,113158654-113172383,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA052006,Enhanced,,,,Liver cancer:3.46e-4 (favourable),Tissue enriched,Group enriched,14,kidney: 14.5;liver: 27.4,testis: 1.5,Cell line enhanced,,HaCaT: 1.9;Hep G2: 2.4
PRPF19,"hPSO4, NMP200, PRP19, PSO4, SNEV, UBOX4",ENSG00000110107,Pre-mRNA processing factor 19,11,60890730-60906588,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012448, HPA038051, HPA059070",Supported,,Enhanced,Nuclear speckles,Liver cancer:4.11e-8 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 128.9,Expressed in all,,
PRPF4B,"KIAA0536, PR4H, Prp4",ENSG00000112739,Pre-mRNA processing factor 4B,6,4021267-4064983,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA020638,Approved,,Supported,Nuclear speckles,"Urothelial cancer:6.82e-5 (favourable), Liver cancer:2.27e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 37.7,Expressed in all,,
PRPS1,"CMTX5, DFN2, DFNX1",ENSG00000147224,Phosphoribosyl pyrophosphate synthetase 1,X,107628424-107651026,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA043760,Uncertain,,Approved,Cytosol,,Expressed in all,Expressed in all,,,thyroid gland: 73.9,Expressed in all,,
PRPS1L1,"PRPS3, PRPSL",ENSG00000229937,Phosphoribosyl pyrophosphate synthetase 1-like 1,7,18026774-18027863,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,575,testis: 57.5,all non-specific tissues: 0.0,Not detected,,
PRPS2,,ENSG00000101911,Phosphoribosyl pyrophosphate synthetase 2,X,12791355-12824222,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA067599, CAB070417",Enhanced,,Approved,Vesicles,Cervical cancer:1.90e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 242.3,seminal vesicle: 117.1,Expressed in all,,
PRSS1,TRY1,ENSG00000204983,"Protease, serine 1",7,142749468-142753076,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025487, CAB025538, HPA062452, HPA063471",Enhanced,,,,"Endometrial cancer:6.41e-6 (unfavourable), Thyroid cancer:4.91e-4 (favourable), Ovarian cancer:7.05e-4 (favourable)",Tissue enriched,Tissue enriched,318,pancreas: 81683.0,ovary: 257.2,Cell line enhanced,,EFO-21: 1.3;RPMI-8226: 2.0;U-2 OS: 1.7
PRSS12,"BSSP-3, MRT1",ENSG00000164099,"Protease, serine 12",4,118280038-118353003,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA035054, HPA035055",Uncertain,,Approved,Nucleus<br>Actin filaments,"Head and neck cancer:1.03e-4 (favourable), Glioma:1.53e-4 (favourable)",Mixed,Mixed,,,"cervix, uterine: 22.4",Cell line enhanced,,SH-SY5Y: 228.5;THP-1: 67.4
PRSS16,TSSP,ENSG00000112812,"Protease, serine 16",6,27247701-27256624,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA017743,Uncertain,,,,Ovarian cancer:6.46e-5 (favourable),Mixed,Tissue enhanced,,thyroid gland: 22.0,epididymis: 16.5,Cell line enhanced,,hTCEpi: 14.7;RPMI-8226: 7.9
PRSS2,TRY2,ENSG00000275896,"Protease, serine 2",7,142760398-142774564,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA062452, HPA063471",Supported,,Approved,Endoplasmic reticulum<br>Vesicles,Breast cancer:2.32e-4 (favourable),Tissue enriched,Tissue enriched,53,pancreas: 30215.4,small intestine: 567.7,Group enriched,6,RPMI-8226: 46.1;U-2 OS: 14.3
PRSS21,"ESP-1, TEST1",ENSG00000007038,"Protease, serine 21",16,2817180-2826304,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008477,Enhanced,,Approved,Cytosol,,Tissue enhanced,Tissue enriched,10,testis: 49.5,bone marrow: 4.7,Cell line enhanced,,CAPAN-2: 22.0;HEL: 25.5;HeLa: 48.0;K-562: 30.5;U-698: 70.6
PRSS22,"BSSP-4, hBSSP-4, SP001LA",ENSG00000005001,"Protease, serine 22",16,2852727-2858170,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA049161,Approved,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,esophagus: 7.7;stomach: 11.1,salivary gland: 3.1,Cell line enhanced,,CAPAN-2: 67.3;SK-BR-3: 14.6;T-47d: 16.5
PRSS23,"SIG13, SPUVE",ENSG00000150687,"Protease, serine 23",11,86791059-86952910,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA030591,Uncertain,,,,"Head and neck cancer:2.12e-4 (unfavourable), Renal cancer:3.06e-4 (unfavourable), Pancreatic cancer:5.56e-4 (unfavourable)",Expressed in all,Expressed in all,,,"cervix, uterine: 397.1",Cell line enhanced,,HUVEC TERT2: 503.9;TIME: 926.9
PRSS27,"CAPH2, MPN",ENSG00000172382,"Protease, serine 27",16,2712418-2720551,"Enzymes, Predicted secreted proteins",Evidence at protein level,CAB024920,Approved,,,,,Tissue enhanced,Tissue enriched,7,esophagus: 210.7,tonsil: 28.1,Cell line enhanced,,BEWO: 6.1;SK-BR-3: 18.9;T-47d: 14.0
PRSS3,"PRSS4, TRY3, TRY4",ENSG00000010438,"Protease, serine 3",9,33750466-33799231,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA062452, HPA063471",Supported,,Approved,Endoplasmic reticulum<br>Vesicles,Endometrial cancer:4.30e-4 (unfavourable),Group enriched,Tissue enriched,64,pancreas: 6301.2,small intestine: 99.1,Cell line enriched,9,PC-3: 632.8
PRSS33,EOS,ENSG00000103355,"Protease, serine 33",16,2783953-2787948,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA058082,Uncertain,,,,,Tissue enhanced,Tissue enriched,7,fallopian tube: 7.4,small intestine: 1.0,Group enriched,10,HMC-1: 2.4;SK-MEL-30: 4.5;U-2 OS: 2.1
PRSS35,"C6orf158, dJ223E3.1, MGC46520",ENSG00000146250,"Protease, serine 35",6,83512538-83525704,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA038787, HPA038788",Uncertain,,,,,Tissue enhanced,Tissue enhanced,,ovary: 12.9,cerebral cortex: 9.9,Cell line enhanced,,CACO-2: 71.2;HAP1: 13.2;RPTEC TERT1: 18.6
PRSS36,FLJ90661,ENSG00000178226,"Protease, serine 36",16,31138925-31150094,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA036079,Uncertain,,,,Cervical cancer:2.97e-7 (favourable),Mixed,Mixed,,,skin: 1.2,Cell line enhanced,,HeLa: 1.4
PRSS37,,ENSG00000165076,"Protease, serine 37",7,141836286-141841487,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA020541,Enhanced,,,,,Not detected,Tissue enriched,162,testis: 55.3,skin: 0.3,Not detected,,
PRSS38,MPN2,ENSG00000185888,"Protease, serine 38",1,227815693-227846470,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA028003, HPA055809",Enhanced,,,,,Not detected,Tissue enriched,41,testis: 4.2,epididymis: 0.1,Not detected,,
PRSS41,TESSP1,ENSG00000215148,"Protease, serine 41",16,2798485-2805302,"Enzymes, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enriched,6,testis: 1.6,stomach: 0.2,Cell line enriched,11,BEWO: 1.7
PRSS42,TESSP2,ENSG00000178055,"Protease, serine 42",3,46829542-46834095,"Enzymes, Predicted secreted proteins",Evidence at transcript level,HPA046925,Uncertain,,,,,Not detected,Group enriched,6,epididymis: 4.8;heart muscle: 8.8;parathyroid gland: 3.1;skeletal muscle: 8.4;testis: 2.0;thyroid gland: 1.9,"breast,cervix, uterine,prostate,seminal vesicle: 0.7",Cell line enhanced,,NTERA-2: 1.0
PRSS45,TESSP5,ENSG00000188086,"Protease, serine 45",3,46742092-46744755,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA060284,Uncertain,,,,,Mixed,Tissue enhanced,,epididymis: 9.8;parathyroid gland: 8.6,skeletal muscle: 3.7,Not detected,,
PRSS46,TESSP6,ENSG00000261603,"Protease, serine 46",3,46719583-46736429,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,epididymis: 4.5;testis: 8.4,parathyroid gland: 2.7,Not detected,,
PRSS48,ESSPL,ENSG00000189099,"Protease, serine 48",4,151277171-151291453,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA053801,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 1.4,skin: 0.4,Not detected,,
PRSS50,"CT20, TSP50",ENSG00000206549,"Protease, serine 50",3,46712115-46812574,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA040768,Supported,,,,,Mixed,Tissue enhanced,,epididymis: 5.7;parathyroid gland: 4.1,"skeletal muscle,testis,thyroid gland: 2.0",Not detected,,
PRSS50,"CT20, TSP50",ENSG00000283706,"Protease, serine 50",3,46712115-46717907,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA040768,Supported,,,,,,Tissue enriched,14,testis: 38.7,thyroid gland: 2.7,Cell line enhanced,,HMC-1: 1.2
PRSS53,POL3S,ENSG00000151006,"Protease, serine 53",16,31083425-31089628,"Enzymes, Predicted secreted proteins",Evidence at transcript level,"HPA034955, HPA034956",Uncertain,,,,,Mixed,Tissue enhanced,,skin: 1.1,prostate: 0.5,Cell line enhanced,,SCLC-21H: 5.5
PRSS54,"CT67, FLJ25339, KLKBL4",ENSG00000103023,"Protease, serine 54",16,58279997-58295047,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA041549,Enhanced,,,,,Not detected,Tissue enriched,461,testis: 63.1,"cerebral cortex,urinary bladder: 0.1",Not detected,,
PRSS55,"CT153, T-SP1, UNQ9391",ENSG00000184647,"Protease, serine 55",8,10525546-10554166,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,92,testis: 26.1,epididymis: 0.2,Not detected,,
PRSS56,,ENSG00000237412,"Protease, serine 56",2,232520463-232525716,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,skeletal muscle: 3.4,testis: 0.8,Not detected,,
PRSS57,"PRSSL1, UNQ782",ENSG00000185198,"Protease, serine 57",19,685546-695498,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,173,bone marrow: 103.3,spleen: 0.5,Group enriched,9,NB-4: 239.3;THP-1: 126.5
PRSS58,TRYX3,ENSG00000258223,"Protease, serine 58",7,142252143-142258058,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,123,testis: 21.1,"cervix, uterine,smooth muscle: 0.1",Not detected,,
PRSS8,,ENSG00000052344,"Protease, serine 8",16,31131433-31135762,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA030436, HPA063533",Uncertain,,Uncertain,Cytosol,Renal cancer:2.05e-10 (favourable),Mixed,Mixed,,,small intestine: 164.8,Cell line enhanced,,BEWO: 230.2;CACO-2: 133.7;CAPAN-2: 96.1;hTCEpi: 111.3;SK-BR-3: 136.6
PRTN3,"ACPA, AGP7, C-ANCA, MBT, P29, PR-3",ENSG00000196415,Proteinase 3,19,840960-848175,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA005938, CAB017558",Enhanced,,,,,Tissue enhanced,Tissue enriched,724,bone marrow: 616.4,spleen: 0.8,Cell line enriched,6,THP-1: 696.6
PRUNE1,"DRES-17, H-PRUNE, HTCD37, PRUNE",ENSG00000143363,Prune exopolyphosphatase,1,151008420-151035713,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028411,Uncertain,,Supported,Cytosol,"Renal cancer:3.48e-4 (unfavourable), Endometrial cancer:3.86e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 53.9,Expressed in all,,
PSAT1,PSA,ENSG00000135069,Phosphoserine aminotransferase 1,9,78297143-78330093,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB014882, CAB040567, HPA042924",Enhanced,,Enhanced,Cytosol,"Renal cancer:6.00e-7 (unfavourable), Endometrial cancer:5.62e-5 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 186.0,liver: 138.7,Cell line enhanced,,hTCEpi: 853.3
PSEN1,"AD3, FAD, PS1, S182",ENSG00000080815,Presenilin 1,14,73136418-73223691,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB006844, HPA030760, HPA067496",Approved,,Approved,Nucleus<br>Golgi apparatus<br>Cell Junctions,"Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 66.0,Expressed in all,,
PSEN2,"AD3L, AD4, PS2, STM2",ENSG00000143801,Presenilin 2,1,226870184-226896105,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB013634, HPA038005",,,Supported,Nucleus,,Expressed in all,Expressed in all,,,parathyroid gland: 28.8,Mixed,,
PSKH1,,ENSG00000159792,Protein serine kinase H1,16,67893272-67929678,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA053927,Approved,,Approved,Nucleoplasm,Renal cancer:4.28e-10 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 49.5,Expressed in all,,
PSKH2,,ENSG00000147613,Protein serine kinase H2,8,86048373-86088621,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA015095,Uncertain,,,,,Tissue enhanced,Not detected,,,testis: 0.4,Cell line enriched,21,HEL: 8.2
PSMA1,"HC2, MGC14542, MGC14575, MGC14751, MGC1667, MGC21459, MGC22853, MGC23915, NU, PROS30",ENSG00000129084,Proteasome subunit alpha 1,11,14504874-14643635,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB033765, HPA037646, HPA043891",Supported,,Enhanced,Nucleoplasm,"Renal cancer:4.03e-11 (unfavourable), Liver cancer:3.79e-5 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 120.9,Expressed in all,,
PSMA2,"HC3, MU, PMSA2",ENSG00000106588,Proteasome subunit alpha 2,7,42916857-42932223,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA008188,Uncertain,,,,"Ovarian cancer:6.73e-5 (favourable), Liver cancer:1.29e-4 (unfavourable)",Expressed in all,Expressed in all,,,liver: 165.2,Expressed in all,,
PSMA3,HC8,ENSG00000100567,Proteasome subunit alpha 3,14,58244831-58272012,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA000905,Approved,,Approved,Microtubules<br>Cytokinetic bridge,Thyroid cancer:2.91e-4 (favourable),Expressed in all,Expressed in all,,,epididymis: 150.8,Expressed in all,,
PSMA4,"HC9, HsT17706",ENSG00000041357,Proteasome subunit alpha 4,15,78540405-78552419,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004973, HPA055466, HPA060613",Supported,,Enhanced,Nucleus<br>Vesicles<br>Cytosol,Renal cancer:6.74e-10 (unfavourable),Expressed in all,Expressed in all,,,testis: 174.1,Expressed in all,,
PSMA5,ZETA,ENSG00000143106,Proteasome subunit alpha 5,1,109399031-109426427,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA028392, HPA028398, HPA028441",Approved,,Approved,Cytosol,"Colorectal cancer:1.45e-5 (favourable), Liver cancer:2.28e-4 (unfavourable)",Expressed in all,Mixed,,,cerebral cortex: 14.9,Cell line enhanced,,MOLT-4: 36.7
PSMA6,"IOTA, MGC22756, MGC2333, MGC23846, p27K, PROS27",ENSG00000100902,Proteasome subunit alpha 6,14,35278633-35317493,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003049,Approved,,Supported,Nucleoplasm,Ovarian cancer:3.27e-4 (favourable),Expressed in all,Expressed in all,,,testis: 390.4,Expressed in all,,
PSMA7,"C6, HSPC, RC6-1, XAPC7",ENSG00000101182,Proteasome subunit alpha 7,20,62136735-62143440,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB046007, CAB046008, HPA047266",Enhanced,,,,Liver cancer:2.54e-5 (unfavourable),Expressed in all,Expressed in all,,,adipose tissue: 208.4,Expressed in all,,
PSMA8,"MGC26605, PSMA7L",ENSG00000154611,Proteasome subunit alpha 8,18,26133852-26193355,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,20,testis: 39.0,"lymph node,tonsil: 1.9",Group enriched,73,Daudi: 24.2;U-266/70: 15.3;U-266/84: 15.8
PSMB1,"HC5, PMSB1",ENSG00000008018,Proteasome subunit beta 1,6,170535117-170553341,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA029635, HPA029637, CAB033911",Enhanced,,Supported,Nucleus,Renal cancer:3.76e-6 (unfavourable),Expressed in all,Expressed in all,,,epididymis: 320.2,Expressed in all,,
PSMB10,"beta2i, LMP10, MECL1, MGC1665",ENSG00000205220,Proteasome subunit beta 10,16,67934502-67937087,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030224, HPA030225, CAB034384",Enhanced,,Enhanced,Cytosol,Urothelial cancer:5.44e-4 (favourable),Expressed in all,Expressed in all,,,lymph node: 91.2,Mixed,,
PSMB11,beta5t,ENSG00000222028,Proteasome subunit beta 11,14,23042167-23044276,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028967, HPA056970",Enhanced,,,,,Not detected,Not detected,,,testis: 0.2,Not detected,,
PSMB2,HC7-I,ENSG00000126067,Proteasome subunit beta 2,1,35599544-35641844,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA026322, HPA026324",Approved,,Enhanced,Nucleoplasm,"Liver cancer:3.49e-7 (unfavourable), Renal cancer:2.80e-6 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 43.3,Expressed in all,,
PSMB3,"HC10-II, MGC4147",ENSG00000277791,Proteasome subunit beta 3,17,38752736-38764231,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042775, HPA048147",Approved,,Enhanced,Mitochondria,Renal cancer:1.71e-6 (unfavourable),Expressed in all,Expressed in all,,,epididymis: 83.6,Expressed in all,,
PSMB4,"HN3, PROS26",ENSG00000159377,Proteasome subunit beta 4,1,151399534-151401944,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006700,Approved,,Approved,Intermediate filaments<br>Centrosome<br>Cytosol,"Renal cancer:2.90e-10 (unfavourable), Liver cancer:7.45e-4 (unfavourable)",Expressed in all,Expressed in all,,,fallopian tube: 275.5,Expressed in all,,
PSMB5,"MB1, X",ENSG00000100804,Proteasome subunit beta 5,14,23016543-23035230,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA049518, HPA061796",Approved,,Supported,Nucleus<br>Centrosome,"Liver cancer:2.90e-5 (unfavourable), Ovarian cancer:1.08e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable), Urothelial cancer:4.73e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 141.7,Expressed in all,,
PSMB6,"DELTA, Y",ENSG00000142507,Proteasome subunit beta 6,17,4796144-4798503,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA023312, HPA063656",Supported,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:5.93e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 200.1,Expressed in all,,
PSMB7,,ENSG00000136930,Proteasome subunit beta 7,9,124353466-124415444,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA052408, HPA054902",Enhanced,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 236.9,Expressed in all,,
PSMB8,"beta5i, D6S216E, LMP7, PSMB5i, RING10",ENSG00000204264,Proteasome subunit beta 8,6,32840717-32844703,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA046995, HPA050327",Enhanced,,Approved,Vesicles<br>Cytokinetic bridge,"Breast cancer:5.08e-4 (favourable), Endometrial cancer:7.16e-4 (favourable)",Expressed in all,Mixed,,,lymph node: 23.0,Mixed,,
PSMB9,"beta1i, LMP2, PSMB6i, RING12",ENSG00000240065,Proteasome subunit beta 9,6,32844136-32859585,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB015180, HPA042818, HPA053280",Enhanced,,Supported,Cytosol,Renal cancer:1.33e-4 (unfavourable),Expressed in all,Mixed,,,spleen: 39.1,Cell line enhanced,,Daudi: 46.2;REH: 43.8
PSMD14,"pad1, POH1, Rpn11",ENSG00000115233,"Proteasome 26S subunit, non-ATPase 14",2,161308038-161411717,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA002114, HPA003828",Approved,,Supported,Nucleoplasm,"Liver cancer:2.66e-8 (unfavourable), Renal cancer:3.10e-6 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 56.1,Expressed in all,,
PSMD7,"MOV34, P40, Rpn8, S12",ENSG00000103035,"Proteasome 26S subunit, non-ATPase 7",16,74296775-74306288,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB019379, HPA049824, HPA056069",Enhanced,,Enhanced,Nucleoplasm,"Liver cancer:7.71e-6 (unfavourable), Head and neck cancer:6.64e-5 (unfavourable)",Expressed in all,Expressed in all,,,prostate: 107.1,Expressed in all,,
PSPH,PSP,ENSG00000146733,Phosphoserine phosphatase,7,56011051-56051604,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020376, HPA029515",Approved,,Approved,Cytosol,"Liver cancer:2.75e-5 (unfavourable), Breast cancer:2.30e-4 (unfavourable), Pancreatic cancer:3.77e-4 (favourable)",Expressed in all,Expressed in all,,,fallopian tube: 25.3,Expressed in all,,
PSTK,"C10orf89, MGC35392",ENSG00000179988,Phosphoseryl-tRNA kinase,10,122954381-122997513,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037780, HPA037781",Approved,,Approved,Nucleoli<br>Nuclear bodies<br>Actin filaments,,Mixed,Mixed,,,testis: 5.9,Mixed,,
PTDSS1,"KIAA0024, PSS1, PSSA",ENSG00000156471,Phosphatidylserine synthase 1,8,96261715-96336995,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA016852,Uncertain,,Approved,Nucleoplasm<br>Endoplasmic reticulum,"Liver cancer:1.08e-5 (unfavourable), Lung cancer:9.83e-4 (unfavourable)",Expressed in all,Mixed,,,parathyroid gland: 14.1,Expressed in all,,
PTDSS2,PSS2,ENSG00000174915,Phosphatidylserine synthase 2,11,448268-491399,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA038928, HPA038929",Approved,,,,Liver cancer:5.12e-9 (unfavourable),Expressed in all,Expressed in all,,,testis: 25.5,Expressed in all,,
PTEN,"BZS, MHAM, MMAC1, PTEN1, TEP1",ENSG00000171862,Phosphatase and tensin homolog,10,87863113-87971930,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004076, HPA031335",Uncertain,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:7.35e-4 (unfavourable),Expressed in all,Expressed in all,,,"cervix, uterine: 83.6",Expressed in all,,
PTGDS,"L-PGDS, PGDS",ENSG00000107317,Prostaglandin D2 synthase,9,136975092-136981742,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA004938, CAB009916",Approved,,Supported,Nucleoplasm,Renal cancer:1.19e-7 (unfavourable),Expressed in all,Expressed in all,,,testis: 2581.3,Group enriched,7,HHSteC: 440.4;HSkMC: 186.3
PTGES,"MGST-IV, MGST1-L1, MGST1L1, PIG12, TP53I12",ENSG00000148344,Prostaglandin E synthase,9,129738331-129753047,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045064,Enhanced,,Supported,Endoplasmic reticulum,"Pancreatic cancer:7.97e-5 (unfavourable), Colorectal cancer:2.32e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 82.9;seminal vesicle: 119.5,urinary bladder: 36.3,Cell line enhanced,,BEWO: 155.0;HaCaT: 189.3;U-2197: 372.3
PTGES2,"C9orf15, FLJ14038",ENSG00000148334,Prostaglandin E synthase 2,9,128120693-128128462,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA020631, HPA020733",Approved,,Approved,Mitochondria,Renal cancer:5.83e-7 (favourable),Expressed in all,Expressed in all,,,skeletal muscle: 35.1,Expressed in all,,
PTGES3,"cPGES, p23, TEBP",ENSG00000110958,Prostaglandin E synthase 3,12,56663341-56688408,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB034319, HPA038672, HPA038673",Enhanced,,Supported,Nucleoplasm<br>Cytosol,"Liver cancer:4.44e-6 (unfavourable), Breast cancer:2.15e-5 (unfavourable), Ovarian cancer:4.36e-4 (favourable)",Expressed in all,Expressed in all,,,fallopian tube: 347.2,Expressed in all,,
PTGIS,"CYP8A1, PGIS",ENSG00000124212,Prostaglandin I2 synthase,20,49503874-49568146,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB009517, HPA014193, HPA052244",Enhanced,,Approved,Endoplasmic reticulum,"Renal cancer:4.74e-8 (unfavourable), Urothelial cancer:9.99e-5 (unfavourable)",Expressed in all,Mixed,,,fallopian tube: 78.2,Cell line enhanced,,ASC diff: 30.9;ASC TERT1: 31.6;U-2197: 133.1
PTGR1,"LTB4DH, ZADH3",ENSG00000106853,Prostaglandin reductase 1,9,111549722-111599855,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA036724,Enhanced,,,,Renal cancer:5.53e-4 (favourable),Expressed in all,Expressed in all,,,small intestine: 315.8,Mixed,,
PTGR2,"FLJ39091, ZADH1",ENSG00000140043,Prostaglandin reductase 2,14,73851844-73886827,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001125,Approved,,Approved,Vesicles,Renal cancer:4.55e-12 (favourable),Expressed in all,Mixed,,,thyroid gland: 21.2,Cell line enhanced,,T-47d: 39.4
PTGS1,"COX1, PGHS-1, PTGHS",ENSG00000095303,Prostaglandin-endoperoxide synthase 1,9,122370530-122395703,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA002834, CAB020315",Enhanced,,Supported,Golgi apparatus<br>Vesicles,"Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 161.6,fallopian tube: 86.1,Cell line enhanced,,ASC diff: 104.2;BJ: 149.8;BJ hTERT+: 187.6;HMC-1: 391.6
PTGS2,COX2,ENSG00000073756,Prostaglandin-endoperoxide synthase 2,1,186671791-186680427,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,"CAB000113, HPA001335",Approved,,Supported,Endoplasmic reticulum,Renal cancer:9.79e-4 (unfavourable),Mixed,Tissue enhanced,,seminal vesicle: 180.6,"cervix, uterine: 99.3",Group enriched,7,BJ: 78.6;BJ hTERT+: 327.8
PTK2,"FADK, FAK, FAK1, PPP1R71",ENSG00000169398,Protein tyrosine kinase 2,8,140657900-141002216,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001842, CAB004036, HPA029671",Approved,,Supported,Vesicles<br>Focal adhesion sites<br>Cytosol,"Breast cancer:3.21e-4 (unfavourable), Endometrial cancer:9.11e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 107.1,Mixed,,
PTK2B,"CADTK, CAKB, FAK2, PTK, PYK2, RAFTK",ENSG00000120899,Protein tyrosine kinase 2 beta,8,27311482-27459391,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003850, HPA026091, HPA026276",Approved,,Enhanced,Plasma membrane<br>Cytosol,"Cervical cancer:3.32e-4 (favourable), Thyroid cancer:5.11e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 91.1,Cell line enhanced,,REH: 128.1
PTK6,BRK,ENSG00000101213,Protein tyrosine kinase 6,20,63528001-63537370,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB032952, HPA036070, HPA036071",Approved,,Supported,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,"Renal cancer:1.26e-9 (unfavourable), Pancreatic cancer:1.96e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 61.0;skin: 60.4,duodenum: 29.2,Cell line enhanced,,A-431: 19.4;CAPAN-2: 36.5;HaCaT: 30.0;hTCEpi: 32.5;RT4: 21.3;T-47d: 23.7
PTK7,CCK4,ENSG00000112655,Protein tyrosine kinase 7 (inactive),6,43076268-43161719,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA003222,Approved,,,,,Expressed in all,Mixed,,,endometrium: 117.3,Mixed,,
PTP4A1,"PRL-1, PTPCAAX1",ENSG00000112245,"Protein tyrosine phosphatase type IVA, member 1",6,63521748-63583587,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003281,Approved,,,,Cervical cancer:5.53e-4 (unfavourable),Expressed in all,Expressed in all,,,liver: 354.5,Expressed in all,,
PTP4A2,"HU-PP-1, OV-1, PRL-2, ptp-IV1a, PTP4A, PTPCAAX2",ENSG00000184007,"Protein tyrosine phosphatase type IVA, member 2",1,31906421-31944856,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003281, CAB011204",Uncertain,,,,"Renal cancer:5.10e-11 (unfavourable), Liver cancer:2.62e-5 (unfavourable), Urothelial cancer:2.72e-5 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 283.0,Expressed in all,,
PTP4A3,"PRL-3, PRL-R, PRL3",ENSG00000184489,"Protein tyrosine phosphatase type IVA, member 3",8,141391993-141432454,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003281,Uncertain,,,,Renal cancer:1.81e-5 (unfavourable),Expressed in all,Group enriched,6,heart muscle: 69.6;skeletal muscle: 153.1,prostate: 19.1,Cell line enhanced,,HDLM-2: 232.0;Karpas-707: 52.7;RPMI-8226: 54.1;U-266/84: 59.5
PTPA,"PPP2R4, PR53",ENSG00000119383,Protein phosphatase 2 phosphatase activator,9,129110950-129148946,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA005695, CAB022068, CAB035999",Approved,,Enhanced,Nucleoplasm<br>Cytosol,Endometrial cancer:6.50e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 225.9,Expressed in all,,
PTPMT1,"DUSP23, MOSP, PLIP",ENSG00000110536,"Protein tyrosine phosphatase, mitochondrial 1",11,47565430-47573461,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA040348, HPA043932",Approved,,Supported,Mitochondria,Liver cancer:3.04e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 92.8,Expressed in all,,
PTPN1,PTP1B,ENSG00000196396,"Protein tyrosine phosphatase, non-receptor type 1",20,50510321-50585241,"Enzymes, Predicted membrane proteins",Evidence at protein level,"CAB009329, HPA012542, CAB015217",Enhanced,,Enhanced,Endoplasmic reticulum,,Expressed in all,Expressed in all,,,parathyroid gland: 62.6,Expressed in all,,
PTPN11,"BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2",ENSG00000179295,"Protein tyrosine phosphatase, non-receptor type 11",12,112418351-112509913,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,CAB005377,Approved,,Supported,Nucleus<br>Nucleoli<br>Actin filaments<br>Cytosol,,Expressed in all,Expressed in all,,,cerebral cortex: 126.0,Expressed in all,,
PTPN12,"PTP-PEST, PTPG1",ENSG00000127947,"Protein tyrosine phosphatase, non-receptor type 12",7,77537275-77640071,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007097,Approved,,Approved,Plasma membrane<br>Cytosol,"Renal cancer:7.27e-6 (unfavourable), Cervical cancer:1.15e-4 (unfavourable), Pancreatic cancer:2.01e-4 (unfavourable), Liver cancer:8.78e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 107.2,Expressed in all,,
PTPN13,"PTP-BAS, PTP-BL, PTP1E, PTPL1",ENSG00000163629,"Protein tyrosine phosphatase, non-receptor type 13",4,86594315-86815171,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002213, HPA048888, HPA065290",Approved,,Approved,Plasma membrane<br>Cytosol,,Mixed,Mixed,,,skin: 65.9,Cell line enhanced,,AF22: 114.7
PTPN14,PEZ,ENSG00000152104,"Protein tyrosine phosphatase, non-receptor type 14",1,214348696-214552449,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB011469, HPA053864, CAB069441",Uncertain,,Enhanced,Nucleoplasm,"Pancreatic cancer:2.29e-4 (unfavourable), Stomach cancer:5.16e-4 (unfavourable)",Expressed in all,Mixed,,,skin: 19.9,Mixed,,
PTPN18,BDP1,ENSG00000072135,"Protein tyrosine phosphatase, non-receptor type 18",2,130356007-130375409,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB012174, HPA053367",Uncertain,,Approved,Intermediate filaments,,Expressed in all,Expressed in all,,,lymph node: 47.5,Expressed in all,,
PTPN2,"PTPT, TC-PTP, TCELLPTP, TCPTP",ENSG00000175354,"Protein tyrosine phosphatase, non-receptor type 2",18,12785478-12929643,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015004, HPA046176",Enhanced,,Enhanced,Nucleoplasm,"Renal cancer:1.20e-8 (unfavourable), Ovarian cancer:1.37e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 52.5,Expressed in all,,
PTPN20,"bA142I17.1, bA42B19.1, CT126, DKFZP566K0524, PTPN20A, PTPN20B",ENSG00000204179,"Protein tyrosine phosphatase, non-receptor type 20",10,46911396-47002488,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA043337, HPA046896, HPA048310",Uncertain,,Supported,Microtubule organizing center,,Mixed,Tissue enhanced,,testis: 25.3,adrenal gland: 12.2,Cell line enhanced,,HDLM-2: 46.4;SiHa: 9.6
PTPN21,"PTPD1, PTPRL10",ENSG00000070778,"Protein tyrosine phosphatase, non-receptor type 21",14,88465778-88554733,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB011468, HPA073999",Approved,,Approved,Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol,Renal cancer:3.16e-9 (favourable),Expressed in all,Mixed,,,skin: 34.5,Cell line enhanced,,RH-30: 34.1
PTPN22,"Lyp, Lyp1, Lyp2, PTPN8",ENSG00000134242,"Protein tyrosine phosphatase, non-receptor type 22",1,113813811-113871759,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004912, CAB012209, HPA013350",Approved,,Uncertain,Nucleoplasm<br>Vesicles<br>Plasma membrane,,Mixed,Tissue enhanced,,bone marrow: 24.8,lymph node: 23.3,Cell line enhanced,,Daudi: 49.5;U-698: 25.4
PTPN23,"DKFZP564F0923, HD-PTP, KIAA1471",ENSG00000076201,"Protein tyrosine phosphatase, non-receptor type 23",3,47381011-47413441,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA016845,Approved,,Supported,Nucleoplasm<br>Nuclear bodies,Renal cancer:1.82e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 56.9,Expressed in all,,
PTPN3,PTPH1,ENSG00000070159,"Protein tyrosine phosphatase, non-receptor type 3",9,109375466-109498313,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038343, HPA046728",Approved,,,,"Renal cancer:1.22e-15 (favourable), Endometrial cancer:1.52e-4 (favourable), Breast cancer:6.71e-4 (unfavourable)",Mixed,Mixed,,,skin: 35.8,Mixed,,
PTPN4,PTPMEG,ENSG00000088179,"Protein tyrosine phosphatase, non-receptor type 4",2,119759631-119983818,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019351,Uncertain,,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Lung cancer:5.16e-4 (favourable),Expressed in all,Mixed,,,thyroid gland: 24.5,Mixed,,
PTPN5,"PTPSTEP, STEP, STEP61",ENSG00000110786,"Protein tyrosine phosphatase, non-receptor type 5",11,18727928-18792721,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA031014, HPA072091",Supported,,Approved,Endoplasmic reticulum,,Group enriched,Tissue enriched,15,cerebral cortex: 58.8,testis: 3.8,Cell line enhanced,,NTERA-2: 1.7
PTPN6,"HCP, HCPH, PTP-1C, SHP-1, SHP1",ENSG00000111679,"Protein tyrosine phosphatase, non-receptor type 6",12,6946468-6961316,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001466, CAB004572, CAB072845",Enhanced,,Supported,Nucleus<br>Nucleoli,"Urothelial cancer:2.64e-8 (favourable), Cervical cancer:1.87e-4 (favourable), Colorectal cancer:5.42e-4 (unfavourable), Endometrial cancer:6.65e-4 (favourable)",Expressed in all,Mixed,,,lymph node: 161.5,Cell line enhanced,,HEL: 143.6;HMC-1: 527.9;THP-1: 163.9
PTPN7,"HEPTP, LC-PTP",ENSG00000143851,"Protein tyrosine phosphatase, non-receptor type 7",1,202147013-202161588,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009530, HPA019118",Approved,,,,"Renal cancer:2.42e-8 (unfavourable), Endometrial cancer:1.52e-4 (favourable), Head and neck cancer:1.84e-4 (favourable)",Expressed in all,Tissue enhanced,,bone marrow: 25.2;lymph node: 24.3,tonsil: 19.3,Cell line enhanced,,HEL: 48.4;HL-60: 93.9;HMC-1: 132.7;U-937: 65.7
PTPN9,MEG2,ENSG00000169410,"Protein tyrosine phosphatase, non-receptor type 9",15,75463251-75579289,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041922,Approved,,Approved,Vesicles,Renal cancer:2.49e-6 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 54.8,Expressed in all,,
PTPRA,"HLPR, HPTPA, LRP, PTPA, PTPRL2, RPTPA",ENSG00000132670,"Protein tyrosine phosphatase, receptor type A",20,2864184-3039076,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA029412, CAB034366, HPA069480",Approved,,Approved,Nucleus<br>Vesicles,Renal cancer:3.29e-6 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 167.4,Expressed in all,,
PTPRB,PTPB,ENSG00000127329,"Protein tyrosine phosphatase, receptor type B",12,70515866-70637440,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB004782, HPA067868",Uncertain,,Approved,Vesicles<br>Plasma membrane<br>Cell Junctions,"Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable)",Expressed in all,Mixed,,,lung: 54.0,Cell line enhanced,,EFO-21: 22.9;HUVEC TERT2: 51.3;TIME: 74.1
PTPRD,"HPTP, PTPD",ENSG00000153707,"Protein tyrosine phosphatase, receptor type D",9,8314246-10612723,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054829,Uncertain,,Approved,Vesicles,Renal cancer:7.45e-6 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 32.7;parathyroid gland: 47.0,ovary: 11.7,Cell line enhanced,,AF22: 27.3;RH-30: 9.9
PTPRE,PTPE,ENSG00000132334,"Protein tyrosine phosphatase, receptor type E",10,127907061-128085855,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA015870, HPA021872",Supported,,Approved,Intermediate filaments,Renal cancer:4.08e-5 (unfavourable),Expressed in all,Mixed,,,appendix: 34.8,Cell line enhanced,,HUVEC TERT2: 34.9;TIME: 64.9
PTPRF,LAR,ENSG00000142949,"Protein tyrosine phosphatase, receptor type F",1,43525187-43623666,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012710,Uncertain,,Approved,Golgi apparatus,"Liver cancer:3.47e-4 (unfavourable), Stomach cancer:7.03e-4 (favourable)",Expressed in all,Mixed,,,skin: 128.2,Mixed,,
PTPRG,"PTPG, RPTPG",ENSG00000144724,"Protein tyrosine phosphatase, receptor type G",3,61561569-62297613,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA064237,Uncertain,,,,Renal cancer:3.10e-6 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 73.5,thyroid gland: 22.8,Mixed,,
PTPRH,SAP-1,ENSG00000080031,"Protein tyrosine phosphatase, receptor type H",19,55181248-55209506,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA042300,,,Approved,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 68.9;small intestine: 77.0,gallbladder: 38.6,Cell line enhanced,,HHSteC: 10.1;K-562: 13.5;SK-MEL-30: 17.2
PTPRJ,"CD148, DEP1, HPTPeta",ENSG00000149177,"Protein tyrosine phosphatase, receptor type J",11,47980558-48170841,"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA006026,Approved,,,,Renal cancer:1.13e-5 (favourable),Expressed in all,Mixed,,,parathyroid gland: 38.6,Mixed,,
PTPRK,R-PTP-kappa,ENSG00000152894,"Protein tyrosine phosphatase, receptor type K",6,127968779-128520674,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA054056, HPA054822",Uncertain,,Supported,Vesicles<br>Plasma membrane<br>Cell Junctions,"Renal cancer:9.33e-5 (favourable), Pancreatic cancer:1.99e-4 (unfavourable)",Expressed in all,Mixed,,,gallbladder: 27.8,Mixed,,
PTPRM,"hR-PTPu, PTPRL1, RPTPU",ENSG00000173482,"Protein tyrosine phosphatase, receptor type M",18,7566782-8406861,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA003891, CAB022442, CAB022443",Supported,,Approved,Plasma membrane,"Cervical cancer:8.65e-5 (unfavourable), Urothelial cancer:1.07e-4 (favourable)",Expressed in all,Mixed,,,thyroid gland: 91.6,Mixed,,
PTPRN2,"IA-2beta, ICAAR, KIAA0387, phogrin",ENSG00000155093,"Protein tyrosine phosphatase, receptor type N2",7,157539056-158587788,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA006900, HPA026656",Approved,,Supported,Vesicles,"Glioma:7.72e-5 (unfavourable), Renal cancer:8.68e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 82.3,stomach: 38.9,Cell line enhanced,,AF22: 28.0;HDLM-2: 38.8;NB-4: 27.1;SCLC-21H: 26.6;SH-SY5Y: 24.3;U-87 MG: 27.1
PTPRO,"GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2",ENSG00000151490,"Protein tyrosine phosphatase, receptor type O",12,15322397-15597399,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA034525,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,rectum: 33.0,cerebral cortex: 21.7,Cell line enhanced,,NTERA-2: 6.6;SCLC-21H: 4.7;SH-SY5Y: 8.4
PTPRR,"EC-PTP, PCPTP1, PTP-SL, PTPBR7, PTPRQ",ENSG00000153233,"Protein tyrosine phosphatase, receptor type R",12,70638073-70920843,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB011461, HPA011851, HPA071067",Uncertain,,Supported,Plasma membrane<br>Cell Junctions<br>Cytosol,Urothelial cancer:1.40e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 20.8,endometrium: 9.0,Group enriched,11,HDLM-2: 18.5;RT4: 29.7;SH-SY5Y: 6.2
PTPRS,,ENSG00000105426,"Protein tyrosine phosphatase, receptor type S",19,5158495-5340803,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054747,,,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable)",Expressed in all,Mixed,,,cerebral cortex: 70.7,Cell line enhanced,,AN3-CA: 112.7;HaCaT: 110.4
PTPRT,"KIAA0283, RPTPrho",ENSG00000196090,"Protein tyrosine phosphatase, receptor type T",20,42072752-43189970,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA017336, CAB069423",Approved,,,,,Tissue enhanced,Group enriched,5,cerebral cortex: 24.3;fallopian tube: 17.4,placenta: 4.0,Cell line enhanced,,BEWO: 1.1
PTPRU,"FMI, hPTP-J, PCP-2, PTP, PTPRO",ENSG00000060656,"Protein tyrosine phosphatase, receptor type U",1,29236516-29326813,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB011476, HPA039832",Approved,,,,Head and neck cancer:8.32e-4 (unfavourable),Expressed in all,Mixed,,,"cervix, uterine: 28.0",Cell line enhanced,,BEWO: 92.2
PTPRZ1,"phosphacan, PTP18, PTPRZ, PTPZ, RPTPB",ENSG00000106278,"Protein tyrosine phosphatase, receptor type Z1",7,121873089-122062036,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA015103, CAB025106, HPA071024",Enhanced,Supported,Supported,Cytosol,Urothelial cancer:9.36e-4 (unfavourable),Tissue enriched,Tissue enriched,9,cerebral cortex: 257.9,skin: 30.1,Group enriched,12,AF22: 420.6;NTERA-2: 119.0;WM-115: 185.9
PTRH1,"C9orf115, PTH1",ENSG00000187024,Peptidyl-tRNA hydrolase 1 homolog,9,127692978-127724873,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021223,Uncertain,,,,,Not detected,Expressed in all,,,adipose tissue: 11.1,Expressed in all,,
PTRH2,"BIT1, CFAP37, CGI-147, PTH2",ENSG00000141378,Peptidyl-tRNA hydrolase 2,17,59674636-59707626,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA012897,Supported,,Supported,Mitochondria,"Renal cancer:1.01e-8 (unfavourable), Liver cancer:1.50e-4 (unfavourable)",Expressed in all,Expressed in all,,,epididymis: 43.9,Expressed in all,,
PTRHD1,"C2orf79, LOC391356",ENSG00000184924,Peptidyl-tRNA hydrolase domain containing 1,2,24789734-24793382,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA019951,Approved,,Approved,Nucleoplasm,Renal cancer:2.31e-4 (unfavourable),Expressed in all,Expressed in all,,,adrenal gland: 14.0,Expressed in all,,
PTS,PTPS,ENSG00000150787,6-pyruvoyltetrahydropterin synthase,11,112226365-112269955,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA001481,Uncertain,,Approved,Cytosol,,Expressed in all,Expressed in all,,,adrenal gland: 66.9,Expressed in all,,
PUDP,"DXF68S1E, FAM16AX, GS1, HDHD1, HDHD1A",ENSG00000130021,Pseudouridine 5'-phosphatase,X,7048920-7148190,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA072672,Approved,,,,"Thyroid cancer:4.80e-4 (favourable), Pancreatic cancer:7.27e-4 (unfavourable)",Expressed in all,Expressed in all,,,fallopian tube: 31.3,Mixed,,
PUS1,,ENSG00000177192,Pseudouridylate synthase 1,12,131929200-131945896,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA051636, HPA057593",Approved,,Supported,Nucleus<br>Mitochondria,Renal cancer:3.49e-8 (unfavourable),Expressed in all,Expressed in all,,,lymph node: 21.4,Expressed in all,,
PUS10,"CCDC139, FLJ32312",ENSG00000162927,Pseudouridylate synthase 10,2,60940222-61018259,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA044736, HPA049582",Approved,,Approved,Nucleoplasm<br>Nuclear bodies<br>Mitochondria,,Expressed in all,Mixed,,,thyroid gland: 10.3,Expressed in all,,
PUS3,FKSG32,ENSG00000110060,Pseudouridylate synthase 3,11,125893485-125903221,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038040, HPA063802",Uncertain,,Approved,Nucleus<br>Cytosol,Head and neck cancer:8.10e-4 (unfavourable),Expressed in all,Expressed in all,,,liver: 16.9,Expressed in all,,
PXDN,"D2S448, D2S448E, KIAA0230, MG50, PRG2, PXN",ENSG00000130508,Peroxidasin,2,1631887-1744852,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA012375,Approved,,,,"Endometrial cancer:2.75e-4 (unfavourable), Cervical cancer:6.28e-4 (unfavourable), Stomach cancer:6.73e-4 (unfavourable)",Expressed in all,Tissue enhanced,,smooth muscle: 87.2,adipose tissue: 66.9,Mixed,,
PXDNL,"FLJ25471, PMR1",ENSG00000147485,Peroxidasin like,8,51319578-51809445,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007919,,,Approved,Nucleoplasm<br>Cytosol,Breast cancer:3.27e-5 (unfavourable),Mixed,Group enriched,8,epididymis: 11.5;heart muscle: 24.1;testis: 9.0,adipose tissue: 1.8,Group enriched,7,AF22: 7.6;Daudi: 4.2;SH-SY5Y: 6.5
PXK,FLJ20335,ENSG00000168297,PX domain containing serine/threonine kinase like,3,58332880-58426126,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA024068,Supported,,Supported,Plasma membrane<br>Microtubule organizing center<br>Cytosol,Lung cancer:5.68e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 124.5,Expressed in all,,
PYCR1,P5C,ENSG00000183010,Pyrroline-5-carboxylate reductase 1,17,81932384-81942412,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA047660,Approved,,,,"Renal cancer:7.33e-12 (unfavourable), Liver cancer:2.33e-4 (unfavourable)",Expressed in all,Mixed,,,salivary gland: 52.3,Mixed,,
PYCR2,P5CR2,ENSG00000143811,Pyrroline-5-carboxylate reductase family member 2,1,225919877-225924340,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA056873,Approved,,Approved,Mitochondria,"Renal cancer:1.42e-6 (unfavourable), Colorectal cancer:5.02e-5 (unfavourable)",Expressed in all,Expressed in all,,,fallopian tube: 71.9,Expressed in all,,
PYCRL,FLJ13852,ENSG00000104524,Pyrroline-5-carboxylate reductase-like,8,143603913-143609773,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA063416, HPA069706",Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Mixed,,,cerebral cortex: 4.1,Expressed in all,,
PYGB,,ENSG00000100994,Glycogen phosphorylase B,20,25248069-25298014,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA031067,Approved,,Approved,Cytosol,"Lung cancer:1.10e-4 (unfavourable), Urothelial cancer:1.43e-4 (unfavourable), Liver cancer:4.37e-4 (unfavourable)",Expressed in all,Expressed in all,,,seminal vesicle: 149.4,Expressed in all,,
PYGL,,ENSG00000100504,Glycogen phosphorylase L,14,50857891-50944736,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000962, HPA004119",Enhanced,,Supported,Plasma membrane<br>Cytosol,"Pancreatic cancer:2.63e-4 (unfavourable), Head and neck cancer:5.97e-4 (unfavourable)",Expressed in all,Mixed,,,adipose tissue: 116.5,Mixed,,
PYGM,,ENSG00000068976,"Glycogen phosphorylase, muscle associated",11,64746389-64760297,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA056003,Enhanced,,,,,Mixed,Tissue enriched,32,skeletal muscle: 2831.9,esophagus: 89.0,Cell line enhanced,,HSkMC: 2.6
QARS,,ENSG00000172053,Glutaminyl-tRNA synthetase,3,49095932-49105135,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036986, HPA036987",Enhanced,,Enhanced,Cytosol,"Renal cancer:5.60e-6 (favourable), Breast cancer:1.43e-4 (favourable)",Expressed in all,Expressed in all,,,rectum: 117.0,Expressed in all,,
QDPR,"DHPR, PKU2, SDR33C1",ENSG00000151552,Quinoid dihydropteridine reductase,4,17460261-17512234,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA058951, HPA065649",Enhanced,,Approved,Mitochondria,Renal cancer:7.84e-6 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 226.3,Expressed in all,,
QPCT,"GCT, QC",ENSG00000115828,Glutaminyl-peptide cyclotransferase,2,37344574-37373322,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008406,Enhanced,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,adrenal gland: 158.9;epididymis: 121.6,skin: 41.1,Cell line enhanced,,SCLC-21H: 130.6;SK-MEL-30: 299.7;U-266/84: 218.7
QPCTL,FLJ20084,ENSG00000011478,Glutaminyl-peptide cyclotransferase like,19,45692483-45703989,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040797,Approved,,Supported,Golgi apparatus,Renal cancer:2.15e-8 (unfavourable),Expressed in all,Mixed,,,thyroid gland: 8.6,Expressed in all,,
QPRT,QPRTase,ENSG00000103485,Quinolinate phosphoribosyltransferase,16,29679008-29698699,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA011887,Approved,,,,"Breast cancer:5.10e-5 (unfavourable), Glioma:7.45e-4 (unfavourable)",Expressed in all,Expressed in all,,,kidney: 112.3,Cell line enhanced,,EFO-21: 469.3
QRSL1,"DKFZP564C1278, FLJ10989, FLJ12189, FLJ13447, GatA",ENSG00000130348,Glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1,6,106629578-106668417,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA029585, HPA029587",Approved,,Approved,Vesicles<br>Centrosome,"Liver cancer:7.97e-5 (unfavourable), Renal cancer:3.83e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 18.6,Expressed in all,,
QSOX1,QSCN6,ENSG00000116260,Quiescin sulfhydryl oxidase 1,1,180154834-180204030,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA042127, HPA056243",Uncertain,,Supported,Golgi apparatus<br>Vesicles,Renal cancer:1.86e-5 (unfavourable),Expressed in all,Expressed in all,,,gallbladder: 233.0,Expressed in all,,
QSOX2,"DKFZp762A2013, QSCN6L1, SOXN",ENSG00000165661,Quiescin sulfhydryl oxidase 2,9,136206333-136245841,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012716, HPA017280",Uncertain,,Enhanced,Nucleoplasm<br>Golgi apparatus,Renal cancer:9.64e-6 (unfavourable),Expressed in all,Expressed in all,,,lymph node: 20.7,Expressed in all,,
QTRT1,TGT,ENSG00000213339,Queuine tRNA-ribosyltransferase catalytic subunit 1,19,10701430-10713437,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042695, HPA048651, HPA049440",Approved,,Approved,Mitochondria,"Renal cancer:1.13e-6 (unfavourable), Cervical cancer:7.63e-5 (favourable), Pancreatic cancer:2.13e-4 (favourable), Head and neck cancer:4.90e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 25.5,Expressed in all,,
RABGGTA,PTAR3,ENSG00000100949,Rab geranylgeranyltransferase alpha subunit,14,24265538-24271739,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043488,Approved,,Enhanced,Nucleoplasm,"Thyroid cancer:1.51e-4 (favourable), Renal cancer:5.44e-4 (favourable)",Expressed in all,Expressed in all,,,esophagus: 34.0,Expressed in all,,
RABGGTB,,ENSG00000137955,Rab geranylgeranyltransferase beta subunit,1,75786197-75795079,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026585, HPA027167, HPA030793",Approved,Approved,Supported,Vesicles,"Renal cancer:1.12e-5 (unfavourable), Liver cancer:9.80e-5 (unfavourable)",Expressed in all,Expressed in all,,,kidney: 69.4,Expressed in all,,
RAD1,"HRAD1, REC1",ENSG00000113456,RAD1 checkpoint DNA exonuclease,5,34905264-34918989,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006692,Approved,,Supported,Nucleoplasm<br>Vesicles,"Liver cancer:1.06e-5 (unfavourable), Breast cancer:6.30e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 11.9,Expressed in all,,
RAD18,RNF73,ENSG00000070950,"RAD18, E3 ubiquitin protein ligase",3,8775402-8963773,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006716, HPA006724, HPA008752",Supported,Approved,Enhanced,Nucleoplasm<br>Nuclear bodies,"Renal cancer:3.65e-5 (unfavourable), Liver cancer:1.12e-4 (unfavourable), Prostate cancer:3.73e-4 (unfavourable)",Expressed in all,Mixed,,,duodenum: 10.2,Expressed in all,,
RAD54L2,"ARIP4, KIAA0809, SRISNF2L",ENSG00000164080,RAD54-like 2 (S. cerevisiae),3,51541144-51668667,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035004, HPA039992",,,Supported,Nucleus<br>Cytosol,Renal cancer:1.71e-5 (favourable),Expressed in all,Expressed in all,,,testis: 8.8,Expressed in all,,
RAD9A,RAD9,ENSG00000172613,RAD9 checkpoint clamp component A,11,67317871-67398410,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006725, HPA048155",Enhanced,,Enhanced,Nucleoplasm,"Urothelial cancer:7.52e-6 (favourable), Renal cancer:2.82e-5 (unfavourable), Cervical cancer:6.95e-4 (favourable)",Expressed in all,Expressed in all,,,fallopian tube: 15.0,Mixed,,
RAF1,"c-Raf, CRAF, Raf-1",ENSG00000132155,"Raf-1 proto-oncogene, serine/threonine kinase",3,12583601-12664226,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA002640, CAB019291",Approved,,Approved,Nuclear speckles,,Expressed in all,Expressed in all,,,parathyroid gland: 100.7,Expressed in all,,
RAG1,"MGC43321, RNF74",ENSG00000166349,Recombination activating 1,11,36510709-36593156,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA043939,,,Supported,Nucleus,,Mixed,Tissue enhanced,,thyroid gland: 4.2,spleen: 3.6,Group enriched,102,MOLT-4: 227.0;REH: 243.3
RARS,DALRD1,ENSG00000113643,Arginyl-tRNA synthetase,5,168486445-168519299,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA003979, HPA004130",Approved,,Enhanced,Nucleoplasm<br>Cytosol,"Liver cancer:1.10e-8 (unfavourable), Head and neck cancer:7.59e-5 (unfavourable)",Expressed in all,Expressed in all,,,duodenum: 54.4,Expressed in all,,
RARS2,"DALRD2, dJ382I10.6, MGC14993, MGC23778, PRO1992, RARSL",ENSG00000146282,"Arginyl-tRNA synthetase 2, mitochondrial",6,87514378-87590003,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA039987, HPA042645",Uncertain,,Approved,Nuclear bodies<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 56.9,Expressed in all,,
RBBP6,"P2P-R, PACT, SNAMA",ENSG00000122257,"RB binding protein 6, ubiquitin ligase",16,24537693-24572863,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB032866, HPA041725, HPA043544",Approved,,Enhanced,Nuclear speckles,,Expressed in all,Expressed in all,,,bone marrow: 91.5,Expressed in all,,
RBCK1,"C20orf18, HOIL1, RBCK2, RNF54, UBCE7IP3, XAP4, ZRANB4",ENSG00000125826,RANBP2-type and C3HC4-type zinc finger containing 1,20,407498-430966,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,Renal cancer:7.41e-9 (unfavourable),Expressed in all,Expressed in all,,,spleen: 51.2,Expressed in all,,
RBKS,"DKFZp686G13268, RBSK",ENSG00000171174,Ribokinase,2,27781364-27891098,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019725, HPA028285",Enhanced,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,adrenal gland: 34.7,kidney: 19.5,Cell line enhanced,,EFO-21: 10.8;RPTEC TERT1: 18.4
RBP3,"D10S64, D10S65, D10S66, RP66",ENSG00000265203,Retinol binding protein 3,10,47348371-47357875,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA041301, HPA044239",Supported,,,,,Not detected,Not detected,,,duodenum: 0.4,Not detected,,
RC3H2,"FLJ20301, FLJ20713, MNAB, RNF164",ENSG00000056586,Ring finger and CCCH-type domains 2,9,122844556-122905341,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA042863, HPA062144",Approved,,Supported,Vesicles,Renal cancer:5.50e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 25.5,Expressed in all,,
RCE1,"FACE-2, FACE2, hRCE1, RCE1A, RCE1B",ENSG00000173653,Ras converting CAAX endopeptidase 1,11,66842835-66846546,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Expressed in all,Mixed,,,skin: 23.3,Expressed in all,,
RCHY1,"ARNIP, CHIMP, DKFZp586C1620, PIRH2, PRO1996, RNF199, ZCHY, ZNF363",ENSG00000163743,Ring finger and CHY zinc finger domain containing 1,4,75479037-75514764,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA030339,Approved,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:3.62e-5 (favourable), Urothelial cancer:7.89e-5 (favourable), Colorectal cancer:9.09e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 31.7,Expressed in all,,
RDH10,SDR16C4,ENSG00000121039,Retinol dehydrogenase 10,8,73294612-73325281,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA049199,,,Approved,Lipid droplets,,Expressed in all,Expressed in all,,,placenta: 51.8,Expressed in all,,
RDH11,"ARSDR1, MDT1, SDR7C1",ENSG00000072042,Retinol dehydrogenase 11 (all-trans/9-cis/11-cis),14,67676801-67695814,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB046011,Enhanced,,,,"Renal cancer:1.30e-7 (favourable), Head and neck cancer:2.89e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable)",Tissue enriched,Tissue enriched,7,prostate: 941.3,parathyroid gland: 125.7,Expressed in all,,
RDH5,"HSD17B9, RDH1, SDR9C5",ENSG00000135437,Retinol dehydrogenase 5,12,55720367-55724705,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA063345,,,Approved,Vesicles,,Mixed,Tissue enhanced,,adipose tissue: 97.7,liver: 30.0,Cell line enhanced,,ASC diff: 19.5;ASC TERT1: 17.1;hTEC/SVTERT24-B: 15.2;LHCN-M2: 12.8;U-87 MG: 26.2
RECQL,"RecQ1, RecQL1",ENSG00000004700,RecQ like helicase,12,21468911-21501669,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009743, HPA030960, HPA064259",Enhanced,,Enhanced,Nucleoplasm,Ovarian cancer:3.15e-4 (unfavourable),Expressed in all,Expressed in all,,,lymph node: 51.1,Expressed in all,,
RECQL5,"FLJ90603, RecQ5",ENSG00000108469,RecQ like helicase 5,17,75626845-75667189,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA029971,,,Supported,Nucleus<br>Cytosol,"Endometrial cancer:1.73e-6 (unfavourable), Pancreatic cancer:4.34e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 26.9,Expressed in all,,
REN,,ENSG00000143839,Renin,1,204154819-204190324,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA005131, CAB025903",Approved,,,,Renal cancer:6.45e-5 (unfavourable),Tissue enriched,Tissue enhanced,,kidney: 51.2;placenta: 21.0,endometrium: 8.9,Cell line enhanced,,BJ: 1.7;HMC-1: 2.3;SK-BR-3: 1.4
RENBP,"RBP, RNBP",ENSG00000102032,Renin binding protein,X,153935263-153944691,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000428, HPA000522",Enhanced,,,,"Renal cancer:3.08e-5 (favourable), Cervical cancer:3.95e-4 (favourable)",Expressed in all,Tissue enhanced,,spleen: 58.5,kidney: 37.8,Cell line enhanced,,EFO-21: 31.9;HMC-1: 101.6;SK-MEL-30: 61.5;U-266/84: 49.9
RET,"CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51",ENSG00000165731,Ret proto-oncogene,10,43077027-43130351,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002581, HPA008356, HPA008495, CAB018342",Approved,Supported,Supported,Vesicles<br>Plasma membrane<br>Cytosol,Endometrial cancer:5.02e-4 (unfavourable),Tissue enhanced,Tissue enriched,5,parathyroid gland: 154.5,adrenal gland: 29.8,Cell line enriched,5,SH-SY5Y: 404.3
RETSAT,FLJ20296,ENSG00000042445,Retinol saturase,2,85342088-85354620,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007961, HPA046513",Uncertain,,Approved,Nucleoli,"Renal cancer:1.95e-10 (favourable), Liver cancer:4.23e-4 (favourable)",Expressed in all,Expressed in all,,,adipose tissue: 265.4,Expressed in all,,
REV3L,"POLZ, REV3",ENSG00000009413,"REV3 like, DNA directed polymerase zeta catalytic subunit",6,111299028-111483715,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA064853, HPA069382",Uncertain,,Approved,Nucleoplasm,,Expressed in all,Expressed in all,,,"cervix, uterine: 41.2",Expressed in all,,
RFFL,"CARP-2, CARP2, fring, rififylin, RNF189, RNF34L",ENSG00000092871,Ring finger and FYVE like domain containing E3 ubiquitin protein ligase,17,35005990-35089319,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB008096, HPA017910, HPA019492",Approved,,Approved,Vesicles,"Renal cancer:2.43e-5 (unfavourable), Colorectal cancer:4.92e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 54.1,Expressed in all,,
RFK,"FLJ11149, RIFK",ENSG00000135002,Riboflavin kinase,9,76385517-76394517,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA023259, CAB033887, HPA057163",Approved,,Approved,Golgi apparatus,,Expressed in all,Expressed in all,,,cerebral cortex: 37.8,Expressed in all,,
RFNG,,ENSG00000169733,RFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase,17,82047902-82051831,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA011564, HPA031673",Uncertain,,Supported,Nucleus,Pancreatic cancer:4.81e-4 (favourable),Expressed in all,Expressed in all,,,fallopian tube: 19.7,Expressed in all,,
RFWD2,"COP1, FLJ10416, RNF200",ENSG00000143207,Ring finger and WD repeat domain 2,1,175944831-176207493,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Endometrial cancer:3.96e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 42.2,Expressed in all,,
RFWD3,"FLJ10520, RNF201",ENSG00000168411,Ring finger and WD repeat domain 3,16,74621394-74666881,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA048258, HPA075649",,,Enhanced,Nucleoplasm<br>Cytosol,,Expressed in all,Mixed,,,testis: 46.9,Expressed in all,,
RGN,"RC, SMP30",ENSG00000130988,Regucalcin,X,47078355-47093314,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA029102, HPA029103",Enhanced,,Approved,Nucleus,"Renal cancer:5.10e-10 (favourable), Liver cancer:7.55e-4 (favourable)",Tissue enriched,Tissue enhanced,,adrenal gland: 202.7;liver: 196.4,kidney: 57.0,Group enriched,6,CACO-2: 17.9;fHDF/TERT166: 5.3;Hep G2: 22.3
RHBDD1,DKFZp547E052,ENSG00000144468,Rhomboid domain containing 1,2,226835581-226999215,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA013972, HPA057125",Approved,,Supported,Endoplasmic reticulum,,Expressed in all,Expressed in all,,,testis: 32.2,Mixed,,
RHBDD2,"NPD007, RHBDL7",ENSG00000005486,Rhomboid domain containing 2,7,75842602-75888926,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA045074, HPA051960",Uncertain,,Enhanced,Golgi apparatus,"Renal cancer:8.68e-6 (favourable), Colorectal cancer:3.31e-5 (unfavourable), Glioma:1.25e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 258.6,Expressed in all,,
RHBDF1,"C16orf8, Dist1, EGFR-RS, FLJ2235, iRhom1",ENSG00000007384,Rhomboid 5 homolog 1,16,58059-76355,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA077399,,,Uncertain,Vesicles,Renal cancer:2.49e-5 (unfavourable),Expressed in all,Mixed,,,placenta: 39.8,Mixed,,
RHBDF2,"FLJ22341, iRhom2, RHBDL5, RHBDL6, TOC, TOCG",ENSG00000129667,Rhomboid 5 homolog 2,17,76470891-76501790,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA018080,Uncertain,,,,Renal cancer:3.96e-11 (unfavourable),Expressed in all,Expressed in all,,,appendix: 49.4,Mixed,,
RHBDL1,"RHBDL, RRP",ENSG00000103269,Rhomboid like 1,16,675666-678268,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA030359, HPA030360, HPA046593",Uncertain,,Approved,Nucleoplasm,Breast cancer:8.12e-4 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 8.0,adrenal gland: 3.3,Mixed,,
RHBDL2,FLJ20435,ENSG00000158315,Rhomboid like 2,1,38885807-38941799,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA043807,Approved,,,,,Mixed,Mixed,,,skin: 22.1,Cell line enhanced,,CAPAN-2: 40.9;HaCaT: 21.4;RT4: 37.8
RHBDL3,"RHBDL4, VRHO",ENSG00000141314,Rhomboid like 3,17,32266176-32324661,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA059607,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 20.7,adrenal gland: 5.5,Cell line enhanced,,A549: 4.0;AF22: 4.3;HDLM-2: 5.7;NTERA-2: 6.4;U-2 OS: 4.6
RIMKLA,"FAM80A, MGC47816, NAAGS-II, RP11-157D18.1",ENSG00000177181,Ribosomal modification protein rimK like family member A,1,42380795-42422578,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027826,Uncertain,,Uncertain,Nucleoli fibrillar center,Lung cancer:1.43e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 10.2,"parathyroid gland,rectum: 3.8",Cell line enhanced,,AN3-CA: 6.7;SCLC-21H: 12.8
RIMKLB,"FAM80B, KIAA1238, NAAGS, NAAGS-I",ENSG00000166532,Ribosomal modification protein rimK like family member B,12,8681600-8783095,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA059552,,,Approved,Nucleoplasm<br>Microtubule organizing center,,Mixed,Expressed in all,,,endometrium: 74.7,Cell line enhanced,,U-698: 113.0
RING1,RNF1,ENSG00000204227,Ring finger protein 1,6,33208495-33212722,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA008701,Supported,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Mixed,,,endometrium: 8.2,Mixed,,
RIOK1,"AD034, bA288G3.1, FLJ30006, RRP10",ENSG00000124784,RIO kinase 1,6,7389496-7418037,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA017866, HPA051446",Enhanced,,Approved,Nucleoli<br>Nuclear speckles<br>Cytosol,"Liver cancer:3.41e-5 (unfavourable), Renal cancer:5.85e-5 (unfavourable), Melanoma:4.43e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 29.6,Expressed in all,,
RIOK2,FLJ11159,ENSG00000058729,RIO kinase 2,5,97160867-97183260,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA005681,Uncertain,,Approved,Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 22.1,Expressed in all,,
RIOK3,SUDD,ENSG00000101782,RIO kinase 3,18,23452823-23486603,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA001620, HPA024184",Approved,,Approved,Golgi apparatus<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol,"Pancreatic cancer:4.10e-4 (unfavourable), Prostate cancer:5.80e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 74.9,Expressed in all,,
RIOX1,"C14orf169, FLJ21802, JMJD9, MAPJD, NO66",ENSG00000170468,Ribosomal oxygenase 1,14,73490964-73493392,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003730,,,Supported,Nucleoli,,Expressed in all,Expressed in all,,,testis: 17.7,Mixed,,
RIPK1,RIP,ENSG00000137275,Receptor interacting serine/threonine kinase 1,6,3063991-3115187,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB010302, HPA015257",Enhanced,,Enhanced,Plasma membrane<br>Cytosol,Urothelial cancer:6.71e-4 (favourable),Expressed in all,Expressed in all,,,skin: 26.1,Expressed in all,,
RIPK2,"CARD3, CARDIAK, RICK, RIP2",ENSG00000104312,Receptor interacting serine/threonine kinase 2,8,89757747-89791063,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA015273, HPA016499",Approved,,Enhanced,Cytosol,"Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:5.00e-6 (unfavourable), Lung cancer:6.33e-5 (unfavourable), Urothelial cancer:8.05e-4 (favourable)",Expressed in all,Mixed,,,gallbladder: 13.9,Mixed,,
RIPK3,RIP3,ENSG00000129465,Receptor interacting serine/threonine kinase 3,14,24336021-24340045,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA055087,Uncertain,,,,,Mixed,Mixed,,,small intestine: 25.1,Cell line enhanced,,CAPAN-2: 11.3;HDLM-2: 6.9;SK-BR-3: 15.6
RIPK4,"ANKK2, ANKRD3, DIK, PKK, RIP4",ENSG00000183421,Receptor interacting serine/threonine kinase 4,21,41739369-41767106,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA030942,Enhanced,,,,"Ovarian cancer:6.22e-5 (unfavourable), Pancreatic cancer:3.48e-4 (unfavourable), Renal cancer:6.52e-4 (favourable)",Mixed,Tissue enhanced,,esophagus: 31.5,small intestine: 15.0,Cell line enhanced,,CAPAN-2: 27.8;HaCaT: 41.4
RLIM,"MGC15161, NY-REN-43, RNF12",ENSG00000131263,"Ring finger protein, LIM domain interacting",X,74585217-74614617,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA018895,Approved,,Supported,Nucleoplasm<br>Cytosol,Thyroid cancer:6.04e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 29.0,Expressed in all,,
RNASE1,"RAC1, RNS1",ENSG00000129538,"Ribonuclease A family member 1, pancreatic",14,20801228-20803278,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA001140,Supported,,Approved,Nucleoplasm<br>Vesicles,,Expressed in all,Expressed in all,,,pancreas: 1946.8,Group enriched,6,HUVEC TERT2: 239.6;RT4: 91.0;TIME: 122.8
RNASE2,"EDN, RAF3, RNS2",ENSG00000169385,Ribonuclease A family member 2,14,20955452-20956436,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA044983,Enhanced,,,,Renal cancer:3.28e-13 (unfavourable),Tissue enriched,Tissue enriched,73,bone marrow: 995.8,smooth muscle: 13.6,Group enriched,286,HL-60: 411.9;NB-4: 325.9;THP-1: 920.7;U-937: 968.9
RNASEH1,,ENSG00000171865,Ribonuclease H1,2,3544793-3558616,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA043037,Uncertain,,,,Liver cancer:7.83e-6 (unfavourable),Expressed in all,Expressed in all,,,smooth muscle: 10.9,Expressed in all,,
RNASEH2A,"AGS4, RNASEHI, RNHIA, RNHL",ENSG00000104889,Ribonuclease H2 subunit A,19,12802063-12813638,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA042692,,,Enhanced,Nucleus<br>Cytosol,"Renal cancer:6.29e-6 (unfavourable), Liver cancer:8.72e-5 (unfavourable), Cervical cancer:1.18e-4 (favourable), Ovarian cancer:1.22e-4 (favourable), Colorectal cancer:6.18e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 26.5,Expressed in all,,
RNASEL,"PRCA1, RNS4",ENSG00000135828,Ribonuclease L,1,182573634-182589256,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA002633, CAB010906",Approved,,Supported,Cytosol,,Expressed in all,Mixed,,,parathyroid gland: 17.6,Mixed,,
RNF103,"hkf-1, KF1, ZFP103",ENSG00000239305,Ring finger protein 103,2,86603393-86623866,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA057922,Approved,,,,Urothelial cancer:6.77e-5 (favourable),Expressed in all,Expressed in all,,,epididymis: 55.3,Expressed in all,,
RNF111,"ARK, Arkadia, DKFZP761D081, FLJ38008",ENSG00000157450,Ring finger protein 111,15,58865175-59097419,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038576, HPA038577",Enhanced,,Supported,Nucleus<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 22.9,Expressed in all,,
RNF114,"PSORS12, ZNF313",ENSG00000124226,Ring finger protein 114,20,49936336-49953892,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021184,Approved,,Supported,Plasma membrane<br>Cytosol,"Endometrial cancer:8.10e-6 (unfavourable), Thyroid cancer:3.01e-4 (favourable), Liver cancer:3.11e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 149.2,Expressed in all,,
RNF115,"CL469780, ZNF364",ENSG00000265491,Ring finger protein 115,1,145738868-145824077,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA019130,Approved,,Approved,Nucleoli<br>Mitochondria,Liver cancer:2.95e-4 (unfavourable),Expressed in all,Mixed,,,heart muscle: 16.4,Expressed in all,,
RNF123,"FLJ12565, KPC1",ENSG00000164068,Ring finger protein 123,3,49689499-49721529,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA065983, HPA071879",Approved,,Approved,Cytosol,Renal cancer:1.33e-8 (favourable),Expressed in all,Expressed in all,,,skeletal muscle: 53.1,Expressed in all,,
RNF125,FLJ20456,ENSG00000101695,Ring finger protein 125,18,32018372-32073213,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA041514,Uncertain,,Uncertain,Nucleoli<br>Golgi apparatus<br>Cytosol,Renal cancer:4.06e-4 (unfavourable),Expressed in all,Mixed,,,small intestine: 11.5,Cell line enhanced,,HMC-1: 42.3
RNF126,FLJ20552,ENSG00000070423,Ring finger protein 126,19,647526-663277,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043050,Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 38.2,Expressed in all,,
RNF128,"FLJ23516, GRAIL",ENSG00000133135,"Ring finger protein 128, E3 ubiquitin protein ligase",X,106693794-106796993,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA019675,Uncertain,,,,Renal cancer:1.07e-7 (unfavourable),Mixed,Mixed,,,small intestine: 66.9,Cell line enhanced,,BEWO: 40.1;CAPAN-2: 30.6;RT4: 70.6;WM-115: 52.6
RNF13,RZF,ENSG00000082996,Ring finger protein 13,3,149812708-149962139,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA064784,Approved,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:2.00e-8 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 94.4,Expressed in all,,
RNF130,"G1RZFP, GOLIATH, GP",ENSG00000113269,Ring finger protein 130,5,179911651-180072118,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA014499,Approved,,,,Cervical cancer:6.32e-4 (favourable),Expressed in all,Expressed in all,,,adipose tissue: 74.8,Mixed,,
RNF133,,ENSG00000188050,Ring finger protein 133,7,122697712-122699156,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enriched,182,testis: 60.9,lung: 0.3,Not detected,,
RNF135,MGC13061,ENSG00000181481,Ring finger protein 135,17,30968785-30999911,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021576, HPA052404",Approved,,Approved,Vesicles,Renal cancer:7.51e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 28.7,Mixed,,
RNF138,"NARF, STRIN",ENSG00000134758,Ring finger protein 138,18,32091855-32131561,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041101,,,Approved,Mitochondria,,Expressed in all,Expressed in all,,,testis: 167.7,Expressed in all,,
RNF139,"HRCA1, RCA1, TRC8",ENSG00000170881,Ring finger protein 139,8,124474738-124487914,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA001202,Approved,,,,Pancreatic cancer:3.54e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 114.8,Expressed in all,,
RNF146,"dactylidin, dJ351K20.1, DKFZp434O1427",ENSG00000118518,Ring finger protein 146,6,127266610-127288567,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA027158, HPA027209",Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:5.26e-5 (favourable), Renal cancer:7.32e-4 (favourable)",Expressed in all,Expressed in all,,,endometrium: 94.6,Expressed in all,,
RNF149,FLJ90504,ENSG00000163162,Ring finger protein 149,2,101271219-101308701,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA011424,Approved,,Approved,Vesicles<br>Plasma membrane,"Renal cancer:2.04e-8 (unfavourable), Urothelial cancer:2.91e-4 (favourable)",Expressed in all,Expressed in all,,,appendix: 67.8,Mixed,,
RNF152,FLJ39176,ENSG00000176641,Ring finger protein 152,18,61808063-61894247,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,"Renal cancer:1.13e-8 (favourable), Stomach cancer:2.85e-5 (unfavourable)",Expressed in all,Tissue enriched,5,kidney: 56.6,liver: 10.3,Cell line enhanced,,HaCaT: 18.4;SH-SY5Y: 13.4;U-138 MG: 20.3
RNF165,"ARKL2, RNF111L2",ENSG00000141622,Ring finger protein 165,18,46326809-46463140,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041615, HPA047798",Uncertain,,Approved,Nucleus<br>Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 9.3;parathyroid gland: 9.8,thyroid gland: 7.0,Cell line enhanced,,AF22: 13.9;SCLC-21H: 17.1;SH-SY5Y: 17.5
RNF167,DKFZP566H073,ENSG00000108523,Ring finger protein 167,17,4940008-4945222,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA049810,Approved,,Approved,Cytosol,"Pancreatic cancer:2.03e-6 (favourable), Renal cancer:4.47e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 116.9,Expressed in all,,
RNF168,FLJ35794,ENSG00000163961,Ring finger protein 168,3,196468783-196503768,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA046109,,,Enhanced,Nucleoplasm<br>Nuclear bodies,"Liver cancer:2.29e-4 (unfavourable), Cervical cancer:8.21e-4 (favourable), Pancreatic cancer:8.31e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 20.0,Expressed in all,,
RNF169,KIAA1991,ENSG00000166439,Ring finger protein 169,11,74748868-74842413,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA046138, HPA058368",Uncertain,,Supported,Nuclear speckles,Pancreatic cancer:8.04e-4 (unfavourable),Expressed in all,Mixed,,,parathyroid gland: 14.8,Expressed in all,,
RNF170,"ADSA, DKFZP564A022, SNAX1",ENSG00000120925,Ring finger protein 170,8,42849637-42897290,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA050931, HPA054621",Uncertain,,,,,Expressed in all,Expressed in all,,,thyroid gland: 47.9,Expressed in all,,
RNF180,,ENSG00000164197,Ring finger protein 180,5,64165844-64372869,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006897,Approved,,Approved,Cytosol,Renal cancer:6.81e-5 (favourable),Tissue enhanced,Tissue enhanced,,parathyroid gland: 62.4,thyroid gland: 24.8,Cell line enriched,5,RPMI-8226: 20.6
RNF181,HSPC238,ENSG00000168894,Ring finger protein 181,2,85595725-85597613,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA046112, HPA062121",Approved,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:1.06e-6 (unfavourable), Thyroid cancer:4.59e-5 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 171.6,Expressed in all,,
RNF182,MGC33993,ENSG00000180537,Ring finger protein 182,6,13924446-13980302,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012309,Approved,,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,Endometrial cancer:4.66e-5 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 14.6,testis: 6.9,Cell line enhanced,,HeLa: 57.3;RPTEC TERT1: 51.0
RNF183,MGC4734,ENSG00000165188,Ring finger protein 183,9,113297093-113303376,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA057675,Uncertain,,,,"Endometrial cancer:7.95e-6 (favourable), Renal cancer:3.51e-4 (favourable)",Tissue enhanced,Tissue enhanced,,epididymis: 20.0;gallbladder: 9.0,kidney: 4.3,Cell line enriched,10,SCLC-21H: 22.2
RNF185,FLJ38628,ENSG00000138942,Ring finger protein 185,22,31160183-31207019,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:4.82e-5 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 86.7,Expressed in all,,
RNF187,,ENSG00000168159,Ring finger protein 187,1,228487061-228495766,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA030098,Approved,,Supported,Nucleoplasm<br>Cytosol,Colorectal cancer:2.83e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 143.2,Expressed in all,,
RNF2,"BAP-1, BAP1, DING, HIPI3, RING1B, RING2",ENSG00000121481,Ring finger protein 2,1,185045364-185102608,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026803,Uncertain,,Enhanced,Nucleoplasm<br>Nuclear bodies,"Renal cancer:1.94e-7 (unfavourable), Liver cancer:1.08e-5 (unfavourable)",Expressed in all,Expressed in all,,,testis: 42.2,Expressed in all,,
RNF20,"BRE1, BRE1A, FLJ11189, FLJ20382, hBRE1, KAIA2779",ENSG00000155827,Ring finger protein 20,9,101533851-101563344,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB012478, HPA051773",Supported,,Enhanced,Nucleoplasm,Renal cancer:1.64e-6 (favourable),Expressed in all,Expressed in all,,,testis: 59.3,Expressed in all,,
RNF213,"C17orf27, KIAA1554, KIAA1618, MYMY2, NET57",ENSG00000173821,Ring finger protein 213,17,80260866-80398786,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA003347, HPA026790",Approved,,Supported,Cytosol,Endometrial cancer:4.65e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 65.3,Expressed in all,,
RNF216,"TRIAD3, UBCE7IP1, ZIN",ENSG00000011275,Ring finger protein 216,7,5620047-5781739,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA018955, HPA021123",Supported,,Supported,Nucleoplasm<br>Cytosol,"Pancreatic cancer:6.24e-5 (favourable), Liver cancer:2.26e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 50.0,Expressed in all,,
RNF220,"C1orf164, FLJ10597",ENSG00000187147,Ring finger protein 220,1,44405194-44651724,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA027577, HPA027578",Uncertain,,Approved,Nucleus,"Liver cancer:2.35e-6 (unfavourable), Renal cancer:5.12e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 47.8,Expressed in all,,
RNF25,"AO7, FLJ13906",ENSG00000163481,Ring finger protein 25,2,218663864-218672411,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036420, HPA036421",Uncertain,,Approved,Nucleoplasm<br>Cytosol,Liver cancer:6.58e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 14.6,Expressed in all,,
RNF31,"FLJ10111, FLJ23501, HOIP, ZIBRA",ENSG00000092098,Ring finger protein 31,14,24146683-24160661,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009063, HPA048745",Approved,,Approved,Cytosol,,Expressed in all,Expressed in all,,,skin: 44.4,Expressed in all,,
RNF34,"FLJ21786, RIF, RIFF",ENSG00000170633,Ring finger protein 34,12,121400041-121430623,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA074151,,,Supported,Nucleoplasm<br>Nuclear bodies,"Liver cancer:6.72e-8 (unfavourable), Urothelial cancer:3.02e-4 (favourable), Renal cancer:4.63e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 45.8,Expressed in all,,
RNF38,,ENSG00000137075,Ring finger protein 38,9,36336396-36487548,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA015853,Approved,,Supported,Nucleoplasm,Renal cancer:2.90e-6 (favourable),Expressed in all,Expressed in all,,,testis: 116.8,Expressed in all,,
RNF4,"RES4-26, SLX5, SNURF",ENSG00000063978,Ring finger protein 4,4,2462220-2625320,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA049356,Approved,,,,Lung cancer:6.38e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 57.0,Expressed in all,,
RNF40,"BRE1B, KIAA0661, RBP95, STARING",ENSG00000103549,Ring finger protein 40,16,30761745-30776307,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041330, HPA054227",Approved,,Enhanced,Nucleoplasm,Renal cancer:8.11e-8 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 78.9,Expressed in all,,
RNF41,"NRDP1, SBBI03",ENSG00000181852,Ring finger protein 41,12,56202175-56221933,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA016812,Approved,,Approved,Nucleus<br>Nuclear bodies<br>Midbody ring,"Renal cancer:2.52e-5 (favourable), Liver cancer:6.49e-4 (unfavourable)",Expressed in all,Expressed in all,,,prostate: 55.3,Expressed in all,,
RNF43,"DKFZp781H0392, FLJ20315, URCC",ENSG00000108375,Ring finger protein 43,17,58352500-58417595,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA008079,Uncertain,,,,Renal cancer:6.04e-9 (favourable),Tissue enhanced,Mixed,,,duodenum: 23.4,Cell line enhanced,,CACO-2: 20.6;Hep G2: 33.5
RNF5,"G16, NG2, RING5, RMA1",ENSG00000204308,Ring finger protein 5,6,32178354-32180793,"Enzymes, Predicted membrane proteins",Evidence at protein level,"CAB034107, HPA065032",Uncertain,,Supported,Endoplasmic reticulum,Ovarian cancer:2.44e-4 (favourable),Expressed in all,Mixed,,,kidney: 18.6,Mixed,,
RNF6,DKFZp686P0776,ENSG00000127870,Ring finger protein 6,13,26132115-26222493,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA039343, HPA040048",Approved,,Supported,Nuclear membrane,Cervical cancer:3.07e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 61.0,Mixed,,
RNF8,KIAA0646,ENSG00000112130,Ring finger protein 8,6,37353972-37394738,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA050731, HPA064925",Approved,,Supported,Nucleus<br>Cytosol,"Liver cancer:3.33e-5 (unfavourable), Prostate cancer:4.99e-5 (unfavourable), Melanoma:1.91e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 18.5,Expressed in all,,
RNGTT,"hCAP, HCE, HCE1",ENSG00000111880,RNA guanylyltransferase and 5'-phosphatase,6,88610272-88963721,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003750,Approved,,Approved,Nucleoplasm,Liver cancer:1.37e-4 (unfavourable),Expressed in all,Mixed,,,lymph node: 21.1,Expressed in all,,
RNLS,"C10orf59, FLJ11218, renalase",ENSG00000184719,"Renalase, FAD dependent amine oxidase",10,88273864-88584530,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Expressed in all,,,kidney: 26.5,Mixed,,
RNMT,RG7MT1,ENSG00000101654,RNA guanine-7 methyltransferase,18,13726660-13764558,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039409,Approved,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,testis: 31.0,Expressed in all,,
RNPEP,,ENSG00000176393,Arginyl aminopeptidase,1,201982372-202006147,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA036074, HPA036075, HPA061487",Approved,,Supported,Nucleoplasm<br>Golgi apparatus,,Expressed in all,Expressed in all,,,duodenum: 66.5,Expressed in all,,
RNPEPL1,,ENSG00000142327,Arginyl aminopeptidase like 1,2,240565804-240581372,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036772,Uncertain,,Approved,Nucleus<br>Nucleoli,"Liver cancer:5.06e-4 (unfavourable), Head and neck cancer:7.43e-4 (favourable)",Expressed in all,Expressed in all,,,skin: 29.2,Mixed,,
ROCK1,p160ROCK,ENSG00000067900,Rho associated coiled-coil containing protein kinase 1,18,20946906-21111851,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004562, HPA007567, HPA045639",Approved,,,,Pancreatic cancer:9.93e-4 (unfavourable),Expressed in all,Mixed,,,bone marrow: 12.3,Expressed in all,,
ROCK2,,ENSG00000134318,Rho associated coiled-coil containing protein kinase 2,2,11179761-11348330,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA007459, CAB008666, HPA044109",Approved,,Supported,Cytosol,Renal cancer:1.57e-5 (unfavourable),Expressed in all,Expressed in all,,,adipose tissue: 41.0,Expressed in all,,
ROR1,NTRKR1,ENSG00000185483,Receptor tyrosine kinase like orphan receptor 1,1,63774022-64181498,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA057016,,,Uncertain,Microtubules<br>Cytokinetic bridge,,Mixed,Tissue enhanced,,parathyroid gland: 52.0,endometrium: 12.1,Cell line enhanced,,ASC TERT1: 35.2;NTERA-2: 43.3
ROR2,"BDB, BDB1, NTRKR2",ENSG00000169071,Receptor tyrosine kinase like orphan receptor 2,9,91563091-91950162,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA021868,Uncertain,,,,"Thyroid cancer:4.28e-8 (unfavourable), Renal cancer:9.86e-7 (unfavourable)",Mixed,Tissue enhanced,,parathyroid gland: 35.1,endometrium: 21.4,Cell line enhanced,,AF22: 25.3;HHSteC: 55.3;HSkMC: 39.9;U-266/70: 29.6
ROS1,"c-ros-1, MCF3, ROS",ENSG00000047936,"ROS proto-oncogene 1, receptor tyrosine kinase",6,117288300-117425855,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA049098, HPA072424",Uncertain,,Approved,Vesicles,,Tissue enriched,Group enriched,18,epididymis: 70.9;lung: 47.2,seminal vesicle: 3.2,Cell line enhanced,,HSkMC: 7.5;hTCEpi: 15.7;LHCN-M2: 12.7
RP1-5O6.7,,ENSG00000283900,Casein kinase I isoform epsilon ,22,38291918-38398522,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026288,Uncertain,,,,,,Tissue enhanced,,parathyroid gland: 6.5,cerebral cortex: 2.6,Cell line enhanced,,Karpas-707: 5.1
RPAP2,"C1orf82, FLJ13150, Rtr1",ENSG00000122484,RNA polymerase II associated protein 2,1,92298965-92402056,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA046443,Approved,,Supported,Nucleoli<br>Cytosol,,Expressed in all,Mixed,,,thyroid gland: 4.8,Expressed in all,,
RPE,,ENSG00000197713,Ribulose-5-phosphate-3-epimerase,2,210002565-210022259,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036498, HPA036499",Approved,,,,"Liver cancer:1.42e-6 (unfavourable), Pancreatic cancer:7.00e-6 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 49.6,Expressed in all,,
RPE65,"BCO3, LCA2, rd12, RP20",ENSG00000116745,"RPE65, retinoid isomerohydrolase",1,68428822-68449959,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 2.7;prostate: 3.0;seminal vesicle: 6.2,endometrium: 1.0,Group enriched,27,A-431: 3.0;PC-3: 5.3;U-2 OS: 1.4
RPEL1,,ENSG00000235376,Ribulose-5-phosphate-3-epimerase like 1,10,103245887-103248016,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,"HPA036498, HPA036499",Approved,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
RPIA,,ENSG00000153574,Ribose 5-phosphate isomerase A,2,88691644-88750935,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA042620,Approved,,,,"Renal cancer:8.53e-6 (unfavourable), Liver cancer:1.46e-5 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 54.2,Expressed in all,,
RPP14,P14,ENSG00000163684,Ribonuclease P/MRP subunit p14,3,58306247-58324695,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036194,Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:3.07e-10 (favourable), Thyroid cancer:2.96e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 21.1,Expressed in all,,
RPP21,"C6orf135, Em:AB014085.3, FLJ22638",ENSG00000241370,Ribonuclease P/MRP subunit p21,6,30345131-30346884,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:1.04e-5 (unfavourable), Urothelial cancer:6.78e-5 (favourable)",Expressed in all,Mixed,,,skin: 16.1,Cell line enhanced,,HEK 293: 51.3;SCLC-21H: 53.7
RPP25,FLJ20374,ENSG00000178718,Ribonuclease P and MRP subunit p25,15,74954416-74957464,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046900,Approved,,Supported,Nucleoplasm<br>Microtubule organizing center,Glioma:3.67e-5 (unfavourable),Expressed in all,Mixed,,,ovary: 12.2,Cell line enhanced,,SCLC-21H: 38.4;SK-MEL-30: 39.1
RPP30,TSG15,ENSG00000148688,Ribonuclease P/MRP subunit p30,10,90871716-90908553,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA037578,Enhanced,,Approved,Nucleus<br>Nucleoli<br>Microtubule ends<br>Cytosol,Renal cancer:1.01e-6 (unfavourable),Expressed in all,Expressed in all,,,testis: 50.5,Expressed in all,,
RPP38,,ENSG00000152464,Ribonuclease P/MRP subunit p38,10,15097180-15139818,"Enzymes, Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,"HPA045128, HPA050398",Approved,,Supported,Nucleoli,"Urothelial cancer:2.89e-6 (favourable), Liver cancer:1.46e-4 (unfavourable), Renal cancer:6.25e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 76.3,Expressed in all,,
RPP40,"bA428J1.3, RNASEP1",ENSG00000124787,Ribonuclease P/MRP subunit p40,6,4994732-5004063,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035685, HPA035686",Uncertain,,Approved,Nucleoplasm,"Renal cancer:7.54e-8 (unfavourable), Endometrial cancer:6.10e-6 (unfavourable), Liver cancer:5.41e-4 (unfavourable)",Expressed in all,Mixed,,,adrenal gland: 11.9,Expressed in all,,
RPS3,"FLJ26283, FLJ27450, MGC87870, S3",ENSG00000149273,Ribosomal protein S3,11,75399486-75422280,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,HPA063339,Uncertain,,Enhanced,Endoplasmic reticulum<br>Cytosol,Renal cancer:6.92e-6 (unfavourable),Expressed in all,Expressed in all,,,ovary: 3537.9,Expressed in all,,
RPS6KA1,"HU-1, p90Rsk, RSK, RSK1",ENSG00000117676,Ribosomal protein S6 kinase A1,1,26529761-26575030,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB003852, HPA007981",Enhanced,,Supported,Nucleus<br>Cytosol,"Endometrial cancer:7.20e-7 (favourable), Renal cancer:1.84e-4 (favourable), Stomach cancer:4.58e-4 (favourable), Urothelial cancer:8.33e-4 (favourable)",Expressed in all,Mixed,,,small intestine: 38.9,Mixed,,
RPS6KA2,"HU-2, RSK, RSK3",ENSG00000071242,Ribosomal protein S6 kinase A2,6,166409364-166906451,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB026243, HPA045061, HPA054237, CAB069428",Approved,,Supported,Nucleoplasm,"Renal cancer:2.86e-5 (favourable), Ovarian cancer:8.63e-5 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 74.4,Cell line enhanced,,ASC diff: 147.2;HHSteC: 133.3;hTERT-HME1: 133.1
RPS6KA3,"CLS, HU-3, MRX19, RSK, RSK2",ENSG00000177189,Ribosomal protein S6 kinase A3,X,20149911-20267100,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA003221, CAB003853, CAB013520",Approved,,Approved,Nucleus<br>Nucleoli<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 92.7,Mixed,,
RPS6KA4,"MSK2, RSK-B",ENSG00000162302,Ribosomal protein S6 kinase A4,11,64359148-64372215,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB008649, HPA023225",Approved,,Supported,Nucleus<br>Cytosol,"Liver cancer:8.17e-4 (unfavourable), Lung cancer:9.27e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 23.1,Expressed in all,,
RPS6KA5,"MSK1, RLPK",ENSG00000100784,Ribosomal protein S6 kinase A5,14,90847862-91060636,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA001274, HPA001780, CAB025458",Approved,,Enhanced,Nucleoplasm,,Mixed,Mixed,,,breast: 12.1,Cell line enhanced,,HMC-1: 40.2
RPS6KA6,RSK4,ENSG00000072133,Ribosomal protein S6 kinase A6,X,84058346-84187907,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA002852, HPA003904",Uncertain,,Supported,Nucleus<br>Nucleoli<br>Mitochondria,,Mixed,Tissue enhanced,,parathyroid gland: 18.9;thyroid gland: 21.9,kidney: 8.9,Cell line enhanced,,PC-3: 13.7;RH-30: 17.3;SH-SY5Y: 15.2
RPS6KB1,"p70(S6K)-alpha, PS6K, S6K1, STK14A",ENSG00000108443,Ribosomal protein S6 kinase B1,17,59893046-59950564,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB003838, CAB018346, HPA039442",Approved,,Supported,Nucleoplasm,Renal cancer:5.09e-7 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 28.3,Expressed in all,,
RPS6KB2,"KLS, P70-BETA, p70S6Kb, STK14B",ENSG00000175634,Ribosomal protein S6 kinase B2,11,67428460-67435408,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA010010, CAB019404",Approved,,Supported,Cytosol,Renal cancer:2.03e-7 (unfavourable),Expressed in all,Expressed in all,,,skin: 65.3,Expressed in all,,
RPS6KC1,humS6PKh1,ENSG00000136643,Ribosomal protein S6 kinase C1,1,213051233-213274773,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026531, HPA031565",Approved,,Enhanced,Endosomes<br>Lysosomes<br>Cytosol,Renal cancer:2.70e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 35.4,Expressed in all,,
RPS6KL1,MGC11287,ENSG00000198208,Ribosomal protein S6 kinase like 1,14,74903954-74923396,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,"HPA027451, HPA027794",Approved,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,cerebral cortex: 31.4,testis: 14.7,Cell line enhanced,,SCLC-21H: 41.7
RRM1,,ENSG00000167325,Ribonucleotide reductase catalytic subunit M1,11,4094707-4138876,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB022093, HPA057265, HPA064297",Enhanced,,Enhanced,Cytosol,Liver cancer:1.53e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 60.4,Expressed in all,,
RRM2,,ENSG00000171848,Ribonucleotide reductase regulatory subunit M2,2,10122328-10131419,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA056994,Enhanced,,Supported,Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Pancreatic cancer:1.62e-4 (unfavourable)",Expressed in all,Mixed,,,bone marrow: 47.5,Mixed,,
RRM2B,p53R2,ENSG00000048392,Ribonucleotide reductase regulatory TP53 inducible subunit M2B,8,102204502-102239118,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB006854, HPA028812",Approved,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 75.1,Expressed in all,,
RTCA,"RPC, RTC1, RTCD1",ENSG00000137996,RNA 3'-terminal phosphate cyclase,1,100266207-100292769,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027982, HPA027990, HPA028151",Uncertain,,Enhanced,Nucleus,Liver cancer:2.76e-5 (unfavourable),Expressed in all,Expressed in all,,,kidney: 35.8,Expressed in all,,
RTCB,"C22orf28, FAAP, HSPC117",ENSG00000100220,"RNA 2',3'-cyclic phosphate and 5'-OH ligase",22,32387582-32412255,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000535, HPA001103",Enhanced,,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:4.25e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 104.2,Expressed in all,,
RTEL1,"bK3184A7.3, C20orf41, DKFZP434C013, KIAA1088, NHL, RTEL",ENSG00000258366,Regulator of telomere elongation helicase 1,20,63657810-63696253,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020622, HPA067329, HPA078328",,,Approved,Nuclear speckles<br>Nuclear bodies,,Not detected,Expressed in all,,,testis: 13.2,Expressed in all,,
RUVBL1,"ECP54, INO80H, NMP238, Pontin52, RVB1, TIH1, TIP49, TIP49a",ENSG00000175792,RuvB like AAA ATPase 1,3,128064778-128153914,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019947, HPA019948",Enhanced,,Supported,Nucleoplasm<br>Cytosol,Liver cancer:1.21e-8 (unfavourable),Expressed in all,Expressed in all,,,fallopian tube: 81.6,Expressed in all,,
RUVBL2,"ECP51, INO80J, Reptin52, RVB2, TIH2, TIP48, TIP49b",ENSG00000183207,RuvB like AAA ATPase 2,19,48993448-49015995,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012432, HPA042880, HPA067966",Enhanced,,Supported,Nucleoplasm<br>Centrosome<br>Cytosol,Liver cancer:9.28e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 72.4,Expressed in all,,
SARDH,"DMGDHL1, SDH",ENSG00000123453,Sarcosine dehydrogenase,9,133663560-133739955,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA057267, HPA058086",Approved,,Approved,Mitochondria,Glioma:3.50e-4 (unfavourable),Tissue enriched,Tissue enhanced,,epididymis: 59.3;liver: 43.0,kidney: 12.5,Group enriched,5,AN3-CA: 16.3;Hep G2: 20.7;LHCN-M2: 9.2;MOLT-4: 18.0;RH-30: 17.5;RPMI-8226: 26.5;SH-SY5Y: 15.4
SARS,SERS,ENSG00000031698,Seryl-tRNA synthetase,1,109213918-109238169,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA016939, HPA064668",Uncertain,,Enhanced,Cytosol,"Liver cancer:6.13e-5 (unfavourable), Head and neck cancer:5.75e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 240.7,Expressed in all,,
SARS2,"FLJ20450, mtSerRS, SARS, SARSM, SerRSmt, SERS, SYS",ENSG00000104835,"Seryl-tRNA synthetase 2, mitochondrial",19,38915266-38930896,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA052730, HPA056957",Approved,,,,,Expressed in all,Expressed in all,,,thyroid gland: 8.9,Expressed in all,,
SAT1,"SAT, SSAT",ENSG00000130066,Spermidine/spermine N1-acetyltransferase 1,X,23783173-23786226,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB047343, HPA055312, CAB069914",Supported,,,,Endometrial cancer:2.87e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 1269.5,Expressed in all,,
SAT2,SSAT2,ENSG00000141504,Spermidine/spermine N1-acetyltransferase family member 2,17,7626234-7627876,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA022136, HPA057096",Enhanced,,,,"Endometrial cancer:8.76e-6 (favourable), Pancreatic cancer:6.05e-5 (favourable), Lung cancer:6.71e-4 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 91.0,Mixed,,
SBK1,Sbk,ENSG00000188322,SH3 domain binding kinase 1,16,28292519-28323849,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,Cervical cancer:6.88e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 10.9;skeletal muscle: 12.0,parathyroid gland: 4.1,Cell line enhanced,,AF22: 27.9;NTERA-2: 29.2;REH: 29.2;SCLC-21H: 52.5;SH-SY5Y: 44.5
SBK2,SGK069,ENSG00000187550,SH3 domain binding kinase family member 2,19,55529733-55537089,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA030631,Uncertain,,,,,Tissue enhanced,Tissue enriched,30,heart muscle: 24.2,testis: 0.8,Group enriched,5,A549: 2.5;Hep G2: 1.4;MCF7: 2.2;NTERA-2: 5.5;RH-30: 4.9;U-2 OS: 3.1
SBK3,SgK110,ENSG00000231274,SH3 domain binding kinase family member 3,19,55540656-55545543,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA078322,,,Approved,Mitochondria,,Not detected,Tissue enriched,6,heart muscle: 17.8,adipose tissue: 2.7,Cell line enhanced,,A549: 4.5;CACO-2: 1.4;CAPAN-2: 2.6;RH-30: 2.1
SC5D,SC5DL,ENSG00000109929,Sterol-C5-desaturase,11,121292453-121308694,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA066283, HPA070248",Approved,,Approved,Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,"Renal cancer:1.07e-7 (favourable), Head and neck cancer:3.30e-4 (unfavourable), Melanoma:3.98e-4 (unfavourable)",Expressed in all,Expressed in all,,,liver: 193.5,Expressed in all,,
SCD,"FADS5, SCDOS",ENSG00000099194,Stearoyl-CoA desaturase,10,100347124-100364834,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA012107, HPA063921",Uncertain,,Enhanced,Endoplasmic reticulum,"Renal cancer:7.56e-5 (unfavourable), Urothelial cancer:7.79e-5 (unfavourable)",Expressed in all,Expressed in all,,,adipose tissue: 1255.0,Expressed in all,,
SCD5,"ACOD4, FADS4, FLJ21032, HSCD5, SCD4",ENSG00000145284,Stearoyl-CoA desaturase 5,4,82629539-82798857,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA042380,Uncertain,,,,Renal cancer:2.32e-5 (favourable),Group enriched,Tissue enhanced,,adrenal gland: 200.6;cerebral cortex: 500.3,epididymis: 117.0,Mixed,,
SCLY,SCL,ENSG00000132330,Selenocysteine lyase,2,238060889-238099413,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA055760,Uncertain,,Approved,Golgi apparatus,,Not detected,Expressed in all,,,testis: 12.9,Expressed in all,,
SCP2,,ENSG00000116171,Sterol carrier protein 2,1,52927229-53051703,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA027101, HPA027135, HPA027317",Supported,,Enhanced,Peroxisomes,"Renal cancer:7.85e-8 (favourable), Colorectal cancer:7.05e-5 (favourable)",Expressed in all,Expressed in all,,,liver: 601.5,Expressed in all,,
SCPEP1,RISC,ENSG00000121064,Serine carboxypeptidase 1,17,56978105-57006768,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA039102, HPA057200",Approved,,Approved,Golgi apparatus,Liver cancer:1.96e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 621.6,Expressed in all,,
SCRN1,KIAA0193,ENSG00000136193,Secernin 1,7,29920103-29990289,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA024517,Enhanced,,Approved,Cytosol,"Renal cancer:1.15e-5 (favourable), Endometrial cancer:4.00e-5 (unfavourable), Urothelial cancer:2.60e-4 (unfavourable), Ovarian cancer:7.27e-4 (unfavourable), Breast cancer:8.32e-4 (unfavourable), Cervical cancer:8.46e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 172.0,parathyroid gland: 129.1,Mixed,,
SCRN2,,ENSG00000141295,Secernin 2,17,47837692-47841333,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA022934, HPA023434",Enhanced,,Supported,Nucleoplasm<br>Golgi apparatus,"Liver cancer:3.86e-4 (favourable), Urothelial cancer:5.83e-4 (favourable)",Expressed in all,Expressed in all,,,adipose tissue: 84.3,Expressed in all,,
SCRN3,FLJ23142,ENSG00000144306,Secernin 3,2,174395730-174429575,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA034689, HPA034690",Approved,,Approved,Vesicles<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 48.4,Mixed,,
SCYL1,"GKLP, HT019, MGC78454, NKTL, NTKL, P105, TAPK, TEIF, TRAP",ENSG00000142186,SCY1 like pseudokinase 1,11,65525077-65538704,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA015015,Uncertain,,Supported,Cytosol,,Expressed in all,Expressed in all,,,thyroid gland: 55.2,Expressed in all,,
SCYL2,"CVAK104, KIAA1360",ENSG00000136021,SCY1 like pseudokinase 2,12,100267140-100341724,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021050,Approved,,,,,Expressed in all,Expressed in all,,,parathyroid gland: 41.8,Expressed in all,,
SCYL3,"PACE-1, PACE1",ENSG00000000457,SCY1 like pseudokinase 3,1,169849631-169894267,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA005624,Approved,,Uncertain,Nuclear bodies<br>Microtubules,Urothelial cancer:8.85e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 24.6,Expressed in all,,
SDHA,"FP, SDH2, SDHF",ENSG00000073578,Succinate dehydrogenase complex flavoprotein subunit A,5,218241-256700,"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB034929, HPA041981, HPA064582",Enhanced,,Enhanced,Mitochondria,"Renal cancer:9.53e-8 (favourable), Breast cancer:6.00e-4 (unfavourable)",Expressed in all,Expressed in all,,,heart muscle: 248.9,Expressed in all,,
SDHB,"SDH, SDH1",ENSG00000117118,Succinate dehydrogenase complex iron sulfur subunit B,1,17018722-17054170,"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA002868, CAB009822, CAB068233, CAB068234, CAB068235",Enhanced,,Supported,Nucleoplasm<br>Plasma membrane<br>Mitochondria,Renal cancer:2.93e-7 (favourable),Expressed in all,Expressed in all,,,kidney: 215.2,Expressed in all,,
SDR16C5,"EPHD-2, RDH-E2, RDHE2",ENSG00000170786,Short chain dehydrogenase/reductase family 16C member 5,8,56300010-56320776,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA025224,Enhanced,,,,Head and neck cancer:7.88e-4 (favourable),Mixed,Group enriched,6,breast: 15.2;esophagus: 36.3;lung: 40.3;skin: 72.9;small intestine: 21.7;stomach: 21.0;tonsil: 25.3,"cervix, uterine: 5.6",Cell line enhanced,,CAPAN-2: 22.6;HaCaT: 11.3;hTCEpi: 15.1;T-47d: 9.2
SDS,SDH,ENSG00000135094,Serine dehydratase,12,113392445-113426301,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA039230,Uncertain,,Approved,Mitochondria<br>Cytosol,Cervical cancer:5.24e-4 (favourable),Tissue enriched,Tissue enriched,18,liver: 189.8,cerebral cortex: 10.5,Cell line enhanced,,HMC-1: 1.5
SDSL,"cSDH, SDS-RS1",ENSG00000139410,Serine dehydratase like,12,113422237-113438276,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA005740,Approved,,Approved,Cytosol,"Renal cancer:3.09e-5 (favourable), Pancreatic cancer:8.58e-4 (favourable)",Expressed in all,Mixed,,,thyroid gland: 35.2,Cell line enhanced,,MCF7: 64.8
SEC11A,"SEC11L1, sid2895, SPC18, SPCS4A",ENSG00000140612,"SEC11 homolog A, signal peptidase complex subunit",15,84669538-84716716,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA047533,,,Approved,Nuclear membrane<br>Golgi apparatus,"Endometrial cancer:1.94e-5 (favourable), Head and neck cancer:5.99e-5 (unfavourable), Thyroid cancer:2.95e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 211.1,Expressed in all,,
SEC11C,"SEC11L3, SPC21, SPCS4C",ENSG00000166562,"SEC11 homolog C, signal peptidase complex subunit",18,59139477-59158836,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA026816, HPA047533",Approved,,Approved,Nuclear membrane<br>Golgi apparatus,,Expressed in all,Expressed in all,,,prostate: 271.8,Expressed in all,,
SELENOI,"EPT1, KIAA1724, SELI, SEPI",ENSG00000138018,Selenoprotein I,2,26308547-26395891,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Expressed in all,Expressed in all,,,parathyroid gland: 33.7,Expressed in all,,
SENP1,,ENSG00000079387,SUMO1/sentrin specific peptidase 1,12,48042898-48106308,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA011765, HPA046491",,,Enhanced,Nucleus<br>Focal adhesion sites,"Liver cancer:7.72e-5 (unfavourable), Renal cancer:8.37e-4 (unfavourable)",Expressed in all,Tissue enriched,8,testis: 110.1,lymph node: 13.3,Expressed in all,,
SENP2,"AXAM2, DKFZp762A2316, KIAA1331, SMT3IP2",ENSG00000163904,SUMO1/sentrin/SMT3 specific peptidase 2,3,185582496-185633551,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA029247, HPA029248",Approved,,Supported,Cytosol,Endometrial cancer:7.98e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 26.9,Expressed in all,,
SENP3,"DKFZP586K0919, DKFZp762A152, SMT3IP1, SSP3, Ulp1",ENSG00000161956,SUMO1/sentrin/SMT3 specific peptidase 3,17,7561875-7571969,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA060290,Supported,,Supported,Nucleus<br>Nucleoli,Pancreatic cancer:6.22e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 57.4,Expressed in all,,
SENP5,MGC27076,ENSG00000119231,SUMO1/sentrin specific peptidase 5,3,196867856-196934714,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:2.14e-5 (unfavourable), Endometrial cancer:4.04e-4 (unfavourable), Liver cancer:4.15e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 37.8,Expressed in all,,
SENP6,"KIAA0797, SUSP1",ENSG00000112701,SUMO1/sentrin specific peptidase 6,6,75601509-75718278,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA024376,Approved,,Supported,Nucleoplasm<br>Cytosol,"Thyroid cancer:2.83e-5 (unfavourable), Renal cancer:6.09e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 75.2,Expressed in all,,
SENP7,,ENSG00000138468,SUMO1/sentrin specific peptidase 7,3,101324205-101513241,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027259,Approved,,Approved,Nucleoplasm<br>Cytosol,Head and neck cancer:4.23e-4 (favourable),Expressed in all,Expressed in all,,,endometrium: 44.4,Expressed in all,,
SENP8,"DEN1, HsT17512, NEDP1, PRSC2",ENSG00000166192,"SUMO/sentrin peptidase family member, NEDD8 specific",15,72114258-72143688,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036273,Approved,,Approved,Nucleoplasm<br>Vesicles,,Mixed,Tissue enhanced,,testis: 27.7,thyroid gland: 8.3,Expressed in all,,
SEPHS1,"SPS, SPS1",ENSG00000086475,Selenophosphate synthetase 1,10,13317424-13348298,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA037645, HPA062118",Enhanced,,Uncertain,Nucleoplasm,"Liver cancer:2.16e-7 (unfavourable), Pancreatic cancer:3.12e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 92.9,Expressed in all,,
SEPHS2,"SPS2, SPS2b",ENSG00000179918,Selenophosphate synthetase 2,16,30443631-30446181,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047931,Approved,,Approved,Nucleoplasm,Renal cancer:4.35e-8 (favourable),Expressed in all,Expressed in all,,,liver: 180.4,Expressed in all,,
SEPSECS,"SLA, SLA/LP",ENSG00000109618,Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase,4,25120014-25160442,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA070409,,,Approved,Vesicles,,Expressed in all,Expressed in all,,,liver: 16.7,Expressed in all,,
SESN1,"PA26, SEST1",ENSG00000080546,Sestrin 1,6,108986437-109094819,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA073659,,,Supported,Nucleus<br>Nucleoli fibrillar center,"Head and neck cancer:6.47e-5 (favourable), Prostate cancer:2.07e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 78.9,Expressed in all,,
SESN2,"DKFZp761M0212, HI95, SES2, SEST2",ENSG00000130766,Sestrin 2,1,28259527-28282491,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA018191,Uncertain,,Approved,Cytosol,Liver cancer:4.78e-4 (unfavourable),Expressed in all,Mixed,,,bone marrow: 25.6,Expressed in all,,
SETD1A,"KIAA0339, KMT2F, Set1",ENSG00000099381,SET domain containing 1A,16,30957294-30984664,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA020646, HPA058376",Enhanced,,Supported,Nuclear speckles,Liver cancer:8.47e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 24.5,Expressed in all,,
SETD1B,"KIAA1076, KMT2G, Set1B",ENSG00000139718,SET domain containing 1B,12,121804180-121832584,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021667, HPA059412",Approved,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,endometrium: 19.0,Expressed in all,,
SETD2,"FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A",ENSG00000181555,SET domain containing 2,3,47016429-47163967,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA042451,Approved,,Approved,Nuclear speckles<br>Cytosol,"Renal cancer:7.99e-6 (favourable), Melanoma:8.19e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 31.8,Expressed in all,,
SETD3,"C14orf154, FLJ23027",ENSG00000183576,SET domain containing 3,14,99397746-99480889,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003591, HPA003639",Approved,,Approved,Mitochondria,"Renal cancer:1.89e-15 (favourable), Head and neck cancer:6.46e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 154.4,Expressed in all,,
SETD7,"KIAA1717, KMT7, SET7, SET7/9, Set9",ENSG00000145391,SET domain containing lysine methyltransferase 7,4,139495941-139606699,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA058111,Approved,,Supported,Nucleoli,Breast cancer:8.28e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 60.7,Mixed,,
SETDB1,"ESET, KG1T, KIAA0067, KMT1E, TDRD21",ENSG00000143379,SET domain bifurcated 1,1,150926263-150964744,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA018142, HPA058484",Uncertain,,Enhanced,Nucleoplasm<br>Cytosol,"Renal cancer:4.25e-4 (unfavourable), Liver cancer:8.88e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 46.3,Expressed in all,,
SETDB2,"C13orf4, CLLD8, CLLL8, KMT1F",ENSG00000136169,SET domain bifurcated 2,13,49444374-49495003,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012190, HPA071677",Approved,,Approved,Nucleoplasm,Renal cancer:1.92e-7 (favourable),Expressed in all,Mixed,,,testis: 28.2,Expressed in all,,
SETMAR,metnase,ENSG00000170364,SET domain and mariner transposase fusion gene,3,4303304-4317567,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA057999,,,Supported,Nucleoli,"Renal cancer:6.61e-6 (favourable), Liver cancer:2.85e-4 (unfavourable)",Expressed in all,Expressed in all,,,smooth muscle: 16.0,Mixed,,
SGK1,SGK,ENSG00000118515,Serum/glucocorticoid regulated kinase 1,6,134169246-134318112,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB022085, CAB025148, HPA051251",Approved,,Enhanced,Nuclear speckles,Cervical cancer:5.26e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 793.4,Cell line enhanced,,RPTEC TERT1: 354.6;TIME: 304.3
SGK2,,ENSG00000101049,"SGK2, serine/threonine kinase 2",20,43558968-43588237,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA008859, HPA011387",Uncertain,,Supported,Nucleoplasm,Urothelial cancer:5.65e-4 (favourable),Group enriched,Mixed,,,kidney: 43.2,Group enriched,5,A549: 16.2;CAPAN-2: 12.2;EFO-21: 6.5;Hep G2: 12.5;RPTEC TERT1: 19.0
SGK3,"SGK2, SGKL",ENSG00000104205,Serum/glucocorticoid regulated kinase family member 3,8,66712418-66862022,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006699, HPA027146",Supported,,Approved,Nucleoplasm<br>Vesicles,"Breast cancer:5.52e-6 (favourable), Cervical cancer:8.28e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 48.5,Mixed,,
SGMS2,"MGC26963, SMS2",ENSG00000164023,Sphingomyelin synthase 2,4,107824563-107915047,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA015076,Enhanced,,,,Renal cancer:1.37e-4 (favourable),Expressed in all,Mixed,,,gallbladder: 64.4,Mixed,,
SGPL1,SPL,ENSG00000166224,Sphingosine-1-phosphate lyase 1,10,70815961-70881173,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA021125, HPA023086",Enhanced,,Supported,Endoplasmic reticulum,,Expressed in all,Expressed in all,,,skin: 34.5,Expressed in all,,
SGSH,"HSS, MPS3A, SFMD",ENSG00000181523,N-sulfoglucosamine sulfohydrolase,17,80206716-80220923,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA023436, HPA023451",Enhanced,,,,"Renal cancer:2.66e-4 (unfavourable), Lung cancer:2.72e-4 (favourable), Pancreatic cancer:3.10e-4 (favourable), Testis cancer:5.37e-4 (unfavourable), Liver cancer:7.71e-4 (unfavourable)",Expressed in all,Expressed in all,,,adrenal gland: 36.3,Mixed,,
SH3RF1,"KIAA1494, POSH, RNF142, SH3MD2",ENSG00000154447,SH3 domain containing ring finger 1,4,169094256-169271105,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA074783,,,Supported,Vesicles<br>Intermediate filaments,Renal cancer:5.51e-8 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 32.1,Mixed,,
SH3RF2,"FLJ23654, Hepp1, POSHER, PPP1R39, RNF158",ENSG00000156463,SH3 domain containing ring finger 2,5,145936579-146081791,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035903, HPA058119",Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,skin: 67.3,heart muscle: 26.1,Cell line enhanced,,CACO-2: 57.4
SHMT1,"CSHMT, MGC15229, MGC24556, SHMT",ENSG00000176974,Serine hydroxymethyltransferase 1,17,18327860-18363563,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA023314,Approved,,Supported,Nucleus<br>Cytosol,"Renal cancer:8.54e-6 (favourable), Liver cancer:2.52e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 271.5,Expressed in all,,
SHMT2,SHMT,ENSG00000182199,Serine hydroxymethyltransferase 2,12,57229327-57234935,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA020543, HPA020549",Enhanced,,Enhanced,Microtubules<br>Mitochondria,"Renal cancer:4.84e-8 (unfavourable), Breast cancer:8.37e-5 (unfavourable)",Expressed in all,Expressed in all,,,liver: 74.8,Expressed in all,,
SHPK,"CARKL, SHK",ENSG00000197417,Sedoheptulokinase,17,3608262-3636322,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA024361, HPA064939",Enhanced,,Approved,Nucleoplasm<br>Nuclear speckles,,Expressed in all,Mixed,,,duodenum: 13.4,Expressed in all,,
SHPRH,"bA545I5.2, FLJ90837, KIAA2023",ENSG00000146414,SNF2 histone linker PHD RING helicase,6,145864245-145964423,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA034854, HPA034950",Approved,,Approved,Mitochondria,,Mixed,Mixed,,,ovary: 15.1,Expressed in all,,
SI,,ENSG00000090402,Sucrase-isomaltase,3,164978898-165078495,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA011897,Enhanced,,,,,Tissue enhanced,Group enriched,15,duodenum: 547.3;small intestine: 493.2,rectum: 34.5,Cell line enhanced,,BEWO: 1.0;CACO-2: 1.3;RPMI-8226: 1.3;SH-SY5Y: 1.2
SIAE,"CSE-C, LSE, MGC87009, YSG2",ENSG00000110013,Sialic acid acetylesterase,11,124633113-124695707,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA038052, HPA038053",Approved,,,,"Renal cancer:4.42e-11 (favourable), Endometrial cancer:4.66e-5 (favourable)",Expressed in all,Expressed in all,,,rectum: 114.5,Mixed,,
SIAH1,hSIAH1,ENSG00000196470,Siah E3 ubiquitin protein ligase 1,16,48356364-48448402,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB018724,Enhanced,,Approved,Nucleoplasm<br>Mitochondria,,Expressed in all,Expressed in all,,,placenta: 70.4,Expressed in all,,
SIAH2,,ENSG00000181788,Siah E3 ubiquitin protein ligase 2,3,150741127-150763477,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA061293, CAB069930",Approved,,Supported,Nucleoplasm<br>Vesicles,"Pancreatic cancer:8.21e-5 (unfavourable), Breast cancer:1.17e-4 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 95.3,Expressed in all,,
SIK1,"msk, SNF1LK",ENSG00000142178,Salt inducible kinase 1,21,43414515-43427128,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"CAB023801, HPA038211",Approved,,Supported,Cytosol,,Mixed,Mixed,,,seminal vesicle: 13.9,Cell line enhanced,,HaCaT: 18.5;HBEC3-KT: 22.7;HeLa: 32.3;hTCEpi: 25.9;SiHa: 16.7;U-266/84: 20.5
SIK2,"DKFZp434K1115, KIAA0781, LOH11CR1I, QIK, SNF1LK2",ENSG00000170145,Salt inducible kinase 2,11,111602391-111730853,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA016026,Approved,,Approved,Golgi apparatus,"Renal cancer:1.17e-9 (favourable), Liver cancer:4.93e-4 (favourable)",Expressed in all,Expressed in all,,,adipose tissue: 32.1,Expressed in all,,
SKIV2L2,"Dob1, fSAP118, KIAA0052, Mtr4",ENSG00000039123,Ski2 like RNA helicase 2,5,55307760-55425581,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA037379,Supported,,Supported,Nucleus,,Expressed in all,Expressed in all,,,parathyroid gland: 37.1,Expressed in all,,
SLC27A2,"ACSVL1, FACVL1, FATP2, hFACVL1, HsT17226, VLACS, VLCS",ENSG00000140284,Solute carrier family 27 member 2,15,50182196-50236395,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,HPA026089,Enhanced,,,,"Renal cancer:7.48e-6 (favourable), Urothelial cancer:6.40e-4 (favourable)",Tissue enhanced,Group enriched,5,epididymis: 80.1;kidney: 162.3;liver: 145.5,placenta: 24.7,Cell line enhanced,,HaCaT: 78.4;HL-60: 52.3;SCLC-21H: 47.4
SLC27A5,"ACSB, ACSVL6, FACVL3, FATP5, FLJ22987, VLACSR, VLCS-H2, VLCSH2",ENSG00000083807,Solute carrier family 27 member 5,19,58479512-58512413,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA007292, CAB056160, CAB068239",Enhanced,,,,Liver cancer:1.57e-4 (favourable),Tissue enriched,Tissue enriched,23,liver: 337.5,fallopian tube: 14.7,Mixed,,
SLK,"KIAA0204, se20-9, STK2",ENSG00000065613,STE20 like kinase,10,103967201-104029233,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA015757,Approved,,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:2.77e-5 (unfavourable), Renal cancer:3.95e-5 (favourable)",Expressed in all,Expressed in all,,,esophagus: 61.0,Expressed in all,,
SMARCAD1,"DKFZP762K2015, ETL1, KIAA1122",ENSG00000163104,"SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1",4,94207611-94291292,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA016737,Approved,,Enhanced,Nucleoplasm,Liver cancer:3.22e-5 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 25.6,Expressed in all,,
SMG1,"ATX, KIAA0421, LIP",ENSG00000157106,"SMG1, nonsense mediated mRNA decay associated PI3K related kinase",16,18804853-18926454,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006870, HPA031623, HPA073972",Approved,,Supported,Nucleoplasm,,Expressed in all,Expressed in all,,,skin: 50.1,Expressed in all,,
SMOX,"C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO",ENSG00000088826,Spermine oxidase,20,4120980-4187747,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA047117, HPA060198",Approved,,Supported,Nucleoplasm<br>Nuclear membrane<br>Vesicles,"Liver cancer:3.33e-6 (unfavourable), Renal cancer:1.06e-4 (unfavourable), Lung cancer:1.36e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 49.7,gallbladder: 23.5,Cell line enhanced,,A549: 104.6;Karpas-707: 139.7
SMPD1,ASM,ENSG00000166311,Sphingomyelin phosphodiesterase 1,11,6390431-6394998,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:4.57e-6 (favourable), Glioma:1.09e-4 (unfavourable), Pancreatic cancer:7.47e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 63.5,Mixed,,
SMPD2,"ISC1, nSMase",ENSG00000135587,Sphingomyelin phosphodiesterase 2,6,109440763-109443919,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA018110, HPA018125",Uncertain,,Approved,Vesicles<br>Plasma membrane<br>Cell Junctions,"Liver cancer:1.17e-4 (unfavourable), Urothelial cancer:1.70e-4 (favourable), Pancreatic cancer:1.00e-3 (favourable)",Expressed in all,Mixed,,,testis: 55.8,Expressed in all,,
SMPD3,NSMASE2,ENSG00000103056,Sphingomyelin phosphodiesterase 3,16,68358325-68448688,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB033885, HPA065535, HPA069383",Approved,,Supported,Endoplasmic reticulum,"Endometrial cancer:3.86e-4 (favourable), Cervical cancer:7.72e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 61.0;small intestine: 62.9,stomach: 22.6,Cell line enhanced,,HMC-1: 8.5;MOLT-4: 11.7;RPMI-8226: 8.3;SCLC-21H: 15.6
SMPD4,"FLJ20297, FLJ20756, KIAA1418, NET13, nSMase-3, NSMASE3",ENSG00000136699,Sphingomyelin phosphodiesterase 4,2,130151392-130182750,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046279, HPA049426",Approved,,Approved,Nuclear membrane<br>Cytosol,"Renal cancer:8.16e-8 (unfavourable), Liver cancer:8.37e-6 (unfavourable), Endometrial cancer:7.47e-5 (unfavourable), Prostate cancer:1.73e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 36.0,Expressed in all,,
SMS,"MRSR, SPMSY, SpS, SRS",ENSG00000102172,Spermine synthase,X,21940573-21994835,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA029849, HPA029852",Approved,,Approved,Nuclear bodies<br>Cytosol,"Liver cancer:7.79e-8 (unfavourable), Renal cancer:7.85e-5 (unfavourable), Head and neck cancer:7.49e-4 (unfavourable)",Expressed in all,Expressed in all,,,prostate: 202.4,Expressed in all,,
SMURF1,KIAA1625,ENSG00000198742,SMAD specific E3 ubiquitin protein ligase 1,7,99027438-99144100,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA055245,Approved,,,,,Expressed in all,Expressed in all,,,testis: 22.9,Expressed in all,,
SMURF2,,ENSG00000108854,SMAD specific E3 ubiquitin protein ligase 2,17,64542295-64662068,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA071508,Enhanced,,Supported,Nuclear speckles,,Expressed in all,Mixed,,,testis: 32.9,Expressed in all,,
SMYD1,"BOP, KMT3D, ZMYND22",ENSG00000115593,SET and MYND domain containing 1,2,88067780-88113387,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA062282,Enhanced,,,,,Tissue enhanced,Group enriched,9,heart muscle: 107.0;skeletal muscle: 170.8;smooth muscle: 38.5,parathyroid gland: 11.6,Not detected,,
SMYD2,"HSKM-B, KMT3C, ZMYND14",ENSG00000143499,SET and MYND domain containing 2,1,214281102-214337131,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA029023,Uncertain,,Approved,Intermediate filaments<br>Mitochondria<br>Cytosol,"Cervical cancer:1.53e-5 (unfavourable), Renal cancer:8.68e-4 (favourable)",Expressed in all,Expressed in all,,,heart muscle: 153.5,Expressed in all,,
SMYD3,"KMT3E, ZMYND1, ZNFN3A1",ENSG00000185420,SET and MYND domain containing 3,1,245749342-246507312,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB012229, HPA045821, HPA054352",Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,"epididymis,thyroid gland: 27.0",Expressed in all,,
SNRK,"FLJ20224, HSNFRK, KIAA0096",ENSG00000163788,SNF related kinase,3,43286512-43424764,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA042163,Uncertain,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cell Junctions,"Renal cancer:9.41e-5 (favourable), Breast cancer:9.28e-4 (favourable)",Expressed in all,Expressed in all,,,placenta: 47.8,Expressed in all,,
SNRNP200,"ASCC3L1, BRR2, HELIC2, KIAA0788, RP33, U5-200KD",ENSG00000144028,Small nuclear ribonucleoprotein U5 subunit 200,2,96274336-96305515,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA029321,Approved,,Supported,Nucleoplasm,Endometrial cancer:3.89e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 116.4,Expressed in all,,
SOAT1,"ACAT, SOAT, STAT",ENSG00000057252,Sterol O-acyltransferase 1,1,179293714-179358680,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB009533, HPA047171",Enhanced,,Enhanced,Endoplasmic reticulum,,Expressed in all,Tissue enhanced,,adrenal gland: 218.2,prostate: 45.1,Expressed in all,,
SOAT2,ACAT2,ENSG00000167780,Sterol O-acyltransferase 2,12,53103518-53124538,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Group enriched,Group enriched,5,duodenum: 12.1;small intestine: 22.0,spleen: 3.2,Cell line enhanced,,CACO-2: 8.8;Hep G2: 15.8;U-266/70: 5.6
SOD1,"ALS, ALS1, IPOA",ENSG00000142168,Superoxide dismutase 1,21,31659622-31668931,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001401, CAB008670",Enhanced,,Supported,Nucleus<br>Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,liver: 768.9,Expressed in all,,
SOD2,,ENSG00000112096,Superoxide dismutase 2,6,159669057-159762529,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001814, CAB002013",Supported,,,,Renal cancer:1.72e-4 (unfavourable),Expressed in all,Expressed in all,,,appendix: 734.4,Expressed in all,,
SOD3,EC-SOD,ENSG00000109610,Superoxide dismutase 3,4,24789912-24800842,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA042110,Supported,,,,,Expressed in all,Tissue enhanced,,adipose tissue: 179.2,fallopian tube: 66.5,Cell line enhanced,,ASC diff: 41.5;PC-3: 46.6;RPTEC TERT1: 158.1
SORD,,ENSG00000140263,Sorbitol dehydrogenase,15,45023104-45077185,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040260, HPA040621",Enhanced,,Approved,Cytosol,Liver cancer:6.14e-5 (favourable),Expressed in all,Expressed in all,,,"cervix, uterine: 404.7",Mixed,,
SPACA5,"dJ54B20.3, LYC5, LYZL5, PNPK6288, SLLP2, UNQ6288",ENSG00000171489,Sperm acrosome associated 5,X,48004336-48009729,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA044747, HPA047149",Supported,,,,,Not detected,Tissue enriched,10,testis: 13.6,thyroid gland: 1.4,Not detected,,
SPACA5B,LYZL5B,ENSG00000171478,Sperm acrosome associated 5B,X,48130657-48132613,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA044747, HPA047149",Supported,,,,,Not detected,Tissue enriched,149,testis: 16.5,fallopian tube: 0.1,Not detected,,
SPAM1,"HYAL5, PH-20, SPAG15",ENSG00000106304,Sperm adhesion molecule 1,7,123925237-123971414,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017984,Enhanced,,,,,Not detected,Tissue enriched,66,testis: 30.2,"duodenum,small intestine: 0.4",Not detected,,
SPAST,"ADPSP, FSP2, KIAA1083, SPG4",ENSG00000021574,Spastin,2,32063611-32157637,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017311,Approved,,Approved,Nucleoplasm<br>Cytosol,"Liver cancer:1.62e-4 (unfavourable), Renal cancer:4.15e-4 (unfavourable)",Expressed in all,Mixed,,,cerebral cortex: 20.0,Expressed in all,,
SPEG,"APEG1, BPEG, KIAA1297, MGC12676, SPEGalpha, SPEGbeta",ENSG00000072195,SPEG complex locus,2,219434846-219498287,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA018904,Enhanced,,Approved,Vesicles,,Mixed,Mixed,,,skeletal muscle: 43.2,Cell line enhanced,,U-2 OS: 22.8;U-87 MG: 23.6
SPG7,"CAR, CMAR, SPG5C",ENSG00000197912,"SPG7, paraplegin matrix AAA peptidase subunit",16,89490917-89557768,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,"Endometrial cancer:2.22e-4 (favourable), Urothelial cancer:4.25e-4 (favourable), Pancreatic cancer:4.91e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 52.2,Expressed in all,,
SPHK1,SPHK,ENSG00000176170,Sphingosine kinase 1,17,76376584-76387860,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA022829, HPA028761",Uncertain,,Supported,Plasma membrane<br>Cytosol,Renal cancer:5.14e-6 (unfavourable),Expressed in all,Mixed,,,gallbladder: 19.0,Mixed,,
SPHK2,,ENSG00000063176,Sphingosine kinase 2,19,48619291-48630717,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA065508,,,Supported,Vesicles,"Renal cancer:2.59e-5 (favourable), Endometrial cancer:5.19e-4 (unfavourable), Pancreatic cancer:9.30e-4 (favourable)",Expressed in all,Mixed,,,duodenum: 22.1,Expressed in all,,
SPO11,"CT35, SPATA43, TOPVIA",ENSG00000054796,"SPO11, initiator of meiotic double stranded breaks",20,57329759-57343994,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enriched,154,testis: 15.3,all non-specific tissues: 0.0,Not detected,,
SPPL2A,"IMP3, PSL2",ENSG00000138600,Signal peptide peptidase like 2A,15,50702266-50765808,"Enzymes, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036062, HPA067304",Enhanced,,Supported,Vesicles,,Expressed in all,Expressed in all,,,parathyroid gland: 291.5,Expressed in all,,
SPPL2B,"IMP4, KIAA1532, PSL1",ENSG00000005206,Signal peptide peptidase like 2B,19,2328615-2354806,"Enzymes, Predicted membrane proteins",Evidence at protein level,"CAB005592, HPA039292",Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Centrosome,"Endometrial cancer:5.00e-5 (favourable), Pancreatic cancer:1.33e-4 (favourable), Renal cancer:6.45e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 49.1,Expressed in all,,
SPPL2C,IMP5,ENSG00000185294,Signal peptide peptidase like 2C,17,45844835-45847072,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,21,testis: 2.1,all non-specific tissues: 0.0,Not detected,,
SPPL3,"DKFZP586C1324, IMP2, MGC126674, MGC126676, MGC90402, PSL4",ENSG00000157837,Signal peptide peptidase like 3,12,120762510-120904371,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA004194, HPA059958",Uncertain,,Supported,Vesicles<br>Plasma membrane,Liver cancer:1.29e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 84.1,Mixed,,
SPR,SDR38C1,ENSG00000116096,"Sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase)",2,72887360-72892158,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA039505,Uncertain,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Mixed,,,parathyroid gland: 49.9,Mixed,,
SPTLC1,"hLCB1, HSAN1, HSN1, LCB1, SPTI",ENSG00000090054,Serine palmitoyltransferase long chain base subunit 1,9,92031999-92115384,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA010860, CAB018747, HPA063907",Supported,,Supported,Endoplasmic reticulum,Renal cancer:1.36e-6 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 108.3,Expressed in all,,
SPTLC2,"hLCB2a, KIAA0526, LCB2, LCB2A",ENSG00000100596,Serine palmitoyltransferase long chain base subunit 2,14,77505997-77616773,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA027552,,,Approved,Mitochondria,"Renal cancer:6.69e-8 (favourable), Liver cancer:3.62e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 29.0,Expressed in all,,
SPTLC3,"C20orf38, FLJ11112, hLCB2b, LCB2B, SPTLC2L",ENSG00000172296,Serine palmitoyltransferase long chain base subunit 3,20,13008979-13169103,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA044247, HPA048079",Enhanced,,Approved,Microtubules,"Renal cancer:4.51e-7 (favourable), Pancreatic cancer:6.02e-4 (unfavourable)",Expressed in all,Mixed,,,thyroid gland: 40.8,Cell line enhanced,,RPTEC TERT1: 33.2;U-87 MG: 56.0
SQLE,,ENSG00000104549,Squalene epoxidase,8,124998497-125022283,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA018038, HPA020762",Enhanced,,Uncertain,Vesicles<br>Cytosol,"Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 107.8,Expressed in all,,
SRC,"ASV, c-src, SRC1",ENSG00000197122,"SRC proto-oncogene, non-receptor tyrosine kinase",20,37344685-37406050,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004023, HPA030875",Approved,,Enhanced,Plasma membrane<br>Cytosol,"Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable)",Expressed in all,Mixed,,,gallbladder: 43.6,Mixed,,
SRD5A1,,ENSG00000145545,Steroid 5 alpha-reductase 1,5,6633343-6674386,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA051402,Approved,,,,Endometrial cancer:8.73e-6 (unfavourable),Expressed in all,Mixed,,,skin: 16.8,Mixed,,
SRD5A2,,ENSG00000277893,Steroid 5 alpha-reductase 2,2,31522480-31581067,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Group enriched,Group enriched,11,epididymis: 27.9;fallopian tube: 31.6;liver: 30.6;prostate: 26.6;seminal vesicle: 24.5,testis: 2.5,Cell line enhanced,,RT4: 1.2
SRD5A3,"FLJ13352, SRD5A2L, SRD5A2L1",ENSG00000128039,Steroid 5 alpha-reductase 3,4,55346109-55373096,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA027006,Uncertain,,Approved,Plasma membrane<br>Cytosol,"Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable)",Expressed in all,Expressed in all,,,gallbladder: 28.2,Expressed in all,,
SRM,"SPS1, SRML1",ENSG00000116649,Spermidine synthase,1,11054584-11060024,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA015746,Approved,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:3.80e-8 (unfavourable), Liver cancer:2.25e-5 (unfavourable)",Expressed in all,Expressed in all,,,appendix: 73.5,Expressed in all,,
SRMS,"C20orf148, dJ697K14.1, PTK70, SRM",ENSG00000125508,Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites,20,63540810-63547504,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB044668, CAB044669, HPA073987",Uncertain,,Approved,Intermediate filaments<br>Actin filaments<br>Cytosol,,Mixed,Mixed,,,stomach: 1.4,Cell line enhanced,,CAPAN-2: 2.9;MCF7: 2.2;RT4: 4.8
SRPK1,SFRSK1,ENSG00000096063,SRSF protein kinase 1,6,35832966-35921342,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA016431, HPA056486",Approved,,Supported,Nucleus<br>Plasma membrane<br>Cytosol,"Liver cancer:7.90e-6 (unfavourable), Pancreatic cancer:6.53e-5 (unfavourable)",Expressed in all,Expressed in all,,,testis: 81.0,Expressed in all,,
SRPK2,SFRSK2,ENSG00000135250,SRSF protein kinase 2,7,105110704-105399308,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA015522, HPA020876",Approved,,Supported,Nucleus<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 197.4,Expressed in all,,
SRPK3,"MSSK1, STK23",ENSG00000184343,SRSF protein kinase 3,X,153776412-153785732,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,heart muscle: 28.7;skeletal muscle: 73.6,prostate: 10.9,Cell line enhanced,,RH-30: 45.4
SRR,"ILV1, ISO1",ENSG00000167720,Serine racemase,17,2303383-2325260,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007529, CAB015343",Approved,,Approved,Vesicles,"Renal cancer:2.45e-6 (favourable), Endometrial cancer:6.20e-5 (favourable), Pancreatic cancer:8.16e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 25.5,Expressed in all,,
SRXN1,"C20orf139, dJ850E9.2, Npn3, SRX1, YKL086W",ENSG00000271303,Sulfiredoxin 1,20,646615-653370,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Liver cancer:6.22e-5 (unfavourable),Mixed,Expressed in all,,,adrenal gland: 44.5,Mixed,,
SSH1,KIAA1298,ENSG00000084112,Slingshot protein phosphatase 1,12,108778192-108857590,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA019845,Uncertain,,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:5.80e-5 (unfavourable),Expressed in all,Mixed,,,parathyroid gland: 9.5,Expressed in all,,
SSH2,KIAA1725,ENSG00000141298,Slingshot protein phosphatase 2,17,29625938-29930276,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB017189, HPA057099",Uncertain,,,,,Expressed in all,Expressed in all,,,bone marrow: 35.7,Expressed in all,,
SSH3,"FLJ10928, FLJ20515",ENSG00000172830,Slingshot protein phosphatase 3,11,67303448-67312607,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019949, HPA019957",Approved,,Approved,Nuclear speckles<br>Plasma membrane<br>Actin filaments<br>Cytosol,Pancreatic cancer:2.89e-4 (unfavourable),Expressed in all,Expressed in all,,,seminal vesicle: 37.5,Cell line enhanced,,RT4: 69.9
SSU72,HSPC182,ENSG00000160075,"SSU72 homolog, RNA polymerase II CTD phosphatase",1,1541673-1574869,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA069290, HPA070604",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,thyroid gland: 149.3,Expressed in all,,
ST14,"HAI, MT-SP1, PRSS14, SNC19, TMPRSS14",ENSG00000149418,Suppression of tumorigenicity 14,11,130159562-130210376,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA047014,,,Approved,Nucleoplasm<br>Vesicles,Renal cancer:5.03e-11 (favourable),Expressed in all,Mixed,,,small intestine: 149.0,Cell line enhanced,,CAPAN-2: 361.3;HaCaT: 255.1;RPMI-8226: 192.2;T-47d: 268.8
ST3GAL1,"SIAT4A, SIATFL, ST3GalA.1, ST3O",ENSG00000008513,"ST3 beta-galactoside alpha-2,3-sialyltransferase 1",8,133454848-133571940,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA040466,Approved,,,,,Expressed in all,Expressed in all,,,thyroid gland: 115.9,Cell line enhanced,,PC-3: 125.9;RT4: 84.6
ST3GAL2,"SIAT4B, ST3GalA.2, ST3GALII",ENSG00000157350,"ST3 beta-galactoside alpha-2,3-sialyltransferase 2",16,70375978-70439237,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA017270,Approved,,Approved,Vesicles,"Renal cancer:3.34e-6 (unfavourable), Pancreatic cancer:2.33e-4 (favourable), Liver cancer:2.79e-4 (unfavourable)",Expressed in all,Mixed,,,appendix: 15.2,Mixed,,
ST3GAL3,"MRT12, SIAT6",ENSG00000126091,"ST3 beta-galactoside alpha-2,3-sialyltransferase 3",1,43705824-43931165,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA051102,Uncertain,,,,,Expressed in all,Expressed in all,,,skeletal muscle: 30.5,Mixed,,
ST3GAL5,"SIAT9, SIATGM3S, ST3GalV",ENSG00000115525,"ST3 beta-galactoside alpha-2,3-sialyltransferase 5",2,85837120-85905199,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA034708, HPA040425, HPA068928",Uncertain,,Approved,Vesicles,"Renal cancer:2.25e-7 (unfavourable), Urothelial cancer:4.48e-4 (favourable), Thyroid cancer:4.99e-4 (favourable)",Expressed in all,Tissue enhanced,,thyroid gland: 44.7,cerebral cortex: 40.7,Cell line enhanced,,AN3-CA: 50.3;RT4: 37.4
ST6GAL1,SIAT1,ENSG00000073849,"ST6 beta-galactoside alpha-2,6-sialyltransferase 1",3,186930485-187078553,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB015018, CAB016122",Supported,,,,,Expressed in all,Expressed in all,,,liver: 270.5,Cell line enhanced,,U-266/70: 590.1;U-266/84: 742.8;U-698: 257.3
ST6GAL2,"KIAA1877, SIAT2, St6gal2, St6GalII",ENSG00000144057,"ST6 beta-galactoside alpha-2,6-sialyltransferase 2",2,106801600-106887108,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014459,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center,,Tissue enriched,Tissue enhanced,,cerebral cortex: 22.1;thyroid gland: 47.9,testis: 9.8,Cell line enhanced,,A549: 4.8;PC-3: 5.5;RPMI-8226: 6.7;SCLC-21H: 7.2;U-138 MG: 7.4;U-266/70: 7.5
ST6GALNAC1,"SIAT7A, ST6GalNAcI",ENSG00000070526,"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1",17,76624761-76643838,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014975,Uncertain,,,,Head and neck cancer:2.54e-5 (favourable),Mixed,Tissue enhanced,,colon: 162.6;rectum: 235.5,"cervix, uterine: 90.7",Cell line enhanced,,EFO-21: 9.1;HaCaT: 9.7;HEL: 16.1;K-562: 48.8
ST6GALNAC4,"SIAT3C, SIAT7D, ST6GALNACIV",ENSG00000136840,"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4",9,127907886-127917038,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA009042,,,Approved,Nucleus<br>Golgi apparatus,"Liver cancer:8.63e-7 (unfavourable), Ovarian cancer:5.12e-4 (unfavourable), Renal cancer:8.39e-4 (unfavourable)",Expressed in all,Mixed,,,bone marrow: 24.4,Cell line enhanced,,HDLM-2: 98.1;RPMI-8226: 103.5
ST8SIA1,"SIAT8, SIAT8A",ENSG00000111728,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1",12,22063773-22437041,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA026775,Approved,,,,,Mixed,Mixed,,,cerebral cortex: 9.0,Cell line enhanced,,AF22: 6.4;SK-MEL-30: 4.8;WM-115: 6.4
STAMBP,AMSH,ENSG00000124356,STAM binding protein,2,73828916-73873659,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035800, HPA035801",Uncertain,,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Endometrial cancer:4.70e-5 (unfavourable), Pancreatic cancer:5.79e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 39.1,Cell line enriched,11,LHCN-M2: 926.0
STAMBPL1,"ALMalpha, AMSH-FP, AMSH-LP, bA399O19.2, FLJ31524, KIAA1373",ENSG00000138134,STAM binding protein like 1,10,88879734-88975153,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040202,Uncertain,,Approved,Plasma membrane,Renal cancer:1.08e-5 (unfavourable),Mixed,Mixed,,,"adrenal gland,testis: 29.7",Mixed,,
STK10,"LOK, PRO2729",ENSG00000072786,Serine/threonine kinase 10,5,172042073-172188386,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA015083, CAB020840",Enhanced,,,,"Renal cancer:1.63e-4 (unfavourable), Colorectal cancer:2.76e-4 (favourable)",Expressed in all,Expressed in all,,,spleen: 61.0,Expressed in all,,
STK11,"LKB1, PJS",ENSG00000118046,Serine/threonine kinase 11,19,1177558-1228435,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB016231, HPA017254, CAB022105, HPA067481",Approved,,Supported,Nucleoplasm<br>Cytosol,"Endometrial cancer:3.69e-5 (favourable), Head and neck cancer:1.96e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 77.1,Mixed,,
STK16,"MPSK, PKL12",ENSG00000115661,Serine/threonine kinase 16,2,219245455-219250337,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA029450,Approved,,Approved,Cytosol,Endometrial cancer:6.09e-4 (favourable),Expressed in all,Expressed in all,,,"testis,thyroid gland: 28.6",Expressed in all,,
STK17A,DRAK1,ENSG00000164543,Serine/threonine kinase 17a,7,43582758-43626786,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA018138, HPA037979",Uncertain,,Approved,Nuclear speckles<br>Plasma membrane,,Expressed in all,Expressed in all,,,lymph node: 49.2,Expressed in all,,
STK17B,DRAK2,ENSG00000081320,Serine/threonine kinase 17b,2,196133566-196176503,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA034858,Enhanced,,Uncertain,Plasma membrane<br>Cytosol,Renal cancer:5.72e-8 (unfavourable),Expressed in all,Tissue enhanced,,bone marrow: 248.5,lymph node: 133.3,Expressed in all,,
STK19,"D6S60, G11, RP1",ENSG00000204344,Serine/threonine kinase 19,6,31971091-31982821,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA031510, HPA031511, HPA068559",Uncertain,,Supported,Nuclear speckles,Melanoma:1.18e-4 (unfavourable),Expressed in all,Mixed,,,testis: 1.2,Cell line enhanced,,HDLM-2: 1.9;REH: 1.7
STK24,"MST-3, MST3, MST3B, STE20, STK3",ENSG00000102572,Serine/threonine kinase 24,13,98445185-98577940,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026435, HPA026502",Enhanced,,Supported,Nucleoli<br>Cytosol,"Lung cancer:6.23e-6 (unfavourable), Renal cancer:6.91e-5 (favourable), Pancreatic cancer:5.81e-4 (unfavourable)",Expressed in all,Expressed in all,,,esophagus: 169.5,Expressed in all,,
STK25,"SOK1, YSK1",ENSG00000115694,Serine/threonine kinase 25,2,241492674-241509730,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA047147,Uncertain,,,,"Liver cancer:3.91e-8 (unfavourable), Colorectal cancer:6.03e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 168.2,Expressed in all,,
STK26,"MASK, MST4",ENSG00000134602,Serine/threonine kinase 26,X,132023265-132075943,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA059921,Approved,,Approved,Nucleus<br>Golgi apparatus<br>Centrosome<br>Cytosol,"Renal cancer:6.87e-5 (unfavourable), Liver cancer:6.82e-4 (unfavourable)",Expressed in all,Mixed,,,epididymis: 68.5,Mixed,,
STK3,"KRS1, MST2",ENSG00000104375,Serine/threonine kinase 3,8,98401403-98942827,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA007120, CAB025316",Uncertain,,Approved,Intermediate filaments<br>Rods & Rings,"Pancreatic cancer:9.21e-5 (unfavourable), Endometrial cancer:1.53e-4 (unfavourable), Lung cancer:4.25e-4 (unfavourable)",Expressed in all,Expressed in all,,,endometrium: 41.5,Mixed,,
STK31,"SgK396, TDRD8",ENSG00000196335,Serine/threonine kinase 31,7,23710167-23832513,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023194,Enhanced,,,,,Mixed,Tissue enriched,197,testis: 112.9,lung: 0.5,Cell line enriched,7,CACO-2: 15.0
STK32A,"MGC22688, YANK1",ENSG00000169302,Serine/threonine kinase 32A,5,147234963-147387852,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040236,Uncertain,,Approved,Centrosome,,Tissue enhanced,Tissue enhanced,,adrenal gland: 15.6;thyroid gland: 16.1,cerebral cortex: 7.3,Group enriched,6,RT4: 12.4;SK-MEL-30: 43.0
STK32B,"HSA250839, STK32, STKG6, YANK2",ENSG00000152953,Serine/threonine kinase 32B,4,5051442-5500998,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA058536,,,Approved,Microtubules,Renal cancer:1.63e-8 (favourable),Mixed,Tissue enhanced,,kidney: 15.8,testis: 8.6,Cell line enhanced,,HUVEC TERT2: 22.9;REH: 22.7;U-2197: 40.5;WM-115: 110.5
STK32C,"MGC23665, PKE, YANK3",ENSG00000165752,Serine/threonine kinase 32C,10,132207492-132331847,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA017894,Uncertain,,,,"Liver cancer:1.68e-6 (unfavourable), Renal cancer:5.31e-6 (unfavourable), Endometrial cancer:1.09e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 52.6,Expressed in all,,
STK33,,ENSG00000130413,Serine/threonine kinase 33,11,8391868-8594289,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA015742, HPA056855",Uncertain,,Approved,Nucleus<br>Nucleoli<br>Cytosol,Renal cancer:4.89e-6 (favourable),Mixed,Tissue enhanced,,fallopian tube: 67.1;testis: 93.1,parathyroid gland: 43.4,Cell line enhanced,,SCLC-21H: 26.8
STK35,"bA550O8.2, CLIK1",ENSG00000125834,Serine/threonine kinase 35,20,2101611-2177038,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026452, HPA051673",Uncertain,,Supported,Nucleus<br>Nuclear bodies,Liver cancer:9.46e-6 (unfavourable),Expressed in all,Expressed in all,,,testis: 25.2,Expressed in all,,
STK36,"FU, KIAA1278",ENSG00000163482,Serine/threonine kinase 36,2,218672026-218702716,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA027409, HPA027453, HPA030058",Approved,,Supported,Cytosol,Liver cancer:5.20e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 59.0,Expressed in all,,
STK38,NDR,ENSG00000112079,Serine/threonine kinase 38,6,36493892-36547470,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004673, HPA038623, HPA051324",Uncertain,,Approved,Cytosol,Melanoma:9.44e-5 (unfavourable),Expressed in all,Expressed in all,,,rectum: 40.3,Expressed in all,,
STK38L,"KIAA0965, NDR2",ENSG00000211455,Serine/threonine kinase 38 like,12,27243968-27325959,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038623, HPA051324",Approved,,Approved,Cytosol,Pancreatic cancer:5.82e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 65.3,Expressed in all,,
STK39,"DCHT, SPAK",ENSG00000198648,Serine/threonine kinase 39,2,167954020-168248141,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB046022, HPA061803, HPA062802",Enhanced,,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,"Liver cancer:5.67e-5 (unfavourable), Breast cancer:3.96e-4 (favourable)",Expressed in all,Mixed,,,testis: 71.4,Mixed,,
STK4,"KRS2, MST1, YSK3",ENSG00000101109,Serine/threonine kinase 4,20,44966474-45079959,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004038, HPA015270",Approved,,Enhanced,Nucleoplasm<br>Nuclear bodies<br>Cytosol,"Renal cancer:1.84e-5 (unfavourable), Liver cancer:8.04e-4 (unfavourable)",Expressed in all,Expressed in all,,,lymph node: 50.6,Expressed in all,,
STK40,"MGC4796, SgK495",ENSG00000196182,Serine/threonine kinase 40,1,36339624-36385896,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA008026,Uncertain,,Supported,Nucleoplasm<br>Cytosol,Pancreatic cancer:5.59e-4 (favourable),Expressed in all,Expressed in all,,,testis: 57.0,Expressed in all,,
STKLD1,"C9orf96, MGC43306, SGK071",ENSG00000198870,Serine/threonine kinase like domain containing 1,9,133376367-133406096,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA029902,Uncertain,,,,,Mixed,Tissue enriched,14,testis: 5.7,"cerebral cortex,epididymis: 0.3",Not detected,,
STRADA,"LYK5, NY-BR-96, Stlk, STRAD",ENSG00000266173,STE20-related kinase adaptor alpha,17,63682336-63741986,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA031637,Approved,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:6.08e-7 (unfavourable), Pancreatic cancer:5.34e-5 (favourable), Urothelial cancer:6.43e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 67.7,Expressed in all,,
STRADB,"ALS2CR2, CALS-21, ILPIP, ILPIPA, PAPK",ENSG00000082146,STE20-related kinase adaptor beta,2,201387858-201480846,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026549, HPA028520",Approved,,Supported,Aggresome<br>Cytosol,"Renal cancer:1.35e-4 (unfavourable), Thyroid cancer:4.45e-4 (favourable)",Expressed in all,Expressed in all,,,kidney: 73.4,Cell line enhanced,,LHCN-M2: 154.7
STS,"ARSC, ARSC1",ENSG00000101846,Steroid sulfatase,X,7219456-7354810,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA002904,Enhanced,,,,Pancreatic cancer:3.47e-4 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 36.5,adipose tissue: 18.9,Cell line enhanced,,U-266/70: 79.0
STT3A,"ITM1, MGC9042, STT3-A, TMC",ENSG00000134910,"STT3A, catalytic subunit of the oligosaccharyltransferase complex",11,125591712-125625215,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA030735,Approved,,Uncertain,Nucleoplasm<br>Vesicles<br>Cytosol,"Endometrial cancer:1.32e-4 (favourable), Liver cancer:3.57e-4 (unfavourable), Renal cancer:4.96e-4 (unfavourable)",Expressed in all,Tissue enriched,7,parathyroid gland: 1131.8,epididymis: 173.0,Expressed in all,,
STT3B,"FLJ90106, SIMP, STT3-B",ENSG00000163527,"STT3B, catalytic subunit of the oligosaccharyltransferase complex",3,31532638-31637622,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA036448, HPA036646",Approved,,Supported,Endoplasmic reticulum,Colorectal cancer:7.91e-5 (favourable),Expressed in all,Expressed in all,,,testis: 165.5,Expressed in all,,
STUB1,"CHIP, HSPABP2, NY-CO-7, SDCCAG7, UBOX1",ENSG00000103266,STIP1 homology and U-box containing protein 1,16,680224-682870,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB037202, CAB037209, HPA041222, HPA043531",Enhanced,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:6.49e-9 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 137.7,Expressed in all,,
STYK1,"DKFZp761P1010, NOK, SuRTK106",ENSG00000060140,Serine/threonine/tyrosine kinase 1,12,10618939-10674318,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA040468, HPA048569",Uncertain,,Approved,Nucleus<br>Plasma membrane,,Mixed,Mixed,,,rectum: 17.4,Cell line enhanced,,CAPAN-2: 23.5;HUVEC TERT2: 20.0;TIME: 18.2
SUCLA2,,ENSG00000136143,Succinate-CoA ligase ADP-forming beta subunit,13,47936491-48001354,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA039435, HPA039536, HPA061528",Enhanced,Supported,Enhanced,Mitochondria,"Renal cancer:7.59e-14 (favourable), Urothelial cancer:1.22e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 78.7,Expressed in all,,
SUCLG1,,ENSG00000163541,Succinate-CoA ligase alpha subunit,2,84423523-84460045,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA036683, HPA036684",Enhanced,,Supported,Plasma membrane<br>Mitochondria,"Renal cancer:2.21e-8 (favourable), Endometrial cancer:5.23e-4 (unfavourable)",Expressed in all,Expressed in all,,,kidney: 471.2,Expressed in all,,
SUCLG2,,ENSG00000172340,Succinate-CoA ligase GDP-forming beta subunit,3,67360460-67654614,"Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA046705, HPA051998",Enhanced,,Supported,Plasma membrane<br>Mitochondria,"Renal cancer:2.79e-10 (favourable), Colorectal cancer:1.08e-4 (favourable)",Expressed in all,Expressed in all,,,colon: 168.2,Expressed in all,,
SUGCT,"C7orf10, DERP13, FLJ11808, ORF19",ENSG00000175600,Succinyl-CoA:glutarate-CoA transferase,7,40134977-40860763,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026698, HPA026704, HPA026705",Enhanced,,,,"Renal cancer:3.93e-7 (favourable), Urothelial cancer:2.53e-4 (unfavourable)",Expressed in all,Tissue enhanced,,kidney: 45.0,liver: 14.6,Cell line enhanced,,HBEC3-KT: 30.6;LHCN-M2: 21.2
SULT1A1,"P-PST, STP, STP1",ENSG00000196502,Sulfotransferase family 1A member 1,16,28605196-28623625,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049500, HPA051051",Supported,,,,Lung cancer:7.02e-4 (favourable),Expressed in all,Expressed in all,,,duodenum: 136.6,Cell line enhanced,,EFO-21: 161.0;Hep G2: 241.3
SULT1A2,"HAST4, STP2",ENSG00000197165,Sulfotransferase family 1A member 2,16,28591943-28597109,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049500, HPA051051",Supported,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 49.2;small intestine: 49.2,liver: 21.0,Cell line enhanced,,BEWO: 9.6;EFO-21: 12.0;Hep G2: 33.5
SULT1A3,"STM, TL-PST",ENSG00000261052,Sulfotransferase family 1A member 3,16,30199228-30204310,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049500, HPA051051",Supported,,,,,Not detected,Expressed in all,,,duodenum: 106.1,Expressed in all,,
SULT1A4,,ENSG00000213648,Sulfotransferase family 1A member 4,16,29459889-29464976,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049500, HPA051051",Supported,,,,,Not detected,Tissue enhanced,,duodenum: 173.4;small intestine: 131.0,colon: 38.4,Cell line enhanced,,CAPAN-2: 107.9;EFO-21: 93.9;HEL: 76.5;Hep G2: 188.0;Karpas-707: 114.2
SULT1C3,,ENSG00000196228,Sulfotransferase family 1C member 3,2,108247195-108265351,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enriched,142,breast: 450.3,duodenum: 3.1,Not detected,,
SULT1E1,"EST, STE",ENSG00000109193,Sulfotransferase family 1E member 1,4,69810780-69860152,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028213, HPA028728, CAB047344",Enhanced,,Uncertain,Nuclear membrane<br>Cytosol,Cervical cancer:4.06e-4 (favourable),Mixed,Group enriched,7,duodenum: 27.7;liver: 18.7;skin: 7.6;small intestine: 29.7,adrenal gland: 3.1,Group enriched,17,HHSteC: 59.4;HSkMC: 23.3;hTCEpi: 19.7;HUVEC TERT2: 16.9
SULT2A1,"DHEA-ST, STD",ENSG00000105398,Sulfotransferase family 2A member 1,19,47870466-47886397,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB018755, HPA041487, HPA063633",Enhanced,,Supported,Cytosol,,Tissue enriched,Tissue enhanced,,adrenal gland: 189.9;liver: 514.2,small intestine: 91.1,Group enriched,30,Hep G2: 25.8;RT4: 20.3
SULT2B1,HSST2,ENSG00000088002,Sulfotransferase family 2B member 1,19,48552075-48599425,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB033013, HPA041724, HPA043539",Approved,,Supported,Vesicles<br>Cytosol,,Mixed,Tissue enhanced,,esophagus: 152.2;skin: 152.4,"cervix, uterine: 45.8",Cell line enhanced,,CAPAN-2: 59.3;MCF7: 32.5;T-47d: 31.4
SULT6B1,,ENSG00000138068,Sulfotransferase family 6B member 1,2,37167820-37196598,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,11,fallopian tube: 1.0;testis: 4.3,bone marrow: 0.2,Cell line enriched,6,WM-115: 2.2
SUOX,,ENSG00000139531,Sulfite oxidase,12,55997180-56006641,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038208, HPA038209",Approved,,,,"Renal cancer:4.77e-7 (favourable), Urothelial cancer:8.32e-5 (favourable), Pancreatic cancer:6.28e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 108.9,Mixed,,
SUPT16H,"CDC68, FACT, FACTP140, FLJ10857, FLJ14010, SPT16/CDC68",ENSG00000092201,"SPT16 homolog, facilitates chromatin remodeling subunit",14,21351472-21384266,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB022551, HPA049787",Enhanced,,Supported,Nucleus<br>Nucleoli fibrillar center,,Expressed in all,Expressed in all,,,parathyroid gland: 95.7,Expressed in all,,
SUPV3L1,SUV3,ENSG00000156502,Suv3 like RNA helicase,10,69180232-69209099,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038380, HPA038405",Enhanced,,Supported,Mitochondria,,Expressed in all,Expressed in all,,,testis: 29.0,Expressed in all,,
SUV39H1,"KMT1A, SUV39H",ENSG00000101945,Suppressor of variegation 3-9 homolog 1,X,48695554-48709012,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:1.91e-7 (unfavourable), Cervical cancer:8.93e-5 (favourable)",Expressed in all,Mixed,,,epididymis: 14.4,Expressed in all,,
SUV39H2,"FLJ23414, KMT1B",ENSG00000152455,Suppressor of variegation 3-9 homolog 2,10,14878820-14904315,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA045901, HPA057554",Enhanced,,Approved,Mitochondria,"Liver cancer:2.01e-6 (unfavourable), Renal cancer:5.71e-5 (unfavourable), Breast cancer:5.55e-4 (unfavourable)",Expressed in all,Tissue enriched,12,testis: 73.2,placenta: 6.1,Expressed in all,,
SYK,,ENSG00000165025,Spleen associated tyrosine kinase,9,90801787-90898549,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA001384, CAB007773",Enhanced,,Approved,Vesicles<br>Plasma membrane<br>Cytosol,,Expressed in all,Mixed,,,parathyroid gland: 96.0,Cell line enhanced,,Daudi: 89.3;HEL: 64.8;HL-60: 80.0;REH: 76.3
SYNJ1,"INPP5G, PARK20",ENSG00000159082,Synaptojanin 1,21,32628759-32728048,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA011916,Enhanced,,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,"Prostate cancer:2.58e-4 (unfavourable), Head and neck cancer:4.43e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 65.9,testis: 18.4,Expressed in all,,
SYNJ2,INPP5H,ENSG00000078269,Synaptojanin 2,6,157981887-158099176,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031575,Approved,,Approved,Microtubules<br>Cytosol,"Renal cancer:4.02e-6 (unfavourable), Breast cancer:2.63e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 34.8,Mixed,,
SYVN1,"DER3, HRD1",ENSG00000162298,Synoviolin 1,11,65121780-65134533,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA005480, HPA024300, CAB037030",Enhanced,,Supported,Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane,Head and neck cancer:6.88e-4 (favourable),Expressed in all,Expressed in all,,,tonsil: 73.8,Expressed in all,,
TAF1,"BA2R, CCG1, CCGS, DYT3, DYT3/TAF1, KAT4, NSCL2, TAF2A, TAFII250",ENSG00000147133,TATA-box binding protein associated factor 1,X,71366239-71532374,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001075, CAB016283",Supported,,Enhanced,Nucleoplasm,"Renal cancer:6.03e-4 (unfavourable), Lung cancer:6.54e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 26.2,Expressed in all,,
TALDO1,,ENSG00000177156,Transaldolase 1,11,747329-765024,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA040373, HPA048089",,,Enhanced,Nucleoplasm<br>Cytosol,Liver cancer:2.29e-4 (unfavourable),Expressed in all,Expressed in all,,,esophagus: 262.9,Expressed in all,,
TAMM41,"C3orf31, DKFZp434E0519, MGC16471",ENSG00000144559,TAM41 mitochondrial translocator assembly and maintenance homolog,3,11790442-11846919,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036834, HPA044861",Uncertain,,Approved,Cytosol,Colorectal cancer:1.23e-4 (favourable),Expressed in all,Mixed,,,epididymis: 11.8,Expressed in all,,
TAOK1,"FLJ14314, KIAA1361, MAP3K16, MARKK, PSK2, TAO1",ENSG00000160551,TAO kinase 1,17,29390464-29551904,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007669,Approved,,Approved,Vesicles,,Expressed in all,Expressed in all,,,parathyroid gland: 41.5,Expressed in all,,
TAOK2,"KIAA0881, MAP3K17, PSK, PSK1, TAO1, TAO2",ENSG00000149930,TAO kinase 2,16,29973641-29992261,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010650,Approved,,Supported,Nucleus<br>Nucleoli<br>Cytosol,"Endometrial cancer:3.87e-5 (favourable), Colorectal cancer:2.51e-4 (unfavourable), Renal cancer:3.66e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 36.9,Expressed in all,,
TAOK3,"DPK, JIK, MAP3K18",ENSG00000135090,TAO kinase 3,12,118149801-118372945,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA017160,Approved,,Uncertain,Mitochondria,,Expressed in all,Expressed in all,,,cerebral cortex: 48.8,Expressed in all,,
TARS,,ENSG00000113407,Threonyl-tRNA synthetase,5,33440696-33469539,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA037425,Approved,,Supported,Actin filaments<br>Cytosol,"Liver cancer:9.88e-7 (unfavourable), Breast cancer:6.14e-5 (unfavourable), Endometrial cancer:5.17e-4 (unfavourable), Renal cancer:9.63e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 44.3,Expressed in all,,
TARS2,"FLJ12528, TARSL1",ENSG00000143374,"Threonyl-tRNA synthetase 2, mitochondrial (putative)",1,150487364-150507609,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA028626,Approved,,Approved,Nucleoplasm<br>Intermediate filaments<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 29.2,Expressed in all,,
TARSL2,FLJ25005,ENSG00000185418,Threonyl-tRNA synthetase like 2,15,101653598-101724604,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA066697,Approved,,Approved,Cytosol,,Expressed in all,Expressed in all,,,cerebral cortex: 15.7,Expressed in all,,
TAT,,ENSG00000198650,Tyrosine aminotransferase,16,71565660-71577130,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,Liver cancer:6.51e-4 (favourable),Tissue enriched,Tissue enriched,8,liver: 619.8,breast: 75.9,Cell line enhanced,,Hep G2: 1.7
TBCK,"HSPC302, MGC16169",ENSG00000145348,TBC1 domain containing kinase,4,106041599-106321495,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA039951, HPA051611",Uncertain,,Approved,Nucleoplasm<br>Nucleoli fibrillar center,Renal cancer:3.20e-4 (favourable),Expressed in all,Mixed,,,testis: 16.0,Expressed in all,,
TBK1,NAK,ENSG00000183735,TANK binding kinase 1,12,64451880-64502108,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA045797, HPA060211",Uncertain,,Supported,Nucleoplasm,"Renal cancer:4.20e-6 (unfavourable), Liver cancer:3.30e-4 (unfavourable), Melanoma:3.48e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 49.3,Expressed in all,,
TBXAS1,"CYP5, CYP5A1, THAS, TS, TXAS, TXS",ENSG00000059377,Thromboxane A synthase 1,7,139777051-140020325,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA031257, HPA031258, HPA031259",Enhanced,,Supported,Vesicles,Renal cancer:1.14e-4 (unfavourable),Expressed in all,Mixed,,,spleen: 56.3,Cell line enhanced,,NB-4: 48.5;PC-3: 22.1;U-937: 48.2
TDG,,ENSG00000139372,Thymine DNA glycosylase,12,103965804-103988874,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA052263,Supported,,Supported,Nucleoplasm,"Renal cancer:1.90e-10 (unfavourable), Liver cancer:6.27e-5 (unfavourable), Melanoma:6.90e-5 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 23.8,Expressed in all,,
TDO2,"TDO, TPH2",ENSG00000151790,"Tryptophan 2,3-dioxygenase",4,155854738-155920406,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039611,Uncertain,,Uncertain,Plasma membrane<br>Cytosol,,Tissue enriched,Tissue enriched,18,liver: 278.3,appendix: 15.7,Group enriched,5,EFO-21: 7.3;HDLM-2: 14.7;U-87 MG: 8.6
TDRD12,"ECAT8, FLJ13072",ENSG00000173809,Tudor domain containing 12,19,32719753-32829580,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,8,epididymis: 10.9;testis: 33.5,ovary: 2.6,Group enriched,34,HDLM-2: 23.6;NTERA-2: 93.5
TDRD9,"C14orf75, DKFZp434N0820, FLJ36164, NET54",ENSG00000156414,Tudor domain containing 9,14,103928462-104052667,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Thyroid cancer:5.52e-4 (unfavourable),Mixed,Group enriched,6,parathyroid gland: 39.7;testis: 75.0,thyroid gland: 9.1,Cell line enhanced,,HDLM-2: 22.6;HeLa: 13.9;HMC-1: 82.8;RPTEC TERT1: 19.5
TEC,PSCTK4,ENSG00000135605,Tec protein tyrosine kinase,4,48135783-48269864,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA005733, HPA024657",Approved,,Supported,Plasma membrane,Ovarian cancer:7.12e-4 (favourable),Mixed,Mixed,,,epididymis: 5.0,Cell line enhanced,,HEL: 11.8;HMC-1: 17.4;U-266/70: 15.1;U-266/84: 10.6
TECR,"GPSN2, MRT14, SC2, TER",ENSG00000099797,"Trans-2,3-enoyl-CoA reductase",19,14517085-14565980,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA029780, HPA056488",Supported,,Supported,Endoplasmic reticulum,Urothelial cancer:2.60e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 404.6,Expressed in all,,
TEK,"CD202b, TIE-2, TIE2, VMCM, VMCM1",ENSG00000120156,TEK receptor tyrosine kinase,9,27109141-27230175,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB010359, HPA073265",Approved,,Supported,Plasma membrane<br>Microtubule organizing center,"Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 65.9,lung: 42.6,Group enriched,8,HUVEC TERT2: 74.6;NTERA-2: 44.2;TIME: 80.0
TERT,"EST2, hEST2, TCS1, TP2, TRT",ENSG00000164362,Telomerase reverse transcriptase,5,1253147-1295069,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA054641, HPA065897",Supported,,Enhanced,Nucleoplasm<br>Nuclear speckles<br>Cytosol,,Mixed,Not detected,,,"lymph node,testis: 0.5",Cell line enhanced,,ASC TERT1: 349.5;fHDF/TERT166: 388.9;HBEC3-KT: 725.5;hTEC/SVTERT24-B: 626.8;TIME: 672.9
TESK1,,ENSG00000107140,Testis-specific kinase 1,9,35605305-35610041,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,Liver cancer:9.68e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 46.2,Expressed in all,,
TESK2,,ENSG00000070759,Testis-specific kinase 2,1,45343883-45491166,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027257, HPA063869",Uncertain,,Enhanced,Nucleoplasm,Cervical cancer:2.22e-4 (favourable),Expressed in all,Mixed,,,prostate: 25.0,Mixed,,
TET1,"bA119F7.1, CXXC6, KIAA1676, LCX",ENSG00000138336,Tet methylcytosine dioxygenase 1,10,68560656-68694482,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA019032, HPA057273",,,Supported,Nucleus<br>Nuclear membrane,,Tissue enriched,Mixed,,,parathyroid gland: 2.4,Cell line enhanced,,BEWO: 17.6;HAP1: 21.7;K-562: 11.0;NTERA-2: 12.2
TET2,"FLJ20032, KIAA1546",ENSG00000168769,Tet methylcytosine dioxygenase 2,4,105145875-105279816,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA043135,Supported,,Approved,Nucleoplasm,,Mixed,Mixed,,,bone marrow: 15.7,Mixed,,
TET3,"hCG_40738, MGC22014",ENSG00000187605,Tet methylcytosine dioxygenase 3,2,73986404-74108176,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA050845,Approved,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:3.58e-5 (unfavourable),Expressed in all,Mixed,,,skin: 17.9,Mixed,,
TEX14,CT113,ENSG00000121101,"Testis expressed 14, intercellular bridge forming factor",17,58556678-58692055,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA030620, HPA077020",Enhanced,,Approved,Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol,,Mixed,Tissue enriched,43,testis: 48.9,bone marrow: 1.1,Cell line enhanced,,HDLM-2: 5.9;Karpas-707: 5.7;MCF7: 2.5
TFR2,"HFE3, TFRC2",ENSG00000106327,Transferrin receptor 2,7,100620416-100642779,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA011937, CAB016255",Enhanced,,,,Liver cancer:2.48e-4 (favourable),Tissue enriched,Tissue enriched,11,liver: 155.5,bone marrow: 13.9,Group enriched,14,HEL: 62.3;HMC-1: 81.2;K-562: 58.4
TFRC,"CD71, p90, TFR1",ENSG00000072274,Transferrin receptor,3,196027183-196082189,"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000153, HPA028598",Enhanced,,Supported,Endosomes<br>Lysosomes,"Liver cancer:1.15e-4 (unfavourable), Thyroid cancer:2.96e-4 (unfavourable), Cervical cancer:3.67e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 157.4,Expressed in all,,
TGDS,"SDR2E1, TDPGD",ENSG00000088451,"TDP-glucose 4,6-dehydratase",13,94574051-94596257,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA039927, HPA040857",Approved,,Approved,Nucleus<br>Nucleoli<br>Intermediate filaments<br>Cleavage furrow,Prostate cancer:2.48e-4 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 21.7,Expressed in all,,
TGFBR1,"ACVRLK4, ALK-5, ALK5, ESS1, MSSE",ENSG00000106799,Transforming growth factor beta receptor 1,9,99104038-99154192,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002441, CAB031481, HPA056473",Uncertain,,Supported,Vesicles<br>Plasma membrane,,Expressed in all,Expressed in all,,,placenta: 69.8,Expressed in all,,
TGFBR2,MFS2,ENSG00000163513,Transforming growth factor beta receptor 2,3,30606502-30694142,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,CAB073537,,,Supported,Plasma membrane,,Expressed in all,Expressed in all,,,adipose tissue: 292.3,Cell line enhanced,,ASC TERT1: 366.2;LHCN-M2: 371.8;TIME: 336.9
TGM1,"ICR2, LI, LI1, TGASE, TGK",ENSG00000092295,Transglutaminase 1,14,24249114-24264432,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB015159, HPA040171",Enhanced,,,,,Tissue enhanced,Tissue enriched,12,esophagus: 831.8,tonsil: 72.2,Cell line enhanced,,BEWO: 33.0;HaCaT: 42.3;MCF7: 27.0;SK-BR-3: 31.6
TGM2,TGC,ENSG00000198959,Transglutaminase 2,20,38127387-38166578,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002598, HPA021019, HPA029518",Enhanced,,Approved,Plasma membrane<br>Cytosol,"Renal cancer:1.67e-7 (unfavourable), Pancreatic cancer:2.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 461.0",placenta: 319.8,Cell line enhanced,,CAPAN-2: 1300.3;EFO-21: 458.7;HUVEC TERT2: 559.8;TIME: 720.5
TGM3,TGE,ENSG00000125780,Transglutaminase 3,20,2296001-2341078,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA004728,Enhanced,,,,,Tissue enriched,Tissue enriched,12,esophagus: 1513.9,tonsil: 126.4,Cell line enriched,7,EFO-21: 5.7
TGM4,TGP,ENSG00000163810,Transglutaminase 4,3,44874608-44914990,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA032072, CAB033571",Enhanced,,,,,Tissue enriched,Tissue enriched,465,prostate: 689.9,adrenal gland: 1.4,Cell line enhanced,,BEWO: 4.7;NB-4: 1.7;RPMI-8226: 1.3;SH-SY5Y: 1.5
TGM5,TGX,ENSG00000104055,Transglutaminase 5,15,43232595-43266857,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,7,esophagus: 8.4;skin: 22.3,breast: 2.3,Cell line enriched,8,HEL: 16.7
TGM6,"dJ734P14.3, SCA35, TGM3L, TGY",ENSG00000166948,Transglutaminase 6,20,2380908-2432753,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA059196,Uncertain,,,,,Not detected,Not detected,,,tonsil: 0.4,Not detected,,
TGM7,TGMZ,ENSG00000159495,Transglutaminase 7,15,43276280-43302255,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at transcript level,,,,,,,Tissue enriched,Group enriched,5,testis: 1.5;tonsil: 1.5,esophagus: 0.2,Cell line enriched,33,EFO-21: 3.3
TH,DYT5b,ENSG00000180176,Tyrosine hydroxylase,11,2163929-2171877,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB002522, HPA013768, HPA061003, CAB072340",Enhanced,Supported,,,,Tissue enhanced,Tissue enriched,81,adrenal gland: 259.8,adipose tissue: 3.2,Group enriched,26,PC-3: 54.8;SK-BR-3: 15.7
THEM4,CTMP,ENSG00000159445,Thioesterase superfamily member 4,1,151873584-151909808,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028161,Approved,,,,"Liver cancer:1.38e-4 (unfavourable), Pancreatic cancer:2.51e-4 (favourable)",Expressed in all,Expressed in all,,,"epididymis,kidney: 11.6",Mixed,,
THEM5,FLJ37964,ENSG00000196407,Thioesterase superfamily member 5,1,151847263-151853697,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enriched,25,skin: 204.8,cerebral cortex: 8.3,Cell line enriched,6,HDLM-2: 64.7
THG1L,"FLJ11601, FLJ20546, hTHG1, ICF45, IHG-1",ENSG00000113272,TRNA-histidine guanylyltransferase 1 like,5,157731197-157741448,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035877, HPA035878",Approved,,,,Renal cancer:3.93e-6 (unfavourable),Expressed in all,Mixed,,,endometrium: 10.3,Expressed in all,,
THOP1,,ENSG00000172009,Thimet oligopeptidase 1,19,2785460-2815807,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB025497, HPA035262",Uncertain,,Supported,Cytosol,"Endometrial cancer:2.35e-4 (favourable), Stomach cancer:5.90e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 36.1,Mixed,,
THTPA,THTPASE,ENSG00000259431,Thiamine triphosphatase,14,23555988-23560271,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028876,Approved,,Uncertain,Nucleus<br>Nucleoli,Renal cancer:1.70e-9 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 33.5,Expressed in all,,
TIE1,"JTK14, TIE",ENSG00000066056,Tyrosine kinase with immunoglobulin like and EGF like domains 1,1,43300993-43323108,"Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enhanced,,placenta: 70.6,lung: 40.1,Cell line enhanced,,EFO-21: 100.1;HUVEC TERT2: 199.8;TIME: 171.4
TIGAR,C12orf5,ENSG00000078237,TP53 induced glycolysis regulatory phosphatase,12,4307763-4354593,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB034010, HPA040354, HPA044111",Approved,,Enhanced,Cytosol,Liver cancer:3.18e-4 (unfavourable),Expressed in all,Mixed,,,smooth muscle: 9.9,Cell line enhanced,,BEWO: 81.8
TINAG,,ENSG00000137251,Tubulointerstitial nephritis antigen,6,54307859-54390152,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA035427,Approved,,,,"Liver cancer:2.05e-5 (unfavourable), Renal cancer:8.75e-5 (favourable)",Tissue enhanced,Tissue enriched,7,kidney: 113.9,small intestine: 15.7,Cell line enriched,36,RPTEC TERT1: 69.3
TINAGL1,"ARG1, LCN7, LIECG3, P3ECSL, TINAGRP",ENSG00000142910,Tubulointerstitial nephritis antigen like 1,1,31576485-31587686,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048695,Approved,,,,"Renal cancer:3.65e-6 (favourable), Thyroid cancer:9.64e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 268.9,adipose tissue: 102.6,Cell line enhanced,,BEWO: 313.9;EFO-21: 383.9;TIME: 309.9
TIPARP,"DDF1, DKFZP434J214, DKFZp686N0351, PARP-1, PARP-7, PARP7, pART14, RM1",ENSG00000163659,TCDD inducible poly(ADP-ribose) polymerase,3,156673235-156706770,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA036796,Uncertain,,Approved,Microtubules,Breast cancer:2.00e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 232.4,Expressed in all,,
TK1,,ENSG00000167900,Thymidine kinase 1,17,78174075-78187233,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB004683,Enhanced,,,,"Renal cancer:6.50e-11 (unfavourable), Lung cancer:3.03e-5 (unfavourable), Liver cancer:6.87e-4 (unfavourable)",Expressed in all,Mixed,,,bone marrow: 45.7,Expressed in all,,
TK2,SCA31,ENSG00000166548,"Thymidine kinase 2, mitochondrial",16,66508003-66552544,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA041162,Uncertain,,,,Renal cancer:2.18e-6 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 89.9,Mixed,,
TKFC,"DAK, DKFZP586B1621, NET45",ENSG00000149476,Triokinase and FMN cyclase,11,61333210-61353295,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039486, HPA048186",Enhanced,,Approved,Nucleus<br>Cytosol,"Endometrial cancer:1.32e-5 (favourable), Renal cancer:8.38e-5 (favourable)",Expressed in all,Expressed in all,,,duodenum: 194.2,Expressed in all,,
TKT,,ENSG00000163931,Transketolase,3,53224707-53256052,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA029480, HPA029481",Enhanced,,Enhanced,Nucleoplasm,Liver cancer:7.21e-6 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 431.3,Expressed in all,,
TKTL1,"TKR, TKT2",ENSG00000007350,Transketolase like 1,X,154295671-154330350,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000505, CAB032191",Enhanced,,,,,Tissue enriched,Tissue enriched,141,testis: 225.8,"heart muscle,lung: 1.5",Cell line enriched,147,THP-1: 315.9
TKTL2,"DKFZP434L1717, FLJ32975",ENSG00000151005,Transketolase like 2,4,163471093-163473746,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,495,testis: 103.8,spleen: 0.2,Not detected,,
TLK1,"KIAA0137, PKU-BETA",ENSG00000198586,Tousled like kinase 1,2,170990823-171231314,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA016043,Approved,,Enhanced,Nucleus,,Expressed in all,Expressed in all,,,parathyroid gland: 40.9,Expressed in all,,
TLK2,"MGC44450, PKU-ALPHA",ENSG00000146872,Tousled like kinase 2,17,62458658-62615481,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,Liver cancer:9.40e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 96.2,Expressed in all,,
TLL1,,ENSG00000038295,Tolloid like 1,4,165873258-166103895,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA060767,,,Approved,Vesicles,,Mixed,Tissue enhanced,,placenta: 10.5,gallbladder: 4.4,Cell line enhanced,,HeLa: 4.3;Karpas-707: 7.1;PC-3: 3.3
TLL2,,ENSG00000095587,Tolloid like 2,10,96364606-96513918,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 1.9,heart muscle: 1.0,Cell line enriched,8,RPTEC TERT1: 15.3
TM7SF2,"ANG1, DHCR14A, NET47",ENSG00000149809,Transmembrane 7 superfamily member 2,11,65111845-65116384,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA030691, HPA072704",Approved,,Supported,Endoplasmic reticulum<br>Vesicles,Renal cancer:8.49e-8 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 160.5,Cell line enhanced,,T-47d: 122.6
TMEM129,D4S2561E,ENSG00000168936,Transmembrane protein 129,4,1715952-1721358,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA060920,,,Approved,Vesicles,Renal cancer:9.64e-8 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 36.1,Expressed in all,,
TMEM55A,DKFZp762O076,ENSG00000155099,Transmembrane protein 55A,8,90993796-91041064,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014591,Approved,,,,"Liver cancer:3.76e-5 (unfavourable), Cervical cancer:1.01e-4 (unfavourable), Head and neck cancer:1.54e-4 (unfavourable), Stomach cancer:8.01e-4 (unfavourable)",Expressed in all,Mixed,,,cerebral cortex: 21.7,Mixed,,
TMEM55B,"C14orf9, MGC26684",ENSG00000165782,Transmembrane protein 55B,14,20457719-20461612,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA048528,Approved,,,,Renal cancer:1.01e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 42.0,Expressed in all,,
TMEM86B,MGC30208,ENSG00000180089,Transmembrane protein 86B,19,55226639-55229264,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA057689,Uncertain,,Approved,Midbody<br>Centrosome,"Pancreatic cancer:9.97e-6 (favourable), Liver cancer:3.13e-4 (favourable)",Tissue enriched,Mixed,,,gallbladder: 6.6,Mixed,,
TMLHE,"BBOX2, FLJ10727, TMLH, XAP130",ENSG00000185973,"Trimethyllysine hydroxylase, epsilon",X,155490115-155669944,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA034589, HPA040331",Approved,,Supported,Mitochondria,Renal cancer:3.68e-6 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 30.7,Mixed,,
TMPRSS11A,ECRG1,ENSG00000187054,"Transmembrane protease, serine 11A",4,67909385-67964140,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Group enriched,Group enriched,64,esophagus: 96.0;tonsil: 26.0,"cervix, uterine: 0.9",Not detected,,
TMPRSS11B,,ENSG00000185873,"Transmembrane protease, serine 11B",4,68226653-68245720,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Head and neck cancer:6.91e-4 (favourable),Group enriched,Group enriched,184,esophagus: 311.6;tonsil: 74.5,"cervix, uterine: 1.0",Not detected,,
TMPRSS11D,,ENSG00000153802,"Transmembrane protease, serine 11D",4,67820876-67884032,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA052834,Uncertain,,,,,Group enriched,Group enriched,39,esophagus: 70.5;tonsil: 30.6,"cervix, uterine: 1.3",Not detected,,
TMPRSS11E,"DESC1, TMPRSS11E2",ENSG00000087128,"Transmembrane protease, serine 11E",4,68447449-68497604,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA051062,Uncertain,,,,Lung cancer:6.73e-4 (unfavourable),Group enriched,Tissue enriched,5,esophagus: 128.2,epididymis: 25.0,Cell line enhanced,,HaCaT: 1.4
TMPRSS11F,FLJ16046,ENSG00000198092,"Transmembrane protease, serine 11F",4,68053198-68129880,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA026911,Uncertain,,,,,Group enriched,Group enriched,7,esophagus: 16.7;skin: 11.0;tonsil: 3.7,breast: 1.5,Cell line enhanced,,K-562: 1.4
TMPRSS12,"CT151, MGC57341",ENSG00000186452,"Transmembrane protease, serine 12",12,50842920-50887884,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,75,testis: 39.5,epididymis: 0.5,Not detected,,
TMPRSS13,"MSPL, TMPRSS11",ENSG00000137747,"Transmembrane protease, serine 13",11,117900643-117929459,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 36.4,"cervix, uterine,esophagus: 10.5",Cell line enhanced,,BEWO: 32.1;MCF7: 22.3;SK-BR-3: 36.2;T-47d: 46.4
TMPRSS15,"ENTK, MGC133046, PRSS7",ENSG00000154646,"Transmembrane protease, serine 15",21,18269116-18485879,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA015611, HPA072934",Enhanced,,,,,Group enriched,Tissue enriched,44,duodenum: 1010.9,small intestine: 22.7,Group enriched,22,U-138 MG: 50.9;U-87 MG: 140.8
TMPRSS2,PRSS10,ENSG00000184012,"Transmembrane protease, serine 2",21,41464551-41531116,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA034493, HPA035787",Enhanced,,Supported,Nucleoplasm<br>Cell Junctions,"Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable)",Tissue enriched,Tissue enhanced,,prostate: 489.3,stomach: 142.6,Cell line enhanced,,CACO-2: 21.8;RT4: 50.4;SK-BR-3: 9.5
TMPRSS3,"DFNB10, DFNB8",ENSG00000160183,"Transmembrane protease, serine 3",21,42371890-42396846,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,"Colorectal cancer:3.64e-4 (unfavourable), Renal cancer:8.24e-4 (unfavourable)",Mixed,Tissue enhanced,,fallopian tube: 35.2,stomach: 13.7,Cell line enhanced,,HEL: 58.2;SiHa: 35.3;U-266/84: 182.5
TMPRSS4,"MT-SP2, TMPRSS3",ENSG00000137648,"Transmembrane protease, serine 4",11,118077012-118121890,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006238,Uncertain,,Approved,Nucleoplasm<br>Cytosol,Pancreatic cancer:3.14e-4 (unfavourable),Mixed,Tissue enhanced,,rectum: 77.1;urinary bladder: 77.3,esophagus: 73.8,Group enriched,9,A-431: 25.3;CAPAN-2: 123.9;HaCaT: 53.5;RPTEC TERT1: 73.7;RT4: 99.4
TMPRSS5,"MGC141886, MGC148044",ENSG00000166682,"Transmembrane protease, serine 5",11,113687550-113706373,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA010992,,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 10.1,salivary gland: 3.0,Cell line enhanced,,CAPAN-2: 2.9;WM-115: 2.6
TMPRSS6,FLJ30744,ENSG00000187045,"Transmembrane protease, serine 6",22,37065436-37109563,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Liver cancer:8.16e-6 (favourable),Group enriched,Group enriched,6,liver: 40.8;testis: 8.6,stomach: 4.0,Cell line enhanced,,Hep G2: 3.6;SCLC-21H: 10.1
TMPRSS7,,ENSG00000176040,"Transmembrane protease, serine 7",3,112034843-112081269,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA040630,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 2.5,fallopian tube: 0.6,Not detected,,
TMPRSS9,,ENSG00000178297,"Transmembrane protease, serine 9",19,2389771-2426239,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA051483,Uncertain,,,,,Mixed,Tissue enhanced,,spleen: 2.3;testis: 1.7,skin: 0.8,Cell line enhanced,,Karpas-707: 1.8;U-266/70: 1.7
TMX3,"FLJ20793, KIAA1830, PDIA13, TXNDC10",ENSG00000166479,Thioredoxin related transmembrane protein 3,18,68673688-68715298,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA014157,Uncertain,,,,Renal cancer:2.87e-4 (unfavourable),Expressed in all,Expressed in all,,,lymph node: 31.4,Expressed in all,,
TNFAIP3,"A20, OTUD7C",ENSG00000118503,TNF alpha induced protein 3,6,137867188-137883312,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002116, HPA067479",Approved,,Supported,Vesicles,Renal cancer:6.05e-4 (unfavourable),Expressed in all,Expressed in all,,,bone marrow: 345.2,Cell line enhanced,,Karpas-707: 118.8;REH: 135.9
TNIK,KIAA0551,ENSG00000154310,TRAF2 and NCK interacting kinase,3,171061339-171460408,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA012128, HPA012297",Approved,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Mixed,,,cerebral cortex: 35.5,Cell line enhanced,,HEL: 58.9;HMC-1: 63.1;WM-115: 53.8
TNK1,,ENSG00000174292,Tyrosine kinase non receptor 1,17,7380534-7389774,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA012065, HPA056452",Uncertain,,Approved,Cell Junctions,"Urothelial cancer:1.52e-4 (favourable), Endometrial cancer:4.28e-4 (favourable), Renal cancer:6.40e-4 (favourable)",Mixed,Mixed,,,skin: 5.1,Cell line enhanced,,HaCaT: 8.0;T-47d: 6.9
TNK2,"ACK, ACK1, p21cdc42Hs",ENSG00000061938,Tyrosine kinase non receptor 2,3,195863364-195911945,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA041954,Approved,,Approved,Cytosol,"Urothelial cancer:1.00e-4 (favourable), Renal cancer:1.30e-4 (unfavourable), Endometrial cancer:8.96e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 109.5,Expressed in all,,
TNKS,"PARP-5a, PARP5A, pART5, TIN1, TINF1, TNKS1",ENSG00000173273,Tankyrase,8,9555914-9782346,"Enzymes, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA025690,Approved,,Approved,Nucleoplasm<br>Nuclear membrane,,Expressed in all,Expressed in all,,,testis: 52.8,Expressed in all,,
TNKS2,"PARP-5b, PARP-5c, PARP5B, PARP5C, pART6, TANK2, TNKL",ENSG00000107854,Tankyrase 2,10,91798312-91865276,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA036606,,,Approved,Microtubules,,Expressed in all,Expressed in all,,,thyroid gland: 50.4,Expressed in all,,
TNNI3K,CARK,ENSG00000116783,TNNI3 interacting kinase,1,74235401-74544428,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,7,heart muscle: 39.5,testis: 5.3,Not detected,,
TOP1,,ENSG00000198900,Topoisomerase (DNA) I,20,41028818-41124487,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB009058, HPA019039",Enhanced,,Supported,Nucleus<br>Nucleoli fibrillar center,Liver cancer:6.42e-4 (unfavourable),Expressed in all,Expressed in all,,,placenta: 71.7,Expressed in all,,
TOP1MT,,ENSG00000184428,"Topoisomerase (DNA) I, mitochondrial",8,143304384-143359979,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001915, HPA021542",Approved,,Supported,Mitochondria,Renal cancer:1.52e-7 (unfavourable),Expressed in all,Expressed in all,,,testis: 41.2,Expressed in all,,
TOP2A,TOP2,ENSG00000131747,Topoisomerase (DNA) II alpha,17,40388516-40417950,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002448, HPA006458, HPA026773",Enhanced,Approved,Supported,Nucleus<br>Nucleoli,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.92e-6 (unfavourable), Pancreatic cancer:3.83e-5 (unfavourable), Lung cancer:4.99e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 108.5,lymph node: 47.7,Expressed in all,,
TOP2B,,ENSG00000077097,Topoisomerase (DNA) II beta,3,25597905-25664907,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004601, HPA024120, HPA050441",Supported,,Enhanced,Nucleus,"Liver cancer:1.86e-7 (unfavourable), Renal cancer:2.43e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 107.4,Expressed in all,,
TOP3A,"TOP3, ZGRF7",ENSG00000177302,Topoisomerase (DNA) III alpha,17,18271428-18315007,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,CAB002449,Approved,,,,"Pancreatic cancer:1.39e-4 (favourable), Prostate cancer:4.59e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 12.4,Expressed in all,,
TOP3B,,ENSG00000100038,Topoisomerase (DNA) III beta,22,21957025-21982816,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA069678,,,Approved,Vesicles,,Not detected,Mixed,,,spleen: 18.9,Expressed in all,,
TOPORS,"LUN, RP31, TP53BPL",ENSG00000197579,TOP1 binding arginine/serine rich protein,9,32540544-32552553,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA060640, HPA065661",Enhanced,,Supported,Nucleoplasm,"Renal cancer:6.64e-6 (favourable), Ovarian cancer:7.07e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 27.6,Expressed in all,,
TP53RK,"BUD32, C20orf64, dJ101A2.2, Nori-2p, prpk",ENSG00000172315,TP53 regulating kinase,20,46684365-46689779,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004688, HPA015837",Approved,,,,"Liver cancer:6.27e-5 (unfavourable), Endometrial cancer:6.70e-5 (unfavourable)",Expressed in all,Expressed in all,,,testis: 16.6,Expressed in all,,
TPH1,"TPH, TPRH",ENSG00000129167,Tryptophan hydroxylase 1,11,18017564-18042426,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB010767, HPA022483",Enhanced,,Uncertain,Cytosol,,Mixed,Group enriched,6,colon: 8.8;duodenum: 10.2;rectum: 21.0;small intestine: 12.6;stomach: 15.5,prostate: 2.4,Mixed,,
TPH2,"FLJ37295, NTPH",ENSG00000139287,Tryptophan hydroxylase 2,12,71938846-72186618,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA046274, CAB078198",Enhanced,Supported,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.0,testis: 0.2,Not detected,,
TPI1,,ENSG00000111669,Triosephosphate isomerase 1,12,6867119-6870948,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA050924, HPA053568",Uncertain,,Enhanced,Nucleoplasm,"Liver cancer:1.04e-5 (unfavourable), Renal cancer:6.54e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 942.7,Expressed in all,,
TPK1,"HTPK1, PP20",ENSG00000196511,Thiamin pyrophosphokinase 1,7,144451941-144836395,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA021545, HPA021849",Approved,,Approved,Vesicles,,Mixed,Mixed,,,duodenum: 14.4,Cell line enhanced,,AN3-CA: 65.0;EFO-21: 19.9
TPMT,,ENSG00000137364,Thiopurine S-methyltransferase,6,18128311-18155074,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA019851,Approved,,,,"Endometrial cancer:8.45e-5 (unfavourable), Renal cancer:1.10e-4 (favourable), Ovarian cancer:1.41e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 129.8,Expressed in all,,
TPO,TPX,ENSG00000115705,Thyroid peroxidase,2,1374223-1543711,"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007987, CAB009587",Enhanced,,,,,Tissue enriched,Tissue enriched,103,thyroid gland: 1817.4,spleen: 17.6,Cell line enhanced,,Karpas-707: 6.9;RPMI-8226: 2.9
TPP1,"CLN2, SCAR7",ENSG00000166340,Tripeptidyl peptidase 1,11,6612763-6619461,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA037709, HPA044868",Enhanced,,,,"Liver cancer:1.11e-4 (unfavourable), Head and neck cancer:4.31e-4 (unfavourable), Stomach cancer:4.46e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 206.9,Expressed in all,,
TPP2,TPPII,ENSG00000134900,Tripeptidyl peptidase 2,13,102597003-102679958,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021069, HPA049630",Approved,,Supported,Nuclear bodies<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 66.8,Expressed in all,,
TPSAB1,"TPS1, TPS2, TPSB1",ENSG00000172236,Tryptase alpha/beta 1,16,1240696-1242554,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016369, CAB022175, HPA049153, HPA049554",Supported,,,,Head and neck cancer:9.62e-6 (favourable),Mixed,Tissue enhanced,,gallbladder: 211.6,lung: 158.5,Cell line enriched,163,HMC-1: 3406.5
TPSB2,,ENSG00000197253,Tryptase beta 2 (gene/pseudogene),16,1227272-1230184,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA049153, HPA049554",Supported,,,,,Mixed,Tissue enhanced,,gallbladder: 156.9,lung: 117.5,Cell line enriched,7,HMC-1: 262.0
TPSD1,,ENSG00000095917,Tryptase delta 1,16,1256059-1258998,"Enzymes, Predicted secreted proteins",Evidence at protein level,"CAB002215, CAB032871, HPA040182, HPA049554",Supported,,Uncertain,Nuclear speckles,,Mixed,Tissue enhanced,,lung: 26.9,gallbladder: 20.3,Group enriched,46,HEL: 25.4;HMC-1: 36.4
TPSG1,"PRSS31, TMT",ENSG00000116176,Tryptase gamma 1,16,1221651-1225257,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA060458,Enhanced,,,,Renal cancer:1.76e-8 (unfavourable),Tissue enhanced,Tissue enhanced,,colon: 14.6;duodenum: 14.3;rectum: 9.5;small intestine: 10.5,ovary: 2.5,Group enriched,8,HMC-1: 20.4;MCF7: 6.0
TPST1,TANGO13A,ENSG00000169902,Tyrosylprotein sulfotransferase 1,7,66205199-66420543,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA047415, HPA061837",Approved,,Approved,Golgi apparatus,"Renal cancer:8.16e-6 (unfavourable), Urothelial cancer:3.73e-5 (unfavourable), Stomach cancer:8.78e-4 (unfavourable)",Expressed in all,Mixed,,,gallbladder: 55.7,Mixed,,
TPST2,TANGO13B,ENSG00000128294,Tyrosylprotein sulfotransferase 2,22,26521983-26596717,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA021054,Approved,,,,"Renal cancer:2.34e-6 (unfavourable), Endometrial cancer:8.08e-5 (favourable)",Expressed in all,Expressed in all,,,epididymis: 135.8,Expressed in all,,
TPTE,"CT44, PTEN2",ENSG00000274391,Transmembrane phosphatase with tensin homology,21,10521553-10606140,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA049690, HPA068342",Enhanced,,Approved,Endoplasmic reticulum<br>Cytosol,,Tissue enriched,Tissue enriched,247,testis: 191.3,placenta: 0.7,Cell line enhanced,,BEWO: 6.4;K-562: 7.3;Karpas-707: 4.6;PC-3: 4.4;RPMI-8226: 6.2;U-2 OS: 4.3;U-266/70: 5.8
TPTE2,TPIP,ENSG00000132958,Transmembrane phosphoinositide 3-phosphatase and tensin homolog 2,13,19422877-19536762,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA068342,,,Approved,Endoplasmic reticulum<br>Cytosol,,Tissue enriched,Tissue enriched,35,testis: 11.9,tonsil: 0.3,Cell line enhanced,,HDLM-2: 4.4
TRAF2,TRAP3,ENSG00000127191,TNF receptor associated factor 2,9,136881912-136926607,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004603, HPA009972, HPA010634",Uncertain,,Enhanced,Cytosol,"Renal cancer:2.09e-4 (unfavourable), Liver cancer:3.06e-4 (unfavourable), Colorectal cancer:9.32e-4 (unfavourable)",Expressed in all,Expressed in all,,,lymph node: 22.5,Expressed in all,,
TRAF3,"CAP-1, CD40bp, CRAF1, LAP1",ENSG00000131323,TNF receptor associated factor 3,14,102777476-102911500,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002933,Uncertain,,,,"Liver cancer:1.02e-5 (unfavourable), Pancreatic cancer:2.42e-5 (favourable)",Expressed in all,Mixed,,,appendix: 25.7,Expressed in all,,
TRAF6,RNF85,ENSG00000175104,TNF receptor associated factor 6,11,36487027-36510272,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB004605, HPA019805, HPA020599",Approved,,Supported,Nucleoli<br>Mitochondria,Renal cancer:1.36e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 16.2,Expressed in all,,
TRAF7,"DKFZp586I021, MGC7807, RFWD1, RNF119",ENSG00000131653,TNF receptor associated factor 7,16,2155698-2178129,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041229,Approved,,Supported,Vesicles<br>Plasma membrane,,Expressed in all,Expressed in all,,,skin: 40.6,Expressed in all,,
TRAIP,"RNF206, TRIP",ENSG00000183763,TRAF interacting protein,3,49828599-49856574,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036261, HPA036262",Enhanced,,Supported,Plasma membrane<br>Cytosol,Liver cancer:8.77e-5 (unfavourable),Expressed in all,Mixed,,,testis: 11.3,Mixed,,
TRDMT1,"DNMT2, RNMT1",ENSG00000107614,TRNA aspartic acid methyltransferase 1,10,17142254-17202054,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB009468, HPA036945, HPA036946",Approved,,Approved,Nucleus<br>Nucleoli<br>Centrosome,,Mixed,Mixed,,,parathyroid gland: 8.7,Mixed,,
TREH,"MGC129621, TRE, TREA",ENSG00000118094,Trehalase,11,118657316-118679690,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA039913, HPA042045",Enhanced,,,,"Renal cancer:2.33e-6 (favourable), Liver cancer:3.76e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 60.6;small intestine: 72.6,kidney: 13.5,Cell line enhanced,,BEWO: 1.5
TREX1,"AGS1, DRN3",ENSG00000213689,Three prime repair exonuclease 1,3,48465811-48467645,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA035437, HPA046721",Supported,,Supported,Cytosol,,Not detected,Expressed in all,,,spleen: 30.9,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 66.5
TREX2,,ENSG00000183479,Three prime repair exonuclease 2,X,153444720-153470587,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA054060,Uncertain,,,,,Mixed,Tissue enriched,8,skin: 28.8,seminal vesicle: 3.4,Cell line enhanced,,U-937: 5.4
TRHDE,"PAP-II, PGPEP2, TRH-DE",ENSG00000072657,Thyrotropin releasing hormone degrading enzyme,12,72087266-72670757,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:1.53e-7 (favourable),Tissue enhanced,Mixed,,,cerebral cortex: 7.9,Cell line enhanced,,BJ: 25.6;BJ hTERT+: 23.6;EFO-21: 14.6
TRIB1,"C8FW, GIG2, TRB1",ENSG00000173334,Tribbles pseudokinase 1,8,125430321-125438405,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA063982,,,Approved,Plasma membrane,,Expressed in all,Expressed in all,,,bone marrow: 243.6,Cell line enhanced,,HEL: 173.6
TRIB2,"GS3955, TRB2",ENSG00000071575,Tribbles pseudokinase 2,2,12716889-12742734,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA001305,Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,ovary: 117.2,Cell line enhanced,,AN3-CA: 170.0;K-562: 229.8;WM-115: 243.3
TRIB3,"C20orf97, dJ1103G7.3, TRB3",ENSG00000101255,Tribbles pseudokinase 3,20,362835-397559,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA055442,Approved,,Supported,Nucleus<br>Nuclear membrane<br>Nucleoli,"Renal cancer:2.07e-13 (unfavourable), Liver cancer:6.75e-5 (unfavourable), Head and neck cancer:1.70e-4 (unfavourable)",Expressed in all,Tissue enhanced,,thyroid gland: 51.4,liver: 12.5,Cell line enhanced,,HHSteC: 437.1;hTERT-HME1: 292.4;SK-MEL-30: 388.6
TRIM11,"BIA1, RNF92",ENSG00000154370,Tripartite motif containing 11,1,228393673-228406840,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA028541, HPA043879",Approved,,Enhanced,Nucleus<br>Cytosol,"Liver cancer:7.42e-5 (unfavourable), Renal cancer:1.62e-4 (unfavourable)",Expressed in all,Mixed,,,bone marrow: 18.8,Expressed in all,,
TRIM13,"DLEU5, Leu5, RFP2, RNF77",ENSG00000204977,Tripartite motif containing 13,13,49995888-50020481,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA000367,Enhanced,,,,,Expressed in all,Expressed in all,,,testis: 141.2,Expressed in all,,
TRIM17,"RBCC, RNF16, terf",ENSG00000162931,Tripartite motif containing 17,1,228407940-228416861,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA054908,Uncertain,,Approved,Vesicles,Breast cancer:1.86e-4 (favourable),Mixed,Tissue enhanced,,testis: 27.8,cerebral cortex: 6.1,Cell line enhanced,,BEWO: 8.7;SH-SY5Y: 5.0;T-47d: 10.6
TRIM2,"CMT2R, KIAA0517, RNF86",ENSG00000109654,Tripartite motif containing 2,4,153152342-153339320,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA035853, HPA035854",Enhanced,,Approved,Centrosome,Renal cancer:6.58e-14 (favourable),Expressed in all,Tissue enhanced,,cerebral cortex: 155.1,thyroid gland: 110.7,Cell line enhanced,,AF22: 68.3
TRIM21,"RNF81, Ro/SSA, RO52, SSA1",ENSG00000132109,Tripartite motif containing 21,11,4384897-4393696,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004566, HPA005673",Approved,,Approved,Nucleoplasm,"Thyroid cancer:2.26e-6 (favourable), Breast cancer:4.83e-5 (favourable), Liver cancer:1.87e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 41.2,Mixed,,
TRIM22,"GPSTAF50, RNF94, STAF50",ENSG00000132274,Tripartite motif containing 22,11,5689689-5737089,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003307, HPA003575",Approved,,Supported,Nucleoplasm<br>Nuclear bodies,,Expressed in all,Expressed in all,,,spleen: 174.9,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 183.3
TRIM23,"ARD1, ARFD1, RNF46",ENSG00000113595,Tripartite motif containing 23,5,65589680-65625975,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039605,Approved,,,,,Expressed in all,Expressed in all,,,cerebral cortex: 46.9,Expressed in all,,
TRIM24,"hTIF1, RNF82, TIF1, Tif1a",ENSG00000122779,Tripartite motif containing 24,7,138460334-138589993,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA043495, HPA061717",Approved,,Enhanced,Nucleoplasm,"Lung cancer:6.57e-4 (favourable), Liver cancer:9.94e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 49.6,Expressed in all,,
TRIM25,"EFP, RNF147, ZNF147",ENSG00000121060,Tripartite motif containing 25,17,56887909-56914038,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA005909,Approved,,Approved,Nucleoplasm<br>Nuclear bodies<br>Cytosol,"Pancreatic cancer:3.36e-4 (favourable), Stomach cancer:9.35e-4 (favourable), Liver cancer:9.37e-4 (unfavourable)",Expressed in all,Expressed in all,,,skin: 34.8,Mixed,,
TRIM27,"RFP, RNF76",ENSG00000204713,Tripartite motif containing 27,6,28903002-28923989,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA048684, HPA053408",Approved,,Approved,Nucleus<br>Nucleoli,"Renal cancer:3.50e-6 (unfavourable), Urothelial cancer:2.71e-4 (favourable)",Expressed in all,Mixed,,,appendix: 5.6,Mixed,,
TRIM28,"KAP1, PPP1R157, RNF96, TF1B, TIF1B",ENSG00000130726,Tripartite motif containing 28,19,58544091-58550722,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB010066, HPA064033",Enhanced,,Enhanced,Nucleoplasm,Liver cancer:1.85e-6 (unfavourable),Expressed in all,Expressed in all,,,ovary: 215.8,Expressed in all,,
TRIM31,"C6orf13, HCG1, HCGI, RNF",ENSG00000204616,Tripartite motif containing 31,6,30102897-30113106,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046400,Uncertain,,,,,Group enriched,Group enriched,6,colon: 10.0;small intestine: 2.3;stomach: 2.1;urinary bladder: 2.7,duodenum: 0.7,Cell line enriched,527,RT4: 232.7
TRIM32,"BBS11, HT2A, LGMD2H, TATIP",ENSG00000119401,Tripartite motif containing 32,9,116687302-116701300,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA050060,Approved,,Approved,Intermediate filaments,"Head and neck cancer:4.53e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable)",Expressed in all,Mixed,,,fallopian tube: 21.2,Mixed,,
TRIM33,"FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA",ENSG00000197323,Tripartite motif containing 33,1,114392777-114511160,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA004345,Supported,,Approved,Nucleoplasm<br>Vesicles,"Colorectal cancer:6.20e-4 (favourable), Head and neck cancer:8.93e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 46.2,Expressed in all,,
TRIM36,"HAPRIN, RBCC728, RNF98",ENSG00000152503,Tripartite motif containing 36,5,115124762-115180546,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA061321,,,Approved,Nucleus<br>Cytosol,,Tissue enhanced,Tissue enriched,16,testis: 313.5,cerebral cortex: 19.9,Cell line enhanced,,RH-30: 23.2;SCLC-21H: 31.3;SH-SY5Y: 20.6
TRIM37,"KIAA0898, MUL, POB1, TEF3",ENSG00000108395,Tripartite motif containing 37,17,58982638-59106921,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA021911,Uncertain,,,,Liver cancer:4.99e-6 (unfavourable),Expressed in all,Expressed in all,,,testis: 117.5,Expressed in all,,
TRIM38,"RNF15, RORET",ENSG00000112343,Tripartite motif containing 38,6,25962802-25991226,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA031685,Approved,,Approved,Plasma membrane<br>Cell Junctions<br>Centrosome,"Urothelial cancer:4.94e-9 (favourable), Thyroid cancer:8.20e-5 (favourable), Ovarian cancer:8.95e-5 (favourable)",Expressed in all,Mixed,,,spleen: 19.7,Mixed,,
TRIM39,RNF23,ENSG00000204599,Tripartite motif containing 39,6,30326479-30343729,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA051120, HPA059496",Uncertain,,Supported,Cytosol,Pancreatic cancer:2.50e-4 (favourable),Expressed in all,Mixed,,,testis: 4.1,Mixed,,
TRIM4,RNF87,ENSG00000146833,Tripartite motif containing 4,7,99876958-99919600,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019356, HPA029461",Approved,,Supported,Plasma membrane<br>Cytosol,Renal cancer:7.36e-6 (favourable),Expressed in all,Expressed in all,,,ovary: 50.6,Mixed,,
TRIM41,"MGC1127, RINCK",ENSG00000146063,Tripartite motif containing 41,5,181222499-181235809,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA024204,Approved,,Supported,Nucleoli<br>Nuclear bodies,Thyroid cancer:4.22e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 21.7,Expressed in all,,
TRIM5,"RNF88, TRIM5alpha",ENSG00000132256,Tripartite motif containing 5,11,5663557-5938619,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB013497, HPA023420, HPA023422",Approved,,Supported,Cytosol,,Expressed in all,Mixed,,,epididymis: 26.9,Expressed in all,,
TRIM50,"FLJ32804, TRIM50A",ENSG00000146755,Tripartite motif containing 50,7,73312539-73328082,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019862, HPA047843",Uncertain,,Approved,Cytosol,Renal cancer:9.36e-7 (favourable),Group enriched,Tissue enhanced,,stomach: 10.4;testis: 4.6,kidney: 1.7,Cell line enriched,25,Hep G2: 4.6
TRIM56,RNF109,ENSG00000169871,Tripartite motif containing 56,7,101085439-101097967,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA024358,Approved,,Approved,Nucleoplasm<br>Cytosol,"Urothelial cancer:2.13e-4 (favourable), Liver cancer:3.87e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 29.5,Mixed,,
TRIM58,BIA2,ENSG00000162722,Tripartite motif containing 58,1,247857199-247878205,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023637,Uncertain,,,,,Mixed,Group enriched,6,bone marrow: 16.1;placenta: 6.8;testis: 5.4;thyroid gland: 22.0,prostate: 2.1,Group enriched,5,HAP1: 15.0;HEL: 35.6;K-562: 19.9;PC-3: 34.5;U-2 OS: 31.0;U-937: 8.8;WM-115: 38.8
TRIM6,RNF89,ENSG00000121236,Tripartite motif containing 6,11,5596109-5612958,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA060514,Uncertain,,,,,Mixed,Tissue enhanced,,kidney: 22.5,testis: 17.2,Cell line enhanced,,NTERA-2: 22.2;U-2 OS: 22.5
TRIM62,"DEAR1, FLJ10759",ENSG00000116525,Tripartite motif containing 62,1,33145402-33182059,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA050061,,,Approved,Vesicles<br>Focal adhesion sites,Renal cancer:7.08e-5 (unfavourable),Expressed in all,Mixed,,,skin: 11.6,Expressed in all,,
TRIM63,"IRF, MURF-1, RNF28, SMRZ",ENSG00000158022,Tripartite motif containing 63,1,26051304-26068436,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,16,heart muscle: 101.2;skeletal muscle: 139.3,esophagus: 7.6,Group enriched,35,ASC diff: 11.0;SK-MEL-30: 42.2
TRIM68,"FLJ10369, RNF137, SS-56",ENSG00000167333,Tripartite motif containing 68,11,4598672-4608259,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023455,Uncertain,,Supported,Nucleus<br>Cytosol,Renal cancer:4.14e-6 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 16.0,Mixed,,
TRIM69,"RNF36, Trif, TRIMLESS",ENSG00000185880,Tripartite motif containing 69,15,44728988-44767829,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028894,Enhanced,,,,Renal cancer:2.26e-5 (favourable),Expressed in all,Tissue enriched,17,testis: 57.2,cerebral cortex: 3.4,Cell line enhanced,,Karpas-707: 1.8;U-266/70: 6.7
TRIM71,"LIN-41, LIN41",ENSG00000206557,Tripartite motif containing 71,3,32818018-32897826,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038141, HPA038142",Uncertain,,Approved,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,,Tissue enriched,Tissue enriched,8,testis: 9.1,lung: 1.1,Group enriched,6,AF22: 31.1;BEWO: 91.3;CACO-2: 19.0;Hep G2: 43.4;NTERA-2: 84.2
TRIM8,"GERP, RNF27",ENSG00000171206,Tripartite motif containing 8,10,102644496-102658407,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA023560, HPA023561",Approved,,Enhanced,Nucleoplasm<br>Vesicles<br>Cytosol,,Expressed in all,Expressed in all,,,adipose tissue: 60.9,Expressed in all,,
TRIM9,"RNF91, SPRING",ENSG00000100505,Tripartite motif containing 9,14,50975262-51096061,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041489,,,Supported,Cytosol,,Tissue enriched,Tissue enriched,11,cerebral cortex: 79.2,gallbladder: 6.9,Cell line enhanced,,AN3-CA: 29.8;HAP1: 23.6;HDLM-2: 33.8;SCLC-21H: 38.5
TRIML1,"FLJ36180, RNF209",ENSG00000184108,Tripartite motif family like 1,4,188139419-188147743,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,147,testis: 14.7,all non-specific tissues: 0.0,Cell line enriched,12,BEWO: 1.5
TRIML2,"FLJ25801, SPRYD6",ENSG00000179046,Tripartite motif family like 2,4,188091273-188109603,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043838,Uncertain,,Approved,Plasma membrane<br>Cytosol,,Tissue enriched,Group enriched,26,placenta: 5.9;testis: 3.4,"cerebral cortex,lung: 0.1",Cell line enhanced,,A549: 30.5;BEWO: 17.7;hTCEpi: 15.4;NTERA-2: 34.0
TRIO,ARHGEF23,ENSG00000038382,Trio Rho guanine nucleotide exchange factor,5,14143702-14532128,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA008157, HPA064664",Supported,,Approved,Vesicles<br>Cytosol,"Renal cancer:3.11e-5 (unfavourable), Endometrial cancer:1.90e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 47.2,Cell line enhanced,,hTEC/SVTERT24-B: 190.1;U-87 MG: 248.3
TRIP12,KIAA0045,ENSG00000153827,Thyroid hormone receptor interactor 12,2,229763838-229923239,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036835, HPA045893",Enhanced,,Approved,Nuclear speckles,Liver cancer:3.60e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 270.8,Expressed in all,,
TRIT1,"FLJ20061, IPT",ENSG00000043514,TRNA isopentenyltransferase 1,1,39841022-39883511,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA024174,Approved,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:7.08e-8 (unfavourable), Liver cancer:5.34e-6 (unfavourable), Endometrial cancer:8.80e-4 (unfavourable)",Expressed in all,Expressed in all,,,endometrium: 25.1,Expressed in all,,
TRMT1,"FLJ20244, TRM1",ENSG00000104907,TRNA methyltransferase 1,19,13104902-13117567,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041130, HPA041380",Approved,,Approved,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:9.87e-7 (unfavourable),Expressed in all,Expressed in all,,,lymph node: 26.6,Expressed in all,,
TRMT12,"FLJ20772, Trm12, TYW2",ENSG00000183665,TRNA methyltransferase 12 homolog,8,124450820-124462150,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023939,Approved,,Approved,Nucleoplasm<br>Mitochondria,"Head and neck cancer:2.99e-5 (unfavourable), Liver cancer:5.10e-4 (unfavourable), Thyroid cancer:9.25e-4 (unfavourable)",Expressed in all,Mixed,,,thyroid gland: 14.7,Cell line enhanced,,MCF7: 55.6
TRMT13,"CCDC76, FLJ10287, FLJ11219",ENSG00000122435,TRNA methyltransferase 13 homolog,1,100133150-100150497,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028494,Approved,,Approved,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,"Renal cancer:6.89e-6 (unfavourable), Liver cancer:5.81e-5 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 29.5,Expressed in all,,
TRMT2B,"CXorf34, FLJ12687",ENSG00000188917,TRNA methyltransferase 2 homolog B,X,101009346-101052116,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003745, HPA035120, HPA040814",Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies,"Renal cancer:2.30e-7 (favourable), Breast cancer:1.58e-5 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 21.5,Expressed in all,,
TRMT44,"C4orf23, FLJ35725, METTL19, TRM44",ENSG00000155275,TRNA methyltransferase 44 homolog (S. cerevisiae),4,8436140-8493531,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045461,Uncertain,,Approved,Nucleoplasm,,Expressed in all,Mixed,,,endometrium: 10.0,Expressed in all,,
TRMT5,"KIAA1393, TRM5",ENSG00000126814,TRNA methyltransferase 5,14,60971451-60981358,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA000943,Supported,,Approved,Nucleus<br>Nucleoli,,Expressed in all,Expressed in all,,,testis: 31.3,Expressed in all,,
TRMT61A,"C14orf172, FLJ40452, GCD14, Gcd14p, hTRM61",ENSG00000166166,TRNA methyltransferase 61A,14,103529184-103537073,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Liver cancer:1.60e-4 (unfavourable),Expressed in all,Expressed in all,,,seminal vesicle: 10.1,Expressed in all,,
TRMT61B,FLJ20628,ENSG00000171103,TRNA methyltransferase 61B,2,28849821-28870301,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026747, HPA026751",Enhanced,,Uncertain,Cytosol,"Renal cancer:9.61e-5 (favourable), Liver cancer:3.61e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 23.5,Expressed in all,,
TRMU,"FLJ10140, MTO2, TRMT",ENSG00000100416,TRNA 5-methylaminomethyl-2-thiouridylate methyltransferase,22,46330875-46357340,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000824, HPA035273, HPA043300",Uncertain,,Supported,Nucleoplasm<br>Mitochondria,"Renal cancer:5.63e-6 (unfavourable), Liver cancer:3.04e-5 (unfavourable), Pancreatic cancer:6.86e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 17.0,Expressed in all,,
TRNT1,"CCA1, CGI-47, MtCCA",ENSG00000072756,TRNA nucleotidyl transferase 1,3,3126916-3150879,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA036938,Uncertain,,Enhanced,Mitochondria,,Expressed in all,Expressed in all,,,prostate: 24.5,Expressed in all,,
TRPM6,"CHAK2, FLJ22628, HOMG, HSH",ENSG00000119121,Transient receptor potential cation channel subfamily M member 6,9,74722495-74888094,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,colon: 13.1;rectum: 18.2,small intestine: 8.7,Cell line enhanced,,BEWO: 3.7;HeLa: 1.5;RT4: 3.0
TRPM7,"CHAK1, LTRPC7, TRP-PLIK",ENSG00000092439,Transient receptor potential cation channel subfamily M member 7,15,50552473-50686815,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA052173,Enhanced,,Approved,Nucleoplasm,,Expressed in all,Tissue enriched,7,parathyroid gland: 216.4,thyroid gland: 29.0,Expressed in all,,
TRPT1,MGC11134,ENSG00000149743,TRNA phosphotransferase 1,11,64223799-64226254,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038705, HPA038706",Uncertain,,Approved,Mitochondria,,Expressed in all,Expressed in all,,,testis: 44.9,Expressed in all,,
TSEN2,"MGC2776, SEN2, SEN2L",ENSG00000154743,TRNA splicing endonuclease subunit 2,3,12484432-12539623,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA027120, HPA027125, HPA027268",Approved,,Enhanced,Nucleoplasm<br>Cytosol,"Liver cancer:1.13e-5 (unfavourable), Urothelial cancer:3.49e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 14.7,Expressed in all,,
TSEN34,"LENG5, SEN34, SEN34L",ENSG00000170892,TRNA splicing endonuclease subunit 34,19,54189938-54194536,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA041111, HPA048208",Approved,,Supported,Nucleus,Liver cancer:1.44e-7 (unfavourable),Expressed in all,Mixed,,,fallopian tube: 37.2,Mixed,,
TSSK1B,"FKSG81, SPOGA4, STK22D, TSSK1",ENSG00000212122,Testis specific serine kinase 1B,5,113432554-113435031,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA027827,Enhanced,,,,,Not detected,Tissue enriched,222,testis: 62.0,skin: 0.2,Not detected,,
TSSK2,"FLJ38613, SPOGA2, STK22B",ENSG00000206203,Testis specific serine kinase 2,22,19130808-19132623,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,290,testis: 120.4,ovary: 0.4,Cell line enhanced,,SCLC-21H: 1.0
TSSK3,"SPOGA3, STK22C",ENSG00000162526,Testis specific serine kinase 3,1,32351521-32364312,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037516,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Nuclear bodies,,Not detected,Tissue enhanced,,testis: 25.5,bone marrow: 5.5,Mixed,,
TSSK4,"C14orf20, STK22E",ENSG00000139908,Testis specific serine kinase 4,14,24205697-24208362,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA060660, HPA077103",Enhanced,,Approved,Cell Junctions,,Mixed,Tissue enhanced,,testis: 42.2,skin: 10.1,Mixed,,
TSSK6,"CT72, FLJ24002, SSTK",ENSG00000178093,Testis specific serine kinase 6,19,19512418-19515685,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enriched,24,testis: 18.6,"duodenum,spleen: 0.7",Cell line enhanced,,BEWO: 3.9
TST,RDS,ENSG00000128311,Thiosulfate sulfurtransferase,22,37010859-37020183,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003044, HPA003643, CAB009546",Enhanced,,Supported,Mitochondria,"Renal cancer:7.59e-6 (favourable), Urothelial cancer:1.04e-4 (favourable)",Expressed in all,Expressed in all,,,colon: 143.5,Mixed,,
TSTA3,"FX, P35B, SDR4E1",ENSG00000104522,Tissue specific transplantation antigen P35B,8,143612618-143618048,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023361,Approved,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:1.59e-4 (unfavourable), Ovarian cancer:2.41e-4 (favourable)",Expressed in all,Expressed in all,,,stomach: 50.3,Expressed in all,,
TTBK1,KIAA1855,ENSG00000146216,Tau tubulin kinase 1,6,43243680-43288259,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA031735, HPA031736",Enhanced,,Supported,Nucleoplasm<br>Cytosol,,Tissue enhanced,Tissue enriched,6,cerebral cortex: 18.9,small intestine: 3.1,Group enriched,13,SCLC-21H: 24.9;SH-SY5Y: 8.7
TTBK2,"KIAA0847, SCA11",ENSG00000128881,Tau tubulin kinase 2,15,42738734-42920809,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA018113, HPA049866",Approved,,Uncertain,Intermediate filaments,,Mixed,Tissue enhanced,,testis: 61.5,cerebral cortex: 16.6,Mixed,,
TTC3,"DCRR1, RNF105, TPRD, TPRDI, TPRDII, TPRDIII",ENSG00000182670,Tetratricopeptide repeat domain 3,21,37073226-37203112,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA016810, HPA023964, HPA036304",Uncertain,,Approved,Nucleus<br>Nucleoli<br>Cytosol,,Expressed in all,Expressed in all,,,thyroid gland: 108.0,Expressed in all,,
TTK,"CT96, MPH1, MPS1, MPS1L1",ENSG00000112742,TTK protein kinase,6,80003887-80042527,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB010166, CAB013229",Enhanced,,Approved,Nucleoli<br>Cytosol,"Liver cancer:3.84e-10 (unfavourable), Endometrial cancer:1.44e-5 (unfavourable), Pancreatic cancer:2.54e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 60.8,bone marrow: 15.5,Mixed,,
TTL,MGC46235,ENSG00000114999,Tubulin tyrosine ligase,2,112482154-112541739,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA066819,,,Approved,Nucleoplasm<br>Vesicles,Liver cancer:5.65e-4 (unfavourable),Expressed in all,Mixed,,,cerebral cortex: 4.4,Mixed,,
TTN,"CMD1G, CMH9, CMPD4, FLJ32040, LGMD2J, MYLK5, TMD",ENSG00000155657,Titin,2,178525989-178830802,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007042, CAB022682, HPA030048",Enhanced,,,,,Tissue enhanced,Tissue enriched,7,skeletal muscle: 322.5,heart muscle: 46.7,Mixed,,
TUT1,"FLJ21850, FLJ22267, FLJ22347, PAPD2, RBM21, TUTase",ENSG00000149016,"Terminal uridylyl transferase 1, U6 snRNA-specific",11,62575045-62592177,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA069055, HPA071838",,,Supported,Nucleus<br>Cytosol,Colorectal cancer:9.51e-4 (unfavourable),Expressed in all,Expressed in all,,,fallopian tube: 17.8,Expressed in all,,
TWNK,"C10orf2, FLJ21832, IOSCA, PEO, PEO1, TWINKLE, TWINL",ENSG00000107815,Twinkle mtDNA helicase,10,100987367-100994401,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002532,Uncertain,,,,,Expressed in all,Expressed in all,,,testis: 13.6,Expressed in all,,
TXK,"BTKL, PSCTK5, PTK4, RLK, TKL",ENSG00000074966,TXK tyrosine kinase,4,48066393-48134256,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA062482,,,Approved,Vesicles,,Mixed,Tissue enhanced,,lymph node: 17.9,epididymis: 15.1,Cell line enhanced,,HMC-1: 12.2;WM-115: 31.5
TXNDC12,"AGR1, ERP18, ERP19, hAG-1, PDIA16, TLP19",ENSG00000117862,Thioredoxin domain containing 12,1,52020131-52056171,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:1.40e-12 (unfavourable), Liver cancer:1.28e-5 (unfavourable), Head and neck cancer:2.61e-4 (unfavourable), Colorectal cancer:4.44e-4 (favourable)",Expressed in all,Expressed in all,,,fallopian tube: 49.8,Expressed in all,,
TXNRD1,"GRIM-12, Trxr1, TXNR",ENSG00000198431,Thioredoxin reductase 1,12,104215779-104350305,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001395, CAB004607, CAB015834, HPA043871",Approved,,Supported,Nucleus,"Liver cancer:1.12e-5 (unfavourable), Renal cancer:1.20e-5 (unfavourable)",Expressed in all,Expressed in all,,,adrenal gland: 109.1,Expressed in all,,
TXNRD2,"TR, TR3, TRXR2",ENSG00000184470,Thioredoxin reductase 2,22,19875517-19941992,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB002007, HPA003323",Supported,,Supported,Mitochondria<br>Cytosol,Renal cancer:1.10e-7 (favourable),Expressed in all,Expressed in all,,,adrenal gland: 34.3,Expressed in all,,
TYK2,JTK1,ENSG00000105397,Tyrosine kinase 2,19,10350529-10380676,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA005157,Uncertain,,Supported,Cytosol,"Head and neck cancer:1.05e-5 (favourable), Pancreatic cancer:1.02e-4 (favourable), Urothelial cancer:4.16e-4 (favourable), Renal cancer:4.43e-4 (unfavourable), Endometrial cancer:9.62e-4 (favourable)",Expressed in all,Expressed in all,,,spleen: 68.2,Expressed in all,,
TYMP,"ECGF1, MNGIE",ENSG00000025708,Thymidine phosphorylase,22,50525752-50530056,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000530, HPA001072, CAB002518",Enhanced,,Approved,Nuclear bodies<br>Golgi apparatus,"Renal cancer:3.50e-8 (unfavourable), Endometrial cancer:4.34e-5 (favourable)",Expressed in all,Tissue enhanced,,appendix: 100.6,spleen: 53.1,Cell line enhanced,,CAPAN-2: 37.3;HHSteC: 84.7;Karpas-707: 72.1;U-266/70: 36.4
TYMS,"HsT422, TMS, TS, Tsase",ENSG00000176890,Thymidylate synthetase,18,657604-673578,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB002784,Enhanced,,,,Liver cancer:5.10e-6 (unfavourable),Expressed in all,Mixed,,,testis: 59.1,Expressed in all,,
TYR,"OCA1, OCA1A, OCAIA",ENSG00000077498,Tyrosinase,11,89177452-89295759,"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB000079, HPA043241, HPA050889",Enhanced,,Enhanced,Vesicles,,Tissue enriched,Tissue enriched,33,skin: 29.8,breast: 0.9,Cell line enriched,1211,SK-MEL-30: 256.2
TYRO3,"Brt, Dtk, Etk-2, Rek, RSE, Sky, Tif",ENSG00000092445,TYRO3 protein tyrosine kinase,15,41557675-41583586,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA071245,Approved,,,,,Expressed in all,Tissue enhanced,,cerebral cortex: 67.4;ovary: 61.6,testis: 37.0,Cell line enhanced,,BEWO: 66.6
TYSND1,"MGC34695, NET41",ENSG00000156521,Trypsin domain containing 1,10,70137981-70146676,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA030304,Uncertain,,Uncertain,Nucleoplasm<br>Centrosome<br>Cytosol,,Expressed in all,Mixed,,,adipose tissue: 5.8,Cell line enhanced,,HaCaT: 24.4;PC-3: 39.1
TYW1,"FLJ10900, MGC23001, MGC60291, RSAFD1, TYW1A, YPL207W",ENSG00000198874,TRNA-yW synthesizing protein 1 homolog,7,66995173-67239519,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA013568, HPA014118, HPA015535, HPA043136, HPA047029, HPA047052, HPA052097",Approved,,Approved,Nucleus<br>Nucleoli,Ovarian cancer:1.73e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 23.1,Expressed in all,,
TYW3,"C1orf171, FLJ40918",ENSG00000162623,TRNA-yW synthesizing protein 3 homolog,1,74733152-74766678,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA029641,Approved,,Approved,Plasma membrane<br>Cytosol,Liver cancer:1.49e-7 (unfavourable),Expressed in all,Expressed in all,,,ovary: 32.6,Expressed in all,,
TYW5,"C2orf60, FLJ37953",ENSG00000162971,TRNA-yW synthesizing protein 5,2,199929975-199955736,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028294, HPA045803",Uncertain,,Approved,Nuclear bodies,,Expressed in all,Mixed,,,appendix: 1.6,Mixed,,
UAP1,"AgX, AGX1, SPAG2",ENSG00000117143,UDP-N-acetylglucosamine pyrophosphorylase 1,1,162561506-162599842,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA014659,Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Renal cancer:5.12e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 166.1,Expressed in all,,
UBA1,"A1S9T, CFAP124, GXP1, POC20, UBE1, UBE1X",ENSG00000130985,Ubiquitin like modifier activating enzyme 1,X,47190861-47215128,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000289, HPA001506, CAB019435, CAB073410",Approved,,Enhanced,Nucleoplasm,"Liver cancer:6.10e-5 (unfavourable), Thyroid cancer:1.78e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 239.4,Expressed in all,,
UBA6,"FLJ10808, UBE1L2",ENSG00000033178,Ubiquitin like modifier activating enzyme 6,4,67612652-67701179,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037001,Uncertain,,Enhanced,Nucleoplasm<br>Cytosol,Renal cancer:7.01e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 18.7,Expressed in all,,
UBASH3B,"KIAA1959, STS-1, TULA2",ENSG00000154127,Ubiquitin associated and SH3 domain containing B,11,122655675-122814473,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038605, HPA038607",Approved,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,placenta: 19.6;spleen: 21.3,lung: 6.7,Cell line enhanced,,HEL: 108.5;HMC-1: 77.6
UBE2A,"HHR6A, RAD6A, UBC2",ENSG00000077721,Ubiquitin conjugating enzyme E2 A,X,119574467-119591083,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA003875, HPA051765, HPA065898",,,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:2.20e-6 (unfavourable), Cervical cancer:2.16e-4 (favourable), Head and neck cancer:9.07e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 76.5,Expressed in all,,
UBE2B,"HHR6B, RAD6B, UBC2",ENSG00000119048,Ubiquitin conjugating enzyme E2 B,5,134371179-134391992,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003875, HPA051765, HPA065898",,,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol,,Expressed in all,Expressed in all,,,adrenal gland: 99.1,Expressed in all,,
UBE2C,UBCH10,ENSG00000175063,Ubiquitin conjugating enzyme E2 C,20,45812576-45816957,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB011464, HPA034569, CAB035990, HPA054975",Approved,,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.24e-6 (unfavourable), Pancreatic cancer:6.91e-4 (unfavourable)",Expressed in all,Mixed,,,tonsil: 56.9,Mixed,,
UBE2D1,"E2(17)KB1, SFT, UBC4/5, UBCH5, UbcH5A",ENSG00000072401,Ubiquitin conjugating enzyme E2 D1,10,58334975-58370753,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003920,Approved,,Approved,Plasma membrane<br>Cytosol,"Renal cancer:8.04e-6 (unfavourable), Liver cancer:5.58e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 47.8,Mixed,,
UBE2D2,"UBC4, UbcH5B",ENSG00000131508,Ubiquitin conjugating enzyme E2 D2,5,139526431-139628433,"Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA003920,Approved,,Approved,Plasma membrane<br>Cytosol,"Liver cancer:9.63e-7 (unfavourable), Renal cancer:2.09e-5 (unfavourable), Colorectal cancer:5.09e-5 (favourable), Endometrial cancer:5.90e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 239.4,Expressed in all,,
UBE2D3,UbcH5C,ENSG00000109332,Ubiquitin conjugating enzyme E2 D3,4,102794383-102868896,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003920,Uncertain,,Approved,Plasma membrane<br>Cytosol,Renal cancer:4.51e-4 (favourable),Expressed in all,Expressed in all,,,bone marrow: 300.9,Expressed in all,,
UBE2D4,HBUCE1,ENSG00000078967,Ubiquitin conjugating enzyme E2 D4 (putative),7,43926438-43956136,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003920,Approved,,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:4.86e-4 (favourable), Prostate cancer:5.77e-4 (favourable), Renal cancer:6.51e-4 (favourable)",Expressed in all,Expressed in all,,,cerebral cortex: 12.5,Expressed in all,,
UBE2E1,UbcH6,ENSG00000170142,Ubiquitin conjugating enzyme E2 E1,3,23805903-23891316,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030445, CAB073413",Approved,,Approved,Nucleoplasm,Liver cancer:9.97e-7 (unfavourable),Expressed in all,Expressed in all,,,placenta: 119.1,Expressed in all,,
UBE2E2,"FLJ25157, UbcH8",ENSG00000182247,Ubiquitin conjugating enzyme E2 E2,3,23203020-23591793,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003303, HPA028872, HPA030445, CAB073417",Approved,,Approved,Nucleoplasm,,Expressed in all,Expressed in all,,,cerebral cortex: 40.1,Mixed,,
UBE2E3,UbcH9,ENSG00000170035,Ubiquitin conjugating enzyme E2 E3,2,180967248-181076585,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003303, HPA030445",Approved,,,,"Pancreatic cancer:1.78e-5 (unfavourable), Head and neck cancer:8.08e-5 (unfavourable), Liver cancer:9.11e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 131.8,Expressed in all,,
UBE2G1,"UBC7, UBE2G",ENSG00000132388,Ubiquitin conjugating enzyme E2 G1,17,4269259-4366628,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA045681, HPA050551",Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,skeletal muscle: 73.2,Expressed in all,,
UBE2G2,UBC7,ENSG00000184787,Ubiquitin conjugating enzyme E2 G2,21,44768580-44802019,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003332,Approved,,,,Renal cancer:7.02e-5 (unfavourable),Expressed in all,Expressed in all,,,seminal vesicle: 26.5,Expressed in all,,
UBE2H,"GID3, UBC8, UBCH",ENSG00000186591,Ubiquitin conjugating enzyme E2 H,7,129830732-129952949,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003302,Approved,,Supported,Mitochondria,Pancreatic cancer:2.33e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 94.5,Expressed in all,,
UBE2J1,"CGI-76, HSPC153, NCUBE1, UBC6",ENSG00000198833,Ubiquitin conjugating enzyme E2 J1,6,89326625-89352848,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA003509, CAB073419",Enhanced,,,,"Liver cancer:6.90e-5 (unfavourable), Renal cancer:1.11e-4 (unfavourable), Endometrial cancer:2.87e-4 (favourable), Ovarian cancer:7.43e-4 (favourable)",Expressed in all,Expressed in all,,,lymph node: 102.3,Mixed,,
UBE2J2,"NCUBE2, Ubc6p",ENSG00000160087,Ubiquitin conjugating enzyme E2 J2,1,1253909-1273885,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:2.00e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 115.2,Expressed in all,,
UBE2K,"HIP2, HYPG, UBC1",ENSG00000078140,Ubiquitin conjugating enzyme E2 K,4,39698044-39782792,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028869, CAB033212, CAB033515",Supported,,Supported,Intermediate filaments<br>Actin filaments<br>Cytosol,Pancreatic cancer:8.60e-4 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 64.7,Expressed in all,,
UBE2L3,UBCH7,ENSG00000185651,Ubiquitin conjugating enzyme E2 L3,22,21549447-21624034,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA045609, HPA062415",Approved,,Approved,Nucleus<br>Cytosol,"Ovarian cancer:3.82e-6 (favourable), Liver cancer:1.29e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 67.1,Expressed in all,,
UBE2L6,UBCH8,ENSG00000156587,Ubiquitin conjugating enzyme E2 L6,11,57551656-57568284,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003328, CAB073407",Enhanced,,Approved,Cytosol,"Pancreatic cancer:4.88e-4 (unfavourable), Breast cancer:6.75e-4 (favourable)",Expressed in all,Expressed in all,,,spleen: 148.0,Mixed,,
UBE2N,"MGC8489, UBC13, UbcH-ben",ENSG00000177889,Ubiquitin conjugating enzyme E2 N,12,93405673-93442262,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA044976,Enhanced,,Supported,Nucleus<br>Nucleoli fibrillar center,Liver cancer:2.41e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 253.6,Expressed in all,,
UBE2O,E2-230K,ENSG00000175931,Ubiquitin conjugating enzyme E2 O,17,76389451-76453206,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023605,Uncertain,,Supported,Nucleus<br>Nuclear bodies,"Renal cancer:4.34e-9 (unfavourable), Liver cancer:6.84e-8 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 36.0,Expressed in all,,
UBE2Q1,"NICE-5, PRO3094, UBE2Q",ENSG00000160714,Ubiquitin conjugating enzyme E2 Q1,1,154548577-154559028,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA063368,Approved,,Approved,Nucleoplasm<br>Centrosome,"Renal cancer:4.84e-7 (unfavourable), Thyroid cancer:1.86e-5 (favourable), Liver cancer:8.74e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 57.0,Expressed in all,,
UBE2Q2,DKFZp762C143,ENSG00000140367,Ubiquitin conjugating enzyme E2 Q2,15,75843285-75901078,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Ovarian cancer:5.73e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 51.5,Expressed in all,,
UBE2QL1,FLJ25076,ENSG00000215218,Ubiquitin conjugating enzyme E2 Q family like 1,5,6448623-6494909,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA057414,,,Supported,Nucleus<br>Plasma membrane,Renal cancer:6.81e-8 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 41.8,seminal vesicle: 10.4,Cell line enhanced,,Karpas-707: 29.4;PC-3: 32.0;SCLC-21H: 37.2;U-266/70: 57.9;U-266/84: 50.5
UBE2R2,"CDC34B, FLJ20419, MGC10481, UBC3B",ENSG00000107341,Ubiquitin conjugating enzyme E2 R2,9,33817567-33920404,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA061000,,,Approved,Nucleus<br>Nucleoli,Liver cancer:4.37e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 68.7,Expressed in all,,
UBE2S,E2-EPF,ENSG00000108106,Ubiquitin conjugating enzyme E2 S,19,55399745-55407777,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB015228, HPA057150",Approved,,Approved,Nucleoplasm<br>Plasma membrane,"Renal cancer:8.16e-8 (unfavourable), Liver cancer:8.00e-6 (unfavourable), Endometrial cancer:2.05e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 120.1,Expressed in all,,
UBE2T,"FANCT, HSPC150",ENSG00000077152,Ubiquitin conjugating enzyme E2 T,1,202331657-202341980,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002831,,,Approved,Nucleus<br>Nucleoli,"Renal cancer:2.22e-16 (unfavourable), Liver cancer:4.79e-6 (unfavourable), Ovarian cancer:6.90e-6 (favourable)",Expressed in all,Mixed,,,testis: 36.0,Expressed in all,,
UBE2U,MGC35130,ENSG00000177414,Ubiquitin conjugating enzyme E2 U (putative),1,64203627-64267368,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,39,testis: 79.4,stomach: 2.0,Not detected,,
UBE2W,"FLJ11011, UBC-16",ENSG00000104343,Ubiquitin conjugating enzyme E2 W,8,73780097-73878910,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA045161, HPA073181",Uncertain,,Supported,Nucleoli,,Expressed in all,Expressed in all,,,testis: 19.6,Expressed in all,,
UBE2Z,"FLJ13855, USE1",ENSG00000159202,Ubiquitin conjugating enzyme E2 Z,17,48908369-48929056,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007922,Approved,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:1.05e-4 (unfavourable), Colorectal cancer:4.62e-4 (favourable), Liver cancer:5.57e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 82.7,Expressed in all,,
UBE3A,"ANCR, AS, E6-AP, EPVE6AP, FLJ26981, HPVE6A",ENSG00000114062,Ubiquitin protein ligase E3A,15,25333728-25439056,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009723, HPA039410, HPA040380",Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 86.1,Expressed in all,,
UBE3B,,ENSG00000151148,Ubiquitin protein ligase E3B,12,109477402-109536705,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA041012,Approved,,Approved,Nuclear speckles<br>Mitochondria,Renal cancer:2.49e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 34.1,Expressed in all,,
UBE3C,"KIAA0010, KIAA10",ENSG00000009335,Ubiquitin protein ligase E3C,7,157138913-157269372,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039915,Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Mitochondria,Renal cancer:9.18e-6 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 51.1,Expressed in all,,
UBE3D,"C6orf157, DKFZp434A1520, H10BH, UBE2CBP, YJR141W",ENSG00000118420,Ubiquitin protein ligase E3D,6,82892398-83065841,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027231,Uncertain,,Approved,Rods & Rings,,Mixed,Mixed,,,fallopian tube: 6.3,Expressed in all,,
UBE4A,"E4, KIAA0126, UBOX2, UFD2",ENSG00000110344,Ubiquitination factor E4A,11,118359585-118399211,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA055035, HPA064010",Approved,,Supported,Nuclear speckles,,Expressed in all,Expressed in all,,,parathyroid gland: 43.7,Expressed in all,,
UBE4B,"E4, KIAA0684, UBOX3, UFD2",ENSG00000130939,Ubiquitination factor E4B,1,10032832-10181239,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019219,Approved,,,,Liver cancer:3.69e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 43.4,Expressed in all,,
UBLCP1,"CPUB1, MGC10067",ENSG00000164332,Ubiquitin like domain containing CTD phosphatase 1,5,159263081-159286040,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039615,Approved,,Enhanced,Nucleus<br>Nucleoli,Liver cancer:4.46e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 49.9,Expressed in all,,
UBOX5,"KIAA0860, RNF37, Ubce7ip5, UIP5",ENSG00000185019,U-box domain containing 5,20,3107573-3160196,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028871,Approved,,Approved,Nucleoplasm,"Pancreatic cancer:1.80e-5 (favourable), Head and neck cancer:4.52e-5 (favourable)",Expressed in all,Expressed in all,,,fallopian tube: 7.1,Expressed in all,,
UBR1,,ENSG00000159459,Ubiquitin protein ligase E3 component n-recognin 1,15,42942897-43106113,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA038838,Approved,,Approved,Nucleoplasm<br>Vesicles,,Expressed in all,Expressed in all,,,parathyroid gland: 27.4,Expressed in all,,
UBR2,"bA49A4.1, C6orf133, dJ392M17.3, KIAA0349",ENSG00000024048,Ubiquitin protein ligase E3 component n-recognin 2,6,42564062-42693504,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA027869, HPA027880",Approved,,Approved,Nucleoplasm<br>Plasma membrane,Ovarian cancer:1.65e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 30.5,Expressed in all,,
UBR3,"DKFZp434P117, FLJ37422, KIAA2024, ZNF650",ENSG00000144357,Ubiquitin protein ligase E3 component n-recognin 3 (putative),2,169827458-170084131,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035390,Approved,,Approved,Nucleus<br>Nucleoli,,Expressed in all,Expressed in all,,,parathyroid gland: 39.6,Expressed in all,,
UBR4,"KIAA0462, KIAA1307, RBAF600, ZUBR1",ENSG00000127481,Ubiquitin protein ligase E3 component n-recognin 4,1,19074506-19210276,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA013394, HPA021046",Approved,,Supported,Nucleoplasm<br>Centrosome<br>Cytosol,,Expressed in all,Expressed in all,,,skin: 90.3,Expressed in all,,
UBR5,"DD5, EDD, EDD1, HYD, KIAA0896",ENSG00000104517,Ubiquitin protein ligase E3 component n-recognin 5,8,102253012-102412841,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA053688,,,Supported,Nucleoplasm<br>Cytosol,Liver cancer:1.26e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 80.2,Expressed in all,,
UBR7,C14orf130,ENSG00000012963,Ubiquitin protein ligase E3 component n-recognin 7 (putative),14,93207056-93229215,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000861,Approved,,Approved,Nucleus,"Liver cancer:8.12e-5 (unfavourable), Renal cancer:9.76e-5 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 23.3,Expressed in all,,
UCHL1,"PARK5, PGP9.5, Uch-L1",ENSG00000154277,Ubiquitin C-terminal hydrolase L1,4,41256413-41268455,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB002580, HPA005993, CAB079024",Enhanced,Supported,Enhanced,Nucleoplasm<br>Cytosol,"Endometrial cancer:4.08e-5 (unfavourable), Urothelial cancer:1.93e-4 (unfavourable)",Expressed in all,Tissue enriched,7,cerebral cortex: 785.9,adrenal gland: 107.9,Cell line enhanced,,EFO-21: 912.4;SCLC-21H: 1141.2;U-87 MG: 916.2
UCHL3,,ENSG00000118939,Ubiquitin C-terminal hydrolase L3,13,75549480-75606020,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019678, CAB037139, CAB037208",Approved,,Supported,Nucleus<br>Cytosol,Liver cancer:6.41e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 90.7,Expressed in all,,
UCHL5,"CGI-70, INO80R, UCH37",ENSG00000116750,Ubiquitin C-terminal hydrolase L5,1,193012250-193060080,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA005908, HPA006069, HPA075383",Approved,Approved,Approved,Nucleoplasm<br>Mitochondria,Thyroid cancer:7.10e-5 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 43.0,Expressed in all,,
UCK1,"FLJ12255, URK1",ENSG00000130717,Uridine-cytidine kinase 1,9,131523801-131531268,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA050969,Approved,,Approved,Nucleus,"Renal cancer:2.21e-7 (favourable), Cervical cancer:3.19e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 31.2,Expressed in all,,
UCK2,UMPK,ENSG00000143179,Uridine-cytidine kinase 2,1,165827531-165911618,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA057128,,,Approved,Nucleus,"Renal cancer:5.12e-13 (unfavourable), Liver cancer:9.22e-8 (unfavourable), Lung cancer:4.98e-4 (unfavourable), Melanoma:6.70e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 41.1,Expressed in all,,
UCKL1,"FLJ20517, URKL1",ENSG00000198276,Uridine-cytidine kinase 1 like 1,20,63939829-63956415,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA004722, HPA004769",Approved,,Approved,Endoplasmic reticulum,Pancreatic cancer:4.42e-4 (favourable),Expressed in all,Expressed in all,,,spleen: 40.1,Expressed in all,,
UFSP1,UFSP,ENSG00000176125,UFM1 specific peptidase 1 (inactive),7,100888723-100889718,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA027099,Uncertain,,,,,Expressed in all,Mixed,,,adipose tissue: 2.0,Mixed,,
UFSP2,"C4orf20, FLJ11200",ENSG00000109775,UFM1 specific peptidase 2,4,185399540-185425985,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA039985, HPA043298",Approved,,Approved,Nucleus<br>Cytosol,Renal cancer:1.07e-8 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 53.0,Expressed in all,,
UGCG,GCS,ENSG00000148154,UDP-glucose ceramide glucosyltransferase,9,111896766-111935369,"Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA024124,Approved,,,,"Endometrial cancer:4.44e-5 (favourable), Cervical cancer:6.62e-4 (favourable)",Expressed in all,Expressed in all,,,adrenal gland: 84.1,Expressed in all,,
UGDH,,ENSG00000109814,UDP-glucose 6-dehydrogenase,4,39498755-39528311,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB034444, HPA036656, HPA036657",Enhanced,,Enhanced,Nucleoplasm,Renal cancer:5.51e-10 (unfavourable),Expressed in all,Expressed in all,,,colon: 95.4,Expressed in all,,
UGP2,"UGP1, UGPP1",ENSG00000169764,UDP-glucose pyrophosphorylase 2,2,63840940-63891562,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA034696, HPA034697, HPA064836",Enhanced,,Approved,Nucleoplasm<br>Centrosome<br>Mitochondria,Liver cancer:2.50e-5 (favourable),Expressed in all,Expressed in all,,,liver: 593.9,Expressed in all,,
UGT1A1,"GNT1, UGT1, UGT1A",ENSG00000241635,UDP glucuronosyltransferase family 1 member A1,2,233760248-233773299,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,33,duodenum: 199.5;liver: 155.8;small intestine: 81.9,kidney: 4.3,Cell line enhanced,,HaCaT: 12.7;PC-3: 6.0;RT4: 27.4
UGT1A10,UGT1J,ENSG00000242515,UDP glucuronosyltransferase family 1 member A10,2,233636454-233773305,"Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Pancreatic cancer:4.55e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,colon: 49.7;duodenum: 80.9;small intestine: 59.1,rectum: 39.6,Cell line enriched,108,RT4: 416.9
UGT1A3,UGT1C,ENSG00000243135,UDP glucuronosyltransferase family 1 member A3,2,233729108-233773299,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,7,liver: 38.2,small intestine: 5.6,Cell line enriched,11,HaCaT: 10.9
UGT1A4,"HUG-BR2, UGT1D",ENSG00000244474,UDP glucuronosyltransferase family 1 member A4,2,233718778-233773299,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enriched,31,liver: 212.3,duodenum: 6.7,Not detected,,
UGT1A5,UGT1E,ENSG00000240224,UDP glucuronosyltransferase family 1 member A5,2,233712992-233773299,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Group enriched,7,duodenum: 7.5;gallbladder: 3.9;small intestine: 6.8,liver: 0.9,Not detected,,
UGT1A6,"GNT1, HLUGP, UGT1F",ENSG00000167165,UDP glucuronosyltransferase family 1 member A6,2,233691607-233773300,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009819, HPA054065",Enhanced,,,,Liver cancer:2.89e-6 (unfavourable),Tissue enhanced,Group enriched,6,kidney: 75.4;liver: 72.4;urinary bladder: 107.9,esophagus: 15.2,Cell line enhanced,,CACO-2: 44.4;EFO-21: 75.2;HaCaT: 258.5;RT4: 119.0
UGT1A7,UGT1G,ENSG00000244122,UDP glucuronosyltransferase family 1 member A7,2,233681938-233773299,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enriched,13,esophagus: 61.4,tonsil: 4.6,Cell line enriched,21,SiHa: 118.8
UGT1A8,UGT1H,ENSG00000242366,UDP glucuronosyltransferase family 1 member A8,2,233617645-233773310,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,colon: 16.0;gallbladder: 10.3;rectum: 9.7;urinary bladder: 22.7,small intestine: 4.9,Cell line enriched,53,RT4: 96.7
UGT1A9,"HLUGP4, LUGP4, UGT1AI",ENSG00000241119,UDP glucuronosyltransferase family 1 member A9,2,233671853-233773300,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:5.04e-5 (unfavourable),Group enriched,Group enriched,592,kidney: 465.5;liver: 93.3,"cerebral cortex,colon: 0.4",Cell line enhanced,,A549: 1.2
UGT2A1,,ENSG00000173610,UDP glucuronosyltransferase family 2 member A1 complex locus,4,69588417-69653249,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA017261, HPA045108",Uncertain,,,,,Tissue enhanced,Group enriched,7,kidney: 8.1;liver: 5.5,skin: 0.9,Not detected,,
UGT2A2,,ENSG00000271271,UDP glucuronosyltransferase family 2 member A2,4,69589309-69639642,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Uncertain,,,,,Not detected,Not detected,,,"cervix, uterine,skin: 0.2",Not detected,,
UGT2A3,FLJ21934,ENSG00000135220,UDP glucuronosyltransferase family 2 member A3,4,68928463-68951791,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Supported,,,,"Renal cancer:6.07e-7 (favourable), Colorectal cancer:3.31e-4 (favourable)",Tissue enriched,Tissue enhanced,,duodenum: 82.1;gallbladder: 46.3;kidney: 46.8;small intestine: 85.9,rectum: 23.9,Cell line enriched,8,Hep G2: 13.5
UGT2B10,,ENSG00000109181,UDP glucuronosyltransferase family 2 member B10,4,68815993-68831196,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Uncertain,,,,,Tissue enriched,Tissue enriched,87,liver: 304.0,gallbladder: 3.4,Cell line enriched,33,Hep G2: 7.9
UGT2B11,,ENSG00000213759,UDP glucuronosyltransferase family 2 member B11,4,69199951-69214731,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA045108,Uncertain,,,,,Group enriched,Tissue enriched,17,breast: 320.4,gallbladder: 18.3,Not detected,,
UGT2B15,UGT2B8,ENSG00000196620,UDP glucuronosyltransferase family 2 member B15,4,68646630-68670628,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Approved,,,,"Urothelial cancer:4.50e-4 (favourable), Liver cancer:9.82e-4 (favourable)",Tissue enriched,Group enriched,5,gallbladder: 110.7;liver: 107.6,small intestine: 20.6,Not detected,,
UGT2B17,,ENSG00000197888,UDP glucuronosyltransferase family 2 member B17,4,68537184-68568527,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Supported,,,,,Group enriched,Tissue enhanced,,colon: 372.4;duodenum: 371.2;small intestine: 522.5,rectum: 151.7,Cell line enhanced,,RPMI-8226: 1.2
UGT2B28,,ENSG00000135226,UDP glucuronosyltransferase family 2 member B28,4,69280499-69295050,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA045108,Uncertain,,,,,Tissue enriched,Tissue enriched,12,breast: 267.2,gallbladder: 21.5,Group enriched,9,Daudi: 2.1;NB-4: 1.7
UGT2B4,UGT2B11,ENSG00000156096,UDP glucuronosyltransferase family 2 member B4,4,69480165-69526014,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB033260, HPA045108",Enhanced,,,,,Tissue enriched,Tissue enriched,78,liver: 655.5,heart muscle: 8.3,Cell line enriched,11,RH-30: 4.5
UGT2B7,UGT2B9,ENSG00000171234,UDP glucuronosyltransferase family 2 member B7,4,69051363-69112987,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA045108,Uncertain,,,,"Colorectal cancer:7.65e-5 (favourable), Renal cancer:3.79e-4 (favourable), Urothelial cancer:5.38e-4 (favourable)",Group enriched,Group enriched,13,kidney: 1326.3;liver: 825.7,fallopian tube: 79.7,Cell line enhanced,,EFO-21: 73.2;RPTEC TERT1: 235.7;U-2197: 40.2
UGT3A1,FLJ34658,ENSG00000145626,UDP glycosyltransferase family 3 member A1,5,35951010-36001028,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA047697, HPA056290",Uncertain,,Approved,Vesicles<br>Cytosol,,Group enriched,Tissue enhanced,,kidney: 53.4;liver: 29.2,duodenum: 9.5,Cell line enriched,51,RH-30: 26.5
UGT3A2,,ENSG00000168671,UDP glycosyltransferase family 3 member A2,5,36035017-36071358,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA059475,Uncertain,,Approved,Nucleus<br>Cytosol,,Tissue enriched,Tissue enhanced,,skin: 11.9;testis: 4.6,bone marrow: 3.2,Cell line enhanced,,HDLM-2: 6.3;MOLT-4: 9.8;REH: 25.8;T-47d: 6.7;THP-1: 11.2
UGT8,CGT,ENSG00000174607,UDP glycosyltransferase 8,4,114598455-114678224,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA014405, HPA065785",Approved,,Approved,Mitochondria,Renal cancer:8.55e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 101.0,kidney: 29.8,Cell line enhanced,,CAPAN-2: 44.4;RPTEC TERT1: 37.0;SCLC-21H: 32.8
UHMK1,"KIS, Kist",ENSG00000152332,U2AF homology motif kinase 1,1,162497251-162529629,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA071190,,,Supported,Nucleoplasm<br>Golgi apparatus,,Expressed in all,Expressed in all,,,parathyroid gland: 44.2,Expressed in all,,
UHRF1,"FLJ21925, ICBP90, Np95, RNF106, TDRD22",ENSG00000276043,Ubiquitin like with PHD and ring finger domains 1,19,4903080-4962154,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA049408, HPA055446",Enhanced,,Supported,Nucleoplasm,"Pancreatic cancer:4.52e-5 (unfavourable), Liver cancer:1.63e-4 (unfavourable), Melanoma:6.81e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lymph node: 18.8,bone marrow: 17.5,Expressed in all,,
UHRF2,"MGC33463, NIRF, RNF107, TDRD23, URF2",ENSG00000147854,Ubiquitin like with PHD and ring finger domains 2,9,6413151-6507054,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026633, HPA026697",,,Enhanced,Nucleoplasm,,Expressed in all,Expressed in all,,,bone marrow: 32.8,Expressed in all,,
ULK1,"ATG1, ATG1A",ENSG00000177169,Unc-51 like autophagy activating kinase 1,12,131894651-131923167,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA063990,,,Approved,Cytosol,,Expressed in all,Expressed in all,,,skin: 23.7,Expressed in all,,
ULK2,"ATG1B, KIAA0623, Unc51.2",ENSG00000083290,Unc-51 like autophagy activating kinase 2,17,19770829-19867936,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA009027, CAB037021",Approved,,,,,Expressed in all,Expressed in all,,,testis: 65.9,Mixed,,
ULK3,"DKFZP434C131, FLJ90566",ENSG00000140474,Unc-51 like kinase 3,15,74836116-74843346,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040474,Approved,,,,Pancreatic cancer:7.47e-4 (favourable),Expressed in all,Expressed in all,,,esophagus: 28.4,Expressed in all,,
ULK4,"FAM7C1, FLJ20574, REC01035",ENSG00000168038,Unc-51 like kinase 4,3,41246599-41962430,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017930,Uncertain,,Approved,Nucleoplasm<br>Mitochondria<br>Cytosol,,Mixed,Tissue enhanced,,testis: 38.1,parathyroid gland: 14.4,Mixed,,
UMPS,,ENSG00000114491,Uridine monophosphate synthetase,3,124730366-124749273,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036178, HPA036179",Uncertain,,Supported,Cytosol,Prostate cancer:9.20e-4 (unfavourable),Expressed in all,Mixed,,,"parathyroid gland,spleen: 3.4",Expressed in all,,
UNG,"DGU, HIGM4, UDG, UNG1, UNG2",ENSG00000076248,Uracil DNA glycosylase,12,109097574-109110992,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,CAB011605,Uncertain,,Approved,Cytosol,"Melanoma:3.06e-4 (unfavourable), Liver cancer:6.40e-4 (unfavourable)",Expressed in all,Expressed in all,,,adrenal gland: 56.2,Expressed in all,,
UPB1,BUP1,ENSG00000100024,Beta-ureidopropionase 1,22,24494107-24528390,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA000728,Enhanced,,,,Liver cancer:2.30e-7 (favourable),Tissue enriched,Group enriched,23,kidney: 51.2;liver: 161.7,testis: 4.6,Cell line enhanced,,CACO-2: 6.0;NB-4: 1.9;THP-1: 2.7;U-937: 3.5
UPP1,"UDRPASE, UP, UPASE, UPP",ENSG00000183696,Uridine phosphorylase 1,7,48088628-48108733,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA054040, HPA055394",Enhanced,,Enhanced,Nucleoplasm,"Cervical cancer:1.02e-4 (unfavourable), Lung cancer:1.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,,esophagus: 35.1,appendix: 17.8,Cell line enhanced,,hTERT-HME1: 369.7;WM-115: 110.3
UPP2,"UDRPASE2, UP2, UPASE2",ENSG00000007001,Uridine phosphorylase 2,2,157876702-158136154,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035225, HPA035226",,,Approved,Nucleus<br>Vesicles<br>Mitochondria,,Tissue enriched,Group enriched,14,kidney: 52.2;liver: 14.3,cerebral cortex: 2.4,Not detected,,
UQCRC1,"D3S3191, QCR1, UQCR1",ENSG00000010256,Ubiquinol-cytochrome c reductase core protein I,3,48599002-48610976,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA002815, HPA003525, CAB033782",Enhanced,,Supported,Mitochondria<br>Cytosol,Renal cancer:2.35e-10 (favourable),Expressed in all,Expressed in all,,,skeletal muscle: 88.3,Expressed in all,,
UQCRC2,"QCR2, UQCR2",ENSG00000140740,Ubiquinol-cytochrome c reductase core protein II,16,21952660-21983660,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA007998, HPA019146",Enhanced,,Enhanced,Mitochondria,Renal cancer:6.58e-9 (favourable),Expressed in all,Expressed in all,,,heart muscle: 151.1,Expressed in all,,
UQCRFS1,"RIP1, RIS1, RISP, UQCR5",ENSG00000169021,"Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1",19,29205321-29213541,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041863, HPA050339",Enhanced,,Enhanced,Mitochondria,"Renal cancer:3.92e-9 (favourable), Colorectal cancer:3.29e-4 (favourable), Ovarian cancer:3.84e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 70.9,Expressed in all,,
URAD,PRHOXNB,ENSG00000183463,Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase,13,27977714-27988654,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA038972,Uncertain,,,,,Tissue enriched,Group enriched,6,colon: 12.6;duodenum: 8.3;small intestine: 17.9,appendix: 2.3,Group enriched,12,BEWO: 2.6;CACO-2: 2.1
UROC1,"FLJ31300, HMFN0320",ENSG00000159650,Urocanate hydratase 1,3,126481281-126517773,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA069863,Enhanced,,,,,Tissue enriched,Tissue enriched,126,liver: 43.0,fallopian tube: 0.3,Cell line enriched,7,NB-4: 2.6
UROD,,ENSG00000126088,Uroporphyrinogen decarboxylase,1,45012147-45015575,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA027468, HPA028668, HPA030350",Uncertain,,Supported,Nucleoplasm<br>Cytosol,Liver cancer:2.48e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 115.4,Expressed in all,,
UROS,,ENSG00000188690,Uroporphyrinogen III synthase,10,125784980-125823248,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA044038,Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:6.27e-4 (unfavourable),Expressed in all,Expressed in all,,,epididymis: 84.7,Expressed in all,,
USP1,,ENSG00000162607,Ubiquitin specific peptidase 1,1,62436297-62451804,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA028387, HPA028440",Approved,,Supported,Nucleoplasm,Liver cancer:5.81e-5 (unfavourable),Expressed in all,Expressed in all,,,testis: 92.3,Expressed in all,,
USP10,"KIAA0190, UBPO",ENSG00000103194,Ubiquitin specific peptidase 10,16,84699978-84779922,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006731, HPA006749",Enhanced,,Enhanced,Nucleoplasm<br>Cytosol,Renal cancer:1.00e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 63.1,Expressed in all,,
USP11,UHX1,ENSG00000102226,Ubiquitin specific peptidase 11,X,47232690-47248328,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA003103, HPA037536",Enhanced,Approved,Supported,Nucleoplasm,"Renal cancer:4.13e-5 (favourable), Endometrial cancer:2.95e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 212.7,Expressed in all,,
USP12,USP12L1,ENSG00000152484,Ubiquitin specific peptidase 12,13,27066142-27171896,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007288,Uncertain,,,,,Expressed in all,Expressed in all,,,bone marrow: 45.6,Expressed in all,,
USP13,IsoT-3,ENSG00000058056,Ubiquitin specific peptidase 13 (isopeptidase T-3),3,179652755-179789401,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA004827,Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:3.46e-6 (unfavourable), Liver cancer:2.40e-5 (unfavourable), Urothelial cancer:3.06e-4 (unfavourable)",Expressed in all,Expressed in all,,,skeletal muscle: 52.2,Mixed,,
USP14,TGT,ENSG00000101557,Ubiquitin specific peptidase 14,18,158383-214629,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA001308,Approved,,Supported,Cytosol,"Liver cancer:4.30e-5 (unfavourable), Head and neck cancer:7.81e-5 (unfavourable), Ovarian cancer:7.91e-4 (favourable)",Expressed in all,Expressed in all,,,prostate: 48.2,Expressed in all,,
USP15,"KIAA0529, UNPH4",ENSG00000135655,Ubiquitin specific peptidase 15,12,62260338-62417431,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006237, HPA006428, HPA071014",Approved,,Enhanced,Cytosol,"Renal cancer:1.58e-5 (unfavourable), Liver cancer:8.04e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 121.6,Expressed in all,,
USP16,Ubp-M,ENSG00000156256,Ubiquitin specific peptidase 16,21,29024629-29054488,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA021140,Supported,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,parathyroid gland: 57.2,Expressed in all,,
USP17L1,USP17L1P,ENSG00000230549,Ubiquitin specific peptidase 17-like family member 1,8,7332387-7333979,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,cerebral cortex: 0.3,Not detected,,
USP17L10,,ENSG00000231396,Ubiquitin specific peptidase 17-like family member 10,4,9210657-9212608,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L11,,ENSG00000233136,Ubiquitin specific peptidase 17-like family member 11,4,9215405-9217356,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,thyroid gland: 0.2,Not detected,,
USP17L12,,ENSG00000227551,Ubiquitin specific peptidase 17-like family member 12,4,9220152-9221744,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L13,,ENSG00000232399,Ubiquitin specific peptidase 17-like family member 13,4,9224896-9226847,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L15,,ENSG00000223569,Ubiquitin specific peptidase 17-like family member 15,4,9234385-9236334,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L17,,ENSG00000249104,Ubiquitin specific peptidase 17-like family member 17,4,9243879-9245830,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L18,,ENSG00000250844,Ubiquitin specific peptidase 17-like family member 18,4,9248630-9250581,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L19,,ENSG00000248920,Ubiquitin specific peptidase 17-like family member 19,4,9253378-9255329,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L2,DUB3,ENSG00000223443,Ubiquitin specific peptidase 17-like family member 2,8,12137168-12139077,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L20,,ENSG00000250745,Ubiquitin specific peptidase 17-like family member 20,4,9258124-9260075,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L21,,ENSG00000249811,Ubiquitin specific peptidase 17-like family member 21,4,9262872-9264823,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L22,,ENSG00000248933,Ubiquitin specific peptidase 17-like family member 22,4,9267619-9269570,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L23,,ENSG00000250913,Ubiquitin specific peptidase 17-like family member 23,4,9272364-9272914,"Enzymes, Predicted intracellular proteins",No evidence,,,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L24,,ENSG00000232264,Ubiquitin specific peptidase 17-like family member 24,4,9325165-9327116,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L25,,ENSG00000230430,Ubiquitin specific peptidase 17-like family member 25,4,9329911-9331862,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L26,,ENSG00000229579,Ubiquitin specific peptidase 17-like family member 26,4,9334658-9336609,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L27,,ENSG00000235780,Ubiquitin specific peptidase 17-like family member 27,4,9344148-9345740,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L28,,ENSG00000231051,Ubiquitin specific peptidase 17-like family member 28,4,9348893-9350485,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L29,,ENSG00000231637,Ubiquitin specific peptidase 17-like family member 29,4,9353638-9355230,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L3,"USP17B, USP17F",ENSG00000225327,Ubiquitin specific peptidase 17-like family member 3,8,7976393-7977985,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L30,,ENSG00000228856,Ubiquitin specific peptidase 17-like family member 30,4,9363129-9364721,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L4,,ENSG00000236125,Ubiquitin specific peptidase 17-like family member 4,8,7337115-7338707,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L5,,ENSG00000227140,Ubiquitin specific peptidase 17-like family member 5,4,9339403-9340995,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L7,,ENSG00000226430,Ubiquitin specific peptidase 17-like family member 7,8,12132417-12134438,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP17L8,,ENSG00000237038,Ubiquitin specific peptidase 17-like family member 8,8,7971661-7973253,"Enzymes, Predicted intracellular proteins",No evidence,HPA045642,Uncertain,,,,,Not detected,Not detected,,,all non-specific tissues: 0.0,Not detected,,
USP18,,ENSG00000184979,Ubiquitin specific peptidase 18,22,18149899-18177397,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044768,Uncertain,,Approved,Cytosol,,Expressed in all,Mixed,,,testis: 15.4,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 144.8;BJ hTERT+ SV40 Large T+ RasG12V: 163.7
USP19,"KIAA0891, ZMYND9",ENSG00000172046,Ubiquitin specific peptidase 19,3,49108046-49120938,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:7.05e-9 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 45.7,Expressed in all,,
USP2,UBP41,ENSG00000036672,Ubiquitin specific peptidase 2,11,119355215-119381726,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006777, HPA007222",Approved,,Supported,Plasma membrane<br>Cytosol,Renal cancer:3.09e-11 (favourable),Expressed in all,Tissue enhanced,,testis: 119.4,skeletal muscle: 59.3,Cell line enhanced,,U-266/70: 43.2
USP20,KIAA1003,ENSG00000136878,Ubiquitin specific peptidase 20,9,129834698-129881838,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006287, HPA007008",Uncertain,Approved,Approved,Nucleus<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:1.54e-7 (favourable), Renal cancer:5.65e-5 (favourable), Colorectal cancer:2.48e-4 (unfavourable), Endometrial cancer:4.01e-4 (favourable), Cervical cancer:8.01e-4 (favourable)",Expressed in all,Expressed in all,,,thyroid gland: 22.1,Expressed in all,,
USP21,"USP16, USP23",ENSG00000143258,Ubiquitin specific peptidase 21,1,161159450-161165723,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA028397,Uncertain,Supported,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:9.50e-6 (unfavourable), Urothelial cancer:3.35e-5 (favourable), Liver cancer:1.68e-4 (unfavourable), Endometrial cancer:7.05e-4 (unfavourable)",Expressed in all,Expressed in all,,,fallopian tube: 45.7,Expressed in all,,
USP22,"KIAA1063, USP3L",ENSG00000124422,Ubiquitin specific peptidase 22,17,20999593-21043760,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044980,Supported,,Supported,Nuclear speckles,"Renal cancer:1.53e-7 (favourable), Liver cancer:9.66e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 154.1,Expressed in all,,
USP24,KIAA1057,ENSG00000162402,Ubiquitin specific peptidase 24,1,55066359-55215113,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026723, HPA028428, HPA067124",Approved,,Supported,Nucleoplasm<br>Cytosol,Liver cancer:1.34e-7 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 38.1,Expressed in all,,
USP25,USP21,ENSG00000155313,Ubiquitin specific peptidase 25,21,15730025-15880069,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA018297, HPA024142",Approved,,Supported,Cytosol,,Expressed in all,Expressed in all,,,testis: 97.6,Expressed in all,,
USP26,,ENSG00000134588,Ubiquitin specific peptidase 26,X,133024631-133097109,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,7,testis: 1.1,"bone marrow,breast,endometrium,epididymis,gallbladder,lymph node,prostate,skin,spleen,thyroid gland: 0.1",Not detected,,
USP27X,USP27,ENSG00000273820,"Ubiquitin specific peptidase 27, X-linked",X,49879948-49882565,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA077264,,,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:6.14e-4 (unfavourable), Pancreatic cancer:9.31e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 19.7,cerebral cortex: 10.3,Mixed,,
USP28,KIAA1515,ENSG00000048028,Ubiquitin specific peptidase 28,11,113797874-113875570,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006778, HPA006779",Enhanced,,Supported,Nucleoplasm<br>Nuclear bodies,,Expressed in all,Expressed in all,,,heart muscle: 40.2,Expressed in all,,
USP29,,ENSG00000131864,Ubiquitin specific peptidase 29,19,57119138-57131926,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA021064,Uncertain,,,,,Not detected,Tissue enriched,5,testis: 9.0,skin: 1.7,Not detected,,
USP3,,ENSG00000140455,Ubiquitin specific peptidase 3,15,63504511-63594640,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA053275, HPA060513, HPA077975",,,Supported,Nucleoplasm,Urothelial cancer:1.38e-4 (favourable),Expressed in all,Expressed in all,,,bone marrow: 32.1,Expressed in all,,
USP30,"FLJ40511, MGC10702",ENSG00000135093,Ubiquitin specific peptidase 30,12,109023089-109088026,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA016952,Approved,,,,Renal cancer:5.23e-6 (favourable),Expressed in all,Expressed in all,,,testis: 25.4,Expressed in all,,
USP31,KIAA1203,ENSG00000103404,Ubiquitin specific peptidase 31,16,23061406-23149270,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006937,Uncertain,,Approved,Cytosol,Renal cancer:4.41e-5 (unfavourable),Expressed in all,Mixed,,,testis: 22.2,Expressed in all,,
USP32,"NY-REN-60, USP10",ENSG00000170832,Ubiquitin specific peptidase 32,17,60179094-60422470,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA044365,Approved,,Approved,Golgi apparatus<br>Cytosol,Endometrial cancer:1.50e-4 (unfavourable),Expressed in all,Expressed in all,,,testis: 155.0,Expressed in all,,
USP33,"KIAA1097, VDU1",ENSG00000077254,Ubiquitin specific peptidase 33,1,77695987-77759852,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA005719,Uncertain,,Supported,Nucleoplasm<br>Golgi apparatus,,Expressed in all,Expressed in all,,,parathyroid gland: 55.5,Expressed in all,,
USP34,"KIAA0570, KIAA0729",ENSG00000115464,Ubiquitin specific peptidase 34,2,61187463-61470769,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA025815, HPA070764",Uncertain,,Approved,Nucleus,,Expressed in all,Expressed in all,,,epididymis: 66.0,Expressed in all,,
USP35,KIAA1372,ENSG00000118369,Ubiquitin specific peptidase 35,11,78188812-78214711,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA055213, HPA058592",Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center,,Expressed in all,Tissue enhanced,,parathyroid gland: 34.3,adrenal gland: 14.8,Expressed in all,,
USP36,"FLJ12851, KIAA1453",ENSG00000055483,Ubiquitin specific peptidase 36,17,78787381-78841441,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA012082, HPA012395, HPA052860",Uncertain,Approved,Enhanced,Nucleoli<br>Nuclear speckles,Endometrial cancer:5.18e-5 (unfavourable),Expressed in all,Expressed in all,,,skin: 38.4,Expressed in all,,
USP37,KIAA1594,ENSG00000135913,Ubiquitin specific peptidase 37,2,218450251-218568361,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA045160,Approved,,Approved,Nucleus<br>Nucleoli,Head and neck cancer:2.85e-4 (favourable),Mixed,Mixed,,,testis: 23.2,Expressed in all,,
USP38,"HP43.8KD, KIAA1891",ENSG00000170185,Ubiquitin specific peptidase 38,4,143184917-143223830,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036990, HPA047948",Uncertain,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:1.20e-4 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 14.1,Expressed in all,,
USP39,"CGI-21, SAD1, SNRNP65",ENSG00000168883,Ubiquitin specific peptidase 39,2,85602856-85649282,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA034823,,Approved,Supported,Nucleoplasm,"Renal cancer:4.05e-7 (unfavourable), Liver cancer:2.84e-6 (unfavourable), Endometrial cancer:5.52e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 38.4,Expressed in all,,
USP4,"UNP, Unph",ENSG00000114316,Ubiquitin specific peptidase 4,3,49277831-49340712,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA018499,Approved,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:4.29e-5 (favourable), Lung cancer:4.46e-5 (favourable)",Expressed in all,Expressed in all,,,testis: 56.8,Expressed in all,,
USP40,FLJ10785,ENSG00000085982,Ubiquitin specific peptidase 40,2,233475520-233566782,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA005821,Uncertain,,Approved,Vesicles,,Expressed in all,Expressed in all,,,parathyroid gland: 31.5,Mixed,,
USP41,,ENSG00000161133,Ubiquitin specific peptidase 41,22,20350578-20390758,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,,,,,,,Not detected,Not detected,,,cerebral cortex: 0.3,Cell line enhanced,,RH-30: 1.2;SCLC-21H: 1.8
USP42,FLJ12697,ENSG00000106346,Ubiquitin specific peptidase 42,7,6104884-6161564,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006752, HPA064800",Uncertain,,Approved,Nucleus,,Expressed in all,Tissue enhanced,,testis: 27.8,parathyroid gland: 8.8,Expressed in all,,
USP43,FLJ30626,ENSG00000154914,Ubiquitin specific peptidase 43,17,9644698-9729691,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA023389, HPA027762",Uncertain,,,,Stomach cancer:5.39e-4 (favourable),Mixed,Mixed,,,placenta: 11.9,Cell line enhanced,,BEWO: 11.2;T-47d: 9.2
USP44,FLJ14528,ENSG00000136014,Ubiquitin specific peptidase 44,12,95516560-95551490,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026543,,,Approved,Nucleoli fibrillar center<br>Microtubules,,Tissue enhanced,Tissue enriched,7,testis: 43.6,parathyroid gland: 6.0,Cell line enriched,6,NTERA-2: 137.8
USP45,MGC14793,ENSG00000123552,Ubiquitin specific peptidase 45,6,99432379-99521728,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA029602, HPA029604",Uncertain,,Approved,Nucleus<br>Cytosol,,Expressed in all,Mixed,,,gallbladder: 9.9,Expressed in all,,
USP46,FLJ12552,ENSG00000109189,Ubiquitin specific peptidase 46,4,52590972-52659335,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA007288, CAB076369, CAB076370",Uncertain,,Enhanced,Nucleoli,,Expressed in all,Expressed in all,,,cerebral cortex: 44.7,Mixed,,
USP47,,ENSG00000170242,Ubiquitin specific peptidase 47,11,11841423-11959323,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA029286, HPA029289",Supported,,Approved,Intermediate filaments,,Expressed in all,Expressed in all,,,parathyroid gland: 75.4,Expressed in all,,
USP48,"FLJ11328, FLJ20103, FLJ23054, FLJ23277, MGC14879, USP31",ENSG00000090686,Ubiquitin specific peptidase 48,1,21678298-21783606,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030045, HPA030046",Approved,Approved,Supported,Nucleoplasm<br>Mitochondria<br>Cytosol,Liver cancer:6.09e-8 (unfavourable),Expressed in all,Expressed in all,,,adrenal gland: 54.0,Expressed in all,,
USP49,MGC20741,ENSG00000164663,Ubiquitin specific peptidase 49,6,41789896-41895361,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA030254, HPA030255",Uncertain,,,,,Mixed,Mixed,,,testis: 9.1,Cell line enhanced,,REH: 42.8;U-698: 45.4
USP5,IsoT,ENSG00000111667,Ubiquitin specific peptidase 5,12,6852128-6866632,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006756,Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,cerebral cortex: 87.5,Expressed in all,,
USP50,,ENSG00000170236,Ubiquitin specific peptidase 50,15,50500562-50546708,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA039470,Uncertain,,,,,Not detected,Tissue enriched,18,testis: 1.8,all non-specific tissues: 0.0,Not detected,,
USP51,,ENSG00000247746,Ubiquitin specific peptidase 51,X,55484616-55489202,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001942,Uncertain,,Approved,Nucleoli fibrillar center<br>Cytosol,"Renal cancer:2.63e-5 (favourable), Ovarian cancer:5.70e-4 (favourable)",Mixed,Tissue enriched,7,epididymis: 62.9,parathyroid gland: 9.3,Mixed,,
USP53,KIAA1350,ENSG00000145390,Ubiquitin specific peptidase 53,4,119212587-119295517,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035844, HPA035845",Uncertain,,Approved,Nucleoplasm<br>Golgi apparatus,"Renal cancer:3.58e-8 (favourable), Colorectal cancer:3.15e-6 (favourable), Prostate cancer:7.54e-6 (unfavourable)",Expressed in all,Mixed,,,fallopian tube: 48.8,Cell line enhanced,,BJ hTERT+: 265.8;SK-MEL-30: 79.9
USP54,"bA137L10.3, bA137L10.4, C10orf29, FLJ37318",ENSG00000166348,Ubiquitin specific peptidase 54,10,73497538-73625953,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047663,Approved,,Approved,Mitochondria,Lung cancer:7.00e-4 (favourable),Expressed in all,Tissue enhanced,,thyroid gland: 59.6,cerebral cortex: 30.7,Cell line enhanced,,PC-3: 29.7
USP6,"HRP1, Tre-2, TRE17, Tre2, TRESMCR",ENSG00000129204,Ubiquitin specific peptidase 6,17,5116438-5175034,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA046969,,,Uncertain,Vesicles,,Tissue enriched,Group enriched,5,ovary: 3.5;skeletal muscle: 7.5;testis: 17.1,smooth muscle: 1.8,Mixed,,
USP7,HAUSP,ENSG00000187555,Ubiquitin specific peptidase 7,16,8892094-8964514,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB008108, HPA015641",Approved,,,,Renal cancer:8.56e-5 (favourable),Expressed in all,Expressed in all,,,testis: 109.1,Expressed in all,,
USP8,"HumORF8, KIAA0055, SPG59, UBPY",ENSG00000138592,Ubiquitin specific peptidase 8,15,50424380-50514419,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA050215,Approved,,Supported,Golgi apparatus<br>Cytosol,Renal cancer:1.29e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 77.0,Expressed in all,,
USP9X,"DFFRX, FAF, MRX99",ENSG00000124486,"Ubiquitin specific peptidase 9, X-linked",X,41085635-41236579,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB011618, HPA047417, CAB070164",Approved,,Uncertain,Vesicles,,Expressed in all,Expressed in all,,,parathyroid gland: 90.1,Expressed in all,,
USP9Y,DFFRY,ENSG00000114374,"Ubiquitin specific peptidase 9, Y-linked",Y,12701231-12860839,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA057687,,,Uncertain,Vesicles,,Tissue enhanced,Tissue enhanced,,prostate: 9.9,seminal vesicle: 6.9,Cell line enhanced,,RPTEC TERT1: 13.3
USPL1,"bA121O19.1, C13orf22, D13S106E",ENSG00000132952,Ubiquitin specific peptidase like 1,13,30617693-30660770,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039342, HPA040172",Uncertain,,,,,Expressed in all,Expressed in all,,,testis: 40.5,Expressed in all,,
UXS1,"FLJ23591, SDR6E1, UGD",ENSG00000115652,UDP-glucuronate decarboxylase 1,2,106093303-106194339,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008825,Uncertain,,,,"Liver cancer:1.38e-4 (unfavourable), Head and neck cancer:5.45e-4 (unfavourable), Ovarian cancer:7.94e-4 (favourable)",Expressed in all,Expressed in all,,,placenta: 76.1,Expressed in all,,
VARS,VARS2,ENSG00000204394,Valyl-tRNA synthetase,6,31777518-31795953,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA046710,Approved,,Enhanced,Cytosol,"Liver cancer:1.86e-4 (unfavourable), Lung cancer:6.90e-4 (unfavourable), Cervical cancer:7.25e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 5.5,Mixed,,
VARS2,"DKFZP434L1435, G7a, KIAA1885, VARS2L, VARSL",ENSG00000137411,"Valyl-tRNA synthetase 2, mitochondrial",6,30908242-30926459,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA062449, HPA070267",Approved,,Approved,Mitochondria,,Expressed in all,Mixed,,,esophagus: 5.2,Mixed,,
VCP,"IBMPFD, p97",ENSG00000165280,Valosin containing protein,9,35056064-35073249,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB005593, HPA012728, HPA012814",Supported,,Enhanced,Nucleoplasm<br>Cytosol,"Renal cancer:9.63e-7 (favourable), Endometrial cancer:7.30e-4 (favourable)",Expressed in all,Expressed in all,,,parathyroid gland: 94.2,Expressed in all,,
VCPIP1,"DUBA3, FLJ23132, KIAA1850, VCIP135",ENSG00000175073,Valosin containing protein interacting protein 1,8,66628487-66667217,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA023932,Uncertain,,Approved,Plasma membrane,,Expressed in all,Mixed,,,bone marrow: 13.1,Expressed in all,,
VKORC1,VKCFD2,ENSG00000167397,Vitamin K epoxide reductase complex subunit 1,16,31090842-31095980,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA042720,Approved,,Supported,Endoplasmic reticulum,Renal cancer:2.09e-10 (unfavourable),Expressed in all,Expressed in all,,,liver: 141.4,Expressed in all,,
VKORC1L1,,ENSG00000196715,Vitamin K epoxide reductase complex subunit 1 like 1,7,65873267-65959563,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA053954,Approved,,Supported,Endoplasmic reticulum,,Expressed in all,Expressed in all,,,adipose tissue: 57.5,Expressed in all,,
VNN1,Tiff66,ENSG00000112299,Vanin 1,6,132681590-132714049,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA064145,Approved,,,,Renal cancer:2.52e-4 (unfavourable),Tissue enhanced,Group enriched,5,duodenum: 171.4;gallbladder: 174.7;liver: 142.4;small intestine: 106.3,kidney: 27.5,Cell line enhanced,,EFO-21: 10.3
VNN2,"FOAP-4, GPI-80",ENSG00000112303,Vanin 2,6,132743870-132763459,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:2.72e-7 (unfavourable),Mixed,Tissue enhanced,,spleen: 76.9,lymph node: 45.0,Cell line enriched,6,Daudi: 40.8
VNN3,HSA238982,ENSG00000093134,Vanin 3,6,132722787-132734765,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,bone marrow: 35.3;liver: 15.2,spleen: 9.5,Not detected,,
VPS4A,"FLJ22197, SKD1, SKD1A, SKD2, VPS4, VPS4-1",ENSG00000132612,Vacuolar protein sorting 4 homolog A,16,69311356-69326939,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB018751, CAB034411, HPA060092",Approved,,,,Renal cancer:1.76e-4 (favourable),Expressed in all,Expressed in all,,,cerebral cortex: 31.9,Expressed in all,,
VPS4B,"SKD1, SKD1B, VPS4-2",ENSG00000119541,Vacuolar protein sorting 4 homolog B,18,63389190-63422483,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040393, CAB046445, HPA057649",Approved,,Approved,Vesicles<br>Intermediate filaments,Renal cancer:1.23e-4 (favourable),Expressed in all,Expressed in all,,,esophagus: 82.7,Expressed in all,,
VRK1,,ENSG00000100749,Vaccinia related kinase 1,14,96797304-96931722,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000660, HPA017929",Enhanced,,Supported,Nucleus<br>Cytosol,Liver cancer:4.15e-4 (unfavourable),Expressed in all,Mixed,,,testis: 59.5,Expressed in all,,
VRK2,,ENSG00000028116,Vaccinia related kinase 2,2,57907651-58159920,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB046459, HPA047503",Approved,,Supported,Endoplasmic reticulum,"Liver cancer:6.32e-6 (unfavourable), Renal cancer:4.66e-5 (unfavourable), Pancreatic cancer:4.65e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 29.1,Mixed,,
VRK3,,ENSG00000105053,Vaccinia related kinase 3,19,49976467-50025946,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA056489,Approved,,Supported,Nucleus<br>Vesicles,"Renal cancer:1.83e-4 (favourable), Urothelial cancer:5.66e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 168.6,Expressed in all,,
WARS,"IFI53, IFP53",ENSG00000140105,Tryptophanyl-tRNA synthetase,14,100333788-100376805,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA005573, HPA018944",,,Enhanced,Cytosol,"Ovarian cancer:1.94e-4 (favourable), Liver cancer:7.88e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 473.2,Expressed in all,,
WARS2,TrpRS,ENSG00000116874,"Tryptophanyl tRNA synthetase 2, mitochondrial",1,119031216-119140671,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA069692,Enhanced,,Supported,Plasma membrane<br>Mitochondria,Renal cancer:1.45e-4 (favourable),Expressed in all,Expressed in all,,,fallopian tube: 15.2,Expressed in all,,
WBSCR17,"GalNAc-T5L, GALNTL3",ENSG00000185274,Williams-Beuren syndrome chromosome region 17,7,71132169-71713600,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA013624, HPA047986",Approved,,Uncertain,Nucleus<br>Nucleoli<br>Nuclear bodies<br>Golgi apparatus,"Testis cancer:3.91e-4 (favourable), Ovarian cancer:4.60e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 76.4,ovary: 29.1,Cell line enhanced,,AF22: 14.1;NTERA-2: 10.8;RPMI-8226: 8.6;SK-BR-3: 34.1
WDYHV1,"C8orf32, FLJ10204",ENSG00000156795,WDYHV motif containing 1,8,123416725-123467230,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA024823, HPA053680",Approved,,Supported,Nucleoplasm<br>Vesicles,"Endometrial cancer:4.93e-5 (unfavourable), Liver cancer:3.47e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 18.5,Expressed in all,,
WEE1,WEE1A,ENSG00000166483,WEE1 G2 checkpoint kinase,11,9573681-9593457,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004619, HPA068845",Approved,,Approved,Nucleoli,Renal cancer:5.19e-4 (unfavourable),Expressed in all,Expressed in all,,,endometrium: 90.6,Expressed in all,,
WEE2,FLJ16107,ENSG00000214102,WEE1 homolog 2,7,141708353-141731271,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027418,Uncertain,,Supported,Nucleoplasm<br>Cytosol,,Not detected,Not detected,,,"skin,thyroid gland: 0.8",Cell line enhanced,,CACO-2: 2.6
WNK1,"HSAN2, HSN2, PPP1R167, PRKWNK1",ENSG00000060237,WNK lysine deficient protein kinase 1,12,752593-911452,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA046541, HPA059157",Enhanced,,Supported,Cytosol,Ovarian cancer:9.67e-4 (unfavourable),Expressed in all,Expressed in all,,,esophagus: 92.4,Expressed in all,,
WNK2,"KIAA1760, NY-CO-43, PRKWNK2, SDCCAG43",ENSG00000165238,WNK lysine deficient protein kinase 2,9,93184916-93320572,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA015555, HPA016519, CAB017813",Enhanced,,Approved,Cytosol,,Mixed,Mixed,,,heart muscle: 29.1,Cell line enhanced,,Hep G2: 21.0;SCLC-21H: 44.2
WNK3,PRKWNK3,ENSG00000196632,WNK lysine deficient protein kinase 3,X,54192823-54358642,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA077678,,,Approved,Vesicles,,Mixed,Group enriched,6,epididymis: 14.3;testis: 18.6,ovary: 2.6,Cell line enhanced,,AF22: 4.4;HAP1: 5.4;NTERA-2: 9.1;SiHa: 4.8;U-2 OS: 4.1
WNK4,PRKWNK4,ENSG00000126562,WNK lysine deficient protein kinase 4,17,42780678-42796936,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA016500,Approved,,,,,Mixed,Tissue enhanced,,kidney: 19.0;prostate: 15.4;rectum: 12.0,colon: 8.8,Cell line enhanced,,fHDF/TERT166: 26.2;K-562: 34.7;TIME: 29.5;WM-115: 23.9
WRN,"RECQ3, RECQL2",ENSG00000165392,Werner syndrome RecQ like helicase,8,31033801-31173769,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA028661,Approved,,Supported,Nuclear speckles,,Expressed in all,Mixed,,,endometrium: 14.8,Expressed in all,,
WRNIP1,"bA420G6.2, FLJ22526, WHIP",ENSG00000124535,Werner helicase interacting protein 1,6,2765414-2786952,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA031752, HPA031753",Enhanced,,Approved,Nucleoplasm,,Expressed in all,Expressed in all,,,parathyroid gland: 78.7,Expressed in all,,
WWP1,"AIP5, DKFZP434D2111",ENSG00000123124,WW domain containing E3 ubiquitin protein ligase 1,8,86342738-86478420,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA023180,Approved,,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:5.45e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 183.6,Expressed in all,,
WWP2,AIP2,ENSG00000198373,WW domain containing E3 ubiquitin protein ligase 2,16,69762306-69941741,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Renal cancer:5.87e-11 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 50.2,Expressed in all,,
XDH,"XO, XOR",ENSG00000158125,Xanthine dehydrogenase,2,31334321-31414715,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA062641, HPA069323",Supported,,Supported,Nucleus,Urothelial cancer:8.73e-6 (favourable),Mixed,Tissue enhanced,,breast: 48.3;duodenum: 45.6;liver: 35.9;small intestine: 54.6,colon: 11.2,Cell line enhanced,,HBEC3-KT: 14.4;hTERT-HME1: 23.9
XIAP,"API3, BIRC4, hILP",ENSG00000101966,X-linked inhibitor of apoptosis,X,123859724-123913979,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB009203, HPA042428",Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Breast cancer:9.21e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 35.4,Mixed,,
XPNPEP1,"XPNPEP, XPNPEPL, XPNPEPL1",ENSG00000108039,X-prolyl aminopeptidase 1,10,109864766-109923553,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB025196, HPA030419, HPA030420, HPA030422",Supported,,Enhanced,Cytosol,Liver cancer:2.12e-5 (unfavourable),Expressed in all,Expressed in all,,,small intestine: 66.1,Expressed in all,,
XPNPEP2,,ENSG00000122121,X-prolyl aminopeptidase 2,X,129738974-129769538,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA000339, CAB025136, CAB025269",Enhanced,,,,,Group enriched,Group enriched,12,duodenum: 128.1;kidney: 175.9;small intestine: 231.5,liver: 14.3,Cell line enhanced,,ASC diff: 6.9;ASC TERT1: 36.6;HSkMC: 19.4
XPNPEP3,"APP3, ICP55, NPHPL1",ENSG00000196236,X-prolyl aminopeptidase 3,22,40857077-40932815,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA000527,Enhanced,,,,"Thyroid cancer:6.10e-4 (unfavourable), Breast cancer:8.19e-4 (unfavourable)",Expressed in all,Mixed,,,duodenum: 14.5,Mixed,,
XXYLT1,"C3orf21, FLJ35155",ENSG00000173950,Xyloside xylosyltransferase 1,3,195068279-195271167,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:1.70e-4 (unfavourable),Expressed in all,Mixed,,,placenta: 15.0,Expressed in all,,
XYLB,"FLJ10343, FLJ12539",ENSG00000093217,Xylulokinase,3,38346760-38421348,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037863, HPA038415",Uncertain,,Approved,Nuclear speckles,Renal cancer:8.57e-4 (favourable),Mixed,Tissue enhanced,,liver: 15.2,kidney: 9.9,Mixed,,
XYLT1,"PXYLT1, XT-I",ENSG00000103489,Xylosyltransferase 1,16,17101769-17470881,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA007478, HPA007966",Approved,,,,,Mixed,Mixed,,,"cervix, uterine: 12.2",Cell line enhanced,,ASC diff: 38.1;U-2197: 54.3
XYLT2,"PXYLT2, XT-II",ENSG00000015532,Xylosyltransferase 2,17,50346092-50363138,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA016456,,,Approved,Nuclear bodies<br>Cytosol,,Expressed in all,Expressed in all,,,stomach: 31.5,Expressed in all,,
YARS,"tyrRS, YRS, YTS",ENSG00000134684,Tyrosyl-tRNA synthetase,1,32775237-32818153,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA017936, HPA018950, HPA018954",Enhanced,,Enhanced,Cytosol,"Renal cancer:1.02e-11 (unfavourable), Liver cancer:6.97e-11 (unfavourable), Urothelial cancer:6.57e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 81.5,Expressed in all,,
YARS2,"CGI-04, FLJ13995, mt-TyrRS",ENSG00000139131,Tyrosyl-tRNA synthetase 2,12,32727490-32755902,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038721, HPA057610, HPA074097",Uncertain,,Supported,Nuclear bodies<br>Mitochondria,Liver cancer:3.19e-5 (unfavourable),Expressed in all,Mixed,,,placenta: 11.1,Expressed in all,,
YES1,"c-yes, HsT441, Yes",ENSG00000176105,"YES proto-oncogene 1, Src family tyrosine kinase",18,721588-812546,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004370, HPA026480",Approved,,Supported,Plasma membrane<br>Cytosol,Pancreatic cancer:2.46e-4 (unfavourable),Expressed in all,Expressed in all,,,placenta: 62.0,Mixed,,
YME1L1,,ENSG00000136758,YME1 like 1 ATPase,10,27110112-27155266,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA066953,Approved,,Supported,Nuclear bodies<br>Mitochondria,Liver cancer:8.25e-6 (unfavourable),Expressed in all,Expressed in all,,,thyroid gland: 105.7,Expressed in all,,
YOD1,"DKFZp451J1719, DUBA8, OTUD2",ENSG00000180667,YOD1 deubiquitinase,1,207043849-207052980,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028400, HPA028439",Uncertain,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,bone marrow: 37.1,esophagus: 27.8,Cell line enhanced,,HEL: 78.5;K-562: 55.5
YTHDC2,"DKFZp564A186, FLJ10053, FLJ2194",ENSG00000047188,YTH domain containing 2,5,113513683-113595285,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037364, HPA072678",Approved,,Approved,Nucleoplasm<br>Nuclear bodies<br>Cytoplasmic bodies,Colorectal cancer:1.82e-5 (favourable),Expressed in all,Expressed in all,,,parathyroid gland: 37.0,Expressed in all,,
ZADH2,MGC45594,ENSG00000180011,Zinc binding alcohol dehydrogenase domain containing 2,18,75195108-75209348,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021468, HPA053646",Uncertain,,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,"Renal cancer:1.02e-6 (favourable), Thyroid cancer:1.94e-4 (unfavourable)",Expressed in all,Expressed in all,,,placenta: 52.3,Expressed in all,,
ZAP70,"SRK, STD, ZAP-70",ENSG00000115085,Zeta chain of T-cell receptor associated protein kinase 70,2,97713560-97739862,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB002625, HPA003134",Enhanced,,,,"Renal cancer:3.02e-8 (unfavourable), Endometrial cancer:9.66e-8 (favourable), Head and neck cancer:3.93e-6 (favourable), Cervical cancer:6.89e-5 (favourable)",Mixed,Tissue enhanced,,appendix: 36.2;lymph node: 64.3;spleen: 37.7,tonsil: 16.2,Cell line enriched,16,MOLT-4: 144.9
ZCCHC11,"KIAA0191, PAPD3, TUT4",ENSG00000134744,Zinc finger CCHC-type containing 11,1,52408282-52553487,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027412, HPA027973",Supported,,Supported,Nucleoli<br>Cytosol,Liver cancer:9.00e-4 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 59.8,Mixed,,
ZCCHC6,"FLJ13409, KIAA1711, PAPD6, TUT7",ENSG00000083223,Zinc finger CCHC-type containing 6,9,86287733-86354454,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA020615, HPA020620",Approved,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,prostate: 36.1,Expressed in all,,
ZDHHC1,"C16orf1, HSU90653, ZNF377",ENSG00000159714,Zinc finger DHHC-type containing 1,16,67394419-67416833,"Enzymes, Predicted membrane proteins",Evidence at transcript level,"HPA042531, HPA048659",Uncertain,,Approved,Cytosol,"Endometrial cancer:1.25e-6 (favourable), Renal cancer:1.55e-6 (favourable), Pancreatic cancer:5.99e-4 (favourable)",Expressed in all,Mixed,,,fallopian tube: 31.8,Mixed,,
ZDHHC11,"FLJ13153, ZNF399",ENSG00000188818,Zinc finger DHHC-type containing 11,5,795606-850986,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA057886, HPA069008",Uncertain,,Approved,Lipid droplets,,Mixed,Mixed,,,fallopian tube: 10.6,Cell line enhanced,,T-47d: 10.8
ZDHHC11B,,ENSG00000206077,Zinc finger DHHC-type containing 11B,5,710360-766952,"Enzymes, Predicted membrane proteins",Evidence at transcript level,"HPA057886, HPA069008",Uncertain,,Approved,Lipid droplets,Lung cancer:3.98e-4 (favourable),Mixed,Mixed,,,cerebral cortex: 6.2,Cell line enhanced,,HAP1: 2.8;SCLC-21H: 4.1;THP-1: 2.7
ZDHHC12,"FLJ14524, ZNF400",ENSG00000160446,Zinc finger DHHC-type containing 12,9,128720869-128724127,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA059339,Uncertain,,Approved,Nucleoplasm,,Expressed in all,Expressed in all,,,small intestine: 35.8,Mixed,,
ZDHHC13,"FLJ10852, FLJ10941, HIP14L",ENSG00000177054,Zinc finger DHHC-type containing 13,11,19117099-19176422,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA016759, HPA018791",Uncertain,,Enhanced,Vesicles,,Expressed in all,Mixed,,,esophagus: 40.4,Expressed in all,,
ZDHHC14,"FLJ20984, NEW1CP",ENSG00000175048,Zinc finger DHHC-type containing 14,6,157381133-157678146,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA046033, HPA063754",Uncertain,,Approved,Nucleoli<br>Mitochondria,Pancreatic cancer:6.93e-4 (favourable),Expressed in all,Mixed,,,endometrium: 12.3,Cell line enhanced,,HDLM-2: 47.1
ZDHHC15,"FLJ31812, MRX91",ENSG00000102383,Zinc finger DHHC-type containing 15,X,75368427-75523502,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at transcript level,HPA003618,Uncertain,,Approved,Nuclear speckles<br>Cytosol,,Tissue enhanced,Mixed,,,cerebral cortex: 4.8,Cell line enhanced,,HEL: 2.8;MOLT-4: 1.9;NTERA-2: 2.0;RH-30: 3.0;SH-SY5Y: 2.7
ZDHHC16,APH2,ENSG00000171307,Zinc finger DHHC-type containing 16,10,97446131-97457370,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA039893, HPA040214",Uncertain,,Supported,Nucleus<br>Nuclear membrane<br>Cytosol,,Expressed in all,Expressed in all,,,"parathyroid gland,placenta: 31.5",Expressed in all,,
ZDHHC17,"HIP14, HYPH, KIAA0946",ENSG00000186908,Zinc finger DHHC-type containing 17,12,76763588-76853696,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA016807, HPA058674",Approved,,Supported,Golgi apparatus<br>Vesicles<br>Aggresome,Renal cancer:7.11e-5 (unfavourable),Expressed in all,Expressed in all,,,cerebral cortex: 45.2,Expressed in all,,
ZDHHC18,DKFZp667O2416,ENSG00000204160,Zinc finger DHHC-type containing 18,1,26826710-26857602,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA040234,Approved,,Approved,Microtubules,"Renal cancer:1.36e-10 (unfavourable), Liver cancer:7.42e-7 (unfavourable), Glioma:9.53e-4 (unfavourable)",Expressed in all,Expressed in all,,,bone marrow: 75.2,Expressed in all,,
ZDHHC19,MGC33345,ENSG00000163958,Zinc finger DHHC-type containing 19,3,196197449-196211437,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enriched,44,testis: 29.2,adrenal gland: 0.6,Not detected,,
ZDHHC2,ZNF372,ENSG00000104219,Zinc finger DHHC-type containing 2,8,17156029-17224799,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA023331,Uncertain,,,,Renal cancer:3.24e-4 (favourable),Expressed in all,Expressed in all,,,thyroid gland: 53.7,Mixed,,
ZDHHC20,FLJ25952,ENSG00000180776,Zinc finger DHHC-type containing 20,13,21372573-21459370,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA014483, HPA014702",Approved,,Uncertain,Vesicles<br>Plasma membrane<br>Mitochondria,"Renal cancer:1.01e-4 (unfavourable), Pancreatic cancer:6.55e-4 (unfavourable)",Expressed in all,Expressed in all,,,testis: 60.5,Expressed in all,,
ZDHHC21,"DNZ1, HSPC097",ENSG00000175893,Zinc finger DHHC-type containing 21,9,14611071-14693471,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA065254,Approved,,Approved,Golgi apparatus<br>Cytosol,"Urothelial cancer:9.28e-6 (favourable), Renal cancer:1.29e-4 (favourable)",Expressed in all,Mixed,,,cerebral cortex: 16.0,Cell line enhanced,,HEL: 26.6
ZDHHC22,C14orf59,ENSG00000177108,Zinc finger DHHC-type containing 22,14,77131270-77142734,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA049471, HPA072213",,,Enhanced,Plasma membrane,,Tissue enriched,Tissue enriched,113,cerebral cortex: 64.2,testis: 0.5,Cell line enhanced,,AF22: 3.6;NTERA-2: 3.8;RH-30: 6.2;SCLC-21H: 8.2
ZDHHC23,MGC42530,ENSG00000184307,Zinc finger DHHC-type containing 23,3,113947901-113965401,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA016808,Uncertain,,Approved,Nucleus,"Renal cancer:1.48e-7 (favourable), Endometrial cancer:2.85e-4 (unfavourable), Thyroid cancer:5.90e-4 (unfavourable)",Expressed in all,Mixed,,,testis: 22.5,Mixed,,
ZDHHC24,,ENSG00000174165,Zinc finger DHHC-type containing 24,11,66520637-66546238,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA016619,Approved,,Approved,Vesicles<br>Cytosol,Glioma:2.39e-4 (unfavourable),Expressed in all,Mixed,,,parathyroid gland: 10.9,Expressed in all,,
ZDHHC3,"GODZ, ZNF373",ENSG00000163812,Zinc finger DHHC-type containing 3,3,44915257-44976185,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB012465, HPA016616",Approved,,Approved,Golgi apparatus,"Renal cancer:1.81e-8 (favourable), Liver cancer:1.37e-4 (unfavourable), Colorectal cancer:3.43e-4 (favourable)",Expressed in all,Expressed in all,,,"skin,testis: 65.5",Expressed in all,,
ZDHHC4,"FLJ10479, ZNF374",ENSG00000136247,Zinc finger DHHC-type containing 4,7,6577434-6589374,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA032124, HPA064358",Approved,,Approved,Nuclear bodies,"Renal cancer:1.18e-7 (favourable), Head and neck cancer:3.95e-6 (unfavourable), Urothelial cancer:8.94e-4 (unfavourable), Cervical cancer:9.35e-4 (unfavourable)",Expressed in all,Expressed in all,,,thyroid gland: 77.7,Mixed,,
ZDHHC5,"KIAA1748, ZNF375",ENSG00000156599,Zinc finger DHHC-type containing 5,11,57667747-57701187,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014670,Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Cell Junctions<br>Cytosol,Pancreatic cancer:6.74e-5 (unfavourable),Expressed in all,Expressed in all,,,parathyroid gland: 87.5,Expressed in all,,
ZDHHC6,"FLJ21952, ZNF376",ENSG00000023041,Zinc finger DHHC-type containing 6,10,112424428-112446917,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA014357,Approved,,,,,Expressed in all,Expressed in all,,,small intestine: 50.7,Expressed in all,,
ZDHHC7,"FLJ10792, FLJ20279, SERZ-B, SERZ1, ZNF370",ENSG00000153786,Zinc finger DHHC-type containing 7,16,84974181-85011535,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA019215, HPA059054, HPA059642",Uncertain,,Enhanced,Golgi apparatus,"Renal cancer:1.12e-5 (favourable), Liver cancer:4.20e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 64.8,Expressed in all,,
ZDHHC8,"KIAA1292, ZNF378",ENSG00000099904,Zinc finger DHHC-type containing 8,22,20129456-20148007,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA003422,Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:4.04e-4 (unfavourable), Cervical cancer:9.68e-4 (unfavourable)",Expressed in all,Expressed in all,,,spleen: 29.7,Mixed,,
ZDHHC9,"CGI-89, CXorf11, ZDHHC10, ZNF379, ZNF380",ENSG00000188706,Zinc finger DHHC-type containing 9,X,129803288-129843909,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA031814,Uncertain,,Supported,Golgi apparatus<br>Cytosol,"Cervical cancer:4.64e-5 (unfavourable), Breast cancer:9.77e-5 (unfavourable), Head and neck cancer:2.45e-4 (unfavourable)",Expressed in all,Expressed in all,,,cerebral cortex: 71.1,Expressed in all,,
ZFP91,"PZF, ZNF757",ENSG00000186660,ZFP91 zinc finger protein,11,58579111-58621042,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA024037, CAB025417, HPA065325",Approved,,Supported,Nucleus<br>Nucleoli,Pancreatic cancer:3.74e-6 (unfavourable),Expressed in all,Expressed in all,,,testis: 175.7,Expressed in all,,
ZMPSTE24,"FACE-1, HGPS, PRO1, STE24, Ste24p",ENSG00000084073,Zinc metallopeptidase STE24,1,40258107-40294184,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA006988,Approved,,Approved,Golgi apparatus<br>Cytosol,"Liver cancer:5.73e-6 (unfavourable), Thyroid cancer:6.34e-4 (unfavourable)",Expressed in all,Expressed in all,,,parathyroid gland: 90.5,Expressed in all,,
ZNF645,"CT138, FLJ25735, HAKAIL",ENSG00000175809,Zinc finger protein 645,X,22272943-22274461,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,141,testis: 14.1,all non-specific tissues: 0.0,Not detected,,
ZNRF1,"DKFZp434E229, FLJ14846, nin283",ENSG00000186187,Zinc and ring finger 1,16,74999030-75110994,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027470,Approved,,,,Cervical cancer:9.90e-4 (favourable),Expressed in all,Expressed in all,,,testis: 34.3,Expressed in all,,
ZNRF2,RNF202,ENSG00000180233,Zinc and ring finger 2,7,30284307-30367692,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA072244,Approved,,,,"Renal cancer:2.29e-4 (favourable), Endometrial cancer:7.68e-4 (unfavourable), Thyroid cancer:8.71e-4 (favourable)",Expressed in all,Expressed in all,,,testis: 39.7,Expressed in all,,
ZNRF3,"BK747E2.3, FLJ22057, KIAA1133, RNF203",ENSG00000183579,Zinc and ring finger 3,22,28883592-29057487,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA036702, HPA036703",Uncertain,,Uncertain,Golgi apparatus,,Not detected,Mixed,,,epididymis: 16.4,Cell line enhanced,,Hep G2: 31.1
ZNRF4,"RNF204, spzn, Ssrzf1",ENSG00000105428,Zinc and ring finger 4,19,5455431-5456856,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,494,testis: 49.3,all non-specific tissues: 0.0,Not detected,,
ZRANB1,TRABID,ENSG00000019995,Zinc finger RANBP2-type containing 1,10,124942123-124988189,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA029239, HPA029240, HPA029241",Approved,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Expressed in all,,,testis: 35.9,Expressed in all,,
ZSWIM2,"MGC33890, ZZZ2",ENSG00000163012,Zinc finger SWIM-type containing 2,2,186827835-186849208,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enriched,133,testis: 18.4,"cerebral cortex,placenta: 0.1",Not detected,,
